

[illegible]

012024-03-310001380106rmb:A2023InducementPlanMemberbus-gaap:RestrictedStockUnitsRSUMembersrt:VicePresidentMember2024-03-012024-03-310001380106rmb:A2023InducementPlanMember2024-09-3030001380106us-gaap:CostOfSalesMember2024-07-012024-09-300001380106us-gaap:CostOfSalesMember2023-07-012023-09-300001380106us-gaap:CostOfSalesMember2024-01-012024-09-300001380106us-gaap:CostOfSalesMember2023-01-012023-09-300001380106us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-300001380106us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001380106us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-300001380106us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001380106us-gaap:SellingAndMarketingExpenseMember2024-07-012024-09-300001380106us-gaap:SellingAndMarketingExpenseMember2023-07-012023-09-300001380106us-gaap:SellingAndMarketingExpenseMember2024-01-012024-09-300001380106us-gaap:SellingAndMarketingExpenseMember2023-01-012023-09-300001380106us-gaap:GeneralAndAdministrativeExpenseMember2024-07-012024-09-300001380106us-gaap:GeneralAndAdministrativeExpenseMember2023-07-012023-09-300001380106us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-09-300001380106us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-09-300001380106us-gaap:EmployeeStockOptionMember2024-01-012024-09-300001380106us-gaap:CommonClassAMember2024-07-012024-09-300001380106us-gaap:CommonClassAMember2023-07-012023-09-300001380106us-gaap:CommonClassAMember2024-01-012024-09-300001380106us-gaap:CommonClassAMember2023-01-012023-09-300001380106us-gaap:CommonClassBMember2024-07-012024-09-300001380106us-gaap:CommonClassBMember2023-07-012023-09-300001380106us-gaap:CommonClassBMember2024-01-012024-09-300001380106us-gaap:CommonClassBMember2023-01-012023-09-300001380106us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001380106us-gaap:RestrictedStockMember2024-01-012024-09-300001380106us-gaap:RestrictedStockMember2023-01-012023-09-300001380106rmb:CommonStockWarrantsMember2024-01-012024-09-300001380106rmb:CommonStockWarrantsMember2023-01-012023-09-300001380106us-gaap:EmployeeStockMember2024-01-012024-09-300001380106us-gaap:EmployeeStockMember2023-01-012023-09-300001380106srt:MinimumMember2024-09-300001380106srt:MaximumMember2024-09-300001380106srt:MinimumMember2024-01-012024-09-30Table of ContentsUNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 FORM 10-Q (Mark One)QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended September 30, 2024orTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from _____ to _____ Commission File Number: 001-40592 Rapid Micro Biosystems, Inc.(Exact name of registrant as specified in its charter) Delaware20-8121647(State or other jurisdiction of incorporation or organization)(I.R.S. EmployerIdentification Number)25 Hartwell AvenueÂ Lexington, MA(Address of Principal Executive Offices)Â 02421(Zip Code)(978) 349-3200(Registrantâ€™s telephone number, including area code) report) Securities registered pursuant to Section 12(b) of the Act:Title of Each ClassTrading symbol(s)Name of Exchange on which registeredClass A common stock, \$0.01 par value per shareRPIDThe Nasdaq Capital MarketIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ondicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No ondicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act.Large accelerated filerAccelerated filerNon-accelerated filerSmaller reporting companyEmerging growth companyXIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ondicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No xAs of NovemberÂ 5, 2024, there were 37,724,692 shares of the registrantâ€™s Class A common stock, par value \$0.01, outstanding.As of NovemberÂ 5, 2024, there were 5,309,529 shares of the registrantâ€™s Class B common stock, par value \$0.01, outstanding.Table of ContentsTABLE OF CONTENTSPagePart IFinancial InformationItem 1.Financial Statements6Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023 (Unaudited)6Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2024 and 2023 (Unaudited)7Condensed Consolidated Statements of Comprehensive Loss for the three and nine months ended September 30, 2024 and 2023 (Unaudited)8Condensed Consolidated Statements of Stockholdersâ€™ Equity for the three and nine months ended September 30, 2024 and 2023 (Unaudited)9Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2024 and 2023 (Unaudited)11Notes to Condensed Consolidated Financial Statements (Unaudited)13Item 2.Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations31Item 3.Quantitative and Qualitative Disclosures about Market Risk46Item 4.Controls and Procedures46Part IIOther InformationItem 1.Legal Proceedings47Item 1A.Risk Factors47Item 2.Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities78Item 3.Defaults Upon Senior Securities78Item 4.Mine Safety Disclosures78Item 5.Other Information78Item 6.Exhibits79Exhibit Index79Signatures802Table of ContentsFORWARD-LOOKING STATEMENTSThis Quarterly Report on Form 10-Q contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the â€œSecurities Actâ€), and Section 21E of the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€). All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q may be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as â€œmay,â€ â€œwill,â€ â€œshould,â€ â€œexpect,â€ â€œanticipate,â€ â€œestimate,â€ â€œintend,â€ â€œaim,â€ â€œtarget,â€ â€œproject,â€ â€œcontemplate,â€ â€œbelieve,â€ â€œestimate,â€ â€œforecast,â€ â€œpredict,â€ â€œpotentialâ€ or â€œcontinueâ€ or the negative of these terms or other similar expressions. Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to, statements regarding:â€œour business strategy for our Growth Direct platform and systems;â€œour future results of operations and financial position, including our expectations regarding revenue, gross margin, operating expenses and our ability to achieve positive cash flow;â€œthe anticipated impact of our operational efficiency program, our efforts to reduce our use of cash for operating and investing activities and the assumptions underlying our expectation for achieving positive cash flow by the end of 2027;â€œour expectations and assumptions related to our future funding requirements and available capital resources, which may be impacted by market uptake of our Growth Direct platform and systems, our management of inventory and supply chain, our capital expenditures, our research and development activities and our sales, marketing, manufacturing and distribution activities;â€œour ability to maintain and expand our customer base for our Growth Direct platform and systems, including expectations for customer adoption of new applications for our Growth Direct system;â€œthe effectiveness of enhancements to our sales force and our sales processes;â€œanticipated trends and growth rates in our business and in the markets in which we operate;â€œour research and development activities and prospective new features, products and product approvals;â€œour ability to anticipate market needs and successfully develop and launch new and enhanced solutions to meet those needs, including prospective products;â€œour ability to hire and retain necessary qualified employees to grow our business and expand our operations;â€œour expectations regarding the potential impact of inflation and fluctuations in interest rates on our business and operating costs;â€œour ability to regain and remain in compliance with the listing requirements of NasdaqI;â€œour expectations regarding the potential impact of ongoing conditions in the financial markets and banking system on our operations and financial results; andâ€œour ability to adequately protect our intellectual property.We caution you that the foregoing list may not contain all of the forward-looking statements made in this Quarterly Report on Form 10-Q. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the important factors discussed under Part II, Item 1A, "Risk Factors" of this Quarterly Report on Form 10-Q. The forward-looking statements in this Quarterly Report on Form 10-Q are based upon information available to us as of the date of this Quarterly Report on Form 10-Q, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. You should read this Quarterly Report on Form 10-Q and the documents that we reference in this Quarterly Report on Form 10-Q and have filed as exhibits to this Quarterly Report on Form 10-Q with the understanding that our 3Table of Contentsactual future results, levels of activity, performance and achievements may be materially different from what we expect. We caution you not to place undue reliance on forward-looking statements which speak only as of the date hereof. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.SUMMARY RISK FACTORSOur business is subject to numerous risks and uncertainties, including those described in Part II, Item 1A, â€œRisk Factorsâ€ in this Quarterly Report on Form 10-Q. You should carefully consider these risks and uncertainties as part of your evaluation of an investment in our Class A common stock. The principal risks and uncertainties affecting our business include, but are not limited to, the following:â€œWe have incurred significant losses since inception, we expect to incur losses in the future and we may not be able to achieve and maintain positive cash flow and profitability;â€œOur limited operating history makes it difficult to evaluate our future prospects and the risks and challenges we may encounter;â€œOur business depends on the commercial success of our Growth Direct platform, which may not be achieved or maintained;â€œOur operating results have fluctuated significantly in the past and will fluctuate significantly in the future, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations;â€œWe have in the past and may in the future fail to meet our publicly announced guidance or other expectations about our business and future operating results, which could adversely affect our business, reputation and financial results and cause our stock price to decline;â€œIf we cannot maintain the level of sales of our Growth Direct systems or the sales of our consumables and service contracts to existing customers declines, our future operating results would be adversely affected;â€œWe may need to raise additional capital to fund our existing operations, improve our platform or develop and commercialize new products or expand our operations;â€œOur business relies heavily on establishing and maintaining our position in the market as a leading provider of automated microbial quality control ("MQC") testing;â€œWe may not be successful in expanding our business with existing customers and driving adoption of our solutions with new customers;â€œThe size of the markets and forecasts of market growth for automated MQC testing and other of our key performance indicators are based on a number of complex assumptions and estimates, and may be inaccurate;â€œNew product development involves a lengthy and complex process and we may be unable to develop or commercialize products on a timely basis, or at all;â€œOur customers use our Growth Direct platform as part of their quality control workflow, which is subject to regulation by the U.S. Food and Drug Administration ("FDA") and other comparable regulatory authorities;â€œIf we are unable to manage our inventory and support demand for existing and future products on the Growth Direct platform, our business could suffer;â€œWe have limited experience in marketing and sales, and if we are unable to improve the effectiveness of our marketing and sales organization to adequately expand our business with new and existing customers and address our customersâ€™ needs or to expand our customer base, our business may be adversely affected;â€œOur operational efficiency program, including a reduction in workforce, may not result in anticipated savings, could result in total costs and expenses that are greater than expected and could disrupt our business;â€œIf we cannot compete successfully, we may be unable to increase or sustain our revenue, or achieve and sustain profitability;â€œWe must develop new products, adapt to rapid and significant technological change and respond to introductions of new products by competitors to remain competitive;4Table of Contentsâ€œDue to the significant resources required to enable access in new markets, we must make strategic and operational decisions to prioritize certain markets, products and services. We may expend our resources to access markets and develop products and services that do not yield meaningful revenue or we may fail to capitalize on markets, products or services that may be more profitable or with a greater potential for success;â€œThe Growth Direct platform may contain undetected errors or defects and may not meet the expectations of our customers, which means our business, financial condition, results of operations and prospects could suffer;â€œPotential product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of any products that we may develop;â€œIf we lose key management, cannot recruit qualified employees, directors, officers or other significant personnel or experience increases in our compensation costs, our business may be materially harmed; â€œIf our primary manufacturing and development facility becomes damaged or inoperable or we are required to vacate our existing facility, our ability to conduct and pursue our manufacturing and development efforts will be jeopardized;â€œOur manufacturing operations are dependent upon third-party suppliers, including single-source suppliers, making us vulnerable to supply shortages and price fluctuations, which could harm our business;â€œIf we are unable to obtain and maintain sufficient intellectual property protection for our technology, including the Growth Direct platform, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our products may be impaired; â€œPatent terms may be inadequate to protect our competitive position on our products for an adequate amount of time;â€œThe market price of our Class A common stock has been and may continue to be volatile and fluctuate substantially, which could result in substantial losses for our stockholders;â€œIf our Class A common stock is delisted from the Nasdaq Stock Market, the liquidity of our Class A common stock would be adversely affected and the market price of our common stock could decrease; andâ€œWe have been, and may continue to be, subject to the actions of activist shareholders or unsolicited acquisition proposals, which could cause us to incur substantial costs, divert managementâ€™s and the boardâ€™s attention and resources, and have an adverse effect on our business and stock price.TRADEMARKSSolely for convenience, our trademarks and trade names in this Quarterly Report on Form 10-Q are referred to without the Â® and â„¢ symbols, but such references should not be construed as any indicator that we will not assert, to the fullest extent under applicable law, our rights thereto.INTERNET POSTING OF INFORMATIONWe routinely post information that may be important to investors in the â€œInvestorsâ€ section of our website at www.rapidmicrobio.com. We encourage investors and potential investors to consult our website regularly for important information about us. The contents of our website are not incorporated by reference in this Quarterly Report on Form 10-Q and shall not be deemed â€œfiledâ€ under the Exchange Act.5Table of ContentsPART I â€œFINANCIAL INFORMATIONItem 1. Financial StatementsRAPID MICRO BIOSYSTEMS, INC.Condensed consolidated balance sheets(Unaudited)(In thousands, except share and per share amounts)September 30, 2024December 31, 2023AssetsCurrent assets:Cash and cash equivalents\$22,044Â \$24,285Â Short-term investments38,788Â 67,768Â Accounts receivable3,740Â 5,532Â Inventory21,253Â 19,961Â Prepaid expenses and other current assets2,869Â Total current assets87,934Â 120,415Â Property and equipment, net1,563Â 12,832Â Right-of-use assets, net5,420Â 6,240Â Long-term investmentsâ€Â 2,911Â Other long-term assets642Â 770Â Restricted cash284Â 284Â Total assets\$105,843Â \$143,452Â Liabilities and Stockholdersâ€™ EquityCurrent liabilities:Accounts payable\$2,329Â 1,973Â Accrued expenses and other current liabilities7,038Â 9,907Â Deferred revenues3,60Â 5,974Â Lease liabilities, short-term1,193Â 1,132Â Total current liabilities15,920Â 18,966Â Lease liabilities, long-term5,261Â 6,214Â Other long-term liabilities289Â 263Â Total liabilities21,470Â 25,463Â Commitments and contingencies (Note 14)Stockholdersâ€™ equity:Class A common stock, \$0.01 par value; 210,000,000 shares authorized at SeptemberÂ 30, 2024 and DecemberÂ 31, 2023; 37,715,205 shares and 37,099,909 shares issued and outstanding at SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, respectively377Â 371Â Class B common stock, \$0.01 par value; 10,000,000 shares authorized at SeptemberÂ 30, 2024 and DecemberÂ 31, 2023; 5,309,529 shares issued and outstanding at SeptemberÂ 30, 2024 and DecemberÂ 31, 202353Â 53Â Preferred stock, \$0.01 par value: 10,000,000 shares authorized at SeptemberÂ 30, 2024 and DecemberÂ 31, 2023; zero shares issued and outstanding at SeptemberÂ 30, 2024 and DecemberÂ 31, 2023â€Â 1,203Â Additional paid-in capital549,468Â 546,051Â Accumulated deficit(465,608) (428,385)Accumulated other comprehensive loss83Â (101)Total stockholdersâ€™ equity84,373Â 117,989Â Total liabilities and stockholdersâ€™ equity\$105,843Â \$143,452Â The accompanying notes are an integral part of these condensed consolidated financial statements.6Table of ContentsRAPID MICRO BIOSYSTEMS, INC.Condensed consolidated statements of operations(Unaudited)(In thousands, except share and per share amounts)Three Months Ended September 30, 2024202320242023Revenue:Product

revenue\$5,255Â \$4,200Â \$13,505Â \$10,693Â Service revenue2,349Â 1,945Â 6,328Â 5,489Â Total revenue7,604Â 6,145Â 19,833Â 16,182Â Costs and operating expenses:Cost of product revenue\$5,314Â 5,691Â 15,404Â 15,361Â Cost of service revenue1,668Â 2,085Â 5,519Â 6,134Â Research and development3,609Â 3,116Â 11,195Â 9,502Â Sales and marketing3,376Â 3,498Â 10,284Â 10,161Â General and administrative\$5,676Â 6,204Â 17,121Â 19,399Â Total costs and operating expenses19,643Â 20,594Â 59,523Â 60,557Â Loss from operations(12,039)(14,449)(39,690)(44,375)Other income (expense):Interest income, net768Â 1,093Â 2,589Â 3,169Â Other expense, net(39)(26)(91)(66)Total other income, net729Â 1,067Â 2,498Â 3,103Â Loss before income taxes(11,310)(13,382)(37,192)(41,272)Income tax expense13Â 10Â 31Â 23Â Net loss(11,323)(13,392)(37,223)(41,295)Net loss per share â€” basic and diluted(0.26)\$(0.31)\$(0.86)\$(0.96)Weighted average common shares outstanding â€” basic and diluted44,668,6564,080,09543,510,91242,985,184The accompanying notes are an integral part of these condensed consolidated financial statements.7Table of ContentsRAPID MICRO BIOSYSTEMS, INC.Condensed consolidated statements of comprehensive loss(Unaudited)(In thousands)Three Months Ended September 30,Nine Months Ended September 30,2024202320242023Net loss\$(11,323)\$(13,392)\$(37,223)\$(41,295)Other comprehensive income (loss):Â A Unrealized gain on investments, net of tax108Â 242Â 184Â 656Â Comprehensive loss\$(11,215)\$(13,150)\$(37,039)\$(40,639)The accompanying notes are an integral part of these condensed consolidated financial statements.8Table of ContentsRAPID MICRO BIOSYSTEMS, INC.Condensed consolidated statements of stockholdersâ€™ equity (Unaudited)(In thousands, except share amounts)Class ACommon stock Class BCommon stock Additional-paid-incapitalAccumulateddeficitAccumulatedothercomprehensivelossTotalSharesAmountSharesAmountBalances at December 31, 202337,099,909Â 371Â 5,309,529Â 53Â \$546,051Â \$(428,385)\$(101)\$(17,989) Issuance of Class A common stock under ESPP198,299Â 2Â 2Â 166Â 168Â Vesting of restricted stock units185,331Â 2Â 2Â (2)Â 2Â Issuance of Class A common stock upon exercise of common stock options20Â 2Â 2Â 2Â Stock-based compensation expenseÂ 2Â 2Â 1,085Â 1,085Â Net lossÂ 2Â 2Â (13,322)Â (13,322)Other comprehensive incomeÂ 2Â 2Â 23Â 23Â Balances at March 31, 202437,483,559Â 375Â 5,309,529Â 53Â \$547,300Â \$(441,707)\$(78)105,943Â Vesting of restricted stock units113,0741Â 1Â (1)Â 1Â Issuance of Class A common stock upon exercise of common stock options294Â 2Â 2Â 2Â Stock-based compensation expenseÂ 2Â 2Â 1,171Â 1,171Â Net lossÂ 2Â 2Â (12,578)Â (12,578)Other comprehensive incomeÂ 2Â 2Â 53Â 53Â Balances at June 30, 202437,596,927370Â 5,309,52953Â \$548,470Â \$(454,285)\$(25)94,589Â Issuance of Class A common stock under ESPP88,9181Â 2Â 2Â 62Â 63Â Vesting of restricted stock units20,1042Â 2Â 2Â 2Â Issuance of Class A common stock upon exercise of common stock options9,2562Â 2Â 2Â 7Â 7Â Stock-based compensation expenseÂ 2Â 2Â 929Â 929Â Net lossÂ 2Â 2Â (11,323)Â (11,323)Other comprehensive incomeÂ 2Â 2Â 108Â 108Â Balances at September 30, 202437,715,205377Â 5,309,52953Â \$549,468Â \$(465,608)\$(83)84,373Â The accompanying notes are an integral part of these condensed consolidated financial statements.9Table of ContentsRAPID MICRO BIOSYSTEMS, INC.Condensed consolidated statements of stockholdersâ€™ equity(Unaudited), continued(In thousands, except share amounts)Class ACommon stock Class BCommon stock Additional-paid-incapitalAccumulateddeficitAccumulatedothercomprehensivelossTotalSharesAmountSharesAmountBalances at December 31, 202336,538,805Â 366Â 5,553,379Â 555Â \$540,775Â \$(375,918)\$(1,109)164,169Â Issuance of Class A common stock under ESPP125,5361Â 1Â 1Â 123Â 124Â Vesting of restricted stock units96,3031Â 1Â (1)Â 1Â Restricted stock award liability accretionÂ 2Â 2Â 341Â 341Â Issuance of Class A common stock upon exercise of common stock options7,896Â 2Â 2Â 6Â 6Â Stock-based compensation expenseÂ 2Â 2Â 1,243Â 1,243Â Net lossÂ 2Â 2Â (13,887)Â (13,887)Other comprehensive incomeÂ 2Â 2Â 447Â 447Â Balances at March 31, 202336,768,540Â 368Â 5,553,379Â 555Â \$542,487Â \$(389,805)\$(662)152,443Â Vesting of restricted stock units4,954Â 2Â 2Â 2Â 2Â Conversion of Class B common stock to Class A common stock243,8502Â (2)Â 2Â 2Â Stock-based compensation expenseÂ 2Â 2Â 1,234Â 1,234Â Net lossÂ 2Â 2Â (14,016)Â (14,016)Other comprehensive lossÂ 2Â 2Â 2Â 2Â Balances at June 30, 202337,017,344370Â 5,309,529Â 53Â \$543,721Â \$(403,821)\$(695)139,628Â Issuance of Class A common stock under ESPP60,5011Â 1Â 1Â 57Â 58Â Vesting of restricted stock units9,2531Â 1Â 1Â 1Â Issuance of Class A common stock upon exercise of common stock options934Â 2Â 2Â 2Â 2Â Stock-based compensation expenseÂ 2Â 2Â 1,251Â 1,251Â Net lossÂ 2Â 2Â (13,392)Â (13,392)Other comprehensive lossÂ 2Â 2Â 242Â 242Â Balances at September 30, 202337,088,032371Â 5,309,52953Â \$545,029Â \$(417,213)\$(453)127,787Â The accompanying notes are an integral part of these condensed consolidated financial statements.10Table of ContentsRAPID MICRO BIOSYSTEMS, INC.Condensed consolidated statements of cash flows(Unaudited)(In thousands)Nine Months Ended September 30,20242023Cash flows from operating activities:Net loss\$(37,223)\$(41,295)Adjustments to reconcile net loss to net cash used in operating activities:Depreciation and amortization expense2,493Â 2,311Â Stock-based compensation expense3,185Â 3,728Â Provision for excess and obsolete inventory95Â 34Â Noncash lease expense862Â 899Â Accretion on investments(985)(1,766)Other25Â 26Â Changes in operating assets and liabilities:Accounts receivable1,792Â 1,462Â Inventory(1,388)960Â Prepaid expenses and other current assets759Â 1,817Â Other long-term assets(150)5Â Accounts payable357Â (2,157)Accrued expenses and other current liabilities(3,451)(1,462)Deferred revenue(615)(146)Net cash used in operating activities(34,244)(35,584)Cash flows from investing activities:Purchases of property and equipment(1,267)(1,427)Purchases of investments(29,496)(50,928)Sale of investments3,957Â 6Â Maturity of investments58,600Â 84,500Â Net cash provided by investing activities31,794Â 32,145Â Cash flows from financing activities:Proceeds from issuance of Class A common stock - stock option exercise7Â 6Â Proceeds from issuance of Class A common stock - employee stock purchase plan231Â 182Â Payments on finance lease obligations(29)(27)Net cash provided by financing activities209Â 161Â Net decrease in cash, cash equivalents and restricted cash(2,241)(3,278)Cash, cash equivalents and restricted cash at beginning of period24,569Â 27,348Â Cash, cash equivalents and restricted cash at end of period\$22,328Â \$24,070Â The accompanying notes are an integral part of these condensed consolidated financial statements.11Table of ContentsRAPID MICRO BIOSYSTEMS, INC.Condensed consolidated statements of cash flows, continued(Unaudited)(In thousands)Nine Months Ended September 30,20242023Supplemental disclosure of cash flow informationCash paid for interest\$27Â \$29Â Supplemental disclosure of non-cash investing activitiesObtaining a right of operating assets in exchange for lease liability\$4Â \$151Â Purchases of property and equipment in accounts payable and accrued expenses\$28Â \$204Â The accompanying notes are an integral part of these condensed consolidated financial statements.12Table of ContentsRAPID MICRO BIOSYSTEMS, INC.Notes to condensed consolidated financial statements(Amounts in thousands, except share and per share amounts)(Unaudited)1. Nature of the business and basis of presentationRapid Micro Biosystems, Inc. (the â€œCompanyâ€) was incorporated under the laws of the State of Delaware on December 29, 2006. The Company develops, manufactures, markets and sells Growth Direct systems (â€œSystemsâ€) proprietary consumables, laboratory information management system (â€œLIMSâ€) connection software, and services to address rapid microbial analysis used for quality control in the manufacture of pharmaceuticals, medical devices and personal care products. The Companyâ€™s technology uses a highly sensitive camera and the natural auto fluorescence of living cells to identify and quantify microbial growth faster and more accurately than the traditional method, which relies on the human eye. The Company currently sells to customers in North America, Europe and the Asia-Pacific region. The Company is headquartered in Lexington, Massachusetts.Basis of presentationThese condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (â€œGAAPâ€) and include the accounts of the Company and its wholly owned subsidiaries in Germany and Switzerland. All intercompany accounts and transactions have been eliminated in consolidation. Certain information and note disclosures normally included in the consolidated financial statements prepared in accordance with GAAP have been condensed or omitted. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the Companyâ€™s audited consolidated financial statements for the year ended DecemberÂ 31, 2023. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (â€œASCâ€) and Accounting Standards Update (â€œASUâ€) of the Financial Accounting Standards Board (â€œFASBâ€). The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Companyâ€™s financial position as of SeptemberÂ 30, 2024 and the results of its operations and its cash flows for the three and nine months ended SeptemberÂ 30, 2024 and 2023. The financial data and other information disclosed in these notes related to the three and nine months ended SeptemberÂ 30, 2024 and 2023 are also unaudited. The results for the three and nine months ended SeptemberÂ 30, 2024 are not necessarily indicative of results to be expected for the year ending DecemberÂ 31, 2024, any other interim periods, or any future year or period.LiquidityThe Company has incurred recurring losses and net cash outflows from operations since its inception. The Company expects to continue to generate operating losses for the foreseeable future. The Company expects that its existing cash and cash equivalents and investments will be sufficient to fund its operating expenses and capital expenditure requirements for at least twelve months following the date these unaudited interim condensed consolidated financial statements were issued.2. Summary of significant accounting policiesUse of estimatesThe preparation of the Companyâ€™s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, calculating the standalone selling price for revenue recognition, the valuation of inventory, and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific and relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in 13Table of Contentscircumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.There have been no significant changes to the Company's significant accounting policies during both the three and nine months ended SeptemberÂ 30, 2024, as compared to those disclosed in Note 2 of the audited consolidated financial statements as of DecemberÂ 31, 2023 filed with the Companyâ€™s Annual Report on Form 10-K for the fiscal year ended DecemberÂ 31, 2023.Risk of concentrations of credit, significant customers and significant suppliersFinancial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents, short-term and long-term investments and accounts receivable. The Company maintains its cash and cash equivalents and investments with financial institutions that management believes to be of high credit quality, and does not believe that it is subject to unusual credit risk beyond the credit risk associated with commercial banking relationships.Significant customers are those which represent more than 10% of the Companyâ€™s total revenue or accounts receivable balance at each respective balance sheet date. The following table presents customers that represented 10% or more of the Companyâ€™s total revenue:Three Months Ended September 30,Nine Months Ended September 30,2024202320242023Customer A21.0Â %*11.6Â %*Customer B*14.7Â %*14.1Â %*18.2Â %*Customer C*11.4Â %*Customer D*10.2Â %*21.0Â %*36.3Â %*25.7Â %*18.2Â %*The following table presents customers that represented 10% or more of the Companyâ€™s accounts receivable:September 30,December 31,20242023Customer E12.8Â %*21.4Â %*Customer F12.5Â %*Customer G12.3Â %*Customer H*16.4Â %*Customer I*12.4Â %*Customer B*10.7Â %*37.6Â %*60.9Â %*less than 10%The Company relies on third parties for the supply and manufacture of certain components of its products as well as third-party logistics providers. There were no significant concentrations around a single third-party supplier, manufacturer, or logistics provider for the three and nine months ended SeptemberÂ 30, 2024 or 2023.Cash and cash equivalentsThe Company considers all highly liquid investments with an original maturity of 90 days or less at the time of purchase to be cash equivalents. Cash equivalents that are readily convertible to cash are stated at cost, which approximates fair value. At both SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, the Company held cash of \$0.1 million in banks located outside of the United States.14Table of ContentsRestricted cashAs of both SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, the Company was required to maintain guaranteed investment certificates of \$0.3 million with maturities of three months to one year that are subject to an insignificant risk of changes in value. The guaranteed investment certificates are held for the benefit of the landlord in connection with operating leases which have remaining terms of greater than one year and are classified as restricted cash (non-current) on the Companyâ€™s condensed consolidated balance sheets.Accounts receivableAccounts receivable are customer obligations that are unconditional. Accounts receivable are presented net of an allowance for doubtful accounts for expected credit losses, which represents an estimate of amounts that may not be collectible. The Company performs ongoing credit evaluations of its customers and, if necessary, provides an allowance for doubtful accounts and expected credit losses. A provision to the allowance for doubtful accounts for expected credit losses is recorded based on factors including the length of time the receivables are past due, the current business environment, the geographic market, and the Companyâ€™s historical experience. Provisions to the allowance for doubtful accounts for expected credit losses are recorded to general and administrative expenses in the consolidated statements of operations. The Company writes off accounts receivable against the allowance when it determines a balance is uncollectible and no longer actively pursues collection of the receivable. The Company does not have any off-balance-sheet credit exposure related to customers. As of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, the allowance for doubtful accounts for expected credit losses was zero.Software Development CostsThe Company accounts for software development costs for internal-use software under the provisions of ASC 350-40, â€œInternal-Use Softwareâ€ (â€œASC 350â€). Accordingly, certain costs to develop internal-use computer software are capitalized, provided these costs are expected to be recoverable. There was \$1.6 million and \$1.4 million of software development costs related to the Company's enterprise resource planning ("ERP") system capitalized in other long-term assets at SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, respectively, net of accumulated amortization of \$1.0 million and \$0.7 million, respectively. These capitalized costs are being amortized on a straight-line basis over the initial subscription term of five years. For the three and nine months ended SeptemberÂ 30, 2024 and 2023, there was \$0.1 million and \$0.3 million, respectively, of amortization expense related to capitalized software development costs recorded in the condensed consolidated statements of operations.Fair value measurementsCertain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:â€¢Level 1â€”Quoted prices in active markets for identical assets or liabilities.â€¢Level 2â€”Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.â€¢Level 3â€”Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.The Companyâ€™s cash equivalents, short-term and long-term investments are carried at fair value, determined according to the fair value hierarchy described above (see Note 3). The carrying values of the Companyâ€™s accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses and other current liabilities approximate their fair values due to the short-term nature of these assets and liabilities.15Table of ContentsProduct warrantiesThe Company offers a one-year limited assurance warranty on System sales, which is included in the selling price. The accrual for these warranty obligations is included in accrued expenses and other current liabilities in the condensed consolidated balance sheets. The following table presents a summary of changes in the amount reserved for warranty cost (in thousands):Three Months Ended September 30,Nine Months Ended September 30,2024202320242023Balance, beginning of period\$520Â \$526Â \$689Â \$872Â Warranty provisionsÂ 171Â 171Â Warranty repairsÂ (169)Â (346)Â Balance, end of period\$520Â \$697Â \$520Â \$697Â Segment informationThe Company determined its operating segment after considering the Companyâ€™s organizational structure and the information regularly reviewed and evaluated by the Companyâ€™s chief operating decision maker (â€œCODMâ€) in deciding how to allocate resources and assess performance. The Company has determined that its CODM is its Chief Executive Officer. The CODM reviews the financial information on a consolidated basis for purposes of evaluating financial performance and allocating resources. On the basis of these factors, the Company determined that it operates and manages its business as one operating segment, that develops, manufactures, markets and sells Systems and related LIMS connection software, consumables and services; and accordingly has one reportable

segment for financial reporting purposes. Substantially all of the Company’s long-lived assets are held in the United States. Revenue recognition Remaining performance obligations The Company does not disclose the value of remaining performance obligations for (i) contracts with an original contract term of one year or less, (ii) contracts for which the Company recognizes revenue at the amount to which it has the right to invoice when that amount corresponds directly with the value of services performed, and (iii) variable consideration allocated entirely to a wholly unsatisfied performance obligation or to a wholly unsatisfied distinct service that forms part of a single performance obligation. The Company does not have material remaining performance obligations associated with contracts with terms greater than one year. Contract balances from contracts with customers Contract assets arise from customer arrangements when revenue recognized exceeds the amount billed to the customer and the Company’s right to payment is conditional and not only subject to the passage of time. The Company had \$0.2 million and \$0.1 million in contract assets as of September 30, 2024 and December 31, 2023, respectively, included in prepaid expenses and other current assets. Contract liabilities represent the Company’s obligation to transfer goods or services to a customer for which it has received consideration (or the amount is due) from the customer. The Company has a contract liability related to service revenue, which consists of amounts that have been invoiced but that have not been recognized as revenue. Amounts expected to be recognized as revenue within 12 months of the balance sheet date are classified as current deferred revenue and amounts expected to be recognized as revenue beyond 12 months of the balance sheet date are classified as non-current deferred revenue. The Company did not record any non-current deferred revenue as of September 30, 2024 or December 31, 2023. Deferred revenue was \$5.4 million and \$6.0 million at September 30, 2024 and December 31, 2023, respectively. Revenue recognized during each of the three months ended September 30, 2024 and 2023 that was included in deferred revenue at the prior period-end was \$1.2 million. Revenue recognized during the nine months ended September 30, 2024 and 2023 that was included in deferred revenue at the prior period-end was \$3.9 million and \$3.3 million, respectively. 16 Table of Contents Disaggregated revenue The Company disaggregates revenue based on the recurring and non-recurring nature of the underlying sale. Recurring revenue includes sales of consumables and service contracts. The Company considers these to be recurring revenues because customers typically place purchase orders on a periodic basis as they use their Growth Direct system(s) over time. These arrangements typically contain a single performance obligation and thus the entire consideration to which the Company is entitled is allocated entirely to that performance obligation. Non-recurring revenue includes sales of systems, LIMS connection software, validation services, and field services, and typically contains multiple performance obligations. The Company considers these to be non-recurring revenues because customers typically place single purchase orders for a bundle of products and services on a one-time or infrequent basis. For these arrangements, significant judgment is applied in identifying the distinct performance obligations, determination of the transaction price, transaction price allocation, and determination of standalone selling price for each of the distinct performance obligations. The following table presents the Company’s revenue by the recurring or non-recurring nature of the revenue stream (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Product and service revenue € recurring \$3,675A \$3,410A \$11,262A \$10,255A Product and service revenue € non-recurring 3,929A 2,735A 8,571A 5,927A Total revenue \$7,604A \$6,145A \$19,833A \$16,182A The following table presents the Company’s revenue by customer geography (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 United States \$3,423A \$2,665A \$8,232A \$6,987A Switzerland 1,357A 1,058A 3,932A 2,991A Germany 923A 478A 2,358A 1,392A Japan 227A 167A 1,399A 1,621A All other countries 1,674A 1,777A 3,912A 3,191A Total revenue \$7,604A \$6,145A \$19,833A \$16,182A Advertising costs Advertising costs are expensed as incurred and are included in sales and marketing expenses in the condensed consolidated statements of operations. Advertising costs were less than \$0.1 million during each of the three months ended September 30, 2024 and 2023, and were \$0.2 million during each of the nine months ended September 30, 2024 and 2023. Stock-based compensation The Company measures all stock-based awards granted to employees, officers and directors based on their fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. The Company issues stock-based awards with (i) service-based vesting conditions only and (ii) stock-based awards with both service-based and Company performance vesting conditions, and records the expense for these awards using the straight-line method. Forfeitures are accounted for prospectively as they occur. The Company measures all restricted stock units granted to employees based on the common stock value on the date of grant. The purchase price of the restricted stock is the common stock value on the date of grant. Recently issued accounting pronouncements The Company qualifies as an € emerging growth company € as defined in the Jumpstart Our Business Startups (“JOBS”) Act of 2012 and has elected not to € opt out € of the extended transition related to complying with new or revised 17 Table of Contents accounting standards, which means that when a standard is issued or revised and it has different application dates for public and nonpublic companies, the Company will adopt the newer revised standard at the time nonpublic companies adopt the new or revised standard and will do so until such time that the Company either (i) irrevocably elects to € opt out € of such extended transition period or (ii) no longer qualifies as an emerging growth company. The Company may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for nonpublic companies. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures. The new standard requires enhanced disclosures about a public entity’s reportable segments including more detailed information about a reportable segment’s expenses. The amendments in this update apply to all public entities that are required to report segment information, and include those entities that have a single reportable segment. The amendments in this update are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact on its consolidated financial statements and related disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740) - Improvements to Income Tax Disclosures. ASU 2023-09 provides more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The amendments in this update are effective for annual periods beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact on its consolidated financial statements and related disclosures. 3. Fair value of financial assets and liabilities The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values (in thousands): Fair value measurements as of September 30, 2024 Level 1 Level 2 Level 3 Total Assets A A A Cash equivalents 14,293A € A € A € 14,293A Short-term investments 38,788A € A € A 38,788A \$53,081A € A € A \$53,081A Fair value measurements as of December 31, 2023 Level 1 Level 2 Level 3 Total Assets Cash equivalents 20,306A € A € A \$20,306A Short-term investments 62,625A 5,143A € A 67,768A Long-term investments 2,911A € A € A 2,911A \$85,842A \$5,143A € A \$90,985A During the three and nine months ended September 30, 2024 and 2023, there were no transfers in or out of Level 3. Valuation of short-term and long-term investments U.S. Treasury bills and notes included in short-term and long-term investments were valued by the Company using quoted prices in active markets for identical securities, which represents a Level 1 measurement within the fair value hierarchy. The Company’s certificates of deposit included in short-term and long-term investments were valued using quoted prices for similar assets in active markets (or identical assets in inactive markets), which represent a Level 2 measurement within the fair value hierarchy. 18 Table of Contents 4. Investments Short-term and long-term investments by investment type consisted of the following (in thousands): September 30, 2024 Amortized cost Gross unrealized gains Gross unrealized losses Fair value Short-term investments U.S. Government Treasury Notes \$38,705A \$83A € A \$38,788A \$38,705A \$83A € A \$38,788A December 31, 2023 Amortized cost Gross unrealized gains Gross unrealized losses Fair value Short-term investments Certificates of Deposit \$5,164A € A € A \$5,164A U.S. Government Treasury Bills 16,184A 9A € A 16,193A U.S. Government Treasury Notes 46,536A 42A (146) 46,432A \$67,884A \$51A € (167) \$67,768A Long-term Investments U.S. Government Treasury Notes - Maturity Up To Two Years 2,896A 15A € A 2,911A \$2,896A \$15A € A \$2,911A 5. Inventory Inventory consisted of the following (in thousands): September 30, December 31, 2024 2023 Raw materials \$11,544A \$12,873A Work in process 277A 150A Finished goods 9,432A 6,938A Total \$21,253A \$19,961A Raw materials, work in process and finished goods were net of adjustments to net realizable value of \$0.6 million as of both September 30, 2024 and December 31, 2023. 19 Table of Contents 6. Prepaid expenses and other current assets Prepaid expenses and other current assets consisted of the following (in thousands): September 30, December 31, 2024 2023 Prepaid insurance \$28A \$1,282A Contract asset 228A 51A Deposits 638A 667A Other receivables 174A 137A Prepaid financing fees 290A 292A Other 751A 440A \$2,109A \$2,869A 7. Property and equipment, net Property and equipment, net consisted of the following (in thousands): September 30, December 31, 2024 2023 Manufacturing and laboratory equipment \$14,431A \$13,750A Computer hardware and software 2,139A 1,960A Office furniture and fixtures 623A 589A Leasehold improvements 8,998A 8,551A Construction-in-process 1,804A 2,292A 27,995A 27,142A Less: Accumulated depreciation (16,432) (14,310) \$11,563A \$12,832A Depreciation and amortization expense related to property and equipment was \$0.7 million for each of the three months ended September 30, 2024 and 2023, and was \$2.1 million and \$2.0 million for the nine months ended September 30, 2024 and 2023, respectively. 8. Accrued expenses and other current liabilities Accrued expenses and other current liabilities consisted of the following (in thousands): September 30, December 31, 2024 2023 Accrued employee compensation and benefits expense \$4,634A \$4,808A Accrued vendor expenses 1,641A 4,017A Accrued warranty expense 520A 689A Accrued taxes 239A 252A Other 414A 17,038A \$9,907A In July 2024, the Company completed an enterprise-wide review of opportunities to realize operational efficiencies. Based on the results of this review, the Company implemented certain cost actions in the three months ended September 30, 2024, including a reduction in the Company’s workforce, the closure of open and planned positions, and reductions in other non-headcount-related expenses across the business (the € Operational Efficiency Program €). The Company recorded a related charge of \$0.6A million in costs and operating expenses in the third quarter of 2024. The Company made \$0.2A million in payments during the three and nine months ended September 30, 2024 related to the 20 Table of Contents Operational Efficiency Program. The company had \$0.4A million in remaining payments under the Operational Efficiency Program as of September 30, 2024. 9. Common stock and common stock warrants As of both September 30, 2024 and December 31, 2023, the Company’s restated certificate of incorporation authorized the issuance of Class A and Class B common stock. Each share of Class A common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders. The Company’s Class B common stock is non-voting. Class A and Class B common stockholders are entitled to receive dividends, as may be declared by the board of directors, if any, subject to the preferential dividend rights of Preferred Stock. As of September 30, 2024, no cash dividends had been declared or paid. As of September 30, 2024, the Company had reserved 23,915,460 shares of Class A common stock for the exercise of outstanding stock options and warrants, vesting of restricted stock units, the number of shares remaining available for grant under the Company’s 2021 Incentive Award Plan (see Note 10), the number of shares available for purchase under the Company’s Employee Stock Purchase Plan (see Note 10) and the conversion of Class B common stock. Outstanding warrants to purchase common stock consisted of the following: September 30, 2024 Issuance date Contractual term Balance sheet classification Shares of common stock issuable upon exercise of warrant Weighted average exercise price (in years) July 24, 2017 10 Equity 16,954 \$293.42A April 12, 2018 10 Equity 30,000 \$1.00A July 14, 2021 * 10 Equity 975,109 \$1.46A 1,022,063 December 31, 2023 Issuance date Contractual term Balance sheet classification Shares of common stock issuable upon exercise of warrant Weighted average exercise price (in years) July 24, 2017 10 Equity 17,194 \$292.81A April 12, 2018 10 Equity 30,000 \$1.00A July 14, 2021 * 10 Equity 975,109 \$1.46A 1,022,303 * In connection with the Company’s initial public offering (“IPO”), preferred stock warrants were automatically converted to Class A common stock warrants. The contractual term of the converted Class A common stock warrants remained consistent with the original term of the preferred stock warrants, with original issue dates between 2017-2020. 21 Table of Contents 10. Stock-based compensation 2010 Stock Option and Grant Plan The Company’s 2010 Stock Option and Grant Plan (the € 2010 Plan €) provided for the Company to grant incentive stock options or nonqualified stock options, restricted stock awards and other stock-based awards to employees, officers, directors and consultants of the Company. Following the effectiveness of the Company’s IPO in July 2021, no additional awards are being granted under the 2010 Plan and shares of existing outstanding options that were issued under the 2010 Plan and are forfeited or canceled will be available for grant under the 2021 Incentive Award Plan. 2021 Incentive Award Plan In July 2021, the board of directors adopted, and the Company’s stockholders approved, the 2021 Incentive Award Plan (the € 2021 Plan €). The 2021 Plan provides for the grant of stock options, including incentive stock options and non-qualified stock options, stock appreciation rights, restricted stock, restricted stock units, and other stock-based and cash-based awards. The 2021 Plan has a term of ten years. The aggregate number of shares of Class A common stock available for issuance under the 2021 Plan is equal to the sum of (i) 4,200,000 shares; (ii) any shares which are subject to the 2010 Plan awards that become available for issuance under the 2021 Plan; and (iii) an annual increase for ten years on the first day of each calendar year beginning on January 1, 2022, equal to the lesser of (A) 5% of the aggregate number of shares of Class A common stock outstanding on the last day of the immediately preceding calendar year and (B) such smaller amount of shares as determined by the board of directors. No more than 33,900,000 shares of Class A common stock may be issued under the 2021 Plan upon the exercise of incentive stock options. As of September 30, 2024, there were 4,551,792 shares available for issuance under the 2021 Plan. The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted to employees and directors: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Risk-free interest rate * 4.2A % 4.3A % 3.9A % Expected term (in years) * 6.15 96.0 Expected volatility * 47.1A % 50.0A % 47.1A % Expected dividend yield * 0A % 0A % 0A % No options granted in the respective period. 22 Table of Contents Stock options The following table summarizes the Company’s stock option activity since December 31, 2023: Number of shares Weighted average exercise price Weighted average remaining contractual term Aggregate intrinsic value (in years) (in thousands) Outstanding as of December 31, 2023 530,511 \$2.59A 7.12 \$2A € A Granted 952,470 0.93A Exercised (9,570) 0.75A Expired (255,166) 4.96A Forfeited (357,740) 1.67A Outstanding as of September 30, 2024 860,505 \$2.32A 6.51 \$155A Options vested and expected to vest as of September 30, 2024 860,505 \$2.32A 6.51 \$155A Options exercisable as of September 30, 2024 694,428 \$2.59A 5.54 \$132A The aggregate intrinsic value of options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s Class A common stock for those options that had exercise prices lower than such fair value. The intrinsic value of stock options exercised the nine months ended September 30, 2024 was less than \$0.1 million. The weighted average grant-date fair value per share of stock options granted during the three months ended September 30, 2023 was \$0.49, and during the nine months ended September 30, 2024 and 2023 was \$0.48 and \$0.59, respectively. No options were granted in the three months ended September 30, 2024. Restricted stock units Restricted stock unit grants to employees typically have a three-year service-based vesting term in which vesting occurs annually on the anniversary of the grant date. During the nine months ended September 30, 2024, the Company granted restricted stock units with service-based vesting conditions only. The Company expenses the fair value of the restricted stock units over the expected vesting period and accounts for forfeitures prospectively as they occur. The following table summarizes the Company’s restricted stock units activity since December 31, 2023: Number of shares Weighted average fair value Unvested as of December 31, 2023 1,681,760 \$2.28A Granted 1,157,765 \$0.93A Vested (459,024) \$3.11A Forfeited (273,253) \$1.61A Unvested as of September 30, 2024 1,077,248 \$1.44A The weighted average grant-date fair value per share of restricted stock units granted during the three months ended September 30, 2024 and 2023 was \$0.78 and \$0.97, respectively, and during the nine months ended September 30, 2024 and 2023 was \$0.93 and \$1.22, respectively. 23 Table of Contents 2021 Employee Stock Purchase Plan In July 2021, the board of directors adopted, and the Company’s stockholders approved, the 2021 Employee Stock Purchase Plan (the € 2021 ESPP €), which became effective in connection with the IPO of Class A common stock. The aggregate number of shares of Class A common stock available for issuance under the 2021 ESPP is equal to (i) 400,000 shares and (ii) an annual increase for ten years on the first day of each calendar year beginning on January 1, 2022, equal to the lesser of (A) 1% of the aggregate number of shares of Class A common stock outstanding on the last day of the immediately preceding calendar year and (B) such smaller amount of shares as determined by the board of directors. No more than 6,300,000 shares of Class A common stock may be issued under the 2021 ESPP. Under the 2021 ESPP, eligible employees may purchase shares of the Company’s common stock through payroll deductions of up to 15% of eligible compensation during an offering period. Generally, each offering period will be for 6 months as determined by the Company’s board of directors. In no event may an employee purchase more than 100,000 shares per offering period based on the closing price on the first trading date of an offering period or the last trading date of an offering period, or more than \$25,000 worth of stock during any calendar year. The purchase price for shares to be purchased under the 2021 ESPP is 85% of the lesser of the market price of the Company’s common stock on the first trading date of an offering period or on any purchase date during an offering period (March 14 or September 14). During the nine months ended September 30, 2024, there were 287,217 shares of

Class A common stock purchased under the 2021 ESPP. The Company recognized less than \$0.1 million of expense related to the 2021 ESPP for each of the three and nine months ended September 30, 2024 and 2023. As of September 30, 2024, 956,940 shares were available for future issuance under the 2021 ESPP. The Company estimates the fair value of shares issued to employees under the 2021 ESPP using the Black-Scholes option-pricing model. The following weighted average assumptions were used in the calculation of fair value of shares under the 2021 ESPP at the grant date for both the nine months ended September 30, 2024 and 2023: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Risk-free interest rate 4.6% 5.5% 5.0% 5.3% Expected term (in years) 0.50 50.50 50.50 Expected volatility 42.6% 47.7% 46.0% 47.8% Expected dividend yield 0.0% 0.0% 0.0% 0.0% 2023 Inducement Plan In May 2023, the board of directors adopted the 2023 Inducement Plan (the "Inducement Plan") pursuant to which the Company reserved 330,000 shares of Class A common stock to be used exclusively for grants of equity-based awards to individuals who were not previously employees or directors of the Company as an inducement material to the individual's entry into employment with the Company within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. The Inducement Plan provides for the grant of equity-based awards in the form of nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, and dividend equivalent rights. The Inducement Plan was adopted by the board of directors without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. In May 2023, pursuant to the Inducement Plan, the Company granted inducement awards to the Company's Senior Vice President, Sales & Marketing, in the form of an option to purchase 220,000 shares of the Company's Class A common stock, with an exercise price per share of \$0.83, and 110,000 restricted stock units. The option and restricted stock unit awards were granted as inducements material to the commencement of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). In February 2024, the Company amended its Inducement Plan to reserve an additional 225,000 shares of its Class A common stock. The amendment was adopted by the compensation committee of the board of directors, without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. In March 2024, pursuant to the Inducement Plan as amended, the Company granted inducement awards to the Company's Vice President, Legal, in the form of an option to purchase 150,000 shares of the Company's Class A common stock, with an exercise price per share of \$0.99, and 75,000 restricted stock units. The option and restricted stock unit awards were granted as inducements material to the commencement of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). As of September 30, 2024, no shares were available for future issuance under the Inducement Plan. Stock-based compensation Stock-based compensation expense was classified in the condensed consolidated statements of operations as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Cost of revenues \$142A \$159A \$437A \$502A Research and development \$123A \$135A \$395A \$398A Sales and marketing \$98A \$119A \$325A \$385A General and administrative \$566A \$838A \$2,028A \$2,443A Total stock-based compensation expense \$929A \$1,251A \$3,185A \$3,728A As of September 30, 2024, total unrecognized compensation expense related to unvested stock options held by employees and directors was \$2.3 million, which is expected to be recognized over a weighted average period of 1.5 years. Additionally, unrecognized compensation expense related to unvested restricted stock units held by employees and directors was \$1.9 million, which is expected to be recognized over a weighted average period of 1.8 years. 11. Income taxes During both the three and nine months ended September 30, 2024 and 2023, the pretax losses incurred by the Company, as well as the research and development tax credits generated, received no corresponding tax benefit because the Company concluded that it is more likely than not that the Company will be unable to realize the value of any resulting deferred tax assets. The Company will continue to assess its position in future periods to determine if it is appropriate to reduce a portion of its valuation allowance. The Company's tax provision and the resulting effective tax rate for interim periods is determined based upon its estimated annual effective tax rate, adjusted for the effect of discrete items arising in that quarter. The income tax provision was generated from operations in Germany and Switzerland. The impact of such discrete items could result in a higher or lower effective tax rate during a particular quarter, based upon the mix and timing of actual earnings or losses versus annual projections. In each quarter, the Company updates its estimate of the annual effective tax rate, and if the estimated annual tax rate changes, a cumulative adjustment is made in that quarter. The Company has evaluated the positive and negative evidence bearing upon its ability to realize its deferred tax assets, which primarily consist of net operating loss carryforwards. The Company has considered its history of cumulative net losses, estimated future taxable income and prudent and feasible tax planning strategies and has concluded that it is more likely than not that the Company will not realize the benefits of its deferred tax assets. As a result, as of both September 30, 2024 and December 31, 2023 the Company recorded a full valuation allowance against its net deferred tax assets. The Company files income tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by U.S. federal, state and international jurisdictions, where applicable. There are currently no pending tax examinations in the U.S., and the Company has not received notice of examination from any jurisdictions in the U.S. 25 Table of Contents 12. Net loss per share As of September 30, 2024, the Company had Class A common stock and Class B common stock. Both share classes have the same rights to the Company's earnings and neither of the classes have any prior or senior rights to dividends to the other share class. Basic and diluted net loss per share was calculated as follows (in thousands, except share and per share amounts): Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Numerator: Net loss \$(11,323) \$(13,392) \$(37,223) \$(41,295) Denominator: Weighted average Class A common shares outstanding basic and diluted 38,359,127 37,770,566 38,201,382 37,539,885 Weighted average Class B common shares outstanding basic and diluted 5,309,529 5,309,529 5,309,529 5,299,745 Total shares for EPS basic and diluted 43,668,654 43,080,095 43,510,912 42,839,630 Net loss per share attributable to Class A common stockholders basic and diluted \$(0.26) \$(0.31) \$(0.86) \$(0.96) Net loss per share attributable to Class B common stockholders basic and diluted \$(0.26) \$(0.31) \$(0.86) \$(0.96) The Company's potentially dilutive securities, which include stock options, restricted stock units, and common stock warrants, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect: September 30, 2024 2023 Options to purchase common stock 860,506 795,549 Unvested restricted common stock 2,107,248 1,782,401 Warrants to purchase common stock 286,084 286,324 Options to purchase common stock under ESPP 29,699 22,051 283,536 868,325 2 Table of Contents 13. Leases The Company determines if an arrangement is or contains a lease at inception, which is the date on which the terms of the contract are agreed to, and the agreement creates enforceable rights and obligations. Under ASC 842, a contract is or contains a lease when (i) explicitly or implicitly identified assets have been employed in the contract and (ii) the customer obtains substantially all of the economic benefits from the use of that underlying asset and directs how and for what purpose the asset is used during the term of the contract. The Company also considers whether its service arrangements include the right to control the use of an asset. The Company made an accounting policy election not to recognize right-of-use ("ROU") assets and lease liabilities for leases with a term of twelve months or less. For all other leases, the Company recognizes ROU assets and lease liabilities based on the present value of lease payments over the lease term at the commencement date of the lease. Lease payments may include fixed rent escalation clauses or payments that depend on an index (such as the consumer price index). Subsequent changes to an index and any other periodic market-rate adjustments to base rent are recorded in variable lease expense in the period incurred. The ROU assets also include any initial direct costs incurred and lease payments made at or before the commencement date and are reduced by any lease incentives. The Company has made an accounting policy election to account for lease and non-lease components in its contracts as single lease components for all asset classes. The non-lease components typically represent additional services transferred to the Company, such as common area maintenance for real estate, which are variable in nature and recorded in variable lease expense in the period incurred. The Company uses its incremental borrowing rate which is the rate of interest the Company would have to pay to borrow on a collateralized basis over a similar term and amount in a similar economic environment to determine the present value of lease payments as the Company's leases do not have a readily determinable implicit discount rate. Judgment is applied in assessing factors such as Company specific credit risk, lease term, nature, and quality of the underlying collateral, currency, and economic environment in determining the incremental borrowing rate to apply to each lease. The Company leases office and manufacturing space under operating lease agreements that have initial terms ranging from approximately 8 to 10 years. The Company leases furniture under a financing lease agreement that has an initial term of approximately 8 years. The furniture financing lease agreement is immaterial to the Company's condensed consolidated financial statements. Some leases include one or more options to renew, generally at the Company's sole discretion, with renewal terms that can extend the lease term by up to 5 years. In addition, certain leases contain termination options, where the rights to terminate are held by either the Company, the lessor, or both parties. Options to extend a lease are included in the lease term when it is reasonably certain that the Company will exercise the option. Options to terminate a lease are excluded from the lease term when it is reasonably certain that the Company will not exercise the option. The Company's leases generally do not contain any material restrictive covenants or residual value guarantees. Supplemental cash flow information related to leases is as follows (in thousands): Nine Months Ended September 30, 2024 2023 Cash paid for amounts included in measurement of lease liabilities: Operating cash outflows - payments on operating leases \$997A \$956A Operating cash outflows - payments on financing leases \$27A \$29A Financing cash outflows - payments on financing leases \$29A \$27A Right-of-use assets obtained in exchange for new lease obligations: Investing non-cash activities - establishment of right of use operating assets \$151A \$151A 2 Table of Contents Supplemental balance sheet information related to the Company's operating and financing leases is as follows (in thousands): September 30, 2024 December 31, 2023 Operating Leases: Operating lease assets \$5,245A \$5,972A Operating lease liabilities, short-term \$1,148A \$1,090A Operating lease liabilities, long-term \$5,083A \$5,952A Total operating lease liabilities \$6,231A \$7,042A Financing Leases: Office furniture and fixtures \$386A \$386A Accumulated depreciation (211) (118) Net property, plant and equipment \$175A \$268A Lease liabilities, short-term \$46A \$42A Lease liabilities, long-term \$177A \$262A Total financing lease liabilities \$223A \$304A Weighted-average remaining lease term - operating leases (in years): 4.795 5.4 Weighted-average remaining lease term - financing leases (in years): 4.755 5.0 Weighted-average discount rate - operating leases: 3.8% 3.8% Weighted-average discount rate - financing leases: 12.0% 12.0% The components of lease expense were as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Operating lease cost \$305A \$314A \$914A \$899A Financing lease cost - amortization of right-of-use asset \$11A \$12A \$36A \$37A Financing lease cost - interest on lease liability \$10A \$9A \$27A \$29A Variable lease cost \$234A \$172A \$675A \$522A Total lease cost \$560A \$507A \$1,652A \$1,487A Operating lease cost is recognized on a straight-line basis over the lease term. Total rent expense, including the Company's share of the lessor's operating expenses, was \$0.5 million for each of the three months ended September 30, 2024 and 2023, and was \$1.6 million and \$1.4 million for the nine months ended September 30, 2024 and 2023, respectively. Financing lease cost includes asset amortization on a straight-line basis over the lease term and interest accretion calculated using the effective interest method. Total financing lease asset depreciation and interest expense was less than \$0.1 million for each of the three and nine months ended September 30, 2024 and 2023. 28 Table of Contents Maturities of the Company's operating lease liabilities as of September 30, 2024 were as follows (in thousands): Operating Lease Maturities 2024 (excluding the nine months ended September 30) \$337A 2025 1,368A 2026 1,401A 2027 1,435A 2028 1,469A Thereafter \$804A Total lease payments \$6,814A Less imputed interest (583) Total present value of lease liabilities \$6,231A Maturities of the Company's financing lease liability as of September 30, 2024 were as follows (in thousands): Financing Lease Maturities 2024 (excluding the nine months ended September 30) \$18A 2025 75A 2026 75A 2027 75A 2028 75A Thereafter \$38A Total lease payments \$356A Less imputed interest (133) Total present value of lease liabilities \$223A 14. Commitments and contingencies Indemnification agreements In the ordinary course of business, the Company may provide indemnification of varying scope and terms to customers, vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and certain of its executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not currently aware of any indemnification claims and has not accrued any liabilities related to such obligations in its condensed consolidated financial statements as of September 30, 2024 and December 31, 2023. Legal proceedings The Company is not a party to any material litigation and does not have contingency reserves established for any litigation liabilities. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to legal proceedings. 29 Table of Contents 15. Benefit plans The Company maintains a defined contribution savings plan under Section 401(k) of the Code. This plan covers all U.S. employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. Matching contributions to the plan may be made at the discretion of the Company's board of directors. The Company made contributions of \$0.2 million to the plan during each of the three months ended September 30, 2024 and 2023, and made contributions of \$0.7 million and \$0.6 million to the plan during the nine months ended September 30, 2024 and 2023, respectively. 30 Table of Contents Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations The following discussion and analysis of our financial condition and results of operations should be read together with our consolidated condensed financial statements and the related notes appearing elsewhere in this Quarterly Report on Form 10-Q and our audited Consolidated Financial Statements and related notes thereto for the year ended December 31, 2023, included in the Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on March 1, 2024 (the "2023 Form 10-K"). Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the "Risk Factors" section of this Form 10-Q, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. Overview We are an innovative life sciences technology company that enables the safe and efficient manufacture of pharmaceutical products through our rapid automated microbial quality control ("MQC") detection platform. We develop, manufacture, market and sell the Growth Direct system and related proprietary consumables, and value-added services to enable rapid MQC testing in the manufacture of biologics, cell and gene therapies, vaccines, sterile injectables, and other healthcare products. Our system delivers the power of industrial automation to bioprocessing and pharmaceutical manufacturing firms by modernizing and digitizing their MQC operations. Our Growth Direct platform, developed with over 15 years of active feedback from our customers, was purpose-built to meet the growing demands posed by the increasing scale, complexity, and regulatory scrutiny confronting global pharmaceutical manufacturing. Our Growth Direct platform comprises the Growth Direct system, optional laboratory information management system ("LIMS") connection software (which the majority of our customers purchase) and other software, proprietary consumables, and comprehensive field service, validation services and post-warranty service contracts. Once embedded and validated in our customers' facilities, our Growth Direct platform provides for recurring revenues through ongoing sales of consumables and service contracts. Our technology fully automates and digitizes the process of pharmaceutical MQC and is designed to enable our customers to perform this critical testing process more efficiently, accurately, and securely. Our Growth Direct platform accelerates time to results by 50% or more compared to the traditional method, and reduces MQC testing to a simple two-step workflow, eliminating up to 85% of the manual steps of traditional MQC, generating significant time, operational, and cost savings for our customers. We seek to establish the Growth Direct as the trusted global standard in automated MQC by delivering the speed, accuracy, security, and data integrity compliance that our customers depend on to ensure patient safety and consistent drug supply. Since inception, we have devoted a majority of our resources to designing, developing, and building our proprietary Growth Direct platform and associated products, launching our Growth Direct platform commercially, advancing our technological capabilities, expanding our sales and marketing infrastructure to grow our sales, building a global customer support team to deliver our value-added services, investing in robust manufacturing and supply chain operations to serve our customers globally, and providing general and administrative support for these operations. To date, we have funded our operations primarily with proceeds from sales of redeemable convertible preferred stock, borrowings under loan agreements, revenue from products, services and contracts, and proceeds from our IPO, as well as our cost-reimbursement/cost sharing contracts with the U.S. Department of Health and Human Services Biomedical Advanced Research & Development Authority ("BARDA"). In July 2024, we completed an enterprise-wide review of opportunities to realize operational efficiencies. Based on the results of this review, we are implementing certain cost actions including a reduction in our workforce, the closure of open and planned positions and reductions in other non-headcount-related expenses across the business (the "Operational Efficiency Program"). These actions are expected to result in approximately \$7A million in

annual cash savings and enable us to achieve positive cash flow by the end of 2027 without additional financing. We plan to continue to invest in key initiatives that are expected to drive future revenue growth and gross margin improvement, including product development and cost reduction programs. We recorded a charge of \$0.6Å million in the third quarter of 2024 related to the Operational Efficiency Program. Since our inception, we have incurred net losses in each year. We generated revenue of \$7.6 million and \$6.1 million for the three months ended SeptemberÅ 30, 2024 and 2023, respectively, and incurred net losses of \$11.3 million and 31Table of Contents\$13.4 million for those same periods, respectively. As of SeptemberÅ 30, 2024, we had an accumulated deficit of \$465.6 million. We expect to continue to incur net losses in connection with our ongoing activities, including:ÅĖgrowing sales of our products in both the United States and international markets by further expanding our sales and marketing capabilities;ÅĖescalating our manufacturing and supply chain processes and infrastructure to meet growing demand for our products;ÅĖinvesting in research and development to develop new products and further enhance our existing products;ÅĖprotecting and building on our intellectual property portfolio; andÅĖattracting, hiring and retaining qualified personnel. While we implemented our Operational Efficiency Program with the goal of achieving positive cash flow without additional financing, there can be no assurance that we will attain this goal. Our Operational Efficiency Program and intention to attain positive cash flow are based on our expectations and underlying assumptions of business performance that are generally consistent with our historical performance, including with respect to revenue growth and gross margin improvement, which may not be replicated in future periods. Our goal also depends on our ability to realize additional cost savings that we believe are reasonably achievable, but are not guaranteed. While we seek to achieve and sustain positive cash flow, if we are unable to generate revenue, improve our gross margins, and/or control our operating costs sufficiently, we may need to raise additional funding, which we would expect to secure through a combination of equity offerings and debt financings. If we are unable to raise capital or enter into such agreements as, and when, needed, we may have to significantly delay, scale back or discontinue our expansion plans including the further development and commercialization efforts of one or more of our products, or may be forced to reduce or terminate our operations. We believe that our cash and cash equivalents and investments as of SeptemberÅ 30, 2024 enable us to fund our operating expenses and capital expenditure requirements for at least twelve months following the issuance date of the unaudited interim condensed consolidated financial statements contained in this Quarterly Report on Form 10-Q for the quarter ended SeptemberÅ 30, 2024. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. See ÅĖoÅĖLiquidity and Capital Resources.ÅĖEffects of inflation and interest ratesThe current inflationary and interest rate environment could have a negative impact on our results of operations, cash flows and overall financial condition. We may experience inflationary pressures on significant cost categories including labor, materials and freight. We continue to monitor the impact of inflation on these costs in order to minimize its effects through productivity improvements and cost reductions. There can be no assurance, however, that our operating results will not be affected by inflation in the future. In addition, inflation and increased interest rates may decrease demand for our Growth Direct systems, as our customers may face economic uncertainty as a result. A decrease in demand for our products or increases in our costs, as well as any steps we may take to mitigate changes, could impact our overall growth. However, the related financial impact cannot be reasonably estimated at this time. Factors affecting our performanceWe believe that our financial performance has been, and in the foreseeable future will continue to be, primarily driven by multiple factors as described below, each of which presents growth opportunities for our business. Our ability to successfully address these challenges is subject to various risks and uncertainties, including those described under the section titled ÅĖRisk FactorsÅĖ to this Quarterly Report on Form 10-Q. New customer adoption of the Growth Direct platformOur financial performance has largely been driven by, and a key factor to our future success will be, our ability to increase the global adoption of our Growth Direct platform in our key markets. We plan to drive global customer adoption through both direct and indirect sales and marketing organizations in North America, Europe, and the Asia-Pacific region. We are focused on enhancing customer engagement and experience and improving the efficiency and effectiveness of our sales team. We are making targeted investments in these organizations and expect to continue to do so. 32Table of ContentsIn the future. Examples of these investments include new tools and training for the sales organization, targeted marketing initiatives, expanding lead generation capabilities and hosting Growth Direct demonstrations and other customer-focused events. Expansion within our existing customer baseThere is an opportunity to broaden adoption and increase utilization of our Growth Direct platform throughout our existing customers' organizations as these customers purchase more systems. These additional systems will allow our existing customers to convert more of their test volume at existing locations, to support multiple locations, to meet redundancy requirements, or to increase capacity. As of SeptemberÅ 30, 2024, approximately 42% of our customers have purchased Growth Direct systems for multiple sites, and approximately 58% of our customers have purchased multiple Growth Direct systems. Increased utilization amongst existing customers can also occur as customers advance through the Growth Direct platform adoption cycle, from early validation of initial applications to validation and conversion of multiple applications on the Growth Direct platform, or as the result of new product approvals or increases in their manufacturing volumes for existing products. Innovating and launching new products on the Growth Direct platformWe believe the depth, scalability and robust capabilities of our Growth Direct platform allow us to address key opportunities and challenges facing MQC testing in the pharmaceutical industry. As an innovative leader in automated MQC testing, we intend to invest in further enhancements in our existing Growth Direct platform as well as end-to-end workflow solutions in our core market. We plan to further invest in research and development to support the expansion of our Growth Direct platform through development and launch of new applications to capture greater share of customer testing volume, new product formats to broaden our ability to serve different market segments and launch of new products and technologies to address adjacent segments of the overall MQC workflow. We plan to continue to hire employees with the necessary scientific and technical backgrounds to enhance our existing products and help us introduce new products to market. We expect to incur additional research and development expenses as a result. By expanding and continuously enhancing the Growth Direct platform, we believe we can drive incremental revenue from existing clients as well as broaden the appeal of our solutions to potential new customers. We made the Growth Direct Rapid Sterility application available for commercial sale and placed the first Rapid Sterility system at one of our existing customers in the second quarter of 2024. We plan to continue efforts to scale our manufacturing capabilities for the Rapid Sterility application through the end of 2024. Revenue mixOur revenue is derived from sales of our Growth Direct systems, our LIMS connection and other software, proprietary consumables, and services. Growth Direct system revenue involves a capital selling process and tends to be somewhat concentrated within a relatively small (but varied) group of customers each year, so it is subject to variability from quarter to quarter. Gross margin improvementThe majority of our customers are large global pharmaceutical manufacturers and contract development and manufacturing organizations, or CDMOs. In order to meet the expectations of our customers, we have made significant investments to build infrastructure and develop capabilities in areas such as procurement, manufacturing, distribution, quality and after-sales service. Given our current business scale, our revenues are not yet sufficient to fully cover these costs, impacting our current gross margin profile. In order to improve our gross margins, we are actively targeting numerous areas including: ÅĖReducing instrument and consumable product costs (materials and labor) through activities including strategic sourcing and product redesign; ÅĖIncreasing product manufacturing efficiency through activities including increased throughput on our automated consumables manufacturing line and manufacturing process optimization; andÅĖIncreasing productivity and efficiency in our service organization. 33Table of ContentsAt the same time, we also expect future revenues from both products and services to grow at rates significantly higher than the related costs to provide and support those products and services. As a result, we also expect increasing revenues from both products and services to contribute significantly to future gross margin expansion. We have recently experienced positive trends in our gross margins, improving from (27)% for the three months ended SeptemberÅ 30, 2023 to 8% for the three months ended SeptemberÅ 30, 2024, and from (33)% for the nine months ended SeptemberÅ 30, 2023 to (5)% for the nine months ended SeptemberÅ 30, 2024. While we expect gross margins to continue to trend positively, expansion in gross margins in future periods may not be linear and may be subject to variability from period to period. Key business metricsWe regularly review the following key business metrics to evaluate our business, measure our performance, identify trends affecting our business, formulate financial projections and make strategic decisions. We believe that the following metrics are representative of our current business; however, we anticipate these may change or be substituted for additional or different metrics as our business grows and evolves. Three Months Ended September 30, Change20242023Amount\$(dollars in thousands)Systems placed:Systems placed in period752Å 40.0Å %Cumulative systems placed1561352115.6Å %Systems validated:Systems validated in period440ÅĖÅ %Cumulative systems validated133122118.8Å %Product and service revenue ÅĖ totals7,604Å \$6,145Å 1,459Å 23.7Å %Product and service revenue ÅĖ recurring\$3,675Å \$3,410Å \$265Å 7.8Å %Nine Months Ended September 30, Change20242023Amount\$(dollars in thousands)Systems placed:Systems placed in period1510550.0Å %Cumulative systems placed1561352115.6Å %Systems validated:Systems validated in period129333.3Å %Cumulative systems validated133122118.8Å %Product and service revenue ÅĖ totals19,833Å \$16,182Å 3,651Å 22.6Å %Product and service revenue ÅĖ recurring\$11,262Å \$10,255Å \$1,007Å 9.8Å %Growth Direct system placementsWe consider a Growth Direct system to be ÅĖplacedÅĖ upon transfer of control of the system to the customer, at which point the revenue for that system is recognized. We regularly review the number of Growth Direct systems placed and cumulative Growth Direct system placements in each period as a leading indicator of our business performance. Our revenue has historically been driven by, and in the future will continue to be impacted by, the rate of Growth Direct system placements as a reflection of our success selling and delivering our products. We expect our Growth Direct system placements to continue to grow over time as we increase penetration in our existing markets and expand into new markets. The number of Growth Direct system placements and rate of growth varies from period-to-period due to factors including, but not limited to, Growth Direct system order volume and timing, and access to customer sites (including the timing of customer site construction activities). As a result, we expect to experience continued variability in our period-to-period number of Growth Direct system placements due to the aforementioned factors. 34Table of ContentsIn July 2024, we placed our 150th Growth Direct system with an existing global biopharma customer, which we believe represents a significant milestone demonstrating the strong continued interest in and adoption of our technology by customers. Validated systemsWe regularly review the number of Growth Direct systems validated and cumulative Growth Direct systems validated in each period as indicators of our business performance. Management focuses on validated Growth Direct systems as a leading indicator of likely future recurring revenue as well as a reflection of our success supporting our customers in validating placed systems. We expect our validated Growth Direct systems to continue to grow over time as we increase our base of cumulative systems placed and then install and validate those systems. After a Growth Direct system is placed with a customer and installed, we work with the customer to validate the system, which typically has taken anywhere from three to nine months. Once a validation has been completed, we generally expect our customers to transition from their legacy manual method to our automated method and begin regular utilization of consumables over a period of up to three months after the validation is completed. However, the timeline for such transition may be longer depending on the specific circumstances of each individual customer. In addition, in exceptional cases, we have reacquired Growth Direct systems from customers that were previously placed and, in some cases, previously validated. Our metrics showing cumulative systems placed and cumulative systems validated are not reduced to reflect these reacquired systems. The number of validated Growth Direct systems and rate of growth varies from period-to-period due to factors including, but not limited to, Growth Direct system placement volume and timing, whether customers have previously validated Growth Direct systems within their site or network, access to customer sites, customer site readiness, availability of required customer personnel and the time to install and validate each individual system. As a result, we expect to experience continued fluctuations in our period-to-period number of Growth Direct systems validated due to the aforementioned factors. Recurring revenueWe regularly assess trends relating to our recurring revenue, which is the revenue from consumables and service contracts, based on our product offerings, our customer base and our understanding of how our customers use our products. Recurring revenue was 48.3% and 55.5% of our total revenue for the three months ended SeptemberÅ 30, 2024 and 2023, respectively. Recurring revenue was 56.8% and 63.4% of our total revenue for the nine months ended SeptemberÅ 30, 2024 and 2023, respectively. Our recurring revenue as a percentage of the total product and service revenue will generally vary based upon the number of Growth Direct systems placed and the cumulative number of validated systems in the period, as well as other variables such as the volume of tests being conducted and the test application(s) being used on customers' Growth Direct systems. Components of results of operationsRevenueWe generate revenue from sales of our Growth Direct system (including our LIMS connection and other software), consumables, validation services, service contracts, and field service. We primarily sell our products and services through direct sales representatives. The arrangements are noncancellable and nonrefundable after ownership passes to the customer. Three Months Ended September 30, 2024Percentageof TotalRevenueThree Months EndedSeptember 30, 2023Percentageof TotalRevenue(in thousands)(in thousands)Product revenue\$5,255Å 69.1Å %\$4,200Å 68.3Å %Service revenue2,349Å 30.9Å %1,945Å 31.7Å %Total revenue\$7,604Å 100.0Å %\$6,145Å 100.0Å %35Table of ContentsProduct revenueWe derive product revenue primarily from the sale of our Growth Direct systems and related consumables as well as our LIMS connection software, which the majority of our customers purchase. As of SeptemberÅ 30, 2024, we had placed 156 Growth Direct systems with over 40 customers globally, including 70% of the top twenty pharmaceutical companies as measured by revenue, and the manufacturers of approximately 19% of globally approved cell and gene therapies, including manufacturers of 100% of approved gene-modified autologous CAR-T cell therapies. Growth Direct systemsGrowth Direct system revenue is a non-recurring product revenue stream that we recognize as revenue upon transfer of control of the system to the customer. The Growth Direct system is fully functional for use by the customer upon delivery. Although we do not require our customers to use our installation and validation services, our customers typically elect to purchase those services from us. As such, transfer of control occurs at shipment or delivery depending on contractual terms. We expect our Growth Direct system revenue to continue to grow over time as we increase system placements into our existing customers and markets and expand into new customers and markets. ConsumablesOur consumable revenue is a recurring product revenue stream comprised of two proprietary consumables to capture test samples for analysis on the Growth Direct system, an Environmental Monitoring consumable, and a Water/Bioburden consumable. Both proprietary consumables support the growth-based compendial method for MQC testing mandated by global regulators and provide results that are comparable to traditional consumables. Our consumables are designed with features that enable automation on the Growth Direct system, with bar coding for tracking and data integrity, and physical characteristics for robotic handling, to support vision detection and prevent counterfeiting. We expect consumable revenue to increase in future periods as our base of cumulative validated Growth Direct systems grows and those systems enter routine use and utilize our consumables on a recurring, ongoing basis. LIMS Connection SoftwareOur LIMS connection software is a non-recurring product revenue stream. Although optional, the majority of our customers elect to purchase this software, which allows Growth Direct systems to export result reports and securely link to a customer's two-way LIMS connection software to completely eliminate manual data entry and drive productivity. Service revenueWe derive service revenue from validation services, field service including installations, and service contracts sold to our customers. Other than revenue from service contracts, which is recurring service revenue, revenue from all other field services as well as validation services are non-recurring service revenue streams. We offer our customers validation services (including related documentation) that enable them to replace their existing manual testing method and utilize their Growth Direct systems in compliance with relevant MQC regulations. Validation services are recognized as revenue over time as these services are provided to the customer. We offer our customers service contracts that can be purchased after the expiration of the one-year assurance warranty that all of our customers receive with the purchase of a Growth Direct system. Under these contracts, they are entitled to receive phone support, emergency on-site maintenance support and preventative maintenance visits. These service contracts generally have fixed fees and a term of one year. We recognize revenue from the sale of service contracts over time as these services are provided over the respective contract term. We also offer our customers field service which primarily consists of services provided by our field service engineers to install Growth Direct systems at customer sites, perform one-time paid field service, and provide preventative maintenance service during the one-year assurance warranty period. We recognize revenue from installation services, one-time paid field service, and preventative maintenance service during the assurance warranty period over time as these services are provided to the customer. 36Table of ContentsWe expect service revenue to increase in future periods as the number of placed and validated Growth Direct systems grows and we are able to generate increasing non-recurring revenue from validation services and field service for newly placed systems and increasing recurring revenue from service contracts for validated systems. Costs and operating expensesCosts of revenueCost of product revenue primarily consists of costs for raw material parts and associated freight, shipping and handling costs, salaries and other personnel costs including stock-based compensation expense, contract manufacturer costs, scrap, warranty cost, inventory reserves, royalties, depreciation and amortization expense, allocated information technology and facility-related costs, overhead and other costs related to those sales recognized as product revenue in the period. Cost of service revenue primarily consists of salaries and other personnel costs including stock-based compensation expense, travel costs, materials consumed when performing installations, validations and other services, allocated information technology and facility-related costs, costs associated with training, and other expenses related to service revenue recognized in the period. As part of our Operational Efficiency

Program, we have implemented actions to reduce employee-related expenses and certain other non-employee related costs. For future periods, we expect our costs of revenue to increase or decrease commensurate with product and service volumes. Such costs may be further impacted by our ongoing efforts to reduce product costs and increase manufacturing productivity and efficiencies as well as service productivity. Research and development Research and development expenses consist primarily of costs incurred for our research activities, product development, hardware and software engineering and consultant services and other costs associated with our technology Growth Direct platform and products, which include: employee-related expenses, including costs for salaries, bonuses and other personnel costs including stock-based compensation expense, for employees engaged in research and development functions; the cost of developing, maintaining and improving new and existing product designs; the cost of hardware and software engineering; research materials and supplies; external costs of outside consultants engaged to conduct research and development associated with our technology and products; and allocated information technology and facility-related costs, which include headcount-related costs for those functions as well as expenses for information technology systems and services, software, rent, facilities maintenance, and insurance as well as related depreciation and amortization. Our research and development costs are expensed as incurred. As part of our Operational Efficiency Program, we have implemented actions to reduce research and development employee-related expenses associated with reduced headcount and certain other non-employee-related costs. We believe that our continued investment in research and development is essential to our long-term competitive position. For future periods, we expect our research and development expenses to increase or decrease commensurate with the size, scope and complexity of our research and development activities. Sales and marketing Sales and marketing expenses consist primarily of salaries, commissions, benefits and other personnel costs including stock-based compensation expense as well as costs relating to travel, consulting, public relations and allocated information technology and facility-related costs for our employees engaged in sales and marketing activities. As part of the Operational Efficiency Program, we have implemented actions to reduce sales and marketing employee-related costs. Table of Contents expenses associated with reduced headcount and certain other non-employee-related costs. For future periods, we expect sales and marketing expenses to increase or decrease as and when we make investments into our sales and marketing organization, including in the number of sales and marketing personnel and our continued efforts to expand our geographic reach and capabilities, broaden our customer base and introduce new products. General and administrative General and administrative expenses consist primarily of salaries, bonuses and other personnel costs including stock-based compensation expense for our executive, finance, legal, human resources and general management employees, as well as director and officer insurance costs and professional fees for legal, patent, accounting, audit, investor relations, recruiting, consulting, regulatory, compliance, board of directors' fees and other services. General and administrative expenses also include direct and allocated information technology and facility-related costs. As part of our Operational Efficiency Program, we have implemented actions to reduce general and administrative employee-related expenses associated with reduced headcount and certain other non-employee-related costs. For future periods, we expect these expenses to increase or decrease, as applicable, commensurate with the size, scope and complexity of our general and administrative functions. Other income (expense) Interest income, net Interest income, net is comprised primarily of interest income from investments. Other expense, net Other expense, net, primarily consists of other miscellaneous income and expense unrelated to our core operations. Income tax expense We generated significant taxable losses during each of the three and nine months ended September 30, 2024 and 2023 and, therefore, have not recorded any U.S. federal or state income tax expense during those periods. However, we did record an immaterial amount of foreign income tax expense during each of those periods. Table of Contents Results of operations Comparison of the three months ended September 30, 2024 and 2023 The following table summarizes our results of operations for the three months ended September 30, 2024 and 2023: Three Months Ended September 30, Change 2024 2023 Amount % (in thousands) Revenue: Product revenue \$5,255.4 \$4,200.4 \$1,055.0 25.1 % Service revenue \$2,349.4 \$1,945.4 \$404.0 20.8 % Total revenue \$7,604.8 \$6,145.8 \$1,459.0 23.7 % Costs and operating expenses: Cost of product revenue \$5,314.4 \$5,691.4 \$(377.0) (6.6) % Cost of service revenue \$1,668.4 \$2,085.4 \$(417.0) (20.0) % Research and development \$3,609.4 \$3,116.4 \$493.0 15.8 % Sales and marketing \$3,764.4 \$3,498.4 \$266.0 7.6 % General and administrative \$5,676.4 \$6,204.4 \$(528.0) (8.5) % Total costs and operating expenses \$19,643.4 \$20,594.4 \$(951.0) (4.6) % Loss from operations \$(12,039.0) \$(14,449.2) \$2,410.2 16.7 % Other income (expense): Interest income, net \$768.4 \$1,093.4 \$(325.0) (29.7) % Other expense, net \$(39.0) \$(26.0) \$13.0 50.0 % Total other income (expense), net \$729.4 \$1,067.4 \$(338.0) (31.7) % Loss before income taxes \$(11,310.0) \$(13,382.2) \$2,072.2 15.5 % Income tax expense \$13.4 \$10.4 \$3.0 22.1 % Net loss \$(11,323.4) \$(13,392.2) \$2,068.8 15.4 % Revenue Product revenue increased by \$1.1 million, or 25.1%, with the increase largely attributable to higher system placements, improvements in average selling prices during the period, as well as higher system-related revenue, primarily from LIMS connection software and other software sales. Service revenue increased by \$0.4 million, or 20.8%. The increase in service revenue was primarily due to increases in revenue related to validations and installations as well as higher service contract revenue due to an increase in the cumulative number of Growth Direct systems validated and under such contracts. Costs and operating expenses Costs of revenue Cost of product revenue decreased by \$0.4 million, or 6.6%. The decrease was driven by lower material, labor and overhead costs as a result of the impact of cost reduction activities, improvements in production efficiencies and increased production volumes for both systems and consumables, partially offset by the higher volume of Growth Direct systems sold. Cost of service revenue decreased by \$0.4 million, or 20.0%. This decrease was primarily attributable to lower service headcount and headcount-related costs. Table of Contents Research and development Three Months Ended September 30, Change 2024 2023 Amount % (dollars in thousands) Research and development \$3,609.4 \$3,116.4 \$493.0 15.8 % Percentage of total revenue 47.5 % 50.7 % Research and development expenses increased by \$0.5 million, or 15.8%. This increase was primarily due to higher spending on new product development activities, including our rapid sterility application, as well as increased headcount-related costs and facilities costs related to our innovation center and lab in our existing Lexington, Massachusetts facility. Sales and marketing Three Months Ended September 30, Change 2024 2023 Amount % (dollars in thousands) Sales and marketing \$3,764.4 \$3,498.4 \$266.0 7.6 % Percentage of total revenue 44.4 % 56.9 % Sales and marketing expenses remained relatively consistent, decreasing \$0.1 million, or 3.5%. General and administrative Three Months Ended September 30, Change 2024 2023 Amount % (dollars in thousands) General and administrative \$5,676.4 \$6,204.4 \$(528.0) (8.5) % Percentage of total revenue 74.6 % 101.0 % General and administrative expenses decreased by \$0.5 million, or 8.5%. The decrease was largely attributable to lower headcount-related costs and one-time bonus expense related to the 2022 retention bonus program which ended in the third quarter of 2023. Other income (expense) Interest income Interest income, which is related to interest earned on our investments, decreased \$0.3 million primarily as a result of lower investment balances during the three months ended September 30, 2024. Other expense Other expense, which is comprised of miscellaneous expenses unrelated to our core business, was flat for each of the three months ended September 30, 2024 and 2023. Income tax expense Income tax expense was less than \$0.1 million for each of the three months ended September 30, 2024 and 2023. The expense in each period was attributable to an income tax provision related to our German subsidiary. Table of Contents Comparison of the nine months ended September 30, 2024 and 2023 The following table summarizes our results of operations for the nine months ended September 30, 2024 and 2023: Nine Months Ended September 30, Change 2024 2023 Amount % (dollars in thousands) Revenue: Product revenue \$13,505.4 \$10,693.4 \$2,812.0 26.3 % Service revenue \$6,328.4 \$5,489.4 \$839.0 15.3 % Total revenue \$19,833.8 \$16,182.8 \$3,651.0 22.6 % Costs and operating expenses: Cost of product revenue \$15,404.4 \$15,361.4 \$43.0 0.3 % Cost of service revenue \$5,519.4 \$6,134.4 \$(615.0) (10.0) % Research and development \$11,195.4 \$9,502.4 \$1,693.0 17.8 % Sales and marketing \$10,284.4 \$10,161.2 \$123.2 1.2 % General and administrative \$17,121.4 \$19,399.4 \$(2,278.0) (11.7) % Total costs and operating expenses \$59,523.6 \$60,557.4 \$(1,034.0) (1.7) % Loss from operations \$(39,690.0) \$(44,375.4) \$4,685.4 10.6 % Other income (expense): Interest income, net \$2,589.4 \$3,169.4 \$(580.0) (18.3) % Other expense, net \$(91.0) \$(66.0) \$25.0 37.9 % Total other income (expense), net \$2,498.4 \$3,103.4 \$(605.0) (19.5) % Loss before income taxes \$(37,192.0) \$(41,272.4) \$4,080.4 9.9 % Income tax expense \$31.4 \$23.4 \$8.0 24.8 % Net loss \$(37,223.4) \$(41,295.4) \$4,072.0 9.9 % Revenue Product revenue increased by \$2.8 million, or 26.3%. The increase was driven primarily by a higher volume of system placements as well as higher average selling prices in consumables. Higher system-related revenue, particularly from our LIMS connection software and other software sales, also contributed to the increase. Service revenue increased by \$0.8 million, or 15.3%. The increase in service revenue was primarily driven by increases in revenue related to validations and installations as well as higher service contract revenue as a result of an increase in the cumulative number of Growth Direct systems validated and under such contracts. Costs and operating expenses Costs of revenue Cost of product revenue remained relatively consistent, increasing 0.3%. Increased costs due to higher volumes of systems and consumables sold was almost entirely offset by lower material, labor and overhead costs. The cost reductions were primarily the result of material cost reduction activities, improvements in production efficiencies and increased production volumes for both consumables and systems. Cost of service revenue decreased by \$0.6 million, or 10.0%. This decrease was primarily attributable to lower headcount and headcount-related costs and one-time bonus expense related to the 2022 retention bonus program which ended in the third quarter of 2023. Table of Contents Research and development Nine Months Ended September 30, Change 2024 2023 Amount % (dollars in thousands) Research and development \$11,195.4 \$9,502.4 \$1,693.0 17.8 % Percentage of total revenue 56.4 % 58.7 % Research and development expenses increased by \$1.7 million, or 17.8%. This increase was primarily due to higher spending on new product development activities, including our rapid sterility application, as well as increased headcount-related costs, engineering costs, and facilities costs related to our innovation center and lab in our Lexington, Massachusetts facility. Sales and marketing Nine Months Ended September 30, Change 2024 2023 Amount % (dollars in thousands) Sales and marketing \$10,284.4 \$10,161.2 \$123.2 1.2 % Percentage of total revenue 51.9 % 62.8 % Sales and marketing expenses increased by \$0.1 million, or 1.2%. This increase was primarily due to higher headcount-related costs. General and administrative Nine Months Ended September 30, Change 2024 2023 Amount % (dollars in thousands) General and administrative \$17,121.4 \$19,399.4 \$(2,278.0) (11.7) % Percentage of total revenue 86.3 % 119.9 % General and administrative expenses decreased by \$2.3 million, or 11.7%. This decrease was primarily attributable to lower headcount and headcount-related costs as well as lower bonus expense related to the 2022 retention bonus program which ended in the third quarter of 2023. Lower public company operating costs, including third-party legal fees and business insurance premiums, also contributed to the decrease. Other income (expense) Interest income Interest income decreased \$0.6 million, or 18.3% due to lower investment balances during the nine months ended September 30, 2024. Other expense Other expense, which is comprised of miscellaneous expenses unrelated to our core business, were flat for each of the nine months ended September 30, 2024 and 2023. Income tax expense (benefit) Income tax expense was less than \$0.1 million for each of the nine months ended September 30, 2024 and 2023. The expense in each period was attributable to an income tax provision related to our German subsidiary. Table of Contents Liquidity and capital resources Since our inception, we have incurred operating losses. To date, we have funded our operations primarily through proceeds from sales of redeemable convertible preferred stock, borrowings under loan agreements, revenue from sales of our products and services, and the proceeds from our IPO. In July 2024, we completed an enterprise-wide review of opportunities to realize operational efficiencies. Based on the results of this review, we implemented our Operational Efficiency Program for certain cost actions including a reduction in our workforce, the closure of open and planned positions, and reductions in other non-headcount-related expenses across the business. These actions are expected to result in approximately \$7 million in annual cash savings and enable us to achieve positive cash flow by the end of 2027 without additional financing. We plan to continue to invest in key initiatives that are expected to drive future revenue growth and gross margin improvement, including product development and cost reduction programs. We recorded a charge of \$0.6 million in the third quarter of 2024 related to the Operational Efficiency Program. We believe that our cash, cash equivalents and investments will enable us to fund our operating expenses and capital expenditure requirements for at least twelve months following the date the condensed consolidated financial statements contained in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 were issued. As of September 30, 2024, we had the following cash and investment-related assets on our condensed consolidated balance sheet (in thousands): September 30, 2024 Cash and cash equivalents \$22,044.4 Short-term investments \$38,788.4 Restricted cash \$284.4 Total \$61,116.4 Contractual obligations and commitments In October 2013, we entered into an operating lease for office and manufacturing space in Lowell, Massachusetts. In March 2022, we amended the lease to increase the amount of facility space subject to the lease and extend the expiration of the lease from July 2026 to July 2029. The terms of the amendment include options for a one-time, five-year extension of the lease and early termination of the lease in July 2026 (subject to an early termination fee). Monthly rent payments are fixed and future minimum lease payments under the lease (as amended) are \$3.2 million as of September 30, 2024, including \$0.6 million in short-term obligations. In June 2021, we entered into a sublease agreement for our Lexington, Massachusetts headquarters, which expires in June 2029. The sublease includes an option to terminate the sublease in July 2026, subject to an early termination fee. Monthly rent payments are fixed and future minimum lease payments over the term of the sublease are \$3.6 million as of September 30, 2024, including \$0.7 million in short-term obligations. Concurrent with entering into the sublease agreement, we executed an option agreement with the property owner which provides us the option to enter into a new direct lease for our Lexington, Massachusetts facility for an additional five years following expiration of the sublease. Table of Contents Cash flows The following table summarizes our sources and uses of cash for each of the periods presented (in thousands): Nine Months Ended September 30, 2024 2023 Net cash used in operating activities \$(34,244.3) \$(35,584.0) Net cash provided by investing activities \$31,794.4 \$32,145.4 Net cash provided by financing activities \$209.4 \$161.4 Net decrease in cash and cash equivalents and restricted cash \$(2,241.5) \$(3,278.0) Operating activities During the nine months ended September 30, 2024, net cash used in operating activities was \$34.2 million, a decrease of \$1.3 million compared to the prior-year period. The lower use of net cash was primarily a result of the timing of payments to vendors and increased customer cash receipts. This decrease was offset by increased inventory purchases, and higher usage of cash to settle accrued expenses and other current liabilities mainly as a result of higher annual bonus payments made during the nine months ended September 30, 2024. During the nine months ended September 30, 2023, these payments were limited due to annual bonuses being temporarily replaced by a retention bonus program for non-executive employees in that period. The temporary retention bonus program was established in connection with our August 2022 restructuring action and concluded in the third quarter of 2023. Investing activities Net cash provided by investing activities was \$32.1 million during each of the nine months ended September 30, 2024 and 2023. Lower investment maturities and sales were offset by lower investment purchases and a reduction in cash used to purchase property and equipment in the current-year period. Financing activities During the nine months ended September 30, 2024, net cash provided by financing activities was flat compared to the nine months ended September 30, 2023, at \$0.2 million. Nasdaq notice of failure to satisfy a continued listing rule On February 2, 2024, we received a notification letter from the Nasdaq Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") notifying us that the bid price for our Class A common stock, par value \$0.01 per share, had closed below \$1.00 per share for the preceding thirty consecutive business days and that, as a result, we were not in compliance with the minimum bid price requirement for continued inclusion on the Nasdaq Global Select Market under Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Requirement"). To regain compliance, the closing bid price of our common stock must be at least \$1.00 or higher for a minimum of ten consecutive business days, though Nasdaq has the discretion to extend the ten business day period to up to 20 consecutive business days. The initial period during which we were required to regain compliance with the Bid Price Requirement expired on July 31, 2024. Because we did not regain compliance with the requirement during the initial period, we transferred the listing of our Class A common stock to the Nasdaq Capital Market, in order to secure an additional 180 calendar day compliance period ending on January 27, 2025. As a condition of securing such additional compliance period, we informed Nasdaq that we intend to regain compliance with the Bid Price Requirement during the second compliance period, which may include the implementation of a reverse stock split if necessary. We intend to monitor the closing bid price of our Class A common stock and take such reasonable measures to regain compliance with the Bid Price Requirement. However, there can be no assurance that we will be able to regain compliance with the Bid Price Requirement even during the second compliance period, nor can there be any assurance that we will receive the necessary approvals from our stockholders to effect a reverse stock split. If we do not cure the deficiency during the additional compliance period and regain compliance with the Bid Price Requirement, Nasdaq will provide written notice that our common stock will be subject to delisting. In the event of such notification, we may appeal Nasdaq's delisting determination. However, there can be no assurance that, if 44 Table of Contents we receive a delisting notice and appeal the delisting determination by Nasdaq, such appeal would be successful. As a result, there can be no assurance that we will be able to continue the listing of our Class A common stock on Nasdaq. Seasonality Our revenues vary from quarter to quarter as a result of factors such as our customers' budgetary cycles and extended summer vacation periods that can impact our ability to deliver products and provide onsite services to our customers during those periods. We expect this variability to continue for the foreseeable future, which may cause fluctuations in our operating results and financial metrics. Critical accounting estimates Our condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in our consolidated financial statements. Our estimates are based on our historical experience,

known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions. Our significant accounting policies are described in more detail in Note 2 â€” Summary of Significant Accounting Policies to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q. There have been no significant changes in our critical accounting policies and estimates as compared to the critical accounting policies and estimates disclosed in the section titled â€œManagement’s Discussion and Analysis of Financial Condition and Results of Operations” included in the 2023 Form 10-K, other than as disclosed in Note 2 â€” Summary of Significant Accounting Policies â€” to our condensed consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q. Recently issued accounting pronouncements A description of recently issued accounting pronouncements that may potentially impact our financial position, results of operations or cash flows is disclosed in Note 2 â€” Summary of Significant Accounting Policies â€” to our condensed consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q. Emerging growth company status The Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), permits an â€œemerging growth company” such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, we will not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies, and our financial statements may not be comparable to other public companies that comply with new or revised accounting pronouncements as of public company effective dates. We may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for private companies. We will cease to be an emerging growth company on the date that is the earliest of (i) the last day of the fiscal year in which we have total annual gross revenues of \$1.235 billion or more, (ii) the last day of our fiscal year following the fifth anniversary of the date of the closing of the IPO, (iii) the date on which we have issued more than \$1.0 billion in nonconvertible debt during the previous three years or (iv) the date on which we are deemed to be a large accelerated filer under the rules of the Securities and Exchange Commission. Further, even after we no longer qualify as an emerging growth company, we may still qualify as a â€œsmaller reporting company,” which would allow us to take advantage of many of the same exemptions from disclosure requirements, including reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We cannot predict if investors will find our common shares less attractive because we may rely on these 45Table of Contents exemptions. If some investors find our common shares less attractive as a result, there may be a less active trading market for our common shares and our share price may be more volatile. Item 3. Quantitative and Qualitative Disclosures About Market Risk We are exposed to market risk in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily a result of fluctuations in interest rates and inflationary pressure. There has been no material change in our exposure to market risks from that discussed in Part II, Item 7A, â€œQuantitative and Qualitative Disclosures About Market Risk” of the 2023 Form 10-K. Item 4. Controls and Procedures Limitations on effectiveness of controls and procedures In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. Evaluation of disclosure controls and procedures Our management, with the participation of our principal executive officer and principal financial officer, evaluated, as of the end of the period covered by this Quarterly Report on Form 10-Q, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Our disclosure controls and procedures are designed to ensure (a) that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and (b) that information required to be disclosed by us in reports filed or submitted under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer to allow timely decisions regarding required disclosures. Based on that evaluation, our principal executive officer and principal financial officer concluded that, as of September 30, 2024, our disclosure controls and procedures were effective at the reasonable assurance level. Changes in Internal Control over Financial Reporting There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended September 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. 46Table of Contents PART II â€” OTHER INFORMATION Item 1. Legal Proceedings From time to time, we may become involved in litigation or other legal proceedings. We are not currently a party to any material litigation or legal proceedings that, in the opinion of our management, are probable to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on our business, financial condition, results of operations and prospects because of defense and settlement costs, diversion of management resources and other factors. Item 1A. Risk Factors. Our business involves significant risks. Stockholders should carefully consider the risks and uncertainties described below and the other information in this Quarterly Report on Form 10-Q. Our business, financial condition, results of operations, or prospects could be materially and adversely affected if any of these risks occurs, and as a result, the market price of our Class A common stock could decline and stockholders could lose all or part of their investment. This Quarterly Report on Form 10-Q also contains forward-looking statements that involve risks and uncertainties. See â€œForward-Looking Statements” on page 3. Our actual results could differ materially and adversely from those anticipated in these forward-looking statements as a result of certain important factors, including those set forth below. The risk factors denoted with a â€œ*”â€”, if any, are newly added or have been materially updated from our 2023 Form 10-K. Risks Related to Our Financial Position and Need for Capital We have incurred significant losses since inception, we expect to incur losses in the future and we may not be able to achieve and maintain positive cash flow and profitability. We have incurred significant losses since our inception. For the three months ended September 30, 2024, we incurred a net loss of \$11.3 million. As of September 30, 2024, we had an accumulated deficit of \$465.6 million. In July 2024, based on our enterprise-wide review of opportunities to realize operational efficiencies, we implemented certain cost-savings actions including a reduction in our workforce, the closure of open and planned positions and reductions in other non-headcount-related expenses across the business (the â€œOperational Efficiency Program”). However, in future periods, our operating expenses may continue to increase as we grow our business. Since our inception, we have financed our operations primarily from private placements of equity, the incurrence of indebtedness, our initial public offering, and to a lesser extent, revenue derived from our Growth Direct platform and non-commercial contracts. We have devoted substantially all of our resources to the development and commercialization of our Growth Direct platform and to development activities related to advancing and expanding our technological capabilities. While we implemented our Operational Efficiency Program with the goal of achieving positive cash flow without additional financing, there can be no assurance that we will attain this goal. Our Operational Efficiency Program and intention to reach positive cash flow are based on our expectations of business performance that are generally consistent with our historical performance, including with respect to revenue and gross margins, which may not be replicated in future periods. Our goal also depends on our ability to realize additional cost savings that we believe are reasonably achievable, but are not guaranteed. We will need to generate significant additional revenue, significantly improve our gross margin and/or further reduce costs to achieve positive cash flow and profitability, and even if achieved, we cannot be sure that we will sustain positive cash flow and profitability for any substantial period of time. While our goal to achieve positive cash flow is underpinned by our recent and historical performance, such performance is not necessarily indicative of our future results. Our limited operating history makes it difficult to evaluate our future prospects and the risks and challenges we may encounter. We launched our current second-generation Growth Direct platform in 2017 for which we are continuing to grow our manufacturing and sales and marketing capabilities. Consequently, predictions about our future success or viability may not be as accurate as they could be if our products had a longer commercial history. While our product and services revenue has continued to increase in recent periods, if our strategy to grow and scale our business is not successful, we may not be able to achieve continued revenue growth. Our limited operating history, evolving business and rapid growth make it difficult to evaluate our future prospects and the risks and challenges we may encounter, and we may not continue to grow at or near historical rates. 47Table of Contents In addition, as we seek to innovate in and disrupt the current microbial quality control market, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown challenges. We are transitioning to a company capable of supporting commercial manufacturing, sales and marketing at scale in the United States and abroad. We may not be successful in such a transition and, as a result, our business may be adversely affected. Our business depends on the commercial success of our Growth Direct platform, which may not be achieved or maintained. Our business is dependent on sales of our Growth Direct systems and related consumables and services. Our ability to achieve and maintain commercial market acceptance of our Growth Direct platform will depend on a number of factors, including: â€” significant acceptance by drug manufacturers of automated microbial quality control, or MQC, testing; â€” our ability to increase awareness of the capabilities of automated MQC testing and our technology and solutions; â€” our customers’ willingness to adopt new technologies and workflows; â€” our ability to integrate our platform with our customers’ existing workflows, including related to regulatory validation processes; â€” whether our platform reliably provides advantages over the conventional, manual method of MQC testing and other automated technologies and is perceived by customers to be cost effective; â€” the continued growth of the pharmaceutical and biopharmaceutical industry, in particular biologics and cell and gene therapies; â€” our ability to execute on our business strategy, including continuing to expand in the market for cell and gene therapies; â€” the rate of adoption of our platform and solutions by drug manufacturers; â€” prices we charge for our systems and consumables; â€” the relative reliability and robustness of our platform as a whole and the components of our platform; â€” our ability to develop new products for existing customers and to expand our capabilities within the MQC testing workflow; â€” our ability to expand the use of our platform with existing customers; â€” other competitive automated MQC testing platforms; and â€” the impact of our investments in product innovation and commercial growth. We cannot assure our stockholders that we will be successful in addressing each of these criteria or other criteria that might affect the market acceptance of our products. If we are unsuccessful in achieving and maintaining commercial market acceptance of our Growth Direct platform, our business, financial condition, results of operations and prospects could be adversely affected. Our operating results have fluctuated significantly in the past and will fluctuate significantly in the future, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations. Our quarterly and annual operating results have fluctuated significantly in the past and may fluctuate significantly in the future, which makes it difficult for us to predict our future operating results. For example, we have recently experienced positive trends in our gross margins, improving from (27)% for the three months ended September 30, 2023 to 8% for the three months ended September 30, 2024, and from (33)% for the nine months ended September 30, 2023 to (5)% for the nine months ended September 30, 2024. Expansion in gross margins in future periods may not be linear and 48Table of Contents may be subject to variability from period to period. These fluctuations may occur due to a variety of factors, many of which are outside of our control, including, but not limited to: â€” our customers’ tendency to purchase our Growth Direct system, including multiple systems, in a single transaction, resulting in significant variations in sales of our systems over time; â€” the level of demand for our platform and solutions, which may vary significantly; â€” the length of time of the sales cycle for purchases of our systems; â€” seasonality in our business due to our customers’ budgetary cycles and time off during summer vacation and end-of-year periods; â€” lead time needed for validation prior to our customers’ using and purchasing our consumables; â€” changes in demand for our consumables; â€” the timing and cost of, and level of investment in, technology development and commercialization activities, which may change from time to time; â€” the start, completion, and output of manufacturing runs; â€” the costs of manufacturing and shipping our products or of providing services to our customers, which may impact our operating gross margin in any given period; â€” system repairs or replacements that may impact our customers’ confidence in us and our products and our reputation in the market; â€” the relative reliability and robustness of our platform; â€” the introduction of new products or product enhancements by us or others in our industry; â€” expenditures that we may incur to acquire, develop or commercialize additional products and technologies; â€” expenditures involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims; â€” future accounting pronouncements or changes in our accounting policies; â€” the ability of our sales organization to design and execute effective sales processes; â€” our implementation of cost reduction efforts, and the resulting costs and savings related to these actions; and â€” general market conditions and other factors, including factors, such as inflation, unrelated to our operating performance or the operating performance of our competitors. The effect of any single factor, or the cumulative effects of a combination of factors, could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance. We may continue to experience fluctuations in our operating results as a result of these factors. We have in the past and may in the future fail to meet our publicly announced guidance or other expectations about our business and future operating results, which could adversely affect our business, reputation and financial results and cause our stock price to decline. From time to time, we announce earnings guidance and other expectations regarding the future performance of our business in our quarterly and annual earnings conference calls, quarterly and annual earnings releases, or otherwise, that represents our management’s estimates as of the date of such disclosure. This guidance includes forward-looking statements based on projections prepared by our management. Projections are based upon a number of assumptions and estimates that are based on information known when they are issued, and, while presented with numerical specificity, are 49Table of Contents inherently subject to significant business, economic, and competitive uncertainties and contingencies relating to our business, many of which are beyond our control and are based upon specific assumptions with respect to future business decisions, some of which will change. It can be expected that some or all of the assumptions underlying any guidance furnished by us will not materialize or will vary significantly from actual results. From time to time, we provide possible outcomes as high and low ranges, but these are not intended to imply that actual results could not fall outside of the suggested ranges. Our actual business results may vary significantly from such guidance due to a number of factors, many of which are outside of our control, including our customers’ demand for our Growth Direct systems, the length of the sales cycle for purchases of our systems, customer site readiness and the lead time needed for validation of our systems prior to customers using and purchasing our consumables, the costs of manufacturing and shipping our products or of providing services to our customers, as well as the impact of global economic uncertainty and financial market conditions, geopolitical events, such as conflicts in Ukraine and the Middle East, rising inflation, rising interest rates, and public health crises, all of which have in the past and may in the future adversely affect our business and operating results. Furthermore, if we make downward revisions of our previously announced guidance, or if our publicly announced guidance of future operating results fails to meet expectations of securities analysts, investors, or other interested parties, we may experience adverse effects on our business and reputation and the price of our common stock could decline. Guidance is necessarily speculative in nature, and it can be expected that some or all of the assumptions underlying the guidance furnished by us will not materialize or will vary significantly from actual results. Accordingly, our guidance is only an estimate of what management believes is realizable as of the date of such disclosure. Actual results may vary from our guidance and the variations may be material. Investors are urged to exercise caution when using our guidance in making an investment decision regarding our common stock. Any failure to successfully implement our business strategy or the occurrence of any of the events or circumstances set forth in this Risk Factors section in this Quarterly Report on Form 10-Q could result in the actual operating results being different from our guidance, and the differences may be adverse and material. If we cannot maintain the level of sales of our Growth Direct systems or the sales of our consumables and service contracts to existing customers declines, our future operating results would be adversely affected. Many of our customers purchase multiple Growth Direct systems at the same time and we expect them to use these systems for many years before needing to purchase new systems. Our ability to generate revenue depends on our ability to sell our Growth Direct system to new customers or expand the use of our system by existing customers. Our current commercial strategy includes targeting sales to customers that are receptive to entering into multi-system deals with us. As a result, in the near term, we have observed and we continue to expect that a significant portion of our revenue to primarily be generated from a small number of different customers each year. We also rely on consumables and service contracts as a source of recurring revenue from our existing customers. These consumables and service contracts are purchased on an as-needed basis and, as a result, revenue from these sources may be subject to change, as customers’ purchasing practices and

polices change or their demand for our consumables and service contracts change. For example, in the past, we have experienced occasions in which customers’ facilities in which our Growth Direct systems were used have been closed or sold, which resulted in the reduction, suspension, or cessation of purchases of consumables at such sites. If we are unable to sell our Growth Direct system to new customers, if our existing customers do not expand their use of our system, or if our existing customers decide to purchase fewer of our consumables and service contracts or terminate their relationships with us, our revenue could significantly decrease, which would have an adverse effect on our financial condition and results of operations and could adversely impact our ability to execute on our growth strategy. We may need to raise additional capital to fund our existing operations, improve our platform or develop and commercialize new products or expand our operations. We expect that our efforts to maintain our position in the MQC industry, including improving our Growth Direct platform and developing new products, will continue to require significant resources. Based upon our current operating plan, we believe our existing cash, cash equivalents, and short-term investments as of September 30, 2024 of \$60.8 million, and anticipated cash flow from operations, will enable us to fund our operating expenses and capital expenditure requirements for at least twelve months following the date these consolidated financial statements were issued. This estimate and our expectation regarding the sufficiency of our existing cash, cash equivalents, and investments are based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Until such time, if ever, as we can generate sufficient cash flow, we may finance our cash needs through a combination of equity offerings and debt financings or other sources. We do not currently have any committed external source of funds.

50Table of ContentsWhile we implemented our Operational Efficiency Program with the goal of achieving positive cash flow without additional financing, there can be no assurance that we will attain this goal. Our Operational Efficiency Program and intention to reach positive cash flow are based on our expectations of business performance that are generally consistent with our historical performance, including with respect to revenue and gross margins, which may not be replicated in future periods. Our goal also depends on our ability to realize additional cost savings that we believe are reasonably achievable, but are not guaranteed. In addition, we may selectively and opportunistically seek additional capital due to favorable market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans. Our present and future funding requirements will depend on many factors, including: our ability to achieve revenue growth; the costs of manufacturing and shipping our products or of providing services to our customers, which may impact our operating gross margins in any given period; the cost of maintaining our operations, manufacturing, our product offerings, and our sales and marketing efforts; our rate of progress in and costs of launching and commercializing new products, and the cost of the sales and marketing activities associated with, establishing and expanding adoption of our Growth Direct system; our rate of progress in, and cost of research and development activities associated with, products in research and development; the effect of competing technological and market developments; any expenses we may incur in connection with undertaking efforts to improve our environment, social and governance metrics as requested by our customers, investors and other stakeholders; the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims; and costs related to domestic and international expansion. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our common stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. In addition, debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, intellectual property, future revenue streams or products or grant licenses on terms that may not be favorable to us. Furthermore, any capital raising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to advance product development activities. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate product development or commercialization efforts.

Risks Related to Our Business and StrategyOur business relies heavily on establishing and maintaining our position in the market as a leading provider of automated MQC testing. Our future profitability will depend on our ability to successfully execute and maintain a sustainable business model and generate continuous streams of revenue. Our business model is premised on our position as a leader in automated MQC testing and the competitive advantages that such position creates. Our Growth Direct platform, among other things, is designed to reduce the amount of time for MQC testing and the opportunity for human error in what we believe is a more cost-effective manner than traditional MQC testing. However, if competitors develop and commercialize an automated MQC testing platform and are able to obtain traction with customers, we may not be able to maintain our lead position and execute our business strategy. If we are unable to expand or continue to expand our customers in growing areas of drug manufacturing, such as biologics and cell and gene therapies, continue to grow market adoption of our 51Table of ContentsGrowth Direct platform, and maintain our position as the industry leader in automated MQC testing, our business, prospects, financial condition and results of operation could be adversely affected. We may not be successful in expanding our business with existing customers and driving adoption of our solutions with new customers. Our success will depend on our ability to expand our business with existing customers and to target new drug manufacturing customers to capture a greater share of the MQC testing value chain. Our ability to grow our business with existing customers will depend on our ability to broaden the application of our automated MQC testing to a larger portion of the MQC testing workflow and to increase the number of Growth Direct systems in their manufacturing facilities. Our ability to expand our business will also depend on our ability to attract new customers and to integrate our platform with new methods of manufacturing, such as cell and gene therapies. Future revenue growth will also depend on our ability to develop and market new products, technologies and solutions to meet our customers’ evolving needs, as well as our ability to identify new applications and customers for our technology in additional industries beyond the drug manufacturing industry. As we continue to scale our business, we may find that certain of our products, certain customers or certain industries may require a dedicated sales force or sales personnel with different experience than those we currently employ. Identifying, recruiting and training additional qualified personnel would require significant time, expense and attention. If we are unable to drive new customer conversion to automated MQC and our Growth Direct platform, expand adoption of our Growth Direct platform into new industries and markets, or increase the usage and value of our platform to our customers, then our business, financial condition, results of operations and prospects could be adversely affected. We may not successfully expand our Growth Direct platform to customers who manufacture cell and gene therapies. Our ability to expand our Growth Direct platform to customers who manufacture cell and gene therapies depends upon our ability to integrate our platform with the novel manufacturing processes being developed for these therapies. Companies that manufacture cell and gene therapies are developing new approaches to handle this manufacturing method, including novel facility layouts, new processes and workflows, and new quality and risk management frameworks. Unlike traditional “small molecule” drug manufacturing, the manufacture of biologics, and cell and gene therapies in particular, is more time sensitive and subject to increased risk of contamination due to material handling and process change-over. There are also currently a small number of cell and gene therapies approved by the FDA. While we have experience providing automated MQC testing for customers that manufacture a number of these approved therapies, we may encounter challenges or unexpected issues as we apply our Growth Direct platform to testing a greater number of therapies as they are approved in future. We cannot be certain that we will be able to successfully or consistently integrate our platform with this novel manufacturing process. If we are unable to successfully expand our Growth Direct platform into this growing segment of therapeutic manufacturing, our business and financial position may be adversely affected. The size of the markets and forecasts of market growth for automated MQC testing and other of our key performance indicators are based on a number of complex assumptions and estimates, and may be inaccurate. We estimate annual total addressable markets and forecasts of market growth for our Growth Direct platform. We have also developed a standard set of key performance indicators in order to enable us to assess the performance of our business in and across multiple markets, and to forecast future revenue. These estimates, forecasts and key performance indicators are based on a number of complex assumptions, internal and third-party estimates and market studies, and other business data, including assumptions and estimates relating to our ability to generate revenue from the expansion of our platform into new drug manufacturing areas and new industries. While we believe our assumptions and the data underlying our estimates and key performance indicators are reasonable, there are inherent challenges in measuring or forecasting such information. As a result, these assumptions and estimates may not be correct and the conditions supporting our assumptions or estimates may change at any time, thereby reducing the predictive accuracy of these underlying factors and indicators. As a result, our estimates of the total addressable market and our forecasts of market growth for our current or future products may prove to be incorrect, and our key performance indicators may not reflect our actual performance. If the total addressable market or the potential market growth for our platform is smaller than we have estimated or if the key performance indicators we utilize to forecast revenue are inaccurate, it may impair our sales growth and have an adverse impact on our business, financial condition, results of operations and prospects. New product development involves a lengthy and complex process and we may be unable to develop or commercialize products on a timely basis, or at all. 52Table of ContentsProducts from our development programs will take time and considerable resources to develop, and may include improvements or changes to our systems, software and consumables. We may not be able to complete development and commercialize them on a timely basis, or at all. There can be no assurance that our development programs will produce commercial products and solutions and before we can commercialize any new products, we will need to expend significant funds in order to: conduct substantial research and development, which may include validation studies; further develop and scale our engineering and manufacturing processes to accommodate different products; further develop and scale our infrastructure to be able to analyze increasingly large amounts of data; and utilize data and analytical insights generated from existing Growth Direct platform in our research and development programs in order to advance these programs. Our product development processes involve a high degree of risk, and these efforts may be delayed or fail for many reasons, including: failure of the product to perform as expected; higher costs than anticipated; and failure to reliably demonstrate the advantages of our products. In addition, if we are unable to generate additional data and insights from our existing Growth Direct platforms, then we may not be able to advance these programs as quickly, or at all, or without significant additional investment, all of which could have a material adverse effect on our product development efforts. Even if we are successful in developing new products, it will require us to make significant additional investments in marketing and selling resources in order to commercialize any such products. For example, we recently made generally available for commercial sale our Rapid Sterility application for use on the Growth Direct system, for which we have expended significant time and resources to develop. We placed our first Rapid Sterility system with an existing customer in the second quarter of 2024. We plan to continue to scale our manufacturing capabilities for the Rapid Sterility application through the end of 2024. However, there can be no assurance that we will successfully commercialize this new sterility test, scale our manufacturing capabilities to support customer demand or that this product will achieve broad acceptance by customers. Furthermore, because this is a new application, we may encounter technical or other product challenges as customers adopt and implement Growth Direct Rapid Sterility into their workflows. We may be unsuccessful in commercializing new products that we develop, which could adversely affect our business, financial condition, results of operations and prospects. Our customers use our Growth Direct platform as part of their quality-control workflow, which is subject to regulation by the FDA and other comparable regulatory authorities. We provide products and services used for quality-control testing in pharmaceutical product manufacturing. Our customers are subject to extensive regulations by the FDA and similar regulatory authorities in other countries, including, for example, cGMP regulations and associated requirements to validate the methods used to manufacture their products. To meet their regulatory compliance requirements, our customers have implemented quality-control workflows to monitor for microbial growth and contamination. While our Growth Direct platform is not regulated directly by the FDA or other comparable authorities and we have not verified our Growth Direct platform for compliance with such regulations, we have designed our platform to be integrated as part of a compliant quality-control workflow. If our Growth Direct platform is unable to meet regulatory standards for compliance or we are unable to update our platform to meet new regulatory requirements, we will lose customers and our business will be adversely affected. While under our agreements with our customers we are not liable for non-compliance of our Growth Direct platform, if a customer experienced a compliance failure due to our Growth Direct platform, or that the customer attributes to our Growth Direct platform, our reputation could be harmed and our business prospects adversely affected. If we are unable to manage our inventory and support demand for existing and future products on the Growth Direct platform, our business could suffer. 53Table of ContentsAs the number of customers using the Growth Direct platform grows and our volume of installed systems increases, we will need to continue to increase our capacity for customer service and support, including maintenance services of our systems, and expand our manufacturing capabilities. As a result, we will also need to purchase additional equipment, some of which can take several months or more to procure, setup and validate, and increase our personnel levels to meet increased demand. Additionally, we maintain certain levels of inventory to support future manufacturing efforts. If our inventory should exceed our customer demand, then it may not be sold at a pace that keeps up with the development of our technology and may therefore become obsolete or no longer competitive in the marketplace. We may be unable to sell such excess inventory, which could adversely impact our working capital and result in our expenditure of resources to accumulate inventory that we are unable to sell. There is no assurance that any of these measures taken with respect to scale, expansion of personnel, equipment, manufacturing or services will be successfully implemented, or that we will have adequate space, including in our manufacturing facility, to accommodate such required expansion. In addition, if we commercialize additional products in the future, we will need to incorporate new equipment, implement new technology systems and processes, and hire new personnel, possibly with supplemental or different qualifications as compared to our current personnel. Failure to manage this growth or transition could result in product delays, higher cost of product revenue, declining product quality, deteriorating customer service and slower responses to competitive challenges. A failure in any one of these areas could make it difficult for us to meet market expectations for our products and could damage our reputation and the prospects for our business. We have limited experience in marketing and sales, and if we are unable to improve the effectiveness of our marketing and sales organization with new and existing customers and address our customers’ needs or to expand our customer base, our business may be adversely affected. We have limited experience in marketing and selling our products and we currently rely on a small team to make direct sales in countries around the world. There are significant risks involved with relying on our own marketing and sales capabilities, including our ability to design and execute effective sales processes, generate and convert sufficient sales opportunities into new customers and place additional systems with existing customers. We have recently expanded our sales organization and implemented measures designed to improve the effectiveness of our salesforce, but there can be no assurance that those efforts will translate into improved commercial outcomes. Competition for employees capable of selling expensive instruments into the pharmaceutical industry is intense. There are significant expenses and risks involved with having our own sales and marketing team, including our ability to hire, train, retain, and appropriately incentivize a sufficient number of qualified individuals, generate sufficient sales leads and provide our sales and marketing team with adequate access to customers who may want to purchase our products, effectively manage a geographically dispersed sales and marketing team, and other unforeseen costs and expenses. We may not be able to attract and retain personnel or be able to build an efficient and effective sales organization, which could negatively impact sales and market acceptance of our products and limit our revenue growth and potential profitability. In addition, the time and cost of establishing a specialized sales, marketing and service force for a particular product or service may be difficult to justify in light of the revenue generated or projected. We may engage distributors or other strategic partners for the sale of our products, including in jurisdictions outside of the U.S. There can be no assurance that we can identify and enter into arrangements with distributors or other strategic partners on terms that are favorable to us or at all. In some cases, we would exert limited control over these distributors, and if their sales and marketing efforts for our products are not successful, our business would be materially and adversely affected. We may not be successful in locating, qualifying and engaging distributors with industry experience and knowledge, including that of jurisdictions outside of the U.S. Even if we are successful in identifying distributors, such distributors may engage in sales practices that violate federal, state, local or foreign laws or our internal policies. Furthermore, with respect to distributors in non-U.S. jurisdictions, sales practices utilized by any such distributors that are locally acceptable may not comply with sales practices standards required under U.S. laws that apply to us, which could create additional compliance risk. Any of these issues could impair our ability to successfully place our Growth Direct systems and meet our revenue expectations. *Our Operational Efficiency Program, including a reduction in workforce, may not result in anticipated savings, could result in total costs and expenses that are greater than expected and could disrupt our business. In July 2024, we implemented our Operational Efficiency Program, which includes a reduction in our workforce, the closure of open and planned positions and reductions in other non-headcount-related expenses across the business. 54Table of ContentsWhile the goal of our Operational Efficiency Program is to achieve positive cash flow by the end of 2027 without additional financing, there can be no assurance that we will attain this goal. Our Operational Efficiency Program and intention to reach positive cash flow are based on our expectations of business performance that are generally consistent with our historical performance, including with respect to revenue and gross margins,

which may not be replicated in future periods. Our goal also depends on our ability to realize additional cost savings that we believe are reasonably achievable, but are not guaranteed.As a result, we may not realize, in full or in part, the anticipated benefits and cost savings from our Operational Efficiency Program due to unforeseen difficulties, delays or unexpected costs. If we are unable to realize the expected operational efficiencies and cost savings from our Operational Efficiency Program, while maintaining our business performance, our operating results and financial condition could be adversely affected. For example, changes in our commercial salesforce may adversely impact our ability to sell our products to customers in any or across geographies. Reduced headcount in our research and development teams may impair our ability and efforts to develop and commercialize new or improved products. Decreased resources within our operations teams may negatively affect our ability to build our products in an efficient manner or at all, and may contribute to unfavorable movement in gross margins. Within our general and administrative teams, reductions may result in degraded support to our other business functions, including in respect of finance, legal and human resources. If future results of operations lag our expectations, we may undertake additional workforce reductions or restructuring activities. Our Operational Efficiency Program and any additional measures we might take to reduce costs could divert the attention of management, yield attrition beyond our intended reduction in workforce, reduce employee morale, or cause us to delay, limit, reduce or eliminate certain development plans, each of which could have an adverse impact on our business, operating results and financial condition. Our Operational Efficiency Program may also reduce our existing customers’ confidence in us, disrupt our sales initiatives for new system placements, and negatively impact our customer service operations. Our failure to adequately address any of these issues could have a material adverse effect on our business, operating results and financial condition.We may be unable to manage our future growth effectively, which could make it difficult to execute our business strategy.We have devoted significant efforts to streamline our business operations and refocus our personnel strategy, with the goal of achieving resumed growth in our business operations. The volatility in our growth has required significant time and attention from our management, and placed strains on our operational and manufacturing systems and processes, financial systems and internal controls and other aspects of our business. As needed, we expect to selectively increase headcount and to hire more specialized personnel in the future as we grow our business. We will need to continue to hire, train and manage additional qualified engineers, client and account services personnel, sales and marketing staff, software, manufacturing, distribution and quality assurance personnel in order to develop and launch new products, innovate and improve our existing products and successfully commercialize our platform and solutions. We may also need to hire, train and manage individuals with expertise that is separate, supplemental or different from expertise that we currently have, and accordingly we may not be successful in hiring, training and managing such individuals. If our new hires perform poorly, if we are unsuccessful in hiring, training, managing and integrating these new employees, or if we are not successful in retaining our existing employees, our business may be harmed. In addition, our compensation arrangements, such as our equity award programs, may not always be successful in attracting new employees and retaining and motivating our existing employees. We may need to issue additional equity securities to attract job candidates or issue additional securities to retain personnel. In making employment decisions, job candidates and existing personnel often consider the value of the equity awards they would receive in connection with their employment and fluctuations in our stock price, or a perception that the market price of our stock may not increase or may increase more slowly than stock prices at other companies, may make it more difficult to attract, retain, and motivate employees.As we have grown, our employees have become more geographically dispersed. We serve customers located in multiple countries and plan to continue to expand to new countries as part of our growth strategy, which will lead to increased dispersion of our employees, including sales employees and employees who are in our service and support groups. We may face challenges integrating, developing and motivating our rapidly growing and increasingly dispersed employee base.We may not be able to maintain the quality, reliability or robustness of our platform, or the expected turnaround times of our services and support, or to satisfy customer demand as it grows. Our ability to manage our growth properly will require us to continue to improve our operational, financial and management controls, as well as our reporting systems and procedures. To effectively manage our growth, we must continue to improve our operational and manufacturing systems and processes, our financial systems and internal controls and other aspects of our business and continue to 55Table of Contentseffectively expand, train and manage our personnel. The time and resources required to improve our existing systems and procedures, implement new systems and procedures and to adequately staff such existing and new systems and procedures is uncertain, and failure to complete such activities in a timely and efficient manner could adversely affect our operations and negatively impact our business and financial results.If we cannot compete successfully, we may be unable to increase or sustain our revenue, or achieve and sustain profitability.We currently primarily compete with established companies that provide consumables for MQC testing and with a limited number of established and early-stage companies that have automated MQC testing systems. In addition, our customers may also elect to continue to use the traditional MQC testing method rather than our platform and may decide to stop using our platform.Our competitors and potential competitors may enjoy a number of competitive advantages over us, including: a longer operating histories; a larger customer bases; a greater brand recognition and market penetration; a greater financial resources; a greater technological and research and development resources; a better system reliability, robustness and features; a greater selling and marketing capabilities; and a better established, larger scale and lower cost manufacturing capabilities.As a result, our competitors and potential competitors may be able to respond more quickly to changes in customer requirements, devote greater resources to the development, promotion and sale of their platforms or instruments than we can or sell their platforms or instruments, or offer services competitive with our platform and services at prices designed to win significant levels of market share. We may not be able to compete effectively against these organizations.In addition, competitors may be acquired by, receive investments from or enter into other commercial relationships with larger, well-established and well-financed companies. Certain of our competitors may be able to secure key inputs from vendors on more favorable terms, devote greater resources to marketing and promotional campaigns, adopt more aggressive pricing policies and devote substantially more resources to product development than we can. Further, competition in the automated MQC testing market, while currently limited, is growing and may continue to increase in future, and we may not be able to maintain our leading position in the industry as a result. If we are unable to compete successfully, we may be unable to increase market adoption and sales of our platform, which could prevent us from increasing our revenue or achieving profitability.We must develop new products, adapt to rapid and significant technological change and respond to introductions of new products by competitors to remain competitive.We sell our products in industries that are characterized by significant enhancements and evolving industry standards. As a result, our customers’ needs are rapidly evolving. If we do not appropriately innovate and invest in new technologies, our products and services may become less desirable in the markets we serve, and our customers could move to new technologies offered by our competitors or decide to revert to the traditional MQC testing method. Although we believe customers in our markets display a significant amount of loyalty to their supplier of a particular product, we also believe that because of the initial time investment required by many of our customers to reach a purchasing decision for a new product, it may be difficult to regain that customer once the customer migrates away from using our solutions to that of a competitor. Without the timely introduction of new products, services and enhancements, our offerings will likely become less competitive over time, thus harming our competitive position. Accordingly, we focus significant efforts and resources on the development and identification of new technologies, products and markets to further broaden our 56Table of Contentsofferings. To the extent we fail to timely introduce new and innovative products or services, adequately predict our customers’ needs or fail to achieve market acceptance, our business may suffer and our operating results could be adversely affected.Due to the significant resources required to enable access in new markets, we must make strategic and operational decisions to prioritize certain markets, products and services. We may expand our resources to access markets and develop products and services that do not yield meaningful revenue or we may fail to capitalize on markets, products or services that may be more profitable or with a greater potential for success.We believe our platform has potential applications across a wide range of markets and we have targeted certain markets in which we believe our technology has significant advantages or a higher probability of success or greater revenue opportunity, such as the manufacture of cell and gene therapies. We seek to maintain a process of prioritization and resource allocation among our programs to maintain a balance between advancing near-term opportunities and exploring additional markets for our platform. However, due to the significant resources required for the development of products and services for new markets, we must make decisions on which markets to pursue and the amount of resources to allocate to each. Our decisions concerning the allocation of research, development, collaboration, management and financial resources toward particular markets, products or services may not lead to the development of any viable product or service and may divert resources away from better opportunities. Similarly, we may choose to pursue certain markets, which may not be as profitable as other markets that we did not pursue due to our limited resources. As a result, our business, financial condition, results of operations and prospects could be adversely impacted.The Growth Direct platform may contain undetected errors or defects and may not meet the expectations of our customers, which means our business, financial condition, results of operations and prospects could suffer.Our Growth Direct platform includes the Growth Direct system, proprietary consumables and our LIMS connection software. While we rigorously test our platform and its components, there could be undetected errors or defects. Disruptions or other performance problems with our platform or with the components that comprise our platform may adversely impact our customers’ manufacturing process, compliance workflow or business, harm our reputation and result in reduced revenue or increased costs, such as those associated with repairs, replacements or reacquisitions of our systems. If such challenges occur, the attention of our key personnel could be diverted, or other significant customer relations problems may arise. We may also be subject to warranty claims or breach of contract for damages related to errors or defects in our products. Additionally, we may be subject to legal claims arising from any defects or errors in our platform, and in the systems, consumables and software that comprise our platform. In the past, we have repaired, and in exceptional cases, replaced or reacquired Growth Direct systems under warranty. Our failure to prevent or adequately address any of foregoing risks could have a material adverse effect on our business, operating results and financial condition.Our success depends on, among other things, the market’s confidence that the Growth Direct platform is capable of substantially enhancing quality control in the conduct of manufacturing activities as compared to the traditional method of MQC testing or that of competitive products, and will enable more efficient or improved drug manufacturing. Pharmaceutical companies and contract development and manufacturing organizations, or CDMOs, are likely to be particularly sensitive to defects and errors in the use of our platform, including if our platform fails to deliver meaningful improvements in MQC testing with results at least as good as the results generated using the traditional method of MQC testing, or new methods of automated MQC testing being developed and sold by emerging competitors. There can be no guarantee that our platform will meet the expectations or needs of these companies or CDMOs.The complexity of our products and the amount of lead time required to deliver products to our customers have caused in the past, and may cause in the future, delays in releasing new products and workflows. In addition, we have experienced in the past, and may experience in the future, challenges with respect to the reliability of our systems. If there are delays in delivering our products to our customers, or if our products fail to perform as well as or better than traditional MQC testing and competitive products or fail to generate reliable results for our customers, our revenue could be reduced or delayed, which could adversely affect our business, financial condition, results of operations and prospects.These complexities also require that we train our customers to operate our Growth Direct platform, which is expensive and time consuming. Any misuse of our products, including as a result of inadequate training, could cause our products not to perform as expected or to fail to demonstrate the process advantages of our products. The training requirement may also deter some customers from utilizing our products. Any of these results could adversely affect our business, financial condition, results of operations and prospects.57Table of ContentsPotential product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of any products that we may develop.The use of any product we may develop and the sale of any products exposes us to the risk of product liability claims. Product liability claims might be brought against us by pharmaceutical companies, contract organizations or others selling or otherwise coming into contact with our products. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in: a impairment of our business reputation and significant negative media attention; a withdrawal of customers; a significant costs to defend the litigation; a distraction of management’s attention from our primary business; a substantial monetary awards to claimants; a inability to commercialize a product; a product recalls or withdrawals; a decreased market demand for any product; and a loss of revenue.The product liability insurance we currently carry, and any additional product liability insurance coverage we acquire in the future, may not be sufficient to reimburse us for any expenses or losses we may suffer. In the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. A successful product liability claim, or series of claims, brought against us could cause our share price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operation and business, including preventing or limiting the commercialization of any products we develop.If we lose key management, cannot recruit qualified employees, directors, officers or other significant personnel or experience increases in our compensation costs, our business may be materially harmed.We are highly dependent on our management and directors, including our Chief Executive Officer, Robert Spignesi, among others. Due to the specialized knowledge each of our officers and key employees possesses with respect to our products and services and our operations, the loss of service of any of our officers or directors could delay or prevent successful sales and the expansion of our platform. We do not carry key person life insurance on our Chief Executive Officer or our other officers or directors. In general, the employment arrangements that we have with our executive officers do not prevent them from terminating their employment with us at any time.In addition, our future success and growth will depend in part on the continued service of our directors, employees and management personnel and our ability to identify, hire and retain additional personnel. If we lose one or more of our executive officers or key employees, our ability to implement our business strategy successfully could be seriously harmed. Furthermore, replacing executive officers and key employees may be difficult or costly and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to develop, market and sell our products successfully. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or effectively incentivize these additional key personnel on acceptable terms given the competition among numerous technology companies for similar personnel.Our Operational Efficiency Program that we implemented in July 2024 includes a reduction in our workforce and the closure of open and planned positions, and is intended to reduce our use of cash for operating activities with the goal of enabling us to achieve positive cash flow without additional financing. This action, and any future related actions or announcements, may make it increasingly difficult for us to hire and retain our executive officers, key employees, 58Table of Contentsconsultants and advisors. If we are unable to attract qualified personnel and retain our current employees, our ability to develop and sell our products could be limited and our business and customer relationships could be materially harmed.We depend on our information technology systems, and any failure of these systems could harm our business.We depend on information technology and telecommunications systems for significant elements of our operations, including our knowledge management system, our customer reporting, our platform, advanced automation systems, and advanced application and LIMS connection software. We have installed, and expect to expand, a number of enterprise software systems that affect a broad range of business processes and functional areas, including for example, systems handling human resources, financial controls and reporting, contract management, compliance and other infrastructure operations. These implementations can be expensive and require significant time and effort. These information technology and telecommunications systems support a variety of functions, including manufacturing operations, data analysis, quality control, customer service and support, billing, research and development activities, and general administrative activities.Information technology and telecommunications systems are vulnerable to damage from a variety of sources, including telecommunications or network failures, malicious software, bugs or viruses, human acts and natural disasters. For example, in July 2024, many industries and businesses were disrupted globally by a software glitch associated with CrowdStrike’s cybersecurity software. While we did not experience material downtime in our information technology systems, similar events in the future may disrupt our operations. Moreover, despite network security and back-up measures, our servers remain potentially vulnerable to physical or electronic break-ins, computer viruses and similar disruptive problems. Any disruption or loss of information technology or telecommunications systems on which critical aspects of our operations depend could have an adverse effect on our business and our reputation.Security breaches, loss of data and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation.In the ordinary course of our business, we collect and store sensitive data, including personal information, intellectual property and proprietary business information owned or controlled by ourselves or our employees, customers and other parties. We manage and maintain our applications and data utilizing a combination of on-site systems and cloud-based data centers. We utilize external security and infrastructure vendors to manage parts of our data centers. These applications and data encompass a wide variety of business-critical information, including research and development information, customer information, commercial information and business and financial information. We, like all companies storing business-critical information, face a number of risks relative to protecting this critical information, including loss of access, inappropriate use or disclosure, unauthorized access or

exfiltration, inappropriate modification, inappropriate destruction, and the risk of our being unable to adequately monitor and audit and modify our controls over our critical information. This risk extends to the third-party vendors and subcontractors we use to manage this sensitive data or otherwise process it on our behalf. The secure processing, storage, maintenance and transmission of this critical information are vital to our operations and business strategy, and we devote significant resources to protecting such information. Although we take measures to protect sensitive data from unauthorized access, use or disclosure, our information technology and infrastructure may still be vulnerable to, and we have in the past experienced, attacks by hackers or viruses or breaches due to employee error, malfeasance or other malicious or inadvertent disruptions. Further, attacks upon information technology systems, including those involving system disrupting ransomware and digital extortion, fraudulent messages purporting to be from legitimate individuals or organizations in order to induce actions directed by bad actors, sometimes known as “phishing”, and transmission of fraudulent invoices or other requests for payments by malicious organizations purporting to be legitimate vendors and suppliers, are increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives, capabilities, and expertise. We may also face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. While we have measures in place to identify, detect and mitigate security threats and incidents, they are not failproof, so we may also experience security incidents that may remain undetected for an extended period. Any such incident could result in the compromise of our information systems, and the data stored there could be accessed, encrypted, corrupted, modified, publicly disclosed, lost or stolen. Any such incident could result in legal claims or proceedings, including for breaches of confidential information obligations with contractual counterparties, and liability under federal or state laws that protect the privacy of personal information, and regulatory penalties. Notice of breaches may be required to affected individuals, 59Table of Contentscustomers, or other state, federal or foreign regulators, and for extensive breaches, notice may need to be made to the media or State Attorneys General. Such a notice could harm our reputation and our ability to compete. Although we have implemented security measures to prevent, detect and respond to security incidents, our data is currently accessible through multiple channels, and there is no guarantee we can protect our data from breach. Unauthorized access to our information systems, and the loss, destruction or, dissemination of data stored within them could also disrupt or halt our operations and damage our reputation, any of which could adversely affect our business. We are currently subject to, and may in the future become subject to additional, U.S., state, federal, and foreign laws and regulations imposing obligations on how we collect, store and process personal information. Our actual or perceived failure to comply with such obligations could harm our business. Ensuring compliance with such laws could also impair our efforts to maintain and expand our customer base, and thereby decrease our revenue. We are, and may increasingly become, subject to various laws and regulations, as well as contractual obligations, relating to data privacy and security in the jurisdictions in which we operate. The regulatory environment related to data privacy and security is increasingly rigorous, with new and constantly changing requirements applicable to our business, and enforcement practices are likely to remain uncertain for the foreseeable future. These laws and regulations may be interpreted and applied differently over time and from jurisdiction to jurisdiction, and it is possible that they will be interpreted and applied in ways that may have a material adverse effect on our business, financial condition, results of operations and prospects. In the United States, various federal and state regulators, including governmental agencies like the Federal Trade Commission, have adopted, or are considering adopting, laws and regulations concerning personal information and data security. Certain state laws may be more stringent or broader in scope, or offer greater individual rights, with respect to personal information than federal, international or other state laws, and such laws may differ from each other, all of which may complicate compliance efforts. Such laws may have potentially conflicting requirements that would make compliance challenging. A number of other states have proposed their own comprehensive privacy laws. Such proposed legislation, if enacted, may add additional complexity, variation in requirements, restrictions and potential legal risk, require additional investment of resources in compliance programs, impact strategies and the availability of previously useful data and could result in increased compliance costs and/or changes in business practices and policies. The existence of comprehensive privacy laws in different states in the country could make our compliance obligations more complex and costly and may increase the likelihood that we may be subject to enforcement actions or otherwise incur liability for noncompliance. In addition, laws in all 50 U.S. states require businesses to provide notice to consumers whose personally identifiable information has been disclosed as a result of a data breach. Internationally, laws, regulations and standards in many jurisdictions apply broadly to the collection, use, retention, security, disclosure, transfer and other processing of personal information. For example, the EU General Data Protection Regulation, or EU GDPR, has extraterritorial reach and adds a broad array of requirements for handling personal data. In particular, the EU GDPR includes obligations and restrictions concerning the consent and rights of individuals to whom the personal data relates, the transfer of personal data out of the European Economic Area, security breach notifications and the security and confidentiality of personal data. Further, from January 1, 2021, following Brexit, companies handling personal data of individuals in the UK have to comply with the United Kingdom GDPR, or the UK GDPR, which, together with the amended UK Data Protection Act 2018, retains the EU GDPR in UK national law. The complex and evolving nature of data protection laws and regulations may lead to additional compliance costs, including as a result of diverging international data privacy laws and regulations and related uncertainties. There can be no assurances that we will be successful in our efforts to comply with the multitude of U.S., state, federal, and foreign privacy and data security laws, and violations of such laws could result in regulatory investigations and significant fines, as well as civil claims including class actions, and reputational damage. We may evaluate strategic opportunities for our business, including through acquisitions, joint ventures or investments in other companies or technologies that could negatively affect our operating results, dilute our stockholders’ ownership, increase our debt or cause us to incur significant expense. As part of our business strategy, we may opportunistically pursue acquisitions of businesses and assets that we believe may be complementary or synergistic with our own, or strategic alliances and joint ventures that leverage our technology and industry experience to expand our offerings or distribution. We have no experience with acquiring other businesses or assets and limited experience with forming strategic partnerships. We may not be able to find suitable collaborators or acquisition candidates, and we may not be able to complete such transactions on favorable terms, if at all. 60Table of ContentsThe competition for collaborators or acquisition candidates may be intense, and the negotiation process will be time consuming and complex. If we make any acquisitions, we may not be able to integrate these acquisitions successfully into our existing business, these acquisitions may not strengthen our competitive position, the transactions may be viewed negatively by customers or investors, we may be unable to retain key employees of any acquired business, relationships with key suppliers, manufacturers or customers of any acquired business may be impaired due to changes in management and ownership, and we could assume unknown or contingent liabilities. Any future acquisitions also could result in contingent liabilities or future write-offs of intangible assets or goodwill, any of which could have a material adverse effect on our business, financial condition, results of operations and prospects. We cannot guarantee that we will be able to fully recover the costs of any acquisition. Integration of an acquired company also may disrupt ongoing operations and require management resources that we would otherwise focus on developing our existing business. We may not realize the anticipated benefits of any acquisition, technology license, strategic alliance or joint venture. We also may experience losses related to investments in other companies, which could have a material adverse effect on our business, financial condition, results of operations and prospects. To fund any such acquisitions or joint ventures, we may choose from a number of financing alternatives that may be accompanied by drawbacks. For example, if we incur debt, we may be required to abide by restrictive covenants or grant security interests in our assets to secure such debt. If we issue equity as consideration, such issuances would dilute the ownership of our stockholders or, in the case of preferred equity, may impose preferential terms that are senior to those of our common stockholders. Additional funds may not be available on terms that are favorable to us, or at all. If the price of our Class A common stock is low or volatile, we may not be able to acquire companies or fund a joint venture project using our stock as consideration. Repair or replacement costs due to warranties we provide on our Growth Direct systems could have a material adverse effect on our business, financial condition and results of operations. Our standard terms and conditions for customers generally provide for a one-year limited assurance warranty on Growth Direct systems, which is included in the sales price. Existing and future warranties place us at the risk of incurring future repair or replacement costs. We establish our accrual for estimated warranty expenses based on historical information, current cost data and future forecasts. We exercise judgment in determining the expected product warranty costs, using estimated material, labor and other costs. While we believe that historical experience provides a reliable basis for estimating such warranty cost, unforeseen quality issues or component failure rates could result in future costs in excess of such estimates. As of September 30, 2024, we had an amount reserved for warranty costs of \$0.5 million. Substantial amounts of warranty claims could have a material adverse effect on our business, financial condition and results of operations. Our insurance policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured liabilities. We do not carry insurance for all categories of risk that our business may encounter and our policies have limits and significant deductibles. Some of the policies we currently maintain include general liability, property, umbrella, cybersecurity, and directors’ and officers’ insurance. Any additional product liability insurance coverage we acquire in the future may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive and in the future we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses. A successful product liability claim or series of claims in which judgments exceed our insurance coverage could adversely affect our business, financial condition, results of operations and prospects, including preventing or limiting the commercialization of any products we develop. Operating as a public company makes it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage, seek alternative insurance options or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified people to serve on our board of directors, our board committees or as executive officers. Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our business, financial condition, results of operations and prospects. International expansion of our business exposes us to business, regulatory, political, operational, financial and economic risks associated with doing business outside of the United States. 61Table of ContentsOur business strategy includes achieving significant and increasing sales to customers and sites outside of the U.S. As a result, we have established relationships with customers outside of the U.S. and in the future intend to expand our international customer base. To that end, our staff is located in North America, Europe and the Asia-Pacific region, and we intend to further expand our international presence. Doing business internationally involves a number of risks, including: multiple, conflicting and changing laws and regulations such as privacy regulations, tax laws, export and import restrictions, tariffs, economic sanctions and embargoes, employment laws, regulatory requirements and other governmental approvals, permits and licenses; failure by us or our distributors to obtain approvals to conduct our business in various countries; differing intellectual property rights; complexities and difficulties in obtaining intellectual property protection, enforcing our intellectual property and defending against third-party intellectual property claims; difficulties in staffing and managing foreign operations; logistics and regulations associated with shipping systems and parts and components for systems and consumables, as well as transportation delays; travel restrictions that limit the ability of marketing, presales, sales, services and support teams to service customers; financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our products and exposure to foreign currency exchange rate fluctuations; international trade disputes that could result in tariffs and other protective measures; natural disasters, the severity and frequency of which may be amplified by global climate change, political and economic instability, including wars, terrorism and political unrest, outbreak of disease, boycotts, curtailment of trade and other business restrictions; and regulatory and compliance risks, including severe penalties such as criminal and civil penalties, disgorgement and other remedial measures, that relate to the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act 2010 and similar anti-bribery and anticorruption laws in other jurisdictions. Any of these factors could significantly harm our future international expansion and operations and, consequently, our business, financial condition, results of operations and prospects. In addition, certain international markets are subject to significant political and economic uncertainty, including for example the effect of the withdrawal of the United Kingdom from the European Union. Significant political and economic developments in international markets for which we intend to operate, or the perception that any of them could occur, creates further challenges for operating in these markets in addition to creating instability in global economic conditions. Certain legal and political risks are also inherent in foreign operations. There is a risk that foreign governments may nationalize private enterprises in certain countries where we may operate. In certain countries or regions, terrorist activities and the response to such activities may threaten our operations more than in the United States. Social and cultural norms in certain countries may not support compliance with our corporate policies, including those that require compliance with substantive laws and regulations. Also, changes in general economic and political conditions in countries where we may operate are a risk to our financial performance and future growth. In addition, in certain geographies, we may need to rely on distributors, partners and other collaborators to penetrate those markets, and there can be no assurance that we will be able to secure relationships with such parties or that such parties will comply with legal and regulatory standards that are applicable to our business. As we operate our business globally, our success will depend, in part, on our ability to anticipate and effectively manage these and other related risks. There can be no assurance that the consequences of these and other factors relating to our international operations will not have an adverse effect on our business, financial condition or results of operations. 62Table of ContentsHigh inflation rates could negatively impact our revenues and profitability if increases in the prices of our Growth Direct systems or a decrease in customer spending results in lower sales. In addition, if our costs increase and we are not able to pass along these price increases to our customers, our net income would be adversely affected, and the adverse impact may be material. Increased inflation may result in decreased demand for our products and services, increased operating costs (including our labor costs), reduced liquidity, and limitations on our ability to access credit or otherwise raise debt and equity capital. In addition, the United States Federal Reserve has raised, and may again raise, interest rates in response to concerns about inflation. Increases in interest rates, especially if coupled with reduced government spending and volatility in financial markets, may have the effect of further increasing economic uncertainty and heightening these risks. In an inflationary environment, we may be unable to raise the sales prices of our products and services at or above the rate at which our costs increase, which could/would reduce our profit margins and have a material adverse effect on our financial results and net income. We also may experience lower than expected sales and potential adverse impacts on our competitive position if there is a decrease in spending by our customers or they have a negative reaction to our pricing. A reduction in our revenue would be detrimental to our profitability and financial condition and could also have an adverse impact on our future growth. In operating our business, we may experience inflationary pressures on significant cost categories including labor, materials and freight. An inflationary environment, including factors such as tight labor markets and increasing freight and materials prices, could make it more costly for us to do business. In order to meet the compensation expectations of our prospective and current employees due to inflationary factors, we may be required to increase our labor costs, including wages and employee benefits, or risk losing skilled workers to competitors. In addition, changes in global shipping capacity and demand as well as the cost of raw materials and commodities such as oil (including derivative products including fuel and plastics) could negatively impact our freight and materials costs. If we see additional pressure on our labor, materials and freight costs, we could see negative effects on our results of operations (including product costs), cash flows and overall financial condition. Global economic and political instability and geopolitical conflicts could adversely affect our business, financial condition or results of operations. Our business could be adversely affected by unstable economic and political conditions within the United States and foreign jurisdictions, including as a result of an economic downturn, geopolitical conflicts and the U.S. presidential election. The global credit and financial markets have experienced severe volatility and disruptions in the past several years. A severe or prolonged economic downturn, such as the global financial crisis, could result in a variety of risks to our business, including our ability to raise additional capital when needed on acceptable terms, if at all. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. A weak or declining economy could also result in supply chain disruptions, volatile demand for our products, abrupt changes in our customers’ buying patterns, limitations on our customers’ access to financial resources and ability to satisfy obligations to us, or other adverse impacts to our ability to place our Growth Direct systems. Furthermore, although we do not have any customer or direct supplier relationships in Ukraine, Russia or the Middle East at this time, the ongoing military conflicts in those regions and related sanctions, as well as export controls or actions that may be initiated by nations including the United States, the European Union, Russia or other jurisdictions, and other potential uncertainties could adversely affect our business and/or our supply chain, business partners or customers. In the event geopolitical tensions fail to abate or deteriorate further, additional governmental sanctions may be enacted adversely impacting the global economy, its banking and monetary systems, markets or customers for our products. Our

employees, consultants and collaborators may engage in misconduct or other improper activities. We are exposed to the risk of fraud or other misconduct by our employees, consultants and collaborators. Misconduct by these parties could include intentional failures to comply with the applicable laws and regulations in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us. These laws and regulations may restrict or prohibit a wide range of pricing, discounting and other business arrangements. Such misconduct could result in legal or regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct, and any precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses, or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, we could be subject to significant civil, criminal and administrative penalties, which could have a material adverse impact on our business. Whether or not we are successful in 63Table of Contentsdefending against such actions or investigations, we could incur substantial costs, including legal fees and divert the attention of management in defending ourselves against any of these claims or investigations, which could have a material adverse impact on our business.Risks Related to Manufacturing and SupplyIf our primary manufacturing and development facility becomes damaged or inoperable or we are required to vacate our existing facility, our ability to conduct and pursue our manufacturing and development efforts will be jeopardized.We currently conduct our primary development and manufacturing at our facility located in Lowell, Massachusetts. Our facility and equipment could be harmed or rendered inoperable or inaccessible by natural or man-made disasters, the severity and frequency of which may be amplified by global climate change, or other circumstances beyond our control, including fire, power loss, communications failure, war or terrorism, or another catastrophic event, such as a pandemic or similar outbreak or public health crisis, which may render it difficult or impossible for us to support our customers and develop products. The inability to manufacture our systems and consumables could develop if our facility is inoperable or suffers a loss of utilization for even a short period of time and may result in the loss of customers or harm to our reputation. Disruptions in our manufacturing operations could also adversely affect our efforts to improve the gross margins of our products. Furthermore, our facility and the equipment we use to perform our manufacturing and development could be unavailable or costly and time consuming to repair or replace. It would be difficult, time consuming and expensive to rebuild our facility, to locate and qualify a new facility or license or transfer our proprietary technology to a third party. Even in the event we are able to find a third party to assist in manufacturing and development efforts, we may be unable to negotiate commercially reasonable terms to engage with the third party. To mitigate certain of these risks associated with the manufacture of our consumables, we have constructed a back-up consumable manufacturing facility in Lexington, Massachusetts. While we believe that we could, if necessary, transfer our manufacturing capabilities to our back-up facility, there can be no assurance that we would achieve such transfer in a timely manner or at all and mitigate disruption to our overall business.Our manufacturing operations are dependent upon third-party suppliers, including single-source suppliers, making us vulnerable to supply shortages and price fluctuations, which could harm our business.We source the components of our Growth Direct system and consumables from third-party suppliers. We do not have supply agreements with most of our suppliers beyond purchase orders and, although we maintain an inventory of components, forecasted amounts may be inaccurate and we may experience shortages as a result of serious supply problems with these suppliers. There can be no assurance that our supply of components will not be limited, interrupted, or of satisfactory quality or continue to be available at acceptable prices. For example, we experienced disruptions to our supply chain as a result of the coronavirus pandemic and may experience additional disruptions in the future.Certain critical components of our Growth Direct system and consumables we obtain from single suppliers and the loss of supply from any of these suppliers could materially adversely affect our business. To protect against such loss, we maintain, or are working to obtain, sufficient inventory of these components to allow us to continue to manufacture our systems and consumables during the period required to qualify a new supplier. For example, the manufacturer of the camera used in our Growth Direct system discontinued production of the camera, and we have obtained a supply we believe is sufficient to allow us to meet customer demand while qualifying a new camera supplier. While we believe we have, or will have, sufficient inventory to provide protection against changes in our sole suppliers, our estimates of the length of time required to qualify a new supplier or inventory level required to manufacture our systems and consumables during that time may be incorrect, and we may run out of inventory sooner than we anticipate. In addition, we have not obtained sufficient inventory for all of our single-source components and we may not be able to do so in the amounts we predict will be required. In addition, any change to a new supplier will require us to devote substantial time and resources, result in additional costs, and could involve a period in which our products might not be produced in a timely or consistent manner. We may also be unable to enter into agreements with new suppliers on commercially reasonable terms or at all. The occurrence of any of these events could adversely affect our business and customer relationships. In addition, loss of any critical component provided by a single-source supplier could require us to change the design of our manufacturing process based on the functions, limitations, features and specifications of the replacement components.Several other non-critical components and materials that comprise our Growth Direct platform are currently manufactured by a single supplier or a limited number of suppliers. In many of these cases, we have not yet qualified alternate suppliers and rely upon purchase orders, rather than long-term supply agreements. A supply interruption or an increase in demand beyond our current suppliers’ capabilities could harm our ability to manufacture our products unless 64Table of Contentsand until new sources of supply are identified and qualified. Our reliance on these suppliers subjects us to a number of risks that could harm our business, including: interruption of supply resulting from modifications to or discontinuation of a supplier’s operations; delays in product shipments resulting from uncorrected defects, reliability issues, or a supplier’s variation in a component; a lack of long-term supply arrangements for key components with our suppliers; inability to obtain adequate supply in a timely manner, or to obtain adequate supply on commercially reasonable terms; difficulty and cost associated with locating and qualifying alternative suppliers for our components in a timely manner; a modification or change in a manufacturing process or part that unknowingly or unintentionally negatively impacts the operation of our products; production delays related to the evaluation and testing of products from alternative suppliers, and corresponding regulatory qualifications; delay in delivery due to our suppliers prioritizing other customer orders over ours; damage to our brand reputation caused by defective components produced by our suppliers; increased cost of our warranty program due to product repair or replacement based upon defects in components produced by our suppliers; and fluctuation in delivery by our suppliers due to changes in demand from us or their other customers.Any interruption in the supply of components or materials, or our inability to obtain substitute components or materials from alternate sources at acceptable prices in a timely manner, could impair our ability to meet the demand of our customers, which would have an adverse effect on our business.We forecast sales to determine requirements for components and materials used in our products, and if our forecasts are incorrect, we may experience delays in shipments or increased inventory costs.To manage our operations with our third-party suppliers, we forecast anticipated product orders and material requirements to predict our inventory needs and enter into purchase orders on the basis of these requirements. Our limited historical commercial experience and recent growth may not provide us with enough data to consistently and accurately predict future demand. If our business expands and our demand for components and materials increases beyond our estimates, we or our suppliers may be unable to meet our demand. In addition, if we underestimate our component and material requirements, we may have inadequate inventory, which could interrupt, delay, or prevent delivery of our products to our customers. By contrast, if we overestimate our component and material requirements, we may have excess inventory, which would increase our expenses. Any of these occurrences would negatively affect our financial performance and business results.Shipping is a critical part of our business and any changes in our shipping arrangements or damages or losses sustained during shipping could adversely affect our business, financial condition, results of operations and prospects.Shipments of our products are subject to various regulations in the various countries in which we provide our products. For example, shipments of our growth media consumables may be required to comply with the shipping requirements promulgated by the U.S. Department of Transportation and the U.S. Federal Aviation Administration, as well as shipment rules established by the International Air Transport Association. If we are unable to comply with any of these rules or regulations, our ability to deliver our products in a timely manner may be adversely affected. In addition, even if we are able to comply with these rules and regulations, compliance can result in increased costs. In either event, our financial results and condition may be adversely affected.65Table of ContentsWe also currently rely on third-party vendors for our shipping. If we are not able to negotiate acceptable pricing and other terms with these entities or their experience performance problems or other difficulties, it could negatively impact our operating results and our customers’ experience. Our products could sustain serious damage or be lost in transit. If a product is damaged in transit, including damage due to consumable temperature excursion, it may result in a substantial delay in the fulfillment of the customer’s order, and depending on the type and extent of the damage and whether the incident is covered by insurance, it may result in a substantial financial loss. If our products are not delivered in a timely fashion or are damaged or lost during the delivery process, our customers could become dissatisfied and cease using our products or services, which would adversely affect our business, financial condition, results of operations and prospects.We use biological and hazardous materials that require considerable expertise and expense for handling, storage and disposal and may result in claims against us.We work with materials, including chemicals, biological agents and compounds that could be hazardous to human health and safety or the environment. Our operations also produce hazardous and biological waste products. Federal, state and local laws and regulations govern the use, generation, manufacture, storage, handling and disposal of these materials and wastes. We are subject to periodic inspections by federal, state and local authorities to ensure compliance with applicable laws. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental laws and regulations may restrict our operations. If we do not comply with applicable regulations, we may be subject to fines and penalties. In addition, we cannot eliminate the risk of accidental injury or contamination from these materials or wastes, which could cause an interruption of our commercialization efforts, research and development programs and business operations, as well as environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations. In the event of contamination or injury, we could be liable for damages or penalized with fines in an amount exceeding our resources and our operations could be suspended or otherwise adversely affected. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance.Risks Related to Our Intellectual PropertyIf we are unable to obtain and maintain sufficient intellectual property protection for our technology, including the Growth Direct platform, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our products may be impaired. We rely on patent protection as well as trademark, copyright, trade secret and other intellectual property rights protection and contractual restrictions to protect our proprietary technologies, all of which provide limited protection and may not adequately protect our rights or permit us to gain or keep any competitive advantage. If we fail to maintain, protect or enforce our intellectual property, third parties may be able to compete more effectively against us. Our success depends in large part on our ability to obtain and maintain protection of the intellectual property related to our products and technologies, particularly patents, in the United States and other countries. Obtaining, maintaining and enforcing patents in our industry is costly, time consuming and complex, and we may fail to do so with respect to patents on important products, services and technologies in a timely fashion, at a reasonable cost or at all, in the U.S. or in other potentially relevant jurisdictions. If we delay in filing a patent application, and a competitor files a patent application on the same or a similar technology before we do, we may face a limited ability to secure patent rights. Even if we can patent the technology, the patent may be limited in scope, and such limitation may be inadequate to protect our products, or to block competitor products that are similar or adjacent to ours. In addition, the USPTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. There are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business.It is possible that none of our pending patent applications will result in issued patents in a timely fashion or at all, and even if patents are granted, they may not provide a basis for intellectual property protection of commercially viable products or services, may not provide us with any competitive advantages, or may be challenged and invalidated by third parties. It is possible that others will design around our current or future patented technologies. 66Table of ContentsThe issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability. Some of our patents or patent applications may be challenged in opposition, derivation, reexamination, inter partes review, post-grant review, interference, or in court proceedings. See “We may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time consuming and unsuccessful.” Any successful challenge to our patents could result in the unenforceability or invalidity of such patents, which could harm our business. In addition, in patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. The outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on certain aspects of our platform technologies. If the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future products. Patent terms may be inadequate to protect our competitive position on our products for an adequate amount of time.Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date, subject to applicable extensions. Once expired, we may be open to competition from competitive products. If one of our products requires extended development or testing, patents protecting such products might expire before or shortly after such products are commercialized. For example, while our patents and, if issued, our patent applications have terms that will expire through 2043, certain of our earliest unexpired U.S. patents covering the Growth Direct system and its use are scheduled to expire in 2024. Although we own other patents with later expiration dates that cover various improvements and consumables for the Growth Direct platform, these other patents may not provide the same protection as the earliest-filed patents. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing similar or identical products to ours, which would have a material adverse effect on our business.The United States government may exercise certain rights with regard to certain of our inventions developed using government funding.The United States federal government retains certain rights in inventions produced with its financial assistance under the Patent and Trademark Law Amendments Act, or the Bayh-Dole Act. Certain of our inventions for which we have pursued, and in some cases obtained, patent protection were developed using federal funding from BARDA. As a result, the U.S. government may have certain rights, including so-called march-in rights, to any patent rights that were funded in part by the U.S. government and any products or technology developed from such patent rights. When new technologies are developed with U.S. government funding, the U.S. government generally obtains certain rights in any resulting patents, including a nonexclusive license authorizing the U.S. government to use the invention for non-commercial purposes. These rights may permit the U.S. government to disclose our confidential information to third parties and to exercise march-in rights to use or to allow third parties to use our licensed technology. The U.S. government can exercise its march-in rights if it determines that action is necessary because we fail to achieve the practical application of government-funded technology, because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to U.S. industry. In addition, our rights in such inventions may be subject to certain requirements to manufacture products embodying such inventions in the United States. Any exercise by the U.S. government of such rights could harm our business, financial condition, results of operations and prospects.If we are unable to protect the confidentiality of our trade secrets, the value of our technology could be materially adversely affected and our business could be harmed. We rely on trade secrets and confidentiality agreements to protect our unpatented know-how, technology and other proprietary information, including parts of our technology platform, and to maintain our competitive position and we expect our reliance to increase in the near term as the terms for certain of our earliest patents expire. Any disclosure, either intentional or unintentional, by our employees, consultants or vendors, or misappropriation by third parties (such as through a cybersecurity breach) of our trade secrets or proprietary information could enable competitors to duplicate or surpass our technological achievements, thus eroding our competitive position in our market. From time to time, we may share trade secrets with customers, collaborators, suppliers, vendors and other third parties, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.Trade secrets and know-how can be difficult and expensive to protect. We take steps to protect our intellectual property and proprietary technology by maintaining physical and electronic security measures and by entering into agreements, including confidentiality, non-disclosure and intellectual property assignment agreements, with our employees, 67Table of Contentsconsultants, advisors, collaborators and customers. However, we cannot be certain that such agreements have been entered into with all relevant parties, and we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent

information and techniques. For example, if any of these parties breach the agreements and disclose our proprietary information, including our trade secrets, we may expend significant time and resources to assert our rights against such parties and we ultimately may not be able to obtain adequate remedies for such breaches. Such agreements may not be enforceable or may not provide meaningful protection in the event of unauthorized use or disclosure or other breaches of the agreements, and we may not be able to prevent such unauthorized disclosure, which could materially adversely impact our business and financial position. We may in the future in-license intellectual property related to our product offerings. If we lose these rights, our business may be materially adversely affected, our ability to develop improvements to our Growth Direct platform and to develop new technologies may be negatively and substantially impacted, and if disputes arise, we may be subjected to future litigation as well as the potential loss of or limitations on our ability to develop and commercialize products and technology covered by these license agreements. In the future, we may need to obtain licenses from third parties to advance our research, development and commercialization activities. These intellectual property license agreements may impose various development, regulatory and/or commercial diligence obligations, payment of milestones and/or royalties and other obligations on us. Our rights to use the technology we may license may be subject to the continuation of and compliance with the terms of these agreements. Licenses can be terminated and their terms may be materially modified in ways that are significantly adverse to our business interest for any number of reasons. For example, we may fail to comply with our obligations under these agreements, we may use the licensed intellectual property in an unauthorized manner or we may become subject to bankruptcy-related proceedings. Similarly, disputes may arise with respect to our licensing agreements and/or our licensors might conclude that we have materially breached our obligations under our license agreements. If any such in-license agreement is terminated, or if licensed intellectual property fail to provide the intended exclusivity, competitors or other third parties might have the freedom to market or develop products similar to ours. In addition, absent the rights granted to us under such license agreements, we may infringe the intellectual property rights that are the subject of those agreements, we may be subject to litigation by the licensor, and if such litigation by the licensor is successful we may be required to pay damages to the licensor, or we may be required to cease our development and commercialization activities that are deemed infringing, and in such event we may ultimately need to modify our activities or products to design around such infringement, which will consume time and resources and may not be ultimately successful. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. We may not be able to protect our intellectual property rights throughout the world. We intend to continue to expand our commercial operations in territories outside the United States, including in Europe and the Asia-Pacific region. The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States, and we may encounter difficulties in protecting and defending such rights in foreign jurisdictions. Consequently, we may not be able to prevent third parties from practicing our inventions in some or all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. In addition, certain countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to other parties. Furthermore, many countries limit the enforceability of patents against other parties, including government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of any patents. We may not be able to protect and enforce our trademarks and trade names, or build name recognition in our markets of interest thereby harming our competitive position. Our trademarks or trade names may be challenged, infringed, diluted, circumvented, declared generic or determined to be infringing on other marks. We may not be able to protect our rights in these trademarks or trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. We have not yet registered certain of our trademarks in all of our potential markets. During the trademark registration process, we may receive objections that we may be unable to overcome. In addition, third parties may be given an opportunity to oppose pending trademark applications and/or to seek the cancellation of registered trademarks. If we are unable to obtain a registered trademark or establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. 68 Table of Contents We may be subject to claims challenging the inventorship and ownership of our patents and other intellectual property. We may be subject to claims that former employees, collaborators or other third parties have an interest in our patents, trade secrets or other intellectual property as an inventor or by contract. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in our development activities or as a result of questions regarding co-ownership of potential joint inventions. Litigation may be necessary to defend against these and other claims challenging inventorship of patents, trade secrets or other intellectual property. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, important intellectual property. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees, and certain customers or partners may defer engaging with us until the particular dispute is resolved. In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Any of the foregoing could harm our business, financial condition, results of operations and prospects. We may be involved in litigation claiming that we have infringed on a third party's intellectual property, which could be time consuming and costly and may adversely affect our business, financial condition, results of operations and prospects. We may be involved with litigation or actions at the USPTO or foreign patent offices with various third parties that claim we or our collaborators or customers using our solutions and services have infringed, misappropriated or misused other parties' intellectual property rights. We expect that the number of such claims may increase as the number of our products grows, we expand our market share and the level of competition in our markets increases. Moreover, as the automated MQC testing industry expands and more patents are issued, the risk increases that our products may be subject to claims of infringement of third party patent and other proprietary rights. Any infringement claim, regardless of its validity, could harm our business by, among other things, resulting in time consuming and costly litigation, diverting management's time and attention from the development of the business, requiring the payment of monetary damages, fees and expenses or royalty payments, or result in potential or existing customers delaying purchases of our products or entering into engagements with us pending resolution of the dispute. There can be no assurance that we will prevail in any suit initiated against us by third parties, successfully settle or otherwise resolve patent infringement claims. Third parties making claims against us may be able to obtain injunctive or other relief, which could block our ability to develop, commercialize and sell products or services, and could result in the award of substantial damages against us, including treble damages, attorneys' fees, costs and expenses, if we are found to have willfully infringed. In the event of a successful claim of infringement against us, we may be required to pay damages and ongoing royalties, and obtain one or more licenses from third parties, or be prohibited from selling certain products or services. We may not be able to obtain these licenses on acceptable or commercially reasonable terms, if at all, or these licenses may be non-exclusive, which could result in our competitors gaining access to the same intellectual property. In addition, we could encounter delays and incur significant costs, in product or service introductions while we attempt to develop alternative products or services, or redesign our products or services, to avoid infringing third party patents or proprietary rights. Defense of any lawsuit or failure to obtain any of these licenses or to develop a workaround could prevent us from commercializing products or services, and the prohibition of sale or the threat of the prohibition of sale of any of our products or services could materially affect our business and our ability to gain market acceptance for our products or services. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Further, even if we were successful in defending against a lawsuit, such a defense would distract our management team from our operations, which could have an adverse effect on our business. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations or could otherwise have a material adverse effect on our business, results of operations, financial condition and prospects. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other legal proceedings relating to our intellectual property rights, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or other proceedings. In addition, our agreements with some of our customers, suppliers or other entities with whom we do business may require us to defend or indemnify these parties to the extent they become involved in infringement claims, including the types of claims described above. We could also voluntarily agree to defend or indemnify third parties in instances where we are not obligated to do so if we determine it would be important to our business relationships. If we are required or agree to defend or indemnify third parties in connection with any infringement claims, we could incur significant costs and expenses that could adversely affect our business, financial condition, results of operations and prospects. We may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time consuming and unsuccessful. Third parties, including our competitors, could be infringing, misappropriating or otherwise violating our intellectual property rights. Monitoring unauthorized use of our intellectual property is difficult and costly. From time to time, we seek to analyze our competitors' products and services, and may in the future seek to enforce our rights against potential infringement, misappropriation or violation of our intellectual property. However, the steps we have taken to protect our proprietary rights may not be adequate to enforce our rights against such infringement, misappropriation or violation of our intellectual property. We may not be able to detect unauthorized use of, or take appropriate steps to enforce, our intellectual property rights. Any inability to meaningfully enforce our intellectual property rights could harm our ability to compete and reduce demand for our products and services. Litigation may be necessary for us to enforce our patent and proprietary rights or to determine the scope, coverage and validity of the proprietary rights of others. If we do not prevail in such legal proceedings, we may be required to pay damages, we may lose significant intellectual property protection for our products or services, such that competitors could copy our products or services and we could be forced to cease commercialization of certain of our products or services. Even if resolved in our favor, any award of monetary damages or other remedy we receive may not be commercially valuable. Any litigation that may be necessary in the future could result in substantial costs and diversion of resources and could have a material adverse effect on our business, financial condition, results of operations and prospects. In any lawsuit we bring to enforce our intellectual property rights, a court may refuse to stop the other party from using the technology at issue on grounds that our intellectual property rights do not cover the technology in question. Further, in such proceedings, the defendant could counterclaim that our intellectual property is invalid or unenforceable and the court may agree, in which case we could lose valuable intellectual property rights. The outcome in any such lawsuits are unpredictable. Even if we do prevail in any future litigation related to intellectual property rights, the cost and time requirements of the litigation could negatively impact our financial results. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace. Our use of open-source software could compromise our ability to offer our services and subject us to possible litigation. We use open-source software licensed to us by third-party authors under various open-source licenses in connection with our products and services. Use and distribution of open-source software may entail greater risks than use of third-party commercial software, as open-source licensors generally do not provide support, warranties, indemnification or other contractual protections regarding infringement claims or the quality of the code. Further, some open-source software licenses require users who distribute software containing open-source software to publicly disclose all or part of the source code to the licensee's software that incorporates, links or uses such open-source software, and make available to third parties for no cost, any derivative works of the open source code created by the licensee, which could include the licensee's own valuable proprietary code. While we monitor our use of open-source software and try to ensure that none is used in a manner that would require us to disclose our proprietary source code or that would otherwise breach the terms of an open source agreement, such use could inadvertently occur, or could be claimed to have occurred, in part because open source software license terms are often ambiguous. Additionally, we may from time to time face claims from third parties claiming ownership of, or seeking to enforce the terms of, an open source license, including by demanding release of source code for the open-source software, derivative works or our proprietary source code that was developed using, or that is distributed with, such open-source software. These claims could also result in litigation and could require us to make our proprietary software source code freely available, require us to devote additional research and development resources to change or re-engineer our platform, seek costly licenses from third parties or otherwise incur additional costs and expenses, any of which could result in reputational harm and would have a negative effect on our business and operating results. Risks Related to Our Common Stock The market price of our Class A common stock has been and may continue to be volatile and fluctuate substantially, which could result in substantial losses for our stockholders. The market price of our Class A common stock has been and may continue to be volatile. The stock market in general and the market for smaller technology companies in particular has experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, our stockholders may not be able to sell their Class A common stock at or above the price they paid for them. The market price for our Class A common stock may be influenced by many factors, including: actual or anticipated fluctuations in our financial condition and operating results, including fluctuations in our quarterly and annual results; the introduction of new products or product enhancements by us or others in our industry; variances in product and system reliability; overall conditions in our industry and the markets in which we operate; disputes or other developments with respect to our or others' intellectual property rights; actual or anticipated changes in our operating results or growth rate as a result of our competitors' operating results; our ability to develop and market new and enhanced products and expand into new markets on a timely basis; fluctuations in the valuation of companies perceived by investors to be comparable to us; product liability claims or other litigation; announcement or expectation of additional financing effort; sales of our common stock by us or our stockholders; share price and volume fluctuations attributable to inconsistent trading volume levels of our shares; media exposure of our products or of those of others in our industry; changes in earnings estimates or recommendations by securities analysts; general market conditions and other factors, including factors unrelated to our operating performance or the operating performance of our competitors; and the other factors described in this "Risk Factors" section and elsewhere in this Quarterly Report on Form 10-Q. *If our Class A common stock is delisted from the Nasdaq Stock Market, the liquidity of our Class A common stock would be adversely affected and the market price of our common stock could decrease. The Nasdaq Stock Market LLC ("Nasdaq"), on which our Class A common stock is currently listed, has minimum requirements that a company must meet in order to remain listed, including that we maintain a minimum closing bid price of \$1.00 per share for our Class A common stock (the "Bid Price Requirement"). We have previously received notifications from Nasdaq that we were not in compliance with the Bid Price Requirement. Most recently, on February 2, 2024, we received a letter from Nasdaq notifying us that the closing bid price of our Class A common stock was below \$1.00 per share for the preceding 30 consecutive trading days. To regain compliance, the closing bid price of our common stock must be at least \$1.00 or higher for a minimum of ten consecutive business days, though Nasdaq has the discretion to extend the ten business day period to up to 20 consecutive business days. The initial period during which we were required to regain compliance with the Bid Price Requirement expired on July 31, 2024. Because we did not regain compliance with the requirement during the initial period, we transferred the listing of our Class A common stock to the Nasdaq Capital Market, in order to secure an additional 180 calendar day compliance period ending on January 27, 2025. As a condition of securing such additional compliance period, we informed Nasdaq that we intend to regain compliance with the Bid Price Requirement during the second compliance period, which may include the implementation of a reverse stock split if necessary. We intend to monitor the closing bid price of our Class A common stock and take such reasonable measures to regain compliance with the Bid Price Requirement. However, there can be no assurance that we will be able to regain compliance with the Bid Price Requirement even during the second compliance period, nor can there be any assurance that we will receive the necessary approvals from our stockholders to effect a reverse stock split. If implemented, a reverse stock split may have undesirable consequences. For example, a reverse stock split would have the effect of combining the outstanding shares of our Class A common stock into a smaller number of outstanding shares, which may adversely affect the liquidity and trading volume in our Class A common stock. In addition, a reverse stock split may be viewed negatively by some investors, analysts and other stock market participants, and some companies that have implemented reverse stock splits have experienced subsequent declines in their share price and corresponding market capitalization. If we do not cure the deficiency during the additional compliance period and regain compliance with the Bid Price Requirement, Nasdaq will provide written notice that our common stock will be subject to delisting.

In the event of such notification, we may appeal Nasdaq’s delisting determination. However, there can be no assurance that, if we receive a delisting notice and appeal the delisting determination by Nasdaq, such appeal would be successful. As a result, there can be no assurance that we will be able to continue the listing of our Class A common stock on Nasdaq. Even if we regain compliance with the Bid Price Requirement, there can be no assurance that we will continue to comply with the other continued listing standards of Nasdaq. If we fail to comply with one or more other Nasdaq listing rules, our Class A common stock may also become subject to delisting as a result of such deficiencies. A delisting of our Class A common stock from Nasdaq could materially reduce the liquidity of our Class A common stock and result in a corresponding material reduction in the price of our Class A common stock. In addition, delisting could harm our ability to raise capital on terms acceptable to us, or at all, and may result in the potential loss of confidence by investors and employees and fewer business development opportunities. Further, any potential delisting of our Class A common stock from Nasdaq would also make it more difficult for our stockholders to sell their shares in the public market. Sales of a substantial number of shares of our Class A common stock in the public market, or the perception in the market that the holders of a large number of shares intend to sell shares, could depress the market price of our Class A common stock. Except for shares of our Class A common stock that are held by our directors, officers and affiliates, which are subject to certain restrictions on resale under the Securities Act of 1933, as amended, or the Securities Act, and the rules and regulations promulgated thereunder, all other shares of our Class A common stock listed on Nasdaq are generally freely tradable. These include shares held by stockholders, including those that hold large positions in our securities, that are not our affiliates as such term is defined under Rule 144 of the Securities Act. Sales of a substantial number of shares of our common stock by such stockholders, particularly at a time when daily trading volumes in our stock are low, has had and may continue to have the effect of depressing the trading price of our common stock. Such downward pressure in the trading price of our common stock may also be exerted by investors’ expectations or perceptions that such sales could occur. An active trading market for our Class A common stock may not be sustainable. It is possible that an active or liquid market for our Class A common stock may not be sustainable. In the absence of an active trading market for our Class A common stock, it may be difficult for stockholders to sell our shares without depressing the market price for the shares, or at all. Furthermore, an inactive market may also impair our ability to raise capital by selling shares of our Class A common stock and may impair our ability to enter into strategic collaborations or acquire companies or products by using our shares of Class A common stock as consideration.

Table of Contents

Our executive officers, directors and principal stockholders, if they choose to act together, have the ability to control all matters submitted to stockholders for approval. Based on the number of shares of Class A common stock outstanding as of September 30, 2024, our executive officers, directors and stockholders who owned more than 5% of our outstanding common stock and their respective affiliates hold, in the aggregate, a majority of our outstanding voting stock. The holders of shares of our Class B common stock have the ability to convert any portion of their Class B common stock into Class A common stock. Our Class B common stock cannot be converted if, immediately following such conversion, the holder would beneficially own more than 4.9% of the issued and outstanding Class A common stock. Due to this conversion right, holders of our Class B common stock could, at any time, increase their voting control of us. As a result of their combined voting power, if our executive officers, directors and stockholders who own more than 5% of our outstanding common stock choose to act together, they would be able to control all matters submitted to our stockholders for approval that require a majority vote, as well as our management and affairs. For example, these persons, if they choose to act together, would control the election of directors, the composition of our management and approval of any merger, consolidation or sale of all or substantially all of our assets. The dual class structure of our common stock and the option of the holders of shares of our Class B common stock to convert into shares of our Class A common stock may limit our Class A stockholders’ ability to influence corporate matters. Our Class A common stock has one vote per share, while our Class B common stock is non-voting. Nonetheless, each share of our Class B common stock may be converted at any time into one share of issued and outstanding Class A common stock at the option of its holder, subject to the limitations provided for in our restated certificate of incorporation that prohibit the conversion of our Class B common stock into shares of Class A common stock to the extent that, upon such conversion, such holder would beneficially own in excess of 4.9% of our Class A common stock. Consequently, if holders of Class B common stock exercise their option to make this conversion, such exercise will have the effect of increasing the relative voting power of those prior holders of our Class B common stock (subject to the ownership limitation described in the previous sentence) and increasing the number of outstanding shares of our voting common stock, and correspondingly decreasing the relative voting power of the current holders of our Class A common stock, which may limit our current Class A stockholders’ ability to influence corporate matters. We are an “emerging growth company,” and a “smaller reporting company,” and the reduced disclosure requirements applicable to us may make our Class A common stock less attractive to investors. We are an “emerging growth company,” as defined in the JOBS Act, and may remain an emerging growth company until the last day of the fiscal year following the fifth anniversary of the closing of the IPO. However, if certain events occur prior to the end of such five-year period, including if we become a “large accelerated filer,” our annual gross revenues exceed \$1.235 billion or we issue more than \$1.0 billion of non-convertible debt in the previous three-year period, we will cease to be an emerging growth company prior to the end of such five-year period. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include: not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting; reduced disclosure obligations regarding executive compensation; exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved and from providing the pay ratio between our Chief Executive Officer and employees; and an exemption from compliance with the requirements of the Public Company Accounting Oversight Board regarding the communication of critical audit matters in the auditor’s report on the financial statements. We are also a “smaller reporting company” and are therefore entitled to rely on certain reduced disclosure requirements for as long as we remain a smaller reporting company, such as presenting two years of audited financial statements in our annual Form 10-K or reduced disclosure requirements for executive compensation. This reduced disclosure in our SEC filings due to our status as a smaller reporting company may make it harder for investors to analyze our results of operations and financial prospects. We cannot predict whether investors will find our Class A common stock less attractive if we rely on these exemptions. If some investors find our Class A common stock less attractive as a result, there may be a less active trading market for our Class A common stock and our stock price may be reduced or more volatile. In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of these accounting standards until they would otherwise apply to private companies. We intend to utilize the extended transition period and, as a result, we will not be required to comply with new or revised accounting standards on the same timeline as other public companies. If we fail to maintain effective internal control over financial reporting and effective disclosure controls and procedures, we may not be able to accurately report our financial results in a timely manner or prevent fraud, which may adversely affect investor confidence in our company. As a public company, we are required to maintain internal control over financial reporting and to report any material weaknesses in such internal controls. Section 404 of the Sarbanes-Oxley Act of 2002 requires that we evaluate and determine the effectiveness of our internal control over financial reporting and provide a management report on our internal controls on an annual basis. However, while we remain an emerging growth company, we are not required to include an attestation report on internal control over financial reporting issued by our independent registered accounting firm. If we have material weaknesses in our internal control over financial reporting, we may not detect errors on a timely basis and our consolidated financial statements may be materially misstated. We will need to maintain and enhance the systems, processes and documentation necessary to comply with Section 404 of the Sarbanes-Oxley Act as we grow, and we will require additional management and staff resources to do so. Additionally, even if we conclude our internal control over financial reporting is effective for a given period, we may in the future identify one or more material weaknesses, in which case our management will be unable to conclude that our internal control over financial reporting is effective. Our independent registered public accounting firm will be required to issue an attestation report on the effectiveness of our internal control over financial reporting following the date we are no longer an emerging growth company and do not qualify as a non-accelerated filer. Even if our management concludes that our internal control over financial reporting is effective, our independent registered public accounting firm may in the future conclude that there are material weaknesses with respect to our internal controls or the level at which our internal controls are documented, designed, implemented or reviewed. If we are unable to conclude that our internal control over financial reporting is effective or if our auditors were to express an adverse opinion on the effectiveness of our internal control over financial reporting because we had one or more material weaknesses, investors could lose confidence in the accuracy and completeness of our financial disclosures, which could cause the price of our common stock to decline. Irrespective of compliance with Section 404, any failure of our internal control over financial reporting could have a material adverse effect on our reported operating results and harm our reputation. Internal control deficiencies could also result in a restatement of our financial results. Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud. We are subject to the periodic reporting requirements of the Exchange Act. We are continuing to refine our disclosure controls and procedures to provide reasonable assurance that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected, which could have a material adverse effect on investors’ confidence in our reporting and the price of our Class A common stock.

Table of Contents

Provisions in our restated certificate of incorporation and amended and restated bylaws and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management. Provisions in our restated certificate of incorporation and our amended and restated bylaws may discourage, delay or prevent a merger, acquisition or other change in control of our company that stockholders may consider favorable, including transactions in which our stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our Class A common stock, thereby depressing the market price of our Class A common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions include those establishing: a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors; no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates; the exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director, which prevents stockholders from filling vacancies on our board of directors; the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquirer; the ability of our board of directors to alter our bylaws without obtaining stockholder approval; the required approval of the holders of at least two-thirds of the shares entitled to vote at an election of directors to adopt, amend or repeal our bylaws or repeal the provisions of our restated certificate of incorporation regarding the election and removal of directors; the required approval of the holders of at least two-thirds of the shares entitled to vote thereon to (i) effect a reorganization, recapitalization, share exchange, share classification, consolidation, conversion or merger, (ii) sell, lease, exchange, transfer or otherwise dispose of all or substantially all of our assets, or (iii) dissolve our company or revoke a dissolution of our company; a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders; the requirement that a special meeting of stockholders may be called only by the chairman of the board of directors, the chief executive officer, the president or the board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders’ meeting, which may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer’s own slate of directors or otherwise attempting to obtain control of us. We have been, and may continue to be, subject to the actions of activist stockholders or unsolicited acquisition proposals, which could cause us to incur substantial costs, divert management’s and the board’s attention and resources, and have an adverse effect on our business and stock price. From time to time, we may be subject to proposals by stockholders urging us to take certain corporate actions, such as changing the composition of our board of directors, our management team, selling our company or similar strategic initiatives. If activist stockholder initiatives ensue, our business could be adversely affected, as responding to such actions can be costly and time-consuming, disrupt our operations and divert the attention of management and our board of directors. Table of Contents

For example, in connection with the unsolicited proposal from a stockholder to acquire all of our outstanding common stock in June 2022, we retained the services of various advisors, including legal, financial, and communications professionals, to advise us in considering the stockholder’s proposal and during our review of strategic alternatives, the costs of which negatively impacted our financial results, and we may be required to retain such services in the future, which could have a further negative impact on our financial results. In addition, perceived uncertainties as to our future direction, strategy or leadership created as a consequence of activist stockholder initiatives may result in the loss of potential business opportunities, harm our ability to attract new investors, customers, and employees, and cause our stock price to experience periods of volatility or stagnation. Our restated certificate of incorporation designates specific courts as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us. Our restated certificate of incorporation specifies that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for most legal actions involving claims brought against us by stockholders; provided that, the exclusive forum provision will not apply to suits brought to enforce any liability or duty created by the Securities Act, the Exchange Act, the rules and regulations thereunder or any other claim for which the federal courts have exclusive jurisdiction; and provided further that, if and only if the Court of Chancery of the State of Delaware dismisses any such action for lack of subject matter jurisdiction, such action may be brought in another state or federal court sitting in the State of Delaware. Our restated certificate of incorporation further provides that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted by law, be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and to have consented to the provisions of our restated certificate of incorporation described above; provided, however, that stockholders cannot and will not be deemed to have waived our compliance with the U.S. federal securities laws and the rules and regulations thereunder. These provisions may have the effect of discouraging lawsuits against our directors, officers, employees and agents as it may limit any stockholder’s ability to bring a claim in a judicial forum that such stockholder finds favorable for disputes with us or our directors, officers, employees or agents and result in additional litigation costs in pursuing any such claims. In addition, while the Delaware Supreme Court ruled in March 2020 that federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court are “facially valid” under Delaware law, there is uncertainty as to whether other courts will enforce our Federal Forum Provision. If a court were to find the choice of forum provision contained in our restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business, financial condition or results of operations. The choice of forum provision contained in our restated certificate of incorporation may also impose additional litigation costs on stockholders who assert that the provision is not enforceable or invalid. The Court of Chancery of the State of Delaware and the federal district courts of the United States may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our stockholders. Our ability to use our net operating losses and research and development tax credits to offset future taxable income or income tax liabilities is subject to certain limitations. As of December 31, 2023, we had U.S. federal and state net operating loss, or NOL, carryforwards of \$229.3 million and \$100.4 million, respectively. These NOLs may be available to offset future taxable income, if any, that begin to expire in 2038 and 2032, respectively. Additionally, we had federal NOLs of

\$216.5 million generated since 2018, which do not expire. The Tax Cuts and Jobs Act (TCJA) enacted on December 22, 2017 limits a taxpayer’s ability to utilize NOL deduction in a year to 80% taxable income for federal NOL arising in tax years beginning after 2017. In addition, we had federal and state research and development tax credits of \$2.2 million and \$3.2 million, respectively. These tax credits may be available to offset future tax liabilities and begin to expire in 2038 and 2024, respectively. In general, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, a corporation that undergoes an ownership change, generally defined as a greater than 50 percentage point change by value in its equity ownership by one or more stockholders or groups of stockholders owning at least 5% of the corporation’s stock over a rolling three-year period, is subject to limitations on its ability to utilize its pre-ownership change NOLs and Table of Contents tax credits to offset future taxable income or income tax liabilities for U.S. federal income tax purposes. Similar rules may apply under state tax laws. The Company has completed a Section 382 study through July 31, 2020 to assess the limitations on use of NOLs and research and development credits due to changes in control. The study determined that ownership changes materially limited the NOL carryforwards and research and development tax credits available to offset future tax liabilities and the limitations have been reflected in the amounts of NOL carryforwards, research and development tax credits, and deferred tax assets disclosed above. The Company has not completed a Section 382 study for post July 31, 2020 transactions which could create an additional limitation although materially all of the current federal NOL carryforwards can be carried forward indefinitely. We have in the past experienced, and we may in the future experience ownership changes, some of which are outside our control. For these reasons, we are not able to utilize a material portion of the NOLs and tax credits even if we attain profitability. General risk factors There is increasing attention to environmental, social and governance matters that may impact our business. There is an increasing focus by U.S. and international regulators, customers, and other stakeholders on environmental, social and governance (“ESG”) matters in our industry. Complying with new laws or regulations concerning climate related matters or other ESG matters will result in increased compliance costs and create additional non-compliance risks. Failure to adequately meet our customers’ expectations or comply with any such laws or regulations may result in loss of business and an adverse impact on our business, financial condition, and results of operations. Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, would be stockholders’ sole source of gain. We have never declared or paid any cash dividends on our common stock. We currently anticipate that we will retain all available funds and future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. As a result, capital appreciation, if any, of our common stock will be the sole source of gain on an investment in our common stock for the foreseeable future. If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline, even if our business is doing well. The trading market for our Class A common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. If the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, or our stock performance, or if our product development or marketing and sales results fail to meet the expectations of analysts, our stock price could decline. If one or more of these analysts ceases coverage of us or fails to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. If our estimates or judgments relating to our critical accounting policies are based on assumptions that change or prove to be incorrect, our operating results could fall below our publicly announced guidance or the expectations of securities analysts and investors, resulting in a decline in the market price of our Class A common stock. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets, liabilities, equity, revenue and expenses that are not readily apparent from other sources. If our assumptions change or if actual circumstances differ from our assumptions, our operating results may be adversely affected and could fall below our publicly announced guidance or the expectations of securities analysts and investors, resulting in a decline in the market price of our Class A common stock. We could be subject to securities class action litigation. In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because early-stage technology companies have Table of Contents experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs, a diversion of management’s attention and resources, and negative publicity, all of which could harm our business. Conditions in the banking system and financial markets, including the failure of banks and financial institutions, could have an adverse effect on our operations and financial results. Actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. For example, on March 10 and March 12, 2023, the Federal Deposit Insurance Corporation took control and was appointed receiver of Silicon Valley Bank, Signature Bank and Silvergate Capital Corp, respectively, after each bank was unable to continue their operations. Since then, additional financial institutions have experienced similar failures and have been placed into receivership. It is possible that other banks will face similar difficulty in the future. Although we do not maintain any deposit accounts, credit agreements or letters of credit with any financial institution currently in receivership, we are unable to predict the extent or nature of the impacts of these evolving circumstances at this time. If, for example, other banks and financial institutions enter receivership or become insolvent in the future in response to financial conditions affecting the banking system and financial markets, our ability to access our existing cash, cash equivalents and investments may be threatened. While it is not possible at this time to predict the extent of the impact that the failure of these financial institutions or the high market volatility and instability of the banking sector could have on economic activity and our business in particular, the failure of other banks and financial institutions and the measures taken by governments, businesses and other organizations in response to these events could adversely impact our business, financial condition and results of operations. Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities Recent Sales of Unregistered Securities; Purchases of Equity Securities by the Issuer or Affiliated Purchaser None. Use of Proceeds On July 14, 2021, the Registration Statement on Form S-1 (File No. 333-257431) relating to our IPO was declared effective by the SEC. There has been no material change in the expected use of the net proceeds from our IPO as described in our final prospectus. Item 3. Defaults Upon Senior Securities None. Item 4. Mine Safety Disclosures Not applicable. Item 5. Other Information (c) Director and Officer Trading Plans and Arrangements None of our directors or officers adopted, modified or terminated a Rule 10b5-1 trading arrangement, or adopted, modified or terminated a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K) during the quarter ended September 30, 2024. Table of Contents Item 6. Exhibits Exhibit Number Description of Exhibit 3.1 Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-40952) filed on July 21, 2021) 3.2 Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K (File No. 001-40952) filed on July 21, 2021) 3.3 Certificate of Amendment to Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-40952) filed on May 24, 2024) 31.1 Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 31.2 Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 31.3 Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 32.1 Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 101 INS Inline XBRL Instance Document 101 CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document 101 DEF Inline XBRL Taxonomy Extension Definition Linkbase Document 101 LAB Inline XBRL Taxonomy Extension Label Linkbase Document 101 PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) Filed herewith. **Furnished herewith. 79 Table of Contents SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, duly authorized. Date: November 7, 2024 RAPID MICRO BIOSYSTEMS, INC. By: /s/ Robert Spignesi Robert Spignesi President and Chief Executive Officer (Principal Executive Officer) By: /s/ Sean Wirtjes Sean Wirtjes Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) 80 EX-31.1 2 rid-20240930xexx311.htm EX-31.1 Document Exhibit 31.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO RULES 13a-14(a) OR 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002, Robert Spignesi, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Rapid Micro Biosystems, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and 5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. Date: November 7, 2024 By: /s/ Robert Spignesi Name: Robert Spignesi Title: Chief Executive Officer (principal executive officer) EX-31.2 3 rid-20240930xexx312.htm EX-31.2 Document Exhibit 31.2 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO RULES 13a-14(a) OR 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002, Sean Wirtjes, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Rapid Micro Biosystems, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and 5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. Date: November 7, 2024 By: /s/ Sean Wirtjes Name: Sean Wirtjes Title: Chief Financial Officer (principal financial officer and principal accounting officer) EX-32.1 4 rid-20240930xexx321.htm EX-32.1 Document Exhibit 32.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the quarterly report of Rapid Micro Biosystems, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2024 (the “Report”), as filed with the Securities and Exchange Commission on the date hereof, I, the undersigned, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that: (1) The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Date: November 7, 2024 By: /s/ Robert Spignesi Name: Robert Spignesi Title: Chief Executive Officer (principal executive officer) EX-32.2 5 rid-20240930xexx322.htm EX-32.2 Document Exhibit 32.2 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the quarterly report of Rapid Micro Biosystems, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2024 (the “Report”), as filed with the Securities and Exchange Commission on the date hereof, I, the undersigned, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that: (1) The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Date: November 7, 2024 By: /s/ Sean Wirtjes Name: Sean Wirtjes Title: Chief Financial Officer (principal financial officer and principal accounting officer) EX-101. SCH 6 rmb-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover Page link: presentationLink link: calculationLink link: definitionLink 9952151 - Statement - Condensed consolidated balance sheets link: presentationLink link: calculationLink link: definitionLink 9952152 - Statement - Condensed consolidated balance sheets (Parenthetical) link: presentationLink link: calculationLink link: definitionLink 9952153 - Statement - Condensed consolidated statements of operations link: presentationLink link: calculationLink link: definitionLink 9952154 - Statement - Condensed consolidated statements of comprehensive loss link: presentationLink link: calculationLink link: definitionLink 9952155 - Statement - Condensed consolidated statements of stockholders’ equity link: presentationLink link: calculationLink link: definitionLink 9952156 - Statement - Condensed consolidated statements of cash flows link: presentationLink link: calculationLink link: definitionLink 9952157 - Disclosure - Nature of the business and basis of presentation link: presentationLink link: calculationLink link: definitionLink 9952158 - Disclosure - Summary of significant accounting policies link: presentationLink link: calculationLink link: definitionLink 9952159 - Disclosure - Fair value of financial assets and liabilities link: presentationLink link: calculationLink link: definitionLink 9952160 - Disclosure - Investments link: presentationLink link: calculationLink link: definitionLink 9952161 - Disclosure - Inventory link: presentationLink link: calculationLink link: definitionLink 9952162 - Disclosure - Prepaid

expenses and other current assets link:presentationLink link:calculationLink link:definitionLink 9952163 - Disclosure - Property and equipment, net link:presentationLink link:calculationLink link:definitionLink 9952164 - Disclosure - Accrued expenses and other current liabilities link:presentationLink link:calculationLink link:definitionLink 9952165 - Disclosure - Common stock and common stock warrants link:presentationLink link:calculationLink link:definitionLink 9952166 - Disclosure - Stock-based compensation link:presentationLink link:calculationLink link:definitionLink 9952167 - Disclosure - Income taxes link:presentationLink link:calculationLink link:definitionLink 9952168 - Disclosure - Net loss per share link:presentationLink link:calculationLink link:definitionLink 9952169 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 9952170 - Disclosure - Commitments and contingencies link:presentationLink link:calculationLink link:definitionLink 9952171 - Disclosure - Benefit plans link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Summary of significant accounting policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Summary of significant accounting policies (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Fair value of financial assets and liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Prepaid expenses and other current assets (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Property and equipment, net (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Accrued expenses and other current liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Common stock and common stock warrants (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Stock-based compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Net loss per share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Summary of significant accounting policies - Schedule of Concentration Risk (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Summary of significant accounting policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Summary of significant accounting policies - Schedule of Product Warranties (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Summary of significant accounting policies - Schedule of Disaggregated Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Fair value of financial assets and liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Investments (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Inventory - Schedule of Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Inventory - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Prepaid expenses and other current assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Property and equipment, net - Schedule of Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Property and equipment, net - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Accrued expense and other current liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Accrued expenses and other current liabilities - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Common stock and common stock warrants - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Common stock and common stock warrants - Schedule of Outstanding Common Stock Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Stock-based compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Stock-based compensation - Schedule of Black-Scholes Option-Pricing Model (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Stock-based compensation - Schedule of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Stock-based compensation - Schedule of Restricted Stock Units Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Stock-based compensation - Schedule of ESPP Black-Scholes Option-Pricing Model (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Stock-based compensation - Schedule of Stock-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Net loss per share - Schedule of Basic and Diluted Net Loss per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Net loss per share - Schedule of Anti-Dilutive Shares Excluded from Computation of Diluted Net Let per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - Leases - Schedule of Supplemental Balance Sheet Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - Leases - Schedule of Lease Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - Leases - Schedule of Operating Lease Liability Maturities (Details) link:presentationLink link:calculationLink link:definitionLink 9954511 - Disclosure - Leases - Schedule of Finance Lease Liability Maturities (Details) link:presentationLink link:calculationLink link:definitionLink 9954512 - Disclosure - Benefit plans (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 rmb-20240930 cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 rmb-20240930 def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 rmb-20240930 lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Weighted average remaining contractual term of options vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Maximum percentage of payroll deduction Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Statistical Measurement [Domain] Statistical Measurement [Domain] Gross unrealized losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Contract asset Contract with Customer, Asset, after Allowance for Credit Loss, Current Schedule of Supplemental Cash Flow Information and Lease Expense Lease, Cost [Table Text Block] Schedule of Prepaid Expenses and Other Current Assets Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Cover [Abstract] Cover [Abstract] Schedule of Operating Lease Liability Maturities Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Trading Symbol Trading Symbol Accrued warranty expense Standard Product Warranty Accrual, Current Common stock and common stock warrants Common Stock And Common Stock Warrants [Abstract] No definition available. All Trading Arrangements All Trading Arrangements [Member] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Prepaid expenses and other current assets Prepaid Expenses And Other Assets, Current [Text Block] The entire disclosure for prepaid expenses and other current assets as of the balance sheet date. Non-NEOs Non-NEOs [Member] Schedule of Basic and Diluted Net Loss per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Class A Common stock Common Class A [Member] Conversion of Class B common stock to Class A common stock (in shares) Stock Issued During Period, Shares, Conversion of Convertible Securities Pay vs Performance Disclosure [Line Items] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Short-term investments Short-Term Investments [Member] Accounts receivable Increase (Decrease) in Accounts Receivable Costs and operating expenses: Operating Costs and Expenses [Abstract] Operational Efficiency Program Operational Efficiency Program [Member] Operational Efficiency Program Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Vesting of restricted stock units (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Fair value of financial assets and liabilities Fair Value Disclosures [Text Block] Award Timing Disclosures [Line Items] Other Performance Measure, Amount Other Performance Measure, Amount Leases Lessee, Operating Leases [Text Block] Common stock, outstanding (in shares) Balance at beginning of period (in shares) Balance at end of period (in shares) Common Stock, Shares, Outstanding Operating lease cost Operating Lease, Cost Other receivables Other Receivables, Net, Current Office furniture and fixtures Finance Lease, Right-of-Use Asset, before Accumulated Amortization Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Operating lease liabilities, long-term Operating Lease, Liability, Noncurrent Shares available for issuance under plan (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Finance lease renewal term Lessee, Finance Lease, Renewal Term Segment information Segment Reporting, Policy [Policy Text Block] Contractual term Warrants and Rights Outstanding, Term Deferred revenue Current deferred revenue Contract with Customer, Liability, Current Plan Name [Domain] Plan Name [Domain] United States UNITED STATES Other long-term assets Other Assets, Noncurrent Entity Tax Identification Number Entity Tax Identification Number Leases [Abstract] Leases [Abstract] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Benefit plans Defined Benefit Plan [Text Block] Right-of-use assets obtained in exchange for new lease obligations: Right-Of-Use Asset Obtained In Exchange For Lease Liability [Abstract] Right-Of-Use Asset Obtained In Exchange For Lease Liability Product and Service Revenue Product And Service [Member] Product And Service Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] U.S. Government Treasury Notes US Treasury Securities [Member] Aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value [Abstract] No definition available. Plan Name [Axis] Plan Name [Axis] Equity Components [Axis] Equity Components [Axis] Total lease payments Finance Lease, Liability, to be Paid Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Other Other Assets, Current Award Timing Method Award Timing Method [Text Block] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Investments Fair value Debt Securities, Available-for-Sale Accounts receivable Accounts Receivable [Policy Text Block] Measurement Frequency [Axis] Measurement Frequency [Axis] Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Weighted-average remaining lease term - financing leases (in years): Finance Lease, Weighted Average Remaining Lease Term Prepaid Expense and Other Assets, Current [Abstract] Prepaid Expense and Other Assets, Current [Abstract] Insider Trading Policies and Procedures [Line Items] Use of estimates Use of Estimates, Policy [Policy Text Block] Total costs and operating expenses Costs and Expenses Adjustment to Compensation, Amount Adjustment to Compensation Amount Aggregate intrinsic value of options outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Compensation Amount Outstanding Recovery Compensation Amount Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Entity Small Business Entity Small Business Company Selected Measure Amount Company Selected Measure Amount Geographical [Axis] Geographical [Axis] Maturity of investments Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale Tabular List, Table Tabular List [Table Text Block] Level 3 Fair Value, Inputs, Level 3 [Member] Share-based compensation Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Award Date [Axis] Award Date [Axis] Sales and marketing Selling and Marketing Expense [Member] Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Customer G Customer G [Member] Customer G Shares of common stock issuable upon exercise of warrant (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Leases Lessee, Lease, Description [Line Items] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Issuance of Class A common stock under ESPP (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Accrued expenses and other current liabilities Total accrued expenses and other current liabilities Accrued Liabilities, Current Common shares excluded from computation of diluted net loss per share attributable to common stockholders (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Less imputed interest Finance Lease, Liability, Undiscounted Excess Amount Common stock and common stock warrants Class of Warrant or Right [Line Items] Payments for restructuring Payments for Restructuring Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Product and service revenue â€” non-recurring Non-Recurring Contract With Customer [Member] Non-Recurring Contract With Customer Current assets: Assets, Current [Abstract] Allowance for doubtful accounts for expected credit losses Accounts Receivable, Allowance for Credit Loss Inventory Inventory Disclosure [Text Block] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Product and Service [Domain] Product and Service [Domain] Share-Based Payment Arrangement, Option Options to purchase common stock Share-Based Payment Arrangement, Option [Member] Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] 2025 Lessee, Operating Lease, Liability, to be Paid, Year One Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Accrued taxes Accrued Income Taxes, Current Weighted-average discount rate - financing leases: Finance Lease, Weighted Average Discount Rate, Percent Customer E Customer E [Member] Represents information pertaining to customer e. Warranty repairs Standard Product Warranty Accrual, Decrease for Payments Preferred stock, outstanding (in shares) Preferred Stock, Shares Outstanding Security Exchange Name Security Exchange Name 2025 Finance Lease, Liability, to be Paid, Year One Award Type [Axis] Award Type [Axis] Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Restricted cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Number of shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Work in process Inventory, Work in Process, Net of Reserves Property and equipment, net Property plant and equipment, net Property, Plant and Equipment, Net Total liabilities Liabilities Options exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Schedule of Investments Debt Securities, Available-for-Sale [Table Text Block] Research and development Research and Development Expense Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Expiration Date Trading Arrangement Expiration Date Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Operating lease liabilities, short-term Operating Lease, Liability, Current Total Shareholder Return Amount Total Shareholder Return Amount Common stock, issued (in shares) Common Stock, Shares, Issued Schedule of Restricted Stock Units Activity Nonvested Restricted Stock Shares Activity [Table Text Block] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Customer concentration risk Concentration Risk, Percentage Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Less: Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property plant and equipment, gross Property, Plant and Equipment, Gross Prepaid insurance Prepaid Insurance Issuance of Class A common stock upon exercise of common stock options (in shares) Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Research and development Research and Development Expense [Member] Weighted average exercise price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Common stock, authorized (in shares) Common Stock, Shares Authorized Class of Warrant or Right [Table] Class of Warrant or Right [Table] Basis of presentation Basis of Accounting, Policy [Policy Text Block] Unrealized gain on investments, net of tax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Weighted average common shares outstanding - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Other comprehensive income (Loss): Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Numerator: Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Total stockholdersâ€™ equity Balance at beginning of period Balance at end

of period Equity, Attributable to Parent Cash and cash equivalents Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block] Operating Leases: Operating Lease, Liability [Abstract] Manufacturing and laboratory equipment Manufacturing And Laboratory Equipment [Member] Represents information pertaining to manufacturing and laboratory equipment. Property and equipment, net Property, Plant and Equipment Disclosure [Text Block] Concentration Risk [Domain] Concentration Risk Type [Domain] Company contributions to plan Defined Contribution Plan, Cost Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Fair Value, Recurring Fair Value, Recurring [Member] Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Maximum shares available for purchase per employee (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee Cost of revenue Cost of Sales [Member] Options granted (in shares) Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Product Product [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Accounting Policies [Table] Accounting Policies [Table] Accounting Policies Document Fiscal Period Focus Document Fiscal Period Focus All Executive Categories All Executive Categories [Member] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Weighted average remaining contractual term of options outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Assets Assets [Abstract] Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Document Type Document Type Prepaid financing fees Prepaid Financing Fees Prepaid Financing Fees Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Software Development Costs Internal Use Software, Policy [Policy Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] 2027 Finance Lease, Liability, to be Paid, Year Three Weighted average remaining contractual term of options exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Right-of-use assets, net Lease, Right-Of-Use Asset Amount of operating and financing right of use (ROU) assets. Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Maximum Maximum [Member] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Product warranty term Standard Product Warranty, Term The duration of a warranty. Office furniture and fixtures Furniture and Fixtures [Member] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Accounts payable Accounts Payable, Current Accounting Policies [Abstract] Accounting Policies [Abstract] Leasehold improvements Leasehold Improvements [Member] Customer B Customer B [Member] Represents information pertaining to customer b. Expired (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Schedule of Black-Scholes Option-Pricing Model Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Fair value measurements Fair Value Measurement, Policy [Policy Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Less imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Total lease cost Lease, Cost Statistical Measurement [Axis] Statistical Measurement [Axis] PEO Name PEO Name Accumulated depreciation Finance Lease, Right-of-Use Asset, Accumulated Amortization Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Award Type [Domain] Award Type [Domain] Name Outstanding Recovery, Individual Name Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Variable lease cost Variable Lease, Cost Schedule of Anti-Dilutive Shares Excluded from Computation of Diluted Net Let per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Non-PEO NEO Non-PEO NEO [Member] Title of Individual [Axis] Title and Position [Axis] Amortization period of capitalized software costs Finite-Lived Intangible Asset, Useful Life Customer C Customer C [Member] Represents information pertaining to customer c. Net decrease in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Additional paid-in capital Additional Paid-in Capital [Member] Lease liabilities, long-term Finance Lease, Liability, Noncurrent Award Timing Predetermined Award Timing Predetermined [Flag] Software development amortization expense Capitalized Computer Software, Amortization Restricted cash Guaranteed investment certificates Restricted Cash, Noncurrent Recently issued accounting pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Product warranties Standard Product Warranty, Policy [Policy Text Block] Net loss per share - diluted (in dollars per share) Net loss per share attributable to common stockholders - diluted (in dollars per share) Earnings Per Share, Diluted Class of Stock [Axis] Class of Stock [Axis] Title of Individual [Domain] Title and Position [Domain] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] 2028 Finance Lease, Liability, to be Paid, Year Four Revenue recognition Revenue from Contract with Customer [Policy Text Block] Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Accrued vendor expenses Vendor Accruals, Current Carrying value as of the balance sheet date of current portion of obligations incurred through that date and payable for vendor accruals. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer) Deferred revenue Increase (Decrease) in Contract with Customer, Liability Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Sale of investments Proceeds from Sale of Debt Securities, Available-for-Sale Schedule of Outstanding Common Stock Warrants Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Number of operating segments Number of Operating Segments Maximum value of shares available for purchase per employee Share-Based Compensation Arrangement By Share-Based Payment Award, Maximum Employee Subscription Amount Share-Based Compensation Arrangement By Share-Based Payment Award, Maximum Employee Subscription Amount Retirement Benefits [Abstract] Retirement Benefits [Abstract] Preferred stock, issued (in shares) Preferred Stock, Shares Issued Customer [Axis] Customer [Axis] Schedule of Assets and Liabilities Measured on a Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Switzerland SWITZERLAND Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] U.S. Government Treasury Bills US Treasury Bill Securities [Member] Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Sales and marketing Selling and Marketing Expense 2021 Plan 2021 Incentive Award Plan Represents information pertaining to 2021 Incentive award plan. Income tax expense Income Tax Expense (Benefit) Other income (expense): Nonoperating Income (Expense) [Abstract] Deposits Deposits Assets, Current Short-term investments Debt Securities, Available-for-Sale, Current Supplemental disclosure of cash flow information Supplemental Cash Flow Information [Abstract] Weighted average recognition period Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Customer A Customer A [Member] Represents information pertaining to customer a. Total revenue Revenue from Contract with Customer, Excluding Assessed Tax Thereafter Lessee, Operating Lease, Liability, To Be Paid, Due After Year Four Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Total other income, net Nonoperating Income (Expense) Service Service [Member] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Cash held in banks outside of the US Cash Equivalents, at Carrying Value Provision for excess and obsolete inventory Inventory Write-down Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Net cash provided by investing activities Net Cash Provided by (Used in) Investing Activities Loss from operations Operating Income (Loss) Additional shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Vice President, Legal Vice President [Member] 2024 (excluding the nine months ended September 30) Finance Lease, Liability, to be Paid, Remainder of Fiscal Year Number of reportable segments Number of Reportable Segments Total liabilities and stockholders' equity equity liabilities and Equity Common Stock Warrants Warrants to purchase common stock Common Stock Warrants [Member] Common Stock Warrants Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] All Adjustments to Compensation All Adjustments to Compensation [Member] Accrued employee compensation and benefits expense Employee-related Liabilities, Current Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Additional paid-in capital Additional Paid in Capital July 14, 2021 July 14, 2021 Represents information pertaining to July 14 2021. 2026 Finance Lease, Liability, to be Paid, Year Two Restructuring related charges Restructuring Charges Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table] Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table] Interest income, net Interest Income (Expense), Nonoperating Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Inventory adjustments Inventory Adjustments Obtaining a right of operating assets in exchange for lease liability Investing non-cash activities - establishment of right of use operating assets Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Underlying Security Market Price Change Underlying Security Market Price Change, Percent Major Customers Major Customers [Member] Represents information pertaining to significant or major customers. Individual: Individual [Axis] Vesting of restricted stock units Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Accumulated other comprehensive loss AOCI Attributable to Parent [Member] Forfeited (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Expected term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Inventory Total Inventory, Net Product and Service [Axis] Product and Service [Axis] Entity Address, State or Province Entity Address, State or Province Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Statement [Line Items] Statement [Line Items] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Schedule of Property and Equipment Property, Plant and Equipment [Table Text Block] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Financial Instruments [Domain] Financial Instruments [Domain] Unvested units at beginning of period (in dollars per share) Unvested units at end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Liabilities and Stockholders' equity equity Liabilities and Equity [Abstract] Supplemental disclosure of non-cash investing activities Noncash Investing Items [Abstract] NA. Software Development Software Development [Member] Minimum Minimum [Member] Restatement Determination Date Restatement Determination Date Options vested and expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Long-term investments Debt Securities, Available-for-Sale, Noncurrent Adoption Date Trading Arrangement Adoption Date Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Non-current deferred revenue Contract with Customer, Liability, Noncurrent Amortization of software development costs Capitalized Computer Software, Accumulated Amortization Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Outstanding at beginning of period (in dollars per share) Outstanding at end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Operating lease assets Operating Lease, Right-of-Use Asset Concentration Risk [Table] Concentration Risk [Table] Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Outstanding at beginning of period (in shares) Outstanding at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Exercise Price Award Exercise Price All other countries All Other Countries [Member] Represents information pertaining to all other countries other than US, Germany and Switzerland. Net loss per share Earnings Per Share [Text Block] Arrangement Duration Trading Arrangement Duration Issuance of Class A common stock under ESPP Stock Issued During Period, Value, Employee Stock Purchase Plan Schedule of ESPP Black-Scholes Option-Pricing Model Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block] Leases Lessee, Finance Leases [Text Block] Issuance of Class A common stock upon exercise of common stock options Stock Issued During Period, Value, Stock Options Exercised Stockholders' equity equity: Equity, Attributable to Parent [Abstract] Weighted average grant-date fair value per share of units granted (in dollars per share) Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Warranty provisions Standard Product Warranty Accrual, Increase for Warranties Issued Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Restructuring Plan [Axis] Restructuring Plan [Axis] Schedule of Finance Lease Liability Maturities Finance Lease, Liability, to be Paid, Maturity [Table Text Block] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Total financing lease liabilities Total present value of lease liabilities Finance Lease, Liability All Individuals All Individuals [Member] PEO PEO [Member] Contract with Customer, Duration [Domain] Contract with Customer, Duration [Domain] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Name Trading Arrangement, Individual Name Other expense, net Other Nonoperating Income (Expense) Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Gross unrealized gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Other long-term assets Increase (Decrease) in Other Noncurrent Assets Proceeds from issuance of Class A common stock - stock option exercise Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Unrecognized compensation expense related to units Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Schedule of Concentration Risk Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Financing lease cost - interest on lease liability Finance Lease, Interest Expense, Including Adjustments Finance Lease, Interest Expense, Including Adjustments Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Shares reserved (in shares) Shares available for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Depreciation and amortization expense Cost, Depreciation and Amortization Product and service revenue â€ recurring Recurring Contract With Customer [Member] Recurring Contract With Customer Local Phone Number Local Phone Number Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Germany GERMANY Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] PEO Total Compensation Amount PEO Total Compensation Amount Discount percentage from market price Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Schedule of Accrued Expenses and Other Current Liabilities Schedule of Accrued Liabilities [Table Text Block] Income Statement Location [Axis] Statement of Income Location, Balance [Axis] Entity Ex Transition Period Entity Ex Transition Period Options vested and expected to vest (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Commitments and contingencies Commitments and Contingencies Disclosure [Text Block] Common stock Common Stock [Member] Measure: Measure [Axis] Preferred stock, authorized (in shares) Preferred Stock, Shares Authorized Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Entity Emerging Growth Company Entity Emerging Growth Company Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Revenue: Operating Income (Loss) [Abstract] Entity Central Index Key Entity Central Index Key Thereafter Finance Lease, Liability, To Be Paid, Due After Year Four Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). General and administrative General and Administrative Expense [Member] Schedule of Inventory Schedule of Inventory, Current [Table Text Block] Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Accrued expenses and other current liabilities Accounts Payable, Accrued Liabilities,

Other Liabilities Disclosure, Current [Text Block] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Customer D Customer D [Member] Represents information pertaining to customer d. Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Accretion on investments Accretion Of Debt Securities, Available-For-Sale Accretion Of Debt Securities, Available-For-Sale Net property, plant and equipment Finance Lease, Right-of-Use Asset, after Accumulated Amortization Balance, beginning of period Balance, end of period Standard Product Warranty Accrual Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Equity Component [Domain] Equity Component [Domain] Preferred Stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Financial Instrument [Axis] Financial Instrument [Axis] Restricted stock award liability accretion Adjustments To Additional Paid In Capital, Accretion Of Restricted Stock Award Liability Amount of increase (decrease) in additional paid in capital (APIC) due to RSA liability accretion, Japan JAPAN Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Unvested restricted common stock Restricted Stock [Member] Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Class B Common stock Common Class B [Member] Title Trading Arrangement, Individual Title April 12, 2018 April 12, 2018 Represents the information pertaining to April 12, 2018. Accounting Policies [Line Items] Accounting Policies [Line Items] Accounting Policies Statement [Table] Statement [Table] Measurement Frequency [Domain] Measurement Frequency [Domain] Summary of significant accounting policies Significant Accounting Policies [Text Block] Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] 2023 Inducement Plan 2023 Inducement Plan [Member] 2023 Inducement Plan City Area Code City Area Code Current liabilities: Liabilities, Current [Abstract] Computer hardware and software Computer Equipment And Software [Member] Represents information pertaining to computer hardware and software. Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Remaining restructuring payments Restructuring and Related Cost, Expected Cost Remaining Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Level 1 Fair Value, Inputs, Level 1 [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Total current assets Assets, Current Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Cash paid for amounts included in measurement of lease liabilities: Cash Flow, Lessee [Abstract] Cash Flow, Lessee Amortized cost Debt Securities, Available-for-Sale, Amortized Cost, after Allowance for Credit Loss Options exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Document Information [Line Items] Document Information [Line Items] Weighted average remaining contractual term Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term [Abstract] No definition available. Weighted average fair value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Weighted average grant-date fair value of stock options granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Income taxes Income Tax Disclosure [Text Block] 2028 Lessee, Operating Lease, Liability, to be Paid, Year Four Customer F Customer F [Member] Represents information pertaining to customer f. Earnings Per Share [Abstract] Earnings Per Share [Abstract] Raw materials Inventory, Raw Materials, Net of Reserves July 24, 2017 July 24, 2017 Represents the information pertaining to July 24, 2017. Accumulated deficit Retained Earnings (Accumulated Deficit) Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Class of Stock [Domain] Class of Stock [Domain] Revenue Benchmark Revenue from Contract with Customer Benchmark [Member] Inventory Increase (Decrease) in Inventories 2010 Plan 2010 Stock Option And Grant Plan [Member] Represents information pertaining to Stock Option and Grant Plan 2010. General and administrative General and Administrative Expense Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Weighted-average discount rate - operating leases: Operating Lease, Weighted Average Discount Rate, Percent Total operating lease liabilities Operating Lease, Liability Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Underlying Securities Award Underlying Securities Amount Investments Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Cash dividends Dividends, Common Stock, Cash Amendment Flag Amendment Flag Entity Registrant Name Entity Registrant Name Depreciation and interest expense Finance Lease, Depreciation And Interest Expense Total capital lease asset depreciation and interest expense during the period. Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Depreciation and amortization expense Depreciation, Depletion and Amortization Schedule of Product Warranties Schedule of Product Warranty Liability [Table Text Block] Fair Value as of Grant Date Award Grant Date Fair Value Financing lease cost - amortization of right-of-use asset Finance Lease, Right-of-Use Asset, Amortization Customer Concentration Risk Customer Concentration Risk [Member] Aggregate intrinsic value of options vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Level 2 Fair Value, Inputs, Level 2 [Member] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Geographical [Domain] Geographical [Domain] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Schedule of Disaggregated Revenue Disaggregation of Revenue [Table Text Block] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Advertising costs Advertising Expense Schedule of Stock-Based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Restructuring Cost [Table] Restructuring Cost [Table] Restatement Determination Date: Restatement Determination Date [Axis] Customer H Customer H [Member] Represents information pertaining to customer a. Title of 12(b) Security Title of 12(b) Security Concentration Risk Type [Axis] Concentration Risk Type [Axis] Common stock Common Stock, Value, Issued Operating cash outflows - payments on financing leases Finance Lease, Interest Payment on Liability Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Lease liabilities, long-term Lease, Liability, Noncurrent Amount of operating and finance lease liability classified as non current. Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Loss before income taxes Income (Loss) Attributable to Parent, before Tax Certificates of Deposit Certificates of Deposit [Member] Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] U.S. Government Treasury Notes - Maturity Up To Two Years US Treasury Notes Securities [Member] Accrued Liabilities, Current [Abstract] Accrued Liabilities, Current [Abstract] Total present value of lease liabilities Operating Lease, Liability, Including Tenant Improvement Allowance Operating Lease, Liability, Including Tenant Improvement Allowance Forfeited (in dollars per shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 2021 ESPP 2021 Employee Stock Purchase Plan Represents information relating to 2021 Employee Stock Purchase Plan. Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Concentration Risk [Line Items] Concentration Risk [Line Items] Preferred stock, \$0.01 par value: 10,000,000 shares authorized at September 30, 2024 and December 31, 2023; zero shares issued and outstanding at September 30, 2024 and December 31, 2023 Preferred Stock, Value, Issued Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration] Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Number of shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Rent expense Operating Lease, Rental Expense Total rental expense under operating leases. Employee Stock Options to purchase common stock under ESPP Employee Stock [Member] Net loss per share - basic (in dollars per share) Net loss per share attributable to common stockholders - basic (in dollars per share) Earnings Per Share, Basic Accounts payable Increase (Decrease) in Accounts Payable Proceeds from issuance of Class A common stock - employee stock purchase plan Proceeds from Stock Plans Operating cash outflows - payments on operating leases Operating Lease, Payments Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Plan term Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Payments on finance lease obligations Financing cash outflows - payments on financing leases Finance Lease, Principal Payments Purchases of property and equipment in accounts payable and accrued expenses Capital Expenditures Incurred but Not yet Paid Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Customer I Customer I [Member] Customer I Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Total current liabilities Liabilities, Current Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Unrecognized compensation expense Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Total assets Assets Schedule of Supplemental Balance Sheet Information Assets And Liabilities, Lessee [Table Text Block] Assets And Liabilities, Lessee Risk of concentrations of credit, significant customers and significant suppliers Concentration Risk, Credit Risk, Policy [Policy Text Block] Advertising costs Advertising Cost [Policy Text Block] Units granted (in shares) Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Other long-term liabilities Other Liabilities, Noncurrent Movement in Standard Product Warranty Accrual [Roll Forward] Movement in Standard Product Warranty Accrual [Roll Forward] Percentage of aggregate number of shares outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Commitments and contingencies (Note 14) Commitments and Contingencies Stock-based compensation Share-Based Payment Arrangement [Policy Text Block] Termination Date Trading Arrangement Termination Date Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Nature of the business and basis of presentation Business Description and Basis of Presentation [Text Block] Weighted average exercise price (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] 2026 Lessee, Operating Lease, Liability, to be Paid, Year Two Stock-based compensation Share-Based Payment Arrangement [Text Block] Financing Leases: Finance Lease, Right-of-Use Asset, after Accumulated Amortization [Abstract] Maximum number of shares issuable upon exercise of stock option (in shares) Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Issuable Upon Exercise Of Stock Option, Maximum Maximum number of shares issuable upon exercise of stock option under the share based payment arrangement plan. Entity Address, City or Town Entity Address, City or Town Offering period Share-Based Compensation Arrangement By Share-Based Payment Award, Offering Period Share-Based Compensation Arrangement By Share-Based Payment Award, Offering Period Leases Lessee, Leases [Policy Text Block] Schedule of Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Number of votes per share held Number Of Votes Per Common Stock Share Held Number of votes each common stock holder is entitled to vote. Intrinsic value of stock options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Stock-based compensation expense Total stock-based compensation expense Share-Based Payment Arrangement, Expense Net loss Net loss Income (Loss) Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] Investments, Debt and Equity Securities [Abstract] Conversion of Class B common stock to Class A common stock Stock Issued During Period, Value, Conversion of Convertible Securities Granted (in dollars per share) Options granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Shares purchased under plan (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Entity File Number Document Fiscal Year Focus Document Fiscal Year Focus Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Denominator: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Operating lease term Lessee, Operating Lease, Term of Contract Restructuring Plan [Domain] Restructuring Plan [Domain] Other Other Accrued Liabilities, Current Assets Assets, Fair Value Disclosure Accrued expenses and other current liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Name Forgone Recovery, Individual Name 2024 (excluding the nine months ended September 30) Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Aggregate intrinsic value of options exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Weighted-average remaining lease term - operating leases (in years): Operating Lease, Weighted Average Remaining Lease Term Award Date [Domain] Award Date [Domain] Document Period End Date Document Period End Date Lease liabilities, short-term Finance Lease, Liability, Current Finished goods Inventory, Finished Goods, Net of Reserves Other Other Noncash Income (Expense) Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Total lease payments Lessee, Operating Lease, Liability, to be Paid Unvested units at beginning of period (in shares) Unvested units at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Insider Trading Arrangements [Line Items] Contract assets Contract with Customer, Asset, after Allowance for Credit Loss Finance lease term Lessee, Finance Lease, Term of Contract Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount 2027 Lessee, Operating Lease, Liability, to be Paid, Year Three PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Common stock and common stock warrants Common Stock And Common Stock Warrants [Text Block] The entire disclosure for common stock and common stock warrants. Cost of revenue Cost of Revenue Revenue recognized which was included in deferred revenue in prior period Contract with Customer, Liability, Revenue Recognized Adjustment to Compensation: Adjustment to Compensation [Axis] Prepaid expenses and other current assets Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Accounts Receivable Accounts Receivable [Member] Document Transition Report Document Transition Report Document Quarterly Report Document Quarterly Report Noncash lease expense Leases, Noncash Expense Amount of noncash lease expense included in net income that result in no cash flow. Number of finance lease renew options Lessee, Finance Lease, Number Of Renewal Options Lessee, Finance Lease, Number Of Renewal Options Lease liabilities, short-term Lease, Liability, Current Amount of operating and finance lease liability classified as current. Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Customer [Domain] Customer [Domain] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Current Reporting Status Entity Current Reporting Status Accumulated deficit Retained Earnings [Member] Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Long-term Investments Long-Term Investments [Member] Investments which are not otherwise included in another category or item that the entity has the intent to not sell or dispose of within one year from the date of the balance sheet. Weighted average common shares outstanding - basic (in shares) Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Software development costs, net of amortization Capitalized Computer Software, Net Document Information [Table] Document Information [Table] Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Executive Category: Executive Category [Axis] Name Awards Close in Time to MNPI Disclosures, Individual Name Construction-in-process Construction in Progress [Member] Contract

[illegible]

Accounts payable 2,329 1,973 Accrued expenses and other current liabilities 7,038 9,907 Deferred revenue 5,360 5,974 Lease liabilities, short-term 1,193 1,132 Total current liabilities 15,920 18,986 Lease liabilities, long-term 5,261 6,214 Other long-term liabilities 289 263 Total liabilities 21,470 25,463 Commitments and contingencies (Note 14) Stockholdersâ€™ equity: A Preferred stock, \$0.01 par value: 10,000,000 shares authorized at SeptemberA 30, 2024 and DecemberA 31, 2023; zero shares issued and outstanding at SeptemberA 30, 2024 and DecemberA 31, 2023 0 0 Additional paid-in capital 549,468 546,051 Accumulated deficit (465,608) (428,385) Accumulated other comprehensive loss 83 (101) Total stockholdersâ€™ equity 84,373 117,989 Total liabilities and stockholdersâ€™ equity 105,843 143,452 Class A Common stock A Stockholdersâ€™ equity: A Common stock 377 371 Class B Common stock A Stockholdersâ€™ equity: A Common stock \$ 53 X 53 X - DefinitionAmount of operating and finance lease liability classified as current. + ReferencesNo definition available. + Details Name: rmb_LeaseLiabilityCurrent Namespace Prefix: rmb_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of operating and finance lease liability classified as non current. + ReferencesNo definition available. + Details Name: rmb_LeaseLiabilityNoncurrent Namespace Prefix: rmb_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of operating and financing right of use (ROU) assets. + ReferencesNo definition available. + Details Name: rmb_LeaseRightOfUseAsset Namespace Prefix: rmb_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-599-1>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10> + Details Name: us-gaap AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481990/310-10-45-2> + Details Name: us-gaap AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-599-1> + Details Name: us-gaap AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-14>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-14>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(iii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480016/944-40-65-2>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480016/944-40-65-2>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-599-1>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-599-1>Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-14> + Details Name: us-gaap AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-599-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-599-1> + Details Name: us-gaap AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482785/280-10-55-49>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482964/270-10-50-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 5: <http://fasb.org/us-gaap/role/ref/otherTransitionRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481203/810-10-50-3>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481231/810-10-45-25>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(i)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-599-1>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 12: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 13: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-12>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-599-1>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-599-1>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-599-1>Reference 17: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-599-1>Reference 18: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-599-1>Reference 19: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-599-1>Reference 20: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-599-1>Reference 21: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-599-1>Reference 22: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-599-1>Reference 23: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-599-1>Reference 24: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-599-1>Reference 25: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-599-1>Reference 26: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-599-1>Reference 27: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-599-1>Reference 28: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481404/852-10-50-7>Reference 29: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-30>Reference 30: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478546/942-210-599-1> + Details Name: us-gaap Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481203/810-10-50-3>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481231/810-10-45-25>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(i)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-599-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 6: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483467/210-10-45-1>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-599-1>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-599-1>Reference 10: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-599-1>Reference 11: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-599-1>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-599-1>Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-599-1>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-599-1>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-599-1>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-599-1>Reference 17: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-599-1>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-599-1>Reference 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI [https://asc.fasb.org/19432](https://asc.fasb.org/1943274/2147480097/470-10-599-1)

https://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap AvailableForSaleSecuritiesDebtSecuritiesNoncurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap CommitmentsAndContingencies Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap CommonStockValue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap ContractWithCustomerLiabilityCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap InventoryNet Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc

Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 20: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7)Reference 21: [http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: <a href=)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 210 -Topic 954 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: <a href=)Reference 3: [http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details Name: us-gaap_RestrictedCashNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(h\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2)Reference 5: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(6\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: <a href=)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(7\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 11: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 13: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.6-05\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: <a href=)Reference 3:

22Reference 10:

that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1:

A common stock upon exercise of common stock options (in shares) Â Â Â 9,256 Â Â Â Â Issuance of Class A common stock upon exercise of common stock options Â Â Â 7 Â Â 7 Â Â Stock-based compensation expense 929 Â Â Â Â 929 Â Â Â Net loss (11,323) Â Â Â Â (11,323) Â Other comprehensive income (loss) 108 Â Â Â Â Â 108 Balance at end of period (in shares) at Sep. 30, 2024 Â 37,715,205 5,309,529 Â 37,715,205 5,309,529 Â Â Balance at end of period at Sep. 30, 2024 Â \$4,373 Â Â Â Â \$ 377 \$ 53 \$ 549,468 \$ (465,608) \$ 83 X - DefinitionAmount of increase (decrease) in additional paid in capital (APIC) due to RSA liability accretion. + ReferencesNo definition available. + Details Name: rmb AdjustmentsToAdditionalPaidInCapitalAccretionOfRestrictedStockAwardLiability Namespace Prefix: rmb Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480483/718-10-35-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481089/718-20-55-13>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481089/718-20-55-12> + Details Name: us-gaap AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-2>Reference 4: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubParagraph 3 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 6: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3> + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap Data Type: xbrli:sharesItemBalance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward Namespace Prefix: us-gaap Data Type: xbrli:stringItemBalance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147476176/805-60-65-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478666/740-323-65-2>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482765/220-10-50-6>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-1>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480175/815-40-65-1>Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 17: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-10>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479105/946-220-45-7>Reference 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1>Reference 20: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-1>Reference 21: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-1>Reference 22: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 23: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 24: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 25: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 26: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 27: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 28: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 29: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 30: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 31: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 32: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-60B>Reference 33: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 34: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 35: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1>Reference 36: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1>Reference 37: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478524/942-220-S99-1> + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemBalance Type: credit Period Type: duration X - DefinitionAmount after tax of other comprehensive income (loss) attributable to parent entity. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481231/810-10-45-19>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481231/810-10-45-20>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481203/810-10-50-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1>Reference 6: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-3> + Details Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities Namespace Prefix: us-gaap Data Type: xbrli:sharesItemBalance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period as a result of an employee stock purchase plan. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1> + Details Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans Namespace Prefix: us-gaap Data Type: xbrli:sharesItemBalance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1> + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap Data Type: xbrli:sharesItemBalance Type: na Period Type: duration X - DefinitionThe gross value of stock issued during the period upon the conversion of convertible securities. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph

SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap StockIssuedDuringPeriodValueConversionOfConvertibleSecurities Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAggregate change in value for stock issued during the period as a result of employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of stock options. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap StockIssuedDuringPeriodValueStockOptionsExercised Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap StockholdersEquity Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 19 R7.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed consolidated statements of cash flows - USD (\$) \$ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Cash flows from operating activities: $\hat{A}$ Net loss \$ (37,223) \$ (41,295) Adjustments to reconcile net loss to net cash used in operating activities: $\hat{A}$ Depreciation and amortization expense 2,493 2,311 Stock-based compensation expense 3,185 3,728 Provision for excess and obsolete inventory 95 34 Noncash lease expense 862 899 Accretion on investments (985) (1,766) Other 25 26 Changes in operating assets and liabilities: $\hat{A}$ Accounts receivable 1,792 1,462 Inventory (1,388) 960 Prepaid expenses and other current assets 759 1,817 Other long-term assets (150) 5 Accounts payable 357 (2,157) Accrued expenses and other current liabilities (3,451) (1,462) Deferred revenue (615) (146) Net cash used in operating activities (34,244) (35,584) Cash flows from investing activities: $\hat{A}$ Purchases of property and equipment (1,267) (1,427) Purchases of investments (29,496) (50,928) Sale of investments 3,957 0 Maturity of investments 58,600 84,500 Net cash provided by investing activities 31,794 32,145 Cash flows from financing activities: $\hat{A}$ Proceeds from issuance of Class A common stock - stock option exercise 7 6 Proceeds from issuance of Class A common stock - employee stock purchase plan 231 182 Payments on finance lease obligations (29) (27) Net cash provided by financing activities 209 161 Net decrease in cash, cash equivalents and restricted cash (2,241) (3,278) Cash, cash equivalents and restricted cash at beginning of period 24,569 27,348 Cash, cash equivalents and restricted cash at end of period 22,328 24,070 Supplemental disclosure of cash flow information $\hat{A}$ Cash paid for interest 27 29 Supplemental disclosure of non-cash investing activities $\hat{A}$ Obtaining a right of operating assets in exchange for lease liability 0 151 Purchases of property and equipment in accounts payable and accrued expenses \$ 28 \$ 204 X - DefinitionAccretion Of Debt Securities, Available-For-Sale + ReferencesNo definition available. + Details Name: rmb AccretionOfDebtSecuritiesAvailableForSale Namespace Prefix: rmb Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of noncash lease expense included in net income that result in no cash flow. + ReferencesNo definition available. + Details Name: rmb LeasesNoncashExpense Namespace Prefix: rmb Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNA. + ReferencesNo definition available. + Details Name: rmb NoncashInvestingItemsAbstract Namespace Prefix: rmb Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFuture cash outflow to pay for purchases of fixed assets that have occurred. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap CapitalExpendituresIncurredButNotYetPaid Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 + Details Name: us-gaap DepreciationDepletionAndAmortization Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow for principal payment on finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5 + Details Name: us-gaap FinanceLeasePrincipalPayments Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in accrued expenses, and obligations classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap IncreaseDecreaseInContractWithCustomerLiability Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap IncreaseDecreaseInInventories Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap IncreaseDecreaseInOtherNoncurrentAssets Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1:

<http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - Definition Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-17>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-25>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482913/230-10-50-2> + Details Name: us-gaap InterestPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - Definition Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483080/330-10-50-2> + Details Name: us-gaap InventoryWriteDown Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - Definition Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-24> + Details Name: us-gaap NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Definition Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-24> + Details Name: us-gaap NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Definition Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-25> + Details Name: us-gaap NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147476176/805-60-65-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478666/740-323-65-2>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482765/220-10-50-6>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-1>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480175/815-40-65-1>Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 17: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-10>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479105/946-220-45-7>Reference 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1>Reference 20: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-1>Reference 21: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 22: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 23: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 24: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 25: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 26: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 27: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 28: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 29: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 30: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 31: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 32: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-60B>Reference 33: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 34: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 35: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1A>Reference 36: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1B>Reference 37: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478524/942-220-S99-1> + Details Name: us-gaap NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - Definition Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap OtherNoncashIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - Definition Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481830/320-10-45-11>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-13>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2A> + Details Name: us-gaap ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - Definition Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481830/320-10-45-11>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481800/320-10-50-9>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-12>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-11> + Details Name: us-gaap ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - Definition Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481830/320-10-45-11>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481800/320-10-50-9>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-12>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-11> + Details Name: us-gaap ProceedsFromSaleOfAvailableForSaleSecuritiesDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - Definition The cash inflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-13> + Details Name: us-gaap PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - Definition Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-14>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-14> + Details Name: us-gaap ProceedsFromStockPlans Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - Definition Amount of increase in right-of-use asset obtained in exchange for operating lease liability. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479589/842-20-55-53>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 53 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479589/842-20-55-53>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 842 -SubTopic 20 -Name Accounting Standards

Paragraph 4 -Subparagraph (g)(2)- Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 20 R8.htm IDEA: XBRL DOCUMENT v3.24.3 Nature of the business and basis of presentation 9 Months Ended Sep. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] A Nature of the business and basis of presentation Nature of the business and basis of presentationRapid Micro Biosystems, Inc. (the "Company") was incorporated under the laws of the State of Delaware on December 29, 2006. The Company develops, manufactures, markets and sells Growth Direct systems ("Systems") proprietary consumables, laboratory information management system ("LIMS") connection software, and services to address rapid microbial analysis used for quality control in the manufacture of pharmaceuticals, medical devices and personal care products. The Company's technology uses a highly sensitive camera and the natural auto fluorescence of living cells to identify and quantify microbial growth faster and more accurately than the traditional method, which relies on the human eye. The Company currently sells to customers in North America, Europe and the Asia-Pacific region. The Company is headquartered in Lexington, Massachusetts.Basis of presentationThese condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") and include the accounts of the Company and its wholly owned subsidiaries in Germany and Switzerland. All intercompany accounts and transactions have been eliminated in consolidation. Certain information and note disclosures normally included in the consolidated financial statements prepared in accordance with GAAP have been condensed or omitted. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the Company's audited consolidated financial statements for the year ended December 31, 2023. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification ("ASC") and Accounting Standards Update ("ASU") of the Financial Accounting Standards Board ("FASB"). The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company's financial position as of September 30, 2024 and the results of its operations and its cash flows for the three and nine months ended September 30, 2024 and 2023. The financial data and other information disclosed in these notes related to the three and nine months ended September 30, 2024 and 2023 are also unaudited. The results for the three and nine months ended September 30, 2024 are not necessarily indicative of results to be expected for the year ending December 31, 2024, any other interim periods, or any future year or period.LiquidityThe Company has incurred recurring losses and net cash outflows from operations since its inception. The Company expects to continue to generate operating losses for the foreseeable future. The Company expects that its existing cash and cash equivalents and investments will be sufficient to fund its operating expenses and capital expenditure requirements for at least twelve months following the date these unaudited interim condensed consolidated financial statements were issued. X - DefinitionThe entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details Name: us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 21 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of significant accounting policies 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] A Summary of significant accounting policies Summary of significant accounting policiesUse of estimatesThe preparation of the Company's condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, calculating the standalone selling price for revenue recognition, the valuation of inventory, and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific and relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.There have been no significant changes to the Company's significant accounting policies during both the three and nine months ended September 30, 2024, as compared to those disclosed in Note 2 of the audited consolidated financial statements as of December 31, 2023 filed with the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023.Risk of concentrations of credit, significant customers and significant suppliersFinancial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents, short-term and long-term investments and accounts receivable. The Company maintains its cash and cash equivalents and investments with financial institutions that management believes to be of high credit quality, and does not believe that it is subject to unusual credit risk beyond the credit risk associated with commercial banking relationships.Significant customers are those which represent more than 10% of the Company's total revenue or accounts receivable balance at each respective balance sheet date. The following table presents customers that represented 10% or more of the Company's total revenue:Three Months Ended September 30,Nine Months Ended September 30,2024202320242023Customer A21.0%*11.6%*Customer B*14.7%*14.1%*18.2%*Customer C*11.4%**Customer D*10.2%***21.0%*36.3%*25.7%*18.2%*The following table presents customers that represented 10% or more of the Company's accounts receivable:September 30,December 31,20242023Customer E12.8%*21.4%*Customer F12.5%*Customer G12.3%*Customer H*16.4%*Customer I*12.4%*Customer B*10.7%*37.6%*60.9%* *less than 10%The Company relies on third parties for the supply and manufacture of certain components of its products as well as third-party logistics providers. There were no significant concentrations around a single third-party supplier, manufacturer, or logistics provider for the three and nine months ended September 30, 2024 or 2023.Cash and cash equivalentsThe Company considers all highly liquid investments with an original maturity of 90 days or less at the time of purchase to be cash equivalents. Cash equivalents that are readily convertible to cash are stated at cost, which approximates fair value. At both September 30, 2024 and December 31, 2023, the Company held cash of \$0.1 million in banks located outside of the United States.Restricted cashAs of both September 30, 2024 and December 31, 2023, the Company was required to maintain guaranteed investment certificates of \$0.3 million with maturities of three months to one year that are subject to an insignificant risk of changes in value. The guaranteed investment certificates are held for the benefit of the landlord in connection with operating leases which have remaining terms of greater than one year and are classified as restricted cash (non-current) on the Company's condensed consolidated balance sheets.Accounts receivableAccounts receivable are customer obligations that are unconditional. Accounts receivable are presented net of an allowance for doubtful accounts for expected credit losses, which represents an estimate of amounts that may not be collectible. The Company performs ongoing credit evaluations of its customers and, if necessary, provides an allowance for doubtful accounts and expected credit losses. A provision to the allowance for doubtful accounts for expected credit losses is recorded based on factors including the length of time the receivables are past due, the current business environment, the geographic market, and the Company's historical experience. Provisions to the allowance for doubtful accounts for expected credit losses are recorded to general and administrative expenses in the consolidated statements of operations. The Company writes off accounts receivable against the allowance when it determines a balance is uncollectible and no longer actively pursues collection of the receivable. The Company does not have any off-balance-sheet credit exposure related to customers. As of September 30, 2024 and December 31, 2023, the allowance for doubtful accounts for expected credit losses was zero.Software Development CostsThe Company accounts for software development costs for internal-use software under the provisions of ASC 350-40, "Internal-Use Software" ("ASC 350-40"). Accordingly, certain costs to develop internal-use computer software are capitalized, provided these costs are expected to be recoverable. There was \$1.6 million and \$1.4 million of software development costs related to the Company's enterprise resource planning ("ERP") system capitalized in other long-term assets at September 30, 2024 and December 31, 2023, respectively, net of accumulated amortization of \$1.0 million and \$0.7 million, respectively. These capitalized costs are being amortized on a straight-line basis over the initial subscription term of five years. For the three and nine months ended September 30, 2024 and 2023, there was \$0.1 million and \$0.3 million, respectively, of amortization expense related to capitalized software development costs recorded in the condensed consolidated statements of operations.Fair value measurementsCertain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: "Level 1" Quoted prices in active markets for identical assets or liabilities. "Level 2" Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. "Level 3" Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. The Company's cash equivalents, short-term and long-term investments are carried at fair value, determined according to the fair value hierarchy described above (see Note 3). The carrying values of the Company's accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses and other current liabilities approximate their fair values due to the short-term nature of these assets and liabilities.Product warrantiesThe Company offers a one-year limited assurance warranty on System sales, which is included in the selling price. The accrual for these warranty obligations is included in accrued expenses and other current liabilities in the condensed consolidated balance sheets. The following table presents a summary of changes in the amount reserved for warranty cost (in thousands):Three Months Ended September 30,Nine Months Ended September 30,2024202320242023Balance, beginning of period\$520A \$526A \$689A \$872A Warranty provisions\$A 171A \$A 171A Warranty repairs\$A 46A \$A 169(346)Balance, end of period\$520A \$697A \$520A \$697A Segment informationThe Company determined its operating segment after considering the Company's organizational structure and the information regularly reviewed and evaluated by the Company's chief operating decision maker ("CODM") in deciding how to allocate resources and assess performance. The Company has determined that its CODM is its Chief Executive Officer. The CODM reviews the financial information on a consolidated basis for purposes of evaluating financial performance and allocating resources. On the basis of these factors, the Company determined that it operates and manages its business as one operating segment, that develops, manufactures, markets and sells Systems and related LIMS connection software, consumables and services; and accordingly has one reportable segment for financial reporting purposes. Substantially all of the Company's long-lived assets are held in the United States.Revenue recognitionRemaining performance obligationsThe Company does not disclose the value of remaining performance obligations for (i) contracts with an original contract term of one year or less, (ii) contracts for which the Company recognizes revenue at the amount to which it has the right to invoice when that amount corresponds directly with the value of services performed, and (iii) variable consideration allocated entirely to a wholly unsatisfied performance obligation or to a wholly unsatisfied distinct service that forms part of a single performance obligation. The Company does not have material remaining performance obligations associated with contracts with terms greater than one year.Contract balances from contracts with customersContract assets arise from customer arrangements when revenue recognized exceeds the amount billed to the customer and the Company's right to payment is conditional and not only subject to the passage of time. The Company had \$0.2 million and \$0.1 million in contract assets as of September 30, 2024 and December 31, 2023, respectively, included in prepaid expenses and other current assets. Contract liabilities represent the Company's obligation to transfer goods or services to a customer for which it has received consideration (or the amount is due) from the customer. The Company has a contract liability related to service revenue, which consists of amounts that have been invoiced but that have not been recognized as revenue. Amounts expected to be recognized as revenue within 12 months of the balance sheet date are classified as current deferred revenue and amounts expected to be recognized as revenue beyond 12 months of the balance sheet date are classified as non-current deferred revenue. The Company did not record any non-current deferred revenue as of September 30, 2024 or December 31, 2023. Deferred revenue was \$5.4 million and \$6.0 million at September 30, 2024 and December 31, 2023, respectively. Revenue recognized during each of the three months ended September 30, 2024 and 2023 that was included in deferred revenue at the prior period-end was \$1.2 million. Revenue recognized during the nine months ended September 30, 2024 and 2023 that was included in deferred revenue at the prior period-end was \$3.9 million and \$3.3 million, respectively.Disaggregated revenueThe Company disaggregates revenue based on the recurring and non-recurring nature of the underlying sale. Recurring revenue includes sales of consumables and service contracts. The Company considers these to be recurring revenues because customers typically place purchase orders on a periodic basis as they use their Growth Direct system(s) over time. These arrangements typically contain a single performance obligation and thus the entire consideration to which the Company is entitled is allocated entirely to that performance obligation. Non-recurring revenue includes sales of systems, LIMS connection software, validation services, and field services, and typically contains multiple performance obligations. The Company considers these to be non-recurring revenues because customers typically place single purchase orders for a bundle of products and services on a one-time or infrequent basis. For these arrangements, significant judgment is applied in identifying the distinct performance obligations, determination of the transaction price, transaction price allocation, and determination of standalone selling price for each of the distinct performance obligations. The following table presents the Company's revenue by the recurring or non-recurring nature of the revenue stream (in thousands):Three Months Ended September 30,Nine Months Ended September 30,2024202320242023Product and service revenue \$ recurring\$3,675A \$3,410A \$11,262A \$10,255A Product and service revenue \$ non-recurring\$3,929A 2,735A 8,571A 5,927A Total revenue\$7,604A \$6,145A \$19,833A \$16,182A The following table presents the Company's revenue by customer geography (in thousands):Three Months Ended September 30,Nine Months Ended September 30,2024202320242023United States\$3,423A 2,665A \$8,232A \$6,987A Switzerland1,357A 1,058A 3,932A 2,991A Germany923A 478A 2,358A 1,392A Japan227A 167A 1,399A 1,621A All other countries1,674A 1,777A 3,912A 3,191A Total revenue\$7,604A \$6,145A \$19,833A \$16,182A Advertising costsAdvertising costs are expensed as incurred and are included in sales and marketing expenses in the condensed consolidated statements of operations. Advertising costs were less than \$0.1 million during each of the three months ended September 30, 2024 and 2023, and were \$0.2 million during each of the nine months ended September 30, 2024 and 2023.Stock-based compensationThe Company measures all stock-based awards granted to employees, officers and directors based on their fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. The Company issues stock-based awards with (i) service-based vesting conditions only and (ii) stock-based awards with both service-based and Company performance vesting conditions, and records the expense for these awards using the straight-line method. Forfeitures are accounted for prospectively as they occur. The Company measures all restricted stock units granted to employees based on the common stock value on the date of grant. The purchase price of the restricted stock is the common stock value on the date of grant. Recently issued accounting pronouncementsThe Company qualifies as an "emerging growth company" as defined in the Jumpstart Our Business Startups ("JOBS") Act of 2012 and has elected not to

opt-out of the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and nonpublic companies, the Company will adopt the newer revised standard at the time nonpublic companies adopt the new or revised standard and will do so until such time that the Company either (i) irrevocably elects to adopt out of such extended transition period or (ii) no longer qualifies as an emerging growth company. The Company may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for nonpublic companies. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures. The new standard requires enhanced disclosures about a public entity's reportable segments including more detailed information about a reportable segment's expenses. The amendments in this update apply to all public entities that are required to report segment information, and include those entities that have a single reportable segment. The amendments in this update are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact on its consolidated financial statements and related disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740) - Improvements to Income Tax Disclosures. ASU 2023-09 provides more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The amendments in this update are effective for annual periods beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact on its consolidated financial statements and related disclosures. X - ReferencesNo definition available. + Details Name: us-gaap AccountingPoliciesAbstract Namespace Prefix: us-gaap Data Type: xbrl:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1>Reference 2: [http://www.xbrl.org/2003/role/exampleRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 107 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 22 R10.htm IDEA: XBRL DOCUMENT v3.24.3 Fair value of financial assets and liabilities 9 Months Ended Sep. 30, 2024 Fair Value Disclosures [Abstract] A Fair value of financial assets and liabilities Fair value of financial assets and liabilitiesThe following tables present information about the Company's financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values (in thousands):Fair value measurements as of September 30, 2024Level 1Level 2Level 3TotalAssetsA A A Cash equivalents$14,293A $A $A $14,293A Short-term investments$38,788A $A $A $38,788A $53,081A $A $53,081A Fair value measurements as of December 31, 2023Level 1Level 2Level 3TotalAssetsCash equivalents$20,306A $A $A $20,306A Short-term investments$2,625A $A $2,625A Long-term investments$2,911A $A $2,911A $85,842A $5,143A $A $90,985A During the three and nine months ended September 30, 2024 and 2023, there were no transfers in or out of Level 3.Valuation of short-term and long-term investmentsU.S. Treasury bills and notes included in short-term and long-term investments were valued by the Company using quoted prices in active markets for identical securities, which represents a Level 1 measurement within the fair value hierarchy. The Company's certificates of deposit included in short-term and long-term investments were valued using quoted prices for similar assets in active markets (or identical assets in inactive markets), which represent a Level 2 measurement within the fair value hierarchy. X - ReferencesNo definition available. + Details Name: us-gaap FairValueDisclosuresAbstract Namespace Prefix: us-gaap Data Type: xbrl:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + ReferencesReference 1: <a href=)Reference 2: <http://www.xbrl.org/2003/role/exampleRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6](http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6)Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph \(h\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A](http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A](http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A](http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A](http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(h\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1) + Details Name: us-gaap FairValueDisclosuresTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML

Paragraph 1 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482662/260-10-50-1>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2) + Details Name: us-gaap_ EarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 32 R20.htm IDEA: XBRL DOCUMENT v3.24.3 Leases 9 Months Ended Sep. 30, 2024 Leases [Abstract] Â Leases LeasesThe Company determines if an arrangement is or contains a lease at inception, which is the date on which the terms of the contract are agreed to, and the agreement creates enforceable rights and obligations. Under ASC 842, a contract is or contains a lease when (i) explicitly or implicitly identified assets have been deployed in the contract and (ii) the customer obtains substantially all of the economic benefits from the use of that underlying asset and directs how and for what purpose the asset is used during the term of the contract. The Company also considers whether its service arrangements include the right to control the use of an asset. The Company made an accounting policy election not to recognize right-of-use ("ROU") assets and lease liabilities for leases with a term of twelve months or less. For all other leases, the Company recognizes ROU assets and lease liabilities based on the present value of lease payments over the lease term at the commencement date of the lease. Lease payments may include fixed rent escalation clauses or payments that depend on an index (such as the consumer price index). Subsequent changes to an index and any other periodic market-rate adjustments to base rent are recorded in variable lease expense in the period incurred. The ROU assets also include any initial direct costs incurred and lease payments made at or before the commencement date and are reduced by any lease incentives. The Company has made an accounting policy election to account for lease and non-lease components in its contracts as single lease components for all asset classes. The non-lease components typically represent additional services transferred to the Company, such as common area maintenance for real estate, which are variable in nature and recorded in variable lease expense in the period incurred. The Company uses its incremental borrowing rate which is the rate of interest the Company would have to pay to borrow on a collateralized basis over a similar term and amount in a similar economic environment to determine the present value of lease payments as the Company's leases do not have a readily determinable implicit discount rate. Judgment is applied in assessing factors such as Company specific credit risk, lease term, nature, and quality of the underlying collateral, currency, and economic environment in determining the incremental borrowing rate to apply to each lease. The Company leases office and manufacturing space under operating lease agreements that have initial terms ranging from approximately 8 to 10 years. The Company leases furniture under a financing lease agreement that has an initial term of approximately 8 years. The furniture financing lease agreement is immaterial to the Company's condensed consolidated financial statements. Some leases include one or more options to renew, generally at the Company's sole discretion, with renewal terms that can extend the lease term by up to 5 years. In addition, certain leases contain termination options, where the rights to terminate are held by either the Company, the lessor, or both parties. Options to extend a lease are included in the lease term when it is reasonably certain that the Company will exercise the option. Options to terminate a lease are excluded from the lease term when it is reasonably certain that the Company will not exercise the option. The Company's leases generally do not contain any material restrictive covenants or residual value guarantees. Supplemental cash flow information related to leases is as follows (in thousands): Nine Months Ended September 30, 2024 2023 Cash paid for amounts included in measurement of lease liabilities: Operating cash outflows - payments on operating leases \$997.4 \$956.4 Operating cash outflows - payments on financing leases \$27.1 \$29.1 Financing cash outflows - payments on financing leases \$29.1 \$27.1 Right-of-use assets obtained in exchange for new lease obligations: Investing non-cash activities - establishment of right of use operating assets \$6.1 \$5.1 Supplemental balance sheet information related to the Company's operating and financing leases is as follows (in thousands): September 30, 2024 December 31, 2023 Operating Leases: Operating lease assets \$5,245.4 \$5,972.4 Operating lease liabilities, short-term \$1,148.1 \$1,090.4 Operating lease liabilities, long-term \$5,083.4 \$5,952.4 Total operating lease liabilities \$6,231.4 \$7,042.4 Financing Leases: Office furniture and fixtures \$386.4 \$386.4 Accumulated depreciation (211) (118) Net property, plant and equipment \$175.4 \$268.4 Lease liabilities, short-term \$46.4 \$42.4 Lease liabilities, long-term \$17.7 \$26.2 Total financing lease liabilities \$223.4 \$304.4 Weighted-average remaining lease term - operating leases (in years): 4.795.54 Weighted-average remaining lease term - financing leases (in years): 4.755.50 Weighted-average discount rate - operating leases: 3.8% % 3.8% % Weighted-average discount rate - financing leases: 12.0% % 12.0% % The components of lease expense were as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Operating lease cost \$305.4 \$314.4 914.4 899.4 Financing lease cost - amortization of right-of-use asset \$11.4 12.4 36.4 37.4 Financing lease cost - interest on lease liability \$10.4 9.4 27.4 29.4 Variable lease cost \$23.4 17.2 67.5 52.2 Total lease cost \$560.4 \$507.4 1,652.4 1,487.4 Operating lease cost is recognized on a straight-line basis over the lease term. Total rent expense, including the Company's share of the lessor's operating expenses, was \$0.5 million for each of the three months ended September 30, 2024 and 2023, and was \$1.6 million and \$1.4 million for the nine months ended September 30, 2024 and 2023, respectively. Financing lease cost includes asset amortization on a straight-line basis over the lease term and interest accretion calculated using the effective interest method. Total financing lease asset depreciation and interest expense was less than \$0.1 million for each of the three and nine months ended September 30, 2024 and 2023. Maturities of the Company's operating lease liabilities as of September 30, 2024 were as follows (in thousands): Operating Lease Maturities 2024 (excluding the nine months ended September 30) \$337.4 2025.1 368.4 2026.1 401.4 2027.1 435.4 2028.1 469.4 Thereafter \$804.4 Total lease payments \$6,814.4 Less imputed interest (583) Total present value of lease liabilities \$6,231.4 Maturities of the Company's financing lease liability as of September 30, 2024 were as follows (in thousands): Financing Lease Maturities 2024 (excluding the nine months ended September 30) \$18.4 2025.7 5.4 2026.7 5.4 2027.7 5.4 2028.7 5.4 Thereafter \$38.4 Total lease payments \$356.4 Less imputed interest (133) Total present value of lease liabilities \$223.4 Leases LeasesThe Company determines if an arrangement is or contains a lease at inception, which is the date on which the terms of the contract are agreed to, and the agreement creates enforceable rights and obligations. Under ASC 842, a contract is or contains a lease when (i) explicitly or implicitly identified assets have been deployed in the contract and (ii) the customer obtains substantially all of the economic benefits from the use of that underlying asset and directs how and for what purpose the asset is used during the term of the contract. The Company also considers whether its service arrangements include the right to control the use of an asset. The Company made an accounting policy election not to recognize right-of-use ("ROU") assets and lease liabilities for leases with a term of twelve months or less. For all other leases, the Company recognizes ROU assets and lease liabilities based on the present value of lease payments over the lease term at the commencement date of the lease. Lease payments may include fixed rent escalation clauses or payments that depend on an index (such as the consumer price index). Subsequent changes to an index and any other periodic market-rate adjustments to base rent are recorded in variable lease expense in the period incurred. The ROU assets also include any initial direct costs incurred and lease payments made at or before the commencement date and are reduced by any lease incentives. The Company has made an accounting policy election to account for lease and non-lease components in its contracts as single lease components for all asset classes. The non-lease components typically represent additional services transferred to the Company, such as common area maintenance for real estate, which are variable in nature and recorded in variable lease expense in the period incurred. The Company uses its incremental borrowing rate which is the rate of interest the Company would have to pay to borrow on a collateralized basis over a similar term and amount in a similar economic environment to determine the present value of lease payments as the Company's leases do not have a readily determinable implicit discount rate. Judgment is applied in assessing factors such as Company specific credit risk, lease term, nature, and quality of the underlying collateral, currency, and economic environment in determining the incremental borrowing rate to apply to each lease. The Company leases office and manufacturing space under operating lease agreements that have initial terms ranging from approximately 8 to 10 years. The Company leases furniture under a financing lease agreement that has an initial term of approximately 8 years. The furniture financing lease agreement is immaterial to the Company's condensed consolidated financial statements. Some leases include one or more options to renew, generally at the Company's sole discretion, with renewal terms that can extend the lease term by up to 5 years. In addition, certain leases contain termination options, where the rights to terminate are held by either the Company, the lessor, or both parties. Options to extend a lease are included in the lease term when it is reasonably certain that the Company will exercise the option. Options to terminate a lease are excluded from the lease term when it is reasonably certain that the Company will not exercise the option. The Company's leases generally do not contain any material restrictive covenants or residual value guarantees. Supplemental cash flow information related to leases is as follows (in thousands): Nine Months Ended September 30, 2024 2023 2024 2023 Cash paid for amounts included in measurement of lease liabilities: Operating cash outflows - payments on operating leases \$997.4 \$956.4 Operating cash outflows - payments on financing leases \$27.1 \$29.1 Financing cash outflows - payments on financing leases \$29.1 \$27.1 Right-of-use assets obtained in exchange for new lease obligations: Investing non-cash activities - establishment of right of use operating assets \$6.1 \$5.1 Supplemental balance sheet information related to the Company's operating and financing leases is as follows (in thousands): September 30, 2024 December 31, 2023 Operating Leases: Operating lease assets \$5,245.4 \$5,972.4 Operating lease liabilities, short-term \$1,148.1 \$1,090.4 Operating lease liabilities, long-term \$5,083.4 \$5,952.4 Total operating lease liabilities \$6,231.4 \$7,042.4 Financing Leases: Office furniture and fixtures \$386.4 \$386.4 Accumulated depreciation (211) (118) Net property, plant and equipment \$175.4 \$268.4 Lease liabilities, short-term \$46.4 \$42.4 Lease liabilities, long-term \$17.7 \$26.2 Total financing lease liabilities \$223.4 \$304.4 Weighted-average remaining lease term - operating leases (in years): 4.795.54 Weighted-average remaining lease term - financing leases (in years): 4.755.50 Weighted-average discount rate - operating leases: 3.8% % 3.8% % Weighted-average discount rate - financing leases: 12.0% % 12.0% % The components of lease expense were as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Operating lease cost \$305.4 \$314.4 914.4 899.4 Financing lease cost - amortization of right-of-use asset \$11.4 12.4 36.4 37.4 Financing lease cost - interest on lease liability \$10.4 9.4 27.4 29.4 Variable lease cost \$23.4 17.2 67.5 52.2 Total lease cost \$560.4 \$507.4 1,652.4 1,487.4 Operating lease cost is recognized on a straight-line basis over the lease term. Total rent expense, including the Company's share of the lessor's operating expenses, was \$0.5 million for each of the three months ended September 30, 2024 and 2023, and was \$1.6 million and \$1.4 million for the nine months ended September 30, 2024 and 2023, respectively. Financing lease cost includes asset amortization on a straight-line basis over the lease term and interest accretion calculated using the effective interest method. Total financing lease asset depreciation and interest expense was less than \$0.1 million for each of the three and nine months ended September 30, 2024 and 2023. Maturities of the Company's operating lease liabilities as of September 30, 2024 were as follows (in thousands): Operating Lease Maturities 2024 (excluding the nine months ended September 30) \$337.4 2025.1 368.4 2026.1 401.4 2027.1 435.4 2028.1 469.4 Thereafter \$804.4 Total lease payments \$6,814.4 Less imputed interest (583) Total present value of lease liabilities \$6,231.4 Maturities of the Company's financing lease liability as of September 30, 2024 were as follows (in thousands): Financing Lease Maturities 2024 (excluding the nine months ended September 30) \$18.4 2025.7 5.4 2026.7 5.4 2027.7 5.4 2028.7 5.4 Thereafter \$38.4 Total lease payments \$356.4 Less imputed interest (133) Total present value of lease liabilities \$223.4 X - References No definition available. + Details Name: us-gaap_ Leases Abstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Definition The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability. + References Reference 1:

which is attributable to the parent. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference> 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference> 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference](http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference) 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference) 5: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference) 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference) 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference](http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference) 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference](http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference) 9: <http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference> 10: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference> 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference) 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference) 13: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference> 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference) 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference) 16: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference> 17: <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference> 18: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference> 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(18\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference) 20: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference) 21: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(1\)\(d\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference) 22: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference) 23: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference) 24: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference) 25: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference) 26: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference) 27: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference) 28: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(ii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(ii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference) 29: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference) 30: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference) 31: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference) 32: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference) 33: <http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference> 34: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference> 35: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference) 36: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference) 37: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(22\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1) + Details Name: us-gaap NetIncomeLoss Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 36 R24.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 3 Months Ended Sep. 30, 2024 Trading Arrangements, by Individual A Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1:

to be recognized as revenue within 12 months of the balance sheet date are classified as current deferred revenue and amounts expected to be recognized as revenue beyond 12 months of the balance sheet date are classified as non-current deferred revenue. The Company did not record any non-current deferred revenue as of September 30, 2024 or December 31, 2023. Deferred revenue was \$5.4 million and \$6.0 million at September 30, 2024 and December 31, 2023, respectively. Revenue recognized during each of the three months ended September 30, 2024 and 2023 that was included in deferred revenue at the prior period-end was \$1.2 million. Revenue recognized during the nine months ended September 30, 2024 and 2023 that was included in deferred revenue at the prior period-end was \$3.9 million and \$3.3 million, respectively. Disaggregated revenue

The Company disaggregates revenue based on the recurring and non-recurring nature of the underlying sale. Recurring revenue includes sales of consumables and service contracts. The Company considers these to be recurring revenues because customers typically place purchase orders on a periodic basis as they use their Growth Direct system(s) over time. These arrangements typically contain a single performance obligation and thus the entire consideration to which the Company is entitled is allocated entirely to that performance obligation. Non-recurring revenue includes sales of systems, LIMS connection software, validation services, and field services, and typically contains multiple performance obligations. The Company considers these to be non-recurring revenues because customers typically place single purchase orders for a bundle of products and services on a one-time or infrequent basis. For these arrangements, significant judgment is applied in identifying the distinct performance obligations, determination of the transaction price, transaction price allocation, and determination of standalone selling price for each of the distinct performance obligations. Advertising costs

Advertising costs are expensed as incurred and are included in sales and marketing expenses in the condensed consolidated statements of operations. Stock-based compensation

The Company measures all stock-based awards granted to employees, officers and directors based on their fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. The Company issues stock-based awards with (i) service-based vesting conditions only and (ii) stock-based awards with both service-based and Company performance vesting conditions, and records the expense for these awards using the straight-line method. Forfeitures are accounted for prospectively as they occur. The Company measures all restricted stock units granted to employees based on the common stock value on the date of grant. The purchase price of the restricted stock is the common stock value on the date of grant. Recently issued accounting pronouncements

Recently issued accounting pronouncements The Company qualifies as an "emerging growth company" as defined in the Jumpstart Our Business Startups ("JOBS") Act of 2012 and has elected not to "opt out" of the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and nonpublic companies, the Company will adopt the newer revised standard at the time nonpublic companies adopt the new or revised standard and will do so until such time that the Company either (i) irrevocably elects to "opt out" of such extended transition period or (ii) no longer qualifies as an emerging growth company. The Company may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for nonpublic companies. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures. The new standard requires enhanced disclosures about a public entity's reportable segments including more detailed information about a reportable segment's expenses. The amendments in this update apply to all public entities that are required to report segment information, and include those entities that have a single reportable segment. The amendments in this update are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact on its consolidated financial statements and related disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740) - Improvements to Income Tax Disclosures. ASU 2023-09 provides more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The amendments in this update are effective for annual periods beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact on its consolidated financial statements and related disclosures. Leases

The Company determines if an arrangement is or contains a lease at inception, which is the date on which the terms of the contract are agreed to, and the agreement creates enforceable rights and obligations. Under ASC 842, a contract is or contains a lease when (i) explicitly or implicitly identified assets have been deployed in the contract and (ii) the customer obtains substantially all of the economic benefits from the use of that underlying asset and directs how and for what purpose the asset is used during the term of the contract. The Company also considers whether its service arrangements include the right to control the use of an asset. The Company made an accounting policy election not to recognize right-of-use ("ROU") assets and lease liabilities for leases with a term of twelve months or less. For all other leases, the Company recognizes ROU assets and lease liabilities based on the present value of lease payments over the lease term at the commencement date of the lease. Lease payments may include fixed rent escalation clauses or payments that depend on an index (such as the consumer price index). Subsequent changes to an index and any other periodic market-rate adjustments to base rent are recorded in variable lease expense in the period incurred. The ROU assets also include any initial direct costs incurred and lease payments made at or before the commencement date and are reduced by any lease incentives. The Company has made an accounting policy election to account for lease and non-lease components in its contracts as single lease components for all asset classes. The non-lease components typically represent additional services transferred to the Company, such as common area maintenance for real estate, which are variable in nature and recorded in variable lease expense in the period incurred. The Company uses its incremental borrowing rate which is the rate of interest the Company would have to pay to borrow on a collateralized basis over a similar term and amount in a similar economic environment to determine the present value of lease payments as the Company's leases do not have a readily determinable implicit discount rate. Judgment is applied in assessing factors such as Company specific credit risk, lease term, nature, and quality of the underlying collateral, currency, and economic environment in determining the incremental borrowing rate to apply to each lease. X - References

No definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy for advertising cost. + References

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -SubTopic 35 -Topic 720 -Publisher FASB -URI https://asc.fash.org/1943274/2147483406/720-35-50-1](http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 35 -Topic 720 -Publisher FASB -URI https://asc.fash.org/1943274/2147483406/720-35-50-1) + Details Name: us-gaap_AdvertisingCostsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + References

No definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - Definition Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. + References

Reference 1: [http://fash.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-03\(1\) \(a\)\) -Publisher FASB -URI https://asc.fash.org/1943274/2147478546/942-210-S99-1](http://fash.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1) (a)) -Publisher FASB -URI https://asc.fash.org/1943274/2147478546/942-210-S99-1) Reference 2: <http://fash.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fash.org/1943274/2147482913/230-10-50-1> + Details Name: us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances. + References

Reference 1: <http://fash.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fash.org/1943274/2147482913/230-10-50-1> + Details Name: us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy for credit risk. + References

Reference 1: <http://fash.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 825 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fash.org/1943274/2147478898/942-825-50-1> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(d\) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fash.org/1943274/2147482861/275-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fash.org/1943274/2147482861/275-10-50-1) + Details Name: us-gaap_ConcentrationRiskCreditRisk Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities. + References

No definition available. + Details Name: us-gaap_FairValueMeasurementPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy for costs incurred when both (1) the software is acquired, internally developed, or modified solely to meet the entity's internal needs, and (2) during the software's development or modification, no substantive plan exists or is being developed to market the software externally. + References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 40 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fash.org/350-40/tableOfContent> + Details Name: us-gaap_InternalUseSoftwarePolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy for leasing arrangement entered into by lessee. + References

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fash.org/1943274/2147478964/842-20-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fash.org/1943274/2147478964/842-20-50-1) + Details Name: us-gaap_LesseeLeasesPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + References

No definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy for revenue from contract with customer. + References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Publisher FASB -URI https://asc.fash.org/1943274/2147479806/606-10-50-17> Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FASB -URI https://asc.fash.org/1943274/2147479806/606-10-50-19> Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fash.org/1943274/2147479806/606-10-50-18](http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fash.org/1943274/2147479806/606-10-50-18) Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fash.org/1943274/2147479806/606-10-50-18](http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fash.org/1943274/2147479806/606-10-50-18) Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fash.org/1943274/2147479806/606-10-50-20](http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fash.org/1943274/2147479806/606-10-50-20) Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fash.org/1943274/2147479806/606-10-50-20](http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (b) -Publisher FASB -URI https://asc.fash.org/1943274/2147479806/606-10-50-20) Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fash.org/1943274/2147479806/606-10-50-20](http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fash.org/1943274/2147479806/606-10-50-20) Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fash.org/1943274/2147479806/606-10-50-20](http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (d) -Publisher FASB -URI https://asc.fash.org/1943274/2147479806/606-10-50-20) Reference 9: [http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(e\) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fash.org/1943274/2147483426/235-10-50-4](http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (e) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fash.org/1943274/2147483426/235-10-50-4) Reference 10: <http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fash.org/606/tableOfContent> + Details Name: us-gaap_RevenueFromContractWithCustomerPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy for segment reporting. + References

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fash.org/1943274/2147482810/280-10-50-41](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fash.org/1943274/2147482810/280-10-50-41) Reference 2: [http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph \(bb\) -Publisher FASB -URI https://asc.fash.org/1943274/2147482785/280-10-55-47](http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (bb) -Publisher FASB -URI https://asc.fash.org/1943274/2147482785/280-10-55-47) Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fash.org/1943274/2147482810/280-10-50-29](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (f) -Publisher FASB -URI https://asc.fash.org/1943274/2147482810/280-10-50-29) Reference 4: [http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fash.org/1943274/2147482785/280-10-55-54](http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (b) -Publisher FASB -URI https://asc.fash.org/1943274/2147482785/280-10-55-54) Reference 5: <http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 36 -Publisher FASB -URI https://asc.fash.org/1943274/2147482810/280-10-50-36> Reference 6: [http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fash.org/1943274/2147482785/280-10-55-47](http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (b) -Publisher FASB -URI https://asc.fash.org/1943274/2147482785/280-10-55-47) Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fash.org/1943274/2147482810/280-10-50-29](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (a) -Publisher FASB -URI https://asc.fash.org/1943274/2147482810/280-10-50-29) Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fash.org/1943274/2147482810/280-10-50-29](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (b) -Publisher FASB -URI https://asc.fash.org/1943274/2147482810/280-10-50-29) Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fash.org/1943274/2147482810/280-10-50-29](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (c) -Publisher FASB -URI https://asc.fash.org/1943274/2147482810/280-10-50-29) Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fash.org/1943274/2147482810/280-10-50-29](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (d) -Publisher FASB -URI https://asc.fash.org/1943274/2147482810/280-10-50-29) Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph \(e\) -Publisher FASB -URI https://asc.fash.org/1943274/2147482810/280-10-50-29](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (e) -Publisher FASB -URI https://asc.fash.org/1943274/2147482810/280-10-50-29) Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fash.org/1943274/2147482810/280-10-50-29](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (f) -Publisher FASB -URI https://asc.fash.org/1943274/2147482810/280-10-50-29) Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fash.org/1943274/2147482810/280-10-50-29](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (g) -Publisher FASB -URI https://asc.fash.org/1943274/2147482810/280-10-50-29) Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph \(h\) -Publisher FASB -URI https://asc.fash.org/1943274/2147482810/280-10-50-29](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (h) -Publisher FASB -URI https://asc.fash.org/1943274/2147482810/280-10-50-29) Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fash.org/1943274/2147482810/280-10-50-29](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (i) -Publisher FASB -URI https://asc.fash.org/1943274/2147482810/280-10-50-29) Reference 16: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph \(j\) -Publisher FASB -URI https://asc.fash.org/1943274/2147482810/280-10-50-29](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (j) -Publisher FASB -URI https://asc.fash.org/1943274/2147482810/280-10-50-29) Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph \(k\) -Publisher FASB -URI https://asc.fash.org/1943274/2147482810/280-10-50-29](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (k) -Publisher FASB -URI https://asc.fash.org/1943274/2147482810/280-10-50-29) Reference 18: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph \(l\) -Publisher FASB -URI https://asc.fash.org/1943274/2147482810/280-10-50-29](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (l) -Publisher FASB -URI https://asc.fash.org/1943274/2147482810/280-10-50-29) Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph \(m\) -Publisher FASB -URI https://asc.fash.org/1943274/2147482810/280-10-50-29](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (m) -Publisher FASB -URI https://asc.fash.org/1943274/2147482810/280-10-50-29) Reference 20: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph \(n\) -Publisher FASB -URI https://asc.fash.org/1943274/2147482810/280-10-50-29](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (n) -Publisher FASB -URI https://asc.fash.org/1943274/2147482810/280-10-50-29) Reference 21: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph \(o\) -Publisher FASB -URI https://asc.fash.org/1943274/2147482810/280-10-50-29](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (o) -Publisher FASB -URI https://asc.fash.org/1943274/2147482810/280-10-50-29) Reference 22: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph \(p\) -Publisher FASB -URI https://asc.fash.org/1943274/2147482810/280-10-50-29](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (p) -Publisher FASB -URI https://asc.fash.org/1943274/2147482810/280-10-50-29) Reference 23: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph \(q\) -Publisher FASB -URI https://asc.fash.org/1943274/2147482810/280-10-50-29](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (q) -Publisher FASB -URI https://asc.fash.org/1943274/2147482810/280-10-50-29) Reference 24: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph \(r\) -Publisher FASB -URI https://asc.fash.org/1943274/2147482810/280-10-50-29](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (r) -Publisher FASB -URI https://asc.fash.org/1943274/2147482810/280-10-50-29) Reference 25: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph \(s\) -Publisher FASB -URI https://asc.fash.org/1943274/2147482810/280-10-50-29](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (s) -Publisher FASB -URI https://asc.fash.org/1943274/2147482810/280-10-50-29) Reference 26: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph \(t\) -Publisher FASB -URI https://asc.fash.org/1943274/2147482810/280-10-50-29](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (t) -Publisher FASB -URI https://asc.fash.org/1943274/2147482810/280-10-50-29) Reference 27: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph \(u\) -Publisher FASB -URI https://asc.fash.org/1943274/2147482810/280-10-50-29](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (u) -Publisher FASB -URI https://asc.fash.org/1943274/2147482810/280-10-50-29) Reference 28: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph \(v\) -Publisher FASB -URI https://asc.fash.org/1943274/2147482810/280-10-50-29](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (v) -Publisher FASB -URI https://asc.fash.org/1943274/2147482810/280-10-50-29) Reference 29: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph \(w\) -Publisher FASB -URI https://asc.fash.org/1943274/2147482810/280-10-50-29](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (w) -Publisher FASB -URI https://asc.fash.org/1943274/2147482810/280-10-50-29) Reference 30: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph \(x\) -Publisher FASB -URI https://asc.fash.org/1943274/2147482810/280-10-50-29](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (x) -Publisher FASB -URI https://asc.fash.org/1943274/2147482810/280-10-50-29) Reference 31: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph \(y\) -Publisher FASB -URI https://asc.fash.org/1943274/2147482810/280-10-50-29](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (y) -Publisher FASB -URI https://asc.fash.org/1943274/2147482810/280-10-50-29) Reference 32: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph \(z\) -Publisher FASB -URI https://asc.fash.org/1943274/21](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (z) -Publisher FASB -URI https://asc.fash.org/1943274/2147482810/280-10-50-29)

gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for standard warranties including the methodology for measuring the liability. + ReferencesReference 1:

Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 44 R32.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued expenses and other current liabilities (Tables) 9 Months Ended Sep. 30, 2024 Accrued Liabilities, Current [Abstract] A Schedule of Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following (in thousands):September 30,December 31,20242023Accrued employee compensation and benefits expense\$4,634A \$4,808A Accrued vendor expenses1,641A 4,017A Accrued warranty expense\$20A 689A Accrued taxes239A 252A Other4A 141A \$7,038A 9,907A X - ReferencesNo definition available. + Details Name: us-gaap_AccruedLiabilitiesCurrentAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of accrued liabilities. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 45 R33.htm IDEA: XBRL DOCUMENT v3.24.3 Common stock and common stock warrants (Tables) 9 Months Ended Sep. 30, 2024 Common Stock And Common Stock Warrants [Abstract] A Schedule of Outstanding Common Stock Warrants Outstanding warrants to purchase common stock consisted of the following:September 30, 2024Issuance dateContractual termBalance sheetclassificationShares of common stock issuable uponexercise of warrantWeighted average exercise price(in years)July 24, 201710Equity16,954\$293.42A April 12, 201810Equity30,000\$1.00A July 14, 2021 *10Equity975,109\$1.46A 1,022,063December 31, 2023Issuance dateContractual termBalance sheetclassificationShares of common stock issuable uponexercise of warrantWeighted average exercise price (in years)July 24, 201710Equity17,194\$292.81A April 12, 201810Equity30,000\$1.00A July 14, 2021 *10Equity975,109\$1.46A 1,022,303

*[In connection with the Company's initial public offering ("IPO"), preferred stock warrants were automatically converted to Class A common stock warrants. The contractual term of the converted Class A common stock warrants remained consistent with the original term of the preferred stock warrants, with original issue dates between 2017-2020. X - ReferencesNo definition available. + Details Name: rmb_CommonStockAndCommonStockWarrantsAbstract Namespace Prefix: rmb_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1 + Details Name: us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 46 R34.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-based compensation (Tables) 9 Months Ended Sep. 30, 2024 Share-Based Payment Arrangement [Abstract] A Schedule of Black-Scholes Option-Pricing Model The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted to employees and directors:Three Months Ended September 30,Nine Months Ended September 30,2024202320242023Risk-free interest rate *4.2A %4.3A %3.9A %Expected term (in years)*6.15.96Expected volatility*47.1A %50.0A %47.1A %Expected dividend yield*0A %0A %0A %* No options granted in the respective period. Schedule of Stock Option Activity The following table summarizes the Company's stock option activity since December 31, 2023:Number of sharesWeighted average exercise priceWeighted average remaining contractual termAggregate intrinsic value (in years)(in thousands)Outstanding as of December 31, 20236,530,511\$2.59A 7.12\$Ae A Granted 952,4700.93A Exercised(9,570)0.75A Expired(255,166)4.96A Forfeited(357,740)1.67A Outstanding as of September 30, 20248,860,505\$2.32A 6.51\$155A Options vested and expected to vest as of September 30, 20248,860,505\$2.32A 6.51\$155A Options exercisable as of September 30, 20244,694,428\$2.59A 5.54\$132A Schedule of Restricted Stock Units Activity The following table summarizes the Company's restricted stock units activity since December 31, 2023:Number of sharesWeighted average fair valueUnvested as of December 31, 202331,681,760\$2.28A Granted1,157,765\$0.93A Vested(459,024)\$3.11A Forfeited(273,253)\$1.61A Unvested as of September 30, 20242,107,248\$1.44A Schedule of ESPP Black-Scholes Option-Pricing Model The following weighted average assumptions were used in the calculation of fair value of shares under the 2021 ESPP at the grant date for both the nine months ended September 30, 2024 and 2023:Three Months Ended September 30,Nine Months Ended September 30,2024202320242023Risk-free interest rate4.6A %5.5A %5.0A %5.3A %Expected term (in years)0.50.50.5Expected volatility42.6A %47.7A %46.0A %47.8A %Expected dividend yield0A %0A %0A %0A % Schedule of Stock-Based Compensation Expense Stock-based compensation expense was classified in the condensed consolidated statements of operations as follows (in thousands):Three Months Ended September 30,Nine Months Ended September 30,2024202320242023Cost of revenue\$142A \$159A \$437A \$502A Research and development123A 135A 395A 398A Sales and marketing98A 119A 325A 385A General and administrative566A 838A 2,028A 2,443A Total stock-based compensation expense\$929A \$1,251A \$3,185A \$3,728A X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the changes in outstanding nonvested restricted stock shares. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Subparagraph (c) -Paragraph 2 -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 47 R35.htm IDEA: XBRL DOCUMENT v3.24.3 Net loss per share (Tables) 9 Months Ended Sep. 30, 2024 Earnings Per Share [Abstract] A Schedule of Basic and Diluted Net Loss per Share Basic and diluted net loss per share was calculated as follows (in thousands, except share and per share amounts):Three Months Ended September 30,Nine Months Ended September 30,2024202320242023Numerator:Net loss\$(1,323)\$(13,392)\$(37,223)\$(41,295)Denominator:Weighted average Class A common shares outstanding\$basic and diluted 38,359,12737,770,56638,201,38237,539,885Weighted average Class B common shares outstanding\$basic and diluted 5,309,5295,309,5295,309,5295,445,299Total shares for EPS\$basic and diluted 43,668,65643,080,95430,912,4489,851,84Net loss per share attributable to Class A common stockholders\$basic and diluted \$(0.26)\$(0.31)\$(0.86)\$(0.96) Schedule of Anti-Dilutive Shares Excluded from Computation of Diluted Net Loss per Share The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:September 30,20242023Options to purchase common stock6,860,5056,795,549Unvested restricted common stock2,107,2481,782,401Warrants to purchase common stock286,084286,324Options to purchase common stock under ESPP29,69922,0519,283,5368,886,325 X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 48 R36.htm IDEA: XBRL DOCUMENT v3.24.3 Leases (Tables) 9 Months Ended Sep. 30, 2024 Leases [Abstract] A Schedule of Supplemental Cash Flow Information and Lease Expense Supplemental cash flow information related to leases is as follows (in thousands):Nine Months Ended September 30,20242023Cash paid for amounts included in measurement of lease liabilities:Operating cash outflows - payments on operating leases\$997A \$956A Operating cash outflows - payments on financing leases\$27A \$29A Financing cash outflows - payments on financing leases\$29A \$27A Right-of-use assets obtained in exchange for new lease obligations:Investing non-cash activities - establishment of right of use operating assets\$Ae A \$151A The components of lease expense were as follows (in thousands):Three Months Ended September 30,Nine Months Ended September 30,2024202320242023Operating lease cost\$305A \$314A 914A 899A Financing lease cost - amortization of right-of-use asset11A 12A 36A 37A Financing lease cost - interest on lease liability10A 9A 27A 29A Variable lease cost234A 172A 675A 522A Total lease cost\$560A \$507A 1,652A 1,487A Schedule of Supplemental Balance Sheet Information Supplemental balance sheet information related to the Company's operating and financing leases is as follows (in thousands):September 30, 2024December 31, 2023Operating Leases:Operating lease assets\$5,245A \$5,972A Operating lease liabilities, short-term\$1,148A \$1,090A Operating lease liabilities, long-term\$5,083A 5,952A Total operating lease liabilities\$6,231A \$7,042A Financing Leases:Office furniture and fixtures\$386A \$386A Accumulated depreciation(211) (118)Net property, plant and equipment\$175A \$268A Lease liabilities, short-term\$46A \$42A Lease liabilities, long-term177A 262A Total financing lease liabilities\$223A \$304A Weighted-average remaining lease term - operating leases (in years):4.795.54Weighted-average remaining lease term - financing leases (in years):4.755.50Weighted-average discount rate - operating leases:3.8A %3.8A %Weighted-average discount rate - financing leases:12.0A %12.0A % Schedule of Operating Lease Liability Maturities Maturities of the Company's operating lease liabilities as of September 30, 2024 were as follows (in thousands):Operating Lease Maturities2024 (excluding the nine months ended September 30)\$337A 20251,368A 20261,401A 20271,435A 20281,469A Thereafter804A Total lease payments\$6,814A Less imputed interest(583)Total present value of lease liabilities\$6,231A Schedule of Finance Lease Liability Maturities Maturities of the Company's financing lease liability as of September 30, 2024 were as follows (in thousands):Financing Lease Maturities2024 (excluding the nine months ended September 30)\$18A 202575A 202675A 202775A 202875A Thereafter38A Total lease payments\$356A Less imputed interest(133)Total present value of lease liabilities\$223A X - DefinitionAssets And Liabilities, Lessee + ReferencesNo definition available. + Details Name: rmb_AssetsAndLiabilitiesLesseeTableTextBlock Namespace Prefix: rmb_Data Type: dtr-types1:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_LeaseCostTableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 49 R37.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of significant accounting policies - Schedule of Concentration Risk (Details) - Customer Concentration Risk 3 Months Ended 9 Months Ended 12 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Revenue Benchmark | Major Customers A A A A Concentration Risk [Line Items] A A A A Customer concentration risk 21.00% 36.30% 25.70% 18.20% A Revenue Benchmark | Customer A A A A A Concentration Risk [Line Items] A A A A Customer concentration risk 21.00% A 11.60% A A Revenue Benchmark | Customer B A A A A A Concentration Risk [Line Items] A A A A Customer concentration risk A 14.70% 14.10% 18.20% A Revenue Benchmark | Customer C A A A A A Concentration Risk [Line Items] A A A A Customer concentration risk A 11.40% A A A Revenue Benchmark | Customer D A A A A A Concentration Risk [Line Items] A A A A Customer concentration risk A 10.20% A A Accounts Receivable | Major Customers A A A A A Concentration Risk [Line Items] A A A A Customer concentration risk A A 37.60% A 60.90% Accounts Receivable | Customer B A A A A A Concentration Risk [Line Items] A A A A Customer concentration risk A A A 10.70% Accounts Receivable | Customer E A A A A A Concentration Risk [Line Items] A A A A Customer concentration risk A A 12.80% A 21.40% Accounts Receivable | Customer F A A A A A Concentration Risk [Line Items] A A A A Customer concentration risk A A 12.50% A A Accounts Receivable | Customer G A A A A A Concentration Risk [Line Items] A A A A

A Customer concentration risk A A 12.30% Accounts Receivable | Customer H A A A Concentration Risk [Line Items] A A A A Customer concentration risk A A A 12.40% X - Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 954 -SubTopic 310 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-2> + Details Name: us-gaap_ConcentrationRiskLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21)Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20> + Details Name: us-gaap_ConcentrationRiskPercentage1 Namespace Prefix: us-gaap_Data Type: dt-types:percentItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=rmb_MajorCustomersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=rmb_CustomerAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=rmb_CustomerBMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=rmb_CustomerDMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=rmb_CustomerEMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=rmb_CustomerFMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=rmb_CustomerGMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=rmb_CustomerHMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=rmb_CustomerIMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R38.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of significant accounting policies - Narrative (Details) 3 Months Ended Sep. 30, 2024 USD (\$) Sep. 30, 2023 USD (\$) Sep. 30, 2024 USD (\$) (segment Sep. 30, 2023 USD (\$) Dec. 31, 2023 USD (\$) Accounting Policies [Line Items] A A A A Cash held in banks outside of the US \$ 100,000 A \$ 100,000 A \$ 100,000 Guaranteed investment certificates 284,000 A 284,000 A 284,000 Allowance for doubtful accounts for expected credit losses 0 A 0 A 0 Software development costs, net of amortization 1,600,000 A 1,600,000 A 1,400,000 Amortization of software development costs 1,000,000 A 1,000,000 A 700,000 Software development amortization expense 100,000 A 300,000 A 100,000 Product warranty term A 1 year A 0 A 0 Number of operating segments | segment A 1 A 1 Number of reportable segments | segment A 1 A 1 Contract assets 200,000 A \$ 200,000 A 100,000 Non-current deferred revenue 0 A 0 A 0 Current deferred revenue 5,360,000 A 5,360,000 A \$ 5,974,000 Revenue recognized which was included in deferred revenue in prior period 1,200,000 A 1,200,000 A 3,900,000 A 3,300,000 Advertising costs \$ 100,000 A \$ 100,000 A 200,000 A 200,000 A Software Development A A A A Accounting Policies [Line Items] A A A A Amortization period of capitalized software costs 5 years A A X - DefinitionAccounting Policies + ReferencesNo definition available. + Details Name: rmb_AccountingPoliciesLineItems Namespace Prefix: rmb_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe duration of a warranty. + ReferencesNo definition available. + Details Name: rmb_StandardProductWarrantyTerm Namespace Prefix: rmb_Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 720 -SubTopic 35 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483385/720-35-55-1>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 720 -SubTopic 35 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 720 -SubTopic 35 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1) + Details Name: us-gaap_AdvertisingExpense Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of allowance for credit loss on accounts receivable. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/214748777/944-210-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/214748777/944-210-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef-Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4>Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13) + Details Name: us-gaap_AllowanceForDoubtfulAccountsReceivable Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFor each balance sheet presented, the amount of accumulated amortization for capitalized computer software costs. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/194327](http://www.xbrl.org/2003/role/disclosureRef-Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2)

standard product warranty. Excludes extended product warranties. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph \(c\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8 + Details](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8 + Details) Name: us-gaap_StandardProductWarrantyAccrualPayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase in the standard product warranty accrual from warranties issued. Excludes extended product warranties. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph \(c\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8 + Details](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8 + Details) Name: us-gaap_StandardProductWarrantyAccrualWarrantiesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 52 R40.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of significant accounting policies - Schedule of Disaggregated Revenue (Details) - USD (\$) \$ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Disaggregation of Revenue [Line Items] Á Á Á Total revenue 3,423 2,665 8,232 6,987 Switzerland Á Á Á Disaggregation of Revenue [Line Items] Á Á Á Total revenue 1,357 1,058 3,932 2,991 Germany Á Á Á Disaggregation of Revenue [Line Items] Á Á Á Total revenue 923 478 2,358 1,392 Japan Á Á Á Disaggregation of Revenue [Line Items] Á Á Á Total revenue 227 167 1,399 1,621 All other countries Á Á Á Disaggregation of Revenue [Line Items] Á Á Á Total revenue 1,674 1,777 3,912 3,191 Product and Service Revenue | Product and service revenue â€” recurring Á Á Á Disaggregation of Revenue [Line Items] Á Á Á Total revenue 3,675 3,410 11,262 10,255 Product and Service Revenue | Product and service revenue â€” non-recurring Á Á Á Disaggregation of Revenue [Line Items] Á Á Á Total revenue 3,929 2,735 8,571 5,927 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 2: \[http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph \\(a\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: \\[http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: \\\[http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: \\\\[http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: \\\\\[http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\\\\\(b\\\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: \\\\\\[http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\\\\\\(a\\\\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details\\\\\\]\\\\\\(http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\\\\\(a\\\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details\\\\\\) Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: \\\\\\[http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: \\\\\\\[http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\\\\\\\(a\\\\\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details\\\\\\\]\\\\\\\(http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\\\\\\(b\\\\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\\\\\\(a\\\\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details\\\\\\\) Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FinancialInstrumentAxis=rmb_LongTermInvestmentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: XML 54 R42.htm IDEA: XBRL DOCUMENT v3.24.3 Investments \\\\\\\(Details\\\\\\\) - USD \\\\\\\(\\\\\\\\$\\\\\\\) \\\\\\\\$ in Thousands Sep. 30, 2024 Dec. 31, 2023 Short-term investments Á Á Debt Securities, Available-for-sale \\\\\\\[Line Items\\\\\\\] Á Á Amortized cost 38,705 67,884 Gross unrealized gains 83 51 Gross unrealized losses 0 \\\\\\\(167\\\\\\\) Fair value 38,788 67,768 Certificates of Deposit Á Á Debt Securities, Available-for-sale \\\\\\\[Line Items\\\\\\\] Á Á Amortized cost 5,164 Gross unrealized gains 0 0 Gross unrealized losses Á \\\\\\\(21\\\\\\\) Fair value 5,143 U.S. Government Treasury Bills Á Á Debt Securities, Available-for-sale \\\\\\\[Line Items\\\\\\\] Á Á Amortized cost 16,184 Gross unrealized gains Á 9 Gross unrealized losses Á 0 Fair value 16,193 U.S. Government Treasury Notes Á Á Debt Securities, Available-for-sale \\\\\\\[Line Items\\\\\\\] Á Á Amortized cost 38,705 46,536 Gross unrealized gains 83 42 Gross unrealized losses 0 \\\\\\\(146\\\\\\\) Fair value 38,788 46,432 Long-term Investments Á Á Debt Securities, Available-for-sale \\\\\\\[Line Items\\\\\\\] Á Á Amortized cost 2,896 Gross unrealized gains Á 15 Gross unrealized losses Á 0 Fair value 2,911 U.S. Government Treasury Notes - Maturity Up To Two Years Á Á Debt Securities, Available-for-sale \\\\\\\[Line Items\\\\\\\] Á Á Amortized cost Á 2,896 Gross unrealized gains Á 15 Gross unrealized losses Á 0 Fair value Á 2,911 X - DefinitionAmount, before tax, of unrealized gain in accumulated other comprehensive income \\\\\\\(AOCI\\\\\\\) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income \\\\\\\(available-for-sale\\\\\\\). + ReferencesReference 1: \\\\\\\[http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\\\\\\\(b\\\\\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details\\\\\\\]\\\\\\\(http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\\\\\\(b\\\\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details\\\\\\\) Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, before tax, of unrealized loss in accumulated other comprehensive income \\\\\\\(AOCI\\\\\\\) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income \\\\\\\(available-for-sale\\\\\\\). + ReferencesReference 1: \\\\\\\[http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\\\\\\\(c\\\\\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details\\\\\\\]\\\\\\\(http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\\\\\\(c\\\\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details\\\\\\\) Name: us-\\\\\\]\\\\\\(http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\\\\\(b\\\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\\\\\(a\\\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details\\\\\\)\\\\\]\\\\\(http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\\\\(b\\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\\\\(bbb\\\\\)\\\\\(2\\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\\\\(bbb\\\\\)\\\\\(1\\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\\\\(a\\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\\\\(aa\\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \\\\\(b\\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \\\\\(SX 210.9-03\\\\\(6\\\\\)\\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-599-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <a href=\\\\\)\\\\]\\\\(http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\\\(b\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\\\(a\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details\\\\)\\\]\\\(http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\\(b\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\\(bbb\\\)\\\(2\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\\(bbb\\\)\\\(1\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\\(a\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\\(aa\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \\\(b\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \\\(SX 210.9-03\\\(6\\\)\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-599-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details\\\)\\]\\(http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \\(i\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \\(ee\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \\(b\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \\(a\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \\(SAB Topic 11.L\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-599-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph \\(a\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph \\(b\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph \\(a\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \\(a\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_StatementGeographicalAxis=country_US Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_CH Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_JP Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=rmb_AllOtherCountriesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ContractWithCustomerDurationAxis=rmb_RecurringContractWithCustomerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ContractWithCustomerDurationAxis=rmb_NonRecurringContractWithCustomerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: XML 53 R41.htm IDEA: XBRL DOCUMENT v3.24.3 Fair value of financial assets and liabilities \\(Details\\) - USD \\(\\$\\) \\$ in Thousands Sep. 30, 2024 Dec. 31, 2023 Short-term investments Á Á Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis \\[Line Items\\] Á Á Investments 38,788 67,768 Long-term Investments Á Á Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis \\[Line Items\\] Á Á Investments 2,911 Fair Value, Recurring Á Á Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis \\[Line Items\\] Á Á Cash equivalents 14,293 20,306 Assets 53,081 90,985 Fair Value, Recurring | Short-term investments Á Á Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis \\[Line Items\\] Á Á Investments 38,788 67,768 Fair Value, Recurring | Long-term Investments Á Á Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis \\[Line Items\\] Á Á Investments 2,911 Fair Value, Recurring | Level 1 Á Á Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis \\[Line Items\\] Á Á Cash equivalents 14,293 20,306 Assets 53,081 85,842 Fair Value, Recurring | Level 1 | Short-term investments Á Á Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis \\[Line Items\\] Á Á Investments 38,788 62,625 Fair Value, Recurring | Level 1 | Long-term Investments Á Á Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis \\[Line Items\\] Á Á Investments 2,911 Fair Value, Recurring | Level 2 Á Á Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis \\[Line Items\\] Á Á Cash equivalents 0 0 Assets 0 5,143 Fair Value, Recurring | Level 2 | Short-term investments Á Á Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis \\[Line Items\\] Á Á Investments 0 5,143 Fair Value, Recurring | Level 2 | Long-term Investments Á Á Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis \\[Line Items\\] Á Á Investments 0 Fair Value, Recurring | Level 3 Á Á Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis \\[Line Items\\] Á Á Cash equivalents 0 0 Assets 0 0 Fair Value, Recurring | Level 3 | Short-term investments Á Á Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis \\[Line Items\\] Á Á Investments 0 0 Fair Value, Recurring | Level 3 | Long-term Investments Á Á Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis \\[Line Items\\] Á Á Investments 0 0 X - DefinitionFair value portion of asset recognized for present right to economic benefit. + ReferencesReference 1: <a href=\\)\]\(http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details Name: us-gaap_DisaggregationOfRevenueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: <a href=\)](http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details)

[us-gaap_AvailableForSaleSecuritiesDebtSecuritiesAccumulatedLossesBeforeTaxNamespacePrefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition](#) Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103>Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100>Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(bbb\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(bbb\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 5: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(bbb\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(aaa\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(aa\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2)Reference 8: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-03\(6\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1)Reference 10: <http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1> + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNamespacePrefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmortized cost, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2> + Details Name: us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(aa\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(aaa\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2)Reference 8: <http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3>Reference 9:

Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A + Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=rmb_ManufacturingAndLaboratoryEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=rmb_ComputerEquipmentAndSoftwareMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 59 R47.htm IDEA: XBRL DOCUMENT v3.24.3 Property and equipment, net - Narrative (Details) - USD (\$) \$ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Property, Plant and Equipment [Abstract] Â Â Â Depreciation and amortization expense \$ 0.7 \$ 0.7 \$ 2.1 \$ 2.0 X - DefinitionAmount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 60 R48.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued expense and other current liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD (\$) \$ in Thousands Sep. 30, 2024 Dec. 31, 2023 Accrued Liabilities, Current [Abstract] Â Â Accrued employee compensation and benefits expense \$ 4.634 \$ 4.808 Accrued vendor expenses 1,641 4,017 Accrued warranty expense 520 689 Accrued taxes 239 252 Other 4 141 Total accrued expenses and other current liabilities \$ 7,038 \$ 9,907 X - DefinitionCarrying value as of the balance sheet date of current portion of obligations incurred through that date and payable for vendor accruals. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer) + ReferencesNo definition available. + Details Name: rmb_VendorAccrualsCurrent Namespace Prefix: rmb_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionCarrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_AccruedIncomeTaxesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AccruedLiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount as of the balance sheet date of the aggregate standard product warranty liability that is expected to be paid within one year or the normal operating cycle, if longer. Does not include the balance for the extended product warranty liability. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (c)(5) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8 + Details Name: us-gaap_StandardProductWarrantyAccrualCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant XML 61 R49.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued expenses and other current liabilities - Narrative (Details) - Operational Efficiency Program \$ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 USD (\$) Sep. 30, 2024 USD (\$) Restructuring Cost and Reserve [Line Items] Â Â Restructuring related charges \$ 0.6 Â Payments for restructuring 0.2 \$ 0.2 Remaining restructuring payments \$ 0.4 \$ 0.4 X - DefinitionAmount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17 + Details Name: us-gaap_PaymentsForRestructuring Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionAmount of expected cost remaining for the specified restructuring cost. + ReferencesNo definition available. + Details Name: us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.P.3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1 + Details Name: us-gaap_RestructuringCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringCostAndReserveLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Details Name: us-gaap_RestructuringPlanAxis=rmb_OperationalEfficiencyProgramMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 62 R50.htm IDEA: XBRL DOCUMENT v3.24.3 Common stock and common stock warrants - Narrative (Details) 9 Months Ended Sep. 30, 2024 USD (\$) vote shares Dec. 31, 2023 vote Common stock and common stock warrants Â Â Cash dividends | \$ 0 Â Class A Common stock Â Â Common stock and common stock warrants Â Â Number of votes per share held | vote 1 1 Shares reserved (in shares) | shares 23,915,460 Â X - DefinitionNumber of votes each common stock holder is entitled to vote. + ReferencesNo definition available. + Details Name: rmb_NumberOfVotesPerCommonStockShareHeld Namespace Prefix: rmb_ Data Type: xbrli:integerItem Type Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionAggregate number of common shares reserved for future issuance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionAmount of paid and unpaid common stock dividends declared with the form of settlement in cash. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_DividendsCommonStockCash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 63 R51.htm IDEA: XBRL DOCUMENT v3.24.3 Common stock and common stock warrants - Schedule of Outstanding Common Stock Warrants (Details) - Common Stock Warrants - / shares Sep. 30, 2024 Dec. 31, 2023 Common stock and common stock warrants Â Â Shares of common stock issuable upon exercise of warrant (in shares) 1,022,063 1,022,303 July 24, 2017 Â Â Common stock and common stock warrants Â Â Contractual term 10 years 10 years Shares of common stock issuable upon exercise of warrant (in shares) 16,954 17,194 Weighted average exercise price (in dollars per share) \$ 293.42 \$ 292.81 April 12, 2018 Â Â Common stock and common stock warrants Â Â Contractual term 10 years 10 years Shares of common stock issuable upon exercise of warrant (in shares) 30,000 30,000 Weighted average exercise price (in dollars per share) \$ 1.00 \$ 1.00 July 14, 2021 Â Â Common stock and common stock warrants Â Â Contractual term 10 years 10 years Shares of common stock issuable upon exercise of warrant (in shares) 975,109 975,109 Weighted average exercise price (in dollars per share) \$ 1.46 \$ 1.46 X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dt-tr:types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItem Type Balance Type: na Period Type: instant X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rmb_CommonStockWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardDateAxis=rmb_July242017Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardDateAxis=rmb_April2122018Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardDateAxis=rmb_FourteenJuly2021Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 64 R52.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-based compensation - Narrative (Details) - USD (\$) \$ / shares in Units, \$

In thousands 1 Months Ended 3 Months Ended 6 Months Ended Mar. 31, 2024 Feb. 29, 2024 May 31, 2023 Jul. 31, 2021 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Share-based compensation \$ 0.49 \$ 0.48 \$ 0.59 Options granted (in shares) 952,470 Stock-based compensation expense \$ 929 \$ 1,251 \$ 3,185 \$ 3,728 Granted (in dollars per share) \$ 0.93 A Unrecognized compensation expense \$ 2,300 \$ 2,300 Restricted Stock Units (RSUs) A A A A A Share-based compensation A A A A A Vesting period A A A A 3 years A Weighted average grant-date fair value per share of units granted (in dollars per share) A A A A \$ 0.78 \$ 0.97 \$ 0.93 1.22 Units granted (in shares) A A A A 1,157,765 A Weighted average recognition period A A A A 1 year 9 months 18 days A Unrecognized compensation expense related to units A A A A \$ 1,900 A \$ 1,900 A Share-Based Payment Arrangement, Option A A A A A Share-based compensation A A A A A Weighted average recognition period A A A A 1 year 6 months A Class A Common stock A A A A A Share-based compensation A A A A A Shares available for future issuance (in shares) A A A A 23,915,460 A 23,915,460 A 2010 Plan A A A A A Share-based compensation A A A A A Shares authorized (in shares) A A A A 4,551,792 A 4,551,792 A Plan term A A A A 10 years A A A A 2021 Plan | Class A Common stock A A A A A Share-based compensation A A A A A Shares authorized (in shares) A A A A 4,200,000 A A Percentage of aggregate number of shares outstanding A A A A 5.00% A A A A Maximum number of shares issuable upon exercise of stock option (in shares) A A A A 33,900,000 A A A A 2021 ESPP A A A A A Share-based compensation A A A A A Plan term A A A A 10 years A A A A Stock-based compensation expense A A A A \$ 100 \$ 100 \$ 100 100 2021 ESPP | Employee Stock A A A A A Share-based compensation A A A A A Maximum percentage of payroll deduction A A A A 15.00% A A A A Offering period A A A A 6 months A A A A Maximum shares available for purchase per employee (in shares) A A A A 100,000 A A A A Maximum value of shares available for purchase per employee A A A A \$ 25 A A A A Discount percentage from market price A A A A 85.00% A A A A 2021 ESPP | Class A Common stock A A A A A Share-based compensation A A A A A Shares authorized (in shares) A A A A 400,000 A A A A Percentage of aggregate number of shares outstanding A A A A 1.00% A A A A Maximum number of shares issuable upon exercise of stock option (in shares) A A A A 6,300,000 A A A A Shares purchased under plan (in shares) A A A A 287,217 A Shares available for future issuance (in shares) A A A A 956,940 A 956,940 A 2023 Inducement Plan A A A A A Share-based compensation A A A A A Options granted (in shares) A A A A 220,000 A A A A Granted (in dollars per share) A A A A \$ 0.83 A A A A Shares available for issuance under plan (in shares) A A A A 0 A 0 A 2023 Inducement Plan | Vice President, Legal A A A A A Share-based compensation A A A A A Options granted (in shares) 150,000 A A A A A Granted (in dollars per share) \$ 0.99 A A A A 2023 Inducement Plan | Restricted Stock Units (RSUs) A A A A A Share-based compensation A A A A A Units granted (in shares) A A 110,000 A A A A 2023 Inducement Plan | Restricted Stock Units (RSUs) | Vice President, Legal A A A A A Share-based compensation A A A A A Units granted (in shares) 75,000 A A A A A 2023 Inducement Plan | Class A Common stock A A A A A Share-based compensation A A A A A Shares available for future issuance (in shares) A A 330,000 A A A A Additional shares authorized (in shares) A A 225,000 A A A A X - DefinitionShare-Based Compensation Arrangement By Share-Based Payment Award, Maximum Employee Subscription Amount + ReferencesNo definition available. + Details Name: rmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount Namespace Prefix: rmb_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionMaximum number of shares issuable upon exercise of stock option under the share based payment arrangement plan. + ReferencesNo definition available. + Details Name: rmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuableUponExerciseOfStockOptionMaximum Namespace Prefix: rmb_Data Type: xbrli:sharesItemBalance Type: na Period Type: instant X - DefinitionShare-Based Compensation Arrangement By Share-Based Payment Award, Offering Period + ReferencesNo definition available. + Details Name: rmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod Namespace Prefix: rmb_Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAggregate number of common shares reserved for future issuance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemBalance Type: na Period Type: instant X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in "PnYmNdThHnMnS" format, for example, "P1Y5M13D" represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognitionI Namespace Prefix: us-gaap_Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cost to be recognized for option under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in "PnYmNdThHnMnS" format, for example, "P1Y5M13D" represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodI Namespace Prefix: us-gaap_Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemBalance Type: na Period Type: duration X - DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemBalance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fas

Namespaces Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - Definition Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - Definition Gross number of share options (or share units) granted during the period. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(01\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - Definition The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - Definition Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - Definition Number of shares purchased for issuance under share-based payment arrangement. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(I\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (I) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - Definition Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(01\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - Definition Period from grant date that an equity-based award expires, in 'PnYmNdTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/exampleRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - Definition Purchase price of common stock expressed as a percentage of its fair value. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=rmb_A2010StockOptionAndGrantPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=rmb_IncentiveAwardPlan2021Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=rmb_EmployeeStockPurchasePlan2021Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=rmb_A2023InducementPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=srt_VicePresidentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 65 R53.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-based compensation - Schedule of Black-Scholes Option-Pricing Model (Details) - Share-Based Payment Arrangement, Option - 2021 Plan 3 Months Ended 9 Months Ended Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Share-based compensation $\bar{A}$ $\bar{A}$ Risk-free interest rate 4.20% 4.30% 3.90% Expected term (in years) 6 years 1 month 6 days 5 years 10 months 24 days 6 years Expected volatility 47.10% 50.00% 47.10% Expected dividend yield 0.00% 0.00% 0.00% X - Definition The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - Definition The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Definition Expected term of award under share-based payment arrangement, in 'PnYmNdTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: <a href=) Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=rmb_IncentiveAwardPlan2021Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 66 R54.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-based compensation - Schedule of Stock Option Activity (Details) - USD (\$) / shares in Units, \$ in Thousands 3 Months Ended 9 Months Ended 12 Months Ended Sep. 30, 2024 Sep. 30, 2024 Dec. 31, 2023 Number of shares $\bar{A}$ $\bar{A}$ Outstanding at beginning of period (in shares) $\bar{A}$ 6,530,511 $\bar{A}$ Granted (in shares) $\bar{A}$ 9,52,470 $\bar{A}$ Exercised (in shares) $\bar{A}$ (9,570) $\bar{A}$ Expired (in shares) $\bar{A}$ (255,166) $\bar{A}$ Forfeited (in shares) $\bar{A}$ (357,740) $\bar{A}$ Outstanding at end of period (in shares) 6,860,505 6,860,505 6,530,511 Options vested and expected to vest (in shares) 6,860,505 6,860,505 $\bar{A}$ Options exercisable (in shares) 4,694,428 4,694,428 $\bar{A}$ Weighted average exercise price $\bar{A}$ $\bar{A}$ Outstanding at beginning of period (in dollars per share) $\bar{A}$ \$ 2.59 $\bar{A}$ Options granted (in dollars per share) $\bar{A}$ 0.93 $\bar{A}$ Exercised (in dollars per share) $\bar{A}$ 0.75 $\bar{A}$ Expired (in dollars per share) $\bar{A}$ 4.96 $\bar{A}$ Forfeited (in dollars per share) $\bar{A}$ 1.67 $\bar{A}$ Outstanding at end of period (in dollars per share) \$ 2.32 2.32 \$ 2.59 Options vested and expected to vest (in dollars per share) 2.32 2.32 $\bar{A}$ Options exercisable (in dollars per share) \$ 2.59 \$ 2.59 $\bar{A}$ Weighted average remaining contractual term $\bar{A}$ $\bar{A}$ Weighted average remaining contractual term of options outstanding $\bar{A}$ 6 years 6 months 3 days 7 years 1 month 13 days Weighted average remaining contractual term of options vested and expected to vest $\bar{A}$ 6 years 6 months 3 days $\bar{A}$ Weighted average remaining contractual term of options exercisable $\bar{A}$ 5 years 6 months 14 days $\bar{A}$ Aggregate intrinsic value $\bar{A}$ $\bar{A}$ Aggregate intrinsic value of options outstanding \$ 155 \$ 155 \$ 0 Aggregate intrinsic value of options vested and expected to vest 155 155 $\bar{A}$ Aggregate intrinsic value of options exercisable \$ 132 \$ 132 $\bar{A}$ X - ReferencesNo definition available. + Details Name: rmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract Namespace Prefix: rmb_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: rmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract Namespace Prefix: rmb_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Definition The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - Definition The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - Definition Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=rmb_IncentiveAwardPlan2021Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 66 R54.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-based compensation - Schedule of Stock Option Activity (Details) - USD (\$) / shares in Units, \$ in Thousands 3 Months Ended 9 Months Ended 12 Months Ended Sep. 30, 2024 Sep. 30, 2024 Dec. 31, 2023 Number of shares $\bar{A}$ $\bar{A}$ Outstanding at beginning of period (in shares) $\bar{A}$ 6,530,511 $\bar{A}$ Granted (in shares) $\bar{A}$ 9,52,470 $\bar{A}$ Exercised (in shares) $\bar{A}$ (9,570) $\bar{A}$ Expired (in shares) $\bar{A}$ (255,166) $\bar{A}$ Forfeited (in shares) $\bar{A}$ (357,740) $\bar{A}$ Outstanding at end of period (in shares) 6,860,505 6,860,505 6,530,511 Options vested and expected to vest (in shares) 6,860,505 6,860,505 $\bar{A}$ Options exercisable (in shares) 4,694,428 4,694,428 $\bar{A}$ Weighted average exercise price $\bar{A}$ $\bar{A}$ Outstanding at beginning of period (in dollars per share) $\bar{A}$ \$ 2.59 $\bar{A}$ Options granted (in dollars per share) $\bar{A}$ 0.93 $\bar{A}$ Exercised (in dollars per share) $\bar{A}$ 0.75 $\bar{A}$ Expired (in dollars per share) $\bar{A}$ 4.96 $\bar{A}$ Forfeited (in dollars per share) $\bar{A}$ 1.67 $\bar{A}$ Outstanding at end of period (in dollars per share) \$ 2.32 2.32 \$ 2.59 Options vested and expected to vest (in dollars per share) 2.32 2.32 $\bar{A}$ Options exercisable (in dollars per share) \$ 2.59 \$ 2.59 $\bar{A}$ Weighted average remaining contractual term $\bar{A}$ $\bar{A}$ Weighted average remaining contractual term of options outstanding $\bar{A}$ 6 years 6 months 3 days 7 years 1 month 13 days Weighted average remaining contractual term of options vested and expected to vest $\bar{A}$ 6 years 6 months 3 days $\bar{A}$ Weighted average remaining contractual term of options exercisable $\bar{A}$ 5 years 6 months 14 days $\bar{A}$ Aggregate intrinsic value $\bar{A}$ $\bar{A}$ Aggregate intrinsic value of options outstanding \$ 155 \$ 155 \$ 0 Aggregate intrinsic value of options vested and expected to vest 155 155 $\bar{A}$ Aggregate intrinsic value of options exercisable \$ 132 \$ 132 $\bar{A}$ X - ReferencesNo definition available. + Details Name: rmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract Namespace Prefix: rmb_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: rmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract Namespace Prefix: rmb_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Definition The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - Definition The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - Definition Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=rmb_IncentiveAwardPlan2021Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 66 R54.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-based compensation - Schedule of Stock Option Activity (Details) - USD (\$) / shares in Units, \$ in Thousands 3 Months Ended 9 Months Ended 12 Months Ended Sep. 30, 2024 Sep. 30, 2024 Dec. 31, 2023 Number of shares $\bar{A}$ $\bar{A}$ Outstanding at beginning of period (in shares) $\bar{A}$ 6,530,511 $\bar{A}$ Granted (in shares) $\bar{A}$ 9,52,470 $\bar{A}$ Exercised (in shares) $\bar{A}$ (9,570) $\bar{A}$ Expired (in shares) $\bar{A}$ (255,166) $\bar{A}$ Forfeited (in shares) $\bar{A}$ (357,740) $\bar{A}$ Outstanding at end of period (in shares) 6,860,505 6,860,505 6,530,511 Options vested and expected to vest (in shares) 6,860,505 6,860,505 $\bar{A}$ Options exercisable (in shares) 4,694,428 4,694,428 $\bar{A}$ Weighted average exercise price $\bar{A}$ $\bar{A}$ Outstanding at beginning of period (in dollars per share) $\bar{A}$ \$ 2.59 $\bar{A}$ Options granted (in dollars per share) $\bar{A}$ 0.93 $\bar{A}$ Exercised (in dollars per share) $\bar{A}$ 0.75 $\bar{A}$ Expired (in dollars per share) $\bar{A}$ 4.96 $\bar{A}$ Forfeited (in dollars per share) $\bar{A}$ 1.67 $\bar{A}$ Outstanding at end of period (in dollars per share) \$ 2.32 2.32 \$ 2.59 Options vested and expected to vest (in dollars per share) 2.32 2.32 $\bar{A}$ Options exercisable (in dollars per share) \$ 2.59 \$ 2.59 $\bar{A}$ Weighted average remaining contractual term $\bar{A}$ $\bar{A}$ Weighted average remaining contractual term of options outstanding $\bar{A}$ 6 years 6 months 3 days 7 years 1 month 13 days Weighted average remaining contractual term of options vested and expected to vest $\bar{A}$ 6 years 6 months 3 days $\bar{A}$ Weighted average remaining contractual term of options exercisable $\bar{A}$ 5 years 6 months 14 days $\bar{A}$ Aggregate intrinsic value $\bar{A}$ $\bar{A}$ Aggregate intrinsic value of options outstanding \$ 155 \$ 155 \$ 0 Aggregate intrinsic value of options vested and expected to vest 155 155 $\bar{A}$ Aggregate intrinsic value of options exercisable \$ 132 \$ 132 $\bar{A}$ X - ReferencesNo definition available. + Details Name: rmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract Namespace Prefix: rmb_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: rmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract Namespace Prefix: rmb_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Definition The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - Definition The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - Definition Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details)

(c)(1)(iv)(04) - Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - Definition The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - Definition Gross number of share options (or share units) granted during the period. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod Gross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - Definition Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - Definition Number of options outstanding, including both vested and non-vested options. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - Definition A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + References No definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Definition Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - References No definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Definition Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - Definition Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - Definition Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - Definition Weighted average price at which option holders acquired shares when converting their stock options into shares. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - Definition Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - Definition Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - Definition Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - Definition Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValue1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - Definition Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDtnHnMns' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - Definition Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDtnHnMns' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - Definition Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDtnHnMns' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - Definition Number of share options (or share units) exercised during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration XML 67 R55.htm IDEA: XBRL DOCUMENT Y.24.3 Stock-based compensation - Schedule of Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) - \$ / shares 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Number of shares

	Unvested units at beginning of period (in shares)	1,681,760	Granted (in shares)	1,157,765	Vested (in shares)	459,024	Forfeited (in shares)	273,253	Unvested units at end of period (in shares)	2,107,248	Weighted average fair value	1.157	Unvested units at beginning of period (in dollars per share)	2.28	Granted (in dollars per share)	0.78	0.97	0.93	1.22	Vested (in dollars per share)	3.11	Forfeited (in dollars per share)	1.61	Unvested units at end of period (in dollars per share)	1.44	1.44	X - Definition The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - Definition The weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - Definition The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - Definition The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - Definition A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + References No definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Definition Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - References No definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward Namespace Prefix:
--	---	-----------	---------------------	-----------	--------------------	---------	-----------------------	---------	---	-----------	-----------------------------	-------	--	------	--------------------------------	------	------	------	------	-------------------------------	------	----------------------------------	------	--	------	------	--

us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - Details Name: us-gaap AwardTypeAxis=us-gaap RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 68 R56.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-based compensation - Schedule of ESPP Black-Scholes Option-Pricing Model (Details) - Employee Stock - 2021 ESPP 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2023 Share-based compensation \$ A A A Risk-free interest rate 4.60% 5.50% 5.00% 5.30% Expected term (in years) 6 months 6 months 6 months 6 months Expected volatility 42.60% 47.70% 46.00% 47.80% Expected dividend yield 0.00% 0.00% 0.00% 0.00% X - DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480483/718-10-35-1D>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480483/718-10-35-3>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI

http://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap EarningsPerShareBasic Namespace Prefix: us-gaap Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap EarningsPerShareDiluted Namespace Prefix: us-gaap Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (

Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na:Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember Namespace Prefix: Data Type: na:Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rmb_CommonStockWarrantsMember Namespace Prefix: Data Type: na:Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember Namespace Prefix: Data Type: na:Balance Type: Period Type: XML T2 R60.htm IDEA: XBRL DOCUMENT v3.24.3 Leases - Narrative (Details) \$ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 USD (\$) Sep. 30, 2023 USD (\$) Sep. 30, 2024 USD (\$) renewal option Sep. 30, 2023 USD (\$) Leases A A A Finance lease term 8 years A 8 years A Finance lease renewal term 5 years A 5 years A Rent expense \$ 0.5 \$ 0.5 \$ 1.6 \$ 1.4 Depreciation and interest expense \$ 0.1 \$ 0.1 \$ 0.1 \$ 0.1 Minimum A A A Leases A A A Operating lease term 8 years A 8 years A Number of finance lease renewal options | renewal option A A 1 A Maximum A A A Leases A A A Operating lease term 10 years A 10 years A X - DefinitionTotal capital lease asset depreciation and interest expense during the period. + ReferencesNo definition available. + Details Name: rmb_FinanceLeaseDepreciationAndInterestExpense Namespace Prefix: rmb Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLessee, Finance Lease, Number Of Renewal Options + ReferencesNo definition available. + Details Name: rmb_LesseeFinanceLeaseNumberOfRenewalOptions Namespace Prefix: rmb Data Type: xbrli:integerItemType Balance Type: na:Period Type: duration X - DefinitionTotal rental expense under operating leases. + ReferencesNo definition available. + Details Name: rmb_OperatingLeaseRentalExpense Namespace Prefix: rmb Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionTerm of lessee's finance lease renewal, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 842-SubTopic 20-Name Accounting Standards Codification -Section 50-Paragraph 3-Subparagraph \(a\)\(3\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478964/842-20-50-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 842-SubTopic 20-Name Accounting Standards Codification -Section 50-Paragraph 3-Subparagraph (a)(3)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478964/842-20-50-3) + Details Name: us-gaap_LesseeFinanceLeaseRenewalTerm1 Namespace Prefix: us-gaap Data Type: xbrli:durationItemType Balance Type: na:Period Type: instant X - DefinitionTerm of lessee's finance lease, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 842-SubTopic 20-Name Accounting Standards Codification -Section 50-Paragraph 3-Subparagraph \(a\)\(3\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478964/842-20-50-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 842-SubTopic 20-Name Accounting Standards Codification -Section 50-Paragraph 3-Subparagraph (a)(3)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478964/842-20-50-3) + Details Name: us-gaap_LesseeOperatingLeaseTermOfContract Namespace Prefix: us-gaap Data Type: xbrli:durationItemType Balance Type: na:Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification -Section 50-Paragraph 7A-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification -Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147478964/842-20-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification -Section 50-Paragraph 7A-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification -Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147478964/842-20-50-3) + Details Name: us-gaap_LesseeLeaseDescriptionLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na:Period Type: duration X - DefinitionTerm of lessee's operating lease, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 842-SubTopic 20-Name Accounting Standards Codification -Section 50-Paragraph 3-Subparagraph \(a\)\(3\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478964/842-20-50-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 842-SubTopic 20-Name Accounting Standards Codification -Section 50-Paragraph 3-Subparagraph (a)(3)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478964/842-20-50-3) + Details Name: us-gaap_LesseeOperatingLeaseTermOfContract Namespace Prefix: us-gaap Data Type: xbrli:durationItemType Balance Type: na:Period Type: instant X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na:Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na:Balance Type: Period Type: XML T3 R61.htm IDEA: XBRL DOCUMENT v3.24.3 Leases - Schedule of Supplemental Cash Flow Information (Details) - USD (\$) \$ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Cash paid for amounts included in measurement of lease liabilities: A A Operating cash outflows - payments on operating leases \$ 997 \$ 956 Operating cash outflows - payments on financing leases 27 29 Financing cash outflows - payments on financing leases 29 27 Right-of-use assets obtained in exchange for new lease obligations: A A Investing non-cash activities - establishment of right of use operating assets \$ 0 \$ 151 X - DefinitionCash Flow, Lessee + ReferencesNo definition available. + Details Name: rmb_CashFlowLesseeAbstract Namespace Prefix: rmb Data Type: xbrli:stringItemType Balance Type: na:Period Type: duration X - DefinitionRight-Of-Use Asset Obtained In Exchange For Lease Liability + ReferencesNo definition available. + Details Name: rmb_RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract Namespace Prefix: rmb Data Type: xbrli:stringItemType Balance Type: na:Period Type: duration X - DefinitionAmount of interest paid on finance lease liability. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification -Section 50-Paragraph 4-Subparagraph \(g\)\(1\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478964/842-20-50-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification -Section 45-Paragraph 5-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479041/842-20-45-5](http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification -Section 50-Paragraph 4-Subparagraph (g)(1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478964/842-20-50-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification -Section 45-Paragraph 5-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479041/842-20-45-5) + Details Name: us-gaap_FinanceLeaseInterestPaymentOnLiability Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for principal payment on finance lease. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification -Section 50-Paragraph 4-Subparagraph \(g\)\(1\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478964/842-20-50-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification -Section 45-Paragraph 5-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479041/842-20-45-5](http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification -Section 50-Paragraph 4-Subparagraph (g)(1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478964/842-20-50-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification -Section 45-Paragraph 5-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479041/842-20-45-5) + Details Name: us-gaap_FinanceLeasePrincipalPayments Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification -Section 45-Paragraph 5-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification -Section 50-Paragraph 4-Subparagraph \(g\)\(1\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478964/842-20-50-4](http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification -Section 45-Paragraph 5-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification -Section 50-Paragraph 4-Subparagraph (g)(1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478964/842-20-50-4) + Details Name: us-gaap_OperatingLeasePayments Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase in right-of-use asset obtained in exchange for operating lease liability. + ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef-Topic 842-SubTopic 20-Name Accounting Standards Codification -Section 55-Paragraph 53-Publisher FASB-URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification -Section 50-Paragraph 4-Subparagraph \(g\)\(2\)-Publisher FASB-URI https](http://www.xbrl.org/2003/role/exampleRef-Topic 842-SubTopic 20-Name Accounting Standards Codification -Section 55-Paragraph 53-Publisher FASB-URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification -Section 50-Paragraph 4-Subparagraph (g)(2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478964/842-20-50-4)

https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionIndicates line item in statement of financial position that includes operating lease right-of-use asset. + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2 + Details Name: us-gaap OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: instant X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: http://www.xbrli.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for operating lease, in 'PnYmMnDtnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrli.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap OperatingLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant XML 75 R63.htm IDEA: XBRL DOCUMENT v3.24.3 Leases - Schedule of Lease Expense (Details) - USD (\$) \$ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Leases [Abstract] Å Å Å Operating lease cost \$ 305 \$ 314 \$ 914 \$ 899 Financing lease cost - amortization of right-of-use asset 11 12 36 37 Financing lease cost - interest on lease liability 10 9 27 29 Variable lease cost 234 172 675 522 Total lease cost \$ 560 \$ 507 \$ 1,652 \$ 1,487 X - DefinitionFinance Lease, Interest Expense, Including Adjustments + ReferencesNo definition available. + Details Name: rmb FinanceLeaseInterestExpenseIncludingAdjustments Namespace Prefix: rmb_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of amortization expense attributable to right-of-use asset from finance lease. + ReferencesReference 1: http://www.xbrli.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4Reference 3: http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap FinancialLeaseRightOfUseAssetAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of lease cost recognized by lessee for lease contract. + ReferencesReference 1: http://www.xbrli.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap LeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. + ReferencesReference 1: http://www.xbrli.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap OperatingLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases. + ReferencesReference 1: http://www.xbrli.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap VariableLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 76 R64.htm IDEA: XBRL DOCUMENT v3.24.3 Leases - Schedule of Operating Lease Liability Maturities (Details) \$ in Thousands Sep. 30, 2024 USD (\$) Leases [Abstract] Å 2024 (excluding the nine months ended September 30) \$ 337 2025 1,368 2026 1,401 2027 1,435 2028 1,469 Thereafter 804 Total lease payments 6,814 Less imputed interest (583) Total present value of lease liabilities \$ 6,231 X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesNo definition available. + Details Name: rmb LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour Namespace Prefix: rmb_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionOperating Lease, Liability, Including Tenant Improvement Allowance + ReferencesNo definition available. + Details Name: rmb OperatingLeaseLiabilityIncludingTenantImprovementAllowance Namespace Prefix: rmb_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrli.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease. + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 77 R65.htm IDEA: XBRL DOCUMENT v3.24.3 Leases - Schedule of Finance Lease Liability Maturities (Details) - USD (\$) \$ in Thousands Sep. 30, 2024 Dec. 31, 2023 Leases [Abstract] Å Å 2024 (excluding the nine months ended September 30) \$ 18 Å 2025 75 Å 2026 75 Å 2027 75 Å 2028 75 Å Thereafter 38 Å Total lease payments 356 Å Less imputed interest (133) Å Total present value of lease liabilities \$ 223 \$ 304 X - DefinitionAmount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesNo definition available. + Details Name: rmb FinanceLeaseLiabilityToBePaidDueAfterYearFour Namespace Prefix: rmb_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease. + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6Reference 2: http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap FinanceLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments for finance lease. + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap FinanceLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap FinanceLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap FinanceLeaseLiabilityPaymentsDueYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap FinanceLeaseLiabilityPaymentsDueYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap FinanceLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrli.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease. + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap FinanceLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 78 R66.htm IDEA: XBRL DOCUMENT v3.24.3 Benefit plans (Details) - USD (\$) \$ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2023 Sep. 30, 2023 Retirement Benefits [Abstract] Å Å Å Company contributions to plan \$ 0.2 \$ 0.2 \$ 0.7 \$ 0.6 X - ReferencesNo definition available. + Details Name: us-gaap CompensationAndRetirementDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost for defined contribution plan. + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 715 -SubTopic 70 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/21474780794/715-70-50-1 + Details Name: us-gaap DefinedContributionPlanCostRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 79 Financial Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial Report.xlsx M4\$!#1!0 (#2+9UD0!4UB@0+ \$ 0 9&[C4']O<,.087!P+GAM M;,\$V,.0/L',1!\$!QO;=I=P4)B0<I2L+</>XQLOD&1!LD) ^OCGICVX>; QAEWPIG M*N*!#BV&5(C(I(/147BK9.7=-N')=H16-Y #OGDK7A.YNJO<+4&6PZ4A!0W J=OUR;UEA 6#M17E!+ P04 M' TBV=9!4D7L' K @ \$0 &10&0!UR;W!S+V-O&8ULS9+; M2L0P&S(921?+?3!OU!&);&4K! <\$%Q(N0S,6&FPJ2)M0;QIWNX@(<(>9?>' M-S' =D+YB, 1XQD, Y=C(I)+I?>Z(<(>+&YH6IS@P7F7UL?K3C#&1L4GW(M'O)OFFNP2P)+DC #J(06=)J!51\$23X>5HM?/ 9AP+3"G! BXX2M'4+K)G MAL,T= ' &S#&#'-W ?5'+&4#&1J&B&UL[5!;<IHXN?{[OK]X9 ,M'9'8V@;&T&W-I=VMTF83M 13A?&5&B-;EDDB1 OTV23!; 0LZ?0.14?GZ&AY^XN8NB&B)3R M>+&J06N[!3+MUES&6QHO(J)JM O=5H11,*\$81V1+?>XL \$L05%&;U@M,42, ,@5RU2-9.1 M&U=1JKF(M+Y,7VMX&9< 1ATR@6XP&U@&?Y0I 1.6HCA5+&P&IC/U9K MQJ'22(''R7V4!&J)/3%0@R#3LZG5C,=GSVQ,V?C,K;=#1M&N&C#7@XMLO2 MBW A(5M>5 TR M6!VULS2 Y9>*?IUE!K9;O=05SP6.XYB1^~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

[illegible]

#S#J[M(0:09)DL'L'F#W=F=M#-D#5(4)HJ3;J1U3TJ DDJ.Q#H5F#H1A1VQZGJKNJ.C.M+(X#F1)@H1'WSWV.#8PF&FOAN.K# MQT@1'27P2<^HH@Y(KLIL@S/6 C1SSQ7E.JO.BT'PJW6:1.2]. #S M031'BA6GARV15E03CQ1H;J1J.9XC1K(TA+P=>N%1'UTCY&WVW''&=)Q# MBZJ.ZH->Q<J-2+JW9&R&P+J+1+8'IOTB1'1'#\$K?I'HAPU.1+A%#J-UJ MEM 1.ME#>^ZN>4GN/OX.IZ/DV#A8:XYLJZVQPP20ZNN0=0-YAPEJ4DJTRP.54" MTQHT 7FO-F&9ANVN.P.#507B11SV'WBL7\$4CY.VI(=N%M%|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|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|3LPO>+WVJ M21+&J'>@2FJDMO>DFFMUJ13G%Y>X.L\$(<+X;JQR|Q'<=<O1-04 N# Y^' 1 MNJ8JB@U4 M10XWYN4 UY<7- <#>'3P0K@J/K9K3AKWQ>?>A.L; MT6(-R<^@W-U' D(KY<JE-4<6)DMGWJ27&MJFV>#&S= 6ZE^<J.CPH7NH MZ&66.PJ'<LL4H@>VQTF79SB6X'P.UUW1>2NM-S7GZ>6CNEJ3J7FMM'<A@>YUOH@4J.NWZ6B30>5>5@M?>1?^N'8*P?]? @>J,RVDI4(U,140\$+>W.D= M4=-Z&,%2:0%7XDKQ0-3=ZU|P|S'M 'U#UZA|>X|MG.X3#%1 JLOG5=-A MD5AR<%)I%6IH|VD^>YSGQ-V;C8R7%I>XU!E*4MPEV- 5'Z2DU KNE2.'V2'Q^COT@J'>O2W MB B@>2=VLOT9.FAB3\$=>?>JNXXQY&H@&7471=U'@H0'JZPN<Y-T S' MU8P@EQVQU1K12.1U=U-VZ' N47|@<KCRU@K1600[%>1MZ MU^Z<.CSXENZFI2P763.E#Q1/M7JN32%&@>7J|8&J H26A\$J/ RBBC6@APNLAEYB*6CS\$J U MW&Y<W'40I.Q|E220,UIJX\$J,JU5U,0@>#%FEE\$A B|VRUJ0 *%>15SR); J|MA:=<DHO.- +1N7M|C8GN.K|&X@QXG.Y|.[92|M1&S9<?<8P6>=2V9B'<6CXB|M'SP'P@NR.V+1QW+>AHLR7|16F'P|DAJ|J%23Z (WDJXZZI:OKN<^1T2TZFK M%|F.1B\$INFGV+G#&G&F4&E#?<ECJ7Y'>U 9^>J'@%5M?>O@W V:M3SE'1<+>4@GUPD; |LNF=IK|, >2DERZ(<G>+JTFQK (4IB,WJU-NXF MW0:|L|>OS5 3PMXE|>19TRWHEE3U^>4Q.ISW.21'25XZFJ3M=AA25@>M %>=5&8I7-RGJ5>OOZ?Z\$B'ZB|V(6Y+<J\$XX)D&NZ2+>+ZWM6.X;GOT2;6W MBLTR %|I|J%G3H? INOINPH50M243J|G|W#S'DQM2N.W+QY'J3MIEQ1 M.L6(HVV+<5 /Y1ZJ7LRX&V%<Z&V|S; .V?E A%|W9HB4DM@AUYLK *U M5U.C11H07248R+ANYPL20V .9AJOMU+VAO7K.TT>F%EO.KA5T:9F>E9 MT.U+9,WY|B 'J3DEU'<9AN<=R'S5SRDNOJ7 J3>^?3J6/Q24#9<. MN0I1C1'G#(3&.<8>K)A+>L0IIOX9>F70\$? #P#14K'QA:0<-DR2J8AO(RXH-<@<M2;LPS|OTLTD0I\$2.<7<7<014A0%=<QNZQ>+>L(WVVR 9'<R5J0> MHS'<S'<2=18+H.S|C)M."B"<=<AIOVSJ&X7D3 X+63EC4S>*>KGRPU3+< BBP9(VPGJ7N=>^ST3IU> MKH3Q3JBUML-Y'ECK'H|9V|0<JF'>D<SL@J|Q,Y+MU'N'==CGYV<4QC7<J\$@J|+>H.G.1 C\$%K&P D M1&K+>K+KCE1.113=>9Y1W<Y F#G&R'M|+5T8G9L4R7 16^07VP-KMF |L/CU >+3GAQ' PE?&?>BPTF4%I4QMO338T1+>E2J'K+Y';>UDRG1<|Y|I(W-10I'FH1S0 M|J|@F#FCM3M1.BI.WOEP6<+<6 6B|U'X#6XR|XXJ;SZ\$0<|0|6439;U%1C M2'>TJPK-VIMYQ272J.01OWI (\$=>614CEKQ4U.6J\$TJ|MA\$8+>Q>A|J|T MAIME2=>9J N'FOKPKM\$&J.&#P#D. 4ICYR:FS4=>Y72EMW7<2?D|G&FMMR M2->PGF61>.[6SZ2.1K&V?>@5Z& |SL,Y+>#N98RUS<|RDSA,X|DK7+K+5V3. MDG'63&S.CB=I|S2.4 -9IA<5W+ST2,<C|A9?7&5(BF839J) @|X|(<1P> MA9U.X'<R'N7RRE4;T.2=>WM1MKT/7J 9E@<3 T-0J|T:8N8<U>A>F&A'U(9Z@ M-+M+H'AVT10VY M16\$S.I5XC0M|QK|0WVG<Z|S?F&U12617G9+>QG&D MXWX|AU>5+>F'8H0Q50J|AAW+>OS75@|_C|Y@<5Y6K77J|+>P|+>%&L< MT7K:&F%?>2HVCV5U|0I|W@UCZG+>MOY(N+>1<|X1=90<9'9CM6FZ7?<G.H%Y; M9;CJW277?<#H8JQ?U4 UZ9^B116?2?R8W|UJ MUIM %Z) (J4;|>L+>0K.7K;V5E0QDWM5|C&|X=J0RW;1I-IP|H0|33J\$M'<C'0MEFZPAA15=>+>J DMN%>PFFH|<@<SKKZ|U+>

M_#T,WTG[:U^RQ-07XWU/25>MZ1G?69iV1JV4T;F-Q8VG%IL5PAWDP&@R\$SB[MR334JGVXZU57^89[OYP;CK7\$1B]C(RLB[[&RXZHFTQ?;M5;5<Q'K)AXT#M&6>8>S-[GR9/CKH_%UWR(^CR_3#^UWVYK8R-QW3KX_0\$E0_M_`\_1WD7\$MQMMMN)(H(U^V^W)V0VTPJ]JR< VW>[1R1YH&;(H&~0-)]>C=7\_H MG/55NL;9E>~>:X6PL^2+>F3P;C4FO.YAGS4UYBY9XU4F]SJR+@< !E^B4UW MJB\ HIBKNI(@|WYO|T\_`V7B^HNIU M9;*:FF];MK;_HH\$M%!>_>GY6PMA8Z+*~;.*V\^W@^*TD7>86^<(J/.89%E0#B\$>Q!; M^J7]T![(!J|.87^HF<^2=\$5:Y6S@F,Y-AN?XU1E*4MP\5%+C^5Y->YU#!D M)4^D\XJ\ 17[Q[N^ML0NE6]8+&S\N] 2W^VIHDNOZ29^M, 9Y\+<(Y91KIGGQR_ M^?^HL^FBJ+>?6(W#7PNAEP_4FT>SI WOP+JL2ATH=[-!AIESAU^7OD+H0 M!;39T^FN2R?1\ 0_YO^>^L>1R_ J_G^U^V=..WY^?VKV@=DX0 M(4SCN2+Z4;Z7^*~;JV^*GP_QC9>~&~>UJ]N6G3RA-^W+11\$H(<5U3Y)\1JU M\$=PAIEU?)BYT^>3PHYKCYX(MLLXA&HW+~2<%K7*S4@F\$ MBS*.PN/R1O_C44:VP9C2X&F5F+ HOL^N4!;=SM#-J^8F6HC@<^G;J^+ 9^~[!6]IV4I2R8_4X4^NAD)O? M;J!~1^1[6+QKQ#_!B1/V2.TB7/4>~..AFJHF>G^<^&E0>_T8BTBG0YDUD)P_ MO3P3Y!>=C3?>WFAQ5QJ321,29/>~!VYX\$X@<66-6L1V6O?>=^Y_Q_ V70 M3Z3PM_N_NXB&BEVM6&I#J\>MU!79?;RB;~W/_O+<F9TS6\$7^O8O@OY! SAO M^?M4 36CKJ\ JSE?XL51WG7#R\Z7;~;1.?>^FH<[-&B9^A6^O89_R:WP(NB M9N%P=;< 4,"CA4& X*);J%UPECWA\BC@<>:PUJ@=^\$JH^D;H>BY\J^QN MY J\Y^P^A-3^1Z&H(JNN,N/7J_6!>=7^01K:5_!<K>^E-C\<C^?>?V^F*K5=3S41:()<+K^*0ZIENN4 RJ M-;AN0F^LB=EQ0LWQ@>_R5D\>GEK\$0^9V\I(UO)X=F6V78)B0/_34F:H:K4 M^%C@FYM;W^W68#4^FXQ_KJE Z MJ>\$F%/12%H2LN;CV5W-2&41B.4ZW9U41D MGA^*K,TY);KY#GJ?0\$4^OFA[WL/Y3[ZB9NCJ^2)#AR.NU#DFZCXYTMCJ10Z M%I^HVP?;HIY>3T=Y4>G^!<CH8\$@YXQOKN)J8_!';IQ(X(ODE^M^Y662D5Y M4_XVH=J4R=Z14P5Y7=H=1L-193@JG|D.7^F>^<B89<_O4W,<C3J&4JSFZ MP^EC1SK04^F^AWJ7L_7N7<~+^AWJ03DX M/@+;S MJW\$Z;Q6N\\$.I.[I.N(3)]>JFYC4<5?E5ZQ>.=%^>^>?12?9;S P/EZOZ MO\$:<[CQXO?>N9YDQ_[M%JT_L+I6/KGI)>(T="Q^Z5-"G!A.9Z^OJ^I^#[I MJ&4W752RHRM4FV;Y\DU^H^D^<K7NL.G(8N(:ZKD-5YX8Z&G^UX\$ 5\B: M?2]NZ=-%\$E3EGC.[XJL2<"]< "OBE +&^<^V1>?E&S3 \.J9.N6Y11#=#G/J7U!H^,7R^0^ MW^<^C>DQ-TZL^\$_.XAVNUX#Q>|>Z#@LHQW-.FVP5]5Q 0?_JY3QK\$414/P@&W MF:N&ZB7\ A2^743A-H0A&^Y4!MKB[YE]E93OUI^P&EUX^OH^F=42&804^~^Q!; M8V;.R64L7N\^9<_<5?7@>^>~>\$VKA\&^!84(DHOODF5OD8PR-SCR9_@PK^] M\$EQD^DN3@\$<>|Q7^>)9=IR5^5O-^M=T01_(ON6T|-80/LFX?@WT7V^TDP|Z>_MNT+O@34M_W2^<@ORVXW_!>=TG^#5^_2BP;X.DL8.KE^FC\$P23X4MKU03W M3>:F18Q^U^=P,KB_B^,"8-7W^!>=O7OXO4\$!#10_ (#2+9UF!|LMO MR00 &(<- 9>+PO=VJR^W-H965TFXWJ_?<27+JN|JV8#6 M^R1U>|"I9N^TY4:JSWK)F(&O=27TU6!S.IB-+>YDM54#<6^*~>=929\$53@Y^J M^F58K1P0G4U(KX?CVK^Q6!RZ6AW:G(IUZ;B@MTIT.NZIFH|997<7 V^P8YP MS\NEL831Y^)%2S9CYN/J3N^7J--2)H)S:4 Q197@^O@8AI;?L^P&V<?;~& MZ(E\$<_>_2^7%11^ MIR \AK[KO;MW.W= _OYYKH|J_CCE<^<O^?>J?|:0+O:(YNQI@JVB^ME@|O)9 M\$NO>M^"..J3C/NV3&79FL:Z83=j_-%#D3B-5^<#W7GT^A=[?7WL&2PD!7VIPU ML5D&^UL8W=84QK,DAKL^P=1^#X+T JJ^5R4 RJN9UBHKMRV2M!N.U);&V\$#/#\$B4:R MT?4=(JEV\$;YG/%J_KB^&YQ9WF(!.Q>Q[2R/^M&D3,1N8,&)B/UAA.M.?/3^4P=/%!4?8@/OT2M0U2O3D M1KE3LECG|CY1I?>^PPX_U2B\>DZW=6_>Z>ZVLQIR^\$S\$DX4+EV%:VX1^JZA M)OHV#;HMY%(<_<S^G)A;!(.854UP6!PBXKQLQ MQC%,Q\$3A.RBN\$5/Y2.W-[0&5ZKD^601<+<3N+>+B^5=[QMU\%L39.9R^X_A) MCX:)X@2..\$N.UCU%\$G=%\$C^Y2&ZYIF6I6\$EM5[XWQ]:I.NE5^3_JY%3^MZS%:_Y@BVG47V@#K+&_W_.9IWN-] M?>7JY&QX^911X)9VX7LDBZIDJ\$@&H9Y+1#(B7A!&D7H1U^R\$E@8?&P&M_)% [LCVWU>_8@(<R+PU^NNT!20J|J)T^Z\$AY+4M^5+8^IAZ^3.YRQ-8+AYB^F^AO;P NC!<= 2FT\$D8MX61; 6X8O M7K&%/6,DQ2I(7(=@T;@%XK^&'8IG^B!;F,0G@NJI 8HP4N+M^V6<4[B1C M^),DL18"@F.%OYK7DYU^NC@W8MA\JWK7C2&FR=P1^W^0%PW|<8>_>_OXP-5 M>_!IO((6^ (I^W)[X\$JGG1-Q|&KMPK>BX-YM@ME _@GB^G^&@/L+&L^WE57;MLX/V5@1H46T^W7R1\$J M G^QOR^R1 \$?>=A4^&M+<D(J1+DG95=_OD))5% [5=8%_<VVR9J|Z/E6-%5SB MLP;3U#73;PL4:C+DN^P^<(<U674;T7RZ91MV_PF|>?_!W!5D1|<4M_BIG0^P(H<#?>..@1&PT|040^1^2=^IA! M^J(Y^L/Z!<]=M^*R8@;OE?B;E[::!7D):Y9(^R+VO^>)G9ZAPRN4/X+^J9V M-R@:(Q5==>.#&HNVY%JZ[AR"&SSBDG4J/>,>|,L^9MEJ^M4>M+>F-#?Q M4KTND>2_92EU3\$R<_<S^*N8<=<Z[6L2:2R8(S"N^F\$,HTFQ?_YON M/2%\$S^DIP^0^O6M1<:[F!|3/1(5PEH)JFZ^;U^@<^6%KAL^X8O MP14U!;ID? J 1+9-OJ| E3^<~>:J.N J@UE8^VL64Z5152NGROMR67^6231 M^!_A^W\$MRBR/OB|FNIC>H\$5\$;155LT5-18;4HXKJ82GTOR5XTA>|A|H!| MIB-

```

G#GZ3UIX|'R2;DR|,8-794EW|_NF:D OS:;<#%IWQ,K_O,K_2- ZS>'2&2W=X1N8H#4?I$(9A,LAZI)$X'(JR)>#1R|'L' M&DZ2Y*!=|:7>O(!^&^2!U5^
1CXE,XG?2#^%4|49|;A&O?$OC8%"-=vV|;C? M|1^SN|:'?S=O7(GIC= &DK<+&G&UV-Z.W3[NK0+J|:'^HZ^4I??:13RMZD%$[ M SI?V4|'"Q>@?
^+G_P%20P,$% @ -(MG6)=;OOR$O P 6 < !D !X M;|JW;W)K&LUG55M;|LX#<XKA#<,>#>#>KWZ<+&G0
MM'L|I|JE@R/985(K)L|J2|9(5%6|T|9'GC5|9>Z/N)55(N MG.6|T=VKY556IN "I|Q7HNB9J|JZPD|>)%$SC|BB|MS=6X2WG%=>OA&LUC=:] ( M|GJ4G);
|QP/>K 'F|E&R|J|6N,T7CF|)88&9L0B, M/D|XC45A@8C&MP|3Z4:-Q^&^?U#DSOELF$:KV7Q|_ \-?N&D#N2X975AOLC#
M)>SRF5$3|:Z6>0GIUOQ*SA61|=,ADE%<V7?>J,|('1<1^;0K4H|EG M"-G:O Q#6;4HX0LH,[B3PNPUO!|2HIQ4^T|UJ?9P'76(TA|ET( 3 ^ M@Q?U:48-
703K-%VXP8T!)G)X_ZWFY@AK&K&#4<+?PUUMM%T5X^2580V1GPZ MAFV?2UVQ#<1.;|8=&|83;LVK|?'G5T|R"TL,CE%RSO M:9KKO53FK4%5-
H4H-BU$A_IROQ_1|J$2 M#8D^D2Z5D?X+ W|OM<0I>[4G| FC6AYRH-@_ !=IT 37Q^XP:PC&30DH_! M\AK)8Q%&(Q:0QR|G-V*%X6&(&#-(99|VX5
MLS-N;5'6Q)U$^<0A7 1Q,K|R'(44-F)Z6:FK13+>|BFHU8|35+XK;|_! M_F ACAG;2T=XK.!!PL!_PI (E,(036<!)>_?>C. ANW-RVIF%AG6O.IQG6&
MTZY$M6MFN|G)K O3#KY>VS|;5^VT_/_X^<+>;7C0D.16W+UQ|_ ) Z|=XZU@ M9-7,SHTT_!|P|9Z>E3V -FWD0+N|N|OM@?TR7P!02P,$% @ -(MG69G7
M01R% @ _@4 !D !X;|JW;W)K&ULA53+;MLP M$/R5A5H4"6!$3$|K"XB3!LTA0!|GS:'H@9;6%A&*$5DJ3OZ^2TE67,|Q+Q)W MN3.<)3F<|Y1^-
@6BA=-22+P/P'FNFK?>^_K,^2F0M5H:29C=(ELQ3|K6|J|C2QO M$?7PHR 8^27CTD0G3>Y>IW-56$SEWFLP=5DR_9$H78+&+ 3VB0>^>+>Q+&^F\
M8EM5@LUZB;0|G&K O|H3<Q?^H!M^J+ M:5%)S|E|Q^AC <#>|M$+!9!S#|D3B+C2^D-C(|J(1P&<+>_B;A|W;PU;IWT !T MD,0!<3>+
*|RC|!#%$XB|G|QHYH.IJ,OCNVQ?>^!$06V<+>;JA+FMi6SOTV?XQ MNGP|]|%>|OD1W3&^Y-^!P0!>@8CST0+?N;@-KJL91^V7)G|VPH <1M2N@^8U2
M=A^X|?HG-OT+&$L#!|!O ( #2+9UF|)#2|MP( 14& 9 >&PO=VJR M:W-H965TR@6 M+L#M'0;H1:DN>|?#>WX^2^2;TFP/D74AS^&A1&9VD.1|Q$-
/) >?T'-O M;|T|UJ7V=[K^D]D96*|>DEZIDA9JY^M^V(|,LQ979@>?7B|K9C|4QMEH=T( MA|9V$N'UUMK(LG6F$|SHNFB|];O-PXC .7G(6H?
(Q=T0N2AOF6|J,3D#&M- M';B|H0"HX+>RD;B|V4DY|)U@HKQC| 9|IFC1|8R$|;|2IB5|P%>8U@>U7 M|G|BV0?T|P|PWQ6F|;3F6#4?T
L<$|J4P>P|WU(L/L3W^?XNV?CHY!>+Z+@|NL M;J ?|)'HO@>?7K|+OM_A|?>1A+L#^2X^_U!_%DY|U9M+KXMMMHM>DK?SZ6A
M88G|L|CRFNJ^I3CWJ^XTJB?TDC>OPF|PJH^N-,07T|-E2N65T|RS^TJ-| M!V!>+>_B;A|W;PU;IWT !T MD,0!<3>+
MJ3E%,^R/83<6 MNA<&$ <=>#R=PIE|JDU(M4>U<0|YJ85|J|;|7K>HBGUW^9-P|QG:D>ZH<=> M7<|T< #U32A9F%DYOI ^PVU$3?>4]]&90WH|)?
2^!>6H/LG2^X14$L#!|!O M ( #2+9UG1^3M8 @, %& 9 >&PO=VJR:W-H965T|JLX|)7&DS7-$P_7_%0VT60 M|N#N+WQ36W<0+> MR. R62OUVRD?
RT40.T|HL+ @.=^V@>U_8^M$8.KU#"^!6VO6U.$80.6-7LG$EON.QW M|KJB|A|Q<_D_@?>#NG.(?6^>T>Y0VS;#G7:O@61:..$WRJWIO(<>F*7D
M9Y0QEEF^"VTLX|7O:2M$8-2^ MS _|=GOX+;DV5M_#^74H|J1X|XSLFFAF6E;@|J N_!>?>B|>96,X|I>=<=># M|_P8^O^*FK4+L!
(*JX*_2#>0/;3Z?>9CQL7=1^.)8|T%+&R-4"E|S#&*X5HU;6<)>KV:ZW**WMFHRGHE#9-L"DDX'D,|C4F>$|Q@,|LB|J|I|/75B)=,=&9GTLG
MR9BR2D|)R,|LB4|=2DDX&F=-2,)-EL^AEQ_|J;|H&|<:-D/JZ3M^<W^X^;G M9Q3|TGLW|T7O+|J(9+ P(K&PO=VJR M:W-H965T5AV<-LT|)%06?>(DN4G_?
I10S8 TPUXL42|(SQ#>9KF7ZE$? 8<2B|TRBF, MJ1|N;J ?|)2J|O9 4^;W*12FK05M75PIHU@25W T|;^*6E DC7C9G|RI>RMIP
M)N|>5$V7)57/&^!ROW)|IS|X8+O^V ,W7E9T|ULPWZ|A98|H&2L!*&9%$! MOG+6_F(36?_&X3N#O3|:SZLDD?+1&I^RE>-90L A-
1:|XO($U|Y14<OSM, M9TAI X_W|?J1CM|J2:B&E_!L,P4^VY|FQ QR6G|S/!&S!U T'H@N$S4L;ZBA5+!/5^6&|L MIT-1^;Y)FQ1MD;A+&X,$X$Z_35-
60S3A@F35H0D5$E 87:E0I'C^&4T89;A M|>57FG|0Y|NP>06PDV|1)LV4?!"HCFYD|(4FMRM#*+>_ XUTD|/3 >N;X$N$ M|JH<GHC$GAI=
80^%XB;|/##"?|S$YQ>Y(W+=O<|/=-PI_OKU/*6^<#H+!M MJX6N: HK!_M&@WH")W|Q|J|X|_0C@;:T3GT>(MMFM4N20@(&=&|PS)!8E&DS|JUIDW
M&R>>0&1200CQ1Y|(1Q_QGPX^>ZH4?>9Y !L"IG,YH.#H0<,<#<(Y^<9|_! U M1'H@DQ?7CC#>3Z>:U-RJOCN42>7H^_O+%/5@O3-
O5P.HS$>3L)7MS;>7T_ MUX8)33CD&.I=3<<4>V;@TCJVB8N_+&E&FV18YU4-W|W,I36 8!,,?1?P' M4$L#!|!O ( #2+9UEGKULH=O, &D( 9
>&PO=VJR:W-H965TMV)+|LJYL|Y|W;:81E0-^B|Y<+>P++1T MMH4OI$124?W0=Z1DQOD(M".|RXUN^&20F
MG>+Q^H#<J^=-7#;X^T^3SRWQ3RX#B#^+&N%_*W|C,W9XF1+&_T|3RHZC M++&6%5VRN1|R67|9-<[.!P17+^ED^0*B?>[>2]_ L6|RT:D
|4)S?T_5 M:Y-7+1&65M^;SGIV<6M^DL^*MG|H^)+&C@X9IS:OU W|PQ49V1-JZAUPP27LD6ES";_78@_)
MR!F(KR")X..SFML|Q|!>#R^=Y|,T^H@66EN8 X8+671X+D71%)!@Z/>A M8@^7Q/#>2&YZ-
1|T=0+CB80#Z(D&423%#Y@UM&,O5KZ0|)*&L33EF8RO(|L_MYIIE,(_9WZ$<=>=,LBN^S;<%CX?*"LK)O< &>"26TXA|J-X!GQW;)V2781 MW-
U_#BX^0^51YKXO^IH$5E-U9)9G3)#K9(IBY&#)|7DKF#&P/LW+AO^U M<G|Z@ZZ='W&0M^|A-,|S|A|)VF/?2?>E*^2WV Q:O5Z^4ZTTB6)@>|9!
ME/Z,2B8;G^&D5XU/Y+U#L Y QY5D0;3H+&M^J CRW9|(NW0_@3T^2% 8%; M4HV&5^>=>O8BVHU5E1|F&V4I_!Y9T+<>:B= [|=>VB_EA;_ E!+ P04 M
" TBV=9,V1LP? %18$ &0 'AL+W=OG@+&@^S|G>&7R08FUVZHP|N57|CEY^*T|/A$2E2@L(7_5N^)'5!4!@<?>
M'>9@.R1UW^UOT'|JQOL.76V|&A|H^RM+&3P?Y@|5BRI>5O5+&K7T7G3T|XA;J, M'|FZM4W" 2N6QJ|JZPP&M6S:|_4S<-<A|Q_I$|8=0@=>
|W8@Q( EMWQRHM6: M;|&A&E6|;_#705E*|V\^$>EN.X8;C@=>+>"T60Q;Y^@O|
```

%GC?@SH_@/M=-"WVFL&L*W>R8,ZK^4ZYX&J1)DMTN?=@E,KI_P,KFE:G^_RD3[+WFB7^V)&]_<MNG3B>[(<[T]F5W7.,S?1?H(3*U,-=E9:0?T51_!97-:=&AW;FVB^35:ZIJ] M<:-9)0QMHS;6SZ|VRZ?7,(H-KG.YHIE@^L?CZ6%; ^HJ@1FC5Z;I=RRUVW8/MLU^A^TOE<12 MZHAN,O)J#KJ[?DF@K2S6.218E15P^_CA)BKJ6,R+MN"P#"-4)A;YS3QVJJU\| M.C;T-0U'<^W"HFFH+8S-^KQV!3\X;M=LN6_CG7J>Q>49==;5U1@7G^_U;.=K MVNE7YVIM00,8720AP3&[9LO@R5W MYJ9?<+B6_Z&:=IMHOE6TP1": NM_1:Q)S_WOHUL.O:E]1"B7".1\$X?>G M YGGG8V=7R L>D].FZR)4YLF^>?7JVP3H OEHM54Z^1R_!4V";/A;_&CLi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|TVV8H|F|,DAYCK&LR..MW6YCMW04;E.\$N> K8KYNK9=0)=+=BKSO\#1^AANZ-QS=5)L=5=AP&C_-#MS=R6^;_ND>K6JJ_-M#E6#=#X>%/MX245CH4,Y5J#=\$5\$U3_5+!+N".5>ZQR@?4]UG@C _7!N=N,H,M3("F?QS:58% #U) @0^_AL+W=O^_HAD2;1J+13E4)T\$}[V(OF;_BB5-MZ\L<70Z\$S^BYO1X.T^6&QDQ?7;_4JSLKD<215*>)>IAN\$QJ\$>5 <#8EAV_,M#M^PPF^37H+91.ODQ@B^BJ2U^ZB^_/@7Y+@/7E?#0#>@<(H6VID=#5\$X^FVR^5U0 M^_"/j2]39L&O64QYR@="1"5U-IS?XVB=6%I^C?F=TGQX? PNG MR^I\$(J44&46>?IHG\$91QJ3Z7=).J.C:S_(CY_9/^);JV0>@Y3.120^"5F M.A@/4\$A7P2Z2]V+^_RT3RCNX%&%- T7\$FL,T*72A&7P:H^;/%:_M^B# M_!_6C#RIE^&C\$(X\$F6>6>H+HS)@=&H+5AF0ISXLDI4Y78>_CMZWH2 M_6(IVUOAP67;QMN@B.=)%\$WTF67Y2Y^_0AHXKS>[8D? MjN&JQHP|CjDjM^CjDjM^25GAIBZ=EJ^N^_66X-A5A/(S/G, M^WP^R;_&I^F^/_W/34:1)TCG]2U?U@>G>DY^T^C^&IDLZ?>6%3&GR1>S M-Z^P;7S0#3DDF0=)Y@.^1-8HSJHHSZF.??1\$RB)2>YP71U_ (M_/P/_*T^RQ M#36KG@!^M@NR|R|O:0%9_&+ XDF0=)Y@.^1-8KC5,5Q7B8#1,AU_ML^S- \$6FMW7D71&R|+0=T)BBH^4179#MCAVJ|(RK;_>1.2IV3Y#DT@B|@<R M|_T^=YU:DGFOV^X06;_!E4]T(2X\$(61Y+;_@R3S@<@<:Q<%&_!00\$P\$ROC# M98E-RVFI@_YE6..6#&A0IMO1^0^N^N^"6"Ps^L#2X_1^J?70+<LVQH|(^)L/Q=^L M0.W/4!;0"U;J^L^B;_#76+%(MWW^O_3E!#S.N\$B=AX,N"-M.6PPT(-U MVV^@HR+^G@UJ)X3|K=1%"\$A-S1!^00.A.G?&ZSG^WO(-D^4#8?BJU9C]JU MX?&E!^4TH&R>:!L/A1;LT2UK<_IQN0\$?7!UJ|H\$E&; ZDM\$NFW2>)"=+B0(>HH4.1!_DU73%QW>3^VLG11ED0:7SR&|HXL8H|L TS:6%4B@_R MU=5JC|Y-OC.E=2T67!<QYKJ^L_UB|TY-7VP(^APD^93%- &5-LJX&W=VJR.W-H965TUK^!E_.EZ1)_1RX>?7JN_5%\$ESF^",83D+>+M Q/L+Z_"09:01WQC="M^CT^FY9\$HJG\$S7SB15E%^(SF4D0J6M#KV@494JJ M&A|H4|8,TLL|WY6_YR,Y5V8>B:17/1+>S>5RX@TJ;_<+LH|D|=^30>+>IG> MC\$)ZL8!;L2L?^T:4\$F|X(-M\$J^Q^7B2@^_C^NR M6]=>SNDXY5N09M%*+7N0|R;5FY8DFWC@TS5JTSER=EGPE^P(=&_KX^Y:0 M9,9(1@051 DCF(&^ED\$9_,"O#VFDK"(O\$.? !?Z|HVS?OP!O \$O#GDJ^_ M^BA9C7ZJR,G^_MB _ATZX\$=#\$!HJZ_#AX#U^ PIKT^WOZ-9VI=)BG8S=>5^TH M.H^C^J! <+3Q4SI^G^H^>:QV;B0:FAEK2VK3G_78H5F=&0)IVXP0=-,!- M_@+!P6J|U)AV)&99Q81GGZM@V!_R(7@/N|J-ORUM_!=\$QJ#E7+V? KJ9XN%(@!S|F|!;E1_.._CK^R7E%9SUK9+4^>=D^2HU6F:9|X4C_ M<=PO^/|<1JEXUS)&8T;E_T;M|FB^W)37WNQ;JE64CM87!RHH|^SAR^j8!;-@_-P= M^S#R\$;234>V!_OX#QQ.3?8&FAD1^S6R^AB;8+6]3K^!E9K9/U_.L4Y|_|!MKZ!339B%G;"&)VBCIT.3?C15V?4;|H4YN_HJL(+= (BOH%U^U^>Q^Q^739B^N) F+G@<^CB^L^F;_@NA:8;6|HDXCKOV_UBX|H\$LU_KCJ M^_R%_NA;K\$7 • KM3,YFGV0JW8^QW^7C5A?=-1^!+0)J|T(GL5)_MJC+NU1#+N&OFFFV8^S5A+OM^C3?L,R%_7/A;C\$7=LID32P2(Z\$+E!<#_60IH#U M|D+597Y&^9%>R>A^X2>4VS_/7Z^C@G/Y?)\$=>RZ.N^_!U!+ P04_ "T MBV=9:OU!#^L%]0@_0^_AL+W=O@3C8,PQX8F|?62J)^TG:SKQ^E MJZ(544R,K)O)WZJ+Z=PCTI,^XJ!_SAE|OOF=I^_J|C93;R_0BPW-B^AC M6YKJ_U;9TJ4JX.Q)93LBR#LC1@_T\$49^3)>|>^>D-GTW83J9)3FX\$+LL M(-SA_TW98=J#O1^??\$W6&UE\\$,PF6[F M!3R_Q^\$14(|X;|^\$<7C,"BKWC^TK3JZ7T]Z@R(BF="\$_+^+>DE3="2>7Q M3P7^JZ|9|X>_T^#6)79.Z)H)R|DFA@#^|F5^#MFW?@#44AR<+MA.T^R|9@4E4VSB P6%?Z(S|JP_31IG_<= M#5;H^+^TAU_!A0J^93ANA@>^47F7U11B1=V!;A7/8EY9GB53,WT;+B_7 MN=B2!9WVU_<3_3WN_SGGV T^,5\$TA-8@S^N^>;2?>6%Z".5WL>= (3^M^Z^ MB|V;9?^TKY2Z@;X@05^259!X%K23/QM^@;^V60Q/8(UBA^4Q0NO^7V1J_!_MZ1(LF) FJL^XJ(PO^_PZ_X;)P\$^U_!;5%1/!J^!;A&^;> <88GEQ_A1QFVAPRA_!VH3BJR2R|5Y|287JZ2^_!1>NT1 M?1C%Y@3C.L^8FN!^DG^P)^F.FG^6U=4\$SL;/?QJQ.V&^!S_VRXNT+ <04\$W9VCOSG=G\$S/PB>TISPMT?|F5U@(<=M?P?DGOU3XP5T)F6)0F?>W^X?#5)1+>89S03RA-0NB#0>T.XYGB^85P)EN MVY7_";9JA|";0;\$P?5M (A^V|F7\$%VUEH-W+N^BF5S-3H3VGL6B/JU=M^RC_1^H^K^1_!>X0S21=A;(&BPZ1Z,W)LWS8@=T?K^UA-DKQ^T)@JN^FLBK M5_&%UBS(R0J^W=8!+9JH|3|_!|B&86\$TQ%";#;N^"K;E>>K(6K;C-9|KF^_ MB#12U\$8\$V8V(@^A52+9W7<0;@R|ZJCM_K(O%|C%JPI^M)#1>M|!76", IQ_M5P5UZF;VUOV9Y>OC.MOU\$^N^L7CNX+|0F;|WH4Z^S8Z835_OA^!Q9\$NP5D=PO/M\$^_O)@<U30(^C;L>=>T3D-TG.^B65^_#)YA:;#M6^ =L|@(&YV);>%W;_ M1(>#^PIK|8_N^A^T\$|^!<_<7(= 8=KRX8|VPL;UAVPT_V|BA|02P,\$% @_<MG6<U5_...>@T8_!D M !X;!"JW;W)K&ULK55=3]LP%/TK5H8FD#;RG5+6 M1H)6:#Q;JBB,AVD;G+;6#AV9CL_-/O93LA^&|HJ|^7QQSWGGN_/ZTG^Q9,L M !Z+BF34Z=0JKT179D\$54^Y)SBM@>F;18F5|HJ^_RL!_+>@Dkj^YRSNB0ES MTHD=6XATPFM^"8%0+<(N2RQ>KH^R9N^KXSNO =B4R@RXZ;3^UB^_J@600?< MGB46^C)";_UE/GRK^<0^>1^!PGPT,B=C).5|P F_#B9;LYF&71N+UFK^|NX\$5+^HUN32ZW; E-R M+J\$Z1Z^W^05>\$ W_9?A^<@TW+?P!^W^>^&W/XGLC?>P|Y|_M>(P|O<_./D^!;^T<=">+&AIB914|^(|UKVUT+ U^!Q2CLH|YHBWIMT5%M MC|H^F^#6^9Z!^637L0^U>8!\$;_88P2>V^XEY929?39#6%\$J^H^U>4;3@0^@Q M0=)Q^_9|R@Z#DGC^X;2PMZ:4E1Z7=B_#Z?L^Y>NV8 MNM8_8^EO46\$1^!10 (<#2+9UG14/C@<(< % 9>>P#>VJR-W H M965TLM,HX\$7^E1)@<7^E!%5,52^5(4B! |<=B6U|WP+^DX5M8@;UKEAHMUK,4HH+;:"%43#9N4-M7H:S>>S^O<_/07^VG^EQQ;W^F4 MDGQCK^HZ,&90B;I=^4-7AP\$@+^B#I|^<^N /XRX\$V,R|KJP2W\$J^T.1#M0 M9;^?QN/1C6B=G|Q937>"L39|+K>0VV5?B0?R7>N-7=5)><+1%Q(=^3YXC=U+X3)I3(1#>37Y=I8G2_KJRE|+>^X- ^*KMIEI M>_XIQ78RH=-L_?OPFGPY93_?T3V3^O<:X|8QJHY4??&+E;D^VUIPL^S MN^FSPX+1-^&|H9(WG-H,V>="%%NONEPP_56U(9(^_J^&V:4^+;CFL- JQK_-?^M8@OX;8E#^K1SP-N_409HN#|HQUV|!%+! P04_ "T BVV=9G@PG<1|^" #4 M^&_!AL+W=O^YPW M=IS1C0%40! (1%255(R=0LKZV65%7D^%Q16K@;H^!^8K+64KUUI<^!+<(Z!^M_-"^W^TPH4XV,M=F^!NQCP2)A1E^8E-5F/^JA9+MQH|O(%^X)^M^Z@MN-JKQ MN8@<^H95S.WR|(D%5!&^4<5F/GQK^>#^6^?A8^?VQD4WL^L44^+>_ M|X&@A%SJ#%C|;6\$^9:D3^8P_4ZG^ZF%<^G|^F=1^7+ @N8L(G6UGH|/EK|3F9^<V^1Q4+X1D6GM6%4A#;^?CGU84_@1T<= M02L(WBH(6T^H&FW(3%L4+&3^VXFRN(Y6V3>+&4JAM^15. <2Z|N\$J63V8Q^_ MC23T_ (Y\$KN&WG^X4NXJ M^SHS@LZ,P.0+7S^C4V_&^>_>+&^")JTG^OVX60C^U^G_&FFZ|1/8J>E|> MBQKG;4QA/ M^<IDH^_YL?? 19L%_2O;D^_S^R5O3.\$4+^AF.9@Z|9)9L4 M^J6QS8)TY<|W>^<B^>L\$=;\$S^OV^<_43K^_F4/(0^F?>K^&O@<Z^Q^UH9^<N M0<^!>B;+&CQ1U2?^I6<_>DPD4?7>8<\$!M^AHC8<^!U|^F;|^Z^8 MKJ5K I6P4C+&O^E^>_L^7;2:2U>886C^!#C4S+1^G!W=H.ZO&^|SWVR=1R MV3102P,\$% @_<MG68W>_>T+! 1Q0_!D !X;!"JW;W)K&ULM5A=;|LV%/TKA%8,+9!\$HKYL9;!!UMFP BEFU.WV.,R! MD;YLIH^HDI2=^_N1LJ/(1U;G3^ZQ1>G>XW;/#<DKSO;?Q; (D>TR036_%%S_6 MR(1FL)^C;^E^<_2A^_J^F#C<9GNME^><Q^ZQK14X8^Z8^Z.Y86E&D\$ H-0117SM80H) M);7C>P5J+U^107S^B_E<6K8AZ(^@5^_J^1W;Z^8\$BB\$F1R;JL SM4!7M^M^V2)*# 1OHJU^1060K^T2E8,4HH=OLEC)40K_!G\$NPJP? ZO^4Z5X)2%IB5-M9=F1218SSO:(ZVB%IB)^;?*?OZ|OT-LW|_!1#/?T9BCA%3^TU?J=OMQ|:K|J;D)(2YH9:A M+X#8_!S3|BW?NDK?2^PC@Q.+8,SA-Y8)|J5!EFYPYGH>H#J^<^ZDUEM| G M0>#_S^V|L+X^H^IU5?>Q6S_V|BQ?@Q^WZ^T8%FF1\$ F16N!^F) 2O87^T23D3W@_M>2T;UJAW? N(G^8ZV^"KGZY7H?7^A^J|18QJ^EY0P=CSG2|/5^VU#DAKU S_MJ0Y^?Q6\$;MjN. TVY1T+^_&S7;^T@X|Z|D8^ZT@PJ2687^KF(PI MPTA@^1FFM0S32V^T^Y>N=-4R.O)N3Y0S4ZLM;!F^PR7K(T+R1PM^4VA_!_M)6G|8JD^60^V_X;+>G^G^!NT^<^X1;G M^MOKUY8E\$)ISMD_--5^DH-9T_42C&=LIM&^?N7).RH|=8;8^TIHF8)M^S8B MK_!Y(4=IT\$P/39M3Y3G1A.N;H;/_S>+>DF)"_*@X=KFETK^YX9P@N<@TMES M-1);M^ZF1+!6T|L\$!N^JOURU0V^<^U>+&JY1|;MB;+MX/CM MS&R=N^CMB^<^V@F4^Q2K^N)LKV_!J=1A(EI<^/P|;2!6EUL@&7=-H)! M^C;GG@3Y+JLA_!>^4\$LM^!10 (<#2+9UE^!S:1@(<_H^_9>+&P0 M=VJR.W-H965TCO+&5LLC57X2<^D^YB^N2LG^B6-8F=A9E+>6^<+0 ^<R#@D|G+0&SAA^P M;HGP&0U|>XM_#|X|HDXL=8YE1#2/)O|/<+>?>X_D^<=D18+^G@)<1#4@_M9# M7^B8SU;_E^8 MT?^P|V<^_<^F2O3Y(1-8T1;|H+XUQ3B<^<N^Z M8|SK^+<C>J|^PG_Y\$|Z5^QQ.L^<?#U=T@P@&^H^XV^6H-70+V3?^<WO_J0^WQ.RYQ&8.R|G@_E|+L1.N@6>_>)U!+ P04_ MN9=99=69D?(" M^K^&_0^_AL+W=O||@<(<0)Q30DRL3.KRVK9^DD&_Q14KX510^HSGC6^HJ7HBY(13 M^|H3E...>8%8!_L N>33QF^TE)? <8_YR^Y1M)I9K1X|D&4F10;_!M^I=X^3.03^415S_!9*2^H6(\$X+";6C7|L|C;2L^A.8"-8Z0SF3/VK^>? MTXGE:"" @D\$CM_!N_4R14NU(8^RN?5I-2^ULCW? >Y/K<52Y5+&#^Z^2RF0B M119^88^75\$ZP52>H^HQE?PFCOR363WK6^A9^!0^>D^D.D00^96PFE6^_J|0TFW4^<+<5 MOO<^<S^&^<OHEASO^!^CTNOX^R5TGC|?EMBID4TVQ|H9C_/G_!8K|_!O^L^?HCO5>OAE8E3F|H|_RHO^?7L|G+>7_@MNI^HE#_0LBQ;H^<LH1Q0A-#^T2K>_@1-4^ MKIMHAA^%3M08|>\$^#7YP\$OX;B|3O^6)O;U_!JWP;ABX!XO=H^!QA_V_@X9Q M&PO=VJR.W-H965T+X^E|OG0^_M/^26W62M| H^\$2W<4^4*9!;6QZ^H4ES+^|CH1|(EG2R5+IBEX5Z^IM3C^A14 MB#^_HG8#^Z^9;0^MX10^M=E;@U-RK=2^VYOGTR^R MA^!@<AT^H^MSE (T0T? C6807NE^|Q>_!>_>NVDY9H9G^C^GOG66P7B% X/7G70^F>8 M^7!#M|@<CSMX_O<2C=55;BO_YOIFREA?5^C^H1^!\$S<^&ZQ_>#^|BE&#^!Q! M75LY.B5+<110W_"(0?>R17^C^P!^V|G^L.W#Q7_V3VU4&N^<C<^VI+7);?& MZO=WY,2/Y(RZ_#X|=- #9 ZZ=LE^!OZ763^73R&C@<^XU23#?; M88#4^S2 MT^<Q^_0>9>+&PO=VJR.W-H965TV\$3M|Q/GVTH(VV^M^U^I_9 M2??219W/G|+B46;(^IZ^G.F)DRES^7KFN3#(1B#SG)3+I9<5^090VQ=|514^2 M6J9ZXI^M.F0DW MCDJ9O@6JA)_..MM45);0.4,Q^FCC7@Z09Y^RW^|Y2K1G^W(^>DO-8W0) M)XYG\$L(<\$V40B^YM<89Y;H|T^M^3^<-1R|XV? T3Y:YK(D\$F<_T93E4V>ML0.IKL@F5_>^HP-GY^12W@N|J>FVH(R8;J7C1^N|H^Q^DZ=&AXY#;#S@_MX#<_@N^P>4!AZIQ^S1.C-+^TX4B2!^Q^FM48S_ZN_!>9L\$#_!N%!"??Z7;_M3^4S7A1;31TG>03^4DBZ\$Q41@C EX3W^T^TWXOX+^+G.G,X|3F# M+5<(<B_!Y9X<9_VOU^&PE&^AOS.B^TCIE|;(4@D_X60?V1HC MM|BF_FUC+W^W70Z14? Z2PZGE_KCD|_IX1JZV|F12_!<GVI^D|_=%\$L4P%>V%DD@HM6^K^V28|_H4-77P3="ZL".QZ2|8/+P6@80O5Y M>L/_Z4;XG;95H%G;_BIU\$=LP57>P=K;1.%S;/NG^?7E|FZ(6%.F(<=>5=07_ M+S0747?PVE^M\$UPR95N|7-8Z41^/K_?UIQO8N-80^TUZCX%U!+ P04 M^_TBV=965/6M+(&_0\$@&_0^_AL+W=O6V459_L\$7JGL|+A^<X_K\$Q;T^_CTD!);KIV^4OF5ZAKX^F1\$YY# MIM_L(NB)TDVQ=V4N@<06E#>+7| |R9QF^;_="|MV(;<4^O6@&P+)|DV>?/P|M^C^G;G>_C13_4&9^C=S_Y60F^U|_YS="MIR;@;19|+R#_G8K9T/^&1%#P9@ M(-ZA<)^M9V2DW^%<_Q1_&O^_QD|@U@9^)__CK_IQ@R35N/2BM2IQS3_I0_3_M^V|6O!9S1R1L+NEB3JLG86#\$MB1@JG/_/015(^FAB_F3-IO=*IB/0? %A50! MK<Z@Y1FY2IY K1 N^P^"P" _QA?^P@J0&^%EIE96=^>SD6@E^D^J>Z9WS^M MC45K-30STA50K^E&|>B#4J374T13GR2;@<N-UQ(D^03G^CT^FWU_DH^H^HCO MT^="2;6#;_9%<^6QM@<_C^<H^D^H^<TLC_B/7J^7^0/1(!^_>V^P^X@U^MXT(6|NH|U^Q^VZBK|E^UY4Q3Z9 M)6-8SV0V)7.20QK1V12">((3O3S3WCF_<HG>B2R3@F^N@3!\$NTM3-I5D=^ M)Y6R<=ZV12YH^\$#&5=A%554U^O:58M@W=H2I^C=H1S9ETC+^G<JY;31NQ MK^T+O^N(ZLL)85^1KZ1W^/R -2!SOOP&X^Z@2.1=91.;7355UK^T\$%>+M.M)9IP25N@2SP&P)<=2\$(84B+1K!#_!M C\$^?H.WW@<1^LRYK6<_0_9 MBO/G6VVRG(9G&1\$G;H78? !V7-22%H.2;NW?22(\$%H>|&DGPL@|TX8S1 M|<1^FB5^T0YSKR5GK!)^%_H(OS^L^<+<_92UC_2CC@Z6<S;XV31E|X@ M^EOWTDAD^G8;YR^|TH^2D4A4A7&8NN6H66P^L/E0L40Z2^=T\$|4A|7@P<= M^Q^L=+6P|3.CV3G;\$!>#<O^;IP+^K8N^QTNU4^S1N%W+FH|N^@2CX^TP^ MMB;^Q|UYC>I2QF+KJFU^GXMHX)'=2ICL77+T^@5_!\$S9#F? 8FYOB9^X+(&Y0\$;ZX4GRUCP<@<0@3H_0%=/7,1451) M1^N^|4\$^<H^<?>2^>2^>UED&PO=VJR.W-H965T MTNQK_1140;XM

[illegible]

#2>9UF2D7OAR^,5 9>>PO=VIR:W-H965TL:TL"(4ICL2V M+#+'-OH""[>.,HPTW/U1NH&-YY5> T/(&+J6=US5W(XE)R5001A%'%9SYZ-
MD IC<#>M B"P\$P=E1\$-Y9.R;KOR:SOU<=>P0%9%)3B/7W1\$1H"LVDB/76Z M/C7PL/S" ID.7@7SB 4L6?>GR>5FIEPY<
(<5WA:RGNT^0QM0I/DR5HCZ%<T: MVRAR4+85DI4M6'E0\$MKIX^<6B- \$!P!"T@.140MH#P%2"<@&6,XU!ZB M%F"IC:QU(E6.)XQMD.
<6VMY2A5K1&1T(U1/E07+UE2BBPAG, M'63">1/X.O N!O/%&E+)=EM@D2RV11<0?=&^/3>SQ)T(QS0 5>A"0!%X.
M#829XP4HR1G(H)XK<J5>D>Z D<=0)9PCL?SL=W>C#Q;6)MLB56VUI9:?
PSV3\$+ TC>9; 51914ML<WS.GI MF&M\$S/O6GV>7.Y+1+.%CGX5ZU+ R13 0GN@.9ITDVLWZ<1;S= \$G1(%K%17WFBHJEG>9!2; MBF15G3)
I0%>RLBYN.? M8'ZOF).OE1TU>U> X74\$1#H0 (+9UG1 M6*8U.@. (S) 9>>PO=VIR:W-H965T&40J= 4JK5I5UNV\$221\$JF-
GM@/MO! 9@11HBB:M71V MLI1/??F4R:J1YT!&404WTA(O#X)94HP W:N7K0@>_3 (C^GY.F?"BB3N141%>EH8S 7>*Z#+/7J> 9>J= ?V=@?>
W149>>1' MDX*N8 'FH:A3N-/K*PG+06@F15&03KW+1G@<M#X>1>#C=Y:\$<Q)4L1NIE) MIEY@ 0&^V%>@/+/6;
?K2&516=KTZNQOM(KIZYUW>=<1^K*D&N:2 V.)R<:> MT" H+3DYEYNOL'6GYZU%TNNW2 9;&4K&2FE C+*B"G(GJGSYM>=A30#O-
M"N%6(3Q6Z+ZAT-DJ)=RC3+GU4U)HHN2*2JUNW#<.&WTA@D;Q8514)6A MGHF< W*28LL,#<2D@.1*5F41<1*8V4H)W.J.W*
T28WH1L2 Y%1CN/NZ\$ MJ@<1%>U> JHF<=<2;(STR6FH53WR#<1.PM?F\$S;JNPA&1<=&9%;*4RFR5>10"H MJZ/MP/ASKES9>+<@ HH+T@D^DS
(NPUXYO<^NWCDHU-SW7'F-E 820TEZ4P&CF+>8G<6O)RC\$;1/V#MP&AW!&EXPSFT"/ETBM+NTV7VJHP%>7 M-(JAV6N0:W!BSY<^/>#+TV.O).Q
WZZ-3=41C"P4HS"ZQ(K%F"CM.BFEG MDL@.SY8333\$9S"WEZ&K1<J>OKO!K'U-U)OYZW1;&FSZ ECEPH%<1T'L MIU(FJA)U#=#TJL#%QIC;Q 9-
<@U9-HJL6BHUF@X+1K%+B+JXX"G;B#JHSJ Z8J+1GD;6.6G Y#=#ZS MO-DV \$ P.VJX2=0HJ61(\$;HJZS8)Q(T4N=>9KAH2A>6T)>R
MJZAMHFKXJJ2'HZB_EFCWVD=A1>F60YJY8;)K%MEU7OKT_K=12E&Y!YS-1 M7U3/@1/DEJH5\$QHS(\$63P<4U!5 1-.&%FXF;F4!B>P6V;X1@)E!?!H
M179>>P%1;LK<@M02P.\$%>-(MG69.C&12L1 0Q<1D 1X;"IW M3K&CULO5A=>Z;X%ITK%CM:M5)3..2SFT1TJQG-M2-
W9.C1=>5CM@PLF00.V8YNF-?<K64 QAF&F7U1+GW<XM" J">8ZRIWR+ ML0#24SXPMM\$D519-O>W.\$DJ:8R%1"RA(DY"O;V#QE& 5Y4A+;KN<.
I01% MO%K.<^ NV7).Q%1-ASP+D0>SE!L=TM!["@1?K%EVBS%>H+>SE/T0:OL7A(-MIYEVLZLJ091@PB-* /APKJ&5R074PEYO-
11K&19J2!>3TRNWKY%>PL1R" M.2;#*H'DOO>X3A6E2T-V511QI3)>X OU-D#MP?&J>7P.N@.NX0TWZ MRIO<BWW9/O-
TKYEN2V8J>MR=C>OY 74<R0%3#9+1 J@ZDK745\$BJ">AUN5\$ M3Y&Y%Y9<=>IRS)VPM21-CIT=>V=J%BC6Z JUC-5W<1LV5MT"Q#D66A&+N.)
MCMHIGI8C=SB.VT 1K6B"9A.W"FL 1%80AV<F MR ?* 9T#=#P8.\$?T 7X"U MO"*2OFHR?XB(G+<1G.GWE\$?YOAWG >0.1&CG.
I029;D)2GY51>I&4XU>E.1 M=0\$%<GIE3U&IP=FHXFQTE*QQAIZC6%*Y112YD8".P27?>CCH00#J1P M0?.\$#1-(NJ)FEAKLP-(H)Y MI?<
M9DL51R072'DLZY1H3JT+<T@&+BP/8MT411>X#6/&6.C#W?>U+5?>8#05 17V57#<@ ZUJ< <MK#R3P-JOP+>8EK R
F<R+11K1URW14U09XSU ONUL% 1J\$Y241@<_0D M5=1@P+?JNA"Y: H&W" #B+>C1B%\$S-V1>=AAD0MF(\$%\$&?F 0Q">%QTI
MJP.E1F6H.%4DYH:WIAF2-6>EJ"Z:<SR:BTMYA)M6DQTLT7F2U4AXX< MXCI Y8&@)P2631-J14@LHV9!PZ7OL?IX-AS29J>^61=7)MIBZILH;HDV
MT\$&WW<.<J*(%>^<4TUO XG8B)<#A<.-=R(DIU5MS8B">IOFEYR.5@B Y M1XQ:C #.5(<^160+<H>M:HW7 X'4\$1#110 (+9UFR8:\$S5-) +>M
9>>PO=VIR:W-H965T2G=H"MMMI"VRQO=S+PV(2:(NVB41DEJ3CM%< 0T1L8E1@S80DDB=<S.M.)FN1<14F)YP20"X.V&BQ(K&(JM*RM1<<Z?<
MRL(-/"I02TR9DTW.W*WOGRO"LK(K4IR7Y98?+1F131=>JYG+BCVYW2\$VXV MJ?2*6+(GZ5-T*&+DM2TY+PB3E#
FRF317_N5BI(\$&)F2@SQZ1EK)BO.O>O< MGSI>7A IR)H!@RW>S(C1&)81G-9Q.FU(C1 LMA81:EA2691>1(S=5N MZHPD49/K/G6O)@FB@XU-
O4X).&?7HXX(O)6.YG+<@EJ@W763IKL&SR1 D0?.\$J18L)IDE M7CXSGY@1 MMD41&KYPN"C^N5I)>13_M>VP35%0?<
0O1NEK"/.3!TXOR0113)7OWA)IY: MFILO239 2+>+%"Y&=1\$/4ID.TQ)H71&!%65;5)@OAW M;XH<"H)?>?<
!WY(C&82F+UHDH5'ZW!SM66"!!OXD<@)SPZ1E@<1=V14A M<142\$%>.&DLAI\$%<45" H@55WVP&^UU7L> /F31Q4EW\$RT8K1-
!SI&3<#>PL1+!U2ID1:C%<K:FMY.@814 1.6 M910V* M5Z167\$1Q)YW\$+13(0&P/L Y<IOH1T37CVU1+ P04<
TBV=9HUXF/QVNI'G4%<2IYD)@<@JQ.0M#<1<@IOI\$-B#.S\$*JF1+JF6H&P6T M=\$\$U#Y.HRL\$>A\$48S=VJXJO)\$\$S->*Z+;NJ7J< "I7DR-7@;NV+)".Q 6
MXX8N80KXT PJTPO11"6K06@F15&PF 3G1=E%1+>0.WVR 9/SGSOLR:KB4 #LKL9H\$ M>4!<6 "6XYU 5+&11\$Y(\$R0<TJV MFM2CT.TNFSY<+11<-
%I2%11.(7FA311Y)&R8 13"X<1<1WVE"8ZOWEO3> M\$1 MO_Q_EHS?>Z=61=BX\$1AS129;N<@)H'Y236H%03%>W=Q#GW<(S#M M1:;HLA2<
IR\$S7E;VMW&=H@P.T;M15:1@<BA)&91\$H9*+>1\$X+21\$S1* M5T6:CLARJL1T'L0\$5LZ U<4.M5)QFN9U1!G#MUB9CS7<90VBV. *>E.V
M%FOD8V4>5CKTLT181.06* >Q1AY6=NIGY3TKVANKZK14Y 6"1A'S'6(>#2S MTQYXNAHD7+77EHZ+IT<@1<.<1Z"R/7V" T9<B%>VE7X/6A-5-
B^9).&E%L M@T9OX8EV<?>#1/V!OU4TX 1PIRJ'0+*B0 5UL1L.OJF6IDAZ>41Q\$S+TG MZW"KI-OK8J)11/:(18F+>#H9&4JN1W&Z#LK&5?F91<-
GN&9E.FE0=H9&7TB M?<@FQI&PO=VIR M:W-H965T8<@<DPW4CWH" "00X(1 M? R81SW1=1#<75H(\$<4+6A474X%>"M2
%TJH)D3%=R/@<F#D%Y0)>YFZ>[NN:V" @+<1 1X\$1VAP+!!Q28RTH?JWA\$CBW M3LCQIS'UVC6M3?66;RF3?Q2 9+6G%)S>?H0DTM'ZI-MY-HDDTS-
1(6FDCBT.1 4313+1 JQ)0@<?%C2\$Z5T<@<(&7M'9SLZ;BH MHHQB<=A3JPPQ_NQ>XT/Q)ZT MV)>1/L<^1!&E1=>1)=/CUBIEK?<
R#160M U@<0>6\$NP.G1\$ 8%)C.\$<11 M-9P1"U1THY@B#P=J?1OD&K0K1<K@<73.IV@#=>AV&PD&ADG-78P17.M.S3-
5GL0_L.<.&MAR)KRRG4(14.QIC/AJ S8+AS&\$313K1=27\$P."25V/Y6 M@V.IRONJ5DOHQ%BB*C@<8Q%5W;#5 R+U _LI\$.REWV2"LA/P^5)<SRRP
M:53;B> 51+ P04" TBV=96C1P+(P" #1!P 0'<AL+W=O@<LYTQ=<@FQPTZ2F:UB N:MG" F=<QU*P" H1F4A %<
MJY'W.OA-8'UQ<+XSV.F#>.%FE+>VAFW8N0%<D/(3>6>)>@'O/Q@<W1+L-GZW MG%<X7T@<QWQOV+TXL EE2110?I#<"F"OHT<6\$<-
W.Y<PJMGB0+ETNNW9?L M&M8G?<-K)JP:B#BHGF3Q _/!P D*1(P'E<9XDPZ!<@K9DC-J=#D M/ -#&=<7Y#VY6V3D _R"GI\$FR'WC'.15)H!H1;JYVY
<1.<2"0% 1&ZE.Y4F M4U% T81/CN. <1*193 X5C1CA NH+TD4O">A\$.81<YF<#H ZYQ121 D M1W<2C@<1 LCO12 PQ5<LP?2
CN#6EO@B8_Y;*>S!Q I.N<^<1 EL510JFN8P MAK1L51A W#P;7P>>5+&F62;9-7(GMR*6W\$<6OIG0BJY1+Y+Q\$=1 MN;\$551.CW2/M.Y.&A
X/ML9MFEP&2;1C#71SAEO4X?GCI>YVN.Z=<LW10 MDRI01<.&K;." /#X6308<P/S7MY"HTIQNJ5HSS1B' M%8; 6)0\$5W#;"9&UJXB+J71<^NJ&)?<
984-8IUU=2FOW\$INBZ-OH'4\$1#1!0 M (+9UGX(DI=<P. @3->&POVS2\$<C 2K"1.6.F619UD.R.Z;Z\$2U=>Y^6E<HBDF+&%)\$7U-BN MGL5UI1G-
R'5\$(NYU.FE<4B1). 7Y4UJFEBJ M&2=J&(G-IG 1)-WU/(B+W M5CD;DH>SMS6RER B?SIY-W2>?A _H ?N:7P>=>F)T>#0LG-AB;\$1ZPR
M15GT2.60C*G@<SV15="2BY4IR P541IR-A*1JFZ\$E>.<CK>UDC4H1=(N MM1 @OR?<#U@<W0.#7(C681_XP&A046.8EC>VXP:
IX1.H.MKW1H7ZG&FZZO8N-MR8;@<C:11.FO CLFV.0TU32_C.Z" K>=>UMV635<E&%714YM"/3D>Z M/A09N16LX\$O77Q:M
4R1BZO3JA^KCX+1/9.GVY%<@<#2@<UXT5YK_LMF@<58V MP2?>IDV?+H=<E1=<@69EU.RP+WW#M'SW1WG6=>..DW\$MFE<X>\RJHVG\$SI
M1@ONMJ<X#>YK5ZZ?8OC1D>@<PFC(F<^<@<CM;D5AV:HR;0;626;G'&-M1\$<@O#LDW.F*3>)HLN#"< <
GT1CS/F7QRG+RADI LGRD1<G9\$S@<JZ\$>18=D MT_135PSL@V;M;F.L< <MN"N.8IR/A1' L#R8 XSC65B> VD<?70<^L118 (<^7T48YGA9"Q<V1XPIS;
M7N&99EF21" FVHN-QT.861R/1G_X00-EXAS1 V D67AW<R /1;QV<X#114F).DL*N8<PQI@1LQ" H MQ7" IBFR.BEAPON#(25)DF5A1+>P@R3!\$<@<
<01S-1XP)G<=>W#0212OWU/Q MYGIWH102P.\$<@<-(MG69"<NOS P1L 123T1 M&MP>4#M.*2VBZD8 112:5K5N.%(MB61(7-
>=13W+;T11;X"O.DQO0FE(2S..1W2\$S+WAPPU1>5* M(Y5;&GC3Y?YVX\$G1H2)8%I#R=B.5'5 _1@MP4M
MT3\$1B=1(RDGZVW.H<4Y1<^<K1)1\$(Z\$)21)=U81VRJEK<K70BDF M/9P.O7E1C72_V%96#<NWK&1MAT5U/2.B4KOU\$1-
(4TFMPMYGT1)=J(AIM=>*>J&HOF4\$ MW1B?ZS31ZP1LEZ65M;U8C(2=GO3+NCR1?<R0E1F>1+@ESI?PMD2.2EF4%<
M.Q-Z(<KZ)3!N%1P;7!GNHZ"154YD9.E.IXU4E2MAC:UT11R56L1F5 1))@1DLD?<1PF"3 G(M=<^0/0Z2JU\$UM9=WUKKK61 X<6M9#>@<S'P>W(^H1
IE.U.L1/512#1\$8B1<1 MF(AD@G5W&(B2R9S9)A=>M5)70MVV10/AV<%(W&B)S#F)1.YLP<@<C50A"Z MZ_42
YUNXPF "Z."11J1D.F>VR>=>R)WZ19;D=>#G1TG36 _AOK'K13<8 MDQ+*G-DHRXCS MI+05.<Y3J109B/*U90OYLS"^^+<1N)V2B@O).Q>B%U
#UZX1P@<5G.E0&C2.D4 M"1.1E1&K740+<3Z\$10Y1"/VA;P36RNE.M/CX.B\$<U+>.BZT<64*Y(FUQ M9KRLS=<E.G1167G)-
P=Y.G@<(221<(<1'S+FC88">261A%<D6<8>?>24+1)F M691Y=<R.E#>2=F<YF'QVZ6\$ 2O.OECH39'8 1=<=<9Y8Z\$V1UD0AW"/=U12
M29FE0B34V*08D1)RJP5.J6.6Y.23GE?F29E-LV0\$=<B469)N8W MOA<8DS).RFP<@&O. 3UY3QLF8C4.G'AS.LHXV1M>3VFGA.51*Y' 3NC//)Q
M>=>8HJKP72ZBOZJN<+>+2.EF80312/>2YA11.71;W)K&F-PNP9.J1-GDC M-1FS:ZBH!H1QJ3S)FISQ+E.<F7\$&RBCBW9.SNH8/OZ FD
MW).QNX<.<OA@SHR3O\$4VNN81?EE'MR9O>VFL<^URC&1'R4 UN(P(Q2PIB4 MA2)1C78YBG1G+1)0SCVW1F'NA"YK11MT9BCKH09.%3PLQ
R8>6N2A47+N MQ?V70UR:G8;@<0%P<^B1\$>?V9>=V=3 5 MCS\$117."B(Q1W>H114."MHV9?>Z"Q(OQ*045S K:B?D51."WCXRY."<
M4E#H<K"=<F^21%U1V).2D\$%LX&@<XRI>6CY45FOGFE L#1<H NHZIS1"1B M12GK1@+>?P9OG+1K@&Q>H<C.42352K1P>?/CMI<^3V<102P.\$%<@ M-
(MG61H?F5X<@<12< <H 1X;"123G751:Q_Y%27>*_L:UW751.YR; M:CBVXWDY%<?KM_>4FZ7.8TW.YHGHN9RY>/_OR/Q.IS6+<C^H>1C.8W_M&)S<=>_<
1W94R-HO7=MB6<=6DCA U>=TV7C-R=)S>+E1=5.1R29/F#E(1TOF# M#OL1 B">_*> HY@_*\$)3G#1J'H/OY@QX@Z&^<H\$<(<?IP-2)8HXY(@<8U
M@=>7 N1UX)@<'X'8@F0+<F="N1VHD1"X">G+<@<R=" N1W8"X">BGHK
M@=>Z>BN!WCIYV".06U%O)=1.46ET#M1.R706U%O)=1.46ET#M1.R706U%O M)=#>4&@CT-M0;R/0VU1O(1#>B1+>/0VU-L(1#>4VPCT-M3;/0VU-
L(1#>4 MVPCT-M3;/11VU-L1/4VPCT=M3;/21VU-L1)1RVX<01WU=<@125V KT= MJ78"01WU=<@125V KT#10X"00U1@<@1 4.
KT#10X"00U1@<@18 *QDD0# M0+V#01 Q8 -IT"1T@T001+V#0. <F>C<?03/IG0GTS1JAWM HHJZ90.<@<F<? MO31JG0GTS1Z31S1<DJHGRM?K2??<
5X/K=<+>W19?NVX! "0)<@ \$P%M#>VYT96YT7U1Y<<5S M72YX;6S-VLM.PS 0!<1?J)%C>LG#1N@<"VPX=>_J51D1BR72A_CY.\$#@<@J
M4)<XFT.M1;D3CW16/14H0GVZ1LXG1Q81>3/&(O5BCH2<^>ISRM+<@S1A M?P MP+RMUO1FIC-#M/C4=YOL"3A17O U1/W3Q2"U-U-DUL
MTK7MABZV;5E.SRWV1J39>/E-\$1M5<6N+7=<C 8GIWS# MM/OD1<^>9?8%Y1VWP?F8)Q;HJW#Q(OE.3WTN1"U-U_O/367/OCI)AV324/
ML_U/KFPN<1V?<X (X SOB1 B 1\$112) %>@<2&J01+1.4@2)RIJG(<1 MP6&UL4\$1! A0#%<@<-(MG6>U+)>SO M^P<1\$ (<1KP<1Q8UIR;W1\$+V-
Q&UL4\$1! A0# M%<@<-(MG69E&PO=VIR:W-H965T&UL4\$1! A0# M%<@<-(MG6:6 YKQO!< 2AX 1!@ (<1L0X'AL+W=O M&PO=VIR:W-H965T&UL4\$1!
A0#%<@<-(MG66Y?C<8X M P: @L1@ (<1R'O'AL+W=O&PO=VIR:W-H965T&UL4\$1! A0#%<@<-(MG69V2S2)!!P /AC 1!@ M (<1CT'AL+W=OTUEA<^%E* 8
">.%\$<1X;"1W.W)K&PO=VIR:W-H965T&UL4\$1! A0#%<@<-(MG69JX12U> ML 4 ID (<1V0'AL+W=O&PO=VIR:W-H965T=1.CT;"1W.W)K&UL4\$1!
A0#%<@<-(MG629%OUAKK P "PD ID M (<1VT'AL+W=O&PO=VIR:W-H965T7#ZY0 T LM 9 M" @<1V 1X;"1W.W)K&UL4\$1! M A0#%<@<-
(MG6<H1WY610 /T ID (<1.80 'AL M+W=O&PO=VIR:W-H965T0L SPZ 9" M@<2>1/ 1X;"1W.W)K&UL4\$1! A0#%<@<-(MG M64'/S+1 4 L ID (<1UYH
'AL+W=O %> 1D# &PO=VIR:W-H965T&UL4\$1! A0#%<@<-(MG601CZCM#< @ B8 M 1D (<10J8 'AL+W=O&PO=VIR:W-H965T&UL4\$1! A0#%<@<-
(MG614B1(19 P I@<1D M (<1<0'AL+W=O&PO=VIR:W-H965T M&UL4\$1! A0# M%<@<-(MG61D (<1W @ %08 ID (<1LT'AL+W=O M&PO=VIR:W-
H965T&UL4\$1! A0#%<@<-(MG66>O M6RAU P:0 ID (<1ISM8 'AL+W=O&PO=VIR:W-H965T&UL4\$1! A0#%<@<-(MG64K&AQY10 IQ\$ ID M (<1V 4
'AL+W=O&PO M=VIR:W-H965T&UL4\$1! A0#%<@<-(MG676@<(<XQ P QOH ID (<1 MT<^<'AL+W=O?QS:58% #U) &O (<X<P>+>PO=VIR:W-
H965T&UL4\$1! A0#%<@<-(MG66K100PK10 /2\$ ID (<1'9@81 'AL+W=O&PO=VIR:W-H965T&UL4\$1! A0#%<@<-(MG69X.(W/? M @ U @ ID (<1YA!
'AL+W=O&PO=VIR:W-H965T&UL4\$1! A0#%<@<-(MG6675F9 R @ JP ID M (<1'&QL'AL+W=O&PO=VIR:W-H965T2T (<1M 9" @<40A
01X;"1W.W)K&UL4\$1! A0#%<@<-(MG65E3UK2R P D1 ID (<12R01 M'AL+W=O&PO=VIR:W-H965T&UL4\$1! A0#%<@<-(MG6015YTP10" ID
(1"#\$H1'AL+W=O&PO=VIR:W-H965T&UL4\$1! A0#%<@<-(MG691>>^ (<1P XQ4 ID M (<1R#81'AL+W=O&PO=VIR:W-H965T 01X;"1W.W)K&UL4\$1! M
A0#%<@<-(MG61)AH3 4 P D L ID (<1@V.1'AL M+W=O&PO=VIR:W-H965T&UL4\$1! A0#%<@<-(MG 6M5H<YBR. @ P0< ID (<1>FT'AL+W=O&PO0\$
>&PO7W)E";O=VIR:W-O;VLN>&UL+G)E)-02P\$"" 4 M" TBV=9171.<X>X! "0)<@ \$P @ \$+> 6 T-O;G1E;G1?>@5'EP97-=+GAM;#1+108 2@!*" #T4 J?>@<1
end XML 80 Show.js IDEA: XBRL DOCUMENT // Edgar (1) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data

and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105- var Show= {}; Show.LastAR=null; Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){(var ref=((window)? w.document:document).getElementById(r));if(ref){e=ref.cloneNode(10); e.removeAttribute('id'); a.parentNode.appendChild(e)}} if(e.e.style.display='block'; Show.LastAR=e; Show.hideAR=function(){ Show.LastAR.style.display='none'; Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(e.e.style){else if(e.e.style.display){else if(e.e.style.display=='none'){d='block';p='-';}else{d='none';p='+'} e.e.style.display=d;if(a.textContent){fa.textContent=p+a.textContent.substring(1)}else{a.innerHTMLText=p+a.innerHTMLText.substring(1)}} XML 81 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.0.24 */ /* DefRef Styles */ .report table.authRefData { background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a: hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table { font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #ac; clear: both; color: black; font: normal 8pt Helvetica, Arial, sans-serif; margin-bottom: 2em; } .report hr { border: 1px solid #ac; } /* Top labels */ .report th { background-color: #ac; color: black; font-weight: bold; text-align: center; } .report th: void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, sans-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; } .report .pl a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td .pl div a { width: 200px; } .report td .pl a: hover { background-color: #ffe; } /* Header rows */ .report tr .rh { background-color: #ac; color: black; font-weight: bold; } /* Calendars */ .report .rc { background-color: #f0f0f0; } /* Even rows */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 83 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3.html2673321false680false7 falsefalseR1.htm0000001 Document Cover PageSheethttp://www.rapidmicrobio.com/role/CoverPageCover PageCover1 falsefalseR2.htm9952151 Statement Condensed consolidated balance sheetsSheethttp://www.rapidmicrobio.com/role/CondensedconsolidatedbalancesheetsCondensed consolidated balance sheetsStatements2 falsefalseR3.htm9952152 Statement Condensed consolidated balance sheets (Parenthetical)Sheethttp://www.rapidmicrobio.com/role/CondensedconsolidatedbalancesheetsParentheticalCondensed consolidated balance sheets (Parenthetical)Statements3 falsefalseR4.htm9952153 Statement Condensed consolidated statements of operationsSheethttp://www.rapidmicrobio.com/role/CondensedconsolidatedstatementsofoperationsCondensed consolidated statements of operationsStatements4 falsefalseR5.htm9952154 Statement Condensed consolidated statements of comprehensive lossSheethttp://www.rapidmicrobio.com/role/CondensedconsolidatedstatementsofcomprehensivelossCondensed consolidated statements of comprehensive lossStatements5 falsefalseR6.htm9952155 Statement Condensed consolidated statements of stockholders' equitySheethttp://www.rapidmicrobio.com/role/CondensedconsolidatedstatementsofstockholdersequityCondensed consolidated statements of stockholders' equityStatements6 falsefalseR7.htm9952156 Statement Condensed consolidated statements of cash flowsSheethttp://www.rapidmicrobio.com/role/CondensedconsolidatedstatementsofcashflowsCondensed consolidated statements of cash flowsStatements7 falsefalseR8.htm9952157 Disclosure Nature of the business and basis of presentationSheethttp://www.rapidmicrobio.com/role/NatureofthebusinessandbasisofpresentationNature of the business and basis of presentationNotes8 falsefalseR9.htm9952158 Disclosure Summary of significant accounting policiesSheethttp://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesSummary of significant accounting policiesNotes9 falsefalseR10.htm9952159 Disclosure Fair value of financial assets and liabilitiesSheethttp://www.rapidmicrobio.com/role/FairvalueoffinancialassetsandliabilitiesFair value of financial assets and liabilitiesNotes10 falsefalseR11.htm9952160 Disclosure InvestmentsSheethttp://www.rapidmicrobio.com/role/InvestmentsInvestmentsNotes11 falsefalseR12.htm9952161 Disclosure InventorySheethttp://www.rapidmicrobio.com/role/InventoryInventoryNotes12 falsefalseR13.htm9952162 Disclosure Prepaid expenses and other current assetsSheethttp://www.rapidmicrobio.com/role/PrepaidexpensesandothercurrentassetsPrepaid expenses and other current assetsNotes13 falsefalseR14.htm9952163 Disclosure Property and equipment, netSheethttp://www.rapidmicrobio.com/role/PropertyandequipmentnetProperty and equipment, netNotes14 falsefalseR15.htm9952164 Disclosure Accrued expenses and other current liabilitiesSheethttp://www.rapidmicrobio.com/role/AccruedexpensesandothercurrentliabilitiesAccrued expenses and other current liabilitiesNotes15 falsefalseR16.htm9952165 Disclosure Common stock and common stock warrantsSheethttp://www.rapidmicrobio.com/role/CommonstockandcommonstockwarrantsCommon stock and common stock warrantsNotes16 falsefalseR17.htm9952166 Disclosure Stock-based compensationSheethttp://www.rapidmicrobio.com/role/StockbasedcompensationStock-based compensationNotes17 falsefalseR18.htm9952167 Disclosure Income taxesSheethttp://www.rapidmicrobio.com/role/IncometaxesIncome taxesNotes18 falsefalseR19.htm9952168 Disclosure Net loss per shareSheethttp://www.rapidmicrobio.com/role/NetlosspershareNet loss per shareNotes19 falsefalseR20.htm9952169 Disclosure LeasesSheethttp://www.rapidmicrobio.com/role/LeasesLeasesNotes20 falsefalseR21.htm9952170 Disclosure Commitments and contingenciesSheethttp://www.rapidmicrobio.com/role/CommitmentsandcontingenciesCommitments and contingenciesNotes21 falsefalseR22.htm9952171 Disclosure Benefit plansSheethttp://www.rapidmicrobio.com/role/BenefitplansBenefit plansNotes22 falsefalseR23.htm995410 Disclosure Pay vs Performance DisclosureSheethttp://xbrl.sec.gov/ecd/role/PvpDisclosurePay vs Performance DisclosureNotes23 falsefalseR24.htm995445 Disclosure Insider Trading ArrangementsSheethttp://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsInsider Trading ArrangementsNotes24 falsefalseR25.htm9954471 Disclosure Summary of significant accounting policies (Policies)Sheethttp://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesPoliciesSummary of significant accounting policies (Policies)Policies25 falsefalseR26.htm9954472 Disclosure Summary of significant accounting policies (Tables)Sheethttp://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesTablesSummary of significant accounting policies (Tables)Tableshttp://www.rapidmicrobio.com/role/Summaryofsignificantaccountingpolicies26 falsefalseR27.htm9954473 Disclosure Fair value of financial assets and liabilities (Tables)Sheethttp://www.rapidmicrobio.com/role/FairvalueoffinancialassetsandliabilitiesTablesFair value of financial assets and liabilities (Tables)Tableshttp://www.rapidmicrobio.com/role/Fairvalueoffinancialassetsandliabilities27 falsefalseR28.htm9954474 Disclosure Investments (Tables)Sheethttp://www.rapidmicrobio.com/role/InvestmentsTablesInvestments (Tables)Tableshttp://www.rapidmicrobio.com/role/Investments28 falsefalseR29.htm9954475 Disclosure Inventory (Tables)Sheethttp://www.rapidmicrobio.com/role/InventoryTablesInventory (Tables)Tableshttp://www.rapidmicrobio.com/role/Inventory29 falsefalseR30.htm9954476 Disclosure Prepaid expenses and other current assets (Tables)Sheethttp://www.rapidmicrobio.com/role/PrepaidexpensesandothercurrentassetsTablesPrepaid expenses and other current assets (Tables)Tableshttp://www.rapidmicrobio.com/role/Prepaidexpensesandothercurrentassets30 falsefalseR31.htm9954477 Disclosure Property and equipment, net (Tables)Sheethttp://www.rapidmicrobio.com/role/PropertyandequipmentnetTablesProperty and equipment, net (Tables)Tableshttp://www.rapidmicrobio.com/role/Propertyandequipmentnet31 falsefalseR32.htm9954478 Disclosure Accrued expenses and other current liabilities (Tables)Sheethttp://www.rapidmicrobio.com/role/AccruedexpensesandothercurrentliabilitiesTablesAccrued expenses and other current liabilities (Tables)Tableshttp://www.rapidmicrobio.com/role/Accruedexpensesandothercurrentliabilities32 falsefalseR33.htm9954479 Disclosure Common stock and common stock warrants (Tables)Sheethttp://www.rapidmicrobio.com/role/CommonstockandcommonstockwarrantsTablesCommon stock and common stock warrants (Tables)Tableshttp://www.rapidmicrobio.com/role/Commonstockandcommonstockwarrants33 falsefalseR34.htm9954480 Disclosure Stock-based compensation (Tables)Sheethttp://www.rapidmicrobio.com/role/StockbasedcompensationTablesStock-based compensation (Tables)Tableshttp://www.rapidmicrobio.com/role/Stockbasedcompensation34 falsefalseR35.htm9954481 Disclosure Net loss per share (Tables)Sheethttp://www.rapidmicrobio.com/role/NetlosspershareTablesNet loss per share (Tables)Tableshttp://www.rapidmicrobio.com/role/Netlosspershare35 falsefalseR36.htm9954482 Disclosure Leases (Tables)Sheethttp://www.rapidmicrobio.com/role/LeasesTablesLeases (Tables)Tableshttp://www.rapidmicrobio.com/role/Leases36 falsefalseR37.htm9954483 Disclosure Summary of significant accounting policies Schedule of Concentration Risk (Details)Sheethttp://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesScheduleofConcentrationRiskDetailsSummary of significant accounting policies Schedule of Concentration Risk (Details)Details37 falsefalseR38.htm9954484 Disclosure Summary of significant accounting policies Narrative (Details)Sheethttp://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetailsSummary of significant accounting policies Narrative (Details)Details38 falsefalseR39.htm9954485 Disclosure Summary of significant accounting policies Schedule of Product Warranties (Details)Sheethttp://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesScheduleofProductWarrantiesDetailsSummary of significant accounting policies Schedule of Product Warranties (Details)Details39 falsefalseR40.htm9954486 Disclosure Summary of significant accounting policies Schedule of Disaggregated Revenue (Details)Sheethttp://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesScheduleofDisaggregatedRevenueDetailsSummary of significant accounting policies Schedule of Disaggregated Revenue (Details)Details40 falsefalseR41.htm9954487 Disclosure Fair value of

financial assets and liabilities (Details)Sheet[http://www.rapidmicrobio.com/role/FairvalueoffinancialassetsandliabilitiesDetailsFair value of financial assets and liabilities \(Details\)Details](http://www.rapidmicrobio.com/role/FairvalueoffinancialassetsandliabilitiesDetailsFair value of financial assets and liabilities (Details)Details)41 falsefalseR42.htm9954488 – Disclosure – Investments (Details)Sheet[http://www.rapidmicrobio.com/role/InvestmentsDetailsInvestments \(Details\)Details](http://www.rapidmicrobio.com/role/InvestmentsDetailsInvestments (Details)Details)42 falsefalseR43.htm9954489 – Disclosure – Inventory – Schedule of Inventory (Details)Sheet[http://www.rapidmicrobio.com/role/InventoryScheduleofInventoryDetailsInventory – Schedule of Inventory \(Details\)Details](http://www.rapidmicrobio.com/role/InventoryScheduleofInventoryDetailsInventory – Schedule of Inventory (Details)Details)43 falsefalseR44.htm9954490 – Disclosure – Inventory – Narrative (Details)Sheet[http://www.rapidmicrobio.com/role/InventoryNarrativeDetailsInventory – Narrative \(Details\)Details](http://www.rapidmicrobio.com/role/InventoryNarrativeDetailsInventory – Narrative (Details)Details)44 falsefalseR45.htm9954491 – Disclosure – Prepaid expenses and other current assets (Details)Sheet[http://www.rapidmicrobio.com/role/PrepaidexpensesandothercurrentassetsDetailsPrepaid expenses and other current assets \(Details\)Details](http://www.rapidmicrobio.com/role/PrepaidexpensesandothercurrentassetsDetailsPrepaid expenses and other current assets (Details)Details)45 falsefalseR46.htm9954492 – Disclosure – Property and equipment, net – Schedule of Property and Equipment (Details)Sheet[http://www.rapidmicrobio.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentDetailsProperty and equipment, net – Schedule of Property and Equipment \(Details\)Details](http://www.rapidmicrobio.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentDetailsProperty and equipment, net – Schedule of Property and Equipment (Details)Details)46 falsefalseR47.htm9954493 – Disclosure – Property and equipment, net – Narrative (Details)Sheet[http://www.rapidmicrobio.com/role/PropertyandequipmentnetNarrativeDetailsProperty and equipment, net – Narrative \(Details\)Details](http://www.rapidmicrobio.com/role/PropertyandequipmentnetNarrativeDetailsProperty and equipment, net – Narrative (Details)Details)47 falsefalseR48.htm9954494 – Disclosure – Accrued expense and other current liabilities – Schedule of Accrued Expenses and Other Current Liabilities (Details)Sheet[http://www.rapidmicrobio.com/role/AccruedexpenseandothercurrentliabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesExpense and other current liabilities – Schedule of Accrued Expenses and Other Current Liabilities \(Details\)Details](http://www.rapidmicrobio.com/role/AccruedexpenseandothercurrentliabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesExpense and other current liabilities – Schedule of Accrued Expenses and Other Current Liabilities (Details)Details)48 falsefalseR49.htm9954495 – Disclosure – Accrued expenses and other current liabilities – Narrative (Details)Sheet[http://www.rapidmicrobio.com/role/AccruedexpensesandothercurrentliabilitiesNarrativeDetailsAccrued expenses and other current liabilities – Narrative \(Details\)Details](http://www.rapidmicrobio.com/role/AccruedexpensesandothercurrentliabilitiesNarrativeDetailsAccrued expenses and other current liabilities – Narrative (Details)Details)49 falsefalseR50.htm9954496 – Disclosure – Common stock and common stock warrants – Narrative (Details)Sheet[http://www.rapidmicrobio.com/role/CommonstockandcommonstockwarrantsNarrativeDetailsCommon stock and common stock warrants – Narrative \(Details\)Details](http://www.rapidmicrobio.com/role/CommonstockandcommonstockwarrantsNarrativeDetailsCommon stock and common stock warrants – Narrative (Details)Details)50 falsefalseR51.htm9954497 – Disclosure – Common stock and common stock warrants – Schedule of Outstanding Common Stock Warrants (Details)Sheet[http://www.rapidmicrobio.com/role/CommonstockandcommonstockwarrantsScheduleofOutstandingCommonStockWarrantsDetailsCommon stock and common stock warrants – Schedule of Outstanding Common Stock Warrants \(Details\)Details](http://www.rapidmicrobio.com/role/CommonstockandcommonstockwarrantsScheduleofOutstandingCommonStockWarrantsDetailsCommon stock and common stock warrants – Schedule of Outstanding Common Stock Warrants (Details)Details)51 falsefalseR52.htm9954498 – Disclosure – Stock-based compensation – Narrative (Details)Sheet[http://www.rapidmicrobio.com/role/StockbasedcompensationNarrativeDetailsStock-based compensation – Narrative \(Details\)Details](http://www.rapidmicrobio.com/role/StockbasedcompensationNarrativeDetailsStock-based compensation – Narrative (Details)Details)52 falsefalseR53.htm9954499 – Disclosure – Stock-based compensation – Schedule of Black-Scholes Option-Pricing Model (Details)Sheet[http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofBlackScholesOptionPricingModelDetailsStock-based compensation – Schedule of Black-Scholes Option-Pricing Model \(Details\)Details](http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofBlackScholesOptionPricingModelDetailsStock-based compensation – Schedule of Black-Scholes Option-Pricing Model (Details)Details)53 falsefalseR54.htm9954500 – Disclosure – Stock-based compensation – Schedule of Stock Option Activity (Details)Sheet[http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofStockOptionActivityDetailsStock-based compensation – Schedule of Stock Option Activity \(Details\)Details](http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofStockOptionActivityDetailsStock-based compensation – Schedule of Stock Option Activity (Details)Details)54 falsefalseR55.htm9954501 – Disclosure – Stock-based compensation – Schedule of Restricted Stock Units Activity (Details)Sheet[http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofRestrictedStockUnitsActivityDetailsStock-based compensation – Schedule of Restricted Stock Units Activity \(Details\)Details](http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofRestrictedStockUnitsActivityDetailsStock-based compensation – Schedule of Restricted Stock Units Activity (Details)Details)55 falsefalseR56.htm9954502 – Disclosure – Stock-based compensation – Schedule of ESPP-Black-Scholes Option-Pricing Model (Details)Sheet[http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofESPPBlackScholesOptionPricingModelDetailsStock-based compensation – Schedule of ESPP-Black-Scholes Option-Pricing Model \(Details\)Details](http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofESPPBlackScholesOptionPricingModelDetailsStock-based compensation – Schedule of ESPP-Black-Scholes Option-Pricing Model (Details)Details)56 falsefalseR57.htm9954503 – Disclosure – Stock-based compensation – Schedule of Stock-Based Compensation Expense (Details)Sheet[http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofStockBasedCompensationExpenseDetailsStock-based compensation – Schedule of Stock-Based Compensation Expense \(Details\)Details](http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofStockBasedCompensationExpenseDetailsStock-based compensation – Schedule of Stock-Based Compensation Expense (Details)Details)57 falsefalseR58.htm9954504 – Disclosure – Net loss per share – Schedule of Basic and Diluted Net Loss per Share (Details)Sheet[http://www.rapidmicrobio.com/role/NetlosspersshareScheduleofBasicandDilutedNetLossperShareDetailsNet loss per share – Schedule of Basic and Diluted Net Loss per Share \(Details\)Details](http://www.rapidmicrobio.com/role/NetlosspersshareScheduleofBasicandDilutedNetLossperShareDetailsNet loss per share – Schedule of Basic and Diluted Net Loss per Share (Details)Details)58 falsefalseR59.htm9954505 – Disclosure – Net loss per share – Schedule of Anti-Dilutive Shares Excluded from Computation of Diluted Net Let per Share (Details)Sheet[http://www.rapidmicrobio.com/role/NetlosspersshareScheduleofAntiDilutiveSharesExcludedfromComputationofDilutedNetLetperShareloss per share – Schedule of Anti-Dilutive Shares Excluded from Computation of Diluted Net Let per Share \(Details\)Details](http://www.rapidmicrobio.com/role/NetlosspersshareScheduleofAntiDilutiveSharesExcludedfromComputationofDilutedNetLetperShareloss per share – Schedule of Anti-Dilutive Shares Excluded from Computation of Diluted Net Let per Share (Details)Details)59 falsefalseR60.htm9954506 – Disclosure – Leases – Narrative (Details)Sheet[http://www.rapidmicrobio.com/role/LeasesNarrativeDetailsLeases – Narrative \(Details\)Details](http://www.rapidmicrobio.com/role/LeasesNarrativeDetailsLeases – Narrative (Details)Details)60 falsefalseR61.htm9954507 – Disclosure – Leases – Schedule of Supplemental Cash Flow Information (Details)Sheet[http://www.rapidmicrobio.com/role/LeasesScheduleofSupplementalCashFlowInformationDetailsLeases – Schedule of Supplemental Cash Flow Information \(Details\)Details](http://www.rapidmicrobio.com/role/LeasesScheduleofSupplementalCashFlowInformationDetailsLeases – Schedule of Supplemental Cash Flow Information (Details)Details)61 falsefalseR62.htm9954508 – Disclosure – Leases – Schedule of Supplemental Balance Sheet Information (Details)Sheet[http://www.rapidmicrobio.com/role/LeasesScheduleofSupplementalBalanceSheetInformationDetailsLeases – Schedule of Supplemental Balance Sheet Information \(Details\)Details](http://www.rapidmicrobio.com/role/LeasesScheduleofSupplementalBalanceSheetInformationDetailsLeases – Schedule of Supplemental Balance Sheet Information (Details)Details)62 falsefalseR63.htm9954509 – Disclosure – Leases – Schedule of Lease Expense (Details)Sheet[http://www.rapidmicrobio.com/role/LeasesScheduleofLeaseExpenseDetailsLeases – Schedule of Lease Expense \(Details\)Details](http://www.rapidmicrobio.com/role/LeasesScheduleofLeaseExpenseDetailsLeases – Schedule of Lease Expense (Details)Details)63 falsefalseR64.htm9954510 – Disclosure – Leases – Schedule of Operating Lease Liability Maturities (Details)Sheet[http://www.rapidmicrobio.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetailsLeases – Schedule of Operating Lease Liability Maturities \(Details\)Details](http://www.rapidmicrobio.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetailsLeases – Schedule of Operating Lease Liability Maturities (Details)Details)64 falsefalseR65.htm9954511 – Disclosure – Leases – Schedule of Finance Lease Liability Maturities (Details)Sheet[http://www.rapidmicrobio.com/role/LeasesScheduleofFinanceLeaseLiabilityMaturitiesDetailsLeases – Schedule of Finance Lease Liability Maturities \(Details\)Details](http://www.rapidmicrobio.com/role/LeasesScheduleofFinanceLeaseLiabilityMaturitiesDetailsLeases – Schedule of Finance Lease Liability Maturities (Details)Details)65 falsefalseR66.htm9954512 – Disclosure – Benefit plans (Details)Details[http://www.rapidmicrobio.com/role/BenefitplansDetailsBenefit plans \(Details\)Details](http://www.rapidmicrobio.com/role/BenefitplansDetailsBenefit plans (Details)Details)66 falsefalseAll Reports Book All Reports rmb-20240930.htmrmb-20240930.xsd rmb-20240930_cal.xmlrmb-20240930_def.xmlrmb-20240930_lab.xmlrmb-20240930_pre.xml rmb-20240930_g1.jpg

"unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "us-gaap:PreferredStockParOrStatedValuePerShare": { "span": "div", "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofoperations", "longName": "9952153 - Statement - Condensed consolidated statements of operations", "shortName": "Condensed consolidated statements of operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-18", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "div", "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-18", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "div", "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "unique": true } }, "R5": { "role": "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcomprehensive loss", "longName": "9952154 - Statement - Condensed consolidated statements of comprehensive loss", "shortName": "Condensed consolidated statements of comprehensive loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-18", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "div", "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-18", "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "div", "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "unique": true } }, "R6": { "role": "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofstockholdersequity", "longName": "9952155 - Statement - Condensed consolidated statements of stockholders' equity", "shortName": "Condensed consolidated statements of stockholders' equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-58", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "span": "div", "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-64", "name": "us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "span": "div", "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "unique": true } }, "R7": { "role": "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows", "longName": "9952156 - Statement - Condensed consolidated statements of cash flows", "shortName": "Condensed consolidated statements of cash flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "div", "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "div", "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "unique": true } }, "R8": { "role": "http://www.rapidmicrobio.com/role/Natureofthebusinessandbasisofpresentation", "longName": "9952157 - Disclosure - Nature of the business and basis of presentation", "shortName": "Nature of the business and basis of presentation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.rapidmicrobio.com/role/Summaryofsignificantaccountingpolicies", "longName": "9952158 - Disclosure - Summary of significant accounting policies", "shortName": "Summary of significant accounting policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.rapidmicrobio.com/role/Fairvalueoffinancialassetsandliabilities", "longName": "9952159 - Disclosure - Fair value of financial assets and liabilities", "shortName": "Fair value of financial assets and liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.rapidmicrobio.com/role/Investments", "longName": "9952160 - Disclosure - Investments", "shortName": "Investments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.rapidmicrobio.com/role/Inventory", "longName": "9952161 - Disclosure - Inventory", "shortName": "Inventory", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.rapidmicrobio.com/role/Prepaidexpensesandothercurrentassets", "longName": "9952162 - Disclosure - Prepaid expenses and other current assets", "shortName": "Prepaid expenses and other current assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "rmb:PrepaidExpensesAndOtherAssetsCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "rmb:PrepaidExpensesAndOtherAssetsCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.rapidmicrobio.com/role/Propertyandequipmentnet", "longName": "9952163 - Disclosure - Property and equipment, net", "shortName": "Property and equipment, net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.rapidmicrobio.com/role/Accruedexpensesandothercurrentliabilities", "longName": "9952164 - Disclosure - Accrued expenses and other current liabilities", "shortName": "Accrued expenses and other current liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.rapidmicrobio.com/role/Commonstockandcommonstockwarrants", "longName": "9952165 - Disclosure - Common stock and common stock warrants", "shortName": "Common stock and common stock warrants", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "rmb:CommonStockAndCommonStockWarrantsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "rmb:CommonStockAndCommonStockWarrantsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.rapidmicrobio.com/role/Stockbasedcompensation", "longName": "9952166 - Disclosure - Stock-based compensation", "shortName": "Stock-based compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.rapidmicrobio.com/role/Incometaxes", "longName": "9952167 - Disclosure - Income taxes", "shortName": "Income taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes",

```

"order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true }, "R19": { "role": "http://www.rapidmicrobio.com/role/Netlosspershare", "longName": "9952168 - Disclosure - Net loss per share", "shortName": "Net loss per share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true }, "R20": { "role": "http://www.rapidmicrobio.com/role/Leases", "longName": "9952169 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true }, "R21": { "role": "http://www.rapidmicrobio.com/role/Commitmentsandcontingencies", "longName": "9952170 - Disclosure - Commitments and contingencies", "shortName": "Commitments and contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true }, "R22": { "role": "http://www.rapidmicrobio.com/role/Benefitplans", "longName": "9952171 - Disclosure - Benefit plans", "shortName": "Benefit plans", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DefinedBenefitPlanTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DefinedBenefitPlanTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true }, "R23": { "role": "http://xbrl.sec.gov/ecd/rvp/PydDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-18", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "table": "div", "body": "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true }, "uniqueAnchor": null }, "R24": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-18", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-18", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true }, "R25": { "role": "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesPolicies", "longName": "9954471 - Disclosure - Summary of significant accounting policies (Policies)", "shortName": "Summary of significant accounting policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "div", "body": "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true }, "R26": { "role": "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesTables", "longName": "9954472 - Disclosure - Summary of significant accounting policies (Tables)", "shortName": "Summary of significant accounting policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "ix:continuation": "body", "html": "div", "body": "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "ix:continuation": "body", "html": "div", "body": "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true }, "R27": { "role": "http://www.rapidmicrobio.com/role/FairvalueoffinancialassetsandliabilitiesTables", "longName": "9954473 - Disclosure - Fair value of financial assets and liabilities (Tables)", "shortName": "Fair value of financial assets and liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "div", "body": "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "div", "body": "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true }, "R28": { "role": "http://www.rapidmicrobio.com/role/InvestmentsTables", "longName": "9954474 - Disclosure - Investments (Tables)", "shortName": "Investments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true }, "R29": { "role": "http://www.rapidmicrobio.com/role/InventoryTables", "longName": "9954475 - Disclosure - Inventory (Tables)", "shortName": "Inventory (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "div", "body": "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "div", "body": "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true }, "R30": { "role": "http://www.rapidmicrobio.com/role/PrepaidexpensesandothercurrentassetsTables", "longName": "9954476 - Disclosure - Prepaid expenses and other current assets (Tables)", "shortName": "Prepaid expenses and other current assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true }, "R31": { "role": "http://www.rapidmicrobio.com/role/PropertyandequipmentnetTables", "longName": "9954477 - Disclosure - Property and equipment, net (Tables)", "shortName": "Property and equipment, net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap
```

"en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.rapidmicrobio.com/role/StockbasedcompensationTables", "longName": "9954480 - Disclosure - Stock-based compensation (Tables)", "shortName": "Stock-based compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.rapidmicrobio.com/role/NetlosspershareTables", "longName": "9954481 - Disclosure - Net loss per share (Tables)", "shortName": "Net loss per share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.rapidmicrobio.com/role/LeasesTables", "longName": "9954482 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesScheduleofConcentrationRiskDetails", "longName": "9954483 - Disclosure - Summary of significant accounting policies - Schedule of Concentration Risk (Details)", "shortName": "Summary of significant accounting policies - Schedule of Concentration Risk (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-104", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span", "td", "tr", "table", "div", "ix:continuation": "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c-104", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span", "td", "tr", "table", "div", "ix:continuation": "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails", "longName": "9954484 - Disclosure - Summary of significant accounting policies - Narrative (Details)", "shortName": "Summary of significant accounting policies - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:CashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": { "span", "div", "ix:continuation": "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:CashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": { "us-gaap:CashEquivalentsAtCarryingValue", "span", "div", "ix:continuation": "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "unique": true } }, "R39": { "role": "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesScheduleofProductWarrantiesDetails", "longName": "9954485 - Disclosure - Summary of significant accounting policies - Schedule of Product Warranties (Details)", "shortName": "Summary of significant accounting policies - Schedule of Product Warranties (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-47", "name": "us-gaap:StandardProductWarrantyAccrual", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span", "td", "tr", "table", "div", "ix:continuation": "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c-47", "name": "us-gaap:StandardProductWarrantyAccrual", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span", "td", "tr", "table", "div", "ix:continuation": "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesScheduleofDisaggregatedRevenueDetails", "longName": "9954486 - Disclosure - Summary of significant accounting policies - Schedule of Disaggregated Revenue (Details)", "shortName": "Summary of significant accounting policies - Schedule of Disaggregated Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-18", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span", "td", "tr", "table", "div", "ix:continuation": "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c-126", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span", "td", "tr", "table", "div", "ix:continuation": "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "unique": true } }, "R41": { "role": "http://www.rapidmicrobio.com/role/FairvalueoffinancialassetsandliabilitiesDetails", "longName": "9954487 - Disclosure - Fair value of financial assets and liabilities (Details)", "shortName": "Fair value of financial assets and liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-167", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span", "td", "tr", "table", "div", "ix:continuation": "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c-149", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span", "td", "tr", "table", "div", "ix:continuation": "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "unique": true } }, "R42": { "role": "http://www.rapidmicrobio.com/role/InvestmentsDetails", "longName": "9954488 - Disclosure - Investments (Details)", "shortName": "Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-167", "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span", "td", "tr", "table", "div", "ix:continuation": "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c-167", "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span", "td", "tr", "table", "div", "ix:continuation": "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.rapidmicrobio.com/role/InventoryScheduleofInventoryDetails", "longName": "9954489 - Disclosure - Inventory - Schedule of Inventory (Details)", "shortName": "Inventory - Schedule of Inventory (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span", "td", "tr", "table", "div", "ix:continuation": "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span", "td", "tr", "table", "div", "ix:continuation": "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.rapidmicrobio.com/role/InventoryNarrativeDetails", "longName": "9954490 - Disclosure - Inventory - Narrative (Details)", "shortName": "Inventory - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:InventoryAdjustments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": { "span", "div", "ix:continuation": "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:InventoryAdjustments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": { "us-gaap:InventoryAdjustments", "span", "div", "ix:continuation": "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.rapidmicrobio.com/role/PrepaidexpensesandothercurrentassetsDetails", "longName": "9954491 - Disclosure - Prepaid expenses and other current assets (Details)", "shortName": "Prepaid expenses and other current assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:PrepaidInsurance", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span", "td", "tr", "table", "div", "ix:continuation": "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:PrepaidInsurance", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span", "td", "tr", "table", "div", "ix:continuation": "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.rapidmicrobio.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentDetails", "longName": "9954492 - Disclosure - Property and equipment, net - Schedule of Property and Equipment (Details)", "shortName": "Property and equipment, net - Schedule of Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:PropertyandEquipmentNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span", "td", "tr", "table", "div", "ix:continuation": "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:PropertyandEquipmentNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span", "td", "tr", "table", "div", "ix:continuation": "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true } } }

and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true }, "R47": { "role": "http://www.rapidmicrobio.com/role/PropertyandequipmentnetNarrativeDetails", "longName": "9954493 - Disclosure - Property and equipment - net - Narrative (Details)", "shortName": "Property and equipment - net - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-18", "name": "us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": { "span", "div", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-18", "name": "us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": { "span", "div", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true }, "R48": { "role": "http://www.rapidmicrobio.com/role/AccruedexpenseandothercurrentliabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails", "longName": "9954494 - Disclosure - Accrued expense and other current liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)", "shortName": "Accrued expense and other current liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true }, "R49": { "role": "http://www.rapidmicrobio.com/role/AccruedexpensesandothercurrentliabilitiesNarrativeDetails", "longName": "9954495 - Disclosure - Accrued expenses and other current liabilities - Narrative (Details)", "shortName": "Accrued expenses and other current liabilities - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-184", "name": "us-gaap:RestructuringCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": { "span", "div", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-184", "name": "us-gaap:RestructuringCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": { "span", "div", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true }, "R50": { "role": "http://www.rapidmicrobio.com/role/CommonstockandcommonstockwarrantsNarrativeDetails", "longName": "9954496 - Disclosure - Common stock and common stock warrants - Narrative (Details)", "shortName": "Common stock and common stock warrants - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DividendsCommonStockCash", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span", "div", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DividendsCommonStockCash", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span", "div", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true }, "R51": { "role": "http://www.rapidmicrobio.com/role/CommonstockandcommonstockwarrantsScheduleofOutstandingCommonStockWarrantsDetails", "longName": "9954497 - Disclosure - Common stock and common stock warrants - Schedule of Outstanding Common Stock Warrants (Details)", "shortName": "Common stock and common stock warrants - Schedule of Outstanding Common Stock Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-190", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-190", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true }, "R52": { "role": "http://www.rapidmicrobio.com/role/StockbasedcompensationNarrativeDetails", "longName": "9954498 - Disclosure - Stock-based compensation - Narrative (Details)", "shortName": "Stock-based compensation - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": { "span", "div", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": { "span", "div", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true }, "R53": { "role": "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofBlackScholesOptionPricingModelDetails", "longName": "9954499 - Disclosure - Stock-based compensation - Schedule of Black-Scholes Option Pricing Model (Details)", "shortName": "Stock-based compensation - Schedule of Black-Scholes Option Pricing Model (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-200", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-200", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true }, "R54": { "role": "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofStockOptionActivityDetails", "longName": "9954500 - Disclosure - Stock-based compensation - Schedule of Stock Option Activity (Details)", "shortName": "Stock-based compensation - Schedule of Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true }, "R55": { "role": "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofRestrictedStockUnitsActivityDetails", "longName": "9954501 - Disclosure - Stock-based compensation - Schedule of Restricted Stock Units Activity (Details)", "shortName": "Stock-based compensation - Schedule of Restricted Stock Units Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-205", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span", "td", "tr", "table", "div", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-205", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span", "td", "tr", "table", "div", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true }, "R56": { "role": "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofESPPBlackScholesOptionPricingModelDetails", "longName": "9954502 - Disclosure - Stock-based compensation - Schedule of ESPP Black-Scholes Option Pricing Model (Details)", "shortName": "Stock-based compensation - Schedule of ESPP Black-Scholes Option Pricing Model (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-221", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-221", "name": "us-

gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofStockBasedCompensationExpenseDetails", "longName": "9954503 - Disclosure - Stock-based compensation - Schedule of Stock-Based Compensation Expense (Details)", "shortName": "Stock-based compensation - Schedule of Stock-Based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-18", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.rapidmicrobio.com/role/NetlosspershareScheduleofBasicandDilutedNetLossperShareDetails", "longName": "9954504 - Disclosure - Net loss per share - Schedule of Basic and Diluted Net Loss per Share (Details)", "shortName": "Net loss per share - Schedule of Basic and Diluted Net Loss per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-18", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.rapidmicrobio.com/role/NetlosspershareScheduleofAntiDilutiveSharesExcludedfromComputationofDilutedNetLetperShareDetails", "longName": "9954505 - Disclosure - Net loss per share - Schedule of Anti-Dilutive Shares Excluded from Computation of Diluted Net Let per Share (Details)", "shortName": "Net loss per share - Schedule of Anti-Dilutive Shares Excluded from Computation of Diluted Net Let per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.rapidmicrobio.com/role/LeasesNarrativeDetails", "longName": "9954506 - Disclosure - Leases - Narrative (Details)", "shortName": "Leases - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:LesseeFinanceLeaseTermOfContract1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.rapidmicrobio.com/role/LeasesScheduleofSupplementalCashFlowInformationDetails", "longName": "9954507 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information (Details)", "shortName": "Leases - Schedule of Supplemental Cash Flow Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeasePayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.rapidmicrobio.com/role/LeasesScheduleofSupplementalBalanceSheetInformationDetails", "longName": "9954508 - Disclosure - Leases - Schedule of Supplemental Balance Sheet Information (Details)", "shortName": "Leases - Schedule of Supplemental Balance Sheet Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.rapidmicrobio.com/role/LeasesScheduleofLeaseExpenseDetails", "longName": "9954509 - Disclosure - Leases - Schedule of Lease Expense (Details)", "shortName": "Leases - Schedule of Lease Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-18", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.rapidmicrobio.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails", "longName": "9954510 - Disclosure - Leases - Schedule of Operating Lease Liability Maturities (Details)", "shortName": "Leases - Schedule of Operating Lease Liability Maturities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.rapidmicrobio.com/role/LeasesScheduleofFinanceLeaseLiabilityMaturitiesDetails", "longName": "9954511 - Disclosure - Leases - Schedule of Finance Lease Liability Maturities (Details)", "shortName": "Leases - Schedule of Finance Lease Liability Maturities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.rapidmicrobio.com/role/BenefitplansDetails", "longName": "9954512 - Disclosure - Benefit plans (Details)", "shortName": "Benefit plans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-18", "name": "us-gaap:DefinedContributionPlanCostRecognized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": { "span": "div", "body", "html" }, "reportCount": 1, "baseRef": "rmb-20240930.htm", "first": true, "unique": true } }, "tag": { "rmb-A2010StockOptionAndGrantPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rapidmicrobio.com/20240930", "localname": "A2010StockOptionAndGrantPlanMember", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "2010 Plan", "label": "2010 Stock Option And Grant Plan [Member]", "documentation": "Represents information pertaining to Stock Option and Grant Plan 2010." } } } }, "auth_ref": {}, "rmb-A2023InducementPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rapidmicrobio.com/20240930", "localname": "A2023InducementPlanMember", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "2023 Inducement Plan", "label": "2023 Inducement Plan [Member]", "documentation": "2023 Inducement Plan" } } } }, "auth_ref": {}, "us-gaap:AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": {}, "rmb-AccountingPoliciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.rapidmicrobio.com/20240930", "localname": "AccountingPoliciesLineItems", "presentation": {

"http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Line Items]", "label": "Accounting Policies [Line Items]", "documentation": "Accounting Policies" } } }, "auth_ref": { } }, "rmb_AccountingPoliciesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.rapidmicrobio.com/20240930", "localname": "AccountingPoliciesTable", "presentation": { "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Table]", "label": "Accounting Policies [Table]", "documentation": "Accounting Policies" } } }, "auth_ref": { } }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "presentation": { "http://www.rapidmicrobio.com/role/Accruedexpensesandothercurrentliabilities" }, "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current liabilities", "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period." } } }, "auth_ref": { "r383" } }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets" }, "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": { "r48", "r744" } }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableMember", "presentation": { "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesScheduleofConcentrationRiskDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable", "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": { "r674" } }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets" }, "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": { "r900" } }, "rmb_AccretionOfDebtSecuritiesAvailableForSale": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rapidmicrobio.com/20240930", "localname": "AccretionOfDebtSecuritiesAvailableForSale", "crdr": "credit", "calculation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows" }, "lang": { "en-us": { "role": { "negatedTerseLabel": "Accretion on investments", "label": "Accretion Of Debt Securities, Available For Sale", "documentation": "Accretion Of Debt Securities, Available For Sale" } } }, "auth_ref": { } }, "us-gaap_AccruedIncomeTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedIncomeTaxesCurrent", "crdr": "credit", "calculation": { "http://www.rapidmicrobio.com/role/AccruedexpenseandothercurrentliabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/AccruedexpenseandothercurrentliabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Accrued taxes", "label": "Accrued Income Taxes, Current", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations." } } }, "auth_ref": { "r50", "r93" } }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "http://www.rapidmicrobio.com/role/AccruedexpenseandothercurrentliabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.rapidmicrobio.com/role/AccruedexpenseandothercurrentliabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" }, "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets" }, "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current liabilities", "totalLabel": "Total accrued expenses and other current liabilities", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": { "r50" } }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrentAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accrued Liabilities, Current [Abstract]", "label": "Accrued Liabilities, Current [Abstract]" } } }, "auth_ref": { } }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.rapidmicrobio.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentDetails" }, "lang": { "en-us": { "role": { "negatedLabel": "Less: Accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": { "r37", "r127", "r554" } }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets" }, "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": { "r16", "r17", "r66", "r133", "r551", "r578", "r579" } }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofstockholdersequity" }, "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "label": "AOI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": { "r1", "r8", "r17", "r413", "r416", "r474", "r574", "r575", "r877", "r878", "r879", "r887", "r888", "r889", "r890" } }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": { "r808" } }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets" }, "lang": { "en-us": { "role": { "terseLabel": "Additional paid in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": { "r58", "r744", "r1025" } }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofstockholdersequity" }, "lang": { "en-us": { "role": { "terseLabel": "Additional paid in capital", "label": "Additional Paid in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": { "r589", "r887", "r888", "r889", "r890", "r967", "r1026" } }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": { "r821" } }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation [Axis]" } } }, "auth_ref": { "r821" } }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": { "r821" } }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": {

"en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } }, "auth_ref": { "r821" } }, "rmb_AdjustmentsToAdditionalPaidInCapitalAccretionOfRestrictedStockAwardLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rapidmicrobio.com/20240930", "localname": "AdjustmentsToAdditionalPaidInCapitalAccretionOfRestrictedStockAwardLiability", "crdr": "credit", "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofstockholdersequity", "lang": { "en-us": { "role": { "terseLabel": "Restricted stock award liability accretion", "label": "Adjustments To Additional Paid In Capital, Accretion Of Restricted Stock Award Liability", "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) due to RSA liability accretion." } } }, "auth_ref": { "r42", "r43", "r340" } }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofstockholdersequity", "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": { "r42", "r43", "r340" } }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows", "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities", "label": "Adjustments To Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": { "r42", "r43", "r340" } }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdvertisingCostsPolicyTextBlock", "presentation": { "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesPolicies", "lang": { "en-us": { "role": { "terseLabel": "Advertising costs", "label": "Advertising Cost [Policy Text Block]", "documentation": "Disclosure of accounting policy for advertising cost." } } }, "auth_ref": { "r107" } }, "us-gaap_AdvertisingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdvertisingExpense", "crdr": "debit", "presentation": { "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Advertising costs", "label": "Advertising Expense", "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line." } } }, "auth_ref": { "r384", "r731" } }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblyrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblyrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table", "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]" } } }, "auth_ref": { "r854" } }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": { "r780", "r790", "r800", "r832" } }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": { "r783", "r793", "r803", "r835" } }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Aggregate Pension Adjustments Service Cost", "label": "Aggregate Pension Adjustments Service Cost [Member]" } } }, "auth_ref": { "r855" } }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": { "r821" } }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": { "r828" } }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": { "r784", "r794", "r804", "r828", "r836", "r840", "r848" } }, "rmb_AllOtherCountriesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rapidmicrobio.com/20240930", "localname": "AllOtherCountriesMember", "presentation": { "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesScheduleofDisaggregatedRevenueDetails", "lang": { "en-us": { "role": { "terseLabel": "All other countries", "label": "All Other Countries [Member]", "documentation": "Represents information pertaining to all other countries other than US, Germany and Switzerland." } } }, "auth_ref": { "r846" } }, "us-gaap_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": { "r846" } }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": { "r372", "r381" } }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": { "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Allowance for doubtful accounts for expected credit losses", "label": "Accounts Receivable, Allowance for Credit Loss", "documentation": "Amount of allowance for credit loss on accounts receivable." } } }, "auth_ref": { "r134", "r213", "r252", "r255", "r256", "r993" } }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": { "http://www.rapidmicrobio.com/role/CoverPage", "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously filed or accepted submission." } } }, "auth_ref": { "r27" } }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": { "http://www.rapidmicrobio.com/role/NetlosspershareScheduleofAntiDilutiveSharesExcludedfromComputationofDilutedNetLetperShareDetails", "lang": { "en-us": { "role": { "terseLabel": "Common shares excluded from computation of diluted net loss per share attributable to common stockholders (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": { "r184" } }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": { "http://www.rapidmicrobio.com/role/NetlosspershareScheduleofAntiDilutiveSharesExcludedfromComputationofDilutedNetLetperShareDetails", "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": { "r27" } }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": { "http://www.rapidmicrobio.com/role/NetlosspershareScheduleofAntiDilutiveSharesExcludedfromComputationofDilutedNetLetperShareDetails", "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r27" } }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": { "http://www.rapidmicrobio.com/role/NetlosspershareScheduleofAntiDilutiveSharesExcludedfromComputationofDilutedNetLetperShareDetails", "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": { "r27" } }, "rmb_April122018Member": { "xbrltype": "domainItemType", "nsuri": "http://www.rapidmicrobio.com/20240930", "localname": "April122018Member", "presentation": {

"http://www.rapidmicrobio.com/role/CommonstockandcommonstockwarrantsScheduleofOutstandingCommonStockWarrantsDetails", "lang": { "en-us": { "role": { "terseLabel": "April 12, 2018", "label": "April 12, 2018", "documentation": "Represents the information pertaining to April 12, 2018." } } }, "auth_ref": { "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets": { "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": { "r92", "r101", "r129", "r159", "r188", "r192", "r205", "r206", "r249", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r408", "r410", "r444", "r547", "r626", "r707", "r708", "r744", "r771", "r935", "r936", "r981" }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets": { "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": { "rmb_AssetsAndLiabilitiesLesseeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.rapidmicrobio.com/20240930", "localname": "AssetsAndLiabilitiesLesseeTableTextBlock", "presentation": { "http://www.rapidmicrobio.com/role/LeasesTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Supplemental Balance Sheet Information", "label": "Assets And Liabilities, Lessee [Table Text Block]", "documentation": "Assets And Liabilities, Lessee" } } }, "auth_ref": { "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets": { "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": { "r122", "r137", "r159", "r249", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r408", "r410", "r444", "r744", "r935", "r936", "r981" }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets": { "lang": { "en-us": { "role": { "terseLabel": "Current assets", "label": "Assets, Current [Abstract]" } } }, "auth_ref": { "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.rapidmicrobio.com/role/FairvalueoffinancialassetsandliabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.rapidmicrobio.com/role/FairvalueoffinancialassetsandliabilitiesDetails": { "lang": { "en-us": { "role": { "totalLabel": "Assets", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": { "r423", "r424", "r733" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "calculation": { "http://www.rapidmicrobio.com/role/InvestmentsDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "weight": -1.0, "order": 1.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/InvestmentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Gross unrealized gains", "label": "Debt Securities, Available for Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)." } } }, "auth_ref": { "r222" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "calculation": { "http://www.rapidmicrobio.com/role/InvestmentsDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/InvestmentsDetails": { "lang": { "en-us": { "role": { "negatedLabel": "Gross unrealized losses", "label": "Debt Securities, Available for Sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)." } } }, "auth_ref": { "r223" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "calculation": { "http://www.rapidmicrobio.com/role/FairvalueoffinancialassetsandliabilitiesDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "http://www.rapidmicrobio.com/role/InvestmentsDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/FairvalueoffinancialassetsandliabilitiesDetails", "http://www.rapidmicrobio.com/role/InvestmentsDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Investments", "terseLabel": "Fair value", "label": "Debt Securities, Available for Sale", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)." } } }, "auth_ref": { "r220", "r260", "r423", "r543", "r733", "r736", "r904", "r971", "r972", "r973" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "crdr": "debit", "calculation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets": { "lang": { "en-us": { "role": { "terseLabel": "Short-term investments", "label": "Debt Securities, Available for Sale, Current", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale), classified as current." } } }, "auth_ref": { "r216", "r260" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "crdr": "debit", "calculation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets": { "lang": { "en-us": { "role": { "terseLabel": "Long-term investments", "label": "Debt Securities, Available for Sale, Noncurrent", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale), classified as noncurrent." } } }, "auth_ref": { "r125", "r216", "r260" }, "us-gaap_AwardDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardDateAxis", "presentation": { "http://www.rapidmicrobio.com/role/CommonstockandcommonstockwarrantsScheduleofOutstandingCommonStockWarrantsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Award Date [Axis]", "label": "Award Date [Axis]", "documentation": "Information by date or year award under share-based payment arrangement is granted." } } }, "auth_ref": { "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964" }, "us-gaap_AwardDateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardDateDomain", "presentation": { "http://www.rapidmicrobio.com/role/CommonstockandcommonstockwarrantsScheduleofOutstandingCommonStockWarrantsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Award Date [Domain]", "label": "Award Date [Domain]", "documentation": "Date or year award under share-based payment arrangement is granted." } } }, "auth_ref": { "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964" }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": { "r843" }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": { "r844" }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": { "r839" }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": { "r839" }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method [Text Block]" } } }, "auth_ref": { "r839" }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Award Timing-MNPI Considered", "label": "Award Timing-MNPI Considered [Flag]" } } }, "auth_ref": { "r839" }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Award Timing-MNPI Disclosure", "label": "Award Timing-MNPI Disclosure [Text Block]" } } }, "auth_ref": { "r839" }, "ecd_AwardTmgPredtrmdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmdFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined [Flag]" } } }, "auth_ref": { "r839" }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationNarrativeDetails", "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofBlackScholesOptionPricingModelDetails",

"http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofESPPBlackScholesOptionPricingModelDetails",
"http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofRestrictedStockUnitsActivityDetails",
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]",
"documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": { "r343", "r344", "r345", "r347",
"r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r367", "r368",
"r369", "r370", "r371" } }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AwardUndrlygSecuritiesAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "terseLabel":
"Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": { "r842" } }, "ecd_AwardsCloseToMnpiDiscIndName": {
"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": {
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI
Disclosures, Individual Name" } } }, "auth_ref": { "r841" } }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
}, "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures
[Table]" } } }, "auth_ref": { "r840" } }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": {
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures,
Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": { "r840" } }, "us-
gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"BasisOfAccountingPolicyPolicyTextBlock", "presentation": { "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesPolicies"
}, "lang": { "en-us": { "role": { "terseLabel": "Basis of presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation":
"Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US
Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": { } }, "us-
gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": {
"http://www.rapidmicrobio.com/role/Natureofthebusinessandbasisofpresentation" }, "lang": { "en-us": { "role": { "terseLabel": "Nature of the
business and basis of presentation", "label": "Business Description and Basis of Presentation [Text Block]", "documentation": "The entire
disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization
including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business
divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation
describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other
Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": { "r47", "r77", "r78" } }, "country_CH": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/country/2024", "localname": "CH", "presentation": {
"http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesScheduleofDisaggregatedRevenueDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Switzerland", "label": "SWITZERLAND" } } }, "auth_ref": { } }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr":
"credit", "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows" }, "lang": { "en-us": { "role": { "terseLabel": "Purchases of property and equipment in accounts payable and accrued expenses", "label": "Capital Expenditures Incurred but Not
yet Paid", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": { "r23", "r24", "r25" } },
"us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CapitalizedComputerSoftwareAccumulatedAmortization", "crdr": "credit", "presentation": {
"http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel":
"Amortization of software development costs", "label": "Capitalized Computer Software, Accumulated Amortization", "documentation": "For each
balance sheet presented, the amount of accumulated amortization for capitalized computer software costs." } } }, "auth_ref": { "r271", "r689" } },
"us-gaap_CapitalizedComputerSoftwareAmortization1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CapitalizedComputerSoftwareAmortization1", "crdr": "debit", "presentation": {
"http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel":
"Software development amortization expense", "label": "Capitalized Computer Software, Amortization", "documentation": "Amount of expense for
amortization of capitalized computer software costs." } } }, "auth_ref": { "r688", "r689" } }, "us-gaap_CapitalizedComputerSoftwareNet": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalizedComputerSoftwareNet", "crdr": "debit",
"presentation": { "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Software development costs, net of amortization", "label": "Capitalized Computer Software, Net", "documentation": "The carrying
amount of capitalized computer software costs net of accumulated amortization as of the balance sheet date." } } }, "auth_ref": { "r687" } }, "us-
gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": {
"http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } },
"presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets" }, "lang": { "en-us": { "role": { "terseLabel": "Cash and
cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand
deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also
includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they
present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and
discontinued operation." } } }, "auth_ref": { "r21", "r124", "r694" } }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit",
"calculation": { "http://www.rapidmicrobio.com/role/FairvalueoffinancialassetsandliabilitiesDetails": { "parentTag": "us-
gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": {
"http://www.rapidmicrobio.com/role/FairvalueoffinancialassetsandliabilitiesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents",
"label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits
with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-
term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present
insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": { "r969", "r970" } }, "us-
gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "presentation": {
"http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesPolicies" }, "lang": { "en-us": { "role": { "terseLabel": "Restricted
cash", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Entity's cash and
cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating
balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to
particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits." } } },
"auth_ref": { "r22", "r91" } }, "us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy": { "xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy", "presentation": {
"http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesPolicies" }, "lang": { "en-us": { "role": { "terseLabel": "Cash and cash
equivalents", "label": "Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation":
"Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances." } } }, "auth_ref": { "r22" } }, "us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": {
"http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows" }, "lang": { "en-us": { "role": { "periodStartLabel": "Cash, cash
equivalents and restricted cash at beginning of period", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "label":
"Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and
cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not
limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand
deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts
of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": {
"r21", "r74", "r157" } }, "us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "crdr": "debit",
"calculation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows": { "parentTag": null, "weight": null, "order":
null, "root": true } }, "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows" }, "lang": { "en-us": { "role": { "totalLabel": "Net decrease in cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and
Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "documentation": "Amount of increase (decrease) in
cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, excluding effect from exchange rate change. Cash

includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": { "r0", "r74" } }, "us-gaap-CashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": { "http://www.rapidmicrobio.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Cash held in banks outside of the US", "label": "Cash Equivalents, at Carrying Value", "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": { "r872", "r992" } }, "rmb-CashFlowLesseeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.rapidmicrobio.com/20240930", "localname": "CashFlowLesseeAbstract", "presentation": { "http://www.rapidmicrobio.com/role/LeasesScheduleOfSupplementalCashFlowInformationDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Cash paid for amounts included in measurement of lease liabilities", "label": "Cash Flow, Lessee [Abstract]", "documentation": "Cash Flow, Lessee" } } }, "auth_ref": { "r7", "r766", "r767", "r768", "r769" } }, "us-gaap-CertificatesOfDepositMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CertificatesOfDepositMember", "presentation": { "http://www.rapidmicrobio.com/role/InvestmentsDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Certificates of Deposit", "label": "Certificates of Deposit [Member]", "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured." } } }, "auth_ref": { "r7", "r766", "r767", "r768", "r769" } }, "ecd-ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } }, "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": { "r819" } }, "ecd-ChngInFrValAsOfVstngDtOfPrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } }, "lang": { "en-us": { "role": { "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]" } } }, "auth_ref": { "r816" } }, "ecd-ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrYrsMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } }, "lang": { "en-us": { "role": { "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]" } } }, "auth_ref": { "r814" } }, "dei-CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": { "http://www.rapidmicrobio.com/role/CoverPage" } }, "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": { "r814" } }, "us-gaap-ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": { "http://www.rapidmicrobio.com/role/CommonstockandcommonstockwarrantsNarrativeDetails", "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets", "http://www.rapidmicrobio.com/role/CondensedconsolidatedbalancesheetsParentetical", "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofstockholdersequity", "http://www.rapidmicrobio.com/role/CoverPage", "http://www.rapidmicrobio.com/role/NetlosspershareScheduleofBasicandDilutedNetLossperShareDetails", "http://www.rapidmicrobio.com/role/StockbasedcompensationNarrativeDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": { "r118", "r130", "r131", "r132", "r159", "r178", "r179", "r181", "r183", "r190", "r191", "r249", "r293", "r295", "r296", "r297", "r300", "r301", "r305", "r306", "r307", "r308", "r310", "r444", "r583", "r584", "r585", "r586", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r614", "r635", "r653", "r668", "r669", "r670", "r671", "r672", "r859", "r885", "r891" } }, "us-gaap-ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": { "http://www.rapidmicrobio.com/role/CommonstockandcommonstockwarrantsScheduleofOutstandingCommonStockWarrantsDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Axis]", "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": { "r39" } }, "us-gaap-ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": { "http://www.rapidmicrobio.com/role/CommonstockandcommonstockwarrantsScheduleofOutstandingCommonStockWarrantsDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Domain]", "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": { "r311" } }, "us-gaap-ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": { "http://www.rapidmicrobio.com/role/CommonstockandcommonstockwarrantsScheduleofOutstandingCommonStockWarrantsDetails" } }, "lang": { "en-us": { "role": { "verboseLabel": "Weighted average exercise price (in dollars per share)", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": { "r311" } }, "us-gaap-ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightLineItems", "presentation": { "http://www.rapidmicrobio.com/role/CommonstockandcommonstockwarrantsNarrativeDetails", "http://www.rapidmicrobio.com/role/CommonstockandcommonstockwarrantsScheduleofOutstandingCommonStockWarrantsDetails" } }, "lang": { "en-us": { "role": { "verboseLabel": "Common stock and common stock warrants", "label": "Class of Warrant or Right [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r311" } }, "us-gaap-ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": { "http://www.rapidmicrobio.com/role/CommonstockandcommonstockwarrantsScheduleofOutstandingCommonStockWarrantsDetails" } }, "lang": { "en-us": { "role": { "verboseLabel": "Shares of common stock issuable upon exercise of warrant (in shares)", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": { "r311" } }, "us-gaap-ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightTable", "presentation": { "http://www.rapidmicrobio.com/role/CommonstockandcommonstockwarrantsNarrativeDetails", "http://www.rapidmicrobio.com/role/CommonstockandcommonstockwarrantsScheduleofOutstandingCommonStockWarrantsDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Table]", "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame." } } }, "auth_ref": { "r39" } }, "ecd-CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } }, "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": { "r820" } }, "ecd-CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } }, "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": { "r820" } }, "us-gaap-CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets" } }, "parentTag": { "us-gaap-LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets" } }, "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (Note 14)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": { "r54", "r94", "r548", "r613" } }, "us-gaap-CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": { "r54", "r94", "r548", "r613" } }, "us-gaap-CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",

"localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": {
"http://www.rapidmicrobio.com/role/Commitmentsandcontingencies": {
"lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": { "r84", "r286", "r287", "r675", "r924", "r927" } }, "us-gaap_CommonClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonClassAMember", "presentation": {
"http://www.rapidmicrobio.com/role/CommonstockandcommonstockwarrantsNarrativeDetails",
"http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets",
"http://www.rapidmicrobio.com/role/CondensedconsolidatedbalancesheetsParenthetical",
"http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofstockholdersequity", "http://www.rapidmicrobio.com/role/CoverPage",
"http://www.rapidmicrobio.com/role/NetlosspershareScheduleofBasicandDilutedNetLossperShareDetails",
"http://www.rapidmicrobio.com/role/StockbasedcompensationNarrativeDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Class A Common stock", "label": "Common Class A [Member]", "documentation": "Classification of common stock representing ownership interest in a corporation." } } }, "auth_ref": { "r1026" } }, "us-gaap_CommonClassBMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonClassBMember", "presentation": {
"http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets",
"http://www.rapidmicrobio.com/role/CondensedconsolidatedbalancesheetsParenthetical",
"http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofstockholdersequity", "http://www.rapidmicrobio.com/role/CoverPage",
"http://www.rapidmicrobio.com/role/NetlosspershareScheduleofBasicandDilutedNetLossperShareDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Class B Common stock", "label": "Common Class B [Member]", "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation." } } }, "auth_ref": { "r1026" } }, "rmb_CommonStockAndCommonStockWarrantsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.rapidmicrobio.com/20240930", "localname": "CommonStockAndCommonStockWarrantsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Common stock and common stock warrants", "label": "Common Stock And Common Stock Warrants [Abstract]", "documentation": "No definition available." } } }, "auth_ref": { } }, "rmb_CommonStockAndCommonStockWarrantsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.rapidmicrobio.com/20240930", "localname": "CommonStockAndCommonStockWarrantsTextBlock", "presentation": {
"http://www.rapidmicrobio.com/role/Commonstockandcommonstockwarrants" } }, "lang": { "en-us": { "role": { "terseLabel": "Common stock and common stock warrants", "label": "Common Stock And Common Stock Warrants [Text Block]", "documentation": "The entire disclosure for common stock and common stock warrants." } } }, "auth_ref": { } }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": {
"http://www.rapidmicrobio.com/role/CommonstockandcommonstockwarrantsNarrativeDetails",
"http://www.rapidmicrobio.com/role/StockbasedcompensationNarrativeDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Shares reserved (in shares)", "verboseLabel": "Shares available for future issuance (in shares)", "label": "Common Stock Capital Shares Reserved for Future Issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": { "r57" } }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": {
"http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofstockholdersequity" } }, "lang": { "en-us": { "role": { "terseLabel": "Common stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": { "r762", "r763", "r764", "r766", "r767", "r768", "r769", "r887", "r888", "r890", "r967", "r1024", "r1026" } }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": {
"http://www.rapidmicrobio.com/role/CondensedconsolidatedbalancesheetsParenthetical" } }, "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": { "r57" } }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": {
"http://www.rapidmicrobio.com/role/CondensedconsolidatedbalancesheetsParenthetical" } }, "lang": { "en-us": { "role": { "terseLabel": "Common stock, authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": { "r57", "r614" } }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": {
"http://www.rapidmicrobio.com/role/CondensedconsolidatedbalancesheetsParenthetical" } }, "lang": { "en-us": { "role": { "terseLabel": "Common stock, issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": { "r57" } }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": {
"http://www.rapidmicrobio.com/role/CondensedconsolidatedbalancesheetsParenthetical",
"http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofstockholdersequity" } }, "lang": { "en-us": { "role": { "terseLabel": "Common stock, outstanding (in shares)", "periodStartLabel": "Balance at beginning of period (in shares)", "periodEndLabel": "Balance at end of period (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": { "r9", "r57", "r614", "r632", "r1026", "r1027" } }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets": { "lang": { "en-us": { "role": { "terseLabel": "Common stock", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": { "r57", "r550", "r744" } }, "rmb_CommonStockWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rapidmicrobio.com/20240930", "localname": "CommonStockWarrantsMember", "presentation": {
"http://www.rapidmicrobio.com/role/CommonstockandcommonstockwarrantsScheduleofOutstandingCommonStockWarrantsDetails",
"http://www.rapidmicrobio.com/role/NetlosspershareScheduleofAntiDilutiveSharesExcludedfromComputationofDilutedNetLetperShareDetails" } }, "lang": { "en-us": { "role": { "verboseLabel": "Common Stock Warrants", "terseLabel": "Warrants to purchase common stock", "label": "Common Stock Warrants [Member]", "documentation": "Common Stock Warrants" } } }, "auth_ref": { } }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": { "r825" } }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": { "r824" } }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": { "r826" } }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": { "r823" } }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CompensationAndRetirementDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Retirement Benefits [Abstract]", "label": "Retirement Benefits [Abstract]" } } }, "auth_ref": { } }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcomprehensiveloss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcomprehensiveloss": { "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": { "r18", "r143", "r145", "r149", "r544", "r559", "r560" } }, "rmb_ComputerEquipmentAndSoftwareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rapidmicrobio.com/20240930", "localname": "ComputerEquipmentAndSoftwareMember", "presentation": {
"http://www.rapidmicrobio.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Computer hardware and software", "label": "Computer Equipment And Software [Member]", "documentation": "Represents information pertaining to computer hardware and software." } } }, "auth_ref": { } }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": {
"http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesScheduleofConcentrationRiskDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator

in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": { "r30", "r31", "r44", "r45", "r211", "r674" } }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": { "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesScheduleofConcentrationRiskDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": { "r30", "r31", "r44", "r45", "r211", "r581", "r674" } }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": { "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesScheduleofConcentrationRiskDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": { "r30", "r31", "r44", "r45", "r211", "r674", "r863" } }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskCreditRisk", "presentation": { "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesPolicies" }, "lang": { "en-us": { "role": { "terseLabel": "Risk of concentrations of credit, significant customers and significant suppliers", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": { "r46", "r110" } }, "us-gaap_ConcentrationRiskLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskLineItems", "presentation": { "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesScheduleofConcentrationRiskDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk [Line Items]", "label": "Concentration Risk [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r674" } }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": { "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesScheduleofConcentrationRiskDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Customer concentration risk", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": { "r30", "r31", "r44", "r45", "r211" } }, "us-gaap_ConcentrationRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTable", "presentation": { "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesScheduleofConcentrationRiskDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk [Table]", "label": "Concentration Risk [Table]", "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk." } } }, "auth_ref": { "r29", "r30", "r31", "r32", "r44", "r90", "r674" } }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": { "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesScheduleofConcentrationRiskDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": { "r30", "r31", "r44", "r45", "r211", "r674" } }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConstructionInProgressMember", "presentation": { "http://www.rapidmicrobio.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Construction in process", "label": "Construction in Progress [Member]", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": { "r1" } }, "us-gaap_ContractWithCustomerAssetNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetNet", "crdr": "debit", "presentation": { "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Contract assets", "label": "Contract with Customer, Asset, after Allowance for Credit Loss", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time." } } }, "auth_ref": { "r313", "r315", "r326" } }, "us-gaap_ContractWithCustomerAssetNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetNetCurrent", "crdr": "debit", "calculation": { "http://www.rapidmicrobio.com/role/PrepaidexpensesandothercurrentassetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/PrepaidexpensesandothercurrentassetsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Contract asset", "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current." } } }, "auth_ref": { "r313", "r315", "r326" } }, "us-gaap_ContractWithCustomerDurationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerDurationAxis", "presentation": { "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesScheduleofDisaggregatedRevenueDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Contract with Customer, Duration [Axis]", "label": "Contract with Customer, Duration [Axis]", "documentation": "Information by duration of contract with customer. Includes, but is not limited to, short-term and long-term contracts." } } }, "auth_ref": { "r721", "r938" } }, "us-gaap_ContractWithCustomerDurationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerDurationDomain", "presentation": { "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesScheduleofDisaggregatedRevenueDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Contract with Customer, Duration [Domain]", "label": "Contract with Customer, Duration [Domain]", "documentation": "Duration of contract with customer. Includes, but is not limited to, short-term and long-term contracts." } } }, "auth_ref": { "r721", "r938" } }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets" }, "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Current deferred revenue", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": { "r313", "r314", "r326" } }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityNoncurrent", "crdr": "credit", "presentation": { "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Non-current deferred revenue", "label": "Contract with Customer, Liability, Noncurrent", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": { "r313", "r314", "r326" } }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": { "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Revenue recognized which was included in deferred revenue in prior period", "label": "Contract with Customer, Liability, Revenue Recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": { "r327" } }, "us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSoldDepreciationAndAmortization", "crdr": "debit", "presentation": { "http://www.rapidmicrobio.com/role/PropertyandequipmentnetNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization expense", "label": "Cost, Depreciation and Amortization", "documentation": "Amount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service." } } }, "auth_ref": { "r880" } }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfRevenue", "crdr": "debit", "calculation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofoperations": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofoperations" }, "lang": { "en-us": { "role": { "terseLabel": "Cost of revenue", "label": "Cost of Revenue", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": { "r67", "r159", "r249", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r444", "r707", "r935" } }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfSalesMember", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofStockBasedCompensationExpenseDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Cost of revenue", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": { "r1" } }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofoperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofoperations" }, "lang": { "en-us": { "role": { "totalLabel": "Total costs and operating expenses", "label": "Costs and Expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": {

["r72"], {"dei_CoverAbstract": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": {"en-us": {"role": {"terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, {"dei_CurrentFiscalYearEndDate": {"xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": {"http://www.rapidmicrobio.com/role/CoverPage", "lang": {"en-us": {"role": {"terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format -MM-DD." } } }, "auth_ref": [] }, "rmb_CustomerAMember": {"xbrltype": "domainItemType", "nsuri": "http://www.rapidmicrobio.com/20240930", "localname": "CustomerAMember", "presentation": {"http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesScheduleofConcentrationRiskDetails", "lang": {"en-us": {"role": {"terseLabel": "Customer A", "label": "Customer A [Member]", "documentation": "Represents information pertaining to customer a." } } }, "auth_ref": [] }, "rmb_CustomerBMember": {"xbrltype": "domainItemType", "nsuri": "http://www.rapidmicrobio.com/20240930", "localname": "CustomerBMember", "presentation": {"http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesScheduleofConcentrationRiskDetails", "lang": {"en-us": {"role": {"terseLabel": "Customer B", "label": "Customer B [Member]", "documentation": "Represents information pertaining to customer b." } } }, "auth_ref": [] }, "rmb_CustomerCMember": {"xbrltype": "domainItemType", "nsuri": "http://www.rapidmicrobio.com/20240930", "localname": "CustomerCMember", "presentation": {"http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesScheduleofConcentrationRiskDetails", "lang": {"en-us": {"role": {"terseLabel": "Customer C", "label": "Customer C [Member]", "documentation": "Represents information pertaining to customer c." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": {"http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesScheduleofConcentrationRiskDetails", "lang": {"en-us": {"role": {"terseLabel": "Customer Concentration Risk", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": {"r79", "r211" } }, "rmb_CustomerDMember": {"xbrltype": "domainItemType", "nsuri": "http://www.rapidmicrobio.com/20240930", "localname": "CustomerDMember", "presentation": {"http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesScheduleofConcentrationRiskDetails", "lang": {"en-us": {"role": {"terseLabel": "Customer D", "label": "Customer D [Member]", "documentation": "Represents information pertaining to customer d." } } }, "auth_ref": [] }, "rmb_CustomerEMember": {"xbrltype": "domainItemType", "nsuri": "http://www.rapidmicrobio.com/20240930", "localname": "CustomerEMember", "presentation": {"http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesScheduleofConcentrationRiskDetails", "lang": {"en-us": {"role": {"terseLabel": "Customer E", "label": "Customer E [Member]", "documentation": "Represents information pertaining to customer e." } } }, "auth_ref": [] }, "rmb_CustomerFMember": {"xbrltype": "domainItemType", "nsuri": "http://www.rapidmicrobio.com/20240930", "localname": "CustomerFMember", "presentation": {"http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesScheduleofConcentrationRiskDetails", "lang": {"en-us": {"role": {"terseLabel": "Customer F", "label": "Customer F [Member]", "documentation": "Represents information pertaining to customer f." } } }, "auth_ref": [] }, "rmb_CustomerGMember": {"xbrltype": "domainItemType", "nsuri": "http://www.rapidmicrobio.com/20240930", "localname": "CustomerGMember", "presentation": {"http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesScheduleofConcentrationRiskDetails", "lang": {"en-us": {"role": {"terseLabel": "Customer G", "label": "Customer G [Member]", "documentation": "Customer G" } } }, "auth_ref": [] }, "rmb_CustomerHMember": {"xbrltype": "domainItemType", "nsuri": "http://www.rapidmicrobio.com/20240930", "localname": "CustomerHMember", "presentation": {"http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesScheduleofConcentrationRiskDetails", "lang": {"en-us": {"role": {"terseLabel": "Customer H", "label": "Customer H [Member]", "documentation": "Represents information pertaining to customer a." } } }, "auth_ref": [] }, "rmb_CustomerIMember": {"xbrltype": "domainItemType", "nsuri": "http://www.rapidmicrobio.com/20240930", "localname": "CustomerIMember", "presentation": {"http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesScheduleofConcentrationRiskDetails", "lang": {"en-us": {"role": {"terseLabel": "Customer I", "label": "Customer I [Member]", "documentation": "Customer I" } } }, "auth_ref": [] }, "country_DE": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "DE", "presentation": {"http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesScheduleofDisaggregatedRevenueDetails", "lang": {"en-us": {"role": {"terseLabel": "Germany", "label": "GERMANY" } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "crdr": "debit", "calculation": {"http://www.rapidmicrobio.com/role/InvestmentsDetails": {"parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": {"http://www.rapidmicrobio.com/role/InvestmentsDetails", "lang": {"en-us": {"role": {"totalLabel": "Amortized cost", "label": "Debt Securities Available for Sale, Amortized Cost, after Allowance for Credit Loss", "documentation": "Amortized cost, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": {"r906" } }, "us-gaap_DebtSecuritiesAvailableForSaleTable": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": {"http://www.rapidmicrobio.com/role/InvestmentsDetails", "lang": {"en-us": {"role": {"terseLabel": "Debt Securities, Available for sale [Table]", "label": "Debt Securities, Available for Sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)." } } }, "auth_ref": {"r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229" } }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "presentation": {"http://www.rapidmicrobio.com/role/InvestmentsTables", "lang": {"en-us": {"role": {"terseLabel": "Schedule of Investments", "label": "Debt Securities, Available for Sale [Table Text Block]", "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)." } } }, "auth_ref": {"r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918" } }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "presentation": {"http://www.rapidmicrobio.com/role/PrepaidexpensesandothercurrentassetsTables", "lang": {"en-us": {"role": {"terseLabel": "Schedule of Prepaid Expenses and Other Current Assets", "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet, and other deferred costs." } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanTextBlock", "presentation": {"http://www.rapidmicrobio.com/role/Benefitplans", "lang": {"en-us": {"role": {"terseLabel": "Benefit plans", "label": "Defined Benefit Plan [Text Block]", "documentation": "The entire disclosure for defined benefit plan." } } }, "auth_ref": {"r328", "r508", "r726" } }, "us-gaap_DefinedContributionPlanCostRecognized": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanCostRecognized", "crdr": "debit", "presentation": {"http://www.rapidmicrobio.com/role/BenefitplansDetails", "lang": {"en-us": {"role": {"terseLabel": "Company contributions to plan", "label": "Defined Contribution Plan, Cost", "documentation": "Amount of cost for defined contribution plan." } } }, "auth_ref": {"r336" } }, "us-gaap_DepositsAssetsCurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepositsAssetsCurrent", "crdr": "debit", "calculation": {"http://www.rapidmicrobio.com/role/PrepaidexpensesandothercurrentassetsDetails": {"parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": {"http://www.rapidmicrobio.com/role/PrepaidexpensesandothercurrentassetsDetails", "lang": {"en-us": {"role": {"terseLabel": "Deposits", "label": "Deposits Assets, Current", "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter." } } }, "auth_ref": {"r875" } }, "us-gaap_DepreciationDepletionAndAmortization": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": {"http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows": {"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": {"http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows", "lang": {"en-us": {"role": {"terseLabel": "Depreciation and amortization expense", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": {"r5", "r188", "r195", "r206", "r707", "r708" } }, "us-gaap_DisaggregationOfRevenueLineItems": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": {"http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesScheduleofDisaggregatedRevenueDetails", "lang": {"en-us": {"role": {"terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": {"r325", "r717", "r718", "r719", "r720", "r721", "r722", "r723" } }, "us-gaap_DisaggregationOfRevenueTable": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"DisaggregationOfRevenueTable", "presentation": {
"http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesScheduleofDisaggregatedRevenueDetails", "lang": { "en-us": {
"role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": { "r325", "r717", "r718", "r719", "r720", "r721", "r722", "r723" } }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": { "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesTables", "lang": { "en-us": { "role": { "terseLabel": "Schedule of Disaggregated Revenue", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": { "r938" } }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": { "http://www.rapidmicrobio.com/role/Stockbasedcompensation", "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": { "r338", "r342", "r373", "r374", "r376", "r728" } }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": { "r338", "r342", "r373", "r374", "r376", "r728" } }, "us-gaap_DividendsCommonStockCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsCommonStockCash", "crdr": "debit", "presentation": { "http://www.rapidmicrobio.com/role/CommonstockandcommonstockwarrantsNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Cash dividends", "label": "Dividends, Common Stock, Cash", "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash." } } }, "auth_ref": { "r85" } }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": { "http://www.rapidmicrobio.com/role/CoverPage", "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": { "r85" } }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": { "http://www.rapidmicrobio.com/role/CoverPage", "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": { "r85" } }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": { "http://www.rapidmicrobio.com/role/CoverPage", "lang": { "en-us": { "role": { "terseLabel": "Document Information [Line Items]", "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r85" } }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "presentation": { "http://www.rapidmicrobio.com/role/CoverPage", "lang": { "en-us": { "role": { "terseLabel": "Document Information [Table]", "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": { "r85" } }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": { "http://www.rapidmicrobio.com/role/CoverPage", "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": { "r85" } }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": { "http://www.rapidmicrobio.com/role/CoverPage", "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": { "r775" } }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": { "http://www.rapidmicrobio.com/role/CoverPage", "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": { "r807" } }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": { "http://www.rapidmicrobio.com/role/CoverPage", "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": { "r807" } }, "ecd_DvdsOrOthrErngsPdOnEqtyAwrdsNtOthrRsRfctdInThCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvdsOrOthrErngsPdOnEqtyAwrdsNtOthrRsRfctdInThCompForCvrdYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year", "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": { "r818" } }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": { "r818" } }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofoperations", "lang": { "en-us": { "role": { "terseLabel": "Net loss per share - basic (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": { "r150", "r166", "r167", "r168", "r169", "r170", "r171", "r178", "r181", "r182", "r183", "r187", "r404", "r407", "r420", "r421", "r545", "r561", "r701" } }, "us-gaap_EarningsPerShareBasicLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasicLineItems", "presentation": { "http://www.rapidmicrobio.com/role/NetlosspershareScheduleofBasicandDilutedNetLossperShareDetails", "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]", "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r178", "r179", "r181" } }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofoperations", "lang": { "en-us": { "role": { "terseLabel": "Net loss per share - diluted (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": { "r150", "r166", "r167", "r168", "r169", "r170", "r171", "r178", "r181", "r182", "r183", "r187", "r404", "r407", "r420", "r421", "r545", "r561", "r701" } }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": { "http://www.rapidmicrobio.com/role/NetlosspershareScheduleofBasicandDilutedNetLossperShareDetails", "lang": { "en-us": { "role": { "terseLabel": "Net loss per share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": { "r175", "r184", "r185", "r186" } }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.rapidmicrobio.com/role/AccruedexpenseandothercurrentliabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails", "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 }, "presentation": { "http://www.rapidmicrobio.com/role/AccruedexpenseandothercurrentliabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails", "lang": { "en-us": { "role": { "terseLabel": "Accrued employee compensation and benefits expense", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": { "r50" } }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofStockBasedCompensationExpenseDetails", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r50" } }, "us-

gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": ["http://www.rapidmicrobio.com/role/StockbasedcompensationNarrativeDetails", { "lang": { "en-us": { "role": { "terseLabel": "Weighted average recognition period", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } } }], "auth_ref": ["r375"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": ["http://www.rapidmicrobio.com/role/StockbasedcompensationNarrativeDetails", { "lang": { "en-us": { "role": { "terseLabel": "Unrecognized compensation expense related to units", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } } }], "auth_ref": ["r965"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": ["http://www.rapidmicrobio.com/role/StockbasedcompensationNarrativeDetails", { "lang": { "en-us": { "role": { "terseLabel": "Unrecognized compensation expense", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } } }], "auth_ref": ["r965"] }, "us-gaap_EmployeeStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockMember", "presentation": ["http://www.rapidmicrobio.com/role/NetlosspershareScheduleofAntiDilutiveSharesExcludedfromComputationofDilutedNetLetperShareDetails", "http://www.rapidmicrobio.com/role/StockbasedcompensationNarrativeDetails", "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofESPPBlackScholesOptionPricingModelDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", { "lang": { "en-us": { "role": { "verboseLabel": "Employee Stock", "terseLabel": "Options to purchase common stock under ESPP", "label": "Employee Stock [Member]", "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock." } } } }], "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://www.rapidmicrobio.com/role/NetlosspershareScheduleofAntiDilutiveSharesExcludedfromComputationofDilutedNetLetperShareDetails", "http://www.rapidmicrobio.com/role/StockbasedcompensationNarrativeDetails", "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofBlackScholesOptionPricingModelDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", { "lang": { "en-us": { "role": { "verboseLabel": "Share-Based Payment Arrangement, Option", "terseLabel": "Options to purchase common stock", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } } }], "auth_ref": [] }, "rmb_EmployeeStockPurchasePlan2021Member": { "xbrltype": "domainItemType", "nsuri": "http://www.rapidmicrobio.com/20240930", "localname": "EmployeeStockPurchasePlan2021Member", "presentation": ["http://www.rapidmicrobio.com/role/StockbasedcompensationNarrativeDetails", "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofESPPBlackScholesOptionPricingModelDetails", { "lang": { "en-us": { "role": { "terseLabel": "2021 ESPP", "label": "2021 Employee Stock Purchase Plan", "documentation": "Represents information relating to 2021 Employee Stock Purchase Plan." } } } }], "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://www.rapidmicrobio.com/role/CoverPage", { "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } } }], "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://www.rapidmicrobio.com/role/CoverPage", { "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } } }], "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://www.rapidmicrobio.com/role/CoverPage", { "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } } }], "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://www.rapidmicrobio.com/role/CoverPage", { "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province" } } } }], "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://www.rapidmicrobio.com/role/CoverPage", { "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } } }], "auth_ref": ["r773"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://www.rapidmicrobio.com/role/CoverPage", { "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } } }], "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://www.rapidmicrobio.com/role/CoverPage", { "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } } }], "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://www.rapidmicrobio.com/role/CoverPage", { "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } } }], "auth_ref": ["r773"] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": ["http://www.rapidmicrobio.com/role/CoverPage", { "lang": { "en-us": { "role": { "terseLabel": "Entity Ex Transition Period", "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } } }], "auth_ref": ["r858"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://www.rapidmicrobio.com/role/CoverPage", { "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } } }], "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://www.rapidmicrobio.com/role/CoverPage", { "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } } }], "auth_ref": ["r773"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://www.rapidmicrobio.com/role/CoverPage", { "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } } }], "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://www.rapidmicrobio.com/role/CoverPage", { "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } } }], "auth_ref": ["r857"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://www.rapidmicrobio.com/role/CoverPage", { "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } } }], "auth_ref": ["r773"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [

"http://www.rapidmicrobio.com/role/CoverPage", "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": { "r773" } }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": { "http://www.rapidmicrobio.com/role/CoverPage", "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } } }, "auth_ref": { "r773" } }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": { "http://www.rapidmicrobio.com/role/CoverPage", "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } } }, "auth_ref": { "r773" } }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Footnote", "label": "Equity Awards Adjustments, Footnote [Text Block]" } } } }, "auth_ref": { "r812" } }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } } }, "auth_ref": { "r853" } }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments [Member]", "label": "Equity Awards Adjustments [Member]" } } } }, "auth_ref": { "r853" } }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table", "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]" } } } }, "auth_ref": { "r853" } }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": { "http://www.rapidmicrobio.com/role/CondensedConsolidatedStatementsOfStockholderEquity", "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } } }, "auth_ref": { "r9", "r120", "r146", "r147", "r148", "r161", "r162", "r163", "r165", "r170", "r172", "r174", "r189", "r250", "r251", "r275", "r312", "r394", "r395", "r401", "r402", "r403", "r405", "r406", "r407", "r412", "r413", "r414", "r415", "r416", "r417", "r419", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r453", "r474", "r557", "r574", "r575", "r576", "r589", "r653" } }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } } }, "auth_ref": { "r822" } }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } } }, "auth_ref": { "r780", "r790", "r800", "r832" } }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } } }, "auth_ref": { "r777", "r787", "r797", "r829" } }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Executive Category", "label": "Executive Category [Axis]" } } } }, "auth_ref": { "r828" } }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": { "http://www.rapidmicrobio.com/role/FairValueOfFinancialAssetsAndLiabilitiesDetails", "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } }, "auth_ref": { "r423", "r424", "r434", "r733" } }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": { "http://www.rapidmicrobio.com/role/FairValueOfFinancialAssetsAndLiabilitiesDetails", "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } } }, "auth_ref": { "r423", "r424", "r434", "r733" } }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": { "http://www.rapidmicrobio.com/role/FairValueOfFinancialAssetsAndLiabilitiesDetails", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } } }, "auth_ref": { "r302", "r330", "r331", "r332", "r333", "r334", "r335", "r422", "r424", "r425", "r426", "r427", "r433", "r434", "r436", "r478", "r479", "r480", "r714", "r715", "r724", "r725", "r726", "r733", "r736" } }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": { "http://www.rapidmicrobio.com/role/FairValueOfFinancialAssetsAndLiabilitiesDetails", "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } } }, "auth_ref": { "r423", "r424", "r425", "r427", "r733", "r972", "r975" } }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } } }, "auth_ref": { "r423", "r424", "r425", "r427", "r733", "r972", "r975" } }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": { "http://www.rapidmicrobio.com/role/FairValueOfFinancialAssetsAndLiabilities", "lang": { "en-us": { "role": { "terseLabel": "Fair value of financial assets and liabilities", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected; (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } } }, "auth_ref": { "r429", "r431", "r432", "r433", "r436", "r437", "r438", "r439", "r440", "r542", "r733", "r737" } }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": { "http://www.rapidmicrobio.com/role/FairValueOfFinancialAssetsAndLiabilitiesDetails", "lang": { "en-us": { "role": { "terseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } } }, "auth_ref": { "r302", "r330", "r335", "r424", "r434", "r478", "r724", "r725", "r726", "r733" } }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": { "http://www.rapidmicrobio.com/role/FairValueOfFinancialAssetsAndLiabilitiesDetails", "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } } }, "auth_ref": { "r302", "r330", "r335", "r424", "r425", "r434", "r479", "r714", "r715", "r724", "r725", "r726", "r733" } }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": { "http://www.rapidmicrobio.com/role/FairValueOfFinancialAssetsAndLiabilitiesDetails", "lang": { "en-us": { "role": { "terseLabel": "Level 3", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } } }, "auth_ref": { "r302", "r330", "r331", "r332", "r333", "r334", "r335", "r424", "r425", "r426", "r427", "r434", "r480", "r714", "r715", "r724", "r725", "r726", "r733", "r736" } }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": {

"http://www.rapidmicrobio.com/role/FairvalueoffinancialassetsandliabilitiesDetails", "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": { "r423", "r424", "r425", "r427", "r733", "r972", "r975" } }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": { "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesPolicies", "lang": { "en-us": { "role": { "terseLabel": "Fair value measurements", "label": "Fair Value Measurement, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": { } }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": { "http://www.rapidmicrobio.com/role/FairvalueoffinancialassetsandliabilitiesDetails", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": { "r302", "r330", "r331", "r332", "r333", "r334", "r335", "r422", "r424", "r425", "r426", "r427", "r433", "r434", "r436", "r478", "r479", "r480", "r714", "r715", "r724", "r725", "r726", "r733", "r736" } }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": { "http://www.rapidmicrobio.com/role/FairvalueoffinancialassetsandliabilitiesDetails", "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": { "r733", "r969", "r970", "r971", "r972", "r973", "r975" } }, "rmb_FinanceLeaseDepreciationAndInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rapidmicrobio.com/20240930", "localname": "FinanceLeaseDepreciationAndInterestExpense", "crdr": "debit", "presentation": { "http://www.rapidmicrobio.com/role/LeasesNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Depreciation and interest expense", "label": "Finance Lease, Depreciation And Interest Expense", "documentation": "Total capital lease asset depreciation and interest expense during the period." } } }, "auth_ref": { } }, "rmb_FinanceLeaseInterestExpenseIncludingAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rapidmicrobio.com/20240930", "localname": "FinanceLeaseInterestExpenseIncludingAdjustments", "crdr": "debit", "calculation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofLeaseExpenseDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofLeaseExpenseDetails", "lang": { "en-us": { "role": { "terseLabel": "Financing lease cost - interest on lease liability", "label": "Finance Lease, Interest Expense, Including Adjustments", "documentation": "Finance Lease, Interest Expense, Including Adjustments" } } }, "auth_ref": { } }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseInterestPaymentOnLiability", "crdr": "credit", "presentation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofSupplementalCashFlowInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Operating cash outflows - payments on financing leases", "label": "Finance Lease, Interest Payment on Liability", "documentation": "Amount of interest paid on finance lease liability." } } }, "auth_ref": { "r459", "r467" } }, "us-gaap_FinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiability", "crdr": "credit", "calculation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofFinanceLeaseLiabilityMaturitiesDetails_1": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 }, "http://www.rapidmicrobio.com/role/LeasesScheduleofSupplementalBalanceSheetInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofFinanceLeaseLiabilityMaturitiesDetails", "http://www.rapidmicrobio.com/role/LeasesScheduleofSupplementalBalanceSheetInformationDetails", "lang": { "en-us": { "role": { "totalLabel": "Total financing lease liabilities", "verboseLabel": "Total present value of lease liabilities", "label": "Finance Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease." } } }, "auth_ref": { "r455", "r471" } }, "us-gaap_FinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofSupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofSupplementalBalanceSheetInformationDetails", "lang": { "en-us": { "role": { "verboseLabel": "Lease liabilities, short-term", "label": "Finance Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current." } } }, "auth_ref": { "r455" } }, "us-gaap_FinanceLeaseLiabilityCurrentStatementOffinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityCurrentStatementOffinancialPositionExtensibleList", "presentation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofSupplementalBalanceSheetInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes current finance lease liability." } } }, "auth_ref": { "r456" } }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "presentation": { "http://www.rapidmicrobio.com/role/LeasesTables", "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finance Lease Liability Maturities", "label": "Finance Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position." } } }, "auth_ref": { "r979" } }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofSupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofSupplementalBalanceSheetInformationDetails", "lang": { "en-us": { "role": { "verboseLabel": "Lease liabilities, long-term", "label": "Finance Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent." } } }, "auth_ref": { "r455" } }, "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOffinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityNoncurrentStatementOffinancialPositionExtensibleList", "presentation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofSupplementalBalanceSheetInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability." } } }, "auth_ref": { "r456" } }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofFinanceLeaseLiabilityMaturitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.rapidmicrobio.com/role/LeasesScheduleofFinanceLeaseLiabilityMaturitiesDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofFinanceLeaseLiabilityMaturitiesDetails", "lang": { "en-us": { "role": { "totalLabel": "Total lease payments", "label": "Finance Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease." } } }, "auth_ref": { "r471" } }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofFinanceLeaseLiabilityMaturitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofFinanceLeaseLiabilityMaturitiesDetails", "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Finance Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r471" } }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofFinanceLeaseLiabilityMaturitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofFinanceLeaseLiabilityMaturitiesDetails", "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Finance Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r471" } }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofFinanceLeaseLiabilityMaturitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofFinanceLeaseLiabilityMaturitiesDetails", "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Finance Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for

finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r471" } }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofFinanceLeaseLiabilityMaturitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofFinanceLeaseLiabilityMaturitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Finance Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r471" } }, "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofFinanceLeaseLiabilityMaturitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofFinanceLeaseLiabilityMaturitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "2024 (excluding the nine months ended September 30)", "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year." } } }, "auth_ref": { "r979" } }, "rmb_FinanceLeaseLiabilityToBePaidDueAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rapidmicrobio.com/20240930", "localname": "FinanceLeaseLiabilityToBePaidDueAfterYearFour", "crdr": "credit", "calculation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofFinanceLeaseLiabilityMaturitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofFinanceLeaseLiabilityMaturitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Finance Lease, Liability, To Be Paid, Due After Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r471" } }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofFinanceLeaseLiabilityMaturitiesDetails_1": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofFinanceLeaseLiabilityMaturitiesDetails": { "lang": { "en-us": { "role": { "negatedLabel": "Less imputed interest", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease." } } }, "auth_ref": { "r471" } }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "calculation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows": { "http://www.rapidmicrobio.com/role/LeasesScheduleofSupplementalCashFlowInformationDetails": { "lang": { "en-us": { "role": { "negatedLabel": "Payments on finance lease obligations", "terseLabel": "Financing cash outflows - payments on financing leases", "label": "Finance Lease, Principal Payments", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": { "r458", "r467" } }, "us-gaap_FinanceLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofSupplementalBalanceSheetInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofSupplementalBalanceSheetInformationDetails": { "lang": { "en-us": { "role": { "totalLabel": "Net property, plant and equipment", "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease." } } }, "auth_ref": { "r454" } }, "us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAssetAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofSupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_FinanceLeaseRightOfUseAsset", "weight": -1.0, "order": 1.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofSupplementalBalanceSheetInformationDetails": { "lang": { "en-us": { "role": { "negatedLabel": "Accumulated depreciation", "label": "Finance Lease, Right-of-Use Asset, Accumulated Amortization", "documentation": "Amount of accumulated amortization of right-of-use asset from finance lease." } } }, "auth_ref": { "r861", "r864" } }, "us-gaap_FinanceLeaseRightOfUseAssetAfterAccumulatedAmortizationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAssetAfterAccumulatedAmortizationAbstract", "presentation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofSupplementalBalanceSheetInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Financing Leases", "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization [Abstract]" } } }, "auth_ref": { "r458" } }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAssetAmortization", "crdr": "debit", "calculation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofLeaseExpenseDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofLeaseExpenseDetails": { "lang": { "en-us": { "role": { "terseLabel": "Financing lease cost - amortization of right-of-use asset", "label": "Finance Lease, Right-of-Use Asset, Amortization", "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease." } } }, "auth_ref": { "r457", "r464", "r743" } }, "us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization", "crdr": "debit", "calculation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofSupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_FinanceLeaseRightOfUseAsset", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofSupplementalBalanceSheetInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Office furniture and fixtures", "label": "Finance Lease, Right-of-Use Asset, before Accumulated Amortization", "documentation": "Amount, before accumulated amortization, of right-of-use asset from finance lease." } } }, "auth_ref": { "r860" } }, "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "presentation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofSupplementalBalanceSheetInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset." } } }, "auth_ref": { "r456" } }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "presentation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofSupplementalBalanceSheetInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Weighted average discount rate - financing leases", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for finance lease calculated at point in time." } } }, "auth_ref": { "r470", "r743" } }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "presentation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofSupplementalBalanceSheetInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining lease term - financing leases (in years)", "label": "Finance Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r469" } }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": { "http://www.rapidmicrobio.com/role/FairvalueoffinancialassetsandliabilitiesDetails": { "http://www.rapidmicrobio.com/role/InvestmentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": { "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r253", "r254", "r257", "r258", "r259", "r261", "r262", "r263", "r304", "r309", "r418", "r441", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r558", "r712", "r733", "r734", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r745", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r918", "r919", "r920", "r921", "r968", "r971", "r972", "r973", "r974", "r975" } } }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": { "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Amortization period of capitalized software costs", "label": "Finite-Lived Intangible Asset, Useful Life", "documentation": "Useful life of finite-lived

intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. } } } , "auth_ref": { } } , "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": { "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } } , "auth_ref": { "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r510", "r511", "r689" } } , "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": { "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } } , "auth_ref": { "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r689" } } , "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } } , "auth_ref": { "r784", "r794", "r804", "r836" } } , "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } } , "auth_ref": { "r784", "r794", "r804", "r836" } } , "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } } , "auth_ref": { "r784", "r794", "r804", "r836" } } , "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } } , "auth_ref": { "r784", "r794", "r804", "r836" } } , "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } } , "auth_ref": { "r784", "r794", "r804", "r836" } } , "rmb_FourteenJuly2021Member": { "xbrltype": "domainItemType", "nsuri": "http://www.rapidmicrobio.com/20240930", "localname": "FourteenJuly2021Member", "presentation": { "http://www.rapidmicrobio.com/role/CommonstockandcommonstockwarrantsScheduleofOutstandingCommonStockWarrantsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "July 14, 2021", "label": "July 14, 2021", "documentation": "Represents information pertaining to July 14 2021." } } } , "auth_ref": { } } , "ecd_FrValAsOfPrYrEndOfEqtyAwrdsGrntdInPrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrYrEndOfEqtyAwrdsGrntdInPrYrsFldVstngCondsDrngCvrdYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year", "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]" } } } , "auth_ref": { "r817" } } , "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FurnitureAndFixturesMember", "presentation": { "http://www.rapidmicrobio.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Office furniture and fixtures", "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } } , "auth_ref": { } } , "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofoperations": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 } } , "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofoperations": { "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } } , "auth_ref": { "r69", "r637" } } } , "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofStockBasedCompensationExpenseDetails": { "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } } , "auth_ref": { "r69" } } , "rmb_IncentiveAwardPlan2021Member": { "xbrltype": "domainItemType", "nsuri": "http://www.rapidmicrobio.com/20240930", "localname": "IncentiveAwardPlan2021Member", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofBlackScholesOptionPricingModelDetails": { "lang": { "en-us": { "role": { "terseLabel": "2021 Plan", "label": "2021 Incentive Award Plan", "documentation": "Represents information pertaining to 2021 Incentive award plan." } } } , "auth_ref": { } } } , "us-gaap_IncomeLossAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossAttributableToParent", "crdr": "credit", "calculation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofoperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } } , "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofoperations": { "lang": { "en-us": { "role": { "totalLabel": "Loss before income taxes", "label": "Income (Loss) Attributable to Parent, before Tax", "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments." } } } , "auth_ref": { "r68", "r148" } } } , "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } } , "auth_ref": { } } , "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofStockBasedCompensationExpenseDetails": { "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } } , "auth_ref": { "r276", "r277", "r280", "r428", "r430", "r435", "r571", "r573", "r638", "r689", "r735", "r995" } } } , "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofStockBasedCompensationExpenseDetails": { "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } } , "auth_ref": { "r277", "r280", "r428", "r430", "r435", "r571", "r573", "r638", "r689", "r735", "r995" } } } , "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } } , "auth_ref": { } } , "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": { "http://www.rapidmicrobio.com/role/Incometaxes": { "lang": { "en-us": { "role": { "terseLabel": "Income taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } } , "auth_ref": { "r160", "r386", "r388", "r389", "r390", "r391", "r392", "r393", "r396", "r398", "r399", "r400", "r588", "r732" } } } , "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofoperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } } , "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofoperations": { "lang": { "en-us": { "role": { "terseLabel": "Income tax expense", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } } , "auth_ref": { "r105", "r116", "r173", "r174", "r188", "r196", "r206", "r387", "r388", "r397", "r562", "r732" } } } , "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } } , "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows": { "lang":

```

http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": {
"http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows": { "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": { "r4" } }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "crdr": "debit", "calculation": {
"http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": {
"http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows": { "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current liabilities", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other." } } }, "auth_ref": { "r883" } }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "calculation": {
"http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": {
"http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows": { "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Increase (Decrease) in Contract with Customer Liability", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": { "r507", "r883" } }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": {
"http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": {
"http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows": { "lang": { "en-us": { "role": { "negatedLabel": "Inventory", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": { "r4" } }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": {
"http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows": { "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": { } }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "crdr": "credit", "calculation": {
"http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": {
"http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows": { "lang": { "en-us": { "role": { "negatedLabel": "Other long-term assets", "label": "Increase (Decrease) in Other Noncurrent Assets", "documentation": "Amount of increase (decrease) in noncurrent assets classified as other." } } }, "auth_ref": { "r883" } }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": {
"http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows": { "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other current assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": { "r4" } }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": {
"http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofstockholdersequity": { "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": { } }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": {
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Individual", "label": "Individual [Axis]" } } }, "auth_ref": { "r784", "r794", "r804", "r828", "r836", "r840", "r848" } }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": { "r846" } }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": { "r776", "r852" } }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProc", "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": { "r776", "r852" } }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": {
"http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProc", "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": { "r776", "r852" } }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeExpenseNonoperatingNet", "crdr": "credit", "calculation": {
"http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofoperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofoperations": { "lang": { "en-us": { "role": { "verboseLabel": "Interest income, net", "label": "Interest Income (Expense), Nonoperating", "documentation": "Amount of interest income (expense) classified as nonoperating." } } }, "auth_ref": { "r707", "r881", "r895" } }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": {
"http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows": { "lang": { "en-us": { "role": { "terseLabel": "Cash paid for interest", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": { "r153", "r155", "r156" } }, "us-gaap_InternalUseSoftwarePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InternalUseSoftwarePolicy", "presentation": {
"http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesPolicies": { "lang": { "en-us": { "role": { "terseLabel": "Software Development Costs", "label": "Internal Use Software, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs incurred when both (1) the software is acquired, internally developed, or modified solely to meet the entity's internal needs, and (2) during the software's development or modification, no substantive plan exists or is being developed to market the software externally." } } }, "auth_ref": { "r274" } }, "us-gaap_InventoryAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryAdjustments", "crdr": "credit", "presentation": { "http://www.rapidmicrobio.com/role/InventoryNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Inventory adjustments", "label": "Inventory Adjustments", "documentation": "Amount of inventory reserves for last in first out (LIFO) and other inventory valuation methods." } } }, "auth_ref": { "r36", "r874" } }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Inventory Disclosure [Abstract]", "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": { } }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureTextBlock", "presentation": {
"http://www.rapidmicrobio.com/role/Inventory": { "lang": { "en-us": { "role": { "terseLabel": "Inventory", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": { "r264" } }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": {
"http://www.rapidmicrobio.com/role/InventoryScheduleofInventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/InventoryScheduleofInventoryDetails": { "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": { "r81", "r697" } }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "http://www.rapidmicrobio.com/role/InventoryScheduleofInventoryDetails": { "parentTag": null, "weight": null, "order": null, "root":

```

true } }, "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets": { "http://www.rapidmicrobio.com/role/InventoryScheduleofInventoryDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Inventory", "totalLabel": "Total", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": { "r135", "r695", "r744" } }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "calculation": { "http://www.rapidmicrobio.com/role/InventoryScheduleofInventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/InventoryScheduleofInventoryDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Inventory, Raw Materials, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": { "r81", "r699" } }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://www.rapidmicrobio.com/role/InventoryScheduleofInventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/InventoryScheduleofInventoryDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Work in process", "label": "Inventory, Work in Process, Net of Reserves", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": { "r81", "r698" } }, "us-gaap_InventoryWriteDown": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWriteDown", "crdr": "debit", "calculation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "lang": { "en-us": { "role": { "terseLabel": "Provision for excess and obsolete inventory", "label": "Inventory Write-down", "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels." } } }, "auth_ref": { "r265" } }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "auth_ref": { } }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": { "http://www.rapidmicrobio.com/role/Investments": { "parentTag": "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "weight": 1.0, "order": 1.0 } }, "lang": { "en-us": { "role": { "terseLabel": "Investments", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "documentation": "The entire disclosure for investments in certain debt and equity securities." } } }, "auth_ref": { "r97", "r119", "r214", "r217", "r442", "r443", "r990" } }, "country_JP": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "JP", "presentation": { "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesScheduleofDisaggregatedRevenueDetails": { "parentTag": "us-gaap_Revenue", "weight": 1.0, "order": 1.0 } }, "lang": { "en-us": { "role": { "terseLabel": "Japan", "label": "JAPAN" } } }, "auth_ref": { } }, "rmb_July242017Member": { "xbrltype": "domainItemType", "nsuri": "http://www.rapidmicrobio.com/20240930", "localname": "July242017Member", "presentation": { "http://www.rapidmicrobio.com/role/CommonstockandcommonstockwarrantsScheduleofOutstandingCommonStockWarrantsDetails": { "parentTag": "us-gaap_CommonStock", "weight": 1.0, "order": 1.0 } }, "lang": { "en-us": { "role": { "terseLabel": "July 24, 2017", "label": "July 24, 2017", "documentation": "Represents the information pertaining to July 24, 2017." } } }, "auth_ref": { } }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofLeaseExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofLeaseExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "lang": { "en-us": { "role": { "totalLabel": "Total lease cost", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": { "r463", "r743" } }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": { "http://www.rapidmicrobio.com/role/LeasesTables": { "parentTag": "us-gaap_LeaseCostTableTextBlock", "weight": 1.0, "order": 1.0 } }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Supplemental Cash Flow Information and Lease Expense", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": { "r978" } }, "rmb_LeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rapidmicrobio.com/20240930", "localname": "LeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities, short-term", "label": "Lease, Liability, Current", "documentation": "Amount of operating and finance lease liability classified as current." } } }, "auth_ref": { } }, "rmb_LeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rapidmicrobio.com/20240930", "localname": "LeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 5.0 } }, "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities, long-term", "label": "Lease, Liability, Noncurrent", "documentation": "Amount of operating and finance lease liability classified as non current." } } }, "auth_ref": { } }, "rmb_LeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rapidmicrobio.com/20240930", "localname": "LeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets, net", "label": "Lease, Right-Of-Use Asset", "documentation": "Amount of operating and financing right of use (ROU) assets." } } }, "auth_ref": { } }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember", "presentation": { "http://www.rapidmicrobio.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentDetails": { "parentTag": "us-gaap_PropertyAndEquipment", "weight": 1.0, "order": 1.0 } }, "lang": { "en-us": { "role": { "terseLabel": "Leasehold improvements", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": { "r83", "r472" } }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Leases [Abstract]", "label": "Leases [Abstract]" } } }, "auth_ref": { } }, "rmb_LeasesNoncashExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rapidmicrobio.com/20240930", "localname": "LeasesNoncashExpense", "crdr": "debit", "calculation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "lang": { "en-us": { "role": { "terseLabel": "Noncash lease expense", "label": "Leases, Noncash Expense", "documentation": "Amount of noncash lease expense included in net income that result in no cash flow." } } }, "auth_ref": { } }, "rmb_LesseeFinanceLeaseNumberOfRenewalOptions": { "xbrltype": "integerItemType", "nsuri": "http://www.rapidmicrobio.com/20240930", "localname": "LesseeFinanceLeaseNumberOfRenewalOptions", "presentation": { "http://www.rapidmicrobio.com/role/LeasesNarrativeDetails": { "parentTag": "us-gaap_LesseeFinanceLeaseNumberOfRenewalOptions", "weight": 1.0, "order": 1.0 } }, "lang": { "en-us": { "role": { "terseLabel": "Lessee, Finance Lease, Number Of Renewal Options", "label": "Lessee, Finance Lease, Number Of Renewal Options" } } }, "auth_ref": { } }, "us-gaap_LesseeFinanceLeaseRenewalTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeFinanceLeaseRenewalTerm1", "presentation": { "http://www.rapidmicrobio.com/role/LeasesNarrativeDetails": { "parentTag": "us-gaap_LesseeFinanceLeaseRenewalTerm1", "weight": 1.0, "order": 1.0 } }, "lang": { "en-us": { "role": { "terseLabel": "Finance lease renewal term", "label": "Lessee, Finance Lease, Renewal Term", "documentation": "Term of lessee's finance lease renewal, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r977" } }, "us-gaap_LesseeFinanceLeaseTermOfContract1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeFinanceLeaseTermOfContract1", "presentation": { "http://www.rapidmicrobio.com/role/LeasesNarrativeDetails": { "parentTag": "us-gaap_LesseeFinanceLeaseTermOfContract1", "weight": 1.0, "order": 1.0 } }, "lang": { "en-us": { "role": { "terseLabel": "Finance lease term", "label": "Lessee, Finance Lease, Term of Contract", "documentation": "Term of lessee's finance lease, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r977" } }, "us-gaap_LesseeFinanceLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeFinanceLeasesTextBlock", "presentation": { "http://www.rapidmicrobio.com/role/Leases": { "parentTag": "us-gaap_LesseeFinanceLeasesTextBlock", "weight": 1.0, "order": 1.0 } }, "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Lease, Description [Table]", "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability." } } }, "auth_ref": { "r452" } }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionLineItems", "presentation": { "http://www.rapidmicrobio.com/role/LeasesNarrativeDetails": { "parentTag": "us-gaap_LesseeLeaseDescriptionLineItems", "weight": 1.0, "order": 1.0 } }, "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r462", "r473" } }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionTable", "presentation": { "http://www.rapidmicrobio.com/role/LeasesNarrativeDetails": { "parentTag": "us-gaap_LesseeLeaseDescriptionTable", "weight": 1.0, "order": 1.0 } }, "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Table]", "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": { "r462", "r473" } }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeasesPolicyTextBlock", "presentation": { "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesPolicies": { "parentTag": "us-gaap_SummaryOfSignificantAccountingPolicies", "weight": 1.0, "order": 1.0 } }, "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Leases" } } }, "auth_ref": { } } }

"Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } },
"auth_ref": { "r461" } }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": {
"http://www.rapidmicrobio.com/role/LeasesTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Operating Lease Liability Maturities",
"label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash
flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability
recognized in statement of financial position." } } }, "auth_ref": { "r979" } }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit",
"calculation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails": { "parentTag": null, "weight":
null, "order": null, "root": true }, "http://www.rapidmicrobio.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails_1": { "parentTag":
null, "weight": null, "order": null, "root": true }, "presentation": {
"http://www.rapidmicrobio.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails": { "lang": { "en-us": { "role": { "totalLabel": "Total
lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease
payment for operating lease." } } }, "auth_ref": { "r471" } }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
"crdr": "credit", "calculation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails": { "parentTag":
"us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": {
"http://www.rapidmicrobio.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails": { "lang": { "en-us": { "role": { "terseLabel":
"2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease
payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods
are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r471" } }, "us-
gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": {
"http://www.rapidmicrobio.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails": { "parentTag": "us-
gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": {
"http://www.rapidmicrobio.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails": { "lang": { "en-us": { "role": { "terseLabel":
"2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease
payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods
are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r471" } }, "us-
gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": {
"http://www.rapidmicrobio.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails": { "parentTag": "us-
gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": {
"http://www.rapidmicrobio.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails": { "lang": { "en-us": { "role": { "terseLabel":
"2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for
lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim
periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r471" } }, "us-
gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": {
"http://www.rapidmicrobio.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails": { "parentTag": "us-
gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": {
"http://www.rapidmicrobio.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails": { "lang": { "en-us": { "role": { "terseLabel":
"2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease
payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim
periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r471" } }, "us-
gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": {
"http://www.rapidmicrobio.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails": { "parentTag": "us-
gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": {
"http://www.rapidmicrobio.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "2024
(excluding the nine months ended September 30)", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
"documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in
excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": { "r979" } },
"rmb_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.rapidmicrobio.com/20240930", "localname": "LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour", "crdr": "credit",
"calculation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails": { "parentTag": "us-
gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": {
"http://www.rapidmicrobio.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails": { "lang": { "en-us": { "role": { "terseLabel":
"Thereafter", "label": "Lessee, Operating Lease, Liability, To Be Paid, Due After Year Four", "documentation": "Amount of lessee's undiscounted
obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods
when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { } }, "us-
gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": {
"http://www.rapidmicrobio.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails_1": { "parentTag": "us-
gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": {
"http://www.rapidmicrobio.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails": { "lang": { "en-us": { "role": { "negatedLabel":
"Less imputed interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's
undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": { "r471" } }
}, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LesseeOperatingLeaseTermOfContract", "presentation": { "http://www.rapidmicrobio.com/role/LeasesNarrativeDetails": { "lang": { "en-us": {
"role": { "terseLabel": "Operating lease term", "label": "Lessee, Operating Lease, Term of Contract", "documentation": "Term of lessee's operating
lease, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } },
"auth_ref": { "r977" } }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LesseeOperatingLeasesTextBlock", "presentation": { "http://www.rapidmicrobio.com/role/Leases": { "lang": { "en-us": { "role": {
"terseLabel": "Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee.
Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": { "r452" } }, "us-
gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit",
"calculation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets": { "parentTag": "us-
gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": {
"http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets": { "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label":
"Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to
others." } } }, "auth_ref": { "r14", "r49", "r50", "r51", "r52", "r53", "r54", "r55", "r159", "r249", "r294", "r295", "r296", "r297", "r298",
"r299", "r300", "r301", "r409", "r410", "r411", "r444", "r612", "r702", "r771", "r935", "r981", "r982" } }, "us-
gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets": {
"parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": {
"http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets": { "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and
stockholders'2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of
equity attributable to noncontrolling interests, if any." } } }, "auth_ref": { "r62", "r95", "r553", "r744", "r886", "r922", "r976" } }, "us-
gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LiabilitiesAndStockholdersEquityAbstract", "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets": { "lang":
{ "en-us": { "role": { "terseLabel": "Liabilities and Stockholders'2019 Equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": { } },
"us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr":
"credit", "calculation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets": { "parentTag": "us-gaap_Liabilities", "weight":
1.0, "order": 3.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets": { "lang": { "en-us": { "role": {
"totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations
that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": { "r51", "r123", "r159",
"r249", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r409", "r410", "r411", "r444", "r744", "r935", "r981", "r982" } }, "us-
gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract",

```

presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets": { "lang": { "en-us": { "role": { "terseLabel": "Current liabilities", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": { "dei LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": { "http://www.rapidmicrobio.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": { "rmb LongTermInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rapidmicrobio.com/20240930", "localname": "LongTermInvestmentsMember", "presentation": { "http://www.rapidmicrobio.com/role/FairvalueoffinancialassetsandliabilitiesDetails": { "http://www.rapidmicrobio.com/role/InvestmentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Long-term Investments", "label": "Long-Term Investments [Member]", "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to not sell or dispose of within one year from the date of the balance sheet." } } }, "auth_ref": { "srt MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": { "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesScheduleofConcentrationRiskDetails": { "lang": { "en-us": { "role": { "terseLabel": "Customer [Axis]", "label": "Customer [Axis]" } } }, "auth_ref": { "r211", "r719", "r755", "r759", "r938", "r994", "r996", "r997", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023" } }, "rmb MajorCustomersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rapidmicrobio.com/20240930", "localname": "MajorCustomersMember", "presentation": { "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesScheduleofConcentrationRiskDetails": { "lang": { "en-us": { "role": { "terseLabel": "Major Customers", "label": "Major Customers [Member]", "documentation": "Represents information pertaining to significant or major customers." } } }, "auth_ref": { "rmb ManufacturingAndLaboratoryEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rapidmicrobio.com/20240930", "localname": "ManufacturingAndLaboratoryEquipmentMember", "presentation": { "http://www.rapidmicrobio.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentDetails": { "lang": { "en-us": { "role": { "terseLabel": "Manufacturing and laboratory equipment", "label": "Manufacturing And Laboratory Equipment [Member]", "documentation": "Represents information pertaining to manufacturing and laboratory equipment." } } }, "auth_ref": { "srt MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": { "http://www.rapidmicrobio.com/role/LeasesNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": { "r288", "r289", "r290", "r291", "r337", "r382", "r427", "r506", "r570", "r572", "r580", "r604", "r605", "r656", "r658", "r660", "r661", "r663", "r685", "r686", "r711", "r716", "r727", "r736", "r737", "r741", "r742", "r756", "r937", "r983", "r984", "r985", "r986", "r987", "r988" } }, "ecd MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Measure", "label": "Measure [Axis]" } } }, "auth_ref": { "r820" } }, "ecd MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": { "r820" } }, "srt MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": { "http://www.rapidmicrobio.com/role/LeasesNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": { "r288", "r289", "r290", "r291", "r337", "r382", "r427", "r506", "r570", "r572", "r580", "r604", "r605", "r656", "r658", "r660", "r661", "r663", "r685", "r686", "r711", "r716", "r727", "r736", "r737", "r741", "r742", "r756", "r937", "r983", "r984", "r985", "r986", "r987", "r988" } }, "ecd MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": { "r839" } }, "us gaap MovementInStandardProductWarrantyAcerralRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MovementInStandardProductWarrantyAcerralRollForward", "presentation": { "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesScheduleofProductWarrantiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Movement in Standard Product Warranty Acerral [Roll Forward]", "label": "Movement in Standard Product Warranty Acerral [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": { "ecd MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": { "r847" } }, "srt NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": { "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesScheduleofConcentrationRiskDetails": { "lang": { "en-us": { "role": { "terseLabel": "Customer [Domain]", "label": "Customer [Domain]" } } }, "auth_ref": { "r211", "r719", "r755", "r759", "r938", "r994", "r996", "r997", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023" } }, "ecd NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": { "r821" } }, "us gaap NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows": { "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": { "r154" } }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows": { "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": { "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows": { "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": { "r154" } }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows": { "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": { "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows": { "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": { "r74", "r75", "r76" } }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows": { "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": { "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "cr
```

"http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofoperations",
"http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofstockholdersequity",
"http://www.rapidmicrobio.com/role/NetlosspersshareScheduleofBasicandDilutedNetLossperShareDetails",
"http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "totalLabel": "Net loss", "terseLabel": "Net loss", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": { "r68", "r76", "r96", "r121", "r141", "r144", "r148", "r159", "r164", "r166", "r167", "r168", "r169", "r170", "r173", "r174", "r180", "r249", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r404", "r407", "r421", "r444", "r556", "r634", "r651", "r652", "r770", "r935" } }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "presentation": { "http://www.rapidmicrobio.com/role/NetlosspersshareScheduleofBasicandDilutedNetLossperShareDetails", "lang": { "en-us": { "role": { "terseLabel": "Numerator", "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]" } } }, "auth_ref": { } }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": { "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesPolicies", "lang": { "en-us": { "role": { "terseLabel": "Recently issued accounting pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": { } }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": { "r920" } }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": { "r784", "r794", "r804", "r828", "r836" } }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": { "r811" } }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": { "r810" } }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": { "r828" } }, "rmb_NonRecurringContractWithCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rapidmicrobio.com/20240930", "localname": "NonRecurringContractWithCustomerMember", "presentation": { "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesScheduleofDisaggregatedRevenueDetails", "lang": { "en-us": { "role": { "terseLabel": "Product and service revenue in 2014 non-recurring", "label": "Non-Recurring Contract With Customer [Member]", "documentation": "Non-Recurring Contract With Customer" } } }, "auth_ref": { } }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": { "r847" } }, "ecd_NonRule10b51ArrTrmtdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmtdFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": { "r847" } }, "rmb_NoncashInvestingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.rapidmicrobio.com/20240930", "localname": "NoncashInvestingItemsAbstract", "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows", "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosure of non-cash investing activities", "label": "Noncash Investing Items [Abstract]", "documentation": "NA." } } }, "auth_ref": { } }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofoperations", "parentTag": "us-gaap_IncomeLossAttributableToParent", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofoperations", "lang": { "en-us": { "role": { "totalLabel": "Total other income, net", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": { "r70" } }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofoperations", "lang": { "en-us": { "role": { "terseLabel": "Other income (expense)", "label": "Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": { } }, "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationTables", "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restricted Stock Units Activity", "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares." } } }, "auth_ref": { "r13" } }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": { "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Number of operating segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": { "r708", "r894" } }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfReportableSegments", "presentation": { "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Number of reportable segments", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": { "r704", "r710", "r894" } }, "rmb_NumberOfVotesPerCommonStockShareHeld": { "xbrltype": "integerItemType", "nsuri": "http://www.rapidmicrobio.com/20240930", "localname": "NumberOfVotesPerCommonStockShareHeld", "presentation": { "http://www.rapidmicrobio.com/role/CommonstockandcommonstockwarrantsNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Number of votes per share held", "label": "Number Of Votes Per Common Stock Share Held", "documentation": "Number of votes each common stock holder is entitled to vote." } } }, "auth_ref": { } }, "us-gaap_OperatingCostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingCostsAndExpensesAbstract", "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofoperations", "lang": { "en-us": { "role": { "terseLabel": "Costs and operating expenses", "label": "Operating Costs and Expenses [Abstract]" } } }, "auth_ref": { } }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofoperations", "parentTag": "us-gaap_IncomeLossAttributableToParent", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofoperations", "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": { "r100", "r703", "r893", "r895", "r896", "r897", "r898" } }, "us-gaap_OperatingIncomeLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLossAbstract", "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofoperations", "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Operating Income (Loss) [Abstract]" } } }, "auth_ref": { } }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofLeaseExpenseDetails", "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofLeaseExpenseDetails", "lang": { "en-us": { "role": { "terseLabel": "Operating lease cost", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": { "r465", "r743" } }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofSupplementalBalanceSheetInformationDetails", "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofSupplementalBalanceSheetInformationDetails", "lang": { "en-us": { "role": { "totalLabel": "Total operating lease liabilities", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease

payments from operating lease." } } }, "auth_ref": { "r455" } }, "us-gaap_OperatingLeaseLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityAbstract", "presentation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofSupplementalBalanceSheetInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Operating Leases", "label": "Operating Lease, Liability [Abstract]" } } }, "auth_ref": { } }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofSupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofSupplementalBalanceSheetInformationDetails" }, "lang": { "en-us": { "role": { "verboseLabel": "Operating lease liabilities, short-term", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": { "r455" } }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "presentation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofSupplementalBalanceSheetInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes current operating lease liability." } } }, "auth_ref": { "r456" } }, "rmb_OperatingLeaseLiabilityIncludingTenantImprovementAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rapidmicrobio.com/20240930", "localname": "OperatingLeaseLiabilityIncludingTenantImprovementAllowance", "crdr": "credit", "calculation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofOperatingLeaseLiabilityMaturitiesDetails" }, "lang": { "en-us": { "role": { "verboseLabel": "Total present value of lease liabilities", "label": "Operating Lease, Liability, Including Tenant Improvement Allowance", "documentation": "Operating Lease, Liability, Including Tenant Improvement Allowance" } } }, "auth_ref": { } }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofSupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofSupplementalBalanceSheetInformationDetails" }, "lang": { "en-us": { "role": { "verboseLabel": "Operating lease liabilities, long-term", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": { "r455" } }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "presentation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofSupplementalBalanceSheetInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability." } } }, "auth_ref": { "r456" } }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofSupplementalCashFlowInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Operating cash outflows – payments on operating leases", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": { "r460", "r467" } }, "rmb_OperatingLeaseRentalExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rapidmicrobio.com/20240930", "localname": "OperatingLeaseRentalExpense", "crdr": "debit", "presentation": { "http://www.rapidmicrobio.com/role/LeasesNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Rent expense", "label": "Operating Lease, Rental Expense", "documentation": "Total rental expense under operating leases." } } }, "auth_ref": { } }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofSupplementalBalanceSheetInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Operating lease assets", "label": "Operating Lease, Right of Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": { "r454" } }, "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "presentation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofSupplementalBalanceSheetInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Right of Use Asset, Statement of Financial Position [Extensible Enumeration]", "label": "Operating Lease, Right of Use Asset, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset." } } }, "auth_ref": { "r456" } }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofSupplementalBalanceSheetInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Weighted average discount rate – operating leases", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": { "r470", "r743" } }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofSupplementalBalanceSheetInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Weighted-average remaining lease term – operating leases (in years)", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r469", "r743" } }, "rmb_OperationalEfficiencyProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rapidmicrobio.com/20240930", "localname": "OperationalEfficiencyProgramMember", "presentation": { "http://www.rapidmicrobio.com/role/AccruedexpensesandothercurrentliabilitiesNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Operational Efficiency Program", "label": "Operational Efficiency Program [Member]", "documentation": "Operational Efficiency Program" } } }, "auth_ref": { } }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": { } }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.rapidmicrobio.com/role/AccruedexpenseandothercurrentliabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/AccruedexpenseandothercurrentliabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r50" } }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.rapidmicrobio.com/role/PrepaidexpensesandothercurrentassetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/PrepaidexpensesandothercurrentassetsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Other Assets, Current", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": { "r136", "r744" } }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets" }, "lang": { "en-us": { "role": { "terseLabel": "Other long-term assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": { "r128" } }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcomprehensiveloss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcomprehensiveloss" }, "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain on investments, net of tax", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax", "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available for sale." } } }, "auth_ref": { "r138", "r139", "r140", "r557" } }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofstockholdersequity" }, "lang": { "en-us": { "role": { "verboseLabel": "Other

comprehensive income (loss)", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": { "r3", "r8", "r89", "r142", "r145", "r170" } }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcomprehensiveincome": { "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss)", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]" } } }, "auth_ref": { "r3", "r8", "r89", "r142", "r145", "r170" } }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets": { "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r53" } }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "calculation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Other", "label": "Other Noncash Income (Expense)", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": { "r76" } }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofoperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofoperations": { "lang": { "en-us": { "role": { "terseLabel": "Other expense, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": { "r71" } }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": { "r820" } }, "us-gaap_OtherReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherReceivablesNetCurrent", "crdr": "debit", "calculation": { "http://www.rapidmicrobio.com/role/PrepaidexpensesandothercurrentassetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/PrepaidexpensesandothercurrentassetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Other receivables", "label": "Other Receivables, Net, Current", "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer." } } }, "auth_ref": { "r820" } }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": { "r782", "r792", "r802", "r834" } }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": { "r785", "r795", "r805", "r837" } }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": { "r785", "r795", "r805", "r837" } }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": { "r809" } }, "us-gaap_PaymentsForRestructuring": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRestructuring", "crdr": "credit", "presentation": { "http://www.rapidmicrobio.com/role/AccruedexpensesandothercurrentliabilitiesNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Payments for restructuring", "label": "Payments for Restructuring", "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation." } } }, "auth_ref": { "r279", "r882" } }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "crdr": "credit", "calculation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows": { "lang": { "en-us": { "role": { "negatedLabel": "Purchases of investments", "label": "Payments to Acquire Debt Securities, Available for Sale", "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)." } } }, "auth_ref": { "r20", "r151", "r215" } }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows": { "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": { "r73" } }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": { "r819" } }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": { "r819" } }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": { "r811" } }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": { "r828" } }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": { "r821" } }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": { "r810" } }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationNarrativeDetails": { "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofBlackScholesOptionPricingModelDetails": { "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofFESPPBlackScholesOptionPricingModelDetails": { "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Axis]", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": { "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964" } }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationNarrativeDetails": { "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofBlackScholesOptionPricingModelDetails": { "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofFESPPBlackScholesOptionPricingModelDetails": { "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Domain]", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": { "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964" } }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Prior Service Cost", "label": "Pension Adjustments Prior Service Cost [Member]" } } }, "auth_ref": { "r812" } }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Service Cost", "label": "Pension Adjustments Service Cost [Member]" } } }, "auth_ref": { "r856" } }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Pension Benefits Adjustments, Footnote", "label": "Pension Benefits Adjustments, Footnote [Text Block]" } } }, "auth_ref": { "r811" } }, "us-

gaap-PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": {
"http://www.rapidmicrobio.com/role/CondensedconsolidatedbalancesheetsParentetical" }, "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": { "r56", "r305" } }, "us-gaap-PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": { "http://www.rapidmicrobio.com/role/CondensedconsolidatedbalancesheetsParentetical" }, "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": { "r56", "r614" } }, "us-gaap-PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": { "http://www.rapidmicrobio.com/role/CondensedconsolidatedbalancesheetsParentetical" }, "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": { "r56", "r305" } }, "us-gaap-PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": { "http://www.rapidmicrobio.com/role/CondensedconsolidatedbalancesheetsParentetical" }, "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, outstanding (in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": { "r56", "r614", "r632", "r1026", "r1027" } }, "us-gaap-PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets": { "parentTag": "us-gaap-StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets": { "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, \$0.01 par value: 10,000,000 shares authorized at Septemberu00a030, 2024 and Decemberu00a031, 2023; zero shares issued and outstanding at Septemberu00a030, 2024 and Decemberu00a031, 2023; Preferred Stock, Value, Issued", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": { "r56", "r549", "r744" } }, "us-gaap-PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets": { "parentTag": "us-gaap-AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "http://www.rapidmicrobio.com/role/PrepaidexpensesandothercurrentassetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets": { "http://www.rapidmicrobio.com/role/PrepaidexpensesandothercurrentassetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r876" } }, "us-gaap-PrepaidExpenseAndOtherAssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract", "lang": { "en-us": { "role": { "terseLabel": "Prepaid Expense and Other Assets, Current [Abstract]", "label": "Prepaid Expense and Other Assets, Current [Abstract]" } } }, "auth_ref": { } }, "rmb-PrepaidExpensesAndOtherAssetsCurrentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.rapidmicrobio.com/20240930", "localname": "PrepaidExpensesAndOtherAssetsCurrentTextBlock", "presentation": { "http://www.rapidmicrobio.com/role/Prepaidexpensesandothercurrentassets": { "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expenses And Other Assets, Current [Text Block]", "documentation": "The entire disclosure for prepaid expenses and other current assets as of the balance sheet date." } } }, "auth_ref": { } }, "rmb-PrepaidFinancingFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rapidmicrobio.com/20240930", "localname": "PrepaidFinancingFees", "crdr": "debit", "calculation": { "http://www.rapidmicrobio.com/role/PrepaidexpensesandothercurrentassetsDetails": { "parentTag": "us-gaap-PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/PrepaidexpensesandothercurrentassetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Prepaid financing fees", "label": "Prepaid Financing Fees", "documentation": "Prepaid Financing Fees" } } }, "auth_ref": { } }, "us-gaap-PrepaidInsurance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidInsurance", "crdr": "debit", "calculation": { "http://www.rapidmicrobio.com/role/PrepaidexpensesandothercurrentassetsDetails": { "parentTag": "us-gaap-PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/PrepaidexpensesandothercurrentassetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Prepaid insurance", "label": "Prepaid Insurance", "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r696", "r713", "r923" } }, "us-gaap-ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "crdr": "debit", "calculation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows": { "parentTag": "us-gaap-NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows": { "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of Class A common stock - stock option exercise", "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised", "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised." } } }, "auth_ref": { "r2", "r12" } }, "us-gaap-ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "crdr": "debit", "calculation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows": { "parentTag": "us-gaap-NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows": { "lang": { "en-us": { "role": { "terseLabel": "Maturity of investments", "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available for Sale", "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)." } } }, "auth_ref": { "r151", "r152", "r905" } }, "us-gaap-ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "crdr": "debit", "calculation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows": { "parentTag": "us-gaap-NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows": { "lang": { "en-us": { "role": { "terseLabel": "Sale of investments", "label": "Proceeds from Sale of Debt Securities, Available for Sale", "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)." } } }, "auth_ref": { "r19", "r151", "r215", "r248" } }, "us-gaap-ProceedsFromStockPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockPlans", "crdr": "debit", "calculation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows": { "parentTag": "us-gaap-NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows": { "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of Class A common stock - employee stock purchase plan", "label": "Proceeds from Stock Plans", "documentation": "The cash inflow associated with the amount received from the stock plan during the period." } } }, "auth_ref": { "r2" } }, "rmb-ProductAndServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rapidmicrobio.com/20240930", "localname": "ProductAndServiceMember", "presentation": { "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesScheduleofDisaggregatedRevenueDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Product and Service Revenue", "label": "Product And Service [Member]", "documentation": "Product And Service" } } }, "auth_ref": { } }, "us-gaap-ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductMember", "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofoperations": { "lang": { "en-us": { "role": { "terseLabel": "Product", "label": "Product [Member]", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": { "r717" } }, "rmt-ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/rst/2024", "localname": "ProductOrServiceAxis", "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofoperations": { "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": { "r208", "r509", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r691", "r717", "r754", "r756", "r757", "r760", "r761", "r928", "r929", "r938", "r944", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015",

"r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023" } }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofoperations", "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesScheduleofDisaggregatedRevenueDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": { "r208", "r509", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r691", "r717", "r754", "r756", "r757", "r760", "r761", "r928", "r929", "r938", "r994", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023" } }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Abstract]", "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": { } }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": { "http://www.rapidmicrobio.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": { "r6", "r472" } }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": { "http://www.rapidmicrobio.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": { "r82", "r111", "r114", "r115" } }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.rapidmicrobio.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Property plant and equipment, gross", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": { "r83", "r126", "r555" } }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": { "http://www.rapidmicrobio.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r472" } }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://www.rapidmicrobio.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets" } }, "http://www.rapidmicrobio.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "totalLabel": "Property plant and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": { "r6", "r472", "r546", "r555", "r744" } }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": { "http://www.rapidmicrobio.com/role/PropertyandequipmentnetTables" } }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Property and Equipment", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation." } } }, "auth_ref": { "r6" } }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": { "http://www.rapidmicrobio.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": { "r83", "r472" } }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } }, "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": { "r809" } }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } }, "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": { "r809" } }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": { "http://www.rapidmicrobio.com/role/LeasesNarrativeDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": { "r288", "r289", "r290", "r291", "r329", "r337", "r368", "r369", "r370", "r382", "r427", "r481", "r490", "r506", "r570", "r572", "r580", "r604", "r605", "r656", "r658", "r660", "r661", "r663", "r685", "r686", "r711", "r716", "r727", "r736", "r737", "r741", "r742", "r756", "r764", "r925", "r937", "r972", "r984", "r985", "r986", "r987", "r988" } }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": { "http://www.rapidmicrobio.com/role/LeasesNarrativeDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": { "r288", "r289", "r290", "r291", "r329", "r337", "r368", "r369", "r370", "r382", "r427", "r481", "r490", "r506", "r570", "r572", "r580", "r604", "r605", "r656", "r658", "r660", "r661", "r663", "r685", "r686", "r711", "r716", "r727", "r736", "r737", "r741", "r742", "r756", "r764", "r925", "r937", "r972", "r984", "r985", "r986", "r987", "r988" } }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": { "r777", "r787", "r797", "r829" } }, "rmb_RecurringContractWithCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rapidmicrobio.com/20240930", "localname": "RecurringContractWithCustomerMember", "presentation": { "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesScheduleofDisaggregatedRevenueDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Product and service revenue in 2014 recurring", "label": "Recurring Contract With Customer [Member]", "documentation": "Recurring Contract With Customer" } } }, "auth_ref": { } }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofoperations": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofoperations" } }, "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": { "r385", "r689", "r707", "r989" } }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofStockBasedCompensationExpenseDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": { } }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" } }, "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": { "r778", "r788", "r798", "r830" } }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" } }, "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": { "r779", "r789", "r799", "r831" } }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" } }, "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": { "r786", "r796", "r806", "r838" } }, "us-gaap_RestrictedCashNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashNoncurrent", "crdr": "debit", "calculation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets": {

"parentTag": "us-gaap-Assets", "weight": 1.0, "order": 5.0 } }, "presentation": {
"http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets",
"http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel":
"Restricted cash", "verboseLabel": "Guaranteed investment certificates", "label": "Restricted Cash, Noncurrent", "documentation": "Amount of cash
restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks
or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": { "r106", "r873", "r884" } }, "us-
gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockMember",
"presentation": {
"http://www.rapidmicrobio.com/role/NetlosspersshareScheduleofAntiDilutiveSharesExcludedfromComputationofDilutedNetLetperShareDetails" },
"lang": { "en-us": { "role": { "terseLabel": "Unvested restricted common stock", "label": "Restricted Stock [Member]", "documentation": "Stock
including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance
conditions are met." } } }, "auth_ref": { "r27" } }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": {
"http://www.rapidmicrobio.com/role/StockbasedcompensationNarrativeDetails",
"http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofRestrictedStockUnitsActivityDetails",
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Units (RSUs)", "label":
"Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash,
after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": { } }, "us-
gaap_RestructuringAndRelatedCostExpectedCostRemaining1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "RestructuringAndRelatedCostExpectedCostRemaining1", "crdr": "debit", "presentation": {
"http://www.rapidmicrobio.com/role/AccruedexpensesandothercurrentliabilitiesNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel":
"Remaining restructuring payments", "label": "Restructuring and Related Cost, Expected Cost Remaining", "documentation": "Amount of expected
cost remaining for the specified restructuring cost." } } }, "auth_ref": { } }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCharges", "crdr": "debit", "presentation": {
"http://www.rapidmicrobio.com/role/AccruedexpensesandothercurrentliabilitiesNarrativeDetails" }, "lang": { "en-us": { "role": { "verboseLabel":
"Restructuring related charges", "label": "Restructuring Charges", "documentation": "Amount of expenses associated with exit or disposal activities
pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": { "r5",
"r282", "r283", "r296" } }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "RestructuringCostAndReserveLineItems", "presentation": {
"http://www.rapidmicrobio.com/role/AccruedexpensesandothercurrentliabilitiesNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel":
"Restructuring Cost and Reserve [Line Items]", "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent
financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one
or many axes to the table." } } }, "auth_ref": { "r278", "r279", "r280", "r281", "r283", "r284", "r285" } }, "us-gaap_RestructuringPlanAxis": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringPlanAxis", "presentation": {
"http://www.rapidmicrobio.com/role/AccruedexpensesandothercurrentliabilitiesNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel":
"Restructuring Plan [Axis]", "label": "Restructuring Plan [Axis]", "documentation": "Information by individual restructuring plan." } } }, "auth_ref":
{ } }, "us-gaap_RestructuringPlanDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RestructuringPlanDomain", "presentation": { "http://www.rapidmicrobio.com/role/AccruedexpensesandothercurrentliabilitiesNarrativeDetails" },
"lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Domain]", "label": "Restructuring Plan [Domain]", "documentation": "Identification
of the individual restructuring plans." } } }, "auth_ref": { } }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": {
"http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order":
3.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets" }, "lang": { "en-us": { "role": { "terseLabel":
"Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings
(deficit)." } } }, "auth_ref": { "r59", "r85", "r552", "r577", "r579", "r587", "r615", "r744" } }, "us-gaap_RetainedEarningsMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": {
"http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofstockholdersequity" }, "lang": { "en-us": { "role": { "terseLabel":
"Accumulated deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref":
{ "r120", "r161", "r162", "r163", "r165", "r170", "r172", "r174", "r250", "r251", "r275", "r394", "r395", "r401", "r402", "r403", "r405", "r406",
"r407", "r412", "r414", "r415", "r417", "r419", "r451", "r453", "r574", "r576", "r589" } }, "us-
gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": {
"http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofoperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight":
1.0, "order": 1.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofoperations",
"http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesScheduleofDisaggregatedRevenueDetails" }, "lang": { "en-us": { "role": { "verboseLabel": "Total revenue", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount,
excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to
customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-
producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": { "r98", "r99", "r188", "r193", "r194",
"r204", "r206", "r208", "r209", "r211", "r324", "r325", "r509" } }, "us-gaap_RevenueFromContractWithCustomerMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerMember", "presentation": {
"http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesScheduleofConcentrationRiskDetails" }, "lang": { "en-us": { "role": { "terseLabel":
"Revenue Benchmark", "label": "Revenue from Contract with Customer Benchmark [Member]", "documentation": "Revenue from
satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of
risk calculation." } } }, "auth_ref": { "r211", "r862" } }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": {
"http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesPolicies" }, "lang": { "en-us": { "role": { "terseLabel": "Revenue
recognition", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue
from contract with customer." } } }, "auth_ref": { "r117", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r690" } },
"rmb_RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://www.rapidmicrobio.com/20240930", "localname": "RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract", "presentation": {
"http://www.rapidmicrobio.com/role/LeasesScheduleofSupplementalCashFlowInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel":
"Right-of-use assets obtained in exchange for new lease obligations", "label": "Right-Of-Use Asset Obtained In Exchange For Lease Liability
[Abstract]", "documentation": "Right-Of-Use Asset Obtained In Exchange For Lease Liability" } } }, "auth_ref": { } }, "us-
gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": {
"http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows",
"http://www.rapidmicrobio.com/role/LeasesScheduleofSupplementalCashFlowInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel":
"Obtaining a right of operating assets in exchange for lease liability", "verboseLabel": "Investing non-cash activities - establishment of right of use
operating assets", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-
of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": { "r468", "r743" } }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype":
"booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": {
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted",
"label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": { "r847" } }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": {
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated",
"label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": { "r847" } }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
"presentation": { "http://www.rapidmicrobio.com/role/AccruedexpensesandothercurrentliabilitiesTables" }, "lang": { "en-us": { "role": { "terseLabel":
"Schedule of Accrued Expenses and Other Current Liabilities", "label": "Schedule of Accrued Liabilities [Table Text Block]",
"documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": { } }, "us-
gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
"presentation": {
"http://www.rapidmicrobio.com/role/NetlosspersshareScheduleofAntiDilutiveSharesExcludedfromComputationofDilutedNetLetperShareDetails" },
"lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label":
"Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute
basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": { "r27" } }, "us-
gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri":

"http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": { "http://www.rapidmicrobio.com/role/NetLossperShareTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Anti-Dilutive Shares Excluded from Computation of Diluted Net Let per Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": { "r27" } }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": { "http://www.rapidmicrobio.com/role/InvestmentsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available for sale [Line Items]", "label": "Debt Securities, Available for Sale [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229" } }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": { "http://www.rapidmicrobio.com/role/NetLossperShareTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Basic and Diluted Net Loss per Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": { "r892" } }, "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable", "presentation": { "http://www.rapidmicrobio.com/role/NetLossperShareScheduleofBasicandDilutedNetLossperShareDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]", "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]", "documentation": "Disclosure of information about basic earnings per share by class of stock. Includes, but is not limited to, two-class method." } } }, "auth_ref": { "r26", "r28", "r178", "r179", "r181" } }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofStockBasedCompensationExpenseDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": { "r41" } }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock-Based Compensation Expense", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": { "r41" } }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": { "http://www.rapidmicrobio.com/role/FairvalueoffinancialassetsandliabilitiesTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Assets and Liabilities Measured on a Recurring Basis", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": { "r969", "r970" } }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": { "http://www.rapidmicrobio.com/role/InventoryTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Inventory", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": { "r15", "r63", "r64", "r65" } }, "us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfProductWarrantyLiabilityTableTextBlock", "presentation": { "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Product Warranties", "label": "Schedule of Product Warranty Liability [Table Text Block]", "documentation": "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability." } } }, "auth_ref": { "r292" } }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": { "http://www.rapidmicrobio.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation." } } }, "auth_ref": { "r6", "r472" } }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": { "http://www.rapidmicrobio.com/role/AccruedexpensesandothercurrentliabilitiesNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Restructuring Cost [Table]", "label": "Restructuring Cost [Table]", "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve." } } }, "auth_ref": { "r278", "r279", "r280", "r281", "r283", "r284", "r285" } }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofBlackScholesOptionPricingModelDetails", "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofESPPBlackScholesOptionPricingModelDetails", "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofRestrictedStockUnitsActivityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": { "r339", "r341", "r343", "r344", "r345", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r367", "r368", "r369", "r370", "r371" } }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock Option Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": { "r10", "r11", "r86" } }, "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of ESPP Black-Scholes Option-Pricing Model", "label": "Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": { "r88" } }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of

Black-Scholes Option Pricing Model", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": { "r88" } }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": { "http://www.rapidmicrobio.com/role/CommonstockandcommonstockwarrantsTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Outstanding Common Stock Warrants", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": { "r39" } }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "presentation": { "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Concentration Risk", "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]", "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark." } } }, "auth_ref": { "r29", "r30", "r31", "r32", "r44", "r90" } }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": { "http://www.rapidmicrobio.com/role/CoverPage" }, "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": { "r772" } }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": { "http://www.rapidmicrobio.com/role/CoverPage" }, "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": { "r774" } }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": { "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesScheduleofDisaggregatedRevenueDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]" } } }, "auth_ref": { "r209", "r210", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r601", "r602", "r603", "r657", "r659", "r662", "r664", "r673", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r692", "r718", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r758", "r764", "r938", "r994", "r996", "r997", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023" } }, "us-gaap_SegmentReportingPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingPolicyTextBlock", "presentation": { "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesPolicies" }, "lang": { "en-us": { "role": { "terseLabel": "Segment information", "label": "Segment Reporting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": { "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r207", "r209", "r705", "r706", "r709" } }, "us-gaap_SellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingAndMarketingExpense", "crdr": "debit", "calculation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofoperations": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofoperations" }, "lang": { "en-us": { "role": { "terseLabel": "Sales and marketing", "label": "Selling and Marketing Expense", "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services." } } }, "auth_ref": { } }, "us-gaap_SellingAndMarketingExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingAndMarketingExpenseMember", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofStockBasedCompensationExpenseDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Sales and marketing", "label": "Selling and Marketing Expense [Member]", "documentation": "Primary financial statement caption encompassing selling and marketing expense." } } }, "auth_ref": { "r69" } }, "us-gaap_ServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ServiceMember", "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofoperations" }, "lang": { "en-us": { "role": { "terseLabel": "Service", "label": "Service [Member]", "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service." } } }, "auth_ref": { "r717" } }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows" }, "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": { "r4" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Vesting period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": { "r728" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofRestrictedStockUnitsActivityDetails" }, "lang": { "en-us": { "role": { "negatedLabel": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": { "r360" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofRestrictedStockUnitsActivityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Forfeited (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": { "r360" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationNarrativeDetails" }, "lang": { "en-us": { "role": { "verboseLabel": "Units granted (in shares)", "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": { "r358" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationNarrativeDetails" }, "lang": { "en-us": { "role": { "verboseLabel": "Weighted average grant date fair value per share of units granted (in dollars per share)", "terseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation

rights plan, performance target plan." } } }, "auth_ref": { "r358" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofRestrictedStockUnitsActivityDetails" }, "lang": { "en-us": { "role": { "periodStartLabel": "Unvested units at beginning of period (in shares)", "periodEndLabel": "Unvested units at end of period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": { "r355", "r356" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofRestrictedStockUnitsActivityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Number of shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": { } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofRestrictedStockUnitsActivityDetails" }, "lang": { "en-us": { "role": { "periodStartLabel": "Unvested units at beginning of period (in dollars per share)", "periodEndLabel": "Unvested units at end of period (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": { "r355", "r356" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofRestrictedStockUnitsActivityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Weighted average fair value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": { "r359" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofRestrictedStockUnitsActivityDetails" }, "lang": { "en-us": { "role": { "negatedLabel": "Vested (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": { "r359" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofRestrictedStockUnitsActivityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Vested (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": { "r359" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofBlackScholesOptionPricingModelDetails", "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofESPPBlackScholesOptionPricingModelDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Expected dividend yield", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": { "r369" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofBlackScholesOptionPricingModelDetails", "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofESPPBlackScholesOptionPricingModelDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Expected volatility", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": { "r368" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofBlackScholesOptionPricingModelDetails", "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofESPPBlackScholesOptionPricingModelDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Risk free interest rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": { "r370" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationNarrativeDetails", "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofBlackScholesOptionPricingModelDetails", "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofESPPBlackScholesOptionPricingModelDetails", "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofRestrictedStockUnitsActivityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r339", "r341", "r343", "r344", "r345", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r367", "r368", "r369", "r370", "r371" } }, "rmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rapidmicrobio.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount", "crdr": "credit", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Maximum value of shares available for purchase per employee", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Maximum Employee Subscription Amount", "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Maximum Employee Subscription Amount" } } }, "auth_ref": { } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Maximum percentage of payroll deduction", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate", "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan." } } }, "auth_ref": { "r40" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Maximum shares

available for purchase per employee (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee", "documentation": "The highest quantity of shares an employee can purchase under the plan per period." } } }, "auth_ref": { "r40" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Additional shares authorized (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": { "r730" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Shares authorized (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": { "r730" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Shares available for issuance under plan (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": { "r40" } }, "rmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuableUponExerciseOfStockOptionMaximum": { "xbrltype": "sharesItemType", "nsuri": "http://www.rapidmicrobio.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuableUponExerciseOfStockOptionMaximum", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Maximum number of shares issuable upon exercise of stock option (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Issuable Upon Exercise of Stock Option, Maximum", "documentation": "Maximum number of shares issuable upon exercise of stock option under the share-based payment arrangement plan." } } }, "auth_ref": { "r349" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.rapidmicrobio.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Offering period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Offering Period", "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Offering Period" } } }, "auth_ref": { "r349" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofStockOptionActivityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Options exercisable (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": { "r349" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofStockOptionActivityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Options exercisable (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": { "r349" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Intrinsic value of stock options exercised", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": { "r362" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofStockOptionActivityDetails" }, "lang": { "en-us": { "role": { "negatedLabel": "Expired (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": { "r354" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofStockOptionActivityDetails" }, "lang": { "en-us": { "role": { "negatedLabel": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": { "r353" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationNarrativeDetails", "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofStockOptionActivityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Options granted (in shares)", "verboseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": { "r351" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Weighted average grant-date fair value of stock options granted (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option-pricing methodology." } } }, "auth_ref": { "r361" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofStockOptionActivityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Aggregate intrinsic value of options outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": { "r40" } }, "rmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.rapidmicrobio.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofStockOptionActivityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Aggregate intrinsic value", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value [Abstract]", "documentation": "No definition available." } } }, "auth_ref": { "r361" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofStockOptionActivityDetails" }, "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding at beginning of period (in shares)", "periodEndLabel": "Outstanding at end of period (in shares)", "label":

"Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": { "r347", "r348" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofStockOptionActivityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Number of shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": { "r347", "r348" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofStockOptionActivityDetails" }, "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding at beginning of period (in dollars per share)", "periodEndLabel": "Outstanding at end of period (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": { "r347", "r348" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofStockOptionActivityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": { "r347", "r348" } }, "rmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.rapidmicrobio.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofStockOptionActivityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining contractual term", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term [Abstract]", "documentation": "No definition available." } } }, "auth_ref": { "r347", "r348" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "crd": "debit", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofStockOptionActivityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Aggregate intrinsic value of options vested and expected to vest", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": { "r363" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofStockOptionActivityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Options vested and expected to vest (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": { "r363" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofStockOptionActivityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Options vested and expected to vest (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": { "r363" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Percentage of aggregate number of shares outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum", "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock." } } }, "auth_ref": { "r347", "r348" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Shares purchased under plan (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award", "documentation": "Number of shares purchased for issuance under share-based payment arrangement." } } }, "auth_ref": { "r966" } }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": { "r343", "r344", "r345", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r367", "r368", "r369", "r370", "r371" } }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofStockOptionActivityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Exercised (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": { "r352" } }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofStockOptionActivityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Expired (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": { "r354" } }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofStockOptionActivityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Forfeited (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares

with respect to stock options that were terminated." } } }, "auth_ref": { "r353" } }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationNarrativeDetails", "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofStockOptionActivityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Granted (in dollars per share)", "verboseLabel": "Options granted (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": { "r351" } }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": { "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesPolicies" }, "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": { "r338", "r346", "r365", "r366", "r367", "r368", "r371", "r377", "r378", "r379", "r380" } }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Plan term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r729" } }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofBlackScholesOptionPricingModelDetails", "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofFESPPBlackScholesOptionPricingModelDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Expected term (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r367" } }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofStockOptionActivityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Aggregate intrinsic value of options exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": { "r40" } }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofStockOptionActivityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining contractual term of options exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r40" } }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofStockOptionActivityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining contractual term of options outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r87" } }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemaining": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingCont", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationScheduleofStockOptionActivityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining contractual term of options vested and expected to vest", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": { "r363" } }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Discount percentage from market price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent", "documentation": "Purchase price of common stock expressed as a percentage of its fair value." } } }, "auth_ref": { } }, "us-gaap_ShortTermInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermInvestmentsMember", "presentation": { "http://www.rapidmicrobio.com/role/FairvalueoffinancialassetsandliabilitiesDetails", "http://www.rapidmicrobio.com/role/InvestmentsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Short-term investments", "label": "Short-Term Investments [Member]", "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet." } } }, "auth_ref": { "r665", "r666", "r667", "r693" } }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": { "http://www.rapidmicrobio.com/role/Summaryofsignificantaccountingpolicies" }, "lang": { "en-us": { "role": { "terseLabel": "Summary of significant accounting policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": { "r77", "r158" } }, "us-gaap_SoftwareDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SoftwareDevelopmentMember", "presentation": { "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Software Development", "label": "Software Development [Member]", "documentation": "Internally developed software for sale, licensing or long-term internal use." } } }, "auth_ref": { } }, "us-gaap_StandardProductWarrantyAccrual": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StandardProductWarrantyAccrual", "crdr": "credit", "presentation": { "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesScheduleofProductWarrantiesDetails" }, "lang": { "en-us": { "role": { "periodStartLabel": "Balance, beginning of period", "periodEndLabel": "Balance, end of period", "label": "Standard Product Warranty Accrual", "documentation": "Amount as of the balance sheet date of the aggregate standard product warranty liability. Does not include the balance for the extended product warranty liability." } } }, "auth_ref": { "r931", "r934" } }, "us-gaap_StandardProductWarrantyAccrualCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StandardProductWarrantyAccrualCurrent", "crdr": "credit", "calculation": { "http://www.rapidmicrobio.com/role/AccruedexpenseandothercurrentliabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails", "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/AccruedexpenseandothercurrentliabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Accrued warranty expense", "label": "Standard Product Warranty Accrual, Current", "documentation": "Amount as of the balance sheet date of the aggregate standard product warranty liability that is expected to be paid within one year or the normal operating cycle, if longer. Does not include the balance for the extended product warranty liability." } } }, "auth_ref": { "r931", "r934" } }, "us-gaap_StandardProductWarrantyAccrualPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StandardProductWarrantyAccrualPayments", "crdr": "debit", "presentation": { "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesScheduleofProductWarrantiesDetails" }, "lang": { "en-us": { "role": { "negatedLabel": "Warranty repairs", "label": "Standard Product Warranty Accrual, Decrease for Payments", "documentation": "Amount of decrease in the standard product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard product

warranty.Excludes extended product warranties." } }, "auth_ref": { "r932" } }, "us-gaap_StandardProductWarrantyAccrualWarrantiesIssued": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StandardProductWarrantyAccrualWarrantiesIssued", "credit": "credit", "presentation": { "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesScheduleofProductWarrantiesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Warranty provisions", "label": "Standard Product Warranty Accrual, Increase for Warranties Issued", "documentation": "Amount of increase in the standard product warranty accrual from warranties issued. Excludes extended product warranties." } } }, "auth_ref": { "r933" } }, "us-gaap_StandardProductWarrantyPolicy": { "xbrlType": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StandardProductWarrantyPolicy", "presentation": { "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesPolicies" }, "lang": { "en-us": { "role": { "terseLabel": "Product warranties", "label": "Standard Product Warranty, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for standard warranties including the methodology for measuring the liability." } } }, "auth_ref": { "r930" } }, "rmb_StandardProductWarrantyTerm": { "xbrlType": "durationItemType", "nsuri": "http://www.rapidmicrobio.com/20240930", "localname": "StandardProductWarrantyTerm", "presentation": { "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Product warranty term", "label": "Standard Product Warranty Term", "documentation": "The duration of a warranty." } } }, "auth_ref": { } }, "us-gaap_StatementClassOfStockAxis": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": { "http://www.rapidmicrobio.com/role/CommonstockandcommonstockwarrantsNarrativeDetails", "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets", "http://www.rapidmicrobio.com/role/CondensedconsolidatedbalancesheetsParentetical", "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofstockholdersequity", "http://www.rapidmicrobio.com/role/CoverPage", "http://www.rapidmicrobio.com/role/NetlosspershareScheduleofBasicandDilutedNetLossperShareDetails", "http://www.rapidmicrobio.com/role/StockbasedcompensationNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": { "r118", "r130", "r131", "r132", "r159", "r178", "r179", "r181", "r183", "r190", "r191", "r249", "r293", "r295", "r296", "r297", "r300", "r301", "r305", "r306", "r307", "r308", "r310", "r444", "r583", "r584", "r585", "r586", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r614", "r635", "r653", "r668", "r669", "r670", "r671", "r672", "r859", "r885", "r891" } }, "us-gaap_StatementEquityComponentsAxis": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofstockholdersequity" }, "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": { "r9", "r57", "r60", "r61", "r120", "r146", "r147", "r148", "r161", "r162", "r163", "r165", "r170", "r172", "r174", "r189", "r250", "r251", "r275", "r312", "r394", "r395", "r401", "r402", "r403", "r405", "r406", "r407", "r412", "r413", "r414", "r415", "r416", "r417", "r419", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r453", "r474", "r557", "r574", "r575", "r576", "r589", "r653" } }, "srt_StatementGeographicalAxis": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": { "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesScheduleofDisaggregatedRevenueDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]" } } }, "auth_ref": { "r209", "r210", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r601", "r602", "r603", "r657", "r659", "r662", "r664", "r673", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r692", "r718", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r758", "r764", "r938", "r994", "r996", "r997", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023" } }, "us-gaap_StatementLineItems": { "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets", "http://www.rapidmicrobio.com/role/CondensedconsolidatedbalancesheetsParentetical", "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofoperations", "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofstockholdersequity" }, "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r161", "r162", "r163", "r189", "r453", "r509", "r582", "r600", "r606", "r607", "r608", "r609", "r610", "r611", "r614", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r627", "r628", "r629", "r630", "r631", "r633", "r636", "r637", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r653", "r765" } }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets", "http://www.rapidmicrobio.com/role/CondensedconsolidatedbalancesheetsParentetical", "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofoperations", "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofstockholdersequity" }, "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": { } }, "us-gaap_StatementOfFinancialPositionAbstract": { "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets", "http://www.rapidmicrobio.com/role/CondensedconsolidatedbalancesheetsParentetical", "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofoperations", "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofstockholdersequity" }, "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": { } }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets", "http://www.rapidmicrobio.com/role/CondensedconsolidatedbalancesheetsParentetical", "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofoperations", "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofstockholdersequity" }, "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": { } }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets", "http://www.rapidmicrobio.com/role/CondensedconsolidatedbalancesheetsParentetical", "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofoperations", "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofstockholdersequity" }, "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": { } }, "us-gaap_StatementTable": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets", "http://www.rapidmicrobio.com/role/CondensedconsolidatedbalancesheetsParentetical", "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofoperations", "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofstockholdersequity" }, "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": { "r161", "r162", "r163", "r189", "r212", "r453", "r509", "r582", "r600", "r606", "r607", "r608", "r609", "r610", "r611", "r614", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r627", "r628", "r629", "r630", "r631", "r633", "r636", "r637", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r653", "r765" } }, "ecd_StkPrOrTsrEstimationMethodTextBlock": { "xbrlType": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrOrTsrEstimationMethodTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method

"Conversion of Class B common stock to Class A common stock", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities." } } }, "auth_ref": { "r9", "r57", "r60", "r61", "r85" } }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofstockholdersequity" }, "lang": { "en-us": { "role": { "verboseLabel": "Issuance of Class A common stock under ESPP", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": { "r9", "r56", "r57", "r85" } }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOffForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOffForfeitures", "crdr": "credit", "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofstockholdersequity" }, "lang": { "en-us": { "role": { "terseLabel": "Vesting of restricted stock units", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited." } } }, "auth_ref": { "r9", "r85" } }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofstockholdersequity" }, "lang": { "en-us": { "role": { "terseLabel": "Issuance of Class A common stock upon exercise of common stock options", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": { "r9", "r57", "r60", "r61", "r85" } }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets", "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofstockholdersequity" }, "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Balance at beginning of period", "periodEndLabel": "Balance at end of period", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": { "r57", "r60", "r61", "r80", "r616", "r632", "r654", "r655", "r744", "r771", "r886", "r922", "r976", "r1026" } }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedbalancesheets" }, "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 equity", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": { "r57", "r60", "r61", "r80", "r616", "r632", "r654", "r655", "r744", "r771", "r886", "r922", "r976", "r1026" } }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofcashflows" }, "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosure of cash flow information", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": { "r57", "r60", "r61", "r80", "r616", "r632", "r654", "r655", "r744", "r771", "r886", "r922", "r976", "r1026" } }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": { "r827" } }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Title of Individual [Axis]", "label": "Title and Position [Axis]" } } }, "auth_ref": { "r899", "r980" } }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Title of Individual [Domain]", "label": "Title and Position [Domain]" } } }, "auth_ref": { "r899", "r980" } }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": { "r819" } }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": { "r826" } }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": { "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesPolicies" }, "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable", "label": "Accounts Receivable [Policy Text Block]", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth_ref": { "r102", "r103", "r104", "r901", "r902", "r903" } }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": { "r846" } }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": { "r848" } }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": { "http://www.rapidmicrobio.com/role/CoverPage" }, "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": { "r849" } }, "us-gaap_TransfersAndServicingOffFinancialInstrumentsTypesOffFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOffFinancialInstrumentsTypesOffFinancialInstrumentsDomain", "presentation": { "http://www.rapidmicrobio.com/role/FairvalueoffinancialassetsandliabilitiesDetails", "http://www.rapidmicrobio.com/role/InvestmentsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": { "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r304", "r309", "r418", "r441", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r558", "r733", "r734", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r745", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r918", "r919", "r920", "r921", "r968", "r971", "r972", "r973", "r974", "r975" } }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": { "r849" } }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": { "r850" } }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "terseLabel": "Expiration Date", "label": "Trading Arrangement Expiration Date" } } }, "auth_ref": { "r850" } }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": { "r848" } }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": { "r848" } }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": { "r851" } }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": { "r849" } }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": { "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesScheduleofDisaggregatedRevenueDetails" }, "lang": { "en-us": { "role": { "terseLabel": "United States", "label": "UNITED STATES" } } }, "auth_ref": { "r991" } }, "us-gaap_USTreasuryBillSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USTreasuryBillSecuritiesMember", "presentation": { "http://www.rapidmicrobio.com/role/InvestmentsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "U.S. Government Treasury Bills", "label": "US Treasury Bill Securities [Member]", "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government." } } }, "auth_ref": { "r991" } }, "us-gaap_USTreasuryNotesSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USTreasuryNotesSecuritiesMember", "presentation": { "http://www.rapidmicrobio.com/role/InvestmentsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "U.S. Government Treasury Notes - Maturity Up To Two Years", "label": "US Treasury Notes Securities [Member]", "documentation": "This category includes information about negotiable debt

securities issued by the United States Department of the Treasury which generally have maturities of one to ten years, are interest bearing, and are backed by the full faith and credit of the United States government." } } }, "auth_ref": { "r991" } }, "us-gaap-USTreasurySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USTreasurySecuritiesMember", "presentation": { "http://www.rapidmicrobio.com/role/InvestmentsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "U.S. Government Treasury Notes", "label": "US Treasury Securities [Member]", "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)." } } }, "auth_ref": { "r700", "r724", "r726", "r733", "r991" } }, "ecd-UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": { "r845" } }, "us-gaap-UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": { "http://www.rapidmicrobio.com/role/SummaryofsignificantaccountingpoliciesPolicies" }, "lang": { "en-us": { "role": { "terseLabel": "Use of estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": { "r33", "r34", "r35", "r108", "r109", "r112", "r113" } }, "us-gaap-VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableLeaseCost", "crdr": "debit", "calculation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofLeaseExpenseDetails": { "parentTag": "us-gaap-LeaseCost", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/LeasesScheduleofLeaseExpenseDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Variable lease cost", "label": "Variable Lease, Cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": { "r466", "r743" } }, "rmb-VendorAccrualsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rapidmicrobio.com/20240930", "localname": "VendorAccrualsCurrent", "crdr": "credit", "calculation": { "http://www.rapidmicrobio.com/role/AccruedexpenseandothercurrentliabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap-AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.rapidmicrobio.com/role/AccruedexpenseandothercurrentliabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Accrued vendor expenses", "label": "Vendor Accruals, Current", "documentation": "Carrying value as of the balance sheet date of current portion of obligations incurred through that date and payable for vendor accruals. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)" } } }, "auth_ref": { "sr1_VicePresidentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "VicePresidentMember", "presentation": { "http://www.rapidmicrobio.com/role/StockbasedcompensationNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Vice President, Legal", "label": "Vice President [Member]" } } }, "auth_ref": { "r899" } }, "ecd-VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year", "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]" } } }, "auth_ref": { "r815" } }, "us-gaap-WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": { "http://www.rapidmicrobio.com/role/CommonstockandcommonstockwarrantsScheduleofOutstandingCommonStockWarrantsDetails" }, "lang": { "en-us": { "role": { "verboseLabel": "Contractual term", "label": "Warrants and Rights Outstanding, Term", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in PnYnMndTnHnMns format, for example, P1Y5M13D represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r971", "r972", "r973" } }, "us-gaap-WeightedAverageNumberOFDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOFDilutedSharesOutstanding", "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofoperations", "http://www.rapidmicrobio.com/role/NetlosspershareScheduleofBasicandDilutedNetLossperShareDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Weighted average common shares outstanding - diluted (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": { "r177", "r183" } }, "us-gaap-WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": { "http://www.rapidmicrobio.com/role/Condensedconsolidatedstatementsofoperations", "http://www.rapidmicrobio.com/role/NetlosspershareScheduleofBasicandDilutedNetLossperShareDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Weighted average common shares outstanding - basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": { "r176", "r183" } }, "us-gaap-WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "presentation": { "http://www.rapidmicrobio.com/role/NetlosspershareScheduleofBasicandDilutedNetLossperShareDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Denominator", "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]" } } }, "auth_ref": { "ecd-YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]" } } }, "auth_ref": { "r813" } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1", "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28", "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20", "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28", "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28", "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1", "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478353/942-405-50-1", "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A", "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2", "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2", "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A", "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Paragraph": "2", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2", "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)",

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[9E^XNE+6H*5;FRI=-&?22-VS-OCDO)P)%//3^<?7^>\\# MSFPQ>=MYZOX* Q&\$<1HKJ* WNNQGFE:9LU>H:68QU5M:Q>JZ? \$XWIZ6-" MZ 4% @T= IV3 G<=!=&8V1M^G9)>.!F>./JOZ?FAC7_34<,>2)=?FN^YSI M13 M^<_W/29CD29)_'??Uf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

T6IU_9MFJWJ*#^HPZ98?13A(*0A3#S_M7/!7SG-2*M_H2[NOR8(ZO!:"SYU%W[W!P?K7E4R:N_/!R;+48'H'S_^X)?MYW?_4.ZN[O!^79^7!SMWBGY?UMF?U1HO S_/9!>:-*C2P7L)/729\$*X>M!/PSL/8"4G

%M%0)sP=-Z,HQ9"HO-1#.3C(WT%GSDWU3EHY9 M642%4E:F-1%SE^2<F<=-8X*# D1|;P8=U|3L30B810+9<=UIZ,S\^2|L^4X MO,FR|84XR)|?

 QP:RKP: MIS/G60|0\$G BWS/ALT|>QXZ='@7\$AQ3QS+ B& 8A06(9EE+4QM<88G^|/6*|HN%K\$K&YA?M%. L5\$HJZ|LMA\$HT MM?5\$+@5&@E#?

 A&F6H416\$QDWMN|J XJR&E\$E.P^>D*IX8|F(=|HHKP MD& M18GZ8DCRY^D)AGCT+Y&E>X, TFX|E4K'MN#QW:2 B3B9+9^SX|EK.D^ZAJEK^<+

 ?XI9?G*) U TF^LYM7Y@UB*L-LG|U8.II 0=->7G MS%0.T+K|IP|.?&)/P^Q-103#M|)6*DH24,+Z6G,?(Y^#MU.4MSVC\$ L7W*8GXNV;|V^68)F68R

 MFT\$W|>J^7R8|F\$|S5>0)TP(C BRX4PF3\$+7G Q|U|@P|231(# C#I RT\$S&Z MW8M_%^LRRQC^N^X^D,+F>#N^YFSD)GE0LR+W^

 M|;=,F|P.2^W6RT|8<=#ES3N%|E3TB^Z^J.Y|B(0|)BS^=,B M|RX5_E|L|@|9|LN^NWTQ,38^PG6%#5SW|P\$T^|&|>LX?Z(5),=QDLN?!*|?G|/

 MR7F^+7#S-1@_*N?V\$\$.P)4(-)UI-(MS)U>V0^9NG?1%:2LYH.BQQ()^T>1:9EQ33^2#HF|X##@FDL5%1,-&=G

 MCBEL|PS&H_D8,|GYOQ2^T:SB\$9<|FUW/,D|09C+DX:0|'1+SE4F=28FU| M2 R"> RE\$NPMF@,|O&A9B.KH^AM-HJ_HJ|41-

 ^:LQ^:|XO5VEC9%B)4KB M|7PDLT^*#PK|B.BT=A48<+<+,A%_89A,|V-IR|F>OV">|E&|J^D3C9V F M^21=-B(G#5IU_%SKT@3_OW81Q<:VXV?

 C^X6|APT^Q,R34V|BXRU^9*|H+@+5|_% MK|34^F:FD A1G^T YG;^GVE8WW722_28N>P|>,>8>4\$G<C<^Y1:Q.DXO M<Q|O|8DGI4|H^T2+%"%

 <8^FC_YU^F72VXD(OB3,\$>%WZ|H>#D\$C^F|F5SK M|A^XB,^F<56|J##X|2Q4?>|S%^P_C(Y^@Q3Y00L^?J>AUE\$P7R,,/8)T7)

 MA_70A3\$T1@<@_YHV<|ELP(AMS^OOSU^(-D+))O(W^&3&28+U3:G3D#A&|B MN=\$\$XODG9K,A8^|YBRID?>^HCO

 ^660LB5EIDOH,|L^L^ZVU^QR^3U6&,@ M^T^T|TTO+=(O\$6L^10|@_PCHS_Z9(Z395,?S|O)=DZ?)_?TG<^

 MP6\$U|B"M",BVDX\$F3|H^M/8AMY=@@8Z0@|Z^2GL>LE6_.L)^6HPP&6|B<M5)+\$),39F|G=6|>9A^?P#@/6;.=("I@H|J)*U_H|V+\$

 M^X&A>=^R\$BQA&Z7W>V|Z^Y|F#^J)C%<G^G^JG=C|VCG&PR,R^1X^DB^A^I(M4)_@|1=Z29^9G^UE|I#,"3|(>+<+;,O=|WP,X0E<+<_XF,0-/\$_\$YGIQ|O|

 M|UR3^1=|H|9@(|2>+|+D)PSP=,2|D|)^T|J>^92;|HH9T\$4|LGLP^M^0_7Q3+JG:Q9F|2959ID91>=2VRDZ>@H| WKYX_SN?S;KPEL|BX|W|+HHA

 MT57%OP0,\$=R)=TH8)C=%R07R4_4%8|>9|"?261(CP*_%O*,8MZ356|J_0 M7EB|Q&SKGY7P==CS\$?I8KT+4QYN4.7M;|0ZOI47|"YEAC^(23:Z)

 @IP@0X M^_0Q\$4|H94^TJK&D_R^Y%|%<_D<0RZ+RY|3|H;X39A4|,F\$|F,0|NSHNK_M6O5_)K6(W|S=2UP>7=|<#5|J\$)TS=S\$BA/_>^"R,

 MZ>/_S|^G(|DDCN2^EGX^V%>#^HFQ#@-FW,|42,780+@&|3R.J<?7#|V|>^V=0

 M|PF^3Z<^5R)37|L>|AW&Q&2LY|Y|Z8:5^<|FM2|B_|6H^+7&U2B#J\$^A4|)L<M=)4|:4",Y0G338M9\$|=UMG^U|H:1Y=5TEB>5,*^?

 +U&|6B^|0J2K;M5)+B MN#V>U^N|+|K^N=O5|2GUQ=7Y|_25QYK(KFOPHAL2K0<@>FV4<7^Y^C|P^E5 M<_,^*>@>)*6>W=<^>_55^7%U<7>C?+FZN?"

 ^_@;V|D^8 MPN<K18|5H|>^*+&EX@N0&R(F9;S|J\$|BO^<(|I@>?7^K M&M;6|52B>+&@>|H@>9%/ZT;IH|><^&^V^&A#^UBI9L|56X9^Q^Y|YAS<= _94.O"

 M=1-529KN&|G^M|EPN97LA3;9^N+U8@9%.CV5Q M^B;JN_|J\$;O|H|424V MX32P,9S7%

 @@@L76TBX|H0\$1|^F^RDC|B7|>\$S4KIW^3W>=866Y2)J>WY^3U@GTO

 M2^V|H|&A@N|G&|S^S)S4V97OR@(|517QOX;LA,|R|S^L_@#Y|F^MGBR|^^^%|&7M,=(>|SBT:W&PZR7^MP#H@<|VP)YX6^U\$P

 ZAK|QY.DC8Z,S1,BY9<7^\$A<1Y=|L^XA>WX&W^/ MX^2?3PUEZB|V|V+|&1\$0_ QP+KP+9PP43HT|5/#+W6U|2PZ|H+|_#_3|G_|

 MHC75S|N0|N6|M4E4C#8A|CE4|FF4P"&_(A9U|L_21BD(*.F&DKO^G,N3S#G M;:98_G+&5L^W#9G,7VT.6:%"SM_.6M_|X|Z^?L^M<5S4YBOO1=-

 ^)59E7EXQ M^:UVG76^UV|O|RRCN^W84R6<>_J6RMD+X|Q|E:CUFVJZ|V|F+@_Z^N^?DW|0%_/Z M|J5|L0^*5-

 Q+^ZUI@U6:454(XAVA#KFB^Q^*VW3%42XZ3(6|A#)7 M+1^|K|V46|8NB0X.BHC|IRH:M^T=V|;8B=,*0%P^YH=&|T^KZPU#\$L"C-8|

 MRM|M@_J=;5.O(4)^.45FDMP\$2,6>F|JMM,==Y(Q&R45<5JLD678|Z^J9 M_|B|)^GB9F,&|8^LK6M|J1Q(S@&S5|8K;:>NLR+P(CYC+=

 MU_P|&D^OVCU1G/KR_9PQ(^:4Y7|R0&BAXZ^U#"|J+5WO^|3OW^L^<G M^W=ST7HTC MN 2.)^QD|Q|O|BP?

 Q(5Z0P5+P|S;42,54^K^CZR\$|JW5+|)S|<C^<_49 M^*((E@<QMT4QDXW4B|@_&NR^>?7N+IT12-85\$SE 8L@&DB,W<^V^7=X MMBK=|Q_&S+?

 X@<^V|)=*7|C|F\$;P9\$QKM^MF44FY4B|L^|4H620U7>_U|H|O8UQ|F5?9;_) MIR6&A^DO:Y|L(8;8|@|S=@S1_NN^WFG)DD=Y5+>7>8*B#

 <8|F^%C|H|Z7|1Q M=>=<SW@&S^&N|9MU55#ECHJ= 2Y7W%#(<|GMZ6GWE%|DH#H|+R+KVE#HX_ M<6|,E7@VKZ@)@_ \$Q?W>BP<4XA#7Q(<6-

 U|TX|H|ZEB^K+|H(H^XBCG504H=X G M^?24.1WD*^CLDE9DEL^<K_6X^|JC(F)^3=N+^MORA(|^GM^ABCV^)|Y5-SVVM8|A@/|73D)35>|G|E

 G2V|L6U<8.V,\$?2*2NLVZV|O^F88^Q|L2V5NER4 MJH^9|2|06V\$_.PY3X^1HUSOM|H20_X9CZ0@>YCA.S2|>W2V6G|_>5E9U^ MVH-D I=B

 F^<G_C"LU9482A)K&^IA>G;&W<#F^|S@OK7+N;3O>NT_0Q%*_MI0_*FR^8Y+HMRY^|:R_\$69B@RX5B0^4%"^P\$Z>O^|7);2#U5U\$HW^|N= M6GY

 ^&1&BOMGY^<_6L+AOHVYN+XCIQD(|1">K^<C\$^7KB+J7P^Y|HRR| MP^AVH^X^H|D?M|FN,<^>27>2^B<>8|H6RT^L;G?

 VX^9R>RQ0>#LW^=XTV 2 M;COO;2V|O-RW|J-R|J;G\$==,&BY|V=|B&YED.T_H|Y_G.#X,TT7F-XS

 M|J74ALEP6ALHY+^X|I^M0/FZ|_O=UD,HU:5SU5%<^>)^Q^H(Q8H3_BT MS^K2Z8?XEG^+|133#,"T<|@<^>V>M;#=#G= 8V>W(YMG7R;70C%K^_|

 M_YM|>3QCA4W>J+|>N>=>CB_H^CM(4.M^|HFT(|?^76|%>,<K,K|G;#<=>W(5 MANA^|>|>L%NQE\$8PQEH4U|H^4H1= MW=Z%#>O>T^

 |N|&0R^<|^|KTLVLZ3RF6Y M|);=K|);O<_,|>=IWAYG^NV6U^U

+/-&N M.W.D2.FX0.8GIWTM.NU=%?Z.9T1).9M\$%U^P.0U09.P?!(G)@T@INJKN/JXNY&^7)U<-^/M^X?2
+!-=UY>KZ8I&/RYG61!;8FPWH\A.Q&2AI+,\L/O!AO;S1LTHRPSNO)MD?AC>(8=UA7^8G%4Q8-8Z=@*
&#>ZKZ\HAIDX>78%0IX*%K&%MH>%N6P4K/T.MC\^V\$XY<|GKF>&)XZD>?DX\$/RXD2<
MG<@R/RU<^NJC4W\^SHIU3<7.H333UC>ROEUCJ>>F3J185(KY74.8.MIGNPGT2C942NB?
^&F&L+PS)2IN/7R9C5CUSX+;+B6!GD)ZOO\DG&^1.XPZPVXY1>M2^YIU+IF7<^HF4+!@VFB%2.M2M+YY=FK;L9149&%75B&&E.10R3,
(Q1/L\$E.F;^DOFY7O^(\OLOQS&2S.^IUY(I*+&IR%9L15NW3^I&>Y!FQ%2O,^(\W6^L=M0%E94.KEIT.H#4EB,IVP?>Z.MIX;^FUV64<=0TKKA11&
<2F=Y\$^GIZCPEQ>=PPISY5F1GENTDF9"N>YHK31.MR^C1=-\|@<^IVI&K\$H0Q1VIZ2=V3FLI2G.BFI%>A1XJ9C82.G16N&S;0;>%MT&EV9.G10-
^991K@=MII@?4)N%13P.)UA9T4&W7;8Z0CL&VY4Y5J6L.MHXXI-RZU=D^D2LH1VXKV6&HF)S4W+XY&>6.R.B-B=%EOVT^P(1)-;G#D'G.M
*S(HM,^CHZ?@+U+D3B@&ZN&EBVPXZ2&AL;621+EHU!>U^Q590>.A9X\$U.M\$=-)N#=-14=8^Y1^NUODGL5>N197Z<;>AD?SNG66]M;12;ZM9]B&
(N.D)I.M9<98D5]H[00TK4E0.D0H1I]>#5%P&Z<=#5DP4<^25<4%183KIGKHLYG)H(QW.365&(RT;H16U.M94.Q&AEQM.)
(+A!<21V;3&AH;\$T;Y@9^JB\$(S>ECL.2#C;C7E<O)T.21M.M^ZP)BB17PSBN<^3YSISCS(H/S6.F^QW/"-;*RC6/+&-G^RJ2!+SN>V=.%!
M(@XUFI,RA2WD1%P\$EHL\$DCEUE2<C<13#M^MTMX1[A5UW2YT2,3+LQF8M.M4T<.#]!&WP@?#?&G;M;A6;W2^BP2Y^H/N1TCKEWK-CKU
MADY^CA^WGBV->0ZM6X3A^RC55^(E6^RSJHH^XU-^S,E7I@#U,IWOH=-^UNIKAJ+\$8./LA<^MH.^TO4-OP9#?(?3PD->LFGQ=-0A21PBI/2)/KW6-
3KW966R1)@I/N0M&O8I.M41ZYIFW6@MWB^0^GKEV1&RC6J&PILWT8^BB.0KWQJ((002)?>0FS8Q^;DHG.M7RJ<3C<%JCG@8924(FKKB<J4Q?
E17]I=1(180M9/N)NTJ.JHD5YKAK;HSTC0SDQ^5G.M;3M15\$N466^C;CRC5%91QW3A>S8&4<^U.Y.K>6I01@11NZP8F9,063(#
M+V!OFFJMF&S@/!2;RL?>24.M&S!;K=N45L^4;R7*;NH(^T#|,R=6X=Y#^KXNL@<^|A@;V=1;<8\$J^#RV
M5D2*W%60MA+TQ^AX>;6J<^\$04^WKZ09V(JMAS<+>ZQ^K.M56T/7K1+^NH8P1%BW12/0I0YVEV6,1>Z.IVCD/5TQ34R@*G-XX8CV7/_BW.M+!>
K.O9ESBV^VR8BFEXX^@)UXI!H%#^3J1GNO)C;A16.XA04BO.M5=VY0B+!);#]!\$EA&%;TE26!Q.MLCH?>FV0&+7N1C6R*&Z&N9H!;M7-
(<=<\$IVXW3E^D;I.N#^|S1XN46B+N).MNP.>_J^T#>C.^N&Q)3>J56R+N(NI;Y#QA.^YJO,<^!>FER&V.XX/M,^<4
M1P7ZP4MTPZRAIP7;@=5\$PYDM*6^G3E>SVRCJ&(K&I.Z;,>^"Q9PY;I^M;Z;EGLH^Q1A(VW^S;=>W2^S^ZV/^ZY/_RIRKJ!PO>?1/4+F?>1-
M7RIS+UG@P3\$Z7.^((.FFE6=BM?V^I&THN?Q<9IUDPZM;YZFG%2M-#B@>A.M1;18+?Z37HVCW6\$Y?
6VNB&O;SB/Y;S>U1#7.PY)UX<3UPMG,7U#9B]8.MYAC(Z6W2L3IQ.D989,".S!O-XY"%XO^T0BZZAC.\$C.N.@^MMO4&LV^!18Z^)?B2A.J/CC*
(R8A/M9/Z39Z.6AIO<C^I7(HWAQV@&O16.M\$54.8^J)GAPTO=2^;R9TB21E.O\$F6>\$5W/^TWDY^L&Y4R*>WPOL%3G=PO#
<F\$7A6VVI=3CL(3Q+@.^Y?%=&UE^Q?HDIE3^_JK.4=7^\$Z>LB^1>+LOAT8/B=,9MXXID3.M.6M;H.?+@K=#;C^+!48#;OZ!HY?@3OPW-
O9X6X2,I,F^N,6!1PE^!)CQ\$>MOJ\$,>L>I43^1D,^Z^X\$^00</_CAT.40\$T^ZM83IZITY<P^P>J).O2G9R(7HMC22CI.M2UFM.7JS6.%
F1QMB@OG(9JHZRCIWIJL9Y16VY;G^U6\$=5+;O7ZNG.^#I.H.M%2IH\$^0K&(^4.ND%G/T87U8XIESGIEKBIPO^W^NRFOIVOLQ2I^(\+!>M!;GIQV
ST#)@!^P9R8^!1@%JDEI6TP>^RP<4ABH%ZB\$!/^Q;A;MRQ!-MR7L&F&L.S/BC+^;ZD.A^&-XAATN3FHY/H62G4IE.M80C^I%TV^OE9^L?
G5\$&IGGBU^@.GY&(&\$=11.88%HP875V4J=J+^F2^&KR.MYN3K4.CJT+^GIGEJ.S.K113+?S98.21%.UG7ZV398I;K4FEI^2^Y148I6C
MI#1J91VUXCSC7>>ZLS.LPU&K;7!>,KM5=(R+DD=@!7?L^X0;A<@B;RE7L^M.LT#J-BJ/4U+G+=#W)9K^<2?7;DVFF="1>LFRLM-
4W5S74^1.UNWF3V8J3^V.M92U^W/3^4.8\$E10RCKJ&-(KJ\$5V1U;26IDY!A^H4\$<=(W?M4IY4UCJ%!!W.M\$7?
MNR!#YU@^A1S\$7(MQ?SARI/^"HBZ?>2L=,GS)3MK52\$%^_91NF&MZ10/;+25RG(FV.FEVB5,)+U+R#KJF-IL>X%*;O;VXKC(SQ%!_3IYX.M&
(G4&-\$5V00LI=M&F!5L#Y7D57VA9*XF.41,UTJGICC8I++S^X!H/HGEOC.MP(D<^I;_OK'=#;ZJ;P%ZR+*LI=MB8JXF+BXL)R!
(KG8\$!D\$6F;=MW\$Q<3%Q.4Y8F)B8F/B^M.1!%O/PN+C/B.LH2@6^=4BD;862;N06B0MJD6R^IE0+9)U2Q)M(L.Z?1=
(Q^H2MZV/BOCJ302J2\$Q/RHB1UA;I8^ET9T0F*#<FEB/Z05(EA.MG!KFB(E4HEF;X!;R;Z^S#F!K.9I\$5V+I2V91CV)3&EJ_G26Jm>P87+PE
Y_1472,(#<5^D^T=98UDZ6K5.MP.FS^U.RI4?@/I_-%J%SG=<4HEI.H>YHD?7+7+5(^8)XXG.K;8^,4M&S.M&V99X^81==^D)+^XIE1+1+
I^Z2CPEJ.HFPCIBDZR.G2/QO?>+>E^1.4.MHZJ^8MW^G+#+U+BX=5G6E_B+C#\$57Y(ASM^T>5KERU7G6S+!QEGH^!
M29^RE5M;4BMKAQPV,;U;A^L9DBPQU/XMR0NIHG(7#+U^6WC.W<+^N78?;MMF>(KL;U/M1.HY1Y!@_!M;4^I^S*\$7_E@/>=6IV-
+!LO>=>EQ1<Q^YHCJ.M4AQ.9.6PM)%%&ALR2^#OD.123X+K^Y3@I5JW43243KVADP.C7Y<EP00H^WM@<6ZYT1ZQ^K#+K&E9)UINKZ8^7YG-
NMHX^N.(F.NPF2M?+KVY9BYJ.6R&M26^U=MUH5I^I^C\$8<=B&^_8@L.6FO@O@JN+>HH8B!BH.@R4AW!6V*=P082W.MK+56O=,6/RQ1Z>
(LZV^C^S^>-(DICS\$6I8SW6;CB4N4BB7H>W1WCLE\$^/MPPQ-E\$@)/??U/X.742/(H%B)M^M9\$CEW
M3@<(IBM&=J\$4D9(Z^PJM/Y2!^LX+MT^S0,2S1K\$VJ)8C)3^LM/93R!/^D+M^RPG%&FOO5^2)YC#>^7NI!U\$V\$;+>5-#)+!\$1V1NA%U\$!L6^P=0K%
I^2%\$M)RM\$;:(48>H0I0AZA!UB#1\$G6-/91">SDE/Q2T;AB/NA;^;IOC.^#<0A>Y.ML@ST^F2=8@Z1!VB#E%BM#LIE<2SNU.C<-
(M9Z)_MM1#<+7/L^&BKGXO.M8K3^9+F8L5CNL&54Z3G@<=CL7Q>.X=M.O^3SQ%!/DO.NLXIWENH148/^M^482500=8@ZY9_2R?(3;D\$<1\$DP#
^IJS_#^#DNR;GN<?^43T7;Y%\$Z(NXNZ^A!MP>?^7^N@<^N.M;H1C<@U#%<0I0M^HLN\$!^JX2=8@Z1!VB#E&J\$4
M(<K(3YTKI>AOG.D^JSXBUDC?NJ.B0O.#^SEU@_P/>=1%#B1<<1Z+G.P;UG
MO2C+^60SNG1#=#(2\$O)A=7Q_0ZPU)8(2P=U@KZZG.@/P&E&M)FX>80^24^M(VY%<^RSF;C>\$;,"112Y5M!;DMRTXK.MHIDX&'O
&0EMGJU6!<P^"KR2I)H;^#!<7^Q^H^01#&@)Q.VU2.ZT4T\$R6.MD0I^Q#1K6.28=3>=>\$.W8;9_Q55>(H8PZ<25SY4^>2.73IQ>U35-K=Y2
M6JNGX!"R0\$VXK^5^9H,W%X6K>UV)B^^(?XISKDXMIUFE6LIU>PLO0M5^O.MF/+I5D>0.7JLK;#6H.+N^HFIR)4K9D;XIE8^<I\$;BK+7-
I8^PISIGW%QQM^M#M+16S1E!>J[BD&=D@K^!F^2%L^?P=C7B;=^%X@1BXJ6;^K;K%0%WG.^Y.M16L70KJ3;15M]@B\$B\$H(OA(K1\$&BJ-
P45:4C6%HXE19^RU2+K&E43Q(YIOC.M+DQ\$;H-FFK%5V\$1I;MR67I=6Z>J>@4\$!28054P94L(H0I0AZA!UB#1\$5.M^;
(48>H<^<RI#D?^*FLI(LK^)*64>^&Z+)&P[(@.F)F]KJ^PD.B.)^J(44=Z^A1YGBR=(#2D\$N1^<+^X.VD#NQH>!O^A)X.M50^O\$I@S<#9J(44?
FG^USH2KP+AJRE.@^5;AWBK.C3O@AFCYBZN2ID;7.M9FIF0QIN/H^3Y^KMT3^;A0//AH+8&9P^PP8^J\$6^D2=C8]MS!6%IHM0
W(M.F.VBRB]3%B2^TNKCH!W^*661%@ZJ!^HBY6,BSJ3^4=5.NUE+G>XY.M?>X0!>Q1^94-IK.\$1RD<3FNS3F!BU\$%N1F0Z.N^0Z1^82KBZUZL+G^Y?
MM(MI1>+L1Q4GXNNH<+V.K56+XT183.MBZEE1PD^8D7;CJ?I?>B^19!!!U;PYTC.QV5.R>=\$D7EIF@NQ;1%0X=-%0%62.4^76CH?<6:04;.
M=M&XN;G6NKI;UU1JYD/E((@Z1!VB#E&J\$4/>H0=8@Z5(^&M12N2;H\$E.M2
6ISNKY;K=NIZXW>W14IH=^C1UBB^ISG>.FSKX.HHONSXIOFGJM>YB>04^MCY3@=(8FZA!U=BIX&PNEV7<@>
UYI.1^Y3\$<1#;INGCBY5^TD2=8@Z1!VB.M3NDVW2IG>O>M^LA=0+!6160422^2TD8VD>5\$;^_9GK94CJADR2@B.^8^X.M.W
%#<^JH%60V\$BXDZ1!VB#E&J^Y=7(5IFLL=K.11039K/6U;2ZH2>(UV.MZ!_AAIB;J)+NQ<H9UP=TL>
ICZ^DVYJ4DQGW<?77Z3H+U&J\$4/>H0=8@Z.M1)T^I^V^W^KJYD2?C\$IS@P.C^V!;MQ&^C+K?;H8^IEBL;)+U1U17%)CI^MGI^O
PX^UN2FRVJ)IMDF5I&IUI>J^O=E>=&T4T^Z^Z^N^;F^8LA^D7^MT6W4>P96G4I4I=&X=M;B;V;8I7+;EV6W3?OS(@5YI&E(=XEWCU
WLW%NANTIEUD.M2NRV278P.24Q93%W_7=N!K>8^2N#Z8/HJ^+M^FJ6F%-O^S.R=BKF.17I-QYIM#P.N.M;MT3+OU?>=<^/L&^_!HBN-
%#&@KC)B0;3X?24I)#!#&C@VIT^<^>4E^M+C628V8^G(CSOP)P9P^6W.M6>0</_CAT^THV.H^2K^ITY^P^JQ>=^W.R4R9.PNV@P>I(C.RRK=,^*?
M_@<^C)0D.9I4=<@TLX^WG^C#7,8^LJ<0P3V+9(GHJZ?TK2!>LZ.U.M7\$YI82;\$&8.0.TP%\$P;R;7)1I<4^2WS^JIVRCMKI9YI6FV;7J&UF,=
M5;6L7JNG_I%G(F2!^GN@LC^E9BW2PREB%EEO7=\$GOW=WHI57Y<75Q=Z^MN;JY^2IP^6/^IR=7VOR)+E3(\$B6X)-Y19N?
#A3A9^TD6Q15K@H1BC)^C^M1K&QI<#/_I9Q(9^CC^DMR<2N%7^_AB>88=UA;I8^MC#H1J^2HCV.2/2P7^M^3^8IU^8E%M\$Y;BLE^S)
(_/I=V?2^A;2/BJ2)ZFG^M(G.M9?<^YD1SVI>H1.6N1K%B%#OY)C=I3TIB;^EV+55HF.MT=YM(M=9&)91^CWW-/93&RU5B?
6^Y>%H7+&^R.XU(T;L7&E)&H3^W8VO.M^P8C)CO_7UIN;JGU1BGYAKNA#;5=LU8@YIHGCB;M.L@I^VW8_(99UG@X.M=M&9\$;MDI
IYC.1^MTKNIY&_OIOA5LPV_Q2>N^X;2JD#Y+^C?2P6SY8J=KMD0.M58YAY3H=4NW>=5&G5OEPT;<7W6=-
J@KUWL<@W8NPA1%2)7#VA;4)7A;K74;4;#J!NMSC&D.OX^?I3MM0@+K4ZVW6L1M=(&O7.OEI.PV^17-N.TK(4D;F&(EI\$V=^8.^9+09;ECEH(P)O
M.O.DKL3IGXDZ1!VBSBZ;V-/PK>.MP@5L^L#&S^W6(GLOOTB;L.BEJ3.M;0V+P1;Y\$X2ST^XW^D98VL2O^>#T1X%CO;4NXCB+SRU/N5^CQ>R
F^7(9;I.MR8;+8>?+!>Q>733^8?>Y88^&?&6CEKK=HU0IW;5LO&LNO9C0<\$N8)C
M+>N^A;4^U=+>P0B^99DM2Z(48>HDR^Y82^NEYR0\$26<^2R+DS^0A0Q.Y\$M^*E-395Q.FOPO6=UXZ??)O^0A9HMF8.\$MJDYEB-55,C+EI&Z!A^%?
=5C/M9WH8LU!QS!>EQY.1I)H0=8@Z1!VBCK1&ZD\$C68.SNW.S4(UY%=-\$;
MMI.RAK?;L^|B|B6X7FJVF_Z63;KH0R#)\$5K7;"EUKB^H(XGZA!UR@L;M!\$;B^>27R!0BJ&(ZO^JL.R/XDI_PP")_6KN6W^\$.*2%0;KG^OP%_<4ZD#A
M9Z(48>H0I0AZAA;YPIJ&RFWG+M^2_3\$4X3^FK2.70NY^&90^WHBR\$;AU37/I72.P51I^I(=@F.M4WXP40I/IE/15B;NOS
7JR6\$^HN4^R01AHUA15=Q4Y7FY.S;I&N3J284EQ.MA.Z^X@<7HMR\$N-01^T2X&4=AQ\$S=XAMF2+5\$%#5ZND)_?BB;FTB^I6/@7=
(@AEP5OJ/B5XJH9MU!L.HVZTJ MID.MG@0X"?-!/@IVTJP.O.00UB^6*=HV(=+3_KY\$PYZ!F7K=S,@Y(8BYJH8.M<^5^ZFGI>9I;_<
<5FF@K^1M3;ZN+>BQW.@IOFIO@P(Y;R6^&ARVR51.K=ML.MZL1^Q.559H!<+^_ISM%!.FG#;_MO@^FE)SS\$4G4E2=2V^L^S^#00-P
M9OOCGLLS.5A.2;SDHMF0K\$F1H6V1+!W3!>=RS;4W39M84UT5^JOS7RTOA(MGLI^M&4.\$HT)9H238FF19;B.*=&4;H132E&(7?
6;#&+GP/9A.BZSUI_9%MF6LD^OF9I<XON&M.8#"W0J2IVP@8^TQNCB\$HG27)HJYTP[D^T.M.)>+>%DE*>1#J-CS37K<43.&^K)4ER.A-
LJ&C)RCX1=8@Z1^W^HTXN^E0#I%0M13AKCO6=%VZ?_L^2I;6I0;430^&B^I;Q;RU;MMD\$X3R3^BLO+2.ZHE3
M^CQ^U""J\$.4.CSJIY#4519MDZJ(ZCQ6W4C,6D1@^CE&D44^4>[4J^+^LAU.MM0I^G.(^54P=6=E&I<20;Q_XVIG\$K!;J(48>H0I0AZLB;I)K)0?G\$7G8IT
M!&MFUE6M20DNTN.N%MFZN3CIKUT+1=1UV;F.O.PJGKYG137.V.NF4^?C^&E2.MPFH0I0AZA!UB#1\$+>^EY3>Z&B^1^?OJ?>4;11ZQJ+I2K6=Z,(4!
(^FTW.M2>_F4\$&GE?IYK.VORXU.O89.M155K54WSGJ-E^A8RITO^Q^M4&CBT55ADV^6D21(^/S<81^EJZ.L4GZ+^MEZ%VZ@V=FGR1^#N;_<
I02V43-8Y.OJ;AYY8AUAG.199;2)=^733Y.NHM.M72F(N;J.GEB14NM%#969.00ZU3=6HMS/8^H4\$8<=^HJG+5QGI9>^TM1D:543Q
H5V=IR8;4!N6D7VW^9\$T.C.2DIU!+<=M5F^H5^K.EJD^PX9=R1+B^9\$4.EIFD<_OW_7>D^YI@H.18.Y66^XTR9V7.M7^33^8.L%+>#7@_N^LL;K5JW4I
<+2QF2X&#^HL!%E4.(D0=H@Y1AZA^FUI^J.M\$6(N14S9XHX^1.L^EA.*\$;?>N/T+;S\$60;I6I;KHXLN;>)LO\$S+8
M66YW&IQNRH0=0Z8.OF**ZE^J)I>L>NM196T\$M1@AIJX\$7)QIV^8?345S^W^C^H8,"5+EAJA^U^J\$6^D0=MH@Y11WJFY/1.@O-OG?
=DMDT.EW=736\$RS5HJG<=(^F4^TSD.LHJG<^Z.MR<^!T5V;LHE6KIV08D\$^>6^CH>92/PSCX;@9M(^VNZX;BZ^CZ+8;
M^X#&@;5^*G)GJLDF699;\$4W\$3=%\$O.#&%MM^LE^!4A@;R2PHEZW^RWJ3C)M;Y+7I7^EKPNIHF>X64CAJ+V^8LI^F-
+8=3=4W0C;135%5%\$ML2VR1.M22I19WJISA08YUQUK75M4>F3B@BWB7>/7K>+2;2>D;H.LPBP8DUB36)?^MPSOOS=I^Y^R156^U^VZ6*
G^M.9WGHKIE\$TBD81;J\$H&D7,1^HE&RCB)EH.M^C(M(TB9I)1^JN4<1-(I&\$3/1^HEURAB)AI^HXB9;I2.DFL4.1.HE\$3#2\$
M1LDUBIB)1M\$H8B8.1;/D&D7,1^H%#%3C;)1MR%?/-%B\$7PCHC,<I8^@8P0=#ID5AVOEI1ZM=VVGDI9+ZFI1#;^R1.M\$SK8JNDLX^Z+G"?
^&=FOHT^6K6F5GZGZ1^HUB^C3^9;UDP7;P8>#M71856@/FPG\$S^1Z7PN=K)R&HJMLH>ZI&=>5IMF5ZAM9C^56UK%ZKI_3
M5&OICP9;HN01>^0G0H^SGR^L^R1L8^XS>PV1)6;Q^<^W^26W&I9T6.KIG2\$D.M^HOE<^L^F^"G&G=&X^"B8\$Y-
F+LH@P\$YFOZRF3POX&>4/W55^7^U<7=C?+EZN;^4>S59I;O2;3TP.M3%CIZJHLZ.X&2>(\$(?A91>5AY=MPDN2KC^HC9XL&A+7WKL3?C^VU.RFS;I
MFAYZ^R83!/Q9T%7H7")_G/G5IMSJ&\$DBS>+YNP4I.SWX_4%NC30YV1N;M^WW15^K6@;S^R^FOC!K;M?W;Z&Z?;8EAL-
HWR@S+Z=^A>E16)F<^I)O.MY.MHWR&87-/0ALPE>V!+8PH2Y2?>3^6/^0Y;=VT^6&W!6^N^N!><M;I>7.ZY.&63^AB=3AE+I.PI0?<I0^#-
OT^DJC\$S^46BK-DJ^I;N8)M5H.M&6?>FUV0J^@8AVI7^C^O^WRJE97&A+7NR.W^A.S.OU^8KUB.VY7MJ9NCKLI

MJK1TV<6^E6INK.W96H2XLZ2?@OT&^%ZAW.G>X.FH10=/U.VB>M+LFA3GLK10Y;^T7HH=L8=16F.NJ=GAXN2V)1X%;X1^IYW.G@N\H+H-
#GYI@MI^X&W^#>Y>P+T09AV17K0J;6=8^DTA^#FN/I;H\$0L^3<^U^P.PTIK;^N3EJ2^3AZ&Z^MBW(D46@;MZTfAX;{0P-M6I;X@&&<3#5*0;
HA5=1^HF_MIGD^\$AQ5U+~W925WH4@+~K^NR#AVSG4<H.OHHL8V~H0?_39P.MR6Y\...5-OCDT>^HN!H)~ZYH.T%U.WOR&
(/0\$0#)R2~ANMH8#~M:3=0!~MJ5*1^L@QX:H=H51/TRN*9M78Z=BR&WAL@2_E+1^L^MMS%6FX^~3H=5V;Y:T_9ZI4)_R&X^K6!WZIO4!
P=DAZ^R1778.PRB#~M+WCDY^6+4M<HLE.G^OV(TR7CJGP;9SIZ5EZA;B^H^8A^%Y13/5RDUI4I~M3QE4&M@*G+HLO40AU&^L2#12(P-
I=MZ0^~?..#N^+0)S:1UQ0^KB2+IE.M+AA&S=I:=1T&M<()6MS8>ORK%;TY~V5WNI5X<0D)HH0J]^=E*;&\$5)#9YBI
M#I>^G=IAT00QV!0Z93!FT&Z.1.WY!=X.UYI?G794C>~\%IQ0\$Z@?;E,]>%
M0Q.VB1IJCZ#5^NA_8#&L#;\$?7K&V3AWQ+@^A^%MB9;=C=L.M*B?;IQH^Z\$ZJ.FR795J2^>F6(HI>~.S=W\$Q)SY?
~>6X>FID2N7^KICE=H..M>ED51^JTM4.8%~^V.V~MS&N2UCD5:FVD6MVH;^D719:MAG^IBL^;H!IQKC.M3PN:H/444^3.+X#YI341RF73Z\^S
M^~V&HDL4.CGGC?&<~MCXERA?>F9QVY5WME^GJ(M%)<1.3NX~LWXA@=UELO%~S;L.2O.P.VRIR06%9YU#HJCQJ(141EFN(P8=
MP^I+HM^P^0RU>T@4=IUUXU~V>F776HH^(2IU9G1)HIT2A/BSH2=G@/C>MK7Z^HBS(R7E~C^LCK*4,6TU~;6S~;NEE92=JX76W>~^7HILDRIO&-
AI@~MM6906&N.%H(7&^U^#77J^M0=OZKNRQ^N\$SI.99VA648OP&F+EYZXOJ35P.MIW..D;6%DL7E21_17YJID=@+C\$15QJBJ>1_12.57E.KW;F=
CA=IE5^~NE.MV_ZM;7P.@5Q:WN#5=U/KU#E+BW3%G5?0&L=OY+TTHF.XI.G9^4AMEI.MC^=7I^L7QVE2NIK.@&P.L\$YB(^IGY6,9!0I?
AQ(C%)^M)MY<~8=2~.F.MF@9Z^0AUK_1^#345..UM35^KFOQ@/S(HJ/QH;Z;C7X2/QB^H=H@A)2N(#{QN}!MW;^K3214FCF/0C.9-0OMNF0.2@7Y5-
SYQ7INU&Z.AHUFK58XVGS@TMC7?>ARB45_4Y6%+I@10.NI^~YHCO&^YBP^EX;K@JG(M^OV.^JCOAF6GKIKJ;^<C1=4=%MS.B.W;@A7J?
MB!^PO_0@EQJHRW=VY1;+2T<^!~SO2^B^_PPI>^WHPS.H0CM0CZYZ.JR^!=M1HC*7_[1(1.MK8R%IR*8UFV.9;G4,^#H;+TG!5CXHNEN-
96EG#;THE7R64^1.OX1!%*Z_M4Y=VDM+K=K(ID8U(TF^U_>1)3%KZ^;K/ML5_DIL)0PPAN^TD6Y2>7W1^W2;#(\$+^FP@.CS.M0%(AS)^+T7NU^X%
(C_Z3-DLL(RW^5)FTB9(WG+?^DX07.Z=V1&N~LFIK@D^<~JFMKIE^FC^3L5.DML14G1E!T!T!1WL#;6\$6Z<4NI-G>9CWO(\$HM37@=D^)=9H?
E1UR9M;#MA:~OU.G7.NB?ZC9Z6:YO/2IUXNA.RR.6L3^=Y3?+MO.@@PPDF%N~2^!=MK79
>M0).YI^E)Z^<Z\$=^):LY.33GI0V.119WTBVTM2N^3P.BAIU^3B?>~MVG7(I^LY1.3&D^+R~Q^3@N^_AODT_@?&RYWH;M@CO^WMJE>V9&PA&9!8_JP
MO.EFO.\$0;H/F)A/X^5K~8!6V?^S\$1+7ME(^VCRZNJ4I===Y<~?X.A.M.AE8LIV9FDI@U^%1\$3=<~
SSX8M4IN;+7P3MK16ASOIH&^=LRS=^P3T>V~MRRP=P^I>/IN&/P^I^O&40^EV_(@^@~T^?0\$C^?3!H\$+FOCQI4NP)E5-PR+Y.MISRJI?4^IG-
Q&7ZCQM(HH)MUHO^/LI#1\$ZB.NIQ\$H^K>R.F.2427ZJ~V>M3B>#B?>9.FLA^*5T3N3;2DC_~L8#;~.D.T67\$1XWVZ.WGU0/M^I.W.O.MO+NI?_C?<
A^~?S/TE;LOH.T?9HEOILG83^C0L!H(S21)HE0TPZ489..O/K=^MU@=^A\$6_KLN^!FR0^TX=E^%\$HR.V.R)!AT9;^1-B/(<^WANDM+7WU.MOK3IU?
306&89X.S(C=;D.I\$B_SEF5^T8VU^S2\$+?+^YNP4I_SWX_4%NC30V/MI9;~^WV15^K6;@~S^RFJ0A14^*!6U1GXU1;7~;W7CZS+<2X.R)2!JX>1^M70?
#~IG&#;WE(AV1O(L^5PB_ESE4ZIF=)~#P%PB;<54&M^~TMM;=)8^N.MX^RYBP^7IPPR!>H&K8D=G^I^AV^YM&C@LD^I^UJ.5I@LI3D!1.SVY.@2.V5
MD^G+>=<5\$HIX@IU^X=S)P,47>+&W\$4,Z7:FZ2E?^9^T4Z>I5;D^D0T&>)0.1.HTGS65H^W^6H
M+AK^TO>V9Y&Z&MMTZY&GHLOBV21^V^Q^/CX@TANF^IHU5B@+LROPN+X.M.O.R.B.S.^F.4E!EAZ320-
I^T9^R\$^#6IB#JX7^S^1.%!..R4%1/^4?)~M!5:RP)UBIH;S^C!F7,8\$H.H%8<XC+1+;Y/9^MVVG(0\$;9;BU@892B#?Z.MSCX\^0!2;
<+;GR.B#<^>CIU&08J\$G#~S^C+25\$Z1.1^&&E=V5>_450L.M5UN4Q!R!~N88HU%M.JV.O@TDI/P/SHY)%6MO>;=>IG>=>PK^IX=8?M?<
H)WEG.IJ>L&G<+<0CLK2^<^PU?^7H2O98;~@CU3FI^IRD2D-ID@N.A.MIH(X3;N+7;POG;@~%2&APO!EAZ3.VX9S21X/PWG7X+G%^^^O\$-
!%#^#6Q.M74=Y9SK>R@.*!Q(^Z2EO\$(H4M~;HJ\$Y4I^J2^?T^ZTAUP~B7R.NI31K.M)YA;^K.7PO5#;."MX.60(XN/G4TVIWGQ^B.6\$JFW&K.MT^
F/FZR^=;H/HIE35EOITG(1S5R^IP+A/4&6^J^P5HAU^2)=O(3Z(1#1TJX.MI#H69VTL^0K^4.IE^WW^*K+^#C.P+0>/1.P28!IUZ@3!PL^TCF!>^MAT
M3IX^VMDTID>2>XPJ7^H6S1@^T93>9Z^THD^NJDJ^XGCI0^=H^6I\$T=I&A.M^?NT.IX>="I"=S.OF!^1N1Y4/4@H^HPV?>N9^1LW?2
6K;@)FYI!&6.MD9X>CG+~.VZ&JLA(%3_L9^CAQVXJGW7/FZ=S+<0\$Y^A)24X>>)MIS!M^M~J8\$J7?%<IAC=YT/U!N.RY.I@4YIG&!)5@XIF&
MJ.LF?_VO#)P@P_B_3C^XNZ7<6A;H)R&TX60(8S>=S8\$R48SK!BNHOU(&!<^VYCI^CHLC7.G^V<~P.I8\$H^<4!AA^(<MOEP^ER#+
IS\$P.^B!&RP8^_G9I^P@)I_Q_KNF3KX.Z^@HZK>^QH4S&K1!JP.M#~TU/Bi/R^<+^ITQO!+B^*Q;L3XAQ^A2>T.SA1/E9^?HFC=UFZ(W@RO
MP^f;IXUC%&LWS4I2F2S4(8&C@H^VWT^T1@TUBY3.C8P#;XXY1%4)2B<^/D.MZ(^&C&E&+~3?>=>#EK#?2BL7CEH2..IPN^HWP~04M(QI)ND(
_PLLSIB1.M\$8LH)V29(6^~LP2C~2ESEW&MQL8\$H@5/(&+H!*<W+2Q;..UPN0YUIA.S^I.M^NY3DQ^O(5AH.Y;^NK3@Z59.\$AD\$>@7JWF_D^PEN^?
3@/0^~LMP.M.X&?+/6(&^)/+&+BY4C+V+D>XT^I^W@^FRN^T^08_B01^70GN..9*O.M+T^+^H^K/BT.C!@>%O>+^E&?EVH1&~I4\$;
G0)5\$;A^S)N;~>I8(OQ6L+M.T7\$M^O.RK.D%Z0/G.BV.FR.8\$8^KO&D3/C/K+^F&6BASC..B7LD^%LI^TML+;*)=5!A>20)HJ!BUAW
%_Z1M&4A8.Y11>+I+3^6.BVP#%/B.MEAIJ6^@OC^U/P2NIH_3V.Y^~%B^/X^I>H^!X7CQ.YG>KP^K5RZ;BD9B^B
MPU_>S>C.892B0Y4XK7H^A^M\$=^=Y^R.C%BV46+SS83ZFUVRGX8^D^M^#0^0^&BQ&XH5S@SQ!LILG=3+^#H(>>B/M(\$;3^ST\$J!\$8(\$GYZ
~^ZYG!~^KHGE6%Y3XO.M^FPZTO81.PU.V~IRH%>4YV4+I2&T.WMN^&F^0190<+60I4;JH8I.NDI.M1W^U2GPO+1.WIY2IE^PLZ1!\$)&UV\$RB/^
;SFSDD>^H^~&@/_G@5J\$H2L^E!~.=\$Y2.%/W^<\$WP\$7A4\$+QMEC2IF=^@%YD+CK8\$H..M7<.E4X><5_B#A/#YFI=^0ZE.G#/
M^;Y.GB8ZVN^P@T14@CIEA^@V04+514=O>^O@L^W4R14\$0?^IBJO!^B^HJPN@V+YNIYCHXJ^7Z.M~Z+^BE+H<^Y3T^XC<^HIG
HE!R(L^3^NM!&Z!O=CWO.S;@.04A_Q^H2A^?7TR345%;&T1(A.\$0I@U^X881+ID;Z.O.O#H.B;L.MPPE;4E3WX-
!HD#2_1#WH%~HIE+BYIHJ@IDAUS;A)7/S66>I-C-3UP7^W(C.MIT^*7^4X=1G^(*\$>..D+Q(FKIER)+VW=^\$L^EU.M+
!SVHES4KH0J;9NJJEKD^=1UUA54IOY.5LV.9S^L12YEBIY>(S9=8550683V@M^"M^Q&(8E^Q&ATS^NHZZA0HJX5EJ^S^HIM^*D#8>H?F19&@V01B6
B^6G.MZE2EXA?Z(U.CN@IXPO).RB.@7+YLFU^51^63H..H.FLT^5XYV+4+J!^XK!NRH^V03K0!U7C6;0I58SZ(XF);VW8DI^X
MIAZ/M^14J>7P4?=>C/X.#8I9%CT@V93@I9JSOW>XU1S.HI6ZU4J=^C!^H.M@P(NHJ65))C^STBO6@9;=2JLC^4022#WA7)I^M42^#;C!OU^R^V)1)
(M30BDVBAS;53-Q.TDD^H:274=5;K+8%V14AROM\$.*8HWN!6.9>2^0.U>KD.M.W0YA0.Z&Z>J^A7XK+(/^UB/U.81.VO.FH!#(UO^Q;
H4!5.&92XK5.JC.M3\$;=UTZH~LNL@UEF6FLHL\$J;2J?9^KW7VO~HD8Y^IPU5Q;I=+1^3T^QR.MF^YZYZ<3WL^H>N)-5&K37H;1J>C+61\$90;~
~.WJO&OAZC^U^5JLUP.MZG2(^U5U7HU7\$E&?>^5KO1_902SC&^NAGI7FIO4P=RF.N&VW:5HE5>E^*W!M.C\$CN9<5D-
5ZHVKZ+3(ZU29EQ>HZYT^%>62F;RA+W;4.I&\$356K(N^)!FC?#>~O_AEWI@3IU.MTU;P.2PH5Z^I/+57+J.4QY@I=G9EGX7YKH^F=?9;S:I
U#3RR03^N^NP.MPIS/C^I^JWN+IGMIZL2%IW&V(62T<AMM)A^+GV.SV9=&>JRC+2I;^#O.M6-
V;WH&~P=CNW^K\$=IMEG@^/~\$C_5\$V.NN8G^RG8H((RRW0H>GL^Z^&ML?>L.HR2=5(H@J3>L03T@7^P>(^#EO^GY>L.YWKV+66.K2N
[NEO^_O!TN)&KRAMV@~MPUI8)DEF%/38IY8.SL7\$^NIHJB/9>GY3M!_5ETIT(T5Z)ENN@I^+!6EGTJ.MMS!O5UU\$>(@=^7V62;H.9;_IWN.MNBO@1?
~+44\$5ABT&YI@VJ7_Y>U>Y^&OG5.C^2\$XEN\$G#8UR_6_4H.M.JB1J.4W>^MZG@IX^?MO^ZH(DNYLXL^<6_6IX/XG;8^T?B3?>+F5D^U;,>/MZ!0)
~^J;H.H)O^J7I^T!T\$O..W5@1>V0W\$R^M^S?Z#1;1K>~>7S1.MBDJR.N!K20^NIHUPAI;9;0E.C2@I/V%@QLOSUR.MC;8^TB8?>
=+M3H>~WIMTU(D^<K>GT^E@HOUG~R8.L0.U=^C69+PT<=YQUC4.MN+~WTEIO~P^QE^*AO^MG^IOU18OU1&.UP58.M@*~6I@KCX^N@GL6%
(Q(+6<~&4M16+OC3F70&I^!>=>F+D^T.E4^O3^Q+P+^MXXB;?58L[DBS5N]3R^&30A^0^0P1IXF9M^BH\$SV;2&R.M/L\$<%A0.A.^!FLYGIAP+8
N0!1.8\$)(XXVP^FC3A+AOS^M2@35#W0J3ZA@<~TJM3?^DKQ>Z^=OH(8@<^LM^E0!1.M.\$64RBL.YYTXB>?IOF;M~^L!3T^%MXR
BW\$^H2D49;M!^A0%\$E^/N^ST^K7.@KQ79\L!^2L?WH(%&+%S)D~F+3PB43HP^93<5M@F&3.HZLOX!4_@YO>AHPW2/(Q=>2^S.M~L
UN^2%44SVI27.K37)YPRH\$X#;4+8&6!4XO)PFSAU\$S.YL#VP.I^>)FBDNW5NB9+^F13@/M1RY\$70S^!HWDG;WY=Z2+P~E+!<3^A60E8P.7!
SH.VF8/_TW_~G.M.VI^9X3^5GM6&KV^U@O7F2I8.CA3IO5P^M~#^4B^<^YJA?A@^K^05B=>^FMIOV06O!LD<G.H.64JO!+4J^IKT03\$8^3.@~MY3^<
F=N.H^8!E706QC&^X@&+M@UB6(2=1.%HA.M\$~L&RDTH^D=^&H^<KEV^QXU^Y3N^00^"0^"JD%6HJO&QV!&Z5;^6I^I^%\$M~
~3.^#10206Z094+&R/^719LX^*6I^O^\$HAF9+~IL.CXTL&^<~WS3SW4.MJEX(86I(C)=PF5H^W1.A^J>^&2F0J.2J^20W92~PU6G3X84;2_%Q^T^V&(^M-
~*@N.6#3G171VYV@YP.32%0IH\$E\$^*YN^;8.AXP<2;N.N:20\$+8!>~69E1
M!^OP<^2SL=I@H0.P=U<1%7I%K\$2F^MH9+^9LJO!AQY^L8(W&=^@DQC^I.M~8S.^0F>2M^P0MY=^I^<X.E^R!^%JZOY(D<
\$~0\$5NN6T8G5XO^?TIREJZ.ME28NK7VU9J7=N.MUT.OA98;A1.VH;3TPK<<^&11%Y^LW5=DP=NQ/\$9PBKYI?V^*#L^&L00;~MP5L-
^MJ^2BN.Z^UIPR(L)=@+&H^HL0YE^YH^N5H6Q^4O=Y!J5^WM=H1^H.M6N9>87NT9^FSZ>=2J(2+^G^YA)\$^M4)J7Q^YYTBG9U.D^XZZ)H^A5vP(M
M@R;P.OA^6^7^UX#3YCSH9=SA^@Q@!;^3S#~T/I^&R;^>1\$EKGK@4I;C3.6>I^WE^OTP728?/H<L<S>ZRDZJ^=5J;7UO22HY^;WIGNZIOZ
MAKJ2G=F_6YN.UVZKAI^X#8I545=5GI8FSNL_PD5?=.8LWUR^QW(^86S9G@C^FIJMO^ZLOUG0G&M
^ETBHW2^IY8.^Z1.TCHV9^H.O6<5#^A8+D^Y@<%Q^WSDI2^=H^@8U^M^MQX^D8B1(%<=OGL)KP80P\$N^I^GBVT^I^660S0WC^JC5)D^G.XOXF(^L
ZGN.MSQW^PBARON5LB+2O^K^I3M5\$92R>^<I.Y^A@;~&1R2I5^A21+ZK9&ARH3I9.MC^!#?2^9N.P^URG4>I=&M.G;^=HSA0WQ?
E+>\$7.4.89/I_45Y&.E^";/O^<0^E@B#QC7^=N.I.M>W@I^8(B.69;#Q.O.NN^X7IO;^C^C@W)30;DJ&91;@I6)=%I^N.S.KSW+Z~I^?D#^KM7O?
7DY63N!LW+^315GOE5^Y<+5;+1.XLOE^M36WQI8=(XBXF10CR^;CY3L5Q&?KLO!H^I/GWGZ!^GK^@W.L0.X^+XV!\$..BB.M>~.W3I3(ZRC@S
RCIG+^H<SM9/X+20%\$5)NBH!8\$5+P3S+NQN.W^?1~JNU.M0&I20RG2^~WSH.P+OU@&^S;O3U^IH!;DAO.LX^S=9@;
IFRMJEJ67BFKJ;Z.LS.L>0!_JUHVV+96;SVIX&1%#J2DB0EQ90TI%=~21VDI(KCDI^M.C5.24HJEV~1_2%U&^/L+H)^03HU2DI^V\$5^_4S4E1IKCX4
I4THZ02U;MUU\$5M2Z@F4^C^WE@A^LIL^#4%7M.M1U;H&S^S2R_4Z6J+41ZQ1M8B5I^!H2PZ.LOF^SGDN^E.Q92&DBE=EZM)2^?M@2F-
ZL^43J^<.UG5415=)YZ4F4T^*NY^~?(&^!2^O7D.^?TIR^2&^INW^Q%5~MS2NK<5U)A!H(^IX^H52)4..>&4*!>3&^&2J+^IIVLZZUEI?^#EK?^E;S=Z\$
M.JW^N~/7FK6!&%KV/6==0U=(>P.JB@8)AV5#J2.SY.WG;P60W&I@J05.O.M.KM^<3^K^<^&W4IBKRHK!K.M^2)2A^MAD1^54U^U^#7J-
<71457MW2;21J^>M1BL7HW2H1B6)2A^MM1@=7^X8;VQ7I=1Y(3X.U6+^X.6ZZD!WM55I4WAI7B.MX^@WER>G&48K^Q;3YA0!
Z8QKR24K0\$CLK@H2?V2<6UH@J08>V^?M.MCONHNVZ^S^I^HA/DG<C#4K\$>^DN>PPI^O/WP.VX~21<1H7L^YLXS!8.T>~D!^\$KXN#
ME=LI+^S.IM03M79N<I^U+OHNFJ@^454>?IA5^~.FF97/O)^S^EQ40X.MD..8\$Z5VPYK2>A04X&URC084^KT^P^L=^EXO(I^V\$8..A9/E%@HWQ3?
^PZ^M=MM2IGF=&J&K^Q=IYWI=N;9GRR15Q005^Z.M4^S^FC^WZC8?GKZ@0RI;L.D^E^IDSCJ<^&(C=ER.G;+)^RSJO~88^L!
MP@C0FCIOJHE47Y9EB>I.^%OPNK0QIU!P2^4M^#4O~.N%@<(3K@T1S^NU9D.M?1M6+@R;VA#B^0NH.M^!#;2)O4E^E(JFOI4=7RL^BV)-5%~^U@1I
I.ZEWP.AI(HI^IF&IEX@CWD^N^004I=)1.%#0;1^M;2D^I@R.03242U=MUM>R=2266^HQ%~I^=XV^JS&^IH%~PY^B=C91=^*L.MWPMBH
DSI^@.FIH?EPK0^F18^Y7CE>XGZ!^IR!E^GSBA=1N\$C>..OYCV.MDV.&I2UYU6^~.69MI2L0TOVR^Q>~0IM(@2)DNR\$DL<7.N~E9JUCK3
MCGF2^#^V^E!I3?&3IK\$NL13ZNFH2.DX^MMMO^FV^I^L2_OHA^K!&=1.MCX)Q\$+4^H^4!68(^3.1)^FKR#~O92H\$XMBHTW^#A)O?
(HVC)0WS\$3G0<@QH1^*9Q\$5\$7^*\$(92H^I^E16E^I^L<5(U.MJ7S!TIX26K^FOAZC.QQ4Z\$H.O@D^>9;QI=I0^=7E;I^9)HBT2J@K8.MX&?
^(<VWD2>N\$W\$;/=^*6LJMF^VG!6AF^%KP^55^YOU^?LI5;R76B/Q@~)MID>A(8&@Z/9CZ1/F8.T:9V6L;\$K8^S!D;(^HJ6L27@@IRKI<.=OEJ@;
M^I2^%HJ7>=Z6+EX+9&W\$=88Q/QIA3IV!^LW^=6Y\$F^F<I@#1.MYDR5HW=1+WMU>@BR\$@20.^2^UIGT)^2+O\$;9V.^PUL;U!4;UGER.C6;
(AAN4.C6YKHIG!040D5.MR^N8<5M.@!>=&6SIJH41BSZ;36\$JWA7W00SXWR2^MOKC3RL;L!%OZ!+
M5G^V9;H1V19>N;\$JUK^K)U30W6^M^M.WJK6OZO8U.N^..YSI.HL^0+Y;MY8/IZ8^/GLDJ^P!2RC^&0.I;C~;=X0>3MCQB
^3;MWC7>13916.B.U)=PW@;7XN;I&K&=2ZX>MN.R.K+?TBSX=JIC(I0Y;2XJR7&VU@K96G!9EX\$H4F42;~ZRYC#;G.MXF^9N^E7U!^7MU+
I7U6>~GR>5SOBD=WI<^UXKSA\$4T^F^=12Z^KCXW@O.MZIFV04LW&^I^Z!M;NHUWITG^Y^A3^&NRC1P_7G<OD)MVER/7)77^O0?^MM^XU^JP-
^ETH4I?>C(OY4^IDRUKI@A3^H^EFM^&V\$G^>=G9I.C^IX.MUK^\$FDLK\$!USFV7I#@M.M2?G^A0F^R%&H^H^UVC.7_1&@H4F8U5<^12VODIG2

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~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~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s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

[illegible]

```

MCO1 M17V^Z,OY79),FVW\A6^< KUWQ,C=9,NF^<|OFE|,Q# M:+X+%-R^28R",D6=7A_B&8RWO3?T@0YB2T3_ZOTAE M>5|&CTP/X^Y?
2<<S|TIES|E|F|Z+>#)CWCUKU=G,1M<6G2Z^1UU6U^<|A:7K7|LNDH3A_Y/9."Q" M$813FW52<|D|2>AG<MG2NL,BM?
6GG16V|H|JOTS|46#>Hf%0,9+>7D=^ M0C@.AHHF<HE8#>E|H|NH|S^2CU9U,D?H;U|V2^1_>XCX.R2,CU*.B=N%%Z*14H|fM>'B>O*>?
ROWA|AR6=^,9E34I1 M|51AR=|7^FHN1+|fM>'A;M=MIR<2=N|>^:KTI&
MZ"%C#<NMBC"> &%477#?>S1M0;<?W*W*UCIPZT=|R6I9XA5UA@A@K0=A (&% MOU|H%N4U|NY*DKK,WU_KEMU%+;;
(<V2H4!;|ZD,I6C,V$,>90SK^9R1G,MK AGW^0>QX93U+<V71+<:-Z@?>O3E|<@KJU&ZA+>4N|V6^<@FW0+2XXV,># M|V@&-?
MB@>1HCZE|K;Y3@?0S?>,B|H|QNS|VNA67YY#C$@NMK?+ MR>=>3|fM&D|O1U;L|= +L+%%H2G2K27^2T;ZSG;MH|6D&NR4&V^<P
MWIG|>G=|3/9.992|W0,5B&^VZ3BX,O+<NT,Wf5|MU|ZDA55H|H^M|)HJC^ MCZ>=<|RH5Z3^>2<7/NB|D9G+<-RB>A4ZZQ9CG|S1>X|UM|),L|BW?30,
P9|,M-#5/>AO|<T M054.P.C^"T4T+R|+QV2?0968XJ9^W3DDX5RA$!|6-K+|fY M MY*U2?^ GM-B|Y;
>G|KV47|QH|16D|T|QO|fV|>T.T.UG^H RT|AN&C/|^6(O(|X|LXPX?/=>%%E4_Z&WV1 M;|:TN8|U695&F#5.D?G,2|SRX|;M H+KHE+MK_R"
|CH@X>=>#|X#> D7>0. MS_CQ^|O?S3^<@:7=E%|UDZ;3W7Q|3XY;A^>M^9+U5P<|Z#4+>.>+<LOC_MU3_MIR|>)>^V.U71_#5D&|H?>-U?
8XY<|R_&X<9+V|W2H_&8F<|U|<=>^BC|9Z8N M<54;NU?|UKZCN9R;6@<^3O^?|H|H2E8L>+7V_#5BCSEQ;(^<^O|X_0?7|>|CDW_MR@&1&P1
ZUAE+|HC6A^>|TOQSBJ.TC^Z<T M9|PR_M^>|I7U159;C/R3_N#. M_X5L6=N^S^?7|35VAR_/2(&YJU3CG+>R.W;=>PE_7D$K^HK?|I7^RA8FK%|Y|D|X$-
ET^>OABMO98.DWXUOGWX=|7_MCCT&F;L3K?=&#>;U9GV&AW.Q6;|C-L#|I#O:9MUF1M|(*2LTU1+T@(&IFK_M#AF^#>OX0LXYO_EM-
RCHR3DW|>45KM5Q@&A^>A^VC,S1H4C^>S1A^>F|>);,1M.2?K_#H+>#|F^ MH_|B4W<|B&K^>E=NS^E=C%5|?#7J;O@>Z^LDH+QO|UW;=>#<STL>EA^4*M
MNO+>ZS^KI 40SP_B|H|K|J3T0SF0A<_4C33_519I_N|3_1-#>M-H06H M5->0K;U^|700Q%L+A(U|H|L1G^?>7-IH+DNCM M M NNU#PY;6|
%>EC@|MQ^_KH84-0|6&^2OHX_GGT|YYZAJ4T>110?+8Y$S< MBCZP14BKVN^CAJK=&E6W^NW#1>O>@W_B9?^?8J<|G?>W^&BN1X|MTH_7^JXA M^"
|>L9RGQT|,M9_L3M|>CS0^>G^CKTFL&|S6+|%&K|C^A^F6QV?_FM|AUF28 M;X^WZ^23IR>(^<2M932^X3;SUSW64|L
|>=>I9NLK_W^>|NZE|W|=0K3BAAS_MRTUB^EUAZM_(H|Q?T_C|<1VA_S|>C^>|>M^>@QO;|6^PKO|1 C$>PABQ^*X|&E&^&Y MAKI_0|A|_S|&-9,Q#5?%A^<C|H|&|S4-
CK_/WA9M^S^>VAB|QBSDF^>L^A5%01C) M^W;=>7#(M_X99^QS0$&0CC&|E3_7+^F^|D^YTR|L|=T_-MOK^<ND+ XC$PW6|N#
XLR<^<LC^Q|O4B^>M@<^<V|9|B|1VTS2P>)>L&>6.114?F M=H^?WT3>=|IG66_YA5^M4,FQ+QGD^?N|O;Q2ZMK=C^V/&51^550;_|7@G|ELX_M2@<^A.XR&-
|>C93=>=>RA|4+<X^>|W^>| ACV8^4A;| M5G8X>^<BM;8(BL^<VOTS,NW;B|L1C6T|3J;+<CL5A6=L>4OY/ 4228XM ML3B^ MS^<|D=,7B^N|+>Z>|M;1#>#-
X^?F^K;_97|O@<AMXAWOK_0C%>S^_WC^5N^+61P MD^9|Q(4_#S$F|>_2A;|>5RH+>V^>P|(^NSL^_A4992QKN6|U72|S.MNZ;
M|9&+>S$R6^>@1&^_KV/=>ML868_#&^<V2U|L_9%&|<^>Y>1=QS9+2|N+G5D&^>_#* M_7>2#E;L6?^_HY^>+ O^K#81^>|LGF$5D7>8_<IK(0_Q;VOW.%X?
+>S$0@<M MP_E2^<A^>|>N|AW@5K(E59B^4#RP|5<_>M-|L^F^K-<C3L<=>_#P|E|C^FPV_M;704^?|>8+>O_V4B
<^>|X|W^<BOWI&G.C2NZD|YZ^U|Q(Z#TU^Y9C_4#W^P MEFU^<M_X6L465|YXO|RN<4|H^V9_A^>|H?>T$E$RGP_YB9H9<2^>|MU(Y9Y<
M^BF9M6@<C+>D06R(|_Q#^<E<SC>|X_W6W5|/|*6.)Q_>=>7%AB|<NKA_M*1|A4^>?X.G?G|EW@<L707|WC2CUVQA1;O@?
70>|I#80O@<PD|>G6|5&Q^U|@2&LMD3WP.ON>_>|3GY|GX^<#NZ>=>_3B|<+>V MQ|V8|!+>ACN=>|9@<MHW>;#CE$<^<A8S!FNX?EZ?
RZ<^>H>OAOYRY>O_ESZ,H ME3$0EK_VOLLWV|L93=4Z_WJZ_W|IR#2= OS$M^>S^>|C>4+|I$K3P@;_ MNH=|QOT^>9_V;^?Z;S^<CA>*>_P|O|3^#|H6
?>|%@<|6Y4V15_*M=M.M_M_NR><+>|H05,|C.K|)%'-NTEZC.Z=$Y/6?ZG|>@G8@Z%2>*G-#<0K|,B^T|YX_H|16+9=
|U2>|>1^BY44^|_H|E|91CQ=0K3Z0P9|H+>?>^>L MD/(R&X|166V|E|OXM+1^SKEI7YGR-L M,PCZBYE|>C^F;^>Y@>5|WK8_>|A3@|A=X|B9<@
HT$|W|L^>=>A9,2|82^<1_#B/ MX8$OW^<^>|Y|KIR^>2+|H WAS2|E^<A^M6K&T|4|T9Z|@<Y|O|P^<C&_M;1+>O|BXV|^>#> YM(|%>0A_>WA5$>?99^EUI|GQC
>C+4#69BQ+X.T.D@.08_M A|&4E&C/<@W;^>|J<_@>#>_|S>L8:P3_M<^>|A+WPW_<C/X#>_R^>%4W_YH@H0_>|D+GY^<CP|<O+A;|/D_<P|Y^<V6_MN8|C00?
@BR<<|>_>Y%>0HH|>|A4_8^>EDL$^RY_-Y^X<D^>2|>L|A@<O_>MSSDN^#1P_#5$>+<BX@E9|8P2^>)>#^MD&A|8H_E0#47D@_>$?
DWB+9;600>M|/3<|>KFGYGN8AKT4M_MT^M M=M^>D42MEYV5UMNOXG+W+>9|H|^>W6^>B2^?>C^D6LNG^R|8.G.#|>#>_P^>3_D<4N6
|X9|>1>4+H27.11|D^>T^ZG;U=>9.5_M A#>@DE|&KF^<PDIF5_>3G+MYV_1MRW|T^>XIAEFV2XC^>3RN^<$R|> MK<^<B^K|N|^|SQO<29|
Q^>L.W1^<^>A|2LCR8;W6O|>S6 MG^>2D03^>F^ER#&2=>^>9=A^<RW|A4+<CHAS^_>BE/5S|ZND09<@<|RIB^93W0_M_9^>Y^M3^|O-
HXB^5DNKA5HM|)%>_<^8W6CA6>T$SX6E,CUETX^>1|1^>S.Y|Y MS^>+O0+Y82^>S|>9;YR,K=8KXPPY4A|P?H_MRF$S&6?BP8B_H|HC+5<+>R'_>#>XR-
|Wf6|PK&gt
```


PQ#R0IUF&0T\WF%<'9\$MA6IT<(%/I/OYKQ02#^5 M)VU0#(,4107D<5 0JC3D0;&JD7S\<8T-G=8R HNV+PIB\$UH1 MK\!):BFU:=\'GSED95A#4JZ? HM~^7<K19\~1L/7<IWO?72@1-6N3R2+ # IH' M\$O%P46E2(R)YI-D)#M:HG:M/OZH>8 \$LX(%R\$!>1Y(I+9FW=:M\$!RH? CA0YRFC&;VH<,&_9;\$@(<~Y2B1 M38X/2T9T3;74X@R/LFFBQ\(^!5@=-9C@WZ #3ZG+M\DTDW&I6=/B^+V):55~3/@-/~)J;LMTW.# IVE3ZX^&7@>JN~6=MJL-VP=J*O;R\$-PMBY\,P349EYVR9>SSY/ZR<#JNPGLA.G)>:0IDH2ZFAGF<DNCH\$?GO MN"#G-R'662%+EC~? FY3~15(PJ24)>4YNN>1L&UV3GI\MI262Q5\+L&M IG-FYC5XXVC%J-B#/#J9PGCALW~_2BJ2HPICQ6 @) G4*<4P20E)K0S1RWDR:8V^<^(&*U7.TM;J M7H;D;Q;9ZRC2?>Y^0Y)K6^H:AW&X@%9AH3(+3AFJ@I51\^?7GVHNF95%K# M:55N6>G&1#OY4'8K\$R!P!)UEBB~R1.JWUQ1YTF7O(+ Z8ORT4IKM*3_9A7F^M+;H:(Y9-55X^LIT3+7XBB220<59^2>_I7B?_)BIY1R+<+>M9?FE4WNZ&~MJ~;C.WZD2E0L%797VWPH:> (AS0_UMVZBJ^Q^T;D>^Z^N^M:6J0ZH?>60*8L6:M>BO9O\,UKO@H\W~6.L.M->%S3\>E@M>C&K^T6DE^JMB_7^U\$^?7HK4\^!9? B=%M.M:002UBE^H>4^BY M&^C?PI?HEQ4M5N5HIU0X\RS2N\$~76\$G2^QQ_#1@AOY^R2>X10U*+B%L~!~?19YV6#9(CUT M..''A90T.B+4O\+X=76J2\SY-O#7D+H0IP@RE8R.4%\$S\$19^U=T7Y\0EX\SB MPX1@E^L1% 80-1\TJ.FW6V\H=Z\$;_)2F^5WP0#3R9Z^>G>F-AUN>_)64:' MF498JSZ3OJ\&Z9SY2@_)O6RLM^U60@R~M\,MZ3.FEQ2U+M,I=W:D95;VM+J^#T^2^C9%+9WE0\UL^_&01430/M9R^@EU&F;MT;32NO%.D>_? A.LIT^<^CC%AP9NH79% MWBI6/EW_#&1^YMS.B+(<+>C Q-ZI38^<G+I_ZRSI?^H;J\$%VY+;O^YIN:% MW\HK6R3T^B70#;6 S;C.2JFI6K%TKAIEJW9%?5.Y34W31FT.J\$X@NB;~.ZC.M:XJ^A:HAY^~.K2).9+TQ^V9YUY6Z_+D2XYK(H/H#O?<>4+1=N@COE5144 M.C*)77;+26) F1MM^1J7&^(&?>75?FQ3M^M+U8FELZ&\$&0LWZC;YBU\ M=INC\0DENXB1YPZ\YK8.MB<\$GP.V=.#_#1Q6<2T5YJ65\$A;10>5;M<^*!~8 M583XBP4FO-ZL^OU6)<^5@S#C3D+6=&QUTW01\$1\UMF&B;^U0BL(5W8A;M>&6 7^Z17.7R;~/#%Q;R3YGD.15TBX00(7P^~AJH\$-CJ' \!T&O0.WIF4 M^IEZUTFWD*O.F8HDL~.KU%IG#OB0RQVB28^Y.1CI31QJHXRFVELVG)/4 M11/6='CCQB+OF/~JZID1#8@L^%9 2+^#~W\W0*W\W\PIZZA.MY9KN0^FC M;^<1^&8&V^P31V0\BQ6U.3ITX^4K.RU)#DAM5F&95H\G=@^K00/U-7L^!O>_M.9T5^K(+ YX\$<^HJ2R^!&#~O6ROE2VX0H 3GBR\AGI9W<^#TTJ3^<Q-O\NH+ ET M&S^~M\4+8/E^4_ Y9XQ_!(\$6U3SS.BL1L%= I@(&=!8)1GT(W>QE/^\$IY M_4W%KT2D-O^?Y&WO+BI^T>M G#\$S=9%?E,R\$^@OI3!7(UQ6BI62^C<^DV+ MU\HARIP^4X^A9WI~@%8 M.D)%?JV~ HXONROA4X\J2750G1P;#C^K4)<5.ERFZ6G5^ZZ>D(X.FGPT1M\)^D<^975H1^H9TOH2\K1(<-186U;=,R^#JM1Q^?59F0^#@=@=%IYE@*RP MQ\U^M4\Z_FEC8I>4 \$.\$S=QG?FAI8XP2R2059IW L0Q@V\$!MIP^Z>G#~;+IWI\30316.#)XDFQXX.M#~M@>?.\$ON?RDS'.E!BZ^&\$3/2W MH^S0EC=3A2/391-R^=JW^#^@<4!24>5;6^PV;=IB>|C(^7W;=>F^24 UEN%AM^B@E..RZ@7 \$!9>N\!L?P\INTKQDROZ; 4UMR_Q&V3U\XW:3&;4UC18R=KKM M#2M:H3=4>_7A^7.WS_3RV^S9%OR9IXC^PQ&03+LYE%|C~MTA?2077^ WM/41RAM+ ILR>S1^PQH7CIBF=*UC!Z;DYIN=KA MQFI9B#=#GHZA_>W5~8^\$2^ #VHT%*A6V1_#^EY<79VYUDWI@N%LC9) L^!<=MI- .0&@IAOXGT+3JY^H>DHUI_Z8;3+J2=37E8.TL12C^+0&H92.0(W~X^A7^M^PEI9L8/8<YP6+1NNF+4K+95@T%#N%5FZ^D9HK:01W- 3_~PBGW~HD.MH=X=V^9ZV&^X@88^?QP-0+6G)~1RZX)#C(VST1Z(J\$~^OGDWZ2^<@BRXV>YDKI M9IVC40YF>WR24ZJ_VW7C3G%1QT(2ZFSFZ? &B^QU\$QI+BU3OK^XAB9^L^@(&Z2 MU/P.H; RN_9%1H7(IR9^O71QO=EX6E^~_IQ&01GVCX6+WM^BS>#+8/Z M+ QI^NG%K1L/@0? K\N^KAI@GWQ^W7;KM^P;~&^Q1Q)8^T AE^UEH@U\DH MYN^OM-1>V150BZ3216JN^~8D:(35.1^U.L7S1Z;C=(PVG<~#N4QI^9F@M M;@:5="KS\$+14BR0>4FI(U^54^*4(7D?D8H~;9Z&+^#1/E&6P%J;~..SSF ML9:~@1.A0>\$Q@^|L.NF^TY3\)^V>3\$.SOP6V\~.&@VOOOFV=7..J)&?P.P MF3OM&L^Z^!&^_V5(7^~ZFV=9D903RKH420)JD(G9+1LX-M7^VH4VVDX90 M\L1V;JC+ECRU^~)Y(CV3+M^CVP_ :SP@Z/85>~?Z8JY&T);G59&*&VDHC21\$ M+W+4&A^ZV6\$S..WROZ725OUG-W5.2P.R^RYCZ8@4.R5;K^Z*=~^?6!\$A9 MI<|Z6^5=@PXD;BM7_) \$W#SM_D100^2&)O#^H/\$#188>!^#@@|K\ZARU30ONO MK&FO(=OO;\$-CM)1<#5DFB=PN7/3)C%+JTE~@#OY+C^,CIZ;~< MX\ILHZ.^0+1B)0~17W1~RQ2^5\$DQJFR^#^A8 MW^F^~^ABG=WWP^W11N^W.EYGVW2XC\S^CL^!AOET(0(CJ+1:P8&4BL9: MCGHE.9IQ\Z1GOA@_LU_Y)XY\$A^#19^#>~.IG6_UAH3RS0(57VQ^1).8/LR/ M3DUW.N\LTJ.66\{D M^A6?8\$SV>QT-A3.FS AKG@?>SPM> IH;^L196UL;~6.J(EF4; MNLK6~W(4)XC0F^M/GK?;4\$SL^W^4=;~R8X)^.S=ZIJ+EW6IZ^(<=>0IA; MQ\$EP*1#B1P1778G;U^M=HN8CAGID=4A+5T=H0W1>~G^EYKT/7B6#UV30B^~M^P^Z78VGTAN)+3_2^*T(B^TC7#4FE \$!4C;DIVH887BA(6#)D1D1^Q5V C\$;~>4N2.CG*(W)12^CT^9Z#~1\$E MCJ4F~DG89X6K;@R+VHW9V21UH^!#1.R@<~7?I084^X YI+VJ2ZY^")0*;% M\^MB^5 W264&H\ALBU#7%#~.W.F0.I/1L@?T^00M/K)0DFB\$ H0V@9CAD^ M4NIVW.H49ZR^DP-6>8&5;F^8;K@~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~(HWH^1\$;#PQ)^S2NLOUC^R05J^@9(3Q182^T(U@BZ.M&SWA9.E)EY2 WF.1LXFS3+1_J0YJBKZ>RH-ODBZ5%66X9IV2=,HX0C898\$ MBOE=;)UUG2PJ48>A^X,O^W^H8>H/4S^K3^/2-Z CUIS A9_?ZY^%:(42^OH0^M.3R2 I+1+9F=>~>(8Q-G^<*)>=F^EW^Z^=1W2A12W^P.M66\$+^&C13^T MHHMG^FHJ9N=D2+EHFSF9^<12^"ZB@%ZAJWLL+JYPZW7^()^KT- 5N^V6Q\$5^0HWA@.D3P&.6N4F^+1A MW(^4IM8^"CIVJ@A_Q&\$8R#1^L7B1<QO\$K1_63P M^%;6Q.DWAU7.MN^Q)E@U6BX)I8.W-311^!< IM.D\^4C-M=*YI^A^#R7I^?A\$==OHM.^TRU^#82/A^Z0TDRBCH)Y1K SD^NB:5M2\$F5 M<7)7I-6FTIAGZH4GANDV)P+I? #80AY\N=B6AU>QYZ\$5U4)180#14&B^YI90 M3P67%#A^CGPZ7JCI5FXK2^18P^40BZ^(@8GDD23W6R9\$Z21OBY1N<~8TJ^&Z M^+4K1B;\$1_N16XB5U17TBI~(T^M^U^~7G1B@M.^#7IKZJQ%5\$JY\$;P29 MKS0#D.C@PF6EIT^A+SWH4C? B4^0^~KI(R.MB1:30:0C^Y^1^"AD3=PV/TT M2.IA7ZQ7\$65PJL=9)1%YP0I@_I)F&%UGM21L@B96FG@BV_5^_Y=(4T;=R) MZJDF62P7 \$5? 3<~<~67X>J04:1%6D8B.UA~6#L1LS^B1F6(5^17T;B2K M^\$>~;9&GL>ES;MXWPX^|K1M4.NAJ.3-9TR@T1<1E/SIOH_M7UF7;BG1N7 M2^#.N1(^+P>6RG~+<~A^C^M2B DYB3WY0WY@%|^<?1<+>6M<@A3DM-M=>+62H8G1^ZY6) IPZ539S1521^<?I2L@ |K.R;HGR3^1#11/K\$1D12P1 M8RM\$GP4@(&N^%ER7MT\$OQHQLM5)HA#3U\$7^~K+?2.Q@N>M^LFQD4Z^7SSRI^TH8ZT^BR7=1VXOUB M%;5IR#D1\$5@147T4(RU^SH?Y)2.N^6I8FI=YK3RLOEW#3LHD19&TSTS3Q+IV M;~>X^S\PH.OOU2^#WQ3^<U51^W7%O_22^6W\^!O~L X7<~<^G4NI^V5;M41&0W&18^E2IPSH(VWVU^WPB9HU^<R-1%~76G%XLIMN9U;2^~Y)7!B4.ROY^<Z M^~8V+H+L&M^+1I@_#C7IR0<~ :F;#0>~;ZFIHFZ0.S11^A2YICHIU^S\$+^+O2L(C5HC^<7 MUI;51.9+~>O6J^R^Q5LED3ZVZC;KW.3G;IM2;Z9 M^~18Y+940 G BWA@.EM<~8B; I\$G4.WA3+1//?G?M2CB630_~A6;N.3W MWTF^JL.H5YXR-T\$%\$UPM(Y^L0-MNU^~82;9Y3EC2.A^!QI@U+SGUT/A045X&Q7(80 M=QC9- >H^L+JY\$>6JR<~OY009T/7/H7313RCAI^XV<=K D^>=CWB>~. M9MCR8.2.9LKS@=(S<C^1+?8>Q5.E8R1P^L404JHO^1^KSAD^_IS6#3\$ M^6D~9_KVBO>TES\$^@JW_WRVO@M^#^JYIE9MLV<~2K HW^(<RUDN1Y^8IT M^R121A..S0#(Z6J^OL%Y^IYI>J.1502B6725C8 \$# @.X+IS%JFP M MG6D;~;T\$+^Q5HT7.V\$DJAIPH;VTH\$9/Q^<_B\$^E! M033IR&.IU1J.^O5\$=7BR.G\$CK5J%CGSV++%WD4IH;^6;.#C3#&W.XLYUR" M)Z)N^JMB>9WD)IAG^W7^TCB^Q2LQ@IHDD^22H2+2^*R^@<^N.I.S^6F;^M MK KJGJQ(9@3111.2JD9R&NLEAM>5^CL^92&MJC@A^ZQ>~ 142)0X4FHBH@W M3<8BYVM^Z=(X9A_9^+VYIK^T\$O;Z01XJE^IU\$S#Z.ZQ>FNY^("Z0XO^P MSGP+^#9A>Z1^~>YI+J>??).S.XI?^06*OX71W7P2^!;TTFNP/CUD MO*9ZJO@Q%GE^!X1#N/U?PCPN^H.W^%L<(<2K/0P^IQRI/T.340I.KZ+M MV5I&BGDTIAVLN#>4PSI D9(YO(I9=<V I\$W.V192?I?>?_ND W_9;I+\$ M4HC3I7;PCHME^..QIS-B=J.#N^Y&^I4QIE1H^?D)IYO9Z1^%YQ=1*~83TL7@L MJN^=B! (A313/E%)#PO S3?+1<71~9D;YB8AE^QV0L^FIHK^A+1J6&I M^U2JH^2-2R348T6GCFX4QV#1^VY^F8T_3VJ\J(909Z>V) INXO^W!>I; M/6\$F%=(LEL)9C_EU^=1.EI&EJQG0TQO)S7_AG^O180^UD13^G&F4<=>ZY M^G+2PRN.1=6Z1^/X131^%X9CPG5<4.WA?2^4#U3M\$W+I5<4J_ <S6=O&_MEZ280Y>JLH0(DNEI6^4+TU(H A^Z;N9^8UO9^JH50WHK3^MOY&4J@IP^Y9/HH^58M>41P_#~%14D;2(4LMSR7^V^3^>R)LI.ZFY\$1308) MX<~RP;(3YSI^%0^<\$C4PPI+1+06V54XH4J+1)C5I^2^XMD2:8I(=8E.FUT M^N(N^M~L^\$^QFO\$?)^C\$5#~5^JD&+&KH9:TR)9E\$^NW^TF^E9\$T8^WX6 M5M2S43X2#)SUX1SLK_(305^5^GUGC-BIXPIRR~GMR5M2N)4.W@PEE6GWWJB M&T4;U=W^Z1T.BQ_Y9R2RE^(*1.8JN;541\$;4; (1G/IQMR@P(N;YE;R7J M+JFQ)WT4.9;JE5/_< MA^%\$LTY@W=;6W9@GX#;5F%#2;4^R^H(2.8Z3 MI=5O)18V42; ILPO.3.Z1OXIO0\^2XIHIRK8P7H+23Y HG3<~N>~I2H MN.365R3^TF^6^G1:8\$BJ^F;B&~94=YKWRZ?SOS M=>I2^I- MJI&JFN.M;M5Y9J^+V~HJLH?2 D^8I^Q18.46J^YKH>~) MKIN1K@.I03^9C1Q^&8.CXY@SE3L0&0^>I[KRG&6\$GRH2%LZ=BAG^80 MO^< %H101.R4HIZ1TEMRLKXQ~EYI9\$;~.CI50NSZX^=&N1X1CB+=2.% M^YE^BR5.DA\$PW@GO^59Y<~O68Q;NFXN%"FE&^/D=\$E!@_W12>~@0E+IQ4O MDXZ#_Z/LD^L8^*L0JOUI>=9%ZH&H^@#DZJH^T&WPKK6+511^%YB^SR6J7\$S=W M^>Z3^&Z8DU>F.Z9H^C7I^&ME8\$&FI 15XKC9MFE.LM\$>GG&E5FCVZL;SGS M^<U%#D139F0AKLYR/3RC^TQGGR=7^1^6 E-QI>10-0B14HRI@-E2=CP^% MN\$^P9K1D;TG<06EP8NF6;I2 IPRZ@&J4FB+^MB+^QR6B^~^WIZQ3\$^~;7SN/X5/ WE&2 M=>SHCVZ1X&<=F&C5 YG\$S.&P>^;IAO2~VM1V5^9NT4A^2(+N133_F.\$@WLI MN%\$511Y+V0 IDWB1@A:LI1L%<HLY145KH>1%T^W&C> BUECV M\$8X^7&R>~.P5^D^0BC<@&2IPM^AY5OT^JA!^JHWHB^%2^QP2G@+65BQM M^SLW=NCO.IF\$C@(&P^Y2@<6.SY1(AS10EBJ19S=&IQ& M0E13^EB^ZRIAACEV~RD^T80C1O<8YE&S0\$M^!T^H5C0Z^E^MBCI822 M\$%M^Q5XV7^&EY2-67^1.8U/C4GC.HG_*(IT)?BOQ7_ MGUZ^_?@63YT_U^N^>DO#Q/1&7);D03EY;~ I^RFID;S8 @X81^<3^T+3AFFK;239313=>~.RIJW^TVK^IPR\$H6/M^Z.VJ5PADY4S\$R;~<9LD%>@P.YT&TJX(ILKSTL^#;~(47Y/3^2IC<~V/0 M\HCHXZ^~ U9T^AR2^&WAT^TX.SIMBD^;BI#8&6%18&0!OI4(H.E7NY87^ M9C4+SC7^H2&+VDGN%>TTOF@^@A3+10@^I-GMT)^#^A0?7W8H^_ PL#YWIN M=GNZDMJ918F>J>MAN^12Q_2;B^J/4JP8A=&ONGV 1P^T1.PWD=(HAMHMI3+^#1Q^%0%#J~6G)Y321<=>5&+6YGBDM.M.D\$K.SQ(<<~D0- F%~%3@4F^&W&B^R)O5^A^H(5Z^X^M1GT^I>^>7D^YI M^\$^1^RL^+82RJU= M\$YZI%<R^Y^@XOV68Y\$JF%MI^JIS~> ^T>A^5;1CIU7J&12N^X2?R5A>~E M5F UO.LSU)T>C/_^*5 M^VVZ6KV M8;EI91S9&_A&B1661^?1;XIZV3^3 M^L^XVAH^*1T;%NDM^&V)VB^Y@3^OR8 12MFX+Y135A36G\$%6T^08P^=>~J# M^HJ8&^&GC3A6T9H&KOD F^W GSGS21NABJ^%#Z7+~ M^PM^107# MZ&A23M#;2FD\$1^4/IRM=T2;12Q3_!\$WAMM^Z>_W2 J.K^<^J61=6 M3P3I8BH92^_5+16MD4BPKL^V^S;^3;~*VZ29_J.N\$#^@JL4_U;B3EIG M+Q^8IYI?(&#WXX^E^<Q_8.SN UC^RD^D<6.^IC U.X7Q^AMQS&^&2LK\$^#K\$ M@^7@T1)GV\MC_66BG38(W2<M Q^E^Y=VOM=<<=ZP<~_3? Z&XRI0&GHBXDD M4L\$B1^_BJ^X%GDL^5RXX^A^WDM^T5.K14^<BHHU0^O.123&4&=O.J/37 M.<=MQB^6^RQ556H3C^QK\$JH^O_ E^X^W\$+G&^NH9YX_S^< M0-8KG0?Z2.RIR.(P~NM=1^1AWS^11)V1~D8J4I:KB^%\$S(DN2^XG628L@5 M+V2^I-(M&U+GKB- &C\$;0K^>@0P9W1^L+SO&(IUJ^_9X3EM3FEJ^?24^I MHQ&M^A36#%<(K8L)M45;5D9#>14>5+NMIPQ^2U;~ MWX_YBB\$6Z(0^\$DE^V12&^)#RGT8>Q@=<N^H\+I96/20W WPE5>S^/_<MHEV5S40R^Q10^H^_""5XQ=CIN931A16T?&P^H=(*_E_L^Q;ZHLH^*3 MQ)A&ZAS)&KF:06^Q3I>16JP.HD6/(YVGW?>HF/+FT5^~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~<12\$>Z=48Z M^~2@K00A^OXXH+J18V0JXPA^\$>=I^>A<P^MOQRW:X3A_Q:09#A43 M>RJT^QI^F8YQ=BL0.IP#I^07WWS_@/IZ_~.0Y4=

```

D777FUJDBJEJ83$%GV? M:YHC*1ZD5H*Q1Z6 @D:4 FVR.3ZY(.A&KF).MI*~>~>#TAU,DWI79JGQ MI_X12G9$=$EZNRI:8D.5AOE-CO&^0RH 1^
<2.A2~%#A8M3^88@J7QCAOX7_YATK/_MR1/AWCIS:O/W=V1-F/B7EIQKC= WC'H3DXKXO(2_5UB/QM &^1U/B% !RHG MC>
;S5%;>VIE_4S1$A_ESZH "9PIO#M:H M265:UW#YZZR_K<IQIG=M_%J8+Y#Y^CO_P7V1>S5G^HFI/OY,JSYS!&K-1L,F^1TA42KBP1ASIVHUTOQ6!^T/6W
M+(+ PBEBU2NS$B_3IZN1/LI.CZ.#AVS&B #BJ*(M9/(H7.(OHQW)(^V2JT M'O19% #OKY+1G:622^>S%=>3271+7.47DTHX41ZDFE:0 )Q$":ARXQ>TPS
M$PFXC.+>P^&D*PEARG+V/B7 T3>08X^L_XGN-1H&*>P16XF_J5CY M9!C!<=&0!LU@:~M^"WBH!#A#G&BY(BK>R^A(9%7+P5>8MX)=JZ/^"VR
M&^WS#ELKN=EQ_HQ)/2 M-7-O:IG020^<G)XX(1$1_3U!A.XG.SDS997!N:LXOR"$ MYUS.5>_9AD_S!+?+>SA$5X!^L41ECM7!^LR^S^K+N
MI_HL^SF04+@PRO:9$+>R$1N$>?PIR!^E @P=2^T1.TWV2!6BQ13D@GR:H!UM9^YF MSSS+ X$40^8@3^XEM+3$1LH7D HX!0S!
C7T#S12ZIS:0O%U!6 H<1>I#C!T0!9!CM1CHN6_K!#QDX1^GA+9^M26BCZY.L$(G70@>B?4!HN:JMB&8=(^43^"Y7ZR=FX<(!F!&$S^JG-62_!HP-
C/!_V^VR!6!^ M1->B1!W!WK<CB)JL<-1@>?>3"FF7ET?7_Q07W^"X3->T?7^4C%BW5$,$5!T!H^M^B!6^QV_VF/SE:$110P!A88+!H!L-1395_M758Z3N6?
OG1U=S62Z4KW!_ MJDW7M@OXI.DY">400QJZ.(FWXBH1HHE^N:E92:5HG(F!HT4V9!3V^!LW8DM
M576/L6R48#MH.ABZK=)^0J1^CZ,@42CE!#_2OJ^8:X)OF+_*+>OISRR<67-O_MYY)EPthD^%_.KBW^=)^N)42BG<^2=^M9BV>L&-CK@H_?
E=SKOW+C^B!4XDHP7!HZF#N$D+0F>8L(DY^T^C^N5H(E^1*0SL1M2ANT3Q^5BDQ2$;!&ZC.1#E?131_2G<^+,>+@%?AHUM$ MPZ&3D+MTW
H<^YW7%0!_#2LME#:#M!)PCB!OPUA#3Y^>BJSV%22!FPM^N M#>Z^?Q8M@XZ2_!>^M6D6U=^>TH@@:/4N2L!VB5-V%_!5)OX48WB!#F?
2E/&_SD:*SBC MDG.(WZ!^T M>Z^FN^N+J.%(JNB!UUV(TDGI^KMG5NY_5HL">8IQ&@T^T!^*
M^G6T8ZVIS@XP:5LS!+^#VYN&D_FK1GFDIQN87^R<@<=&5X9R3_TFPY0VTL&CH4 MI/(HJY^6TA7>TF=-%458P1YCP)
IV:@U$LOZM+2Y8PA=Q&DLV@D.G.#OFQ6R$FEK//E=C-E.UN%>FQC-2$XP@J!^K3WI@9L_M3!H3DY2@&=>+F1#1L9^!^!KG(9%)=JE:8@)^!$XZA
IG91=YI3.H^M:#ZIR:EAG7M^294B3!1RU!+FUNE!H^PGKW9+&7X<=>3AF<7%~>^FLV^C^XSM_M01&!(UD1M:2HJDU@%2 T+^#XCWWL!S+!W>:;JHY
T~%(R%)G=F2!NTGU^#_MXG$^JYZ.IKV>HDVUYX@XB%>8AA1Q^T^7_!3-V4H.V9MU^N^>J;=:(6:K!_MPAY
UOPIOQ5YIY)LO7Z1C+(6U)E3_H^H.OH)@GJZK9HX$=@IR2$4AUV^-H7D_
M!<C_NFUNEW3=UV7_&8;DIU+NA8IZ9!%Y3+Q.6TK(=ZV=S60GMYTM&HV1UD
ME:T;52(I9G7!_XUL_17L^Z8M$K$;IM$=L5NS1,43YXO6#840J!H!U/52.R_ML91&%)>.(CW8^Y.NE>TZ:~
<~%IM^J!OMPMDJ8<1Q3UD%Z,%!#D$RS(7YK>3A MI3!/_<#>:0T9@FMX^<^<7^PJ^G!_WOJ^42U!:"057^410G(X^~_W^@UM
M!<^E13P^7ELKW1!>#D#+0,=<P!>B(M>6^E)~%9X^BV7H_4X!A(1DX_M5ZD2_FMF>4_?L4Z60Y+X!8UU?CB5DL!^G_A_T?4P!S_*I69H6<&~
^*JZ9$_E$SFU!^M;$SYZNY UC%_>+5_>0>[!J2SYN+E7XVZB2,1<^45_W.M.1JX#_P+1^?F^A=0!B_2@>_O(EY!^@S/XFF^QVLA!NK1)_QAK%0P!_VAO!B
MV_XG0TS!IGQC!)0HNF^!&K_XI=5676M7=I?9>_LC25X_1=P^S.56_K6_M!U=A^X)WP_4P(F+W!JRN?<_LIGEX^>^H+L!B:B$^*!^QFFAH-67!@IW)2+
M?=>H8^P73Z.MJS_IES^#QK5+8147_T8^M2R!U9VEMG^E95_KHCC&^&K!K!P^!IGZ
M!KH2@!MC@V=RR^B^%KQ$=,NMP$^DY^*W^G%$!2^;FG/F4(^WOPI#P-B-UA@_M-20+_YG-CB%G8OAM$T(8;MX=2)>^&DWN84K0%
!<=6HGGA50&$U@5X>EA M!F9!0008!FE9K&L^Y^0!1Q4V^?J!_AOU>YZ!N2N!="WZU>?>N?N(?P_MXZ_OLLE_XMZ!H^XO!L^2A_4G=+!>+!)Y1
PA_G#~ WMN!T^T^M!LL%_N/_MTR2AQ5_VX<^HYO4B!+VH2$2(C)^U^Y=PV!B^>S25RTAH^4!@68C6%_4FD M^*>(7+1O+;U$ D#!H_
IE8G^GAHTOU3:T3ADW<8)>_4L5OF%,BH9CRO^#)1$C_MV&X.1+!^X)KHC=KZZ+?B<^#SHRG8.(S!>WP!10=>G7?CBHMIY_LX%R&U!
M^344E^690V_&0T!P!680_D5LL^!A_53,+&6B^X$Y<P!>=DG+!08&GK^N9!_M!A^C9(^8D!J+YTT!@&9_M!D&_YL(!^W_0VTYBW(K_!>=OC.626X^?Z
D(A>=>S09!KQ8^Y;4!>6W%SL3D_MEL^0!0F%1^CV!NB!+FEQ:9T92!P+>G!>RU^2S!F19M^7?XOEPV^P.YH
M5XF$U1+7_W9!^DZ/H3!$!M2(BIN16)_69W>0B<98M^7THF^8&0Y_M)ISDA4^G3GB)=K<~%5^&B:3EODXEG1?_#O_@G%"TOLD(3!18=(K!U-WRM,G
M;(&(2!N!^#56YH#ME_J0Q7^*6GEZ_)#W4M5A+&1+V_F0A_7EK#F M:&<2!8#KV6#A_U5+>Y(N=&L!O!H(T3O!>#<2)E!A(X1+_M=>1S!G#Z^R-9&-
XY)W8WOS>^GJNZK^GR!5_7OP+!>=V!2C^9^0^4K4_P!_FO>M.FP.B.8S;(RX!R^<6 KEV)0S^!5_G0!%+PMD<=>FG8&E80%!^!50T^!&S7
M(X)WLNME^N7QOR^7L%MENH!^A0.R(6)7312^@O^9^X%$^_SO^TB@^QW^RECH! MM_V5+XMI^XH6K5!H)H!H!HG)EMPM^0_BMHG1%.(IY+++
M^*UZRS3S_YQT?>Y3FE^!Q;@QEF4^&^XZJ_RV3YX3^_#Z4_YH!2>75@G:M_#5N%H@Y2:4?>H!R!0#X_3TZOEOZ43^#Z2^2^8A89!_
M7KVZRD^;TS8B-BC_="^LVWIOZ=$0MT$SAGEWFGA>?7U<^?LG+&O/KBK!%!/_MK9C_TU)Z!H-8B_Y4H!482G4=604DQ^E^K_>?PT^=3!HFL)45X0^D=
USK!L_MZLN!R;6K!H^SY$!>E+^?F5IQFM(5).(WT;H_NJH$SAP1^28!<!(KFTH!%M50M$TACA!U_!FQDD.18J!&@>2N^*UWO>:19_D
M4DQ!J4>C&GRL4&@8!<CV5_UG@UST^&_5ZR4G%)_(!J;Y:0>)^M(J!E.V!A!KOHG7+!W8#!3AZQ^#44G(9^M!0^Z^G=RF!H^K&^C;2HU;$B>?
M^"R^Z=DIR_DMI(0%)?%<826!13QK&0.!)L!FX_U)ROE45?1<6/MEPC_WP9Y<= M2^+>+VE4O)1!Z0$%_52IZ/5!$?1FLIDKY?
G=MY34&1^NY18EG!N48YT$XHFD MU72_NF15FVGE_ZPY;8&^!<J^U9$+Y^YCM$!>_A!W_2ROK.CX^46RG_MU?
DA2^T(2(+G2%=>QP!DON7%&R!>2$S.)C=$#%+6!A:H2!U^D>478.MID_MTM^;DY^!HPDMNRX^F_M4M5!7PP^D^SE?A^O!L_
^N2^BB^7Z.VV8OLGT^+^J1_1^A^NO.W_J0^Q^P_M>M!L!H.H!NBEO!F.OOKD-S^!N^R81V186A;Jm6$5!<LNV(LPLYV!DJG1?<6
MQQT^3^H@BZV!Z711M=Z%^<!(SQCN^Q_<4M$@TBR_)U!H2G!A_XC95($Z=9&B;7$+74UM.E16.(97!+>^BEI^@CN&CXIRH!JN:6QN$O+1TM
MF<_F3(1^L$;^_%NG^>)IVON1_ATLMPS/P!$_(WR?^X9S$@:QN2ZP4.W_~M^88K,>
```

```

[QKX="X9="|Q/?E%."OW?2.5>#&XFB Z\^+B#)&Z> MDZ>5TUT2X3+:::A%M9%*U;:QK5,1/ MZQTIE 6YU+?XC|@|>6=)|DOYNN*^@4@?
FTU"'.DZ+4J81=>?02G5+14Y(1, M2M)S;S(BD+>P5CGS0E6OGZ0*6R* 5F162*8NB&BJ 58@."":8>?QNR<Q MPL\J1(EB#947D)\D9116E#V<^(F
X9,11UCE(T(F@R6B)OE1Z, TNE4 MMYJN@B)R8J<K)R5;130R10;"1*5X35";-W171 HA16A1<&TA+&N.NTA&_6-0,=1%EOUR=1Y@S-U
M(^@2+615**IK7%&:NWEG+0)5%Z;1F11JYVYK8-(2J;+WMXS.&.)&7H MRJK<&-(10G0U$T8MD8E@X-9Q$1-B1@9N7RMH+806.7>*JG>
<9MXM0^A^S M$;N3ALP.YX6IGQZMPB A1@9@S1<&9%2GT KT(583D)"HL QZ8<,DB# M2U00F$&=& #XYAF^1&VY2E11(=$P"*
QB "BZ6Y.#51/3E08Y.NBM1.M3W9M. MZVLPEJ<D-W"1$14"J;H&02LR&$V\H1N"8V39GP+<9>849>1+1+7J5$>1D1
MF^F1$E@JOUY,="=9,F8%04FT4G%U.161 BY3T$*QK$Z1Y3J>=>|X>FAUQ MAB?ALD.V8@;M8549%"IRO* 51^0@RXF7#L.2 M6ZGP@Z4K)B/YR0D^(-
EJD MWN7+>+Z=+1;S;./9.Z4C7T1L W1=;/=O@HSH&PTI29YMTU$&F ORL")D+ M=277PU4JX@;+0+7(N-6)>X$
81H9T%Q4I$N127;0;9$Z=TAZ1H26U2@SFM2@7@ZLPG*XH($*2,TN92A@;JX"*$W71F+5; CFUHN MU06* 22H;ZS139% W...@_T$)N$F%"08M
.8$7L<.&4Q 411HZR9)FK8CX MAEF>M'$(239SN -)%XO";P6 (A>)"U.6% A^1^HBW^@2M,T#12HJU<8"
M($AZMUIWUWUH(+%8@4$U93<S48<5%)EHI+BFN@B* EB.XR6IGTGYX$US68& M'*.30=189W7Z5(.G<2> /0 BUARHCH$);(X)H3EM@P6>
|ICUIU^UO<T.E;+ M+X,LLZE+X4)A:$6*NH(QN144FX*;/$E.BQ*XS.T($A%D H&L.R+ MO8IC7P1=CESSI4. H8)8DBN-2SJ 40E+V* XU017ZCDBK;
I29M2YVX>8 #U7 M1)17L9FW*7L*AIJ J^B1;$81@X@ V/D11^JDJ$*(E/Y.Y^WY27 M$1, W$+=5M1^IM0731>FZ9JA@&G79KDA(D1100;Z-
Q2@C7$>XG &G0N M92*1A<9RCQ@.(89.Z38#60V1GABP8 M5(.6U(D@@3J>E+Q$F";VYQ.2BQ$8#/PW+1ZCR@LP.2.<;6Z8#Y /H2S-W5U=; M
IK17>X194TQ6&$N#Z6#P30B1Z8BV\^1^RWT1F@Q$3XS)*KZZ>";16 MSN91DR7.<0=JFUZ@.E15 S 505Z
<4TG&#9I0IDBV8JCE1+0$*+Q0P*QYX.2 MOY11@ETI&M5$27D12E.;30#6% Y0;1J21@LS(A)OU4T C#R1/O91(* MB(R@B@W'1$X50AA7(B1=O^
((+V.U1=+1#K58+1T T#1@ YTD)/Y *;C/9 MF6VS V2^6HLX;D-1^!&C^J LZ>E4>T;+(O+?(S8-6A:5VL2#&$ L.NDXIFG&
M #+F6=&#%FX;NO+G$N9$1$& CS1% KV(N ^("02319J3J+1L>5<A &7S*GYRIMM^W1AHE^ M+1F3H77HLD
5WN@6T=Z07L;=@S@U03#H$H199&*D4Z*5P$;H MPR7%M$14.IWR7QYR1H1QU1A!FQ3;1&@;H8 G4T$1<@D)+|E>+(|@ MD T^W)/$E.L$T-
Q;3580"=HE&(A)3$;+9F^FH&W5H#R(ZU;ILU1V@EO ME5)\^Q.82\+DP^?15-E B^W1(Q^96KJ&8H8V;Q1, *IU<);+^%; MPHMX7G@Q;(H2@G
OX19A81GX*1=7+XTP06/(3.TB.0.P.GLITW*% M9Q*1^TCO.=K611>_0L<+13Z5^PW+L+Z)S/|H1/>$1P.K729D MBY00D1Y%5<6;1PMFED40@L-
$BG>24H$H592A0;3;EFX=IC 8124G;=IS+Z 3/W813 M-J<@>NOWW -0H1&H)B21518@2^NV@_#)S4(2CSUA)G;9A$LG+&MAQ
M@7.Q# /Q(OD#P38/&$J=)X*7$+(T M'5VLZ1GX5%8(-UAFY%7.8P.4;< MEVDYB<"G.2B/*00RBQAING/*UG$SWJ#2X<F.R<IDR*(<+1?NQ15BD5$
M1$;9+2^T1&X)W&F%;TMU@_1$UZWU0.F&DVV-J.#1 M06AM""&3))Q)0(E^<SOBT3-"1.X#N4Y&K1?=>6M*5AJH(G9GY13H+ DW(E8M MN2
G0$*47N0&FX51<-72CE.+@("P"Q **1S4_YF9;K624ZG61+&*^@43 M201MN.;+^_G%;9<S1%B> R@40AU^NO2(GY;<^&FGB1>8V J-W" S^K1^NV M.;
^2>1>56@B4BSV>=3@&44810"KN6%FID10K>)>1L@&A.RNRP^FA@VZW$F-
M1=WM91V3.MJ=V3-M=G-Z/34*=2^ZG>0JH<@C1N0G0P=PTZ;T1X;S60-D.M) ^2=..X1H%&YNJ6/1.;@91HFL;F)G^Z$R73+ #6_Z>DGB>UJ.4J^1$>
(MX1 MM7L MT^AOAX"/^+JDD83N-GX%UPZ.X63$*$M131^A/U;1;NU;"B^N^TY08 MBJK^9IMM1C50V;);P53(FRE+
(UH^U.3WJ<K0Y% X=ZBHM^1LY.D566QZ1 MP^@=1.L9V;^1$J5-Q;7.P0."1L2.P^Z13."G1D1FEFCAH./Z @Q M9AA-PU.(T8B^UX(^:D
+X28*Z"7&61PH7E++X22$>ACJHDNB;%Y0(^0F MB1U%G7"(N>);@7X=X-2EB21DVZS+T^BN%0W4WS0*30%*XB<6.KH5>Q% M06KC_&-
D0(0=^ZO@/PK)JS.A4K.04S1^NW=VCGS77 3.S0V99G4D.^9B@0MR2*3T1/7.5S@V*2Q1L$^N M=41#+VO@W.A91^22+XFB1=-\BFFOK./@-
*MF3X"/MYM#@A1@6VD R<+3)M1%9B271ZFX13:D)=12O5&B^.(GL16-EJ731D1;U1T$;JZ1/8F1^2HL$
ML1&:%V)KI>|<>K.C8$?)1HA/PF8!M8@65Z=Y0PXD7=-7+??.@.(5"&1% 0<+1?V2NTH">?28C; "$J% M2NC.S*PI^T$1LH'$26<H>N% ^J%N@8$
*01L.0(I9;530!K$1L);&A0NR1X=&M3*Q#1H.HT7&1>1V!BY1$1$>VFXKRRGG+ F^U^G1Y&E#C".12X$=&@OTOF&("S6644X$&HD6X1PH4+4Y
MZVENT T^P4U7^@3.YVO)/#725REP4Q0RF42^03.08>R-6K1$3QGN6Q1U MTUW>5<+>1>34X7 TN%H41@PS&IPGKC9 N^P215(J+
|DW.R2&U)ZTW.LY" M+ZN2B")KE$1$H@B!U0IG/B$JSWUA?RR74+/7WK M<)>6.*$1^!&26C.0G2E)3T)+N.P/9P+12*$VF>:1GM|(#L0U8.U#=#.XJ2
+M**"(215.W52^Y1 MZUU0.1WBC;.#DF.F2057EOM2BP(^6.Q50R0>0.51RP4-0B*ZP62GTQ^1UH MHN9Y719/<@1QPQ^RYV%UY14_6%KZD&^P10@
(C+Q1NP-S14T)9^E9141<M^V(3M05&%)NEH1&E$8J*2XP.41C1$)1$KXBUU1L^TZR$+>+OJLUB2.M.A3415*>+>JG=1%GW8)RP3P$1WM^T1B
UJOD) MIX*>V#Q8+<@-NPNH$9S J4R DJG^120^5(7G^B&2.1@HQ$7-/(-CGUA MLR^EZ2%MKY3@4ZC@R@170EAG<123$
MEG^GHMD<+611%+1Y7$&0*MVD3.D#1M@JD. MQ$F01F5$E$F^TV<?>^9<@.6JRBGS2HQ?^F9Q1=$L$C1N:8.4AU^F.U>FK1 M^U12$ AE59E2
K1PIS)0:5K328+P%04 SG W/C72).KVTB@EJTRSSRP6%N M=(V=6C6>5H3E814Y&VAY M<828N4M510E9-Q4G2*^ _1H%1.L1HG=%
ML6<1^7"C1Z"6^"KAKX)OTOI^9.J71NVH"=C;^_W$R%0:S&5@C SRP+5:4S&AR@H$SD)D5)301T-ZWE#08OR> MH0X)5$&171(6#
2MDGH0H$6G6<^8!#1SHV=AK>Q1^272/XK=U%HM1^;P MFH1#P>_16;11SC08MPJW9T;149WVY90EL+ B1=+G3E.U1>^&BK1S94L$E
M#RZB;FW61W+G2BZ2)(L...=72QSS5.T%YA>^5X^G1_#>;S2SBA0A1&0%O..M#YV=5HG@/$;71M8&79H%#Z1%1
"E5_@KXB3WM^C2KB.4G)6V78($>)RTN MR;9EI<1HR^Y00360!BM;RUB5^V; CR.M-W@/O+VWNV9Q@RF#2>D1/G=14@
MURX05HVY1>7PH+HJBIE$C1Q2+>^G;@08P6>D1^X5YHC ?<5Z4
```

```

^W#867FOL;_C2UU<?<C>>+H_-M??M$[M=17E74;X#A^GQ_N3^|ZB2_-#4;KA+3PXW|PIO;|3N769|F&_K_Cf MIENZAZO^Z#^!O4E7,P&_*MNVA;199-
+ _Q_#<+|=+5|F6>+X|PDH>Q;8&3_M;3^<-MCNX^!@O19^YK|SHX>w~7^R;_S^/_H|82_03_CQ1MYLNGG|NU4R|P+S+
MIMBCADTU@=+1T)>_X)WRF&A@TOLHL$YS=4|GWY_M|U=M;UE_W#A|27U_MNG|OGU=7^|TW|V=3Q#/_L^|T^9F|CP2^G|P>/_#X_MH10OX>_!R>-
'3X|_#YZ>N|ZV^Z|#H<=-PT.WSZO_G|X|W#_806|2GV29-W^X4,F+)_M>Y?MOS;3YP|0;Q_)K|?K+WWR;Y|4;A=W+P|_1MR^%3HTGF%-_(J^*PV|
M=OC^Q25V_7>|_!OCL7^>=V^C=QOC^|D?T|A|E_M6K|2_514_MUM+?_N_UY_MZ|U_-WET@OH|_#MR;_#+=MFI M^
B,U+VWVWYG=G^DC^3|SNQMPVZ&=^>_RW7P|C^Q?2|>|4P|_0_W#_!M92^< MX|7V%|H1S3^!_SM=-,LAPNA21T9MC91M$%;|CM;|PY-
OTF^A1D= >93|7^<_Q_MR(65C2+2X>,3(AVF$F#P?^4S/#C21Z7U_-WS9N_5>^<@^X^<^<1R,Q08|W/_M^<^&1FIFCG9GYDE=XC9GY29^@.S.SVX0??
Q>?XDS<^2^QHX;_C<3@<+H_&_JDC_1P^Z|Q|_P|H|F7XC1^<0X_0U^M^X|<K_|>S?>|FNXWZ|^DM$_4W^H|W^T^|+;_3EY4|PZ3>|C;GAA|
^<7PDKTG+G|<=6%:92Q_MH_PPY+|NPW_9OF|>|V?|^MJWWMOT^01%_2|V_M^9^<2_KQ_MIR|T7^T&F_UR4Y|
Q)=TEB^<HEWP^<LV|NUW0VP6Q@5&|,$>NASO?#+_NX|T|CW@W;80YA_MXY_LDAQ?RV<_H&^UT_8.QPZ?D_-DBWIM^K+0_S,1H>8^3.SS$-IX-
M6N|YQ^S|H|&X|92X|C3IM|?|3X_V3|R>=W;29ZV_NR;_U4ATN2C_|H|M^>D_2OPI&XF6198M|LITWV>?>UQ^T_O|S^|AB^<_BN8|_
|C|S^>W>=B/R_MF^<N=LD$Q_C|P8F|H+22|V5%_!VINBR;B$&|H|U+^+6|+ZKW|W_Z4PK_M3TYV?>??BR?N|_Y^<X>S<|SLY?
^>O|V|>_?BV;41^KTT=C@184*9F>B5_M;T80A1H^Y%G+H,<#RRP9|8Z28@W+P0?^V&BH08SS2_2Q5P(VW|T0<2>DS;MM1=5|5X|NPU|WU;TU)|
<0|HLX_BP|IM|WTZ^_>W^>=+)|H_VCO^L^<4<|H9<^>MKHKR=V_W|RPJQ/^&=X340Z0_7$&+!>_U^ZW8@<Z+&|MY|8
339RU=C^_L|8^_G^63E|A^RSP?>+=+|9.(8/Z|5|_M|Y_-|_WC=|B^*4>^>=8YSO;2=GEW#|<6^YX_SB|;(<#>|>2|B;S9B;X;/_<S1KPI>|>

```

W392Y85SEKO?_VH MVS!_>_NIOE DWD 9G.IYHPNEAZ4?#=-1^%BZ0.TX2KW WJ=-8W!Y1TN17 M1W ZY&-1?>UP6F4KJ1=M.O9?7_4S1#10 (<#2+9UFUKM=2 TP1RX M O CIOV@U\$U\$B.R3@>7S1!M5W CUXT1??A1L G^V2T MNHbV>=\$Q@%3?%#D4#<M=M=O.AQKT U#@IM!<+<H+CP6&[W2]E>+1W MO6fWU-UT^M M^BTXU\$3!P<1!>YTV2Oq68X?#A739W!O1\$982F2FA?SDHbV M1D)3EJMIZ>G-T^RcV:7!4IKC\W\ZH(VT:T#^ONOG/@NRI@>N/ M.B/HW>>=<X)4UN^Q^T.PK)CQ9(H^\$7_1F\$G\$!FF(Z M.C.RSF@CNM^1!^:C=1?>:W8Y&J!<L ML^X.B\DKZ8D>4U/H&E-OL(C^%H)Q.D M^K^<^<5_1RYE09 V4L1Y&AX&ERVY)E1G0L6!027OYKRUYMGIC=:M1E)CWA0B?&2G*=)I*=77#0HBj95.JPDD<^&5U37FEVNA;1768YXR;#AG=MACJL3!)UH@HU6^<1JJS^<6(Z5T4F-UJE1BD19%(\$Y2+1)C0<M1.D)%N1^1SY21+^FLRR/QJ3A+H1^2%Q2IV^+E18P9=>4^*&L.O.%%LA8:46DE1=^<P8BAS;^<V9^QDW)V M .0D.1#%3?2P-7X&SA0308R^Zi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j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

```

#T@#YYDQH900 MJA@#&#EM199!Q!0AE2S(=OM:H, RQ0=<=:B=5. !@AUXC*P!O!HJ2DN^ M@FI01!)@A+;D#NH(RGE9C8XYLY-WNA;((#
!OQ5K$14-DH\1,6^T%MO&$. MZ$@Q!AO! # $, \AC2E:=3@W;EL\AUCV"5PYO*6;JHI%"K+MNGS'R :R X
M9YVNM9 (->PB&C#&#14#TV$<2?>Y1V6RGXRAVATHBJASZDJWNI#R4#J6XG MG-U\9#KK*#1ZQ+4U&CJ>|O>S:R"%RZX*A*|L>TG"l8C&I" Y
Mv$E!>3Ql!PB&C|B#JdUC+;14#M!>5!#&F389*0VR29+XZY101/4F3E S! M3ZD3+YF\ UV Y80,7/=4P2!P-PV!94R^8!O6W">!J06!804Q
8H* KKB2.AOOFOUQA MC=8%>.4DK0\PJ(6T7VYB&P^>YX1W(&QS@>|J2?#IES!S:7<M:HL_B>9!HP!PNG-|B^<2(P-9UQ+!#%>VXG>(<
<H2LO!6D.J(PW-U=L5V MJ!>13W-C6CYX\X\6.FJH!U!0D0%G@DKM\YC#CH4%|!S!S&X+!9Q>X# M<R.RBAM4B&P&ISXH?
R7JX$25%>?7@DO6!<P2F2790350A>|JHB^NZ1LO4& MRY04=&=GN+!8=0'Q43YZB@V.(!HY-1PD!T8R@K044JISLO.7N?N$S_2
Q*COA9#0)VR&8RAH".W9T%>A:Z8*FZIZ M+&Z>NX@H(1>^>|H3X1!&= B49KV>UY2MQ^C^YA7S63G(G44-DHHMF\ MHH4
M6&D3>=88J37W?>?NR=DR5JN.AX>&9-1LR>4!W2>1!>0#V=!:N)*R55KS((& M&M4B0LQ@<200.5019<1(V@OH M%YDYN0-!F5A6<3)8EQO
BVT?&KSM->|KH-7+Q87-TXJP-X1!HA:DA" W MM1@ED_0J!K!HNR(OA!V!AIT?P129(NA4 PKJX6WMM46<0Q!BHP6S!
M/@=-X.C1M:S4Z.@MZ$#4LKFKU$-6ATIDUEGV1)W/69=V'BVAJ_VQ?UVIG8 MBP^CZ-W6&U9(H5GHEI<30$>
<3WW\AC"1$>M6Y17W@+;+@>H5+N!7U/51N- &9=$11/1B/KEP!T;"1B!S!7H) MDO0G\IYN^R#_Z!>7/KM%#I>L?E5D">|A*;>|DD)MRF$U_9J
FOH=CAZ2 MHT748W12N;=>W%5&^8W>#0!7(CS2F9Y.W?M4CYQ&4MR&5R2T7!B@>JTWV@V\!05=1^ZA=&=W) M!@>|>S>6@/W;260<2P!
6!8D?RTAVZ81BNU!HT6!%>7D+&@R(6%|@/ M?IX+X!>53V\G$<O8=C1VYV_W+YDP_TO_P!02P,$% @-(MG6?HD_0U5 M5P K-H#-!0 IR:6(M.C R-#
Y.S!29FZ+GAM;RI:9>N9$N^+U_18WG MZX0+^+13W>HD)6MOF5(GVGY0%|TM XC635)-E>12?/SNRHRY.Y(79#1+5 M!>*213Q@<1
0'3_S!_AZ?C!XXG=>P!|_C^!>|TRCWAQ_XPI_M^KNW_H!_C_MW_H!+X\!NZNWGUZ,TN4%#1<_!HG&^+Z??+!_!T X MTSI&XW_VOX2?
W@f"M(S&#P#_?MGST>20XW!S!>Q).1.7'EGV_E/V+!7 M&^@H$924!+)"H5!HTNBK^X_WS4XY)"&4E!S!B?4/1+>+Q3(#D+SH2 0:09 MEP!ZPW^J2
X2P2P1_HND!>1?_!H^"GP5C M^NOFEL^P^C/7_Y_7%D M&H!&@>_!D^_VK;3A!<DCTH?ZYK_OUOHQ2F.P4!<6?UGZB>@Z6X/Z M1_%B>^!7R?
Y#_Y.S!>=<8?Q>(#0L/RT^&M!OJ!>1=H23G_-8N?%Y Y M.OP&A^CV#=>OG_#C!17WP>X!+!HVOK$6!_G!<I2N<_!M^VAH8_!$0;I
M.B+OG<^PFGA#C^N^<27_W!+!J9P.9@V!SWNYOB^5V?DL!W_GJFAG7P07 M>!%QW!+J<=>!IAG\JC">^!7C+!F2+!J$+!9?>
TRCBYIG@>^!#M^&SIBP_C&M%Q_JHL!9#<5_V&@92=G_8K_Q^;3;Q124H?9 @U^G.C.PXWSB6_PU&Z<^!
M!G7;GV7R!$!S^M^>QWUN>)*^&|WSX:HH7DYX4=>D.(J!B^5Y%SNE0 MR FR9P)!/L;YN J+K+4_033'S^_00Q.X_Q7>6^H^4K/OE M_.08M.
!P8_UA5YNXG.#$#!1WVW!>6Z!P!P0L.WY?TSE\YI\Y!M_TG&A!<CJ! M!8G^TFR.3^0R:SIW^H3L&H!S&,$B9QHS%2/KP_%FLOR3^S-Y$&Q#6!GG
M^W0=G90Z@+<^!RGCMWXM#>1^!38R_&O5O>0"#N(NFH06L=66N!-I87;-M9T8^XC)YBCES+PY!P08M(%C$>=>1>-%!2
Y(M7_3,7RBK<1<1=>UUSH636=>@_I8"!<A!/?>3_969->9%7N^3!*>T.B!9^7^5?W!7X MOKJYK>K!H^M7U:RAJG!9(I6>+Z#^!F2!N6M(2H^A?I
ESSUUV7#_39GK!>1.LC1-025^!>I@H!C!AJZBSOWA0&4OX_0!>#>S$M>9C8(G!#S^F!5!>7!FOAFDT MIHUC_LE9N!>=>F%#ZB-PGKC^!J2CO_&C
MLU%|L.U?M02SOR5^!%>!99IYO_3G5H+K?IZ_U9SF.<3!_J=E/!L8!*&V95IFA^?_M>2 BE,T96<+80\KUKNZ=LUT_9Q^?#/_/HV$-!"#POC^2AN$ F
M!$>2$!1#>+&F&J!H^FK@<1-SSN^*Z623.MSXZ8^>WXJ7_C^1KV$!B@>4 M^C^9Z948A00_!M$OD:6B!+SQU:>?FHW>Z^>E>=>@P-Z.M!P^<Z
MGV=>+2=&(<@>LYDBR(Z!08&^Y&+HLOVB7Q(1.W_!*>=(709Z+(H!4JN!<NV;H!X!MK<2X^K+!7 M_N!H!LOF1<74_
_BN3B1^1(KE$!P+Y>Y%FY74 @2Q@+&E;W$^CMT<^XWN-M)<05&MTK^?9A^&JY_?MO%W$T-Z^X4B@RIW%MT^1>R6!EE;U!FOZ%(8?<99)
(^_4+U^JW_%>HMT$>Z_GE>Q3G=>#5+!C%_URTF!<D!<E_5D8^!JF M5^!Q$>27=(PA*Q;VNV6Z;_0ST^85X;
!0>H!TU;0A%&V!9^Y7C7XV6F@W!5;Y!>Q!<G=CX<4@G!<C^_UHB=7/1<+!M2!A;R!Z!14D^!O2,=>*C8WNF?/NC9Z^AW4:Y0;8!LU?N+
M;!C\O)>Y_.G_8K_H1@K6^2^B!>#!N#^HVJMU=E^M^ M0!JDJ^Y>X/@C^1Y_H!<GWYZ/KKX^C?>MH)YU+&B$;45Z84?
!5TV<L!S!CGX<R!Q!>P!DWOEASAA^ MWBL!MHCKZNU\A4C^PSC9=6P<2ED3 RD!>0RDOV?^EC_!004K_49!G_M&A:Y^!GEN(=(6;H!T-
W<0T^Q^G!JD6_<F!H_!>#J6P.E@+&$2F,U6&=>2 MT=>=&CM5!RK6%>R^VC^#E&Q!<A^F^4S+GZ>9:>@<4A(3&J_2.V75 M204_X8!
Z7N+KX5BESD0_HYUORQ_C^W)ZAAR^X01S&@TCHT$5X;O&=>5 MNFKR^7$ZN8EJOITZ!<I^T^5G=>OCW9+&YX^!IRDZ=(N^PYH M63^+PC%
!7BR^ZG^>Q3_>0F?>P4X!1(4!>A)^$7!<Q_7>H3SCYY>1^B MWVM_IV&R:3!M5PDVXOQ!_EK!>8!2D>/M8^!U8_Q^!2.ERS$H1C&^P>ID
MV&M^!ACWIM!T8O!>#$U9WJMU/4P=0$ M!2!_M!>M>A^!4CU3!_!6=>@<B^<@!<O=24!+^NH2@<@6@3F,!$>G!1&D8!4,RDU/BK=E^
P_SUPCV_PUM!AE!G@<E(3PXH) P$S!Q_C^NNS4^8U=>A^! MM8T404N@N@U@53^3^>>>A;K_<^!T4F=7=0KZON^RGH$7P38,>RAIV4>N+;ZZ!
M+G!+Z$ _J%JKZ/Q>T^X!+>NX^0%QNG5!JY%>FY9D=8:0%U9!HTN%NB X^<M.OV^E!<^>=>HSM(Q^>Z72!E882!_A!E0Y)2;O_>9.>%^C=>E-
!&XQ<+K^M!06=HRHE^J^CLR$X+TRH!JY>+>8!<=A^JWDW9%>8GMU?>+H1B_OQ$D.E5% MSL4PD^!J078KB(=^
T!6D!>J_HG6^+7Q8!>7!>LSX!L3$!L2_23SRZ^>? MZZ4^G6UOH!P2&!/>YX4R2T5F;H1(8!2A(4!4*8!2(R!36^M_ UCE80FOI M_V1V6CGIGC<^D@>-
(!>=>
```

ID\WP@QIK MKX\TY7KX\I>=J\F\Z\I2M\7IT\ZB9QC?9MHJZU GWUKO&.O=>Z4T\$SJ# M8LG0KAX,F*Q009*ZL\$C7?#F=S"3 %Z=VB"J\$ MQ#1826>UTH8<\0\910L\VD\JF>D#P MZC9\>.S<= XEYIG(H0IA<@VD@NVBA\IX>7GV:CB9CB<K#9G;*.66X@ MQ\$H-GHH YW)M)VY#""(Y290;M 5-BHH3SR<J"?#JC/XS#<%)P?/6VE;\ MIHQ _F 7SE9_5=+!WZ#N704\I6;?%#; @9#I# MMO01Z ")P45PB=? *M=I9TRL#11M7>_I-C8W-<C;RC=CPMW\I\UD9?C5\<M_C8:2EP-20#""66\$6DBGD6S*?QP#1#)8&64>5;1AKZT37?O \$3;&P=1-MX M0\1EGT@PM_K&27>D7_0GM;2%->9\$S74\>8EVCJ7HG;2R(SEGD)(V^?2VY#<=<2/HQ=##=I/#C)SIZ\$ _I&-I-ONI#Y7\$G82PJ+L/TZG5 %;7V>PX 57K4GUYU)YTL41\$ K4UOMB^O<=NIU\VO<^))6I>T/X6M4 MO:YDP7U3UN\%SQ92=+J6B01&US8MA6>(C_M1D-G/2%"ZM:=X\$>AN>I\4WMCU M;@XS<=%QCA*F)E-1VYFARIP*4\$DY_*3ED?0G-RWH=A*IBO#MIN4<@VU@7 M)U/KO2X#4ES6P2)*K6B(M;FK5AOBR0*D5(LHO5)=F*YIN8:WS2+OH7D3SXG MN<=)UVPK.1R#O82OIV_L_XEDCYIDM_+AR3O?HN.I!"1F!_M<\;G- UQ601.8I\$!_Z8FV2P6\$64B1\$VQ9J8X!_!J00_7PC"!M95;9!>;UUU#VB4?R.D5K,CF%*(+E+M26=I2IMY=U+R2>I#5>_M MGWHI_FPG? H:~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|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l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||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|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

%;EC;J:MHZNGKZ;H9;UC;V= 44^1WF;VFSYX7%M6_K&YM;VSM ;/IP;0^H07_ G/ 3%10%14_#34/ MPQ>@BO^C8V&5E2>CEW+DAX1K4
MV@HKAWYXQ= VY^1/87Y&@6/4(KE4^,YX%=&O3B)QU3_ (L10IMA4J^,3>U M^MWS=<2A&_9EB5H= %>PZ^G(1
Z(4D\$KTK39:X\$2PWU%1T34PB5Q\>S*=-#D-M,IDK'+V18=2B^HG=ILOIVP;.%J0_/'!)CU=) 0+M%M3O&K%Q\A0C0F3*
MDWYIM^A^C^WHGGO@#W?TfE;Tf@>^AEI+HOA(1; M-Q^+HS12)>G;^V32Y7EB/H^>P+M;P;IQ2FD+6^6#>1JDPG/;K>^C^N^IR
M2^S7N/JHW35\$=J\$P.RSW^;M4Y^&KQ;SMW^/A.O15%HBFFHK&XDI^M1^64N3O;=#\$;U#SU0/RK;*&4&9=OCX,11E197BR/K5SEIU WR
M%5@1^WG68C\$&X;J^M^JGJ10A&1^9(MS=FMO78ZJ8UQWXYI%>QSS=M^2^IXAC(LFV^68>D,3FBV2I@;SMK_MF^Q\$U6^4Z17_1@4^7^;16-
8UK-M&O4ML MK3C)H0DLAHN%JH2^4MI06NN0S\$=IY6L4+,*7;#.#>QSL54UEXY%;T^Q6\$-M=M);+U>_H6K2!;:Q93-V5AWG^6E_S)
(Q;E2I08\$WYC\$#Z=K;E;\$&DF;^EJ7^MS6INM?+C=1_!60Q0^WIO^Q+H;IMDPI9^>20CXU=)CZY%1S;('U^Y^+2; MNQ?
5ZZ>8T;@;@.OFXJ2^>(267;42_X^G(5^'FG;\$&'5)QE@7(^('1QIDQ&8MTIP85<<IV8;^Y=LI^MI&ZL^F;8@/<39E M^+THK">
fTXIM8W,>_W_IW;U^I1^YGL7)ZHSSO.ORI(KZ)BS?C#V@P_L9K-X MK3Q\ /HJ^F,YV9EMLRRYVIOPPC6J8\$6DY<7WM\$)5X_#+80T;_!+MF&TNNRD?
KKVE6#1CMW<IPZCY8B8KA_J_-M_9FG_#H1+&^9T^I8U;BU?>4UC/WJ6^UGT^*S,BX_G;IZ,3Z_5AAQLI^&.IL+FZ(Y^YO)3I;O
M=ACD7+TIVEI%V^ITN3(MQ_EZ^VQ^EY^I52\$7S7_9^QI1I8T7Y^LHD<^Q;L2SO MI;S8^E\$5+URAIRLIQVWCL9Z3K6/NH;+>T6(1^C;O-
^+E_4DA1ECF_!6^M^046QOOSI75K-8G5?N&A#RXWV#P%66450_IDSIL(#2N-L7B*+R7^5HFF;V(S
MMAD^_GE)8R= _9I^="VC:39>=QO53.6^D^DHD^UH6Q=Y51_IG^3E8DQZ2S= MBVO/B\$M^8I<IVU.R2G^F^WR?G^UY^1,1,\$A\$^?Y+GA_\$2EK<+RG?
1#2L^*+Y;IN\$F^<^MZ^<=>8.Q>4JHRIXWPJ_W=Z>7WV;IW1#&\$*7JHKLHM^_JV:N^SBP3)2,<1 MJFN,?MN8U^N;N:BI=I
f8(T45_KN^<3UUM#OICIMMHTISU@C^)^H?+4Q_S24L_MY_GY/^8>#^*="M<^SZ.ZS?@=^SZ^R@fWO[N>RL;A(YG7D37^=C^&);,O1Q/ MM_4!;I
DEMGM^Y\$YK2H^1%98%6J9<55X^\$0\$+P14B@6I.WYB;LV_-CTEZ M4M5RP_R0ICG;5>)3%W^&\$.@P38POOB/LMI(8>8^<^Y_5.ZBW=RB2D/SPNF)
MYH1#2^VN<^9!O&0!PIHJ3H^70;K^8D;YU>L^;LUA0C5^>CVOI0VS9V_M#8IF0Z,2)/^=2\$SA9^,016KSO^1K0\$U^T8;ESSN;#46H5RRD;OI=E+>5
MOH^+OE!WQE?FDE_ZI^OC=,7WMA4NT8WO<^\$7^&B3=9=V_/(WFG>4J3E0+6;_MZOU/^4;V;9SW884_Z^<^2^*LT9^PGPU(L7P)
IG;@C^L0G5;IQ1^AO41 MQ#NEO2C24(96W#F_+^+IZ,Z^QK2_62N=W#D+;7/GB^);^56C^TVW_Y)NI2^&M^9;5&^0;
(TU@+E4/ARRMCEBPXAF/2A^KGD4X<5ZB)02IFVZ,Q=J^*F MWP4C_ GINVW^ECCN^6MSJ7%;^FNN13CfH
M_C\$A&XJ11NOM^OA>6I\$^K/GWN^"/^<+HAOIC6133?N6BT^&\$.NF6NYZ&5S_MQ4R%LZ\$^BV2;^&CL+^#_6V9>HR/YM@P/NM;I>T^8Y)225KRCOT!Z?<
Sj<53%*Q_M6=,I_E.E.BIZ(E1fJW+^_fKZfVMB>^,4L?^AR^M^OE.G&_WO(&L_M?^R^+?@CTI9BKPCl29S;1M?^QUX4WY;\$N9
M2BD^>C_4E;^XMI\$^K^BV;JXT^F)2O&S)%&+D9^ZAO9QM(QD9C^U^Q^8!_M<^\$EL;CQ5#;:SOLO&>HHW0^IBFC^_ANODT^<_3^8TYH4FU
=7#Z;GN285_B_MU2V_2;O7A;1^C+BM=^EK^W1=SB1^!H_Z73>OH5<^NLK6^Q_H\$4^&L^1^M_SBO;9ZS^)(B_4M\$CYY3A.0^95G8I>16_9-&)-
^Z=Z3QNE.KW@Y^\$WBDH;6_M1KN7?#&@VBY8&LI(2I^*11_M_LY5TYRZ9?^&J/QFL^Q=\$I;R%_6=MDMS9IM8F+^8I5;Y8IV.77^NH5Y;GN
M<3A+>;#B0GJ^YZYI^>#_D@;^PLFYD@T<6^&+>=F^W;UE^<^_K2^'(6E;1.8DZK MIU_8I9VR881I_-
HW;L^%127I/G2IKU+LU^NY/VY^%>^<^5XM^>^&G+AF5<1_M8=^2T\$;=1.37M68R^Y;K2Z5>DW5UW^9^<IOBTFH;P5/IU>;<1_Y_T2-
MNX&R;3W1_IUUF0I=OOC<80EDB^5URER2^9VMH0_+IBWZ0IR\$OB?T@9Q%9WY(%G;R;#F_-J5=^*I;9Y_M; >7Z\$J>^E<:DAL7^YF^@KRI&)?<
^3J9/5JX_~\$SU<;3QZL_6BE63@HEH_8+LW3=I5\$-2AX^C2U12STH_~HY>=8I<I297S(N^*+
MW%-9&^;S4K@1\$D(B3F4^QZHU^>^N^J^P.YATIDNE^VTU_~L\$_(C4Z/ MUVEFE1I7GJB
6#TO;Y9Q#4.>9>Q1H%_~E2>UX.BB^2=F4Z%Q4V8C+^K^<KL?R_~\$0.U^~7UHC_M?>BDD?7?DM6+>?)H/Y6>@/EQ?<
2=) &P\$+^/OZ1YX1H3XEA^T46^/SAB;U^O_M1A>=>50I>P/Q0/2YVCAP=C^M^NONB>;^C_4N4Y(2I04>1I&O^8TN^3%3H;2^U_M_A@-XX(X@^;_Q0
^PNBK>^PP5I6;Y1B1^HY+15^&6Q_~Y^<W^T_MQ#6;2JX1?13A2ZX^=+8KQI5B^R_OG;(3#H^I9I_L3FO^Z97\$;^W3;1I_B
M^=^X.V^XLT0+K6#^~91I0VO9U.U.G(2/C3B.ORILCU^107Z\$ZJ2=9=R^YQ_MFH66E@UV^O^Z^I9R_7\$2P#^9UC(X_<^)(O^OI^~MU9X&^&M^;K05^2G-
TJH+;^#0_NV^!KN^~N\$Cp;6LF1_6RJQVS>_~I^Z9RLILB622_MJNHHS;Kl(8\$3J@D%&_~(L_WNV7PP^NZ7^_~R_1#^>?<KZB_U:NOOIG_M7WZ!<
0/R0_R2^_JW?_N_P>_~O3IW?IZS7=WO^5^GA5<^SA+^BCW^P+^MX^MVNZ^F^Y@;(^/2IP1Z^H.@/HJ7GNUOG^LRJ_2^D\$OZ^IDZ^HKBO^<WNT?<
KlM2^#E6OV>8_KS3M,^%RWRXRV>;^SG_~F^7 MNKR17_+^9IJ+^DIX/NZRJ@U^\$SEX7B^<M^<8P^<S^<RWA_1^S^!AWO;_FF%<^S#7BOG?^%MXOBFYVQ>RLM!/?A
(#_Q2RW^I3_BLWU^>Y(7?>5J4ZSITf8N!;VXU;=22^SM7^Z5^I1H(^*N<^<3_~2L@+^/\$^IB0I^\$(\$^0JA_C(2+S4Z;^%GP%2QW<^IY(IU)%_M^XOI&^
I.6^6^U^MM1=OU7(JK?>D6>^>_JV0APRT=0I8P\$=,I)(\$>^<^I8B6+^?B_M20^L^EY;L8I;W\$@;=;?/C_~AQ#^J?ZAM;_O_XRU@;^212_~.G)4\$PE#(8B;fO
MOV^X7^=fT_AZ^7327@6_1^4F^7HGXILG1+217L5^&3_<G_0/5^RG_W&_MUO1_QI7R^=25^T^EU<_B1+5=U_Q_@?M(L
M\$2I0I;^/S_IUU<3KNC\$HIL;L;T1Y3Z^#I^RRH=U+G1#^<J5;D%99)-L_M^=85XY7<^>Z8M_V^Z=107YZ^!@O^~MYMfVfD41^!T^SSUM2TZHL/LD_9I%
M(P^+^LJ_2%\$D5W_~.8B;C%G;9ZF80BCW^@U^!HYI6YHQI<^<G;IU4.91+D\$ MW^<^>RD#f;EBI^+I9<^Y-
FL^P^3U_OACV^IDS^PR^>Q3ICAUOMB^7XH>^ZZ27^R>#;U0=IVJ0QZ_7Tf(IEN2UI>D;M;H11R1K&^~@P01 M#B^*
<^Y8(1%>^36HI^X7>\$5PM(Y\$DL33<42X+%_B33C;0)SG491F(4I%T3^A_M3;U;^4_~R0J!>D>I^GPG&IK5H?^AOKM=I^G=2%42S&K=I%\$AIZL!^;1N;
M;Z^_V0;YRL_N^_M;+<3T69I5B;B)IWM>65M;+^N6_E_S_NQI^E_PU)YO/MG&ZK5B;IW=YME^K4_<^=J0^QJXKC9?<
DOSH1B_3%NN^W^/M^A^&5;15D;1^IOF_M_&+E+5\$<=>E\$0930(L_YMA@&Z878A=;7W(D)&>D>^>Y(4YL=10;MXC7ANZ;
MDRG0I^f@;I7^/BAV@CT_5^&7RI^!6Q_-F>RZ^"=^#V?>@6+T^B_JX^DU^K_MXA(Z5I^Z^\$YfE=4Y;Z^D;R2IH;L6H6=-(I>;M^* MKG>+E.^TB^@&4;P7^)(0
RS=2=DPGC82_G(HP_MRPB,>O)C^<^@PDP\$;\$X\$X@30G^IEU;\$/T^<2^N^LNVRBI^W^!^?+QM67_MCGIS^0%&G^P^=I52\$IOS;16B;1AM
K6K^ORAM!6&G>#_4)FMJ(^&5%>D@R^M_#0\$135HR^H^YD0S^;GZ;RJZH/B4O;<=>MU^IUQP;1I8&KA^A>+^3+M@?M?
^SX/2Y5V/3^YEMG1^K794WEAD%N@O?^?IXPG-(0)^A^&8_1Z^)(@3@B(B8_M,QCS5)CH_J4,S6@D.I9Z_~;DIH^PUR^I5)JN+VZ>\$KT3,B<0)MNJEK^&FNC
M_(PI9^#((8)2P5&181#H>4^8WL23LD>E\$4^;D^I<1M^TEENK1G%&C;^QOE_H0FUYS<^7I^*IU5B^9>HAZ/_(I2GA6@UZ;S^HCN
M%QZ>^5W@I^%@WI68E;MR_<+WJACCL5-ICKICf(FfZ^U;7#T^&J^MX)4^<1>?&RA9X_SYL7^X2<6S;9AYTV_T^&R^XHVV^ML(I5_3SXQU9
M1+QZ>^21PB@#_0K7KB3D@<DU&^M(QYIDB_1>Y@&I&fQI_EH2FTQ_D3^42J1^MMY;S_IHBF;TQHDW6P/QQIMB7^1^#?)2IT^Y9)S2I^&E2T5ZK_K?<
L4JN_MVSO>4UIM;(^_*<^I^F^/H18&@&84^72\$^I0S^G7&YVG)=^!^AZCO3;1^3_M_Y@fXLW^N_C0^WAI^9HYZB8^6-
/NCH;IST^0<^>I^AXB;D;BW)5MM&H/I^@AN_MJY6@K7&5KS8&_RR2L#&^9F/8C2MQ_N^IMW+9D;34I^7BXBI_VUP7^NDB;U
M3;#4&+Z=H^44RZ)WS(7\$IH9Tf8_RTN93=SJ)=S\$OXTEY^<^<^IS(CD4_TIDY ME.W=FFf9U%;72%Z?
=1^WEP^U9VAZ<^VY_1^2+I5N^RO)=^9YHJ#_6?T=D_MZA&S^#T=50+H6E=^0V_L0>BATOPQ>FAH;GD5@JM16_VQ381_M=ZC@1N^9;U^Z(&\$?
QC^&G;IG_WW#E_4^UN@^@;^1A_GI^"SRI^5B2I^>^&MH.XFO8BR_009S/P83;^#N@FPTR;1MD_Y@#^;IUA0;7F<4XRONX?^*!#OH
MT#_9%>^FOWOQA^=4#N;V&P_D2V7%_f;W5I^HO>ZWZ+CPJGJO^*!^>_7Z_M6Y1Z>_>fA7ANC@)<^65-^<
MIV^<^&QV^#D6;IHLI3\$S=+T@CK^UXC7I\$#2,X_SH_MEH^//717)P^VF4UQ(3RNHCV67_P;_fD;J;f(T^7\$S5P?I_E#U?22G+^U5^-%M^A);%+
H6C2TK_Y\$D(OI^f)=\$F4I52^8fN2^f+YJYMDI;Y_X;S8&F_M?7P9_U_X^5EK9K^!MWL?D?G2D^68W_<^S^fTZOINPXT^C_G9^>BOF_M0^
S2S0A<^!>6D7>T4YL0SF&=fL;V790\$T^fW(3CUK\$=972UJ^6ZK?KGJ9_MW92I^DKG1FE=^<^X^NfVQ_&LJ<^IM>
<=5C040IS^<^5R^>_HGQG=<C60^<^MX&^f>IH0=^LB5^>^24GM@KWGAYTOU#LIVD&@=^_HVQ(8^H?CU1+7I75W^>)1_M@F<^>RI^%A^&f
_89Q^P(U3BGC&8616>^)(I^=Q7D4JN.X3JH;L.R%T>H_MZ+GTEIEY^=>+VTfDXHXI5Q5H/BB;#J22^7A<8>+LDE;9X^*K2Q^076IY>
M;ZN=^IOXN_6KI;KK+^5I_M^_2E%+5I>5%Q^H5(1)OIMG1%IV_MYH^_!^*;>^OD;f^K&I;S;M=^U6IS59SW<^+V#^>G>^E+T^N8F3D_<
MW=5PQXGS3D8UWT1Q(^C^f2I9IAB_1�>^XK5_SMA^M1_Z9fI^Y\$^I^C^_&M^%WKRL^4%;=IPX(C^H^6^MG6F^V;QJ_V&^fK7;Q8?>75S15Z>1^TXVJ4
MY_MZ^=^JM^E=VWUTMfI3P_A;DI+4@X9T_~H@P\$G_Af6ZV^ZIOU=N2_DS\$P_M&IKL#A_#;X<^#C_MUA/43H;GOIY>_6\$^/I02^&^CZMI5fTJ;f;fX
MZ8;^7\$AO&MA2@BNBP8^JAWWTM^#PDUG^N61^G10830_25NVf488^!CH_021f^f6)V8U_ML77^GW9EY2^fDFJ^B=33.UU@)3A&=^
6^EZWCV^X^I_<^I0^P=P(0)^f3+6_M^A>^>^f^>LE9+8\$^SJM&M^=M9A5I^T^EJ9I6=-(>4P83&_M^L^fI^f844ZP\$>8DISSH&V2HO>SM^K3)97OZ@?<
UN>^&O7^<EP=^S#4XA_~+^M^QI^>UQV=QM_~71EM6119BF_ZLYT;_J2W02I^>fE0WIGI^%ES="E+3D^_KX_ML5I_K?I=Y06&<<I BBB(X_)<
2^7^6IH46^0XX8WfL>_~fIOG\$S!@<^AS_M\$0LZ_~5TTON4^>^TOF>?N1f2M6JNVZQH^<^WO/1^f70E>;E2&_MU8)&4)YFH_Q3&^@U!
0L\$1B^&BF\$B^BH(W^%FV_W>^<^H\$SU8Z+^KZ_M7972;2>3Y>=^#_WCS3DA_CPN^UOHUISGLRU6U>2WJDfE;@IDPKW5B+FF>
fV@#^XJX4C)1K0^*EM(GH^_KUBPI(K^&M?^#D=1_MSZ@Y^P;8#6P_2^YI^WIN(FD);C^S_~;U;KH27V4N@IY+EQ8^NZHJV^<^&M63XGW_~W7;7W&f+<
f6^GR9IURG(H^9I1253BO_GPYPOZRH_~^Z^YMI74_MZ5^>UV18X_TG;O^CZX^K_#I^!_M)7QIDW1^>2UJ@+138G;6UDB7f1F2R
MT13XVfIR^>+^5HIH^#M_W_4X&M4DLDIS0(@8YP0)^%&^X8_1K2^Y8;USNI#;3Q#;=1WSY7Ib?FPAEQ^EYI@_LU+O!#N^I_M^NY=H?<
W8;NI5=5T26G^ILQ&^84_8X\$_3&\$%\$^1D;J=Y+^#((#33ZC%BWL/B_M^TLC5%)Z3I^?>^&D4NH)3")^J@/Q?T9525^VE<<9_1R(M;
M0H^W^F%YLI+^WW^+9\$_61D>N4C4(ZBW_+C^QO\$QO5%WYI@^#DBfIONX^I#3_MFXIG2^#W#_V9R@#^HDW.SD.WJFGA?^GI
M>4+S^NNDP\$=^_VS9442LB0SQOA9^K1^VWP00I^&3Q\$Q?KBEI3NKW;+M4^M^MNNI=4I_15FGQ4I^&A_&A
GF5Q8.6,^%v\$;8L9%AA^0M^H8;5EQ>?BfW0J_M^HAMM6HBD\$WD3)3?QP/6;J^6.Q%\$&Af0^f1.^A6I80JL9!LM17?K^1&3W\$6
M#%>@+AKPYC;5=B(ZK;JTM&^&^X\$ZRBX=^EX+K8^N^QZWRIR4(K<^WA0)453K<^M!_fCYI_7=-;f!Q^N^fE7M^>7>E)@IXVE8J_~)2>3,
(X4^OX1@>+D^8Y_M\$3#+^?<1%_VVP;DN^7TGEVYN^X9;K)Z=^@D^f;^ESW7Pl=EK&fDZ^N8_M4YM=T&PS=>^V;YNG_GY@1+UNXRSIOKV?\$TC^<
xun2%>@&52EI@<^BZQG_MH66G^<009_V^<^HB5;^&*_9HD_4H0B^\$68Y@7DI^B%\$X1^EW^&^I127U_MLZ_LX6EJH^>^fHYH_~_C17EPZP^%PU-
^6P#;^VYVGA^U8GN6\$KS^M5B^fW5_M3KI@R3_~HDp5(2;fY%Q^PRO%&^I^1K^_K_8ROICX>^\$15V3MS_R^<^~^f^V/M<@<^>f^%2!&^>@K4/^<^%1L^*
fH_GZK;KAI_M\$&TXZ;IOZ?QF7fVLS-8^>@03^\$E/^*K(3Y+EH%_E=YI(X^S7%~9FEJ^<^&H_M9I^BI;IO>=VTC^OK>MLTR^%>^fIM894V\$<^=IH;
^<^MK^&6&+KU+TD;SA^YBO<^EJZK_M4IO@<^N)97_0_~NBDPCS/(Z+^I0Y30(XC2(06J2^GB/CV4;W1^M@UBUA_S_MMW_~_fUIZ@X)Z08XP^C1H^<
R;H6&9_#HEL_~\$T;f\$GB%A=\$KPTfPCDV19_M>H#^HIG_BIB@&LOGY<^TOZV^XYZ^0=LP^%209H^DN%+Q+ISD^>@0@IS^D>_M10PF1NZ<^#E7?
OEG+0U^fE@fL+HfI@O^Z3I^<^<V+H^58I^A!2WMX\$QOW\$SH_M\$TVD=N6G;^&@SfZV3HU7K5%K;6CD^B^DXCIF067^A)A9AYR
MDWS1^fXf5XY@=ETf75D^I^>S^K_NL^f57MIVISODK0^NY^29I6V_6=IS;M^4^UN^71YREB<8_PORf3&32fI0f014A^>6SD&@>@0I>P80;~2SI
f@4>M^<^IK6(-5^S7^&^fC(G^<^E;W;fNE/(8B5Y4PB%(>8F=I+UfC9V_~)H\$Wl@^~VYXF=)A(fNQNA07+f.Q+Z(fS?E3IXU^ZP^?I1?
MR7MQU^fW^Y6H1Y@E(f\$LI^D_#_HQ!@CfIO010BCL^Y_<^K?<C^9V;IB_6^M60^fE6<8^W^<^A9Y_VTMHIL_&PADKZFD9^&GDD%G5;f3@CU5LS-
/f2E44UVZ_M>ES^<GD1<^<3;1_I^A4^>^\$S@&^*Z_M6?;ZIN;SY>KQ3+^f4C^L5>^P5^S_M2^C^K^K0=I^A#1+^!R!^)!<

_S_MG/fSY%6>LUB^fJ23CY>)fM9^X^W^<^f_@4I1TN;XN(W+^8)M^9BDHLB0^2HW=5%*8ZB^?SIR;fMK0#23PXI-
X^P/64=IJO<45UBH^9LEH^_MH^VTVL^+^<^9RC^9GY5^VJCHIBSHBU@KLI+&A^M0&PXP4>4;I6CWSGS^NW_MDI^*80@S1!^BXU%AOE^1T;
fUE!^ZH^TWTO=^#06R_MI333/7W9+^/fTfP_M^fI&Sf;MXfI@Q^<DDT_9J=,UU\$16+K>^f^0^;PH4I^C\$F2^<^%4;VZ4_KR
MB^EOE129X+^0^fY@HVf1I^SRHW^>fHGC^QUR^fI(9ZfND2&3=O1_482P7X=21^M2D^2FU7)=85_JO;fH9@M=^_MT9%G&^!>4E_0Q0!0?fFW
M4^K^fE@<^&6I^T^PSL0\$CM^RKPT^>R=RUW^2_2^GX(f_M/MCFC02IX>^>HJ>2^>R^P^K^<^V17^>1Y;^<^65>=>QIV_M2B;J;OB/9^W12=IRI^MSI2^XZJ)
%_Q/fILT59EE^<^S8MNLfX+JV^=P_MOMET(+B=33P!@IM;_R^1B^\$H^9L5FJ^!;\$)FGK4;ENIBJIA^IL<^%DTNMf

ME"9.FK7=O=AK*O=SS4YVD21YF"J3-O(=POH?YBJ:Q>5G3;NG4V1VY@KXMLVH.OZ>U..8)E9.(63
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f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⣴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j5>JX/I#>^WK\$S^YD/U21F3Mj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

M+S>=<IC_LN) 41>1CSH4R%Z[5C0?U'S7> UZJ(*0*42;UZ(XM?&HKY!~ MC8?KONU?^=>2CINJ7-WM8TPBE4!1@)1QN5?)\$P+R\$*\$0T"Q/DB2...9U> <6< MJN<S^~\$25<~\$IW^&R+Y^G9P0.TIRW~ XP.CRA(X!A^LF=B7TYN^TWT13FQ- MMW=IC0+>1V0U;M\$^IRJU45^+&NfMI(ABIZAOF'\$N%^>^TOKT?+C>[5N^T MQE>^VAC4L\$C"QJB:C36+;>42KS>P=B\IKD:ZCX\$- ^CLE);ZVB\$^42A+>DB(\$ M>8HBD18PGC.2VYR>?)T<4#s^>*G>ZN4NF3&J4K.E@SPPA0/12.%TQF=G>T>NDP M9.JV@LXE@(!N:Gj*!LH=3H^BG;AT!\$Q+6&N97C0%{?R25G>3@/40%CH ZK MI&WY29.(G)H0+#+.#.&%;~"BSC! 16Kf/HH!H@2*~0^EIGYZ7W\$\$.WS)\$S=(M&LXNV9P?)>7>88_>K<~94^K>WC#(D^VACGQBIU20>B7E*~!VJ!*IAM/ MX=6ZWGSB=U/UU=R6)Z((69A2D"!!QZ5_Y@=DS4RHM6U<f-M%P/1#U!>PZ.F>9WYCA<9EN H4"~X4WTA.1R9_MC^!LOL (A)=FP>SE9AE7Q":? 4WGGLZ=SY-NIO\$@V66:<80)>7=1(CTA~W~F7\$!HJ. MAK4SDVP635IQ;JPK#9=S17D3^H6HSH"ZDX>:81H&&(.AC_/C!)QZ48E M@M"BG"~1BU&^A3?<2BK8438S<~K0Z5DQUX"8FJ36^@H3VHB12.# MHT5R5BMB L)34V'TKG5K/E4Y0HWRP=E_Q- >B4)J"6948;2!~72"1(9%#@A2 M&RO"0(9%)E@4\$R2PB1Tf8(=99_W020;6C:=PSISQ0>EKO2GPS;=)DOB>f*WFP_M7*!_j(7FZLC%6?F)E#KD- Q\$M6PY;6(W~RIOG3G2_M2_X>WFWO>N0\$;?WAS_RZN;N?KE^Y'R;PRB.H@0+&+JN)U@~*@(TX1)+_MQ\$S1C>_>/4>56_(HV4)\.f&AE*P>_G2- ZP140>XQU#*S1H3X>;N;L1>H_JL+ML;BOIHS;8_HM=R*MJA(W=;S26?P5D(\$\$)@7\$<X\$2%>92D&2\$U\$P#fKYOCEXH M\7N_>+S<.&AQ2X0TC06ULK7\$/.PFSLKBK.XU/Q9XYVG1'O_9UHL'G:1+Q_MLRH/6K!>M5VJV@ZU\$2=9'A84P(+C)1M%.6+VN#YfY\$1\$88!0SE*8 IYP_31!*>0\$)05D14!-8PS_D7A%>77_M.#6>75VW<_>N_LI2912.IQL<N;NGL1'9Y_9T1SC<_BXTQ)Ff\$Q01LHZ\$Y5M_M.9JB?>.(QXB&@&2%&G3- 9YE(E@S/)<!!BE66C8(L'PNQ1<4D7+>.&fT(+Z>_ML;6RLQ=>60!>*XG17"7M3D8>^ZTS&Q3N1=GGC(E:PV1L~N^L_OZNEVB4Y\$S\$8\$1@~*D M4NTR"*B (6)A@1-H%E=PQ)CO&_2_S4&%XJ!G-%!S' Q85=NYGMGF?E^A_BB_M&X.C@W3/!W-H&;XQGFQ3_X,N>4F.=./G*KfBBJUY8S&P3R*Vf@>? ^C_M_A.3Q\$&*~!53"5) BA/& (HC8"ZH_@3RAB>SW9WON^CT MX7YR/1774 ^>V!U*#3CHRF9-TB?>YMZEK_QOR9U"FYG61!10N:%73^NZM4U M^TJLH_H@H!7=1/TRSL>N9UW_M0E^2H!7 ~%06_5/7TCBUT8H/IHSJ!D~L MPKBEV9.UZV_7H.#N2VJfYP0GXW110F)!Hf7#NS=D)\$RP/BR~/6HF6EAO%R\ MJJ:Q35E3O&R/L=_(G16+#+_CYP#DD*5.12%!.<@BAD"\$*!(11J9PN8- IO5S>2>T_YA3P1JW39=QDIFEfVVB"E_E.MC1#O:~M19WK40'F/6Q7fLANNZF\$=N08ZPAGY5V#CR:BZTCWM#fUGK>7_5225;...:1_M^<KG:KVf? f/;%ZK1U_".1(7SG\$+4_T4Z&A2?<_WJS6&X.&6.03.N@<C-M5!<.>E>#1EM+>+L7%G4T0-X89ZJfX!:\$".GWT1)Wf5-MWIHK_ZK&? f>NHN7N0TBV.2Y@A@<(PA0+Df!_0TSGE\$;0J/f<@<V<_M<13HBNH9.4N MP\$9_Z_MfL#CR9>FG8B/3YN!J_=2)F_V7VPfHR48B\$5!>XER10HKR M!93U\IS46;MWSfVHL_L128(P)VP715#~! MJ*QXO>X9&_~%05Y1N>EYPWF12'A.6%840!~_0%(YA)P@F1418\$!BU+KK_M>XZ f_2QEF0>@fJfX+H1K:8C&N"TG~*87_YD/KX?)<~Y>8BBT_M43!F\$0CR2@G7YML\$V6_Z6\$;RNAS=EFE/ZV\$W>?QUA\$VZfMfLL=*F5/_\$5 M%Z7<f0IR+&UB;N=F(ZW_9#2T?AHB>XAZC84f75ZfDQ9fTL1'f;6;fV~Y_MQRI05+_S7^EKS7_O18;Z3/SKK\$G\$S~&88H 1HGfH9H6Zf\$!#2\$.\$RS4.#~ MY/CB+~"/NMH3"UfSfY;3fT3@Rj!S="R-ME_~1#0!G5FEWQfB/MW13Kf@Qf0V!>2;?7#_DOG3905;08Q_&R^MfL- Y5M^& MBV^1_0!>f:5*OBM^NfH?^!UNB!+fT>~%3;SUH"\$(S^AD+>P%5_M-SN1B"/0Q)fE1FW2M2fE1M7R_HJZ9K8Z:WR^MfPlPj="P<=0R^4@T<~ f_MRLW;5~8"1L_94Q7>55EU;KSUE8WA>_HP+KQ_<3;725G>TK_5E%T\$ MB&BABG(R^A>Q\$4&("=C(9C &F>BP*B'.C>fW/f(+S+3C>TfF\$;2S^0KT-MC.H+GULS^>PRTVX@V)fTfZ"J7DAF78V\$ORfNTNF"+f7F7:7L&(>SVK6W4^*MS_5!fJ8"W MMN8!;0!1#(HfGT5E_PfUfQfKf;525MfPB@SKf;D4*J1_4NE1!R0Q06=^J&_M<L<_<7CM&M@OPf25HHEf8Z_f/HZ<_0?^L^TfHf? D^@EIG7QMMM#7&_#f MT_?H=L2R_Uf(1M5)fP(GN0^A_3BB_M\$6\$S@F:f00\$5F"fTfS#5"Q6_"N6+QfXW#P.PKJ4V1LV0P&fE!PQULTSG MT_!~?BGSfEP^P^Zf_I=O>@7D*H.0O/G.%HRO>?<W^1_MP-BC_M-\$L3V>?GOO!f?K?P(A:4H3Uf(_JK&_Z6>_~L+CX_)F^W%.9<3KP0)f^1!_M+Vf+3HH? @_VfYEQAM?O@<_XfL1_%Z3D@<f)FZTF=;59=V_NfM(669A^EAC(YZ#_M_1A^!2A0\$@<:4\$Q\$O/_Q\$16_VAD\$YfHZ\$G8_~%K>~%PEFC9MWZKH#N^M^< M97f_1fLB7f0Qf_ fMO&XfPfF6\$SXXfZfKfS3fZf@fYf7M="B&53G)f MD0f_KfJGA>fEY73MNfBMAL_?>D/6\$+QQU>f_fYENfDf(9W#_@<fJKfY#4KfE MHAf_<SGL1Sf!fSQ6=4D^MXUSO&=ZP6_-VCBG8fLHCL_!S(4>3fTEDf0X_3_M2^*XSAfMf!_>7L3M#Q_?7Z7CM="2;&+?>RfT80_~!D=B&VX_J!+Wf MfFH7fFLDNfWfP\$&=C&_VYf\8-MJfU\&fHX#1R\$*#>E&(A5C\&6L_081BW-MT^G<_N=P6ZW\$S;BfUROfVfORN_M;7^0TfR=;8(8f:#88@907(HYB_~_~L2+M#~7fJGF>E&=Sf\$5(52Q=1Y2fB^K+@&6Z&X7fXfY8Wf!@9fS>^C>4_70f6U_~M.f%<@<^<S9fA_~GP44K@!fO/fCWfMR?3_UQ+>^L%CW(f/1 &B^f&_K_X_@0B_M^42_QSC6(f^YfCfT#fQZ-B7G&GH4_3fGf98fV-f_ZONB\$<9_>~<KfHf1fF_MfS&CfHUR^fZfH;8fN>f_V:EHD+0UZYfR@_H@25; f5fDf_U;JE&17f9fTf3fM0^C@AZfHOC3%VGEH(2^KHfAP#DF<4H_S6.fF9@+>MD"

f3QLL%/DfA54W>9>fW>?K1^>:&N_E6<5UC^fJVf6= _QZf?N>PSE0DNC_99fF/f?>fJD01_M\$~_K:Q+~5*K^Nf-NOQSZM=W=OLPYH#P9Q% \$Y<^9fU_/&f!_~LZP_M.HONG^0\$4PYL2Z2M:G=)f;YfLHU=UGY;fY!>=XV>?ZQ^RAT.MEXN<54Kf6A0_KB^J.%Z_07f_MfY<8V9f6R>~ MM:~WR3;GHX0fYUZHfV%N0KQ;3f;R5YfJM_925MfMRDQ_M3L+U08QfEZD;~<9=VfXQ_~1%3GS=K^L^>fLEQ+Ef/>7;29f?P)!41\$2\$~8fEV ML3P~109H\$>~P8_OLf7+>GN>5j6=6;GfM;3fTGT~>1fY5=R8f_JE3+MPO_M;7ABN5fVWG27(>>~7W#568_A"TK fN_fW(L_RfH_MfP;B^S^Q=+f0fNF907_M^<L^fHBT^?Z%fBfG65WfGXA>_Z655+2UfPLQUSK^>fHQ+D0f(\\9_1_!<@B^&_M84ZfR/ fL9~DPRK02f>S9W#~WJOZ^>U5W>TY_f!fT8=0SF5f!_~&WMG_RfF_MJ?>J++>ZK!fYMNO/f93R>~>^2+I+9_BY7>1N5NRUNN299!@f&F)0 M9P#P_4\$4A^Q\$C4^1A@C(98)fNKKU+SA^Q^0K;D_UfNfVf10TDP>*UfHfW84H7&;MX\$INTY_2^Y&_NfH_R635">7fH+> U19D2;f@A9?>9VR;B77/^H2_59HB3(D_K^*+%1f;_MG_0E95D45RKNN&TK=+3W4DUCCS8_ZT8E? 8%f&~f4f^<CLfHfPTW\$!V~?70L^0_Y?)~_VXfZ<>#>_4Yf6AP(fYf8_/ZQ^W2;3^11(C3%>_@_M4fK\$3B\$(<~>T)f0Z@E^fA#fJ?<105fKfEBV/6F5; fDBfH\$=G\$A\$(5Q#&6_M\$?>f4T\$XfLHY(f1V)<4_YA/f9fL1^>f1_603C^>f465+fy^C^>f4f@&CWO^WC>_~?M^@_4&8- V79fT8Xf^>Uf01f7_4DfV8fM@f9M>NIU8TQ7P^M0Z8/>f8f!>=7EC36>_M5/>fGf1fMUVfJS8WfTfJf^>fVR2C_~YK!" ~*0\$0\$@2\$0B(54H%(SG"4.62V_M1S- GP0L&4_W8^fJfB98_82f6fKH;fH^<P^f15_71GF76^BfV^fCYfH_fTY_M\$ #QT^*A^DX%GZfAAfMf8ZPfD=50F8M^&SH^&DP_~*6\$RMO@Z^N^KW)f@LH^NKL&_C@R?>G4^&_MAY3_ZO/fVH_1P_Rf5_~? 32T%?%B(C_SUf^C/3f5P\$A_3PfZ)Q:"K6\$R4<_M?W;N_WfCUM)fK%>fLH/fT<7fJ57Y\$%25!~(f0@+>0&D^<2(\$Xf(G^fLS@)_M2fPF^>1HGv?2LZ%H" >*^<+R^M("M_DN3D;9#>=2fKT#fW@SYfL_16fJ_E:NOGfB="U7fD+M^?W^9RZ=^<1^ND_9_MX(B@TSZ_&G_S_J_9M_300HDV? ^A9^HSG+MCO&GQK_R;D6\$GW^fF10Z;H/f_MVWDYKfL>_U;f5_HK#)_f15U0^<KESQMOM^5RfHP@GG^H^8fJUMED?>@&D_M2)K& (6(D\$1%1%N@40<^Z>4A>~7YW#_12%MfPX_A0S^f)H9Y\$Xf1(Q_XV^>S11C_MWT%74D=^P^2Y6=^fT7>?&KL_fHD9@MPf\$;HfWfTZ_L\$;fEYB2).8_9PW^Q M\$G\$@~%~%3GBf1f-W)_+>@6=5f!>M;9&<~>0Z"GR18";>Y_1BfHfYfS%<~<28Q^>fMfJHEGQ7Nj>MU69f60\$%<~<1^A""<_JC<9A^>OW?>5:=<#&~> MLfUMYfVOB_0fFGG6Z\$S&6TYDZ541S=+>ZGM5-fG;69KHfYQfYS?PG#^X3+?P_M7~>B>M3Z70/3HSPfSfY^06=f7&fT1_U#_Q>f?_0.8XPf MfS78~>RB^>3&ZOT+Hf5=B2K3fL^>ZL<4&5&~&A^fAHKX\$U&f1+95_~2%MNfU^fWYNfL51G**^<X_X^3U03fNfA_M?>?>T^0%~%Bj2 f!~*S3f7;D>RTSZ46HNR^H_O>YfL^>C9_VS_Mf<_1RfD&~>G_LZY_Y8=BUH&^<_KG\$<8?<~&^_N3>OU2^W_M9KfHfN\$C=F\$~#6KNY?+_B=~/6WY@MK- Q52WfE!>fK^0^*P9_M\^fU+!+MfH_Q;OUZW=>)fS11_W0\$)3E^>fWG3_f(C_RG&~< @)8DT2(H"%D_09@660Vf#~S0#>@09)!4="<4_P9fLCf4RT^<L=3^fHfOMGYCW7_MfLY9^W)fTf5_5fT^3_!@&_KXf(HDfB_S&@PfP0M\$2%2 14f3_U=^fU#>Q("WK_M_DE"4XZ9f\<=)ZZ?+>M_fEW+H\$^<f&XfJ(f+R^D">8)f3f_D9\$Q/_L^&LHH5fHfGSQ&f1<~&3C\$QfB"; M+>Z^<+5_Y@fPLH@>+YDP&U_5^<fYLM^?Z_>_V^?EBA_&fJYA3?>3fIH>NfL_M^<Q\$R/53_G+V:f7ZU(Z2/U^f068>~26TK7QfNfFM&~7fVJA8_N+0D_GMBfL_M^fE^fK_~*fPTV^XT3fZC3N@U/7fDNfTf3^>fJXNfJ^>D59X0>C@fTfC_&_M/V^CKM\$Mf4MK^U9_f2(fP^f+M^P_26f)!T^C- >0PA@4#%f_:9Q3Q_N<VJAY5^Pf9#MS)6B^G=D)8~>X^<NfX?M^N6E!V!@4S)4AD621R!~_@8@0CE_Mf4H!+>G+>O^>#~*#f"R+~f(\\^<)_8L<~<@fY9A^!~21%_60DP^f@_QT=3_M_LfLD#~>SRXfHfEC=4Gf9HfAJfM^TRU?GX26^B52fCXA?&E^fAF&^*0_RSfU>F" M9Vf_PfCYZ^>2_D66(fU5X%&LRLfE^>\$V\$5_-fG6KfQfX;3^6NfHfXfDP25^>JAW+>fD29KT^<=4_DNB6;fYfL+>f1@>P2AD0^>0%&B\$A^<SFV_BUS86;0_D50 M&fH!>852O_~>L^>+f8_9_M4^7fB;~%~?TU(DS^LUTf1P^VZ^G0_YfY^VAfH^K_M;A360_5S.F0?U_YfIO60GZX?E<5TYf2^>AK^@N_1%0KEP_1EHA^7fY^0_LYQ M4L(RHfE^W#~_00%<C9^fJfFH&(Z_#\$_N;M^C%2_ES^&R^4890&fH^fTB"B>58"~M1+<f%#>9C&f)7\$1%Z8f!>=Q^fH&f&5XNU&N\$S+UKGfJXf9f(X- K9f^QGfH9UP#@SW7fI>@S^HfU)f@U=3CUM;1fME_M<fVL4~fYfKY9fNRA_LfL\$H+!>0E!^4M^P_fY&G;(9%ZfH20fLY_BfH"~MfR;fJK&Y)E5^fTfS2- H8N)fW0(6U\$M8V_AfZf1_R/G^fRY#9QQC\$>^Z9Zf1_GC^85GF6f=ZK_M^X_A_RfE^fG=9HEfKf?7X)fAVfF?>fYfNV6RfJ&Sf5^fT\$<RQ\$>fL_2@<@fL076_MfP&f(9%>0fH(f3V_CZfH08fLHf1fZ0^03~f!^>YfZQ^G^>f!6(f&?245=5@<^G^4_Hf_MYfWU+1^>QGfHfZ0fC_fH138Uf!>6&85A+KVfNY^3^fJVS_&VfH1^92_~H+~P_M^BG#~(4D2D^9A!1_5_@f#SD%81&~%>Q)R4VR;~(2f5WfHfTf_MD)fEZ^>L4^>B\$42fL=^<K^D-CBTGPfETfEV)64>PW^>V#~!62~\$?9AU_L&f&F\$X08 MfA^7&81f1C\$99DP(44fC^>2(f42W#fBP\$S^<fHf\$#;~fG82=6f9F+2>~>~>RZ_3_M8fL\$1047f!N\$S/3+>4_U&Q&=3+!>=Z;5_?fE_S~?V\$%8Y4^>fSSP^5_NfJZ MWfPXS=_%>N:0/>f:00^65Kf1ME&O&K9#A_f1^9^4_U2fL4%>2NWQO7f2f+>f!~>M^C^A9f6EPP>KN^>X4Z@>O^fVfE1Z4H0fDBVfMU5fG GfOX4^P<_48&V0^XfLO=K_M^Q^<fX18NfM(KZ67f9160?4H)f^fEHDG(K^f8ZOD)/+>(3\$6?~(D.TR=^AD_M_)N/66K^#D^C^fJNOP) (UAX^VfV7_006RF^+f7A_Lf>93M^>2DB&f35K^<+>M9SP\$07f!f!f&~2(f99BfVAC_(C^"93=14>~98<~f:5^>R;9>ASW^%f!<+>MfX_Lf!> SO_QC"GW)>E#>XK%VW;6R&U^<S^<9Hf(VY57Y&f!_~\$EBMfMfLZO:OG)?L+>6X%>8fP3fDf2@!_7.8_A^P^B<2@V!^4QO)fRRT"~BKVA0fSYfS_MfIOVfHfBU; D90BA>C>3\$;9Z9<?>D59?T+>PAR;H;H^>N^fW6~!_1_MN5f(88QfA_O9CR_N(f15%_DC@+>PYf3K?>fQ9CX5fDV^>8_#2=(W>?fFSf!>M^V<f? <44^7K;Q_6fJfGf(3>?2^U^T^fE32f1VM>_Gf!>^fTN_fTf<~>24V^EATfMK^f1Xf?>N78265fWROA8fP^fRDB\$~%>fRV7N^>P^R_M^0YB6 \$4fX=1ZXfPDW^<@>f5=Y3W=~R;8#>=A6X^R0f)21\$PZ8^9fL3N@_MP=OIR@f!N_??>f!fJ8^W_Z@fNW^U_?>O)9_XDY= MWfXfH_Q_IDfLY4^f=^?T?? fP_~AW/fHW^2^K@44>Q32G40fM_7M7B8^<@>f_LfR1=^<LBfT^+>fE9_73f4NfE=^fM0fS^>fEG4f>EM4f58>Q=OW MTE\$^fUQ9AZM^<(OC)DZ_7Z_K3fTGB1^0&f40fRfN4<f>f<f#>_f43f1fE=^fM0fS^>fL\$0_Z_fX(380?UXYH^<QDW9fT=^>4;PWHf&C0N0^? +0#fJGX^*~H_MfT^OH@f1D3/_fLNZfLDN&f!fJ9fL_6Y4&f;fH&E60f^6SUCWQ3f1^8fL4BfSZfMYfL2Z;f5fJ^>G>fJGF+>fEJf&fJQ&fTfH4MG4_X#f1=2;#ZfJGW^>+1E^>5Af0_8EBJ_M@P<~9B4@f^&+>D9Q67fU2KPOfTfIZE=El89@<+>P0CQf7fR_M<)N^>QQ(E^>9^<Oj <Z>87NfD;fHfH0=^<G\$8NUQ3G^M<9_2VA6fT_K+S^f6"~7=^<fRfLQ4fH&4?;f#5&f1(30+>~8^>R0_fJX_KMD\$T_H99\$ MVfT_N@8&fKfX&@<0XQf(ZS8^>K&@<E^>f23_~fLZ&f!_~fM0XEHH^>fTMf4@<Rv9^9+>HDfO_HfXN<fNEB^*~MfIZ/0KH\$8J;f5;OC^<EQWf6 M&~&~PR0^f!8D3<77f&f0Y3P^BB^00fD+>f!KD^<fDOZUf1+>32_9^7X3^fTX#8_M<5UEfX^A@OGCPf?_fHV7Cf>~2WEZN^>HfX1^fLFPfYfN1;CfIOUYZfTfO- (G+>f=R^M!>E:GEQfX+V^~+>TfHVR3>^P^>4>f;fRYX/Q^<M^H^<~f34 MK>~>C#M&^AYW6_Q^>Vc!4f6H^fL2fK0fLV@S^>V=L9PE>2fN\$B&_Q^>4^QZ#_~!7_M>G^NA2D_4V;fD_fH00A^>VR7f2QNUfV+08=^2NZ_%3fTUCWS&7# (8RQEDWXA6_M@V+>7/6C^0+Y>UH^f)HSM5^OSKfW^~_WKMUH9U<fIOEJO5fK^>fYfYW<~(23fD8@_MYX0^&4YfP^2+>489X3C%>f4V>C^> @_~L^fHfV!>f_~(8f^UDH0^>f4E48N@N^Mf~^fGDfIPOfTS9?>fUY>T^fH8f\$P_UZ/2D0^8_#>KZ_L1^>BCTfFFf9V@PR^>Q0P260 CC4K^<8@fHfCD^f4T39&01G_3CW080=W^<fAF62B^>fADf1fB_~M03W^>M^>f9>~>~>SfJ3^f142Z_Q^>~*Mf4=AP^E_M<0\$H28GX@fU^>Z30^R+>+>@24^ AZfJ@V\$!@EW?K)_MUZfHMTN?_fL<Q>~>REB18KKEfLOfHfLk4=6;f!2#D;2^9X_f(44fLOf;GfSDQ;M_MPX^1O_~f1UV=+3=8A8fAFZH^f!0fHfG=>E? fBfB.DOC\$>fE40fP^fRG_M_L^>fE(8fA\$A_~\$?7X#f!S^fJfP^&fS0=>fLKP3CNZ_D5^>fP@fVU0^>N0B;fTD\$>M^Wf5 f31^>TR3+75^>DDU@fFfGfTfND>fCCUO65\$;K73Ei^T%>2N>fH^>fC\$0AYC_MV^>fB;L_3f5=^&_O_U+>KHfPU_f!fH_L_~5A^ M^>ADV/2EVR@PS>1Z^>#CKA_fJ#_K_7f!fXVL;f!>?>AS5MNfJTO^>4=FMfHN607SV_M^*~39fLBlV6G>_L33)Q2\$-QD4A^Z<3+8Y%~\$=^>NfR/+>5GX3B_VS?>


```
MEC#A2%?XNC&-L;A=AJ* WSPU9M-QR1D,1) .BZL *4$RZF&D>I%:A=ZTCCBZ/W=6^V:F0^NTKXA M;A6I:O3;65>J8Z;+M&,CXZ4V1^67?
W8X^XSGVSL V$W2R&8!;#F?KXVFS M^FE)V&GHXMQZ4E:VQ>*L% ^/U-U6P^59N-1AT71HJM;22IRNU+OVVDUG M;^Y3?# M-
L>>J^O^D%L;W0X&^U^>JHP^KT3^O^7WJZC 86OCME:E,Y* S- RF4@=T MFT?ZF719-G^>9;^ QX1(3SIBEN2V$C$PO:D,T 3)AL^E.MX+^F)=^%A:A
MU>PC QQ1H1+^0I>H1I(7.S%?YEP#;JH=OAMJ^1;^89^(&#B)6Q/O8L.C2.QV8IBYI%I0A05E7#OE6 KA^7.F.E2VH%F(
M;@GC1%?54V+0;0D/I^L^U0+^U^T^W^P8IV>J&K1 R?C4X^*XGO^ (#= MHLL+YK$D^H^DJ-1>^&9=V8Z*1-08I+^*Y/D=H00?X^&= MK8CJ/-
S^YXE%KY XK58J;Y+1&JY7% DKOAF42^MUKL^I^(>O^>4GN=^?D2 MEM9U;H%7Z_45K?FX>Z>VS;J#^ M+^1A.LKXO+^= 0Y4+^*YUHW^#;2
^UI<(>EYLV>Z-WP66DGJMY<^..04 MOMHY.79R7KQ%#TS01-XD2E-S;^#Y +Q<^ILFTC(9-5I)M^U3VP MIPMK&Z.OJ^HIN-N) UT<
%YFE%F&8QF81 M0PQF$= -T^=@5>3?=@TG9P9GAY;U;$DI04O(S+D@C6)@B4+^1.G)28IY6$J M^M+4K^*V;5^9;M5SKV(OZC$8UZX(K^;9^*C/R7-I
W/L1J1.6M+^KJ+Z-N M8R3H5%<3^>9;X;M/AROU674L X<=<=22/<<10FP7.O^O^I>S^<Z;S RV MKO1>OUM3<4KH^Y^J^>K_4ZPWLH%?
-17I=FLIHZH=^I>5N+AYJ^O2.MK^>6^VC>4^F60HK^SE =^ P;I=D^*K>R^F T^S^&WKM?P>#-S3W;R^W=?-3MRN?F+
I^Q172Z)^TW^_B2B=OVI^*Z93M;NHL 2%;J2H6E&OHNXL=>^*T1WG^_M_3_3DC_*UCENB;:6I5;>;D=LCIQ5N^H^MW=I6JUPH$R&K^JFUS.(QU/(IP
MBF;+^HUN8;Q@L1-8N+GR3+^@3^U^VPR$UP7+^1I@M@M^R3X&BIT^>^7KSQ2:8 M;#IN;I=6 _JZL_G.?ZDJVLBF^F=?
WWRM5O0M>ZP96;N C45FKW>+1_99A00 M^@O3!> >9P)63YDH$1%>^+41PG24$2HVVYV5EAX5B1F&I8T^I7S;IBZOVU
M8;:NH@S^TVIP.WF^CCBX1^X2W_O1:0I^_G.X#^SW_<^AWI?B19S^Q^IXML M1^JP>^/&U)U?$$8)(C07RHCF^_^\DI-")9@FF$(LHTFVQJP0/NWFW^<$NY
M:5K<IC5I8FMQ_1W2ROB^XO!>^2_U<^AUS&CJL<#^PQM68Z&^N1_P2PYIR MTUY^*ZH914YHYH=>MT4EISDS:F0JGHI^+EQ:B0^A^%7C/3?
X0M%Q_% M+J0NHE1<1_1KC/LS$@H5A1(80D1^="&0Y5 HP1^1^65W.G/FBVI M^Q2H-H)Z/G^3^NJRZESBP&0^1^F+61C%
(PX01KK=^DB_MA^*R<^7FT6POLCH MI6CTF8M5D21^2^9L<^MNR>^>1A-JH)^RIU9IX^I^H^SDERSW^@^H$S^WXBG=^U^A^+MNT5;%ICG>0S2
M0GHI^TP2D@&^&0%^(H)XEG:XSIDIZE^I^I36+^1L9$^HNFV:HFTG^>^&^M_KIZ>^7^I$QLB-BTCWI^B>^12R$;JV.NT^?^_A M?
Z3+^%E>J+^NXW^73;1^_PGZ9.$XVC/Y>K<0RLHKBU^?BQ+C@L1A-8J8.P3 M+&S+^&6_1Q3^>82^&14%N529;IBV0_-GG90?
DAXR#;2PX@C4)OLC<^&XA&41&4&$&^_HT M0?M.UH7V7I^(-.0I@)^VDZIRO ZFKO_G0;UUSW^673Y^IX9F@C178^?NKX MP_-T/T,&^&NT>PIP^_?G6^
(1KO=J16LQEOOVY(9)^4=0-8I^/1N.0M;YV=HL9V3_6^*M;:=EGR+B8&VR4I>R45?RX+$$A^Y8VY+Z=5_0&OO,OBBN=GVPON=J^&^&_7Z^KL M
X5^VOIN6(8T>#X^N>5SRZO;WXDQ?_6YI7A)RIK?B$Z^B0G9U^U@ID7.25Y
M%$%L1+M4C$3E1A^1^2B$;4^AD^YT.DMO#1IXQ/CLSK870;I3<@M(Z.M^XVK^I8;HONO:PJDQK&F^?2B_SC(2KX_U;I>XXKL?8;I#J MSJ
I%M+1^#2/HY^$Q>Z1061;M+1BGG1^_U)& MXJ)^"@PAD2@S(5-$5$(4MTT^_?&=TU=@A8$0I^$+63I?2S#;H78U=D M^FEO#
<5&B;13%DEK)Y==+;S2FRA@FLD^_G/3C?^XO9T)(FX>7>3X6R4_ M^KS=^!MA&2_7=^W^PY=V1?^U>B+^B;I9^E^-CD4^D^C( <^&S^D^A^!@M^IA
MB#^I$X252Z)^_?2D>#%8L8Y1^WA^C^Q8GURR;3^JH4^_I^H.P;#%DQ^<^I5704IKT$1&ZC8.K1_M@PEHOVYF&HCYUAPY=J5$8E1;@_61QI^
&8%8^JLX3@^!_TY+^*<^&HUC_-/O.SHCXS25V2(CGDS M5_VZATW_1AE=CP<IND%)H/N5HX+4^XC@V^IP;_9VI^1Z84YU+5;YN=V
M5XE0^Z84_CJ^HN$<^<9973^J M1+5M^FTVW^>QB M1S7L9A6C^&B^).C13+^P+FD^B^P%9<^RA)LY=L;1>1.5 M^?+V+D^T ZR?<^_0JG3_NV&
(F=WN;=EP72^/16R72&Z(^H1+^#ADP^G>_MB^IAORDA6F19M;H^>1^KI?>RB+OP^HLM^U9U61^?^L^UK11^1=VOI5/O#9^T M^T;
(=)D&^2D^W.EOGAXWJGHI^9W^*<^T7.FSY;?^2_3 M.UO=W/B7S1PMWC=^L+P.HI<8?H;I^VMO+^QU;R/HP%;.L0S0HH^BGEE@_M@%)@+A>
(I3^A^"JW6-H;Y<=<X=="#^CK@QJ>^DYS2C09>2KI=P>0>N8 MIQAAEX1I3ZXI=^1WC+^@3P= 1Q^W^1^Q^T9GHV+47ZNC_SWQJFTGUCW61^?>3?I
M%ZUNJ$;Z_H1F@^FLK<=EL@>7^ARF.8I(2^#DB^*^(+1^1VX^>M9LKQ^%0<^U39E^BIXD=VTPS^H$01^14=9)C;H;GS=;_M_7^UD7^KWC62^C;
I3H18WRW<^EMRS.K#;Y7KY2I4UVU;WL>J M;7:5_1^/89YF%#^1P#&^&0(YAAPE^H*1^1^Z^NV2.P^O5+VTH6L-&^&A M;=1JEU^I^JZFZS>?)^R?
Q70V?T^#0M0HY>X74U^YDIL^1@^KMA^B&R;N^X^MK^GI_O^RYT49YS2+^S@1B$E^A/4<8^I^>8PBI(8E7&HU?^#D+1(Y+D$=T$!
M^018T^O/(5)I^+SX74&MUY=^GU^R;@<^8-W=OS MEZE3NBI>^Y606&W;S$G^MDU^H^R;O=CIB6L+C(3XD0+^M^ M6A^68A5=-$J63.&
I^DLOIVSFB$)4+17N1GGQ@74^$S^_W90M^O^T18(2)5?^M M^MZP0&S^%R5;=LD0N^W2HF2+^I^HWOVQD&[SN^C M^U?>E59.6+WL/YI@NZ9=
MPPM&@PJOEG=MLJHNIQ4>^ZVXKVFTT58/GID@JERH^Y=^>_4 M^Q1M^AMIX-5J5TEC2/2%5<_0OU^X^I66VI^JLE^E@^M
^5UNNM>^JH<DL@_P3X^+^17I2^&Q MKA^Y_ EOM;MK>6^W^X2_-AL_5F^XQ1=;P^I;=G9WKE_86MB#^SESA^X^LUTG M^M^6Z63ZSSF7?
Y0DF8Y^V$REB^"U$F^"1$5&Y^62P^#^ MC/1#S3Z^U^AY5E_-ME^F>1JG512(8(D)31A=;_#^12E1F4;BF;A M^FCG&C^KL<@^RK^A^R^%2IG6P_O1^
(P^#7&^?T^Y(4C71G1A@O88P^_AT)IG MD&85^0Y2^Z5 M0 P^AB6^&-0ROS;F5EE+^PHU^NH@OC^UU B5;0F
MO_NDIW>C M^F^JO^<^@003K5T>EJT^I^KV.AIC_#0_/A^AIRU^Z^BY636J M^8>^F9/L4.PSGC15ZU$0E10Q/I^_WS-KV29Y4I$ _7%_?IGW%$'_2QF
M#8;^SSWO^#138&-1A#^S3914I^QDC>5G2TIG6)W68BVSPFEGDHL^2^<K9S;+^I MSIT@Z#(DE^#R;G><3WF=6BV M/>^_UYIS@_#9I0^K^<BM;
ML44-HU#<1U^_F M^F=^F^?52_H9R^T733HJ0FEFKN(QINGY?1YQPDPI^B1$GBJ;O^QQO^U^I^=(=47 MJ&J^_M^HE%_D;^&C5H^1U17.4BSNE_U2#
FFA^J^8IFP(HJ^GOR^M^S7YW1^<^UA;I^KJ758^9W7^M^N(5Y)^#?^5QCFT+^@^(4H$S)^0(8S@^!^A M^
```

0+0<IOV<84&^9^7.Y+Y,==OJ8.M:Q3745FA6>G\^NE>F6L^I^I^?IOY\$T2F1+I5DSU>==""\S.#0 MEU%)P^N% P.MVSSOJ^2Y7IH_1AKL; GP.SI&#W#*1K5/6)^N2;==@VF_?I#;Y:8G/M6288""6>=<@&\$IP%>\$600IA37W>=4H#;B=O%_MAO<=<7#;YJN>1-UJD;I^2HM- SCU)P'!4|ND\$S\$7B75|+^ (+OVOR+O/Z\$W|@_MJR01(<=I M),R".+0P@(|F(8<,#)(\$BBI2JL^|F#MOH_H6I2^JB^H)SD MR;2\7\$JHF=<@8\$FDDF;4.46G1R047\$Z8Q9W5L;7^6U5K0M^I8ZMV^M7^16THKM\$<@3&K X#000^4J^|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|>^V2M7^J7HV-95I_K;|>1S^K5\$%^I/>7_0_YHX3U MD3_S3=AW_Tl-&8P;2A6A2XX;L8V^?+4\$S^+8.(+8A2Q&X\$U IG4@^I^PZOU^M<K^I_N#^A0F^=8U>==?^Z^B2P4;6<@577Z\$TK+WXVF2C^I\$&J^<+*_ MRO0V4IGV^=S^AIK7LHEIU_Z:6PQEG@IQ^+*8A_S@*6 IG7_0^1.#1J M^VP\$23FO^I9P8UQNOH=.;JP5G)N0QFUVN^N10URGE+^32A^%06C K;R5-B_MW&^&V^@IVX8+>|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|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|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|Z;^F^*U_XH42^A^!NBE5P^#)^8^!C&H0LAB^D^*Z_<@5G M=H6E_.\$3WT< M1BB^R^@D?#^K;_ IVX0\$^I^VWFAFKNOMC(3ZY;@+F;O12EAE^IP0Z<^&U_<K MKP^I4^4>1^\$YZ\$;L;PN^;S2IN^FS=25.UK^I^O>?0?#_DUHJMG00WD^I)I5+MF6+S<3? +^@HJH^JH^FA/PEFZEJ4^@B6Z;F;_MYH84E^60996L^T>+>\$+X;U17>^|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f<^I^BH7^<T^&W9^_&OOQ^M^N^*O^M^I^5^6DNF^IM^XG5E9_7^*M^I^Q^O MYLM@9%T2Q91@&+18PA@A^A0^="^I^2^I@<2<1;I^L^AYG^OI= (72AZG+P_M^*^_RNO0TAU^YXS_>@IC9JZ;9)9&&JL^Y@B2_9C^I^HJKI A8=ZJO+EEK8 MF2IO72I2@<^_X9S&8^=.=K<%_KA^>^E8)IBP(XT@JH^I F&8)0^0.@2^I@4 MOA0^C5&8^IF9U>_> W6QPMNR^?Q@P^*KJ42CMY K3FORP;M^I^<AW783NLE^LQ5W2H;I^SKR@;80ZB^\$3R^D23PWXB#@^\$4U2 M^V^*4)M@HHV<^\$ULOJ9@^Y1K3(6SOIT^H7X_#4.S8ZS3^<^< <1.71SR8@<^L MRW2I2>=JN=A^I^PN^MXDRM.ON+QWMI\$!^>I^DR:X2N^_@^?V^VA^PIH^M48I^%A\$AKY^J>X_X%*OX#%D@<8ZA5P7JXB8XSMM+ M+GC_<9_SMA1F3E04N^%G)CU7C6.P0I^P^>JBD=XM2&A^W^O;JFF=OEY<3^69J^<6N^F&#F;5;FVBCJ^H M85;W@=<+E;TCQ(TM.S^I0TWI7MQ^<88IK MGN^N;EKL;7A1A;I09L^#22IPET9;Z00G62^F^Z_K6;^<^JMRB MY;H_AI5P^@GO1GXDO^OBW^64<10%\$401^B5U^W^K82^H1D3^E_1;1^P^I^K) MVJ.PLOKXA^5K;"4 13WW2(=>J M^VL5K\$0(49K\$\$(1\$9>1AC@^IFLO(0BAC^ISXU+ OR H^I^FSJNKY)U>_5+^X M^<H^90G; (ZFWS^IHW52;^BLT&EY7WR_LV9&WJEK3^@00;I^<=600J9%F6;_MK_15_N^7^H^I^+^I^G^4) ZQ;V^ILDG+IM>+S^J&5Z7322(4TT9NK;H^I^<MA_M\$2^F2 E@I^I^E3GN^?2C=H1^71RAYH^5^I_S)H(A D0 A^"KDTV(C^I^+M\$<49;^?2ERB=W<@=IM^A^KKVLVO@O2B^L^HLE^K^K;N7EJB^5GN7Q3B1^ MYH;70= IJ^=7VVG#^/I^KI@)YE^/YF^FJREH3G%;=FK^&PIFK(V^Q#+/NU_ M4Y^W/TN^I^*@K73^IKL7GI^UC>^IG5U^?V>I^F^I_A^I\$W^4;508I^#&<^< MOV\$^YH8^<=<X<^<LH.6GG@&VMXNU8X^I^O^T99O.V^TF^I^Y3)Y^FDIK04XZ^NGX^O;I\$Q^Y^BNQ2^I95;Y8=ZCH7^UI^?^PYF+^<6?Q6M2@ MM9^JX9K2IX>G^H^KAZ^L^I^JMD^I)59>8UBL^DXI^#%<5QU07YQ0D12)28H^M^I^@;I^<OIV^I^XS^U5WDI&A^L^I^J^I^P^P9FO>)=CH>S==G^I=H;^* 20V+5W MVBL^P2I^8>=\$\$706X^DRSNK&W^_*OI^IM7F^9I>O&YGU2^IJOY^ZVKK^I^I^ M36G;9I^M2I054^J>@QCT7>N^T^EW^;=Y2M2,XZ^C^1\$ I2GJ^>2>80J0GIB? M\$HY^1M4^4%YEN^I^R%<9I9TW90GFL^UQU^WM^C.S&DBRVH^YKRLZ(^IHW^7J^M1^7YS_XIMI^NV<+^WA9+3QI2? (^B^_ARNNA^I9NS^3>J^Y^K^KA)^5B_<^M^>@W(O^I^OP>J^N;7ROE3SHN;IOJSVLOI8=EX^I^I^<A^L^W^PW27VD71OJL M+XW18NW^7XG5PZIOKKE^F2G^<^KU^I^7HC M^%2(N^N^I^P0&B^0S_Q^WEI2Q.M8I(1&#;^;RU4KP^IY2G^GM@<=3ZVA M&3^<^5%M=EX;\$.RMQ#1&IG_EF^F55QGYP^X&I^F(NI^@ZA>K^4>7?#V%D^MKE)H20^2BA\$8@^2*\$&AED.B)HAA0<1\$E&0DK^V6%^<SC+^ X1;J5I^>=M=3;6SVB)Y5 R<0MNP(T37)GVX8&#&^&H^_S0? MZK1X^WUS=LT1.S6UBQHUA_4=RFLOZ\$Z^I^@Q^XYHW^9=2VOJM6^N4\$JR@E6% ^I^@?^2^1%<^>+2P2(G^M8@>+1IDK?^QI4 MI;I^77F1^?O^AYZHEKSI^NFFR^I^@_0^FR>3761^I^D&MN7^XDW\$7^V&M^W^M2JH^2^2H0T^@#G80 R^O_ B3Q^L^AB(C^6(E^<P^&9&1.EZ8.=V19RIG9^JOP%O_M_08CY.9^B+Z?@#2.\$X^Y^X\$A.)0374+,\$D(BWS#I@IN>6G5Q^Y^MNS^MZAV# IOGVP\$OS.H^YB.DC2AV_4E^>^BR Z6^&^T5IKL3M% (G7^W(L2QC M45K\$0\$>AE+^I^A13;BKT_D_L29C^<^\$1D(I^Y5\$)>G^96_U^K6QCZEU=>M >OL)QDS4I^E^01&29=4C^SC1UE (59^B^P^S^<^<0T47%GGX+GX^<^<04T^MFC65AGX;25+U_QM0?K9NZZE^4>^ZL)71=2G;F=W>2;2\$? Z;7_M1=702;(^MMPW M^I)=^I.D.4^99=80>66K^I^D2IOO^GGS^IG^ID#_SJFTH_Y;3?K1J^?5M?LI=ND;GO)KPI)I9EM59#5=J2Z4IXW? OWIL=BIHGM>YQ>MRU.ISHRKC+(4Q2&.<@H(T#5^&^MA^<@GT^?^CIAD9E.70IWF35P^XC4^"Y;P^ZYHP&FA;0@P^KP=M1&@^*490\$@ M&8L^HPQOGGY>7_0;5R?7<8>7=T=UU^%9IG1US^WVM^..0+4^W.VN17^MU4&X^@5CL>XW8ZF0K\$;ZS(K;L.M.I0I5H^""N2? OYOGGQ&59TYEWI^+I5D MD^?0TN^OZ^I8I^G77P746RF&40.T=6I2A55CZ_X146 M<N^>63H^30_T_9>=W_Y4>U663PUEIKNY>7N/NQ%PU? NB#^PM;Y7^*N^C(M13#<@09I\$#&^\$S^I^<4D98_2A5\$US^&ZROF=BB8ZLOO<8^E^ZB5E2\$^VB^S^MA6G<^<^@U.M.1E2^PIKU6DEWQ>H0XS4\$>6D;&<# I^KZ^K1GX V3^%R?>M66^<8UEYI^K>\$61K^I^D2B86WGO_E^7^O677-JC>4DW=I^CS9?LI+^2WU2M>"A^29/95G<^2S;I4Q;I;QWA?^< M6)2=MMA2336^I1 5WIZW>1IEKL\$M^<K=1WSU^O6HNO(2K7CDY6;L^P%N;008 MGA5\$^F^51;VH=N&6\$?RHUI72Y(^L_G^M^*4H1CD\$8A^CIC!!

```

:2 (B1G M:4;CV*A9L6L$YTXJ;JZCSW8KGF>;HSW"K:Q4V:V0:VP/K%K-QNXI9(>+R MW [M!!B)OCZVJ;J.73>&O;H!,-&9U3<@,PMRI7/C%6?
2VFEN %* *Z89 S MI0GRJ5- UY1$1N1CH ->J.0EF#2#U7Z69J>D U R:1-7W>Z1$Z8,WQ3 7T1 4 M0!1$17% DW:K OODF7"GIS- NY#GEK9?
BZ<+>8)R64/3V.6RMFVZW MW Q?T97W&?>^V#?U#; MM+WK<- CBNEZ2P/RORQJ$6 1Q:1< @0ZM%46; MQZ3.9QJH83SYB+S-NN0;I
M=47Q1FGEJ (WU2K&0<@308% ^+H"PB(O!B'4/ H1K$>;#5>G4$QMRf1@25 M:~&V)TX#6%>0SG%G6IX)N3:R1>$P192=FY
1<3M@FBAC(WL:AM:82J M-2I:X1JYE6SK( (1.0A%&X0A4#R:8T1!<@>J^21.8Q0$?8F#IHS<&86P.YL
M:0M6IOG"B$U+^A(Q)O)H=W=D4@HU0YJ_@X#67A4HY14H1K_<8?0W>0/>? MC^N0&EAHI #HOJ4QRDC#*6"<@JM)@H.H2QC:F;Y!<-> JV
MISG7C/..TG7 KVQ>BM3U)QP^ P!PBH?+ WJJO.V!%&S G1PR$J44 1?>1/13"1^200A_?BM1Q:JZ6BE% MD#0$ QD&9Z.284C%580P-
*!$XHS%A@W@E_#3>F+VYMLHYU<9G.HG@7 M12:6U28Z.YU^67Z.=U 6H5 5^W9H."Z9IX.N4Y:YX"7(4.CH..U(7^M-
M.TWPA.M..UJWM9IR2WE/..I.UOHJCD"44<9 VW>=>R6 1.20$X5YF2TM@/(JTK-MS@2(5/0 M:J<*>M0)JN9Z36GYO-G^2.FE1%UV^>2M4):N53&=^12
&2&EE0@<X0 M1L_<Q A)F$CL.NI#6$W$1$)HNAJXNBS02V#_QW@+T1Y"NO@<U..05H M=^2$4 6E6(IP@<#62.MRUZP:JOH1ZORR9/>&?
MKR*2DC3+&1(IH.J> @ (M)3%&A@:1 (2&S2CO 1")> F1.V.(U1$Z FEBM24NR$5C;hP%>>0IHE_1 M ^NPO>@49:XZB1Z%LVP3T2ERC-J&3KY@;
(KE>WJEK?_9?2.X3KG#6Z8F>M M1 ZVBK.T0Z Q@>)Y1 00(IX(F 7(8I)BYH=AZ:L.G:H4H9G!X_ XDZU0305TV? MM*(YY&BK_+W-
#AGCN.IE=Z$=0%R.P:1J 8G1Z<=>MY15(MT)ZQ@A+YM;#& M&H8RW"4PXZ9:1_9EZP=ZG3!O.Q43?KEB= QY>?<N"10/SYD+^/$&K MHI+YMV?
660J$2NKP&0+=8L.VLRT107/ZP&JZ1M.)?T^X8TW2K-1(NXX65.Y MM6>67"Q=^IRD80;LQ)/NG/2I<+YFY005%ZX"TR%$9)2BL_HJ.D2GV!$T!
MS.)47A4=1.Q 404DB&E5.IEC&K.JN^<@GOJVV5+165N0KDQ1Y?AF=3%Y M4G5&1VD&7N1;UC@=<$FV;
<M^W/648Q@B1B5Z1)>)%A<5MT5/Q@T$JXKA M1#;NS1A:T$3DU4.M_9@53"448KGA1(2R9+NLBXR-15)U AR2815E?H!A&$0 M^@+
*~R5I9&@&/(P$C@!$&MA_?Y49W!OG9W5S;M9>1%XF@XVA%8-OTN-OL MH)Z2_3^VQ4P)SS"$3>=>_1"U6;GLLIOV"D27+ZR=E>$G2VSGA6@9'-L!EPZ2
M:13:1@<#U..#11"BC(4)FHN991%L8.A1A1@:F(38;K$*P.P.Q4<X"X1 MK0B16?2>$>HJKVLF*HA?B^<WJ9/L0..=T(S$*2
AERWNS6$#MFN80G_4HKQ;2I<KQ:D65A%>=<95$..M8IK1<(<03A.TB-Q16Z/5JNWJF?ZGMB(5<^<1NIFR.62^9KQ/GDC@0!>?>A MO=-4N
KH'R^!CO&E.P.LSCID7N+8=XMIES.HK&*8A2VD*DC@@4K@H TA> MIX#/DS"&4N!"7RM#YBR$F<5K6^W9_04DU.9C_1MW>?
+^N0YH=9.SHP)M2H M/4G.126M^RLN7M1ZDJH3Y.RG!0JF=ZO<16!>=>U"=(&Q;AC(H$<06_0BZQ MYM1K# EAB$41<@8V4R&7
FZ35$ (76JAL$KJ^LZXKH.V">2S!K_ KUCS04K M#..>+03?FGBGHZ!H?ZD1+17I6Z1A">HJQ6_0B^7V_0B8.RK>1^7A2L M^L3KS^(+KWCYS"MS(
2).QX.GPD.H)1K:02 6*(88AH+T3?AO#7/03P'4^N1W^<?>I>?%D)FNZNBRB^(<^>@F=.MV/1^N MMAL'R/9;#ZHL5HSU4%0/SWK#.C0NB&9AN?
TFERO6^MJ_-MB>.$625HG5ER102M<9*&5H33Z8H/7V23F>0C A(=59&^Y.YJ.L+,%(X)R M@DMIF01A4LNA!A(4LU+J.HNGVYTXZ;&#.D-
VE>=>WNSY!U..I-DL2 MB>5Q5OP76Y&V!D^V?I5B1M^UY1Z(Q0WG^M_12VYV!<+;15""QLGVQS_1H79?=>EKO2H@0^8($@-50_@@B@)&#1(Z# M-
?1SQ8:UGD>2POGHMD1U.AE9&<=<UL$Z)R^C.M@131>+<UIC_>Z^IG6P.R^KM@N%20 %/1B9BM<9>X$ M#Z$V1!K&GD)8?
UWG:3E#<#WK^Y3ECCPU.KP.Z MU#?2^<Z80!H."E&HFFAHZ,+N8AW2:M*75_1.U.B;U.WSW51_@JHL M7C.M.C1Q>17X""4B80 3U>D&
(09(DH4J8"^(=1))>^L 8L)EC$SUH^UMT MO1EEDMH(IT.W+=4OU=<@05ZN#=>_G^PZ)6O.TVF^>HDSG43(22YL^Z1CX6 MEN20F.DQ(VF17&P2%<
<CR>(<2%0(<M7)>($ 5E&*&Q;IAU1W<7XKAJ1WH>U>? *TMUG.U^143B.XN..&#D MR-PTN.%>V2&:SHCX<01O!1LSZX>=>Y^1FHVOPB_<
^Z9M@<N)U_1 ME1% M=-2DV9UWH9"CRKW5!_WV=L&_ HE5 M0*2N;OF1212T7^Q2)1B>8IG($S5V9Z0!&24^<#V0QQ@<0>#G5S.#JDU7
MH+U*P6XZ=&A+IYWV.A)K"$ QZ5X/BZ9.MX>?C1@&F%M>+^A'OFF+<#W#1 M=$X86-0GD%KNW!U^>13WWY$OKDGM1Y^0T0FH>1H7*=;
<25H M=M-QM-Z/(12EX6+>+1 GNM:OFV;8RR:BHEGWF^Q%<1A82C*%0NS1^1@<0@5< LNW$1Y6(H."8Q8#3?<# M1XL(8-61+R-10H7@/B=&(R;-
P.ALA!T*8010..1_9K>R^<#)9"1AM7R5^Q<M8USP4F4#<N^J?O=8KN4Q1#B>8^9B"W3E>R!&FBJ.TXD&U!&S_8=0/F%TRS
M8<+>@Q/KYZ#>T8G:P$C54LB1+91^>9EV_@7XD3M.M.JV1^14<82>3R1^1$#L^X D2@ R$=-81#<@L5^X M0^F/W_H1%Q(54V>7PZ$SPH#&F&N
MEF6>#JZ$S_058ARSR_<VW&G$ZSR814#G3>/T2 Q8<&B.F.MKU4V J54=XK<+P1/BJ/YK.Z-F04A:R9_9A&/(S3&3R0@2^A(OP&?
Y1NG)NPNR#4V:8XJ1:RU0EWV")^ARU3#X"AE M.P=/$040GCJ>?M>PKBK!@<BU@YI"1_P9%U-75)N)J 715KV%SU^T470A
MHT471S1@Q338"!!FLO@<O_0$R1E5IYVZXP3B.2^@2%$(N)3 A(19 3G M4@<#<XSK2%>($56! M6&OY.V2.OOA=0+^FI&E3:R5!9^BY2/8.UUQ<1.X0
M=4KRSUCJGH0H!574_01E&U<2&G&(UEO@ #H#HEW2 Q E&4!1 F6HZ M<DU3JA DOI=8NH1F
M.JD(87YJC>B+CFOU:J5H/Z^M>>7/914S=*_SF7;$IOCL*8^Q8R28? *U MQ<+V8T@/_ 2CSIHFG..21:9B81YOP!WGOEJLLH7Y&.51!/@ 0E^R@DA
M@<(1Z1J.7G4YTCQ9#A6=&_Z@2U@QJ0<5H1MR^LC1U)UF M.OHIDK$DAC@F(1G1U)4((1O@&#*40ABGDML*HOST"8634Z&+URGCF.YMMR
M0U.AZMH44FHHPE:14VW&XRI016H<(<?2PXM$<KHU06$NK#E=H.FEV38@ M>A.W28Z4V0F13ZRW1S/BWF/UV4ST+4.5KSG1..9G<5
J"SCIG71C*E43 MES_1.L1/W_!U;JZ57L:59!$U=(1%14^NTHG(13020)E61<+W4.SE7G6. MVV.7@SF57ANIFH=L=MAN)55KUKB;
MA.4.KV7?9KEFYH&+><S1L5=-K3_B1PQ_XC^<LD^0ZP:E(AK&?<(A<Q7 M@_90#!&#&#B.&=>3SL@UTSGZE&fJK^2U*
MQE2$7<@N2=JIA?U.%Q/R+O%YD1I2VSMX<GC;J)ZO34:(2L K<3W/J_4S M;Z?VJ^9FS=2M6_SG^LO")$EYH&.;>
```

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i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f&C^H!K1V!PQ.BXP&P.#%Z4^I4.@L;@1+M) ML@GIN&V^O)HNO^H^<6G? @_3617Z+XOEQ\$^I24B@547E>U\$1Q^1.HYD(18168 M^M^S0VA99H;7U2<0A185>6&P1M1^<=>12PIHW69@C822;KZA;&&+4W1+FZ;IB; MBTAL;H0D+0>561VN5NHHS)@Y6Q?2^N^G \$^HEWN^N^<@P^F+6V%>4_MF&UEF^*F^4@_<NV00N28_#K^OK2_XA:8^5^?ZJ9AKIV.ON.ISO(1WPI*<= MT#>@&3MD)NW68@8(D1=N1H5B^&@+7G8;DIZIW(K=83S^Ff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

QJW+V/K\$,%1CB\$,%0XE#;@.ESF%*C*W/X(^A<IPB MZ!%A+!+A2.P#N8S03&W)W%\$S0_XR_/UNF+_2)FN?=>8YNR"G66BH\$5M)5M FB
MLAQR<9)KSD1R1K4=>#.#C#N)U..!F8T'DJH5RP30NOT3WKW/O9AM'KF199\$6 MG<+>.UU<3A%>C5W)&%'TC H%V\$W\$1..!>8)XPOFN1+*)YS)
<0J0Q,^_V4>UB MI8P)CZXS+3?F1I7=8KGI.8/-!XPJ7+O5%CT&I?7D(J#12G/^@G#F307"LI ML^6M8I#30>^LC!N0">FD@OYOGU='9&J_/F)32*9
W2ZHM>U J+!>7J.*TQ3IWA9+2_FCS0HV6^M16GVI>=O9>F>Rly^!^*76M<14:KPI?&?XIJ R:(H)V..S0M0V6.Q:09B8\$2/ MHNJN^;=F=GI<-KOJYZX/
N<^_J:EAE"RHNB=NP4!P?>!*IDJP>.)\$) M:IT M_78;7I:=!XQEM<+F3GR M9C 96% V#M@_1
MI^W.2>+>13IKQXPWW6U>=OPZ09/3M3I^@7IL%3-G ID=8T!KB5RP31JMDIE
MPKIOZVJ2IC\$8&4RX^3A.=PV80^A6M>PKIOIS:QH8<8XVYK\$94J@!^V^("4" MBGH5.AFCFC<4.H+,<3/=34W3L^KJ (57H, QIHL09JBH!@G3SZC;
(6!1^V M)Y&I">+*@TAF!R\$MACLI USDBB^8TO+ 9<+>YK+W+>4:4^JAJN">^MH616W@2Y MXXP!VC-:XV@X."=UJ#CD5\$P80H?<1P-
R6C%XFW0,&C.RH!/%WHN^HM+EI^M^\$2 _N^Z6KBN:9I6KI^ZM!2F Q)@<+1ZDLAR6TKJ=TPDC#TP G1M.P@_M(C?72(XHJ(ZA77-
T/KF"7%41FZIAIEG?>V\$+(Q!"6SCG6?"#D >1TAD)C M5?ZH+3I_ CU_33)Q)RI=IER62ME8H"G&2&0_!Q2TZ.8U
M08^0U!FDCE7I34@UU\$/_L+J!H^B/TA'Y 4?F^5G3"!ED!<((J+1)U CF33 M?8Z)21<^M8M^IX_1^&Y2!&EVO..5T"6HSGK9+4!OE?&_U L0S;=N0Q>:=@:
=< MH7+!968UJ!_!_JDV=6N3\$/_HO\$Y01P2?>F2VULX0Y21M R D4Y60US/X47_ M+30_124=<^N^GKT(ZPUHIV^HAK%G1RBF
[3="M2IX\,ACXHI1EZ\$_.28AGJ^ME0TD9PMQHIII K0%V RV=I8@M,=5\$ _"/+>5<3_X_M=B>;X^5MNHJ7SK""P MD&@1!%\$;XDJ22U;
<YFX870M@/3X^!A1RY!<=>:Q5V!<=>@_1^!LR+!#X+75% M=<4:#1L%DXK&VA<91CM1QFGW;ZD.LX;F2B_9;U2D<^CZ+!B?>VJ8+7;06 M!B%="?
EL3-IQ3-DI%:ZT72UH447OZ%F5V19+!F&DZ>L0KCKV>_!OI&Z M%=@UE!+NSTE_<4ZZ<5+>+! 8STQ2?BA9H&V7D1E49M5=7C.NI^<KP^GZ
M6:015B=Z?KDC^850\$04#:.Y4!57P!;^M8X&3).69%97N(GE^_Z2_!N=CA-6) MGE_M2!/=6Z2;2!UOIF2GK/40D);!H!UGM\$N^Z/G5_7IN[N-IN=CA-
6)GE_0 M2C(">+Q_4!HEH?!"(X22+7BMM^!Z!\$!A">2D%M48\$;EDZ0!OSE SVTO\$0ZFVY_SU8F>?2FI MLXC!_4&4&B!B!09@?
3^@3L90HS^>2+!WUCL70IV3P,!HCK\$IT_)<+TE B_M_2!X\$&6M7Z!>IQ(H#PX4.Y!G!0X^&G0HR@)!MLT\$,<+JL_="KIE!H#H# MJ@C*1 H:
(D/(Y%\$RAIY(>8C=_K<#1R>C9Z/\$58G>GY!BHHEXU"!5G569&(- M%IQCI!DP1VBA9LE*/59K>=B!H.R?C9Z/\$58^IS2W\$LN_3N?X=HU?5Y_L#(4(M60
61CN0?#2#;2!D!HNR0CM_X6=SU!X!X/T7MPG&^!Q%!"W9%92Q^<QY4 MR!FV:8HWF=50WB@<@.MKM!E98.E2FM:~?0_1TIDAI\$Z?
PQ^QRK@C^!>Q&^<U MUVRIE^WTFK8A+WKJ.Q /MHD^U!#1V-4;_!J8:B)@ MTD%QYBA^4S5P-T MT6!XV%SS2+64!?
6G4DABE!\$D9^BWLS/\$&G_!F&8C9RC4_+MX?;<_!ANIS< M!HM=KMU4;B+&#W>R7Z7RZQE!H7>6W!)#YYRDQ!V^>+^UG.L!(W)ZR%!!Q#
MHJ!"JE%9S<9>N!6U#0.RY%*UJ7H!Y WW@%5\$RCN M^!2R-J8_5L\$!9VME?U!07\$E6BV!Z>8!)@XD<>39WD-!97H(GJRW#F#Y<5'6 MOY/7^<
WG"TVXYAY.YT+!EH^KF3M=I H!#6L=K"QC"53!H;-88@<+2TRW4 M3?S>9>3?0Q=I_06U0#90SD\$B;K:K<F97I!RQ42>^?6?&/(C+2Q!_4PW58
M!6F60L R66V)+_79@9UZF0!U9!H5;10A"RCHYU!"^>K)KS12Z3^3"!TTT <+>+HMM5!<6QWX<1M/1FB-AAJ(O6CT2_>EW!ZN+!>M^;X028A^66Q?
+TXB^MR_KM=33!Q67C^2X(H9^ZW%\$AB6@_!C"#!KD41K2_X M!429>(5.0V%K_!UT8>N3&G>IHK&Y;F+!QNNR80%1XSH^Z%FXA.&53@VWIS730-
!X@&=>23W;M!^!76D7\$ _8Z.WB8W>EIP\$ MQ%!(#2#?P_XH!SK76M^L+>_6?7.T!W^!0JX1<="4QU@>?ZX<^&K).OIZ!20 M06:UN.TB
VTI!%:TJDB\$GH!V7D!0.6VK?AZIO!J!&PEMS;72 L(26TD6% MPTPE 3_3;G<+2<_="H+3%E V!0AMWE;Q2MK&L&Q^V7DE-5'6C\$Y M+//Y2*2
I25NENF3IC!E&_W.HH:BHO^J+(H+G3A(OC\$^43B!3KJ@>5_, M5PI7&B.M9=F! ?KMK.9>WY6+!JDA?>F\$!Q&#&!6DS@62W91XD9KIN^!31NX=
>@#?B!+6"/8"TX8!EH8H@5K5.E!VR=@!) MY>^!T^GVC=Y^5_>O!+!+!GB^8!T2=V!B.JJ!G!+Q!&H^X^*D6E!>_4Q3 M125>0^"NAYTNW#NP?HW0!
(SRMSKGG4+!HH@OSU81N="HBA R_JLLR @ MTD%0ROGB?HJ!>+!<1_2I@/8LTKJ#Z4KWC^V!>3<5K^!U!H(4ANKYKVR H
M0&6I>="N(LP^Z#3!^UWXH>U8)JN;JZ.(@YT&N=CVW+L#2^EYHN @^O<#WO^*P^GH@ZLW(M,<%Y/5R2V-W_4J9TXT5@'
M<#H\$7^C_YA1!<^<9)Q:13DY6\$1K\$X_V9^2L!ZFEUUS4!H3_!58?+FOC7DROT M3T!W(>+>5XW(6<_3S!A(C I3Q@55^>+>P^4(0I4 R:61NIORIQ_N2
M+KYCG92SN!)Z<+KEY=AJE&QF_VR6-8IWY2!LS_V,##;D<D<_>#!PVN20 M!ED:P\$<66.WIS(C<1T_ZSBTNC8:Q!H!)5"8%Y6\$!7M4_+D.I!5&"+5H
M;U-AK9VIARD:%V>#>^!F!7(H!R-M6^_N>A\$R7+H(B!W&>KE9GY+LJ)@/_MBH&E0^E>Q\$S@96WADH(OPG F3?B^8.H+<9.E^<(\$E!W50Q!^!^
MG-4:0 MGO.6\$ZVL%\$S\$Z 7\$0Y\$!#R&YK>SIZ_IW&Z!P6^Q&T=C&Q_>)@32;Z0MU!VCEQ3WXSSYV% MT^<GJ_#YAW*!%G9YJ">+HAJZ^WBH-
XR&3Z6CE+9(RC6^AZVHW!)GIR%!(H.MXY)YD\$S^UCBW=X/XS0&KK2&9^SY<4%<=S4!HJ7EVU MG)?6<M7^
=(0@KEFF(X!>=SKFLHC!>?>O>Q>X8&FGU45#?&C^R^8^J)5B3)!<GX>_!CQ!>_!H^!V!8: MVRP45F4RR7^<@!)5GC0H%SI-
U<4RO9!>#YR:7Z5HW\$16WU\$5\$5TD^ZB)_S M^2885=&2_#1-C5W^Q!>=<5Y!VSM7H^MCXP>IVKT^H<47_Q(Y0RL
MU7\$4+3PP5_M7^Z.11^_BDJ!R^+&C>JZ@C^NSVF@VSOZOZASWMM^G% Z%G0&5/7\$^M!9^TLDGC_@47GY?AVY=I^K!M%JM>\$!/(2KI0^F?P^GJ!6;R
^Q!3NYD@PCK M%Z+&5.9)!QO!<QOS!>G^5A?_YZSEX9ED^K6(\$A9&#S!4QN^28HI^9!WN
M;SR&F/L(<("B:Z3816L!CPB53>IS<6!RMX3E73^AL=;T!1J0P9HJ_!_!Y M<^4QN(>^2%>8_0OY?WGW1.WT-A!^"(V2EN<);\$.=I!JW^I3Y+^4?DLBO-
M1^M7P8^0LZ<=>5.\$RUXR!HSG+X&WAGH!<=(^\$W0W>?PX#97.ZIR5!^O(A=X3 M^?UZ<3=&^T0D)PU2!8)RK?&@
(R9)!I.EETROG6EWT_TG5LM-XB:O.DJ.H#6 MCOY2!2W9W5C>_!F9WDBZ_UR0K=-^5/X8R(SCUEJ^74D<@>QK&KYZ_HZPR
MU#&HUE4G1Y#997W!D3BYU4UU6^4U/%LE3.=AGJ:A-E+^! M!2K.VQW/_2DBVY^OJ%=V=U)O#4JK:LT^H!\$XC3;+\$Z6UXH1^R-J^7!=#6
M.\$EJ5R!C)"^8_8\$Y!L:G^@!<!)_!K0C(G!HUR^!BGC^1%)D?>27Y7>7:6CZ MP&^<+Q+!VY=A-
=WU:M DL:718%CU^3%X!6D!<J%Q%OPF_VIV&F%G)!WE. M0BNW>H!L(HR!C5+Q^>6^9G6L?UGBOY_A/W8!H!H03ITDKP@K#<&G2H0
M9!TV(2/73F=KEW>1VH.L3I#XM(^Y#I_!M<3(1B:~?D!2_4%L:@3A0_Q3&_M3^!%9Z)6OUD!D/YK,>3!9G0^R%13N@UHC070^M=7%BMTE_0.8Z.K^?
U8 M:C/X!<Q!<A@HVMU3TG_&L!N2>=>4^ME9@Y_L!VFFD!2!^QY:~!<4E5?2GQ M^Y!W^M!TDQD!V!_M0H!4204!OLZ!1H.J<5E8^&JXS?
8!RL M>=ENOAVPEPY20 M>76UW>90MZQUL/RVG%9Z R!4/K A@E^7%?DEGL0@WD=@!)Y:Q(4+V_8Y_MU-
43%M_0YVM5QN)!9W!#U&%(D)@&^G.JSI6-O+,@9D@BL9@4>+>E!_9W@ MKT!(H;B1K!%QBOXK).5N&=>#1:4!JU1^HB=;N!K!+!+!3C.I>+>Y^>.&
ESR_~5L Y+KB. MT4@/X#KA+^=K!;+LRJSK1^!&6&PBOC!9^18!SV8^G_H0@DM.M.WYT.T&^US M%RF=@&K<^!&ECH VZ=EF^_HS9?
W&\$E\$!H=W^T^T2-7=_3;@57M\$QK^B\$S_MIFBA(\$MC0?EF1/<.,Q=>R2?VCCX4^5^+3K3;_?<?EDLUW5(S-OY=URM M-YR<@PBTIF-
P\$5SBM="GCE+VRD#10A7?)^!_!>1=2.B!KQ\$^\$SLU_:=8U<MG/PK80!Y:B8\$+YP59B&90DX((527!<^< F0Q61AE30E&C>6>YWKTO&#>#&^!U& MI83?
>@>EJX>~>F%3!\$A>BM!>P7A@-7_OY/X!>=\$5X;E_YF>_NRBI_7/H&H_M_!\$V1T^\$ANA#@AJE!S!H3U.9W6E_!D8?@QU!/@);U>6%!>7W!5!A\$- M#+BR9
A M!L.UHHY54055P~!"QXP57KR6_W\$0A.TR<=A\$6!<Q4ZS_NVH!BK1!>MFGW^0H57S!&8."ZVNOB;4/6-T?
USINKY(W_M+!H8X2!LEIM6W<^&B68G^1!RHO0^FEM!M>IR!<5Y!<2!SZY38_5TX+G=FWHM+NM@%\$56M+G;DB^K>3\$H5(^11
M>D<^Y<1EN&M+K56^!UC^?+O_59-DV!8%.WA3_(P!F&K_%Y\$D4L+^?CO^7!M=?YWVY@8BHFD6G6H!DX MDA_G^43F>S2V!F MQPU7.3
A(CW#^+9IH&C7:5VPN_*\$@V/H)WZUH^PF#W#E\$!RE^!<D!> MVMK("62I#9!BZ_6D6S_~_K MQ6K!HM!K7!QFB!HGZB?
>?7D3M^+!E;K27^N!@!<E!>=;MDB6L1P.KDF=;! MI>9SU_M0(G)4_1RT#CI4&3\$S0Y\$VU6.W)!^2F>?SV9U6!<6^XFO!<!)9
G%;HR9./J^1RK.D@Y^MBY\$;\$#YRA/MD MV^YZ+7=@N(ENB!C2Z:5\$CP^GP^E.K5T L\$K71NW%^_L9L+DUHYK\$Y^CKB!
MA_!Q6NYB!07>U6^N!182+14.X!#8ZHC;(A!KIDT^M&@&QB_!U7Z#595!1Y! MF^B!JF8\$=JHJ3@#<3F<@>?U!587!4MB57!_0L
9K^Y^+2KN+HAG4_UH M!L:D!H2DC=Z?=\$YV>);_WRO+2X!J!RJK!>6-1!4-1!H!DFF:K2!/UQD.R= M2S^<L!S9B!U!0LA^?X.ASOG)HFF
^_DD?^D4VH^@8(28Y6GZ^!YR M3K5A=TM_M^!H9Q/K:3Q>IQF9O2+N+^_P(2E4(6^!D5B!N0)O!>+>(!): MSHS0T94^?0!35;_&J@0^GEJPMHHP
&X^B_9_~O9M^F!H7^Q0A2_0 EM5P M^?2^X!H&G+>4Z7CYR^0^W0Q>4=R^H;EPR.L\$+Z_EB:23!0+ B7_9N\$! M2X^X=HCY4Q\$G^@/X>0?
^!HC/!8E!<M5MWX8""(%)>2Q_#>+D8N.!Z!M48CD5H?>@Z&P!^OZ!\$%HC)=SWH8U5W>AUX^CP4 MIV=K#>!OI?Z
W#%ZVAJ!^0C0^M^!DB0EL0G37+!H6M_4K!@A95^% !G9 M7#>_2 Q_>2<Q0005\$N!U86_7.Y7TV5T=&S_M81Z_V7&(ZW^+!T7.TQIF>9)1?
GB60!%Z+>_TARS>CG;TYNG0M9H_TWZ^!2 M3<J_3ZY=VK_1^WS&?+DVMM%K+3A^1 L_Y\$P^K_R")>J?2!EFZQ/8!#76MU%#8>@JU M3H!
WIRMH%#RF!5!>1TA@<#UE!^L4@5(XN^3^Y&_SL@!&7419>K1\$!H+!J M100GPE=I_30 N4TU^M^P^K!<R")>_UC!XD6#!=5\$E^R^\$0!\$6Y.AT9&27R.G"
<#>1! MELX>+>@!>Q^>+D@5TD;ENNZ M#99.R!O.V!X^O^F!<990M7D.R#K(D,%) M6\$<@!_0TGWMK7K&C^
<1%\$>2+052_/85D(H2YVBH&:=FX!HD<^U\$T\$&_N^*T MILK\$TNE_YU!T0H^!5!04DGX#<_D@J5%4 J<@#;(!"?2?(D2_!HRDH\$D;P4%)
MI6^!Y5%6^!TA%66C!H@_S&?2XGSYPTY#_/?<^O.M\$WCYK!>X@O+G! MA5-R4R=K!F2RJA3Q!)7Z^!HF-CL<^<7U4?
OFIT0^K0W<^?TJHA^OY\$6!J!<M-7&8!AIEZ7D(F^E^JCL_~3F986@&G!SP^C^1X#>_X9Q_G+!NCC\$;HHG1K!#S M76FKG=DJB90=CU(^ZJ>)\$W@^!
!_RA45TU&G^>6\$(6!HA0L!+!\$^6(EPU+TW.0V29EGY%XA!PTW2.GJF8=0!W_="!+P)C!DF4S1)B_!DT^!6Q%T
M<#>NU;W&#<@TYA^3=P\$KV!F4_RUP#.@UQQW_GGVZ?SDL3P>W\$!\$J5(OQR;R)>M<^55!@EQL&EZZZVTV_!6N=83!56 L-X.G7:~?
QZVP2WEU_F!<QX=1^>P\$!M54!>0!X2!>@W<@>K>3R=#BG&29!4>X!>H!H\$FU;W6&150!130!J5>S5>_9GU6S MJL_KJZZ^!H2!^4:2H;
(6\$7D>76@1P=0(&Q71K02U\$YZ:E^!#0N!J8H!H M %4!92?KW>M^2/!%3#&DE^?YDL(B@PD\$^!Y(353D#)>O.3M\$52N/IVND\$_!H
MIF6PK9YGYX^8\$2T44EXJ!>@<T\$V!B7!NDA J6BU^>UK!6H!<?>T!_R!_J.PX EX9 M^#4!KP5O_UQ&^!5.CN^G25P!H!V75Q62!<3^1&A\$@Y^>9#_4_+X
+XU@E) M\$&Q!F% EBK=>#6!1H!P\$G:A647_3W!YVLD?>+^FH+7.(R!>AP!&@!3K\$+1 MZQBQ.X3RLR5?N!X1.W!&K%9%81EWO7!N A6=>5!
!MALCL7G\$IBPC38 M^PO@_RPR@R B!4 FYIT-1H=NKIS(OQW^"M25HJO+UKK1H7GR^?VBUGOAK-M")H\$D=(EE+!+
U00VN1!<=EHL_DOWMR_&UN56V!T^K1Y_!_MO<1_5#EG>VX)Q&K+3 M&R(>?U!2H!Q49/<^!4!^CY#5!HYB(TOE@H>Z^9DJ5K> X2=j=?@/HF_V!
ML\$M6+O7S^X&G) E.WB!#/\$\$<8XLSFOA!^L;M;LK1_!DA47?M;#BE!6!9 MC52^A_T3=N9LOA^8G=PQ0^0SS@2!/+!\$@^F!<
^AE5)^<^WRX^HN^<BW+EXW M^!T&^&F4DV4!YVM;2+>N+!<!@PHU?_G2VOZ2+>QNN;IEB-BA/4D^81(X^1)H
MP0.2G#HC^0ZD>/Z0\$Y%U@HAK4YYS30 MXW(WDW!>D=NI^*_<J&_Q_P MXX&^! PH8P<%A80AFB182?>V+!F+HWKV!"JHP&H#2^@7%+EF-
F.J.A04HJ! M^4X.N#\$2^XIAS^00DK?C>VGJ!_Z!^@^JB+!H^UFO%Q>3>1\$4R13;K6=P_9
M;!(02&=PBHY7!1P6X&E&NQIWEF.U(D;#J9>S@F2!K.YD^07B^!V_!0^4@ M>O-
!MM2^T2)&IB&=BU.EA)U&AA^%0.0B)6>H+MZ39/#4PGUQQ>XK!Y+3>_MA+8YTA!8UT<\$19.D#B_~003^<9A0+L!+!^B^D#3QK^0KLB/(<SW=<
QZ=K^O M^!JNE!D!61PSE9/GJN85FD7^6^W!L.GM)F#4!_X&2^28E\$S^!C#4MA+2RD.H MPFJ?E=9!BT#%_!F^Z2#)!P^KQ+BRE^DF6
H!16^XUZZXB7A.TBI^Z8^2CX\$=MFXQ2KYSZ!AMSE<^!L.W^8W!\$HCU4!V+V^K!_E0!<A(G!&1RR46@4 M@%JQ6^&SZS)!7&H^V7.H L.L:P9F-
5PLV^%5J^!P?IT6@H^MHVO^E.3! M9^!NO!L_#E!5C@_.93N4M^%KE8J<_!XCI704^H^VKG7^>B9%0PPC^!#=\$MN-M7;^D5>*(O+>
_D!LCPHB2+>B8\$4D_2DIBW45+77.T)^>^U6_38 M>N>R\$+>Y^6/G!<A@AC!AG197!/7HOXP9QYRTXF@0B7VN!0 H^8;JBY\$UKTO
M!^5\$ZT!ILO\$7LVNK /SKYG_EYT&^>^G0!8H!WR142J<="HUP!^43^3DR<^AZ7 MPS<_Y6!^M!H;7.WO.A+2^V^M/6!HT@!VMST?24>14J#
(~2!XV/B/JH^YY< M&SNOB^!H M^GV_2SC^_O7S3LOXG^R!<=K6)FDX<+!HJ!>@8;C^7I3.^NZFI MXX_!_MGE.YE!<# Z?
DU!+!ZT!Q0A:2YVG(3!GAA^74(DYLM0DS1RDEKP!8PF M^!&56E!>NOUV\$5.DX3<DRV&=W!X(C^>+>C8%2R2T2 MM
=&L\$0@!L0!RDE.AM;9&4^!NOZ7^?0TN5;3=B:(H M^#2CD!BS1Z_W<8^!<8^E5=V7?DHN+!HW2^N!JDP!<C\$!>1?>R!\$THW^M=1^2H/4Y#4Q%A=^!
B!Z1_VAM0/5?EALLFKAI6S^!B.W^WNW6_RLYF<1ZP2G_MWB-G&=AM+AS2T7F\$0!+!_1FT+Q!0^TMDW2SE@+;5EV7G9^?WWY_F.YR^!
M5DGB9YF6=7.QY)PONSF2=(Y_~36;#_P99!U\$!URG/B_#50!_X2B0\$3 MP=I(2G_4G!_XFB81YQ^!PRW!E\$1.(YX0&\$!&2RLZ_NCTA^J_!%@IE;9RL
M4S18&^<Y1R3F T0DC315!LE(F^A504^8DB56PM^!M^AYR&L3!0K0 J>TJ>=R!HXM
M1^0Q2D42R(7F_XD6N>4Q+%;\$S>9!9TF!N!W0C.@Z^<66E9-E\$E=05.97AM MEYMI^X+H\$!E#^!^2+N L8:1(9BGG<5>226%/Z0NX1

0WF&SX A J+N(=&SYXIX MS9:~!0NF6:XJFMMID-Q-02?<<R:6!)*X=+MP)Z04/FI4WJE[H]#%E6/DO~M~WDI~44\$[4Q>&f& @7B\$FO\$> (N,U;1&)-\$.6Z-2AR/DZJ-1+J/@F.% MP%59TU?2YN;H4!OKWC=@A-4<0T?G5.8T)B<6E.FI3\$)++K4,SU;N)K MG\$?Z/DU>E971=G8S7A8X70\$641+A@#(7E/<_6HQ6+HD\$SL,ZY\$37A(B-6. M= #XIM4KMZTH/8"DFQ@K#~0H!;*2HM%0IH3FHL%-+ (V5N&&\$.BFDE9~N@O ML-Z. MQ SL8IW WC")1DQ;J\$P\$BQ<~<3X\$C2P1+<BC/H-1.~*5C7C.2IT M'A"K1=56\$)U#7- <0\$1-+F*~G,XIC%>+%GA3U"A7~!FHB(R5"4B-<3KA"UDU-P.2BG1+?T? M&~8*Q>4-JV~4O<OD.JKQ&~!>G?2+C_Q? V=~QBO36WKFEPC~M\$Y+A=R~ MCR+VPAQGX+CMCT-(1L)W3B<3714S/B-G=G.#JX&@O+IW-R>I-MA7-P=)C51+8_QXG64B#I- &8<~<~#18~>GZ@~@WTA7JKHX+J!KXS;PMJM MMLM~9X7F~%PAOOE7;SUUQ"MQQ2.%N~F9B"RI~>FMRI;R1ZB+5V>HB@E=, MT/MOF\$1_A<~<H=@M33V(ASAE>W;/#QGB>A3.16(CTA-,<Y254R@)SJ*B+H74MY5I@WSDC5.0T?SM !L&8P4T934~NIRIMVE3@WE">DM,1#_IQ\$>305 MB(E5I0V(Q13.D~U?XACU~NXA0QLX+!<~!WC!7!~6(4J# 8'DU@562B2% M4@&~#W16=~"Q? TACM+KX2X00PB9BLC2\$AFK+>(XQ?_8\$>P%XA(N8!M Q1D2IFSD1M6~MXT?5\$7XVWC@JOD0.~@U)PIVQ/PQ-G4VOJ8IY A+)Z1T@ M@)21(N- <8IY3S04M15\$-P\$<#E;H8/74H;JMXP9POFJ<H-5=R1_3I7+Q M=,?MS61CE"QP82\$>=\$\$QR+C~",80RD@/S)8&~%Z~"GMHU?&RK6MJ\$>4U M@,1~194"XSG\$MP(YXW)T7G=C&2/G2R~<~<PQ+XR+614#CQ1VIBFJ~MCL.L1\$<OT_X85I9Q&~"Q&~HVAWDJK MBK_%? #GZ%GFYW S=,~1F1C=VLOD)MAK&VGS-2/H5<~:9.PSANJ#:=06VZJ~P~B~#S_?IK~VZ(UFW)U@U7RFBDX@&ZE8'_B~_KBH0'Z+K~OGV=OH.OQ ML=M+I~J1(B~K~;Y=~*6_2G_IJ-MHS+0_ASI<_\$4DYNP+3?&EHL4J7\$&~LXB\$DG9")\$8T1KZQ\$S6.9.A4X'P+3E MTPTHJ2~9?7DW8I2C1"HH+1Q1ZW;M~#YSP2-Q<~C&B~38=\$1\$)128X0J M>SH=\$KK#LYN(P=X9MU2,MKO~L!&@M>W2R_NSN:C_XUAI ~7Q@~0K00QX_PMD~469ABZ9AQ?~&RO.1.)F(H+1+4)BD~BE3WA#M@O/17 FI~C=<#&C_\$ M~7@61@H+2)D2<-8YD5OE0YRG@~@2M4)GI>~%2S6I~B~4+IQ-(9I~9(=~*MI0O(=C-M8CV"QSA#UI^KK~NIN_OHFKTE"@E.%B85.RU4C9G!2 ~@VYI2~H542VPRAQO1H!&OY M%28A)RHC.BILL~<-Q?JQ2XDEKSZWEFCFSW,BI M6Y\$SWGZ>+>WDW70Y?T78~CGG=S\$D01;PHCTR~H\$><2 I~6(I2J;~7;N14 M7>~8.8*OR@'IAIX_OP'G16RFU6NB_X\>S=I6\$X^AIG<~#BO_C&WLWIKO_U M>"PRZ+RA">,"935\$AC\$+6;3M9.%AOV? F<5.6TS~W&JGAL+VYW_F46 M~:6H85I9CV@N7>7H>2>~<@K@~1#H54N@W;@QTVCTJYZX9H;7Q#~6_G M7~PATSS3T9;2IACPCIW~IT? ~MSO'DW&M&K ZAVVW=,,\$%OHH07I) M(HB3@3I+N4FMI*~2S?2;2N;GIFL(@DW46_86W28/2>TCB&0D M;/81N5)&)/!/%"6P8E8BPH(E2O!(>3;~0 OW2Y)<~<-1Q+~C7W_3X!K=G M~XAI+8@U 7B;(5<~>24D@&B1G'+~+GU@'T3#~W>'AFM; <~"HJ1A&W>2I,AKT<(\$4VE%20CS;W/M\$5K_YZIHWT\$'Y~"@X(FXA;R.M;)2LEFY3QW!T>" (WGHMC=^7ML/@&@=L359/4I.6P7Q)N~XIQ%~!~B=&MF.0@8HB~^@008P~>~<>66_C9=VLMYL M'T&Y^~^K0?;V9GDCZLBM~F(RVC.5\$YQ#'.SY<~0Y3BV~PP8HDH^#%T? M2V0WI+I46~AA=7H9~?J=H2Z7&(FKDRHB+X%)Q'UN?H HXZE"=P0,+G%FF M7!~%Q\$J03_ M\$M,F\$C>~NVN7Y?09109=Q2IUZ&_5PCC~H=~XAWHEHJ+K_&@~01%G M%IF4\$C)A2~CDHT4YAI(F)UN#Q%_WC;/BY+/HZ>/\$S<~!>3_)@&G."5%1F) M9_VCFB";G.GWE00YQ0SR5!%L E.NEFV6WE9YW1~M@&U=U1ZH/EO<_RX_1C~LITFX&+L4HE!WL=~^@YWR?H9\$Q_MX%HQ1)#U.3+RV0C.IQ2Q(R1)&)%I2N=17H08"C=9.2@*3- 7;IY@&0Y T M1+1VB=,~LGNP?1704K_XOB~@8?>_IWC_111(HD6E&H>=,~LCLN;07043CK+AS&4W<~(1~9.Y9L=~\$~(L1ZM6HU2U@B++@,\$ <~#F.CEG MP1A/RAC-"E=C/2.=E?DSL@T4.LE9_ZO9OFIR?CIW~L.N7QW@KI~6>@&W,M@.YH1;9~Y1~JXICQ1~,38;VLM~\;0"@CIYF_PBO QM1(\$&~.##.21ZC M1?),27(;"U0P\$02HP3~MIDRU^@&HMQ?_Q3SC9\$JSI2T;7<~@J7BYG(= M~X7OSK13S&U~@;Z6JS8?C1CG20HIX>Z M!Y+@~IU.PZ\$DQ~O~H~, MR53CL49AE);)C H4RU<~!#;Y+5>7+LYSB_JB,IDA,~1MEH06~1UL MKEFDIDAKXHS>RF=22! IFY~\$&~)~^~B;H9;N4LA~WDOASED>3<~+~^O>4ISC MD~!1((RQVA\$;MHBS3WR8GA#8TX%U9~OBYW T<^P4@,U+W4FO!~#\$,TK M@5C#0S1~ (J7RBTG)S)6>82=E5;K(\$LHM25Z8ND2D1<INH_VONNNIG06;1 MRBI~L2PQ7H/G8~2NNG<~1ED/URXZ'13R+!>=IPA;YR'4)PEFX20#?2N MH5*YK~?OWMZ4H~T8405Q_HFG<~14FBE160G%N;@3AT,U MB~C@U.IN+PJO&Z64921,<~(LX;C1R1F~\$YX33X/56 A6>CL<3>6%XP& M1/NPBCX>S&8_YFGADOWOHS_7#H~8E1FF3"TD0CY9D(4ADK);(BX~3B0\$ MW4ROC MUL7&CRJ%WC/R147L1~46D;YMZNZ%H;4UT8"Is F#T0@2A)B;1/5 M&~C!~ #0S SQW6Q8SEESQ<~4X,P%V0I4I/BP1&6WJOD M2+*AF8);X7B;6<~7>OG_3\$TQ~1VHJ?ZV?~TW!7_##+?2_5<~DSC7HG M45392Y5;((~1XXY9BE\$9NSL_XLQ%O=D/V~,!~#<~%Y(4W15TN.T(O!>M=\$\$\$\$Q%KJD);HB"P5M!~\$VMGN>,\$5WUK_@;7(;"~!GA@\$/U! (~L;SR\$U+U)~4@~\$~<~A9L MC1~T9Z\$%500B~49 D\$1;1HD3!~*~L1~2SS0BX1(N1Y08DY5@U~%ZJG" MN>6_FWQ.TIX=HZ,U_G!P>~W>~\$DM~?Z(L4V~W1XMR^&(N31D\$~*Q16\$~\$Z6;M5U;AY2S.7RA6S~MX0~X\$C;HEEO&O?)A1L=HO4.8\$F FCA@92B,2(ALM;~)M~.UK!~/+~8F~RCV MI_Q(O~0~6B@;SI'D~A4B6+N);.Y19T LB7MDG?3YVE91+\$(JG@~GE8JWM 7O!&~P(Z ME9L<#G?~? XRY<2\$~.O9=~6Z&SQ)76GN~DD=3Y'I.P#I;DUZXI'3H%_0Q!<~ M W~1#KV. KMHWTTF'CU"OOH@~#3RD'E#DO~%9.4'=F(1;H25D!@&1C5W00Q;YV6SS07~);&_5(NQ,T'Q!>S6HYWP79(C(R4X)H'E'3& MB);_D6\$3H>@QLYXSR8LW,F~@SIE_O!>H2<~ EMI~#NP6D4@J>_4EDGE.M;1)2<~>3KN8>A@=#NAG7;6 AES#JC<5DZN(00R MAW_1% 6QVHDAG3H&#J141T'6#I;MZ'OF6U;QCE~!@RRG.CI~M!MQN;?~F141=MOVVT~OBYZ;6~8&S;29RJQ~X_1&S/ZP7M;~_GJ~9I<RV#~ KI=;QF28;D>MC!;92ZX;LH01_20YAU_E)7V_5I\$~NEA6\$YRIZ';XP+IV;D1L=X18;4S MM~BVIN<0~R;Q.IP0~V/4WX~?PBYM5!<~HHH!~SW%XI(?!V)19X0H@~CWJ72 M;Z~!~@I0~R/ L~>(?!~*0!;47W)HU9R#;R2S"Z=L H>~)62" T@*~<~%I M(HYI<~7C8W_IZIBO=V~!~S4HK M1Y=2X SS5SO=)~Q@GTV_KY~C#IN_YJM8&0L,B)2,&H0Y8Y~4Y(2~9+P~M~TOOHAP? C(4QF~H3;F/XSMMIM=T,FM;+~HVAB !H=~*6B2\$P5(C;\$J MIMGELHKU%L_CKD^C@~VW/(KHA_XUY(*9)A)*%P M1~0*E(9FBCF_Y.U~

```

RDNYN:~#ML|<|Q|Y*~<5B~N;2~"L~A~MZ:1X7U|;BO@&A~6IRKH@4.8~1_FOV2AX(HT'SIS)=7+@=(#GXCE2B2654J0~ME4Y2~4EB4R'C.2~#81S67ACR
4AP0L(7|)1H$$(SG&L/|H$RC2V~"H331|X@&D~M1Q+95~AY~AO~K9X+P|~V~NGGN~ZQSB/V~C~K(1FEH(9YB)R4UN;~+~4
M1~!>X$Q|G&K$Y~K|9W0|A&|VZ~%~*~2~2|P2T$~|H8BCAC=>~C5|~Q~OQ|6YV~H~|~M~+~2~D~B0S2YUkA7.F&6=*~1~*~*~.~J16@G^~E~|~A~U~1~551@~_J18.;~W~|~C~
MU$Z7|Z7Z_S6?25T6KB:3V5_Y.FZD!~@~(UBF$EFXAB4=~J%5$Y~|~40/>SG>M<7~LC4W=2~P&OU.5@X0(9R"P_C9B80P"~
(7|~*~$G@5=3>7WBZ|H$~%$WGK|~4YCB&B~3>ST~MA~SIMEF7~"X~TE@HJ_Y|~F2T|JUQ~@~T2XW47UW0Q|J~EW_Q~X~F2~%~#2~#~^
~MO|D8>S~|~R~R0HY&WN4=~"RH1X~DE~|~@~+~$B4B~|~T@~E~A~6~|~^~|~(F~|~M~FJ~R~JK20$~UB+Z_~2~|~I~Q~WU8+W_UEYV~S^~K|?
3+00P/6ZE'8~NXZ~|G~M~MS#~.~L7CK1~@O8D~T7$|F~KKURO/@~"TQ7?+>~|~WH+8|~*~.~T~P~V7~&WZ:9P7~M~0Q|_P~|~^~^~B9#Y?
M8H1~B~|~VUW~<22(50~5~1~7EUUDHK~G~U~X|~JGK~W2~M~517~^~"SR~GU~R~V~|~P%~|~5XQ2K7|~1~WTM~0~42C6@H~A~T7|68EU~3DR6K7|)3T~MMG|9=&
(HOYK|~M~|~I64MX(ZEH|PH|~+SY~>NZVPW&D7|15~^~KZ|H68~M~<4N~@~+~U0~YV~K73+ZML|~>~*~|~|~F~7C%SS|~TY(3K|~8ZOHE~N~C~^~A~$
~MQ~J~|~>U~F~U~|~PT~|~W~U~M~G~L~X~R~?EN~DO?~>6>3MHIRON~@9~>W|J|D~@~4.W.CA|U~M~W8|T7.U#3|QOQRM1K~|~H~|~CY~>?2PT~"~P~Z~JFX~%~S~P~J.SZ|N
R<>X6~I~?AG~#~MBN~H~|N~EXN.G~P~|~R~Y0$~WS~R<~|~H~F~S0FQ~<~2X4~^~|~(Q~P6~U~^~M~2~C~H~W~O~M~.~$~A~|~KLE$~|~W~Y~N~J~MG~|~P~I~7%~|~K~<~T32@~|~K~>~#WW~^
H~+~^~|~J~P~I~P&Z~A~.~>~^~|~10X~|~IY~YV~B|C6SN>~M~VDG~P54|V7~3~C|H~|~IAMS@~|~^~OQSO|QV|~^~6~RB|~^~C~K~L~&~2908~.~U~>~74~>~M~H~|~H6B0#?SU>WA0
Y5UN&~^~|~TP~.~MV~|~*~.56|~<~|~5W~8%~|~JTR~*~2AYMUGU~@~J&|~J~V~<~^~6~^~|~.~|~ON~I~A~MR~>OQ~<6S%~|~<~3~%~|~JYFU~|~Z~EW$5~0D?2
ERW~#~U~7~P~74S@~X~^~V~S~Y~MSWAW~4L~<2CSJZ~*~|~77F~P~*~@~V~|~K~^~|~TL~I0~6TY+7(CN6~|~|~27E2~>~X735MZ~M~>WT3~|~V~AX&~|~SVF~S~?
VZ~>~JQO~8|U2H~"VDX3Y~*~%~M~X~Y~G~D~Y68WZ?~FEW~M5|DQS~S~^~K~O~(72~|~V~U~+~|~Y~|~|~N$~7~#~|~Q|~L~|~>~QWU~|~V~Z~I~0%~SN~A~4~A~|~PGV~78B~ML~|
(NWYIE~ZQ40%~C~Z03U~A~H~8.(Y~^~N~FPG)3~5ZSHLHX9N~690~7~AQ~COF~^~|~MSJZ4~JW~W~2~+5~ER~T~+~>~*~?F4~|~H~70G|~1~F~I~Z~N~J91~9K~Y~(GDZ?
DC6.A|~>~|~>~KOM~J~K~B~MEQ~U~1~CA2~*~3N$~|~+~6~9PGS~<~ZQ~)~U~MBSQ>J5H9U~|~I~L979V~@~J83~|~(K~UGBY~|~UC2~^~N~Y9%~|~Y~K~M~^~<~7~+~E~^~7~J~U~>~)~T~.W3PN~|~I~>
|O~U~>~O~V5XSD~|~I~>~KM~<~>~4~M~|~I~Z~V~E6G~QU~YR~F8~W~N~>~W~O~^~W3~Q~#~F~T~S~X~J~^~S~|~Y~D~O~L~T~R~I~T~|~#~|~M~B~M&0H
H~>~V~I~C~ZQ~<~E~W5D|8E~&2~P~M~Z~T~P~W~I3~R~E~I~R~|~X&~^~|~T~|~W~W~U~X~0~2L~|~>~|~L~U~F~X~%~ZSG~4~H~Y~M~A4B~H~K~|~T~#~(I~*~J~R~J~E~Y~_#V~Q?
OY~^~<~77~^~|~BA~"~J~J~@~|~A~^~B~W8UC~|~4~J~R~ZU0|~>~|~9~&~YAM~^~B~M~>~T~M~F5K~I~Y~Z05~J~H8X~K~?RRM67~M~2GAKA~K?
4|C~<~N~<~9~X~>~7K~V~<~^~|~^~|~F~R~I~Q~|~Y~APB~Y~<8SVZ~Q~O5L~|~|~>~Y~<~Z~MU7$2Q~C~T~|~Q~J6|2ON$5~N~"~T~E~|~WK50~X~^~Q~K70~+~|~J~|~G~V~>~+~>~V~DQ~|~H~V~M5
MZY~<~2~>~|~ME451~#5WY~Y8V~<3~Y~L~.02%~|~J~F56~#Z6~009~|~G9~5~Y~R~P~|~746.A~M~T~I~AKS6|~M~I3GH~J~H~L~KN~MP7|5|~^~|~>~Q~MUZ&DKY~>X0#P~
~.6|~%~V0~+45~*~)~M~V~|~NU~U~Z~D~@~|~W~^~|~L~4W~T~G&~^~N~G~E~>~H~U~|~3K&KAP150~<~|~G9K$~V~D~>~.K$4~X~3~.~|~G8G6(K~)~|~P9U~0~H~?E~Z~4B~MR~>~.5~.~%2~.~<~7~1~1~J~P
~_W~^~|~R~W~<~3~K~@~O~E~T~M~H~I~H~ZG~D~6~^~Z~W~B~Y~V~Y~C~3~|~+~D~E~^~W~M~2~#~B3Q|O~^~2408V7~.~$~$~F~2~^~J~N~T~K~M~^~H~Y~<~6~H~^~<~2~F~V~C~Y~^~<~77~|~H~X~V~
M1B~5~5MY2X~E~X~M7>~U~<~3~<~_JUO~|~@~60.K~>O6HG~::4S~C~H~H~H~H~^~2~G~Y93|V~$~|~P~R~M~4|5~^~2~A~F~L~.~*~I~G~O~F~?
|E~?~7~A~H~|~4~Z~.~F5U5~9~8%~55Z~X$S~C~"~::85Z~59~K~I~M~X~I~4~^~.~$5~1~>~53W~>~|~Y~X~W~>~|~N~O~Z~T~>~E~|~72P~H~26~|~W~.~$~V~U~29H~T~(^~V~I9>~|~W~V~U~M~E~#~:
OY64OQH~|~H~H~I~?~B3@~E~K~^~F~P3QW~4G9~9R~J>~3M&~W~T~T5~|~C~Y~G~S~91Y~G~C~R~M~8~^~M5~4~M~I~D~@~+~5&~23?X~#~C~L~B~L~>~5S~X~7AU~#5~H3O7P~V~I~V~4V~%
(^(~|~O~J~H~+89S~I~M~A~.~E~?~>~|~D~I~>~O~|~O~9~F6~J~>~:~|~98|6~M~N~I~C~^~D~W~+~(2~H6~W~O~C~C~4~I~O~O~E~H~^~2~M~R~M~0~C~5~P~C~N~7W~>~5~*~Q78O~F~8U~O~64~|~C~D~@~G~%~G~#
|~R~|~L8@S~|~S~I~S~N~Y~H~9~G~N~N~D~5>~%~)~M~I~N~#~$~401|~E~D~+~D~>~6~7~@~H~|~7~C~V~J6~P~Z~L~>~>~R~I~V~2~|~I~Y~|~D~4~<~R~7~T~P~>~8%~W~^~M~|~2~+~1~S~G~C~>~^~H~25~P~1~H~K~|~T~F~?~%~5~
~W~N~E~O5~4K~|~R~T~N~O~Q~I~M~M~B~2~N~U~R~<~@~^~I~V~M~>~X~I~*~|~?G~>~>~K~I~>~?~7~A~>~F~$~+~|~U~G~$~|~Q~G~U~X~W~X~|~^~K~S~+~>~)~Y~E~|~^~V~A~X~W~R~$~M~P~X~^~|~H~B~E~D~J~D~I~|~G~R~I~4K~7W~|~?
<~%~Q~O8~T~4~E~G~|~>~+~D~I~W~K~1~T~M5>~P~
```

[illegible]

FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember 2023-12-31
0001380106 us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember
2023-12-31-0001380106 us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember 2023-12-31-0001380106 us-
gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberrmb:LongTermInvestmentsMember 2023-12-31
0001380106 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberrmb:LongTermInvestmentsMember 2023-
12-31-0001380106 us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberrmb:LongTermInvestmentsMember
2023-12-31-0001380106 us-gaap:FairValueMeasurementsRecurringMemberrmb:LongTermInvestmentsMember 2023-12-31-0001380106 us-
gaap:USTreasurySecuritiesMember 2024-09-30-0001380106 us-gaap:ShortTermInvestmentsMember 2024-09-30-0001380106 us-
gaap:CertificatesOfDepositMember 2023-12-31-0001380106 us-gaap:USTreasuryBillSecuritiesMember 2023-12-31-0001380106 us-
gaap:USTreasurySecuritiesMember 2023-12-31-0001380106 us-gaap:ShortTermInvestmentsMember 2023-12-31-0001380106 us-
gaap:USTreasuryNotesSecuritiesMember 2023-12-31-0001380106 rmb:LongTermInvestmentsMember 2023-12-31-0001380106
rmb:ManufacturingAndLaboratoryEquipmentMember 2024-09-30-0001380106 rmb:ManufacturingAndLaboratoryEquipmentMember 2023-12-31
0001380106 rmb:ComputerEquipmentAndSoftwareMember 2024-09-30-0001380106 rmb:ComputerEquipmentAndSoftwareMember 2023-12-31
0001380106 us-gaap:FurnitureAndFixturesMember 2024-09-30-0001380106 us-gaap:FurnitureAndFixturesMember 2023-12-31-0001380106 us-
gaap:LeaseholdImprovementsMember 2024-09-30-0001380106 us-gaap:LeaseholdImprovementsMember 2023-12-31-0001380106 us-
gaap:ConstructionInProgressMember 2024-09-30-0001380106 us-gaap:ConstructionInProgressMember 2023-12-31-0001380106
rmb:OperationalEfficiencyProgramMember 2024-07-012024-09-30-0001380106 rmb:OperationalEfficiencyProgramMember 2024-01-012024-09-30
0001380106 rmb:OperationalEfficiencyProgramMember 2024-09-30-0001380106 rmb:July242017Memberrmb:CommonStockWarrantsMember
2024-09-30-0001380106 rmb:April122018Memberrmb:CommonStockWarrantsMember 2024-09-30-0001380106
rmb:FourteenJuly2021Memberrmb:CommonStockWarrantsMember 2024-09-30-0001380106 rmb:CommonStockWarrantsMember 2024-09-30
0001380106 rmb:July242017Memberrmb:CommonStockWarrantsMember 2023-12-31-0001380106
rmb:April122018Memberrmb:CommonStockWarrantsMember 2023-12-31-0001380106
rmb:FourteenJuly2021Memberrmb:CommonStockWarrantsMember 2023-12-31-0001380106 rmb:CommonStockWarrantsMember 2023-12-31
0001380106 rmb:A2010StockOptionAndGrantPlanMember 2024-09-30-0001380106 rmb:IncentiveAwardPlan2021Member 2021-07-012021-07-31
0001380106 rmb:IncentiveAwardPlan2021Memberus-gaap:CommonClassAMember 2021-07-31-0001380106
rmb:IncentiveAwardPlan2021Memberus-gaap:CommonClassAMember 2021-07-012021-07-31-0001380106 rmb:IncentiveAwardPlan2021Member
2024-09-30-0001380106 us-gaap:EmployeeStockOptionMemberrmb:IncentiveAwardPlan2021Member 2023-07-012023-09-30-0001380106 us-
gaap:EmployeeStockOptionMemberrmb:IncentiveAwardPlan2021Member 2024-01-012024-09-30-0001380106 us-
gaap:EmployeeStockOptionMemberrmb:IncentiveAwardPlan2021Member 2023-01-012023-09-30-0001380106 2023-01-012023-12-31-0001380106
us-gaap:RestrictedStockUnitsRSUMember 2024-01-012024-09-30-0001380106 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31-0001380106
us-gaap:RestrictedStockUnitsRSUMember 2024-09-30-0001380106 us-gaap:RestrictedStockUnitsRSUMember 2024-07-012024-09-30-0001380106
us-gaap:RestrictedStockUnitsRSUMember 2023-07-012023-09-30-0001380106 us-gaap:RestrictedStockUnitsRSUMember 2023-01-012023-09-30
0001380106 rmb:EmployeeStockPurchasePlan2021Memberus-gaap:CommonClassAMember 2021-07-31-0001380106
rmb:EmployeeStockPurchasePlan2021Member 2021-07-012021-07-31-0001380106 rmb:EmployeeStockPurchasePlan2021Memberus-
gaap:CommonClassAMember 2021-07-012021-07-31-0001380106 us-gaap:EmployeeStockMemberrmb:EmployeeStockPurchasePlan2021Member
2021-07-012021-07-31-0001380106 rmb:EmployeeStockPurchasePlan2021Memberus-gaap:CommonClassAMember 2024-01-012024-09-30-0001380106
rmb:EmployeeStockPurchasePlan2021Member 2023-01-012023-09-30-0001380106 rmb:EmployeeStockPurchasePlan2021Member 2024-07-
012024-09-30-0001380106 rmb:EmployeeStockPurchasePlan2021Member 2023-07-012023-09-30-0001380106
rmb:EmployeeStockPurchasePlan2021Member 2024-01-012024-09-30-0001380106 rmb:EmployeeStockPurchasePlan2021Memberus-
gaap:CommonClassAMember 2024-09-30-0001380106 us-gaap:EmployeeStockMemberrmb:EmployeeStockPurchasePlan2021Member 2024-07-
012024-09-30-0001380106 us-gaap:EmployeeStockMemberrmb:EmployeeStockPurchasePlan2021Member 2023-07-012023-09-30-0001380106 us-
gaap:EmployeeStockMemberrmb:EmployeeStockPurchasePlan2021Member 2024-01-012024-09-30-0001380106 us-
gaap:EmployeeStockMemberrmb:EmployeeStockPurchasePlan2021Member 2023-01-012023-09-30-0001380106
rmb:A2023InducementPlanMemberus-gaap:CommonClassAMember 2023-05-31-0001380106 rmb:A2023InducementPlanMember 2023-05-012023-
05-31-0001380106 us-gaap:RestrictedStockUnitsRSUMemberrmb:A2023InducementPlanMember 2023-05-012023-05-31-0001380106
rmb:A2023InducementPlanMemberus-gaap:CommonClassAMember 2024-02-012024-02-29-0001380106
sr:VicePresidentMemberrmb:A2023InducementPlanMember 2024-03-012024-03-31-0001380106 sr:VicePresidentMemberus-
gaap:RestrictedStockUnitsRSUMemberrmb:A2023InducementPlanMember 2024-03-012024-03-31-0001380106
rmb:A2023InducementPlanMember 2024-09-30-0001380106 us-gaap:CostOfSalesMember 2024-07-012024-09-30-0001380106 us-
gaap:CostOfSalesMember 2023-07-012023-09-30-0001380106 us-gaap:CostOfSalesMember 2024-01-012024-09-30-0001380106 us-
gaap:CostOfSalesMember 2023-01-012023-09-30-0001380106 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-012024-09-30
0001380106 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-012023-09-30-0001380106 us-
gaap:ResearchAndDevelopmentExpenseMember 2024-01-012024-09-30-0001380106 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-
012023-09-30-0001380106 us-gaap:SellingAndMarketingExpenseMember 2024-07-012024-09-30-0001380106 us-
gaap:SellingAndMarketingExpenseMember 2023-07-012023-09-30-0001380106 us-gaap:SellingAndMarketingExpenseMember 2024-01-012024-09-
30-0001380106 us-gaap:SellingAndMarketingExpenseMember 2023-01-012023-09-30-0001380106 us-
gaap:GeneralAndAdministrativeExpenseMember 2024-07-012024-09-30-0001380106 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-
012023-09-30-0001380106 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-012024-09-30-0001380106 us-
gaap:GeneralAndAdministrativeExpenseMember 2023-01-012023-09-30-0001380106 us-gaap:EmployeeStockOptionMember 2024-01-012024-09-30
0001380106 us-gaap:CommonClassAMember 2024-07-0120

in the manufacture of pharmaceuticals, medical devices and personal care products. The Company's technology uses a highly sensitive camera and the natural auto fluorescence of living cells to identify and quantify microbial growth faster and more accurately than the traditional method, which relies on the human eye. The Company currently sells to customers in North America, Europe and the Asia-Pacific region. The Company is headquartered in Lexington, Massachusetts.

Basis of presentation

These condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") and include the accounts of the Company and its wholly owned subsidiaries in Germany and Switzerland. All intercompany accounts and transactions have been eliminated in consolidation. Certain information and note disclosures normally included in the consolidated financial statements prepared in accordance with GAAP have been condensed or omitted. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the Company's audited consolidated financial statements for the year ended December 31, 2023. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification ("ASC") and Accounting Standards Update ("ASU") of the Financial Accounting Standards Board ("FASB").

The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company's financial position as of September 30, 2024 and the results of its operations and its cash flows for the three and nine months ended September 30, 2024 and 2023. The financial data and other information disclosed in these notes related to the three and nine months ended September 30, 2024 and 2023 are also unaudited. The results for the three and nine months ended September 30, 2024 are not necessarily indicative of results to be expected for the year ending December 31, 2024, any other interim periods, or any future year or period.

Liquidity

The Company has incurred recurring losses and net cash outflows from operations since its inception. The Company expects to continue to generate operating losses for the foreseeable future. The Company expects that its existing cash and cash equivalents and investments will be sufficient to fund its operating expenses and capital expenditure requirements for at least twelve months following the date these unaudited interim condensed consolidated financial statements were issued.

Basis of presentation

These condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") and include the accounts of the Company and its wholly owned subsidiaries in Germany and Switzerland. All intercompany accounts and transactions have been eliminated in consolidation. Certain information and note disclosures normally included in the consolidated financial statements prepared in accordance with GAAP have been condensed or omitted. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the Company's audited consolidated financial statements for the year ended December 31, 2023. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification ("ASC") and Accounting Standards Update ("ASU") of the Financial Accounting Standards Board ("FASB").

The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company's financial position as of September 30, 2024 and the results of its operations and its cash flows for the three and nine months ended September 30, 2024 and 2023. The financial data and other information disclosed in these notes related to the three and nine months ended September 30, 2024 and 2023 are also unaudited. The results for the three and nine months ended September 30, 2024 are not necessarily indicative of results to be expected for the year ending December 31, 2024, any other interim periods, or any future year or period.

Summary of significant accounting policies

Use of estimates

The preparation of the Company's condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, calculating the standalone selling price for revenue recognition, the valuation of inventory, and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific and relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in

circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.

There have been no significant changes to the Company's significant accounting policies during both the three and nine months ended September 30, 2024, as compared to those disclosed in Note 2 of the audited consolidated financial statements as of December 31, 2023 filed with the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023.

Risk of concentrations of credit, significant customers and significant suppliers

Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents, short-term and long-term investments and accounts receivable. The Company maintains its cash and cash equivalents and investments with financial institutions that management believes to be of high credit quality, and does not believe that it is subject to unusual credit risk beyond the credit risk associated with commercial banking relationships.

Significant customers

Significant customers are those which represent more than 10% of the Company's total revenue or accounts receivable balance at each respective balance sheet date. The following table presents customers that represented 10% or more of the Company's total revenue:

	2024	2023
Customer A	44.354%	1.01%
Customer B	12.081%	0.1%
Customer C	12.081%	0.1%
Customer D	12.081%	0.1%
Customer E	12.081%	0.1%
Customer F	12.081%	0.1%
Customer G	12.081%	0.1%
Customer H	12.081%	0.1%
Customer I	12.081%	0.1%
Customer J	12.081%	0.1%
Customer K	12.081%	0.1%
Customer L	12.081%	0.1%
Customer M	12.081%	0.1%
Customer N	12.081%	0.1%
Customer O	12.081%	0.1%
Customer P	12.081%	0.1%
Customer Q	12.081%	0.1%
Customer R	12.081%	0.1%
Customer S	12.081%	0.1%
Customer T	12.081%	0.1%
Customer U	12.081%	0.1%
Customer V	12.081%	0.1%
Customer W	12.081%	0.1%
Customer X	12.081%	0.1%
Customer Y	12.081%	0.1%
Customer Z	12.081%	0.1%

[illegible]

[illegible]

capitalized in other long-term assets at September 30, 2024 and December 31, 2023, respectively, net of accumulated amortization of \$1.0 million and \$0.7 million, respectively. These capitalized costs are being amortized on a straight-line basis over the initial subscription term of five years. For the three and nine months ended September 30, 2024 and 2023, there was \$0.1 million and \$0.3 million, respectively, of amortization expense related to capitalized software development costs recorded in the condensed consolidated statements of operations.

Fair Value Measurements

Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:

Level 1—Quoted prices in active markets for identical assets or liabilities.

Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.

Level 3—Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.

The Company's cash equivalents, short-term and long-term investments are carried at fair value, determined according to the fair value hierarchy described above (see Note 3). The carrying values of the Company's accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses and other current liabilities approximate their fair values due to the short-term nature of these assets and liabilities.

Product warranties

The Company offers a one-year limited assurance warranty on System sales, which is included in the selling price. The accrual for these warranty obligations is included in accrued expenses and other current liabilities in the condensed consolidated balance sheets. The following table presents a summary of changes in the amount reserved for warranty cost (in thousands):

	2024	2023
Balance, beginning of period	\$1,081	\$1,081
Warranty expense	44,354	44,354
Payments	(44,354)	(44,354)
Balance, end of period	\$45,781	\$1,081

Warranty provisions

Warranty provisions

--

The Company determined its operating segment after considering the Company's organizational structure and the information regularly reviewed and evaluated by the Company's chief operating decision maker ("CODM") in deciding how to allocate resources and assess performance.

The CODM reviews the financial information on a consolidated basis for purposes of evaluating financial performance and allocating resources. On the basis of these factors, the Company determined that it operates and manages its business as one operating segment, that develops, manufactures, markets and sells Systems and related LIMS connection software, consumables and services; and accordingly has one reportable segment for financial reporting purposes.

Revenue recognition

The Company does not disclose the value of remaining performance obligations for (i) contracts with an original contract term of one year or less, (ii) contracts for which the Company recognizes revenue at the amount to which it has the right to invoice when that amount corresponds directly with the value of services performed, and (iii) variable consideration allocated entirely to a wholly unsatisfied performance obligation or to a wholly unsatisfied distinct service that forms part of a single performance obligation. The Company does not have material remaining performance obligations associated with contracts with terms greater than one year.

Contract balances from contracts with customers >>>

<<< Contract assets arise from customer arrangements when revenue recognized exceeds the amount billed to the customer and the Company's right to payment is conditional and not only subject to the passage of time. The Company had \$0.2 million and \$0.1 million in contract assets as of September 30, 2024 and December 31, 2023, respectively, included in prepaid expenses and other current assets.

>>> Contract liabilities represent the Company's obligation to transfer goods or services to a customer for which it has received consideration (or the amount is due) from the customer. The Company has a contract liability related to service revenue, which consists of amounts that have been invoiced but that have not been recognized as revenue. Amounts expected to be recognized as revenue within 12 months of the balance sheet date are classified as current deferred revenue and amounts expected to be recognized as revenue beyond 12 months of the balance sheet date are classified as non-current deferred revenue. The Company did not record any non-current deferred revenue as of September 30, 2024 or December 31, 2023. Deferred revenue was \$5.4 million and \$6.0 million at September 30, 2024 and December 31, 2023, respectively. Revenue recognized during each of the three months ended September 30, 2024 and 2023 that was included in deferred revenue at the prior period-end was \$1.2 million. Revenue recognized during the nine months ended September 30, 2024 and 2023 that was included in deferred revenue at the prior period-end was \$3.9 million and \$3.3 million, respectively.

Disaggregated revenue

The Company disaggregates revenue based on the recurring and non-recurring nature of the underlying sale. Recurring revenue includes sales of consumables and service contracts. The Company considers these to be recurring revenues because customers typically place purchase orders on a periodic basis as they use their Growth Direct system(s) over time. These arrangements typically contain a single performance obligation and thus the entire consideration to which the Company is entitled is allocated entirely to that performance obligation. Non-recurring revenue includes sales of systems, LIMS connection software, validation services, and field services, and typically contains multiple performance obligations. The Company considers these to be non-recurring revenues because customers typically place single purchase orders for a bundle of products and services on a one-time or infrequent basis. For these arrangements, significant judgment is applied in identifying the distinct performance obligations, determination of the transaction price, transaction price allocation, and determination of standalone selling price for each of the distinct performance obligations.

	Sep-24	Sep-23	% chg Sep-24 vs Sep-23	Dec-23	% chg Dec-23 vs Sep-23
Recurring revenue	\$8.7 million	\$8.2 million	6%	\$8.1 million	-2%
Non-recurring revenue	\$1.1 million	\$1.2 million	(8)%	\$1.1 million	(8)%
Total revenue	\$9.8 million	\$9.4 million	4%	\$9.2 million	-2%

The following table presents the Company's revenue by the recurring or non-recurring nature of the revenue stream (in thousands):

	Sep-24	Sep-23	% chg Sep-24 vs Sep-23	Dec-23	% chg Dec-23 vs Sep-23
Recurring revenue	\$8,700	\$8,200	6%	\$8,100	-2%
Non-recurring revenue	\$1,100	\$1,200	(8)%	\$1,100	(8)%
Total revenue	\$9,800	\$9,400	4%	\$9,200	-2%

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

allowance for doubtful accounts for expected credit losses, which represents an estimate of amounts that may not be collectible. The Company performs ongoing credit evaluations of its customers and, if necessary, provides an allowance for doubtful accounts and expected credit losses. A provision to the allowance for doubtful accounts for expected credit losses is recorded based on factors including the length of time the receivables are past due, the current business environment, the geographic market, and the Company's historical experience. Provisions to the allowance for doubtful accounts for expected credit losses are recorded to general and administrative expenses in the consolidated statements of operations. The Company writes off accounts receivable against the allowance when it determines a balance is uncollectible and no longer actively pursues collection of the receivable.

Software Development Costs

The Company accounts for software development costs for internal-use software under the provisions of ASC 350-40, "Internal-Use Software" ("ASC 350"). Accordingly, certain costs to develop internal-use computer software are capitalized, provided these costs are expected to be recoverable.

Fair value measurements

Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:

Level 1 – Quoted prices in active markets for identical assets or liabilities.

Level 2 – Quoted prices in active markets for identical assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.

Level 3 – Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.

The Company's cash equivalents, short-term and long-term investments are carried at fair value, determined according to the fair value hierarchy described above (see Note 3). The carrying values of the Company's accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses and other current liabilities approximate their fair values due to the short-term nature of these assets and liabilities.

Product warranties

The Company offers a one-year limited assurance warranty on System sales, which is included in the selling price. The accrual for these warranty obligations is included in accrued expenses and other current liabilities in the condensed consolidated balance sheets.

	2024	2023
Balance, beginning of period	\$1.0%	\$12.081%
Additions	\$0.1%	\$0.406%
Deductions	\$12.081%	\$0.1%
Balance, end of period	\$0.1%	\$12.081%

Three Months Ended September 30,

Nine Months Ended September 30,

2024

2023

Balance, beginning of period

2024

2023

Balance, beginning of period

2024

2023

Warranty provisions

[illegible]

present=The following table presents the Company's revenue by the recurring or non-recurring nature of the revenue stream (in thousands):

Three Months Ended September 30, 2023	Three Months Ended September 30, 2024	Nine Months Ended September 30, 2023	Nine Months Ended September 30, 2024	Product and service revenue — recurring	Product and service revenue — non-recurring	Total revenue
3,675	3,410	3,410	3,410	3,929	2,735	8,571
11,262	11,262	11,262	11,262	12,927	5,927	19,833
16,182	16,182	16,182	16,182	17,604	12,927	30,531

The following table presents the Company's revenue by customer geography (in thousands):

North America	Europe	Asia Pacific	Latin America	Total
11,262	11,262	11,262	11,262	45,048

[illegible]

1

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998	1997	1996	1995	1994	1993	1992	1991	1990	1989	1988	1987	1986	1985	1984	1983	1982	1981	1980	1979	1978	1977	1976	1975	1974	1973	1972	1971	1970	1969	1968	1967	1966	1965	1964	1963	1962	1961	1960	1959	1958	1957	1956	1955	1954	1953	1952	1951	1950	1949	1948	1947	1946	1945	1944	1943	1942	1941	1940	1939	1938	1937	1936	1935	1934	1933	1932	1931	1930	1929	1928	1927	1926	1925	1924	1923	1922	1921	1920	1919	1918	1917	1916	1915	1914	1913	1912	1911	1910	1909	1908	1907	1906	1905	1904	1903	1902	1901	1900	1899	1898	1897	1896	1895	1894	1893	1892	1891	1890	1889	1888	1887	1886	1885	1884	1883	1882	1881	1880	1879	1878	1877	1876	1875	1874	1873	1872	1871	1870	1869	1868	1867	1866	1865	1864	1863	1862	1861	1860	1859	1858	1857	1856	1855	1854	1853	1852	1851	1850	1849	1848	1847	1846	1845	1844	1843	1842	1841	1840	1839	1838	1837	1836	1835	1834	1833	1832	1831	1830	1829	1828	1827	1826	1825	1824	1823	1822	1821	1820	1819	1818	1817	1816	1815	1814	1813	1812	1811	1810	1809	1808	1807	1806	1805	1804	1803	1802	1801	1800	1799	1798	1797	1796	1795	1794	1793	1792	1791	1790	1789	1788	1787	1786	1785	1784	1783	1782	1781	1780	1779	1778	1777	1776	1775	1774	1773	1772	1771	1770	1769	1768	1767	1766	1765	1764	1763	1762	1761	1760	1759	1758	1757	1756	1755	1754	1753	1752	1751	1750	1749	1748	1747	1746	1745	1744	1743	1742	1741	1740	1739	1738	1737	1736	1735	1734	1733	1732	1731	1730	1729	1728	1727	1726	1725	1724	1723	1722	1721	1720	1719	1718	1717	1716	1715	1714	1713	1712	1711	1710	1709	1708	1707	1706	1705	1704	1703	1702	1701	1700	1699	1698	1697	1696	1695	1694	1693	1692	1691	1690	1689	1688	1687	1686	1685	1684	1683	1682	1681	1680	1679	1678	1677	1676	1675	1674	1673	1672	1671	1670	1669	1668	1667	1666	1665	1664	1663	1662	1661	1660	1659	1658	1657	1656	1655	1654	1653	1652	1651	1650	1649	1648	1647	1646	1645	1644	1643	1642	1641	1640	1639	1638	1637	1636	1635	1634	1633	1632	1631	1630	1629	1628	1627	1626	1625	1624	1623	1622	1621	1620	1619	1618	1617	1616	1615	1614	1613	1612	1611	1610	1609	1608	1607	1606	1605	1604	1603	1602	1601	1600	1599	1598	1597	1596	1595	1594	1593	1592	1591	1590	1589	1588	1587	1586	1585	1584	1583	1582	1581	1580	1579	1578	1577	1576	1575	1574
------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

General and administrative

Total stock-based compensation expense

Taxes

The Company's tax provision and the resulting effective tax rate for interim periods is determined based upon its estimated annual effective tax rate, adjusted for the effect of discrete items arising in that quarter. The income tax provision was generated from operations in Germany and Switzerland.

The impact of such discrete items could result in a higher or lower effective tax rate during a particular quarter, based upon the mix and timing of actual earnings or losses versus annual projections. In each quarter, the Company updates its estimate of the annual effective tax rate, and if the estimated annual tax rate changes, a cumulative adjustment is made in that quarter.

The Company has evaluated the positive and negative evidence bearing upon its ability to realize its deferred tax assets, which primarily consist of net operating loss carryforwards. The Company has considered its history of cumulative net losses, estimated future taxable income and prudent and feasible tax planning strategies and has concluded that it is more likely than not that the Company will not realize the benefits of its deferred tax assets. As a result, as of both September 30, 2024 and December 31, 2023 the Company recorded a full valuation allowance against its net deferred tax assets.

The Company files income tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by U.S. federal, state and international jurisdictions, where applicable. There are currently no pending tax examinations in the U.S., and the Company has not received notice of examination from any jurisdictions in the U.S.

Net loss per share

As of September 30, 2024, the Company had Class A common stock and Class B common stock. Both share classes have the same rights to the Company's earnings and neither of the classes have any prior or senior rights to dividends to the other share class.

Basic and diluted net loss per share was calculated as follows (in thousands, except share and per share amounts):

	September 30, 2024	September 30, 2023
Numerator: Net loss	(1,251)	(1,185)
Denominator: Weighted average shares outstanding	1,251	1,185
Net loss per share	(1.00)	(1.00)

Three Months Ended September 30,

Nine Months Ended September 30,

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

height:100%">2026</td><td colspan="2" style="background-color:#ceefff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,401</td><td style="background-color:#ceefff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">2027</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,435</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ceefff;padding:2px 1pt;text-align:left;vertical-align:bottom">2028</td><td colspan="2" style="background-color:#ceefff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,469</td><td style="background-color:#ceefff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Thereafter</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">804</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ceefff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total lease payments</td><td colspan="2" style="background-color:#ceefff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">6,814</td><td style="background-color:#ceefff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less imputed interest</td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(583)</td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ceefff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total present value of lease liabilities</td><td colspan="2" style="background-color:#ceefff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">6,231</td><td style="background-color:#ceefff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt">Maturities of the Company's financing lease liability as of September 30, 2024 were as follows (in thousands):</div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:top;width:100%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Financing Lease Maturities</td></tr><tr><td colspan="3" style="background-color:#ceefff;padding:2px 1pt;text-align:left;vertical-align:bottom">2024 (excluding the nine months ended September 30)</td><td colspan="3" style="background-color:#ceefff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">75</td><td colspan="3" style="background-color:#ceefff;padding:2px 1pt;text-align:right;vertical-align:bottom">2025</td><td colspan="3" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">75</td><td colspan="3" style="background-color:#ceefff;padding:2px 1pt;text-align:left;vertical-align:bottom">2026</td><td colspan="3" style="background-color:#ceefff;padding:2px 1pt;text-align:right;vertical-align:bottom">75</td><td colspan="3" style="background-color:#ceefff;padding:2px 1pt;text-align:left;vertical-align:bottom">2027</td><td colspan="3" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">75</td><td colspan="3" style="background-color:#ceefff;padding:2px 1pt;text-align:left;vertical-align:bottom">2028</td><td colspan="3" style="background-color:#ceefff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">75</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Thereafter</td><td colspan="3" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">38</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">Total lease payments</td><td colspan="3" style="background-color:#ceefff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">356</td><td colspan="3" style="background-color:#ceefff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">223</td><td colspan="3" style="background-color:#ceefff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">Leases</td></div><div style="margin-top:12pt;text-indent:36pt">The Company determines if an arrangement is or contains a lease at inception, which is the date on which the terms of the contract are agreed to, and the agreement creates enforceable rights and obligations. Under ASC 842, a contract is or contains a lease when (i) explicitly or implicitly identified assets have been deployed in the contract and (ii) the customer obtains substantially all of the economic benefits from the use of that underlying asset and directs how and for what purpose the asset is used during the term of the contract. The Company also considers whether its service arrangements include the right to control the use of an asset.</div><div style="margin-top:12pt;text-indent:36pt">The Company made an accounting policy election not to recognize right-of-use ("ROU") assets and lease liabilities for leases with a term of twelve months or less. For all other leases, the Company

recognizes ROU assets and lease liabilities based on the present value of lease payments over the lease term at the commencement date of the lease. Lease payments may include fixed rent escalation clauses or payments that depend on an index (such as the consumer price index). Subsequent changes to an index and any other periodic market-rate adjustments to base rent are recorded in variable lease expense in the period incurred. The ROU assets also include any initial direct costs incurred and lease payments made at or before the commencement date and are reduced by any lease incentives.

The Company has made an accounting policy election to account for lease and non-lease components in its contracts as single lease components for all asset classes. The non-lease components typically represent additional services transferred to the Company, such as common area maintenance for real estate, which are variable in nature and recorded in variable lease expense in the period incurred.

The Company uses its incremental borrowing rate which is the rate of interest the Company would have to pay to borrow on a collateralized basis over a similar term and amount in a similar economic environment to determine the present value of lease payments as the Company's leases do not have a readily determinable implicit discount rate. Judgment is applied in assessing factors such as Company specific credit risk, lease term, nature, and quality of the underlying collateral, currency, and economic environment in determining the incremental borrowing rate to apply to each lease.

The Company's leases generally do not contain any material restrictive covenants or residual value guarantees.

Supplemental cash flow information related to leases is as follows (in thousands):

	2024	2023
Operating cash outflows – payments on operating leases	997	956
Operating cash outflows – payments on financing leases	27	29
Financing cash outflows – payments on financing leases	29	27
Right of use assets obtained in exchange for new lease obligations	151	151

Investing non-cash activities – establishment of right of use operating assets

Information related to the Company's operating and financing leases is as follows (in thousands):

	2024	2023
Operating cash outflows – payments on operating leases	997	956
Operating cash outflows – payments on financing leases	27	29
Financing cash outflows – payments on financing leases	29	27
Right of use assets obtained in exchange for new lease obligations	151	151

[illegible]

[illegible]

Financing lease cost - amortization of right-of-use asset

Total lease cost / interest on lease liability

Variable lease cost

Operating lease cost is recognized on a straight-line basis over the lease term. Total rent expense, including the Company's share of the lessors' operating expenses, was \$0.5 million for each of the three months ended September 30, 2024 and 2023, and was \$1.6 million for each of the nine months ended September 30, 2024 and 2023.

Maturities of the Company's operating lease liabilities as of September 30, 2024 were as follows (in thousands):

Year	2024	2025	2026	2027	2028	2029	Total
Operating Lease Liabilities	\$1.4 million	\$1.4 million	\$1.4 million	\$1.4 million	\$1.4 million	\$1.4 million	\$8.4 million

The following table shows the components of the Company's operating lease liabilities:

Component	Amount
Leasehold Improvements	\$1.4 million
Furniture and Equipment	\$1.4 million
Other Assets	\$1.4 million
Total	\$4.2 million

[illegible]

[illegible]

[illegible]

	<td <="" style="width:0.1%" td=""><td <="" style="width:1.0%" td=""><td 5"="" style="width:12.081%</td></tr><tr><td colspan="> September 30, 2024 December 31, 2023 Operating lease assets Operating lease liabilities, long-term Total operating lease liabilities Office furniture and fixtures Net property, plant and equipment Lease liabilities, short-term </td></td></td>	<td <="" style="width:1.0%" td=""><td 5"="" style="width:12.081%</td></tr><tr><td colspan="> September 30, 2024 December 31, 2023 Operating lease assets Operating lease liabilities, long-term Total operating lease liabilities Office furniture and fixtures Net property, plant and equipment Lease liabilities, short-term </td></td>	<td 5"="" style="width:12.081%</td></tr><tr><td colspan="> September 30, 2024 December 31, 2023 Operating lease assets Operating lease liabilities, long-term Total operating lease liabilities Office furniture and fixtures Net property, plant and equipment Lease liabilities, short-term </td>	September 30, 2024 December 31, 2023 Operating lease assets Operating lease liabilities, long-term Total operating lease liabilities Office furniture and fixtures Net property, plant and equipment Lease liabilities, short-term
--	---	--	---	--

[illegible]

[illegible]

